\nThe State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.\n
\n\nIt is a weekly snapshot in time that:\nThis file includes data for states that are implementing their own Marketplaces, also known as State-Based Marketplaces or SBMs, and states with Marketplaces that are supported by or fully run by the federal government, including those run in partnership with states, also known as the Federally-Facilitated Marketplace or FFM. Includes demographic characteristics, and plan selected (by metal level). Please refer to the full report listed under Resources.
","title":"Health Insurance Marketplace: Summary Enrollment Data for the Initial Annual Open Enrollment Period","programCode":["009:082"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://aspe.hhs.gov/health/reports/2014/MarketPlaceEnrollment/Apr2014/excel/workbook.xls","mediaType":"application/vnd.ms-excel","title":"XLS "},{"@type":"dcat:Distribution","downloadURL":"http://aspe.hhs.gov/health/reports/2014/MarketPlaceEnrollment/Apr2014/Marketplace_StateSum.cfm","mediaType":"text/html","title":"Text "}],"describedBy":"https://aspe.hhs.gov/health/reports/2014/MarketPlaceEnrollment/Apr2014/Marketplace_StateSum.cfm","dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2928-wqa7","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["cervical-tumors","nih","apot-technique","viral-cellular-sequences","hpv-integration"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2928-wqa7","description":"Background\n In cervical tumours the integration of human papilloma viruses (HPV) transcripts often results in the generation of transcripts that consist of hybrids of viral and cellular sequences. Mapping data using a variety of techniques has demonstrated that HPV integration occurred without obvious specificity into human genome. However, these techniques could not demonstrate whether integration resulted in the generation of transcripts encoding viral or viral-cellular sequences. The aim of this work was to map the integration sites of HPV DNA and to analyse the adjacent cellular sequences.\n \n \n Methods\n Amplification of the INTs was done by the APOT technique. The APOT products were sequenced according to standard protocols. The analysis of the sequences was performed using BLASTN program and public databases. To localise the INTs PCR-based screening of GeneBridge4-RH-panel was used.\n \n \n Results\n Twelve cellular sequences adjacent to integrated HPV16 (INT markers) expressed in squamous cell cervical carcinomas were isolated. For 11 INT markers homologous human genomic sequences were readily identified and 9 of these showed significant homologies to known genes/ESTs. Using the known locations of homologous cDNAs and the RH-mapping techniques, mapping studies showed that the INTs are distributed among different human chromosomes for each tumour sample and are located in regions with the high levels of expression.\n \n \n Conclusions\n Integration of HPV genomes occurs into the different human chromosomes but into regions that contain highly transcribed genes. One interpretation of these studies is that integration of HPV occurs into decondensed regions, which are more accessible for integration of foreign DNA.","title":"Human papilloma viruses and cervical tumours: mapping of integration sites and analysis of adjacent cellular sequences","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC134465/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["prescription-drugs","drug-information","drug-safety","medications","drug-manufacturers"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA209971","description":"Acyclovir Sodium is an injectable antiviral medication used to treat infections caused by herpes viruses, including herpes simplex and herpes zoster. It is administered intravenously as a solution with a strength of 50 mg/mL. Manufactured by Zydus Pharmaceuticals (USA) Inc., it is available as a prescription drug. This information was generated using AI and is provided for informational and research purposes only.","title":"Acyclovir","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209971","description":"\n Access the FDA dataset for Acyclovir — ANDA 209971 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Acyclovir"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/296h-2my4","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","hospitalized-patients","geriatric-nutrition","dietary-intake","food-preferences"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/296h-2my4","description":"Background\n A cross sectional survey was carried out on 120 hospitalised geriatric patients aged 60 and above in Hospital Universiti Kebangsaan Malaysia, Kuala Lumpur to investigate their nutrient intakes and food preferences.\n \n \n Methods\n Food intakes were recorded using a one day weighed method and diet recall. Food preferences were determined using a five point hedonic score. Food wastages and factors affecting dietary adequacy were also investigated.\n \n \n Results\n The findings indicated that the mean intakes of energy and all nutrients investigated except for vitamin C and fluid were below the individual requirement for energy, protein and fluid, and the Malaysian Recommendation of Dietary Allowances (RDA) for calcium, iron, vitamin A, thiamin, riboflavin, niacin and acid ascorbic. In general, subjects preferred vegetables, fruits and beans to red meat, milk and dairy products. There was a trend of women to have a higher percentage for food wastage. Females, diabetic patients, subjects who did not take snacks and subjects who were taking hospital food only, were more likely to consume an inadequate diet (p < 0.05 for all values).\n \n \n Conclusions\n Food service system in hospital should consider the food preferences among geriatric patients in order to improve the nutrient intake. In addition, the preparation of food most likely to be rejected such as meat, milk and dairy products need some improvements to increase the acceptance of these foods among geriatric patients. This is important because these foods are good sources of energy, protein and micronutrients that can promote recovery from disease or illness.","title":"Food intakes and preferences of hospitalised geriatric patients","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC122060/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2982-fwgf","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","compound","chemistry","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2982-fwgf","description":"Chemical compound data from PubChem database. IUPAC Name: 2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.01,6]dodec-2-ene. Molecular Formula: C15H24O. Molecular Weight: 220.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527157: (3R,5aS,9aR)-2,2,5a,9-Tetramethyl-3,4,5,5a,6,7-hexahydro-2H-3,9a-methanobenzo[b]oxepine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527157","description":"Access the complete Compound 527157: (3R,5aS,9aR)-2,2,5a,9-Tetramethyl-3,4,5,5a,6,7-hexahydro-2H-3,9a-methanobenzo[b]oxepine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2985-aamq","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["treatment-facilities","samhsa","n-ssats","oregon-health","substance-abuse-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2985-aamq","description":"This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing state profiles for Oregon in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.","title":"2011 State Profile — Oregon","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2011-state-profile-oregon","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2985-sujb","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["quadriceps-exercise","osteoarthritis-knee","nih","pain-management","dementia-patients"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2985-sujb","description":"Background\n Osteoarthritis (OA) of the knee, which is prevalent among older adults in nursing homes, causes significant pain and suffering, including disturbance of nocturnal sleep. One nonpharmacologic treatment option is quadriceps-strengthening exercise, however, the feasibility of such a treatment for reducing pain from OA in severely demented elders has not been studied. This report describes our test of the feasibility of such an exercise program, together with its effects on pain and sleep, in a severely demented nursing home resident.\n \n \n Case presentation\n The subject was an elderly man with severe cognitive impairment (Mini-Mental Status Exam score 4) and knee OA (Kellgren-Lawrence radiographic grade 4). He was enrolled in a 5-week, 10-session standardized progressive-resistance training program to strengthen the quadriceps, and completed all sessions. Pain was assessed with the Western Ontario and MacMaster OA Index (WOMAC) pain subscale, and sleep was assessed by actigraphy.\n The patient was able to perform the exercises, with a revision to the protocol. However, the WOMAC OA pain subscale proved inadequate for measuring pain in a patient with low cognitive functioning, and therefore the effects on pain were inconclusive. Although his sleep improved after the intervention, the influence of his medications and the amount of daytime sleep on his nighttime sleep need to be considered.\n \n \n Conclusions\n A quadriceps-strengthening exercise program for treating OA of the knee is feasible in severely demented elders, although a better outcome measure is needed for pain.","title":"Feasibility of using quadriceps-strengthening exercise to improve pain and sleep in a severely demented elder with osteoarthritis – a case report","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC130037/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/298d-mcjz","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","pubchem","chemistry","bioactivity","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/298d-mcjz","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865406: MLS000083272","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865406","description":"Access the complete Substance 865406: MLS000083272 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29a2-593z","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","science","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/29a2-593z","description":"Chemical compound data from PubChem database. IUPAC Name: 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16,18,18,20,20,22,22,24,24,26,26,28,28,30,30,32,32,34,34,36,36,38,38,40,40,42,42,44,44,46,46,48,48,50,50,52,52,54,54,56,56,58,58,60,60,62,62,64,64,66,66,68,68,70,70,72,72,74,74,76,76,78,78,80,80,82,82-dooctacontamethyl-1,3,5,7,9,11,13,15,17,19,21,23,25,27,29,31,33,35,37,39,41,43,45,47,49,51,53,55,57,59,61,63,65,67,69,71,73,75,77,79,81-hentetracontaoxa-2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34,36,38,40,42,44,46,48,50,52,54,56,58,60,62,64,66,68,70,72,74,76,78,80,82-hentetracontasilacyclodooctacontane. Molecular Formula: C82H246O41Si41. Molecular Weight: 3040.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528801: Cyclountetracontasiloxane, dooctacontamethyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528801","description":"Access the complete Compound 528801: Cyclountetracontasiloxane, dooctacontamethyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"http://www.ncbi.nlm.nih.gov/gene","bureauCode":["009:25"],"issued":"2016-09-01","@type":"dcat:Dataset","modified":"2025-07-16","keyword":["genes","api","tools & utilities","phenotype","genomics","dataset"],"contactPoint":{"@type":"vcard:Contact","fn":"National Library of Medicine","hasEmail":"mailto:custserv@nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Library of Medicine"},"identifier":"https://datadiscovery.nlm.nih.gov/api/views/ddn9-p8cj","description":"Gene integrates information from a wide range of species. A record may include nomenclature, Reference Sequences (RefSeqs), maps, pathways, variations, phenotypes, and links to genome-, phenotype-, and locus-specific resources worldwide.","title":"Gene","programCode":["009:041"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://www.ncbi.nlm.nih.gov/gene","mediaType":"text/html","title":"Gene Homepage, Search, and Utilities"},{"@type":"dcat:Distribution","downloadURL":"https://ftp.ncbi.nih.gov/gene/","mediaType":"text/html","title":"Download Gene Data"},{"@type":"dcat:Distribution","downloadURL":"https://www.ncbi.nlm.nih.gov/books/NBK25501/","mediaType":"text/html","title":"Access Gene via E-Utilities API"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Biology"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29cu-xxms","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["water-fluoridation","down-syndrome","incidence-rates","nih","systematic-review"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/29cu-xxms","description":"Background\n A review of the safety and efficacy of drinking water fluoridation was commissioned by the UK Department of Health to investigate whether the evidence supported a beneficial effect of water fluoridation and whether there was any evidence of adverse effects. Down's syndrome was one of the adverse effects reported. The aim of this review is to examine the evidence for an association between water fluoride level and Down's syndrome.\n \n \n Methods\n A systematic review of research. Studies were identified through a comprehensive literature search, scanning citations and online requests for papers. Studies in all languages which investigated the incidence of Down's syndrome in areas with different levels of fluoride in their water supplies were included. Study inclusion and quality was assessed independently by 2 reviewers. A qualitative analysis was conducted.\n \n \n Results\n Six studies were included. All were ecological in design and scored poorly on the validity assessment. The estimates of the crude relative risk ranged from 0.84 to 3.0. Four studies showed no significant associations between the incidence of Down's syndrome and water fluoride level and two studies by the same author found a significant (p < 0.05) positive association (increased Down's syndrome incidence with increased water fluoride level). Only two of the studies controlled for confounding factors and only one of these presented summary outcome measures.\n \n \n Conclusions\n The evidence of an association between water fluoride level and Down's syndrome incidence is inconclusive.","title":"Association of Down's syndrome and water fluoride level: a systematic review of the evidence","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC37313/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29dv-q7xw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/29dv-q7xw","description":"Chemical compound data from PubChem database. IUPAC Name: [3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] butanoate. Molecular Formula: C24H36O2. Molecular Weight: 356.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528804: [3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] butanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528804","description":"Access the complete Compound 528804: [3,7-Dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraenyl] butanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29e3-aywd","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-07-30","keyword":["samhsa","idaho","substance-use","behavioral-health","mental-health-services"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/29e3-aywd","description":"Publications Using SAMHSA DataBehavioral Health Barometer: Idaho, Volume 5","title":"Publications Using SAMHSA DataBehavioral Health Barometer: Idaho, Volume 5","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-idaho-volume-5","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29ff-gc99","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["policy","time","assessment","child","real"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/29ff-gc99","description":"JBS International, Inc.'s Child Welfare Reviews Project oversees a diverse national pool of reviewers who participate in the Child and Family Services Reviews (CFSRs) conducted by the Children's Bureau. JBS recruits reviewers by taking referrals from state and federal staff; contract staff; and current CFSR reviewers, quality assurance specialists, and note-taking specialists (collectively referred to as “agile staff”). It also conducts outreach with Regional Offices and national organizations.\n\nUpon receipt of applications, the Child Welfare Reviews Project reviews and maintains information on candidates’ qualifications and identifies candidates to participate in CFSR reviewer trainings. Once trained, these individuals become eligible to participate as CFSR reviewers. Preference is given to individuals who are experienced in applying the Onsite Review Instrument and Instructions, who demonstrate fluency in Spanish, and/or have lived experience within the child welfare system or within indigenous or tribal social services.\n\nThe Child Welfare Reviews Project conducts CFSR reviewer trainings periodically. Qualified candidates are required to attend an in-person 2-day training and complete online training and other ongoing trainings as needed.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"CFSR Reviewer Recruitment","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/cfsr-reviewer-recruitment","description":"Access the complete CFSR Reviewer Recruitment on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29kb-2hsx","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["state-mental-health","samhsa","national-outcome-measures","mental-health-services","block-grant-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/29kb-2hsx","description":"This is the 2016 Uniform Reporting System (URS) Output Tables for Montana. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2016 Uniform Reporting System (URS) Table for Montana","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2016-uniform-reporting-system-urs-table-montana","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29kh-vpjw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/29kh-vpjw","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(furan-2-ylmethyl)pyrrole-2-carbaldehyde. Molecular Formula: C10H9NO2. Molecular Weight: 175.18. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529880: 1-((Furan-2-yl)methyl)-1H-pyrrole-2-carbaldehyde","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529880","description":"Access the complete Compound 529880: 1-((Furan-2-yl)methyl)-1H-pyrrole-2-carbaldehyde on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/3se3-rwj2","bureauCode":["009:00"],"issued":"2016-09-14","@type":"dcat:Dataset","modified":"2025-04-28","keyword":["cdc","centers for disease control and prevention"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/3se3-rwj2","description":"Rate of deaths by age/gender (per 100,000 population) for people killed in crashes involving a driver with BAC =>0.08%, 2012, 2014. 2012 Source: Fatality Analysis Reporting System (FARS). 2014 Source: National Highway Traffic Administration's (NHTSA) Fatality Analysis Reporting System (FARS), 2014 Annual Report File. Note: Blank cells indicate data are suppressed. Fatality rates based on fewer than 20 deaths are suppressed.","title":"Impaired Driving Death Rate, by Age and Sex, 2012 & 2014, Region 9 - San Francisco","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/3se3-rwj2/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/3se3-rwj2/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/3se3-rwj2/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/3se3-rwj2/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/3se3-rwj2/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/3se3-rwj2/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Motor Vehicle"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","drug-manufacturers","drug-safety","health-care","prescription-drugs"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA200797","description":"Hydrochlorothiazide is a thiazide diuretic medication used to treat high blood pressure and fluid retention (edema). This generic version, in 12.5 mg capsules, is taken orally and was marketed by Alembic Pharmaceuticals. It works by increasing urine output to reduce swelling and blood pressure. Note: This product is discontinued. This information was generated using AI and is provided for informational and research purposes only.","title":"Hydrochlorothiazide","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200797","description":"\n Access the FDA dataset for Hydrochlorothiazide — ANDA 200797 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Hydrochlorothiazide"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29r5-g79n","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","bioactivity","substance","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/29r5-g79n","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864944: MLS000039580","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864944","description":"Access the complete Substance 864944: MLS000039580 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29rv-rxyn","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","substance","bioactivity","references","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/29rv-rxyn","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865354: MLS000083970","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865354","description":"Access the complete Substance 865354: MLS000083970 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29si-6vpr","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","pubchem","compound","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/29si-6vpr","description":"Chemical compound data from PubChem database. IUPAC Name: 2,3-dichlorooxane. Molecular Formula: C5H8Cl2O. Molecular Weight: 155.02. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529964: 2,3-Dichlorotetrahydropyran","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529964","description":"Access the complete Compound 529964: 2,3-Dichlorotetrahydropyran on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29tj-exk4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","chemistry","compound","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/29tj-exk4","description":"Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-(trimethylsilylamino)-3-trimethylsilyloxysulfonylpropanoate. Molecular Formula: C12H31NO5SSi3. Molecular Weight: 385.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530162: Cysteic acid, TMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530162","description":"Access the complete Compound 530162: Cysteic acid, TMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29tq-egkc","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["siderophore-response","seawater-microbial-community","quorum-sensing","nih","bacterial-abundance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/29tq-egkc","description":"Background\n Oceans are iron-deficient and nutrient-poor environments. These conditions impart limitations on our understanding of and our ability to identify microorganisms from the marine environment. However, less of knowledge on the influence of siderophores and N-acyl homoserinelactone as interspecies communication signals on the bacterial diversity of seawater has been understood.\n \n \n Results\n In the presence of 0.1 nM of the commercial siderophore desferroixamine and the known quorum-sensing chemical signals, synthetic N-(3-oxo)-hexanoylhomoserine lactone (0.1 nM) or N-octanoylhomoserine lactone (0.1 nM), the total numbers of bacteria in S9905 seawater increased nearly three-fold, and nearly eight-fold in S0011 seawater as determined by DAPI staining and counting, and increased three-fold by counting colony forming units in S9905 seawater after 7 days of incubation. Similar bacterial changes in bacterial abundance were observed when high concentration of desferroixamine (1 μM) and each of homoserine lactone compounds (1 μM) were presented in seawater samples. The number of cultivable bacterial species observed was also found to increase from 3 (without addition) to 8 (with additions) including three unknown species which were identified by phylogenetic analysis of 16S rDNA sequences. The growth of unknown species was found to be related to their siderophore production with response to the addition of desferroixamine and N-acyl homoserine lactones under iron-limited conditions.\n \n \n Conclusion\n Artificial addition of siderophores and HSLs may be a possible method to aid in the identification and isolation of marine bacterial species which are thought to be unknown.","title":"Bacterial response to siderophore and quorum-sensing chemical signals in the seawater microbial community","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59891/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nchs/covid19/covid-19-mortality-data-files.htm","bureauCode":["009:20"],"issued":"2021-10-21","@type":"dcat:Dataset","modified":"2025-04-21","keyword":["provisional","weekly","united states","race","nvss","nchs","mortality","hispanic origin","deaths","covid-19","coronavirus","children","all causes","age group","age"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/siwp-yg6m","description":"Provisional deaths involving COVID-19 reported to NCHS by MMWR week, race and Hispanic origin, and age group. Deaths occurred in the United States.\n\nAge groups: 0-4, 5-11, 12-17, 18-29, 30-39, 40-49, 50-64, 65-74, and 75+ years","title":"AH Provisional COVID-19 Death Counts by Week, Race, and Age, United States 2020-2023","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/siwp-yg6m/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/siwp-yg6m/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/siwp-yg6m/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"https://www.usa.gov/government-works","accrualPeriodicity":"irregular","theme":["National Center for Health Statistics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/29vt-7ir4","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["policy","reporting","adoption","care","foster"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/29vt-7ir4","description":"Describes the nature, scope, and impact of interjurisdictional adoption placement efforts and the strategies that improve outcomes for children in foster care who are placed for adoption in other jurisdictions.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"A Report to Congress on Interjurisdictional Adoption of Children in Foster Care","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/report-congress-interjurisdictional-adoption-children-foster-care","description":"Access the complete A Report to Congress on Interjurisdictional Adoption of Children in Foster Care on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","drug-information","medications","pharmaceuticals","prescription-drugs"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA078828","description":"Risperidone is an oral solution with 1 mg/mL of the active ingredient, used as an atypical antipsychotic to manage symptoms of schizophrenia, bipolar disorder, and irritability in autism. It's a prescription drug manufactured by Bryant Ranch Prepack under application ANDA079059. This information was generated using AI and is provided for informational and research purposes only.","title":"Risperidone","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078828","description":"\n Access the FDA dataset for Risperidone — ANDA 078828 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Risperidone"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2a46-v2zu","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["asteraceae-evolution","plant-taxonomy","nih","artemisia-phylogeny","molecular-systematics"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2a46-v2zu","description":"Background\n Subtribe Artemisiinae of Tribe Anthemideae (Asteraceae) is composed of 18 largely Asian genera that include the sagebrushes and mugworts. The subtribe includes the large cosmopolitan, wind-pollinated genus Artemisia, as well as several smaller genera and Seriphidium, that altogether comprise the Artemisia-group. Circumscription and taxonomic boundaries of Artemisia and the placements of these small segregate genera is currently unresolved.\n \n \n Results\n We constructed a molecular phylogeny for the subtribe using the internal transcribed spacers (ITS) of nuclear ribosomal DNA analyzed with parsimony, likelihood, and Bayesian criteria. The resulting tree is comprised of three major clades that correspond to the radiate genera (e.g., Arctanthemum and Dendranthema), and two clades of Artemisia species. All three clades have allied and segregate genera embedded within each.\n \n \n Conclusions\n The data support a broad concept of Artemisia s.l. that includes Neopallasia, Crossostephium, Filifolium, Seriphidium, and Sphaeromeria. However, the phylogeny excludes Elachanthemum, Kaschgaria, and Stilnolepis from the Artemisia-group. Additionally, the monophyly of the four subgenera of Artemisia is also not supported, with the exception of subg. Dracunculus. Homogamous, discoid capitula appear to have arisen in parallel four to seven times, with the loss of ray florets. Thus capitular morphology is not a reliable taxonomic character, which traditionally has been one of the defining characters.","title":"Molecular phylogeny of Subtribe Artemisiinae (Asteraceae), including","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC130036/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2a7c-zfnq","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","references","chemistry","bioactivity","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2a7c-zfnq","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865644: MLS000042652","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865644","description":"Access the complete Substance 865644: MLS000042652 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2a7m-dvs2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","chemistry","science","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2a7m-dvs2","description":"Chemical compound data from PubChem database. IUPAC Name: benzyl tridecanoate. Molecular Formula: C20H32O2. Molecular Weight: 304.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529790: Benzyl tridecanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529790","description":"Access the complete Compound 529790: Benzyl tridecanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://opendata.maryland.gov/d/juj8-ujbh","issued":"2022-08-31","@type":"dcat:Dataset","modified":"2026-05-13","keyword":["cases","white","share","race","outbreak","open data","mdh","md imap","md","maryland department of health","maryland","hispanic","health","ethnicity","download","disease","department of health","2019","african american","asian","coronavirus","covid","covid-19","data"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data Administrator","hasEmail":"mailto:no-reply@opendata.maryland.gov"},"publisher":{"@type":"org:Organization","name":"State of Maryland"},"identifier":"https://opendata.maryland.gov/api/views/juj8-ujbh","description":"Regarding all Vaccination Data\nThe date of Last Update is 4/21/2023. Additionally on 4/27/2023 several COVID-19 datasets were retired and no longer included in public COVID-19 data dissemination.\n\nSee this link for more information\nhttps://imap.maryland.gov/pages/covid-data\n\nSummary\nThe cumulative number of COVID-19 vaccinations by race: American Indian or Alaska Native; Asian; Black or African American; White; Native Hawaiian or Other Pacific Islander; Other; Unknown\n\nDescription\nMD COVID-19 - Vaccinations by Race Distribution data layer is a collection of COVID-19 vaccinations that have been reported each day into ImmuNet.\n\n\nTerms of Use\nThe Spatial Data, and the information therein, (collectively the \"Data\") is provided \"as is\" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. \n\nThe Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.","title":"MD COVID-19 - Vaccinations by Race Distribution","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/juj8-ujbh/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/juj8-ujbh/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/juj8-ujbh/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health and Human Services"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/3cfg-ckag","bureauCode":["009:20"],"issued":"2025-07-03","@type":"dcat:Dataset","modified":"2025-07-23","keyword":["industry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIOSH Mining Program","hasEmail":"mailto:mining@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/3cfg-ckag","description":"Coal bursts (damaging seismic events in underground coal mines) pose a substantial threat to operations and mine workers. The underground coal mines in Colorado’s North Fork Valley (NFV) have experienced many coal bursts, often with distinct characteristics from those of other US coal mining regions. To better understand these events and manage their associated risks, the National Institute for Occupational Safety and Health undertook a long-term monitoring campaign at the Elk Creek Mine in the NFV. The monitoring efforts included a seismic network composed of both surface and underground sensors, borehole pressure cells (BPCs), instrumented support Cans, convergence monitors, ground condition surveys, and several other data sources. This dataset consists of the event waveform files from the seismic network for the 983,379 events that were detected during the monitoring campaign. The waveforms are stored in HDF5 files that are broken up by week. Within the HDF5 files, the data are organized by station id, event time, and channel. The amplitudes are velocity in meters/second.\n \nThis is download 9 of 48 and corresponds to the time range between January 3, 2011, and January 10, 2011.","title":"Elk Creek Seismic Waveforms 2011 (Part 1 of 19)","programCode":["009:034"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/download/3cfg-ckag/application/x-zip-compressed","mediaType":"application/x-zip-compressed"}],"license":"https://www.usa.gov/government-works","theme":["National Institute for Occupational Safety and Health"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["pharmaceuticals","fda","drug-safety","prescription-drugs","drug-information"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA212759","description":"Pirfenidone is a prescription oral tablet medication used to treat idiopathic pulmonary fibrosis. Available in strengths of 267 mg, 534 mg, and 801 mg, it belongs to the pyridone class of drugs. Manufactured by ANI Pharmaceuticals, Inc. and Laurus Labs Limited under ANDA212722. This information was generated using AI and is provided for informational and research purposes only.","title":"Pirfenidone","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212759","description":"\n Access the FDA dataset for Pirfenidone — ANDA 212759 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Pirfenidone"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/haed-k2ka","bureauCode":["009:00"],"issued":"2016-09-26","@type":"dcat:Dataset","modified":"2016-09-26","keyword":["cdc","centers for disease control and prevention"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/haed-k2ka","description":"Alcohol-Impaired Driving Fatalities 2005-2014; All persons killed in crashes involving a driver with BAC >= .08 g/dL. Occupant Fatalities 2005-2014; All occupants killed where body type = 1-79. Source: National Highway Traffic Safety Administration's (NHTSA) Fatality Analysis Reporting System (FARS), 2005-2013 Final Reports and 2014 Annual Report File","title":"Occupant and Alcohol-Impaired Driving Deaths in States, 2005-2014","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/haed-k2ka/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/haed-k2ka/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/haed-k2ka/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/haed-k2ka/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/haed-k2ka/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/haed-k2ka/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Motor Vehicle"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/dk4z-k3xb","issued":"2023-06-09","@type":"dcat:Dataset","modified":"2025-03-07","keyword":["pci","cardiac","cabg","valve","revascularization","quality-safety-costs","cardiac surgery","community health and chronic disease","consumer resources","coronary","coronary artery bypass graft"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/dk4z-k3xb","description":"This dataset contains the number of cases, number of in hospital/30 day deaths, observed, expected and risk-adjusted mortality rates for cardiac surgery by surgeon. Physician information is presented for each physician who a) performed 200 or more procedures during the three year analysis and/or b) performed at least one cardiac surgery in each of the three years. The results for physicians not meeting the above criteria are grouped together and reported as “All others” in the hospital in which the procedures are performed. The initial Health Data NY dataset includes patients discharged between January 1, 2008, and December 31, 2010. Analyses of risk-adjusted mortality rates and associated risk factors are provided for 2010 and for the three-year period from 2008 through 2010. Regions represent where the hospitals are located. Subsequent year reports data will be appended to this dataset.","title":"Cardiac Surgery by Surgeon: Beginning 2008","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/dk4z-k3xb/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/dk4z-k3xb/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/dk4z-k3xb/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2adg-8bpq","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","science","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2adg-8bpq","description":"Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-[2-(2-methylpropoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethanol. Molecular Formula: C14H30O6. Molecular Weight: 294.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526856: 2-(2-(2-(2-Isobutoxy-ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethanol","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526856","description":"Access the complete Compound 526856: 2-(2-(2-(2-Isobutoxy-ethoxy)-ethoxy)-ethoxy)-ethoxy)-ethanol on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/mtfm-rxf4","issued":"2017-07-14","@type":"dcat:Dataset","modified":"2025-04-01","keyword":["id removed","discharge","sparcs","quality-safety-costs","ip-d","inpatient","hospital"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/mtfm-rxf4","description":"The Statewide Planning and Research Cooperative System (SPARCS) Inpatient De-identified dataset contains discharge level detail on patient characteristics, diagnoses, treatments, services, charges, and costs. This data contains basic record level detail regarding the discharge; however the data does not contain protected health information (PHI) under Health Insurance Portability and Accountability Act (HIPAA). The health information is not individually identifiable; all data elements considered identifiable have been redacted. For example, the direct identifiers regarding a date have the day and month portion of the date removed.","title":"Hospital Inpatient Discharges (SPARCS De-Identified): 2010","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/mtfm-rxf4/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/mtfm-rxf4/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/mtfm-rxf4/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2agn-j7n4","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["reporting","metadata"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2agn-j7n4","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Appendix II: Website Addresses for State Engagement Reports for April-June","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/11713","description":"Access the complete Appendix II: Website Addresses for State Engagement Reports for April-June on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ahj-uk7b","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","science","research","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2ahj-uk7b","description":"Chemical compound data from PubChem database. IUPAC Name: 3-methyl-1-(2-methylpropylsulfanyl)butane. Molecular Formula: C9H20S. Molecular Weight: 160.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525396: 2,7-Dimethyl-4-thiaoctane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525396","description":"Access the complete Compound 525396: 2,7-Dimethyl-4-thiaoctane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ajw-4dfz","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","science","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2ajw-4dfz","description":"Chemical compound data from PubChem database. IUPAC Name: dodec-9-ynyl 3-methylbenzoate. Molecular Formula: C20H28O2. Molecular Weight: 300.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530476: m-Toluic acid, dodec-9-ynyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530476","description":"Access the complete Compound 530476: m-Toluic acid, dodec-9-ynyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["fda","health-care","drug","drug-information","public-health"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA202170","description":"Felodipine is a prescription medication available as extended-release oral tablets in 2.5 mg, 5 mg, and 10 mg strengths. It is a dihydropyridine calcium channel blocker used to treat high blood pressure by relaxing blood vessels. Manufactured by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. under ANDA201964. This information was generated using AI and is provided for informational and research purposes only.","title":"Felodipine","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202170","description":"\n Access the FDA dataset for Felodipine — ANDA 202170 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Felodipine"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2apk-rvku","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","references","chemistry","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2apk-rvku","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864563: MLS000041210","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864563","description":"Access the complete Substance 864563: MLS000041210 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2apq-7fwf","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","pubchem","research","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2apq-7fwf","description":"Chemical compound data from PubChem database. IUPAC Name: 7,13,17-trimethyltritriacontane. Molecular Formula: C36H74. Molecular Weight: 507.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527085: Tritriacontane, 7,13,17-trimethyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527085","description":"Access the complete Compound 527085: Tritriacontane, 7,13,17-trimethyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ari-exu5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2ari-exu5","description":"Chemical compound data from PubChem database. IUPAC Name: 1,4-dimethyltricyclo[5.2.1.02,6]deca-3,8-diene. Molecular Formula: C12H16. Molecular Weight: 160.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528766: Tricyclo[5.2.1.0(2.6)]deca-3,8-diene, 1,4-dimethyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528766","description":"Access the complete Compound 528766: Tricyclo[5.2.1.0(2.6)]deca-3,8-diene, 1,4-dimethyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/asf2-cwrt","issued":"2019-02-20","@type":"dcat:Dataset","modified":"2019-05-22","keyword":["school","lead","drinking water"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/asf2-cwrt","description":"Lead in Drinking Water in Schools Test Results – Mount Baker Junior High","title":"Mount Baker Junior High","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/asf2-cwrt/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://data.oregon.gov/d/abcp-kbtb","issued":"2024-06-14","@type":"dcat:Dataset","modified":"2026-03-13","contactPoint":{"@type":"vcard:Contact","fn":"Kim Witbeck","hasEmail":"mailto:no-reply@data.oregon.gov"},"publisher":{"@type":"org:Organization","name":"State of Oregon"},"identifier":"https://data.oregon.gov/api/views/abcp-kbtb","description":"The Oregon Health Plan's fee-for-service program does not cover treatment for current codes (with end dates of 12/31/2299) on this list. Codes with other end dates are provided for historical purposes only. For specific coverage information, call Provider Services at 800-336-6016.","title":"Group 6031: Conditions Not Covered","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/abcp-kbtb/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/abcp-kbtb/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/abcp-kbtb/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2awu-6zrm","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","patent","pubchem","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2awu-6zrm","description":"A pressure plate for a mine comprises a hydraulic circuit. The mine is triggered by complete depression of the pressure plate. The hydraulic circuit comprises a pressure chamber containing a fluid that is compressed by a force applied to the pressure plate. The fluid is evacuated from the pressure chamber in a controled manner through a depressurization unit in response to a sustained force greater than a predetermined threshold being applied to the pressure plate. A bistable member moves between a first position in which it prevents communication between the pressure chamber and the depressurization unit and a second position in which it establishes communication between the pressure chamber and the depressurization unit. The bistable member is initially in the first position when no force is exerted on the pressure plate. It remains in the first position so long as the pressure plate is subjected to an increasing or stable force. It switches to the second position when the pressure of the fluid decreases after it has increased due to a force of this kind. Thus, after increasing to a maximum value and then decreasing to a minimum value, any increase in the force results in depressurization of the fluid and complete depression of the pressure plate. This explodes the mine.","title":"Patent AT-E40007-T1: [Translated] PRESSURE PLATE FOR A MINE, PARTICULARLY FOR ANTI-TANK, AND MINE WITH SUCH A PLATE.","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E40007-T1","description":"Access the complete Patent AT-E40007-T1: [Translated] PRESSURE PLATE FOR A MINE, PARTICULARLY FOR ANTI-TANK, AND MINE WITH SUCH A PLATE. on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/index.html","bureauCode":["009:20"],"issued":"2021-05-13","@type":"dcat:Dataset","modified":"2026-04-02","keyword":["hepa","hepatitis b","hepb","hib","immunization","influenza","mmr","pcv","polio","rotavirus","vaccination","vaccination coverage","varicella","vaxviews","combined 7 series","dtap","child vaccination","hepatitis a"],"contactPoint":{"@type":"vcard:Contact","fn":"NCIRD","hasEmail":"mailto:VaxView@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/fhky-rtsk","description":"Vaccination Coverage among Young Children (0-35 Months)\n\n• National, regional, state, and selected local area vaccination coverage estimates for 2-year-old children by birth year and birth year cohorts from the National Immunization Survey-Child.\n\n• Additional information available at https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/index.html","title":"Vaccination Coverage among Young Children (0-35 Months)","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/fhky-rtsk/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/fhky-rtsk/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/fhky-rtsk/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Child Vaccinations"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2b54-7s4h","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","alcohol-abuse","substance-use-disorder","mental-health-utah","nsduh-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2b54-7s4h","description":"This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for Utah overall and for substate regions within Utah. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).","title":"Utah (UT)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/utah-ut-1","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2b65-khkb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","pubchem","patent","innovation","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2b65-khkb","description":"Set up methods, analysis methods and monitoring methods for capillary gel arrays are provided which rigorously determine the number of capillaries for which standards should be used and/or the capillaries in which standards should not be considered and/or for which performance is impaired. The invention includes methods for monitoring capillary gel array performance in which the capillary gel array performs, on a plurality of occasions, a size based separation on an unknown sample in one or more capillaries, a size based separation on a second standard in those one or more capillaries, and a size based separation on a standard in one or more other capillaries, comprising comparing the results of the sample to the results of the standards in which variation in a characteristic of the results from the capillaries provided with the standard are considered with time and variation of the characteristic outside a predetermined position to determine if one or more of the capillaries of the array are providing reduced performance. The invention provides rigour to the results obtained from capillary gel array analysis and prevents analysis being carried out on arrays which have developed problems or broken down.","title":"Patent AT-E399881-T1: [Translated] IMPROVEMENTS RELATED TO CAPILLARY GEL MATRIX ANALYSIS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399881-T1","description":"Access the complete Patent AT-E399881-T1: [Translated] IMPROVEMENTS RELATED TO CAPILLARY GEL MATRIX ANALYSIS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2b6z-76h4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","bioactivity","chemistry","substance","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2b6z-76h4","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864320: MLS000041922","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864320","description":"Access the complete Substance 864320: MLS000041922 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2b7f-x3wx","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["acf","service","social","child","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2b7f-x3wx","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Region 4 Logo","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/5207","description":"Access the complete Region 4 Logo on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"http://www.fda.gov/AboutFDA/Transparency/OpenGovernment/ucm225435.htm","bureauCode":["009:10"],"issued":"2021-02-25","@type":"dcat:Dataset","modified":"2010-10-01","keyword":["health","notifications","pet food","market","recalls","safety","community health"],"contactPoint":{"@type":"vcard:Contact","fn":"FDA Enterprise Data Inventory","hasEmail":"mailto:FDA_Enterprise_Data_Inventory@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"617db889-3907-4429-aa64-b4747156d437","description":"Contains data for FDA pet food recalls since January 1, 2006.","title":"FDA Pet Food Recalls","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://www.accessdata.fda.gov/scripts/newpetfoodrecalls/PetFoodRecallProductsList2009.xls","mediaType":"application/vnd.ms-excel"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2b7z-f7hr","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","research","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2b7z-f7hr","description":"Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2,3-bis(trimethylsilyloxy)butanoate. Molecular Formula: C13H32O4Si3. Molecular Weight: 336.65. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528652: 2-(4-Bromobutyl)-9,10-dihydrophenanthrene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528652","description":"Access the complete Compound 528652: 2-(4-Bromobutyl)-9,10-dihydrophenanthrene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2b8x-8kme","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","innovation","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2b8x-8kme","description":"N-arylsulfonyl-3-substituted indole compounds, derivatives, analogs, tautomeric forms, stereoisomers, geometric forms, N-oxides, polymorphs and pharmaceutically acceptable salts.","title":"Patent AT-E401307-T1: [Translated] N-ARYLSULFONYL-2-SUBSTITUTED INDOLES WITH AFFINITY FOR THE SEROTONIN RECEPTOR, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401307-T1","description":"Access the complete Patent AT-E401307-T1: [Translated] N-ARYLSULFONYL-2-SUBSTITUTED INDOLES WITH AFFINITY FOR THE SEROTONIN RECEPTOR, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/5dtw-tffi","issued":"2024-02-14","@type":"dcat:Dataset","modified":"2025-04-01","keyword":["2022","de-identified","discharges","inpatient","ip-d","sparcs"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/5dtw-tffi","description":"The Statewide Planning and Research Cooperative System (SPARCS) Inpatient De-identified File contains discharge level detail on patient characteristics, diagnoses, treatments, services, and charges. \n\nThis data file contains basic record level detail for the discharge. The de-identified data file does not contain data that is protected health information (PHI) under HIPAA. The health information is not individually identifiable; all data elements considered identifiable have been redacted. For example, the direct identifiers regarding a date have the day and month portion of the date removed.\n\nFor more information visit: https://www.health.ny.gov/statistics/sparcs/","title":"Hospital Inpatient Discharges (SPARCS De-Identified): 2022","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/5dtw-tffi/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/5dtw-tffi/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/5dtw-tffi/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2bab-vu2x","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","substance","pubchem","references","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2bab-vu2x","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865817: MLS000083799","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865817","description":"Access the complete Substance 865817: MLS000083799 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2bcx-569s","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["child","case","policy","reporting","scope"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2bcx-569s","description":"The Children's Bureau Division of State Systems and the Capacity Building Center for Tribes hosted a three-part webinar series on Tribal Child Welfare Data System Procurement.\n\nThis webinar series provides a detailed framework of best practices in planning for and procuring a new case management system. Participants hear directly from tribal staff about their process for selecting and implementing a data system. In addition, facilitators connect participants with resources, technical assistance, and peer supports.\n\nSession 1 - Planning for a New Data System\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Tribal Child Welfare Data System Procurement Webinar Series Part 1: Planning for a New Data System","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/tribal-cw-data-system-procurement-series-part-1","description":"Access the complete Tribal Child Welfare Data System Procurement Webinar Series Part 1: Planning for a New Data System on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2bef-egjr","bureauCode":["009:38"],"issued":"2026-06-30","temporal":"2019-01-01/2019-12-31","@type":"dcat:Dataset","modified":"2026-06-30","keyword":["2019"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Payments","hasEmail":"mailto:openpayments@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"openpaymentsdata.cms.gov"},"identifier":"6c8251d4-3839-444b-810b-5bf035a23326","description":"This dataset is pre-filtered based on the most frequent searches of Open Payments data.","title":"2019 payments grouped by reporting entities, covered recipient, and nature of payments","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.cms.gov/openpayments/SMRY_RPTS_P06302026_06032026/PBLCTN_SMRY_BY_AMGPO_BY_CR_BY_NTR_OF_PYMT_PGYR2019_P06302026_06032026.csv","mediaType":"text/csv","title":"2019 payments grouped by reporting entities, covered recipient, and nature of payments"}],"dataQuality":true,"license":"https://www.usa.gov/government-works","theme":["Summary"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2bgk-p9kx","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","innovation","patent","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2bgk-p9kx","description":"Fluorochemical polymers for use in providing stain-release properties to a substrate material are disclosed. The present invention provides for polymeric fluorochemical polymers that include perfluoroaliphatic, hydrophilic, cationogenic, and either N-hydroxyalkylacrylamide and/or diacrylate monomers.","title":"Patent AT-E399801-T1: [Translated] FLUORALKYL POLYMERS CONTAINING CATIONIC SEGMENTS AND COMPOSITION FOR PROVIDING DIRT RELEASE PROPERTIES TO A SUBSTRATE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399801-T1","description":"Access the complete Patent AT-E399801-T1: [Translated] FLUORALKYL POLYMERS CONTAINING CATIONIC SEGMENTS AND COMPOSITION FOR PROVIDING DIRT RELEASE PROPERTIES TO A SUBSTRATE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["health-care","medications","prescription-drugs","public-health","drug"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA207875","description":"Albuterol Sulfate is a prescription inhaler that delivers 90 micrograms of albuterol per puff to help relieve bronchospasm in conditions like asthma or COPD. It's a generic version manufactured by Padagis Israel Pharmaceuticals Ltd under ANDA203760. This information was generated using AI and is provided for informational and research purposes only.","title":"Albuterol sulfate","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207875","description":"\n Access the FDA dataset for Albuterol sulfate — ANDA 207875 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Albuterol sulfate"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","fda","pharmaceuticals","prescription-drugs","drug-information"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA078218","description":"Cyclobenzaprine Hydrochloride is a prescription muscle relaxant that helps relieve muscle spasms and pain. Available as oral tablets in 5mg, 7.5mg, and 10mg strengths, it's manufactured by Rising Pharma Holdings, Inc. under the brand FEXMID. This information was generated using AI and is provided for informational and research purposes only.","title":"Cyclobenzaprine hydrochloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078218","description":"\n Access the FDA dataset for Cyclobenzaprine hydrochloride — ANDA 078218 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Cyclobenzaprine hydrochloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2bsw-7shs","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2bsw-7shs","description":"Chemical compound data from PubChem database. IUPAC Name: 2-[2-(2-nonoxyethoxy)ethoxy]ethanol. Molecular Formula: C15H32O4. Molecular Weight: 276.41. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526727: Noneth-3","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526727","description":"Access the complete Compound 526727: Noneth-3 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2bur-m8ss","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","science","research","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2bur-m8ss","description":"Chemical compound data from PubChem database. IUPAC Name: 3-chloropentyl acetate. Molecular Formula: C7H13ClO2. Molecular Weight: 164.63. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527882: 1-Pentanol, 3-chloro, acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527882","description":"Access the complete Compound 527882: 1-Pentanol, 3-chloro, acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://opendata.maryland.gov/d/uifv-ymnf","issued":"2016-07-22","@type":"dcat:Dataset","modified":"2025-05-05","keyword":["chrc","community health resource commission","department of health and mental hygiene","dhmh","dynamic","grantees","grants","health","hlth","kml","maryland","md","md imap","vector","wfs","wms"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data Administrator","hasEmail":"mailto:no-reply@opendata.maryland.gov"},"publisher":{"@type":"org:Organization","name":"State of Maryland"},"identifier":"https://opendata.maryland.gov/api/views/uifv-ymnf","description":"This is a MD iMAP hosted service. Find more information at http://imap.maryland.gov. Behavioral Health Grantees - The Maryland Community Health Resources Commission works to expand access to health care services for low-income and under-served communities across the state.Feature Service Link:http://geodata.md.gov/imap/rest/services/Health/MD_CommunityHealthResourceCommission/FeatureServer/0 ADDITIONAL LICENSE TERMS: The Spatial Data and the information therein (collectively \"the Data\") is provided \"as is\" without warranty of any kind either expressed implied or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct indirect incidental consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.","title":"MD iMAP: Maryland Community Health Resource Commission - Behavioral Health Grantees","distribution":[{"@type":"dcat:Distribution","downloadURL":"http://data.imap.maryland.gov/datasets/77e746e0b4a145e5999f7844aa64fa05_0","mediaType":"text/html"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health and Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2byd-jks5","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["childr","service","social","acf","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2byd-jks5","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"sa_csbg_north_carolina_final_fy11","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/12881","description":"Access the complete sa_csbg_north_carolina_final_fy11.pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/7stm-45gi","issued":"2019-05-14","@type":"dcat:Dataset","modified":"2019-11-14","keyword":["school","drinking water","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/7stm-45gi","description":"Lead in Drinking Water in Schools Test Results – Crestwood Elementary","title":"Crestwood Elementary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/7stm-45gi/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2bzz-p6mq","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","chemistry","pubchem","bioactivity","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2bzz-p6mq","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865582: MLS000084086","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865582","description":"Access the complete Substance 865582: MLS000084086 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/jgk8-6dpn","bureauCode":["009:20"],"issued":"2023-02-24","@type":"dcat:Dataset","temporal":"2020-01-22/ 2023-05-10","modified":"2025-02-23","references":["https://data.cdc.gov/Public-Health-Surveillance/Weekly-COVID-19-County-Level-of-Community-Transmis/dt66-w6m6"],"keyword":["laboratory","cases","community transmission","coronavirus","county","covid-19"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC-INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/jgk8-6dpn","description":"Reporting of Aggregate Case and Death Count data was discontinued May 11, 2023, with the expiration of the COVID-19 public health emergency declaration. This dataset will receive a final update on June 1, 2023, to reconcile historical data through May 10, 2023, and will remain publicly available.\n\nThis archived public use dataset contains historical case and percent positivity data updated weekly for all available counties and jurisdictions. Each week, the dataset was refreshed to capture any historical updates. Please note, percent positivity data may be incomplete for the most recent time period.\n\nRelated data \nCDC provides the public with two active versions of COVID-19 county-level community transmission level data: this dataset with historical case and percent positivity data for each county from January 22, 2020 (Weekly Historical Changes dataset) and a dataset with the levels as originally posted (Weekly Originally Posted dataset) since October 20, 2022. Please navigate to the Weekly Originally Posted dataset for the Community Transmission Levels published weekly on Thursdays.\n\nMethods for calculating county level of community transmission indicator\nThe County Level of Community Transmission indicator uses two metrics: (1) total new COVID-19 cases per 100,000 persons in the last 7 days and (2) percentage of positive SARS-CoV-2 diagnostic nucleic acid amplification tests (NAAT) in the last 7 days. For each of these metrics, CDC classifies transmission values as low, moderate, substantial, or high (below and here). If the values for each of these two metrics differ (e.g., one indicates moderate and the other low), then the higher of the two should be used for decision-making. \n\nCDC core metrics of and thresholds for community transmission levels of SARS-CoV-2\nTotal New Case Rate Metric: \"New cases per 100,000 persons in the past 7 days\" is calculated by adding the number of new cases in the county (or other administrative level) in the last 7 days divided by the population in the county (or other administrative level) and multiplying by 100,000. \"New cases per 100,000 persons in the past 7 days\" is considered to have transmission level of Low (0-9.99); Moderate (10.00-49.99); Substantial (50.00-99.99); and High (greater than or equal to 100.00). \n\nTest Percent Positivity Metric: \"Percentage of positive NAAT in the past 7 days\" is calculated by dividing the number of positive tests in the county (or other administrative level) during the last 7 days by the total number of tests resulted over the last 7 days. \"Percentage of positive NAAT in the past 7 days\" is considered to have transmission level of Low (less than 5.00); Moderate (5.00-7.99); Substantial (8.00-9.99); and High (greater than or equal to 10.00). \n\n\nThe data in this dataset are considered provisional by CDC and are subject to change until the data are reconciled and verified with the state and territorial data providers. \n\nThis dataset is created using CDC’s Policy on Public Health Research and Nonresearch Data Management and Access.\n\n\nArchived data \nCDC has archived two prior versions of these datasets. Both versions contain the same 7 data elements reflecting community transmission levels for all available counties and jurisdictions; however, the datasets updated daily. The archived datasets can be found here: \n\nNote: Starting April 27, 2023 updates change from daily to weekly.\n\nSummary\nThe cumulative number of positive COVID-19 cases among Maryland residents.\n\nDescription\nThe MD COVID-19 - Total Cases Statewide data layer is a collection of the statewide positive COVID-19 test results that have been reported each day by each local health department via the ESSENCE system.\n\nTerms of Use\nThe Spatial Data, and the information therein, (collectively the \"Data\") is provided \"as is\" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.","title":"MD COVID-19 - Total Cases Statewide","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/t7ek-pn7n/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/t7ek-pn7n/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/t7ek-pn7n/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health and Human Services"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-safety","drug","drug-information","health-care","medications"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA209307","description":"Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride is a prescription injectable solution used for short-term sedation in intensive care settings. It works as an alpha-2 adrenergic agonist to provide calming effects during procedures or mechanical ventilation. Administered intravenously at 4 mcg/mL strength in 50 mL or 100 mL bottles, it's approved as a generic drug by Sagent Pharmaceuticals. This information was generated using AI and is provided for informational and research purposes only.","title":"Dexmedetomidine hydrochloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209307","description":"\n Access the FDA dataset for Dexmedetomidine hydrochloride — ANDA 209307 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Dexmedetomidine hydrochloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://data.oregon.gov/d/495m-gmu2","issued":"2024-12-27","@type":"dcat:Dataset","modified":"2026-03-26","contactPoint":{"@type":"vcard:Contact","fn":"Kim Witbeck","hasEmail":"mailto:no-reply@data.oregon.gov"},"publisher":{"@type":"org:Organization","name":"State of Oregon"},"identifier":"https://data.oregon.gov/api/views/495m-gmu2","description":"Effective Jan. 1, 2026. Copyright Notice: Current Dental Terminology © 2025 American Dental Association. All rights reserved. \n\nWhere applicable, please refer to Oregon Administrative Rules, Prioritized List placement and Guideline Notes listed for each code for complete information regarding benefit coverage and limitations.\n\nDental/Denturist Services Rules (Chapter 410, Division 123): https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=1711 \n\nEarly and Periodic Screening, Diagnostic and Treatment (EPSDT) Rules (Chapter 410, Division 151): https://secure.sos.state.or.us/oard/displayDivisionRules.action?selectedDivision=8155 \n\nPrioritized List and Guideline Notes: https://www.oregon.gov/oha/hpa/dsi-herc/Pages/index.aspx\n\nFor medical-surgical services, refer to the code groups at https://www.oregon.gov/oha/HSD/OHP/Pages/Policy-Medical-Surgical.aspx. \n\nTo find fee-for-service reimbursement rates, view the OHP Fee-for-Service Fee Schedule at http://www.oregon.gov/oha/hsd/ohp/pages/fee-schedule.aspx. This schedule represents a given point in time and may not include payable codes that were added to MMIS after the posted fee schedule date.","title":"Oregon Medicaid Dental Services","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/495m-gmu2/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/495m-gmu2/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/495m-gmu2/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2dwg-wv6g","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["instruction","child","social","reporting","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2dwg-wv6g","description":"This Program Instruction (PI) provides instruction on the June 30, 1998 submission of the Annual Progress and Services Report required for title IV-B of the Social Security Act (the Act) and the CFS-101, Annual Budget Request and Annual Summary of Child and Family Services.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-98-03)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-98-03","description":"Access the complete PI-98-03 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2dwt-rjkb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","research","pubchem","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2dwt-rjkb","description":"Chemical compound data from PubChem database. IUPAC Name: trimethyl-[2-[(4-trimethylsilyloxyphenyl)methyl]phenoxy]silane. Molecular Formula: C19H28O2Si2. Molecular Weight: 344.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526592: 2,4'-Bis(trimethylsilyloxy)diphenylmethane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526592","description":"Access the complete Compound 526592: 2,4'-Bis(trimethylsilyloxy)diphenylmethane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2dx6-u89x","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","pubchem","research","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2dx6-u89x","description":"Chemical compound data from PubChem database. IUPAC Name: 5-ethyldocosane. Molecular Formula: C24H50. Molecular Weight: 338.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528482: Docosane, 5-ethyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528482","description":"Access the complete Compound 528482: Docosane, 5-ethyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2e3c-crpp","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","mycobacterium-tuberculosis","macrophage-infection","serine-protease","mycosin-1"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2e3c-crpp","description":"Background\n Exported proteases are commonly associated with virulence in bacterial pathogens, yet there is a paucity of information regarding their role in Mycobacterium tuberculosis. There are five genes (mycP1-5) present within the genome of Mycobacterium tuberculosis H37Rv that encode a family of secreted, subtilisin-like serine proteases (the mycosins). The gene mycP1 (encoding mycosin-1) was found to be situated 3700 bp (four ORF's) from the RD1 deletion region in the genome of the attenuated vaccine strain M. bovis BCG (bacille de Calmette et Guérin) and was selected for further analyses due to the absence of expression in this organism.\n \n \n Results\n Full-length, 50 kDa mycosin-1 was observed in M. tuberculosis cellular lysates, whereas lower-molecular-weight species were detected in culture filtrates. A similar lower-molecular-weight species was also observed during growth in macrophages. Mycosin-1 was localized to the membrane and cell wall fractions in M. tuberculosis by Western blotting, and to the cell envelope by electron microscopy. Furthermore, M. tuberculosis culture filtrates were shown to contain a proteolytic activity inhibited by mixed serine/cysteine protease inhibitors and activated by Ca2+, features typical of the subtilisins.\n \n \n Conclusions\n Mycosin-1 is an extracellular protein that is membrane- and cell wall-associated, and is shed into the culture supernatant. The protein is expressed after infection of macrophages and is subjected to proteolytic processing. Although proteolytically active mycosin-1 could not be generated recombinantly, serine protease activity containing features typical of the subtilisins was detected in M. tuberculosis culture filtrates.","title":"Mycosin-1, a subtilisin-like serine protease of","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC131053/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2e73-rurk","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","research","pubchem","innovation","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2e73-rurk","description":"A carrier bush (15) fits on bearings in a drive casing (11) so as to rotate. A drive shaft (13) rotates on bearings in the carrier bush. A tool mount (16A,16B) holds processing tools. A vibration-stimulating device generates vibration overlay for the tool mount. An independent claim is also included for a tool with a drive device.","title":"Patent AT-E401492-T1: [Translated] DRIVE DEVICE FOR ROTATING OSCILLATIONAL TOOLS AND TOOL HEREOF","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401492-T1","description":"Access the complete Patent AT-E401492-T1: [Translated] DRIVE DEVICE FOR ROTATING OSCILLATIONAL TOOLS AND TOOL HEREOF on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/fnd5-jbg4","issued":"2018-12-31","@type":"dcat:Dataset","modified":"2019-11-14","keyword":["lead","drinking water","school"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/fnd5-jbg4","description":"Lead in Drinking Water in Schools Test Results – Foster High School","title":"Foster High School","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/fnd5-jbg4/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2e7h-8wbs","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","substance-abuse-treatment","treatment-admissions","teds-data","alcohol-drug-abuse"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2e7h-8wbs","description":"This report presents results from the Treatment Episode Data Set (TEDS) for 2002 and trend data for 1992-2002. The report provides information on the demographic and substance abuse characteristics of the 1.9 million people admitted to treatment for abuse of alcohol and drugs in 2002 to facilities that report to individual state administrative data systems.","title":"Treatment Episode Data Set (TEDS) 1992-2002 National Admissions to Substance Abuse Treatment Services","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/treatment-episode-data-set-teds-1992-2002-national-ad","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2e82-va75","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","substance","pubchem","references","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2e82-va75","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864923: MLS000042395","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864923","description":"Access the complete Substance 864923: MLS000042395 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2e9i-34ad","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","science","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2e9i-34ad","description":"Chemical compound data from PubChem database. IUPAC Name: N'-(4-ethoxyphenyl)-N-(4-methoxyphenyl)methanimidamide. Molecular Formula: C16H18N2O2. Molecular Weight: 270.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525801: N-(4-Methoxyphenyl)-N'-(4-ethoxyphenyl)formamidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525801","description":"Access the complete Compound 525801: N-(4-Methoxyphenyl)-N'-(4-ethoxyphenyl)formamidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ean-zawd","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2ean-zawd","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864901: MLS000042506","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864901","description":"Access the complete Substance 864901: MLS000042506 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2efk-p3p9","bureauCode":["009:00"],"issued":"2016-03-16","@type":"dcat:Dataset","modified":"2017-08-03","keyword":["quality measures","core sets","performance rates"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:no-reply@data.medicaid.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"2b6a0ec0-efe6-5aec-9fe4-e168b8b6f553","description":"Performance rates on frequently reported health care quality measures in the CMS Medicaid/CHIP Child and Adult Core Sets, for FFY 2014 reporting. Dataset contains both child and adult measures. Source: Mathematica analysis of FFY 2014 Child and Adult CARTS reports as of May 8, 2015, as published in the 2015 Secretary's Reports on the Quality of Care in Medicaid/CHIP.","title":"2014 Child and Adult Health Care Quality Measures","programCode":["009:076"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/2014-child-and-adult-health-care-quality-measures.7ycc-v6ew.csv","mediaType":"text/csv","title":"CSV"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Quality"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2egc-htid","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["reporting","prevention","abuse","foster","grant"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2egc-htid","description":"This Program Instruction (PI) provides instruction to States on the June 30, 2010, submission of the Annual Progress and Services Report (APSR) required under Title IV-B of the Social Security Act (the Act) for the Stephanie Tubbs Jones Child Welfare Services (CWS) and Promoting Safe and Stable Families (PSSF) Programs, the Child Abuse Prevention and Treatment Act (CAPTA) State Grant Program; and the Chafee Foster Care Independence Program (CFCIP) and the Education and Training Vouchers (ETV) Program; and the CFS-101, Part I, Annual Budget Request, Part II, Annual Summary of Child and Family Services, and Part III, Annual Expenditure Report—Title IV-B, subparts 1 and 2, CFCIP, and ETV.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-10-09)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-10-09","description":"Access the complete PI-10-09 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2egd-jdt9","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","community-mental-health","samhsa","national-outcome-measures","evidence-based-practices"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2egd-jdt9","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for New Jersey for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2013 CMHS Uniform Reporting System (URS) Table for New Jersey","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2013-cmhs-uniform-reporting-system-urs-table-new-jersey","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2egz-vj7u","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substitution-matrices","nucleotide-turnover","nih","dna-mutation","dna-composition"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2egz-vj7u","description":"Background\n Any DNA sequence is a result of compromise between the selection and mutation pressures exerted on it during evolution. It is difficult to estimate the relative influence of each of these pressures on the rate of accumulation of substitutions. However, it is important to discriminate between the effect of mutations, and the effect of selection, when studying the phylogenic relations between taxa.\n \n \n Results\n We have tested in computer simulations, and analytically, the available substitution matrices for many genomes, and we have found that DNA strands in equilibrium under mutational pressure have unique feature: the fraction of each type of nucleotide is linearly dependent on the time needed for substitution of half of nucleotides of a given type, with a correlation coefficient close to 1. Substitution matrices found for sequences under selection pressure do not have this property. A substitution matrix for the leading strand of the Borrelia burgdorferi genome, having reached equilibrium in computer simulation, gives a DNA sequence with nucleotide composition and asymmetry corresponding precisely to the third positions in codons of protein coding genes located on the leading strand.\n \n \n Conclusions\n Parameters of mutational pressure allow us to count DNA composition in equilibrium with this mutational pressure. Comparing any real DNA sequence with the sequence in equilibrium it is possible to estimate the distance between these sequences, which could be used as a measure of the selection pressure. Furthermore, the parameters of the mutational pressure enable direct estimation of the relative mutation rates in any DNA sequence in the studied genome.","title":"High correlation between the turnover of nucleotides under mutational pressure and the DNA composition","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64649/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nchs/nvss/index.htm","bureauCode":["009:20"],"issued":"2016-10-20","@type":"dcat:Dataset","modified":"2025-04-21","keyword":["nchs","mortality","injury","united states"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/nt65-c7a7","description":"This dataset describes injury mortality in the United States beginning in 1999. Two concepts are included in the circumstances of an injury death: intent of injury and mechanism of injury. Intent of injury describes whether the injury was inflicted purposefully (intentional injury) and, if purposeful, whether the injury was self-inflicted (suicide or self-harm) or inflicted by another person (homicide). Injuries that were not purposefully inflicted are considered unintentional (accidental) injuries. Mechanism of injury describes the source of the energy transfer that resulted in physical or physiological harm to the body. Examples of mechanisms of injury include falls, motor vehicle traffic crashes, burns, poisonings, and drownings (1,2). \r\n\r\nData are based on information from all resident death certificates filed in the 50 states and the District of Columbia. Age-adjusted death rates (per 100,000 standard population) are based on the 2000 U.S. standard population. Populations used for computing death rates for 2011–2015 are postcensal estimates based on the 2010 census, estimated as of July 1, 2010. Rates for census years are based on populations enumerated in the corresponding censuses. Rates for non-census years before 2010 are revised using updated intercensal population estimates and may differ from rates previously published.\r\n\r\nCauses of injury death are classified by the International Classification of Diseases, Tenth Revision (ICD–10). Categories of injury intent and injury mechanism generally follow the categories in the external-cause-of-injury mortality matrix (1,2). Cause-of-death statistics are based on the underlying cause of death.\r\n\r\nSOURCES\r\n\r\nCDC/NCHS, National Vital Statistics System, mortality data (see http://www.cdc.gov/nchs/deaths.htm); and CDC WONDER (see http://wonder.cdc.gov).\r\n\r\nREFERENCES \r\n\r\n1. National Center for Health Statistics. ICD–10: External cause of injury mortality matrix.\r\n\r\n2. National Center for Health Statistics. Vital statistics data available. Mortality multiple cause files. Hyattsville, MD: National Center for Health Statistics. Available from: https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm.\r\n\r\n3. Murphy SL, Xu JQ, Kochanek KD, Curtin SC, and Arias E. Deaths: Final data for 2015. National vital statistics reports; vol 66. no. 6. Hyattsville, MD: National Center for Health Statistics. 2017. Available from: https://www.cdc.gov/nchs/data/nvsr/nvsr66/nvsr66_06.pdf.\r\n\r\n4. Miniño AM, Anderson RN, Fingerhut LA, Boudreault MA, Warner M. Deaths: Injuries, 2002. National vital statistics reports; vol 54 no 10. Hyattsville, MD: National Center for Health Statistics. 2006.","title":"NCHS - Injury Mortality: United States","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nt65-c7a7/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nt65-c7a7/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nt65-c7a7/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"United States","license":"https://www.usa.gov/government-works","theme":["National Center for Health Statistics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2epv-dbpf","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","substance","references","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2epv-dbpf","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864480: MLS000082315","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864480","description":"Access the complete Substance 864480: MLS000082315 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["public-health","drug","prescription-drugs","medications","drug-information"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA021687","description":"Simvastatin is a prescription medication used to lower cholesterol levels in the blood, reducing the risk of heart disease and stroke. It works by inhibiting an enzyme that produces cholesterol. Available as oral tablets in strengths of 5mg, 10mg, 20mg, 40mg, and 80mg, it's manufactured by Accord Healthcare under application ANDA078155. This information was generated using AI and is provided for informational and research purposes only.","title":"Simvastatin","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021687","description":"\n Access the FDA dataset for Simvastatin — ANDA 021687 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Simvastatin"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["prescription-drugs","drug-information","medications","fda","drug"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA212097","description":"GVOKE is a glucagon injection used to treat severe low blood sugar (hypoglycemia) in people with diabetes. It comes in auto-injectors, pre-filled syringes, and kits for subcutaneous or intravenous use. Glucagon works by raising blood sugar levels quickly. This information was generated using AI and is provided for informational and research purposes only.","title":"Glucagon injection, solution","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212097","description":"\n Access the FDA dataset for Glucagon injection, solution — ANDA 212097 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Glucagon injection, solution"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ev9-4k7a","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","compound","research","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2ev9-4k7a","description":"Chemical compound data from PubChem database. IUPAC Name: 9-chlorononyl acetate. Molecular Formula: C11H21ClO2. Molecular Weight: 220.73. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527932: 9-Chlorononyl acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527932","description":"Access the complete Compound 527932: 9-Chlorononyl acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/xfn3-aupk","issued":"2018-03-29","@type":"dcat:Dataset","modified":"2018-03-29","keyword":["lead","school","drinking water"],"contactPoint":{"@type":"vcard:Contact","fn":"Elizabeth Kimball","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/xfn3-aupk","description":"Lead in Drinking Water in Schools Sampling Results - Toledo Middle School","title":"Toledo Middle","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/xfn3-aupk/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2exp-x3nz","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["reporting","policy","foster","child","assessment"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2exp-x3nz","description":"This report describes the results of the primary review of Maryland's Title IV-E foster care program.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Maryland Primary Title IV-E Foster Care Eligibility Review (2024)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/maryland-primary-title-iv-e-foster-care-eligibility-review-2024","description":"Access the complete Maryland Primary Title IV-E Foster Care Eligibility Review (2024) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/bdg5-g3nq","issued":"2018-12-31","@type":"dcat:Dataset","modified":"2018-12-31","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/bdg5-g3nq","description":"Lead in Drinking Water in Schools Test Results – Kessler Elementary","title":"Kessler Elementary Update","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/bdg5-g3nq/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2eyn-7byz","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["alcohol-drug-abuse","samhsa","substance-abuse-treatment","treatment-episodes","teds-admissions"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2eyn-7byz","description":"This report uses data from the Treatment Episode Data Set (TEDS) to examine treatment admission data in 2012, and trend data from 2002 to 2012, nationally, regionally (by the nine Census divisions), and by state or jurisdiction. The report provides information on the demographic and substance abuse characteristics of admissions to treatment aged 12 and older for abuse of alcohol and/or drugs in facilities that report to individual state administrative data systems.","title":"Treatment Episode Data Set (TEDS): 2002-2012, State Admissions to Substance Abuse Treatment Services","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2002-2012-teds-state-admissions","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2f2e-ju6z","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["national-outcome-measures","samhsa","mental-health-services","georgia-mental-health","substance-abuse-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2f2e-ju6z","description":"This is the 2021 Uniform Reporting System (URS) Output Tables for Georgia. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2021 Uniform Reporting System (URS) Table For Georgia","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2021-uniform-reporting-system-urs-table-georgia","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nchs/covid19/covid-19-mortality-data-files.htm","bureauCode":["009:20"],"issued":"2021-05-19","@type":"dcat:Dataset","modified":"2025-04-21","keyword":["nchs","age","age group","all causes","coronavirus","covid-19","deaths","mortality","nvss","provisional","state","united states","weekly"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/ikd3-vynf","description":"Deaths involving coronavirus disease 2019 (COVID-19) reported to NCHS by jurisdiction of occurrence, week, and age group.","title":"AH Provisional COVID-19 Deaths by Week and Age","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/ikd3-vynf/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/ikd3-vynf/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/ikd3-vynf/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"United States","license":"https://www.usa.gov/government-works","accrualPeriodicity":"irregular","theme":["National Center for Health Statistics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2f4z-4kzy","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","science","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2f4z-4kzy","description":"Chemical compound data from PubChem database. IUPAC Name: [3-(acetyloxymethyl)-5-(bromomethyl)cyclohexyl]methyl acetate. Molecular Formula: C13H21BrO4. Molecular Weight: 321.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530263: 4-(tert-Butylsulfonyl)phenyl(dimethyl)amine oxide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530263","description":"Access the complete Compound 530263: 4-(tert-Butylsulfonyl)phenyl(dimethyl)amine oxide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2f5v-mmwv","bureauCode":["009:38"],"issued":"2016-08-22","@type":"dcat:Dataset","modified":"2026-06-16","keyword":["healthcare","ecp"],"contactPoint":{"@type":"vcard:Contact","fn":"CMS","hasEmail":"mailto:EssentialCommunityProviders@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"6z38-ihx4","description":"ECP Autofill data. Rolling draft list provider map data included.","title":"Auto-population File","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://data.healthcare.gov/sites/default/files/uploaded_resources/ECP-LIST-AUTOPOP-20260612.csv","description":"ECP-LIST-AUTOPOP-20260612.csv","@type":"dcat:Distribution","title":"Auto-population File"}],"license":"https://www.usa.gov/government-works","accrualPeriodicity":"R/P10Y","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2f8b-phje","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2f8b-phje","description":"Chemical compound data from PubChem database. IUPAC Name: 1,5-dimethyl-4-propan-2-ylnaphthalene. Molecular Formula: C15H18. Molecular Weight: 198.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526688: 1,7-Dimethyl-4-isopropyl-naphthalene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526688","description":"Access the complete Compound 526688: 1,7-Dimethyl-4-isopropyl-naphthalene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2f8c-2tib","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2f8c-2tib","description":"Chemical compound data from PubChem database. IUPAC Name: 2-butyloct-2-enoic acid. Molecular Formula: C12H22O2. Molecular Weight: 198.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528752: 2-Butyloct-2-enoic acid","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528752","description":"Access the complete Compound 528752: 2-Butyloct-2-enoic acid on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2f8h-4mz8","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-abuse-treatment","mental-health-services","national-outcome-measures","missouri-mental-health","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2f8h-4mz8","description":"These are the 2019 Uniform Reporting System (URS) Output Tables for Missouri. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2019 Uniform Reporting System (URS) Table for Missouri","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2019-uniform-reporting-system-urs-table-missouri","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2f9h-y4jf","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["tissue-perfusion","nih","gut-oxygenation","cytopathic-hypoxia","sepsis-shock"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2f9h-y4jf","description":"Part of Stephan Jakob's exhaustive review paper in the present issue of Critical Care deals with the notion that intestinal cellular energetics are deranged in sepsis, in terms not only of inadequate tissue perfusion but also of impaired mitochondrial respiration and/or coupling (i.e. organ dysfunction in sepsis may occur as a result of 'cytopathic hypoxia'). This suggests that efforts to improve outcome in septic patients by manipulating systemic oxygen delivery and regional blood flow are doomed to failure. That suggestion remains largely speculative, and experimental and clinical results presented here consistently demonstrate that there is still a place for treatment of abnormal perfusion in the context of early severe sepsis and septic shock.","title":"Gut oxygenation in sepsis: Still a matter of controversy?","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137303/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/v2k9-ctv4","bureauCode":["009:20"],"issued":"2020-04-10","@type":"dcat:Dataset","modified":"2020-04-10","keyword":["division of parasitic diseases and malaria","artesunate","malaria"],"contactPoint":{"@type":"vcard:Contact","fn":"Francisca Abanyie, MD, MPH","hasEmail":"mailto:why6@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/v2k9-ctv4","description":"This dataset includes deidentified data on patients receiving artesunate through the National Artesunate for Severe Malaria Program from April- December 2019. \n\nThis dataset contains microscopy data only.\nPlease see the links below for the other datasets and the attached document 'Guide to NASMP Datasets:\nData from Case Report Form- https://data.cdc.gov/Global-Health/National-Artesunate-for-Severe-Malaria-Program-Cas/igaz-icki\nData on Artesunate Dosing- https://data.cdc.gov/dataset/National-Artesunate-for-Severe-Malaria-Program-Art/qan4-gt4k\nData on Follow-On Dosing- https://data.cdc.gov/Global-Health/National-Artesunate-for-Severe-Malaria-Program-Fol/g3k9-gyw7\n\nAll data can be easily linked using the ParticipantID field, a unique ID number assigned to each participant.","title":"National Artesunate for Severe Malaria Program Microscopy Data- April to December 2019","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/v2k9-ctv4/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/v2k9-ctv4/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/v2k9-ctv4/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Global Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fa8-fpw6","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","florida-mental-health","samhsa","block-grant-data","noms-measures"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2fa8-fpw6","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2010 CMHS Uniform Reporting System (URS) Output Tables for Florida","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2010-cmhs-uniform-reporting-system-urs-output-tables-florida","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fab-r5gs","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["lipid-peroxidation","reperfusion-injury","peg-sod","hepatic-ischemia","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2fab-r5gs","description":"Background:\n Hepatic injury after ischemia/reperfusion is attributed to the\n\t\t\t\tdevelopment of oxygen free radical (OFR)-mediated lipid peroxidation - a\n\t\t\t\tprocess that can be measured through its byproducts, specifically\n\t\t\t\tmalondialdehyde. The use of free radical scavengers can offer significant\n\t\t\t\tprotection against OFR-induced liver injury. We hypothesize that a new potent\n\t\t\t\tOFR scavenger, polyethylene glycol-superoxide dismutase (PEG-SOD), can inhibit\n\t\t\t\tOFR-mediated lipid peroxidation in hepatic ischemia/reperfusion injury.\n \n \n Methods:\n Twelve male Sprague-Dawley rats (300-350 g) were subjected to\n\t\t\t\tocclusion of the left and middle hepatic arteries and portal veins for 90 min,\n\t\t\t\tfollowed by 120 min reperfusion. PEG-SOD (5000 units/kg) was given intravenously\n\t\t\t\tbefore vascular occlusion and again immediately upon reperfusion to six rats.\n\t\t\t\tNormal saline was given to the remaining six rats to be used as a control\n\t\t\t\tgroup. The right hepatic lobe (used as internal control) and left hepatic lobe\n\t\t\t\twere harvested separately and tissue malondialdehyde was measured.\n \n \n Results:\n A marked increase in lipid peroxide was found in the normal saline\n\t\t\t\tgroup after 2 h reperfusion. Treatment with PEG-SOD prevented the rise in tissue\n\t\t\t\tmalondialdehyde. The mean difference in the malondialdehyde between the left\n\t\t\t\tand right hepatic lobes were 13.20 ± 6.35 and 1.70 ± 3.65 nmol/g in the\n\t\t\t\tnormal saline (control) and PEG-SOD groups, respectively. This difference was\n\t\t\t\tfound to be statistically significant (P < 0.005) using\n\t\t\t\tStudent's t-test.\n \n \n Conclusions:\n PEG-SOD can effectively attenuate hepatic ischemia/reperfusion\n\t\t\t\tinjury by inhibiting OFR-mediated lipid peroxidation.","title":"Polyethylene glycol-superoxide dismutase inhibits lipid peroxidation\n\t\t in hepatic ischemia/reperfusion injury","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC29026/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2feh-qqv7","bureauCode":["009:10"],"issued":"2021-02-25","@type":"dcat:Dataset","modified":"2014-09-12","keyword":["web modules"],"contactPoint":{"@type":"vcard:Contact","fn":"FDA Enterprise Data Inventory","hasEmail":"mailto:FDA_Enterprise_Data_Inventory@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"8DFE05EA-9FA0-4DB8-B803-D3AA70564592","description":"This system shares public data that can be downloaded.","title":"CFSAN Web Modules","programCode":["009:001"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://www.accessdata.fda.gov/scripts/fdcc/","mediaType":"text/html","description":"This system shares public data that can be downloaded. "}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ffa-awrs","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["reporting","policy","intervention","sery","time"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2ffa-awrs","description":"This panel shares lessons learned through the Permanency Innovations Initiative (PII) on dissemination; data mining and building evaluation capacity; and defining core functions and developing fidelity measures for child welfare interventions.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"The PII Approach: Early strategies for Building and Evaluating Interventions, and Dissemination","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/pii-approach-early-strategies-building-and-evaluating-interventions-and-dissemination","description":"Access the complete The PII Approach: Early strategies for Building and Evaluating Interventions, and Dissemination on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fg5-kuxz","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2fg5-kuxz","description":"Chemical compound data from PubChem database. IUPAC Name: N,3-bis(trimethylsilyl)-5-(trimethylsilylamino)imidazole-4-carboxamide. Molecular Formula: C13H30N4OSi3. Molecular Weight: 342.66. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530103: 4-Aminoimidazole-5-carboxamide, TMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530103","description":"Access the complete Compound 530103: 4-Aminoimidazole-5-carboxamide, TMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fi5-dx7u","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["child","acf","social","service","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2fi5-dx7u","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"2010alaska","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/11658","description":"Access the complete 2010alaska.pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fia-7w82","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","innovation","patent","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2fia-7w82","description":"The invention relates to a device of the type adapted to deliver fluids, notably medicaments, under pressure. The device comprises a container 1 of variable volume in the form or shape of a pouch or flexible receptacle of generally cylindrical shape with longitudinal pleats 2 containing the fluid under pressure to be delivered and equipped with an actuator C permitting to open a valve 15 a , 15 b to enable the delivery of said fluid, the whole being located inside a container 4 capable of resisting to an elevated internal pressure, the internal volume of the latter container comprised between its wall and the container of variable volume being filled with a neutral gas under a pressure sufficient to exert on the container of variable volume a pneumatic constraint sufficient to permit the delivery of the therein contained fluid when the above-said valve permitting said delivery is operated by the aforementioned actuator C.","title":"Patent AT-E401259-T1: [Translated] DEVICE FOR DISPENSING FLUIDS, PARTICULARLY MEDICINAL FLUIDS UNDER PRESSURE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401259-T1","description":"Access the complete Patent AT-E401259-T1: [Translated] DEVICE FOR DISPENSING FLUIDS, PARTICULARLY MEDICINAL FLUIDS UNDER PRESSURE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fid-gewk","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["child","acf","social","service","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2fid-gewk","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"OCS Logo","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/5218","description":"Access the complete OCS Logo on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fjk-rwm2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2fjk-rwm2","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 13-[tert-butyl(dimethyl)silyl]oxyicosanoate. Molecular Formula: C27H56O3Si. Molecular Weight: 456.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526835: 13-Hydroxy-arachidic, methyl ester, tBDMS ether","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526835","description":"Access the complete Compound 526835: 13-Hydroxy-arachidic, methyl ester, tBDMS ether on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fnc-wtyz","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-data","mental-health","major-depression","depression-prevalence","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2fnc-wtyz","description":"Table 26. Major Depressive Episode in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2013 and 2014 NSDUHs","title":"Table 26. Major Depressive Episode in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2013 and 2014 NSDUHs","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/table-26-major-depressive-episode-past-year-age-group-and-state-percentages-annual-averages","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/ji68-79i6","issued":"2018-12-07","@type":"dcat:Dataset","modified":"2018-12-07","keyword":["drinking water","school","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/ji68-79i6","description":"Lead in Drinking Water in Schools Test Results – Olympic View Elementary Lacey","title":"Olympic View Elementary Lacey Update","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/ji68-79i6/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fp6-fegn","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["alabama-behavioral-health","adult-mental-health","substance-use-treatment","youth-substance-use","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2fp6-fegn","description":"This is a behavioral health report for the state of Alabama. It uses the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2008 to 2012.","title":"Behavioral Health Barometer: Alabama, 2013","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-alabama-2013","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fsj-j6dj","bureauCode":["009:38"],"issued":"2026-06-30","temporal":"2024-01-01/2024-12-31","@type":"dcat:Dataset","modified":"2026-06-30","keyword":["2024"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Payments","hasEmail":"mailto:openpayments@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"openpaymentsdata.cms.gov"},"identifier":"e6b17c6a-2534-4207-a4a1-6746a14911ff","description":"All general (non-research, non-ownership related) payments from the 2024 program year [January 1 – December 31, 2024]NOTE: This is a very large file and, depending on your network characteristics and software, may take a long time to download or fail to download. Additionally, the number of rows in the file may be larger than the maximum rows your version of Microsoft Excel supports. If you can't download the file, we recommend engaging your IT support staff. If you are able to download the file but are unable to open it in MS Excel or get a message that the data has been truncated, we recommend trying alternative programs such as MS Access, Universal Viewer, Editpad or any other software your organization has available for large datasets.
","title":"2024 General Payment Data","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.cms.gov/openpayments/PGYR2024_P06302026_06032026/OP_DTL_GNRL_PGYR2024_P06302026_06032026.csv","mediaType":"text/csv","title":"General Payment Data – Detailed Dataset 2024 Reporting Year"}],"dataQuality":true,"license":"https://www.usa.gov/government-works","theme":["General Payments"]},{"accessLevel":"restricted public","landingPage":"https://www.cdc.gov/nchs/nsrcf/index.htm","bureauCode":["009:20"],"rights":"This dataset is restricted to authorized researchers due to indirect identifying sensitive information. Researchers must apply for data access through a proposal process, take confidentiality and sign a data use agreement. If approved, data access would occur at a NCHS or Federal Statistical Research Data Center. For more information about submitting a proposal for data access, please see: https://www.cdc.gov/rdc/application-process/submission.html","issued":"2023-07-03","@type":"dcat:Dataset","temporal":"2010-03/2010-10","modified":"2025-04-21","references":["https://www.cdc.gov/nchs/data/nsrcf/2010NSRCF_SurveyMethodologyandDocumentation.pdf"],"keyword":["sdoh-use-of-health-care","sdoh-source-of-health-care","sdoh-access-to-health-care","residential care facility staff","residential care facility residents","long-term care","research-data-center","residential care facilities","sdoh-transportation","assisted living facilities"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/6k6h-dzju","description":"The 2010 National Survey of Residential Care Facilities (NSRCF) is a first-ever national probability sample survey that collects data on U.S. residential care providers, their staffs and services, and the people they serve. It is designed to provide national estimates of the number of residential care facilities operating in the United States, the number of residents receiving care, and the characteristics of both the facilities and their residents. NSRCF was conducted between March and November 2010. All residential care facilities that participated in the survey were places that were licensed, registered, listed, certified, or otherwise regulated by the state and that had 4 or more licensed, certified, or registered beds, provided room and board with at least two meals a day, around-the-clock on-site supervision, and help with personal care such as bathing and dressing or health related services such as medication management. These facilities served a predominantly adult population and had at least one current resident. Facilities licensed to serve the mentally ill or the developmentally disabled populations exclusively were excluded from the survey.","title":"National Survey of Residential Care Facilities - Restricted Facility-Level Dataset","isPartOf":"https://www.cdc.gov/nchs/nsrcf/nsrcf_questionnaires.htm","describedByType":"application/pdf","programCode":["009:020"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.cdc.gov/rdc/application-process/submission.html","description":"The 2010 NSRCF data were collected through in-person interviews with facility directors and their \ndesignated staffs; no interviews were conducted directly with residents. Facility data included\nquestions on facility characteristics such as ownership, size, types of living arrangements and \namenities, policies, staffing, services, and general resident characteristics. Data collected on \nresidents included questions on the sampled residents’ demographics, living arrangements, \nactivities, health conditions, cognitive and physical functioning, and services received. The total \nnumber of facilities that participated in the 2010 NSRCF is 2,302, and data are available on 8,094\nresidents from these facilities.","@type":"dcat:Distribution","title":"National Survey of Residential Care Facilities - Restricted Facility-Level Dataset"}],"spatial":"United States","describedBy":"https://www.cdc.gov/nchs/data/nsrcf/2010NSRCF_SurveyMethodologyandDocumentation.pdf","license":"http://opendefinition.org/licenses/odc-odbl/","theme":["National Center for Health Statistics"],"language":["en-US"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fv3-hvim","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","pubchem","chemistry","innovation","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2fv3-hvim","description":"A purifying agent for purifying soil or ground water which comprises a water suspension containing iron composite particles comprising ±-Fe and magnetite, and having an average particle diameter of 0.05 to 0.50 µm, an S content of 3500 to 10000 ppm and an A1 content of 0.10 to 1.50% by weight, and polyaspartic acid or a salt thereof. The purifying agent is capable of decomposing aliphatic organohalogen compounds or aromatic organohalogen compounds contained in the soil or ground water in an efficient, continuous and economical manner.","title":"Patent AT-E400530-T1: [Translated] CLEANING PRODUCT FOR CLEANING SOIL OR GROUNDWATER, PROCESS OF PRODUCTION THEREOF, AND PROCESS FOR CLEANING CONTAMINATED SOIL OR GROUNDWATER USING THIS CLEANING PRODUCT","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400530-T1","description":"Access the complete Patent AT-E400530-T1: [Translated] CLEANING PRODUCT FOR CLEANING SOIL OR GROUNDWATER, PROCESS OF PRODUCTION THEREOF, AND PROCESS FOR CLEANING CONTAMINATED SOIL OR GROUNDWATER USING THIS CLEANING PRODUCT on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fxh-vnms","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","research","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2fxh-vnms","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 4-tert-butylcyclohexane-1-carboxylate. Molecular Formula: C12H22O2. Molecular Weight: 198.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530305: Methyl 4-tert-butylcyclohexane-1-carboxylate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530305","description":"Access the complete Compound 530305: Methyl 4-tert-butylcyclohexane-1-carboxylate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2fzj-tkse","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["social","acf","child","childr","service"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2fzj-tkse","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"ACF TAC Charter","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14310","description":"Access the complete ACF TAC Charter on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://gis.dhcs.ca.gov/datasets/CADHCS::chart-1-2-cumulative-number-of-members-who-received-ecm-since-ecm-launch","issued":"2024-01-24","temporal":"Other","@type":"dcat:Dataset","modified":"2026-06-26","keyword":["cs","community supports","ecm","enhanced care management"],"contactPoint":{"@type":"vcard:Contact","fn":"DHCS","hasEmail":"mailto:gis@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"f924afd4-b772-483b-9758-0af65d716d74","description":"ECM Community Support Services tables for a Quarterly Implementation Report. Including the County and Plan Details for both ECM and Community Support.
This Medi-Cal Enhanced Care Management (ECM) and Community Supports Calendar Year Quarterly Implementation Report provides a comprehensive overview of ECM and Community Supports implementation in the programs' first year. It includes data at the state, county, and plan levels on total members served, utilization, and provider networks.
ECM is a statewide MCP benefit that provides person-centered, community-based care management to the highest need members. The Department of Health Care Services (DHCS) and its MCP partners began implementing ECM in phases by Populations of Focus (POFs), with the first three POFs launching statewide in CY 2022.
Community Supports are services that address members’ health-related social needs and help them avoid higher, costlier levels of care. Although it is optional for MCPs to offer these services, every Medi-Cal MCP offered Community Supports in 2022, and at least two Community Supports services were offered and available in every county by the end of the year.
","title":"Chart 1.2 Cumulative Number of Members Who Received ECM Since ECM Launch","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/datasets/CADHCS::chart-1-2-cumulative-number-of-members-who-received-ecm-since-ecm-launch","mediaType":"text/html","title":"ArcGIS Hub Dataset"},{"@type":"dcat:Distribution","downloadURL":"https://services7.arcgis.com/7MUwsS9z05YumJRZ/arcgis/rest/services/ECM_Community_Support_Data_Tables_for_Quarterly_Implementation_report/FeatureServer/15","mediaType":"application/octet-stream","title":"ArcGIS GeoService"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/csv?layers=15","mediaType":"text/csv","title":"CSV"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/shapefile?layers=15","mediaType":"application/zip","title":"Shapefile"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/geojson?layers=15","mediaType":"application/geo+json","title":"GeoJSON"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/kml?layers=15","mediaType":"application/vnd.google-earth.kml+xml","title":"KML"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/f924afd4-b772-483b-9758-0af65d716d74/resource/d71899d2-aa8c-4975-b59d-d0daf5d7dd0e/download/chart-1-2-cumulative-number-of-members-who-received-ecm-since-ecm-launch-1owjffha.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2g2c-zcib","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2g2c-zcib","description":"Chemical compound data from PubChem database. IUPAC Name: 2,4-dibutyl-6-methyl-1,3,5-dithiazinane. Molecular Formula: C12H25NS2. Molecular Weight: 247.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529053: 1,3,5-Dithiazine, perhydro-2,6-dibutyl-4-methyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529053","description":"Access the complete Compound 529053: 1,3,5-Dithiazine, perhydro-2,6-dibutyl-4-methyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2g3g-gg76","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["moth-reproduction","vas-deferens","circadian-rhythm","glycoprotein-secretion","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2g3g-gg76","description":"Background\n Reproductive systems of male moths contain circadian clocks, which time the release of sperm bundles from the testis to the upper vas deferens (UVD) and their subsequent transfer from the UVD to the seminal vesicles. Sperm bundles are released from the testis in the evening and are retained in the vas deferens lumen overnight before being transferred to the seminal vesicles. The biological significance of periodic sperm retention in the UVD lumen is not understood. In this study we asked whether there are circadian rhythms in the UVD that are correlated with sperm retention.\n \n \n Results\n We investigated the carbohydrate-rich material present in the UVD wall and lumen during the daily cycle of sperm release using the periodic acid-Shiff reaction (PAS). Males raised in 16:8 light-dark cycles (LD) showed a clear rhythm in the levels of PAS-positive granules in the apical portion of the UVD epithelium. The peak of granule accumulation occurred in the middle of the night and coincided with the maximum presence of sperm bundles in the UVD lumen. These rhythms persisted in constant darkness (DD), indicating that they have circadian nature. They were abolished, however, in constant light (LL) resulting in random patterns of PAS-positive material in the UVD wall. Gel-separation of the UVD homogenates from LD moths followed by detection of carbohydrates on blots revealed daily rhythms in the abundance of specific glycoproteins in the wall and lumen of the UVD.\n \n \n Conclusion\n Secretory activity of the vas deferens epithelium is regulated by the circadian clock. Daily rhythms in accumulation and secretion of several glycoproteins are co-ordinated with periodic retention of sperm in the vas deferens lumen.","title":"Circadian rhythm of glycoprotein secretion in the vas deferens of the moth,","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128818/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2g6k-mxz3","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","substance","pubchem","chemistry","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2g6k-mxz3","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864942: MLS000083334","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864942","description":"Access the complete Substance 864942: MLS000083334 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/ac8d-d23d","issued":"2018-12-11","@type":"dcat:Dataset","modified":"2018-12-11","contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/ac8d-d23d","description":"The Nursing Home Cost Report (RHCF) is a uniform report completed by New York nursing homes to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations (Part 86-2.2), nursing homes are required to file financial and statistical data with DOH annually. The data filed is part of the cost report and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends.","title":"Nursing Home Cost Report (RHCF): 2017","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/download/ac8d-d23d/application/zip","mediaType":"application/zip"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2g98-fpnv","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","substance-use","state-prevalence","small-area-estimation","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2g98-fpnv","description":"Browse state-level percentage estimates based on the 2022-2023 National Surveys on Drug Use and Health (NSDUH). The 41 tables include estimates for measures of both substance use and mental health, by age group, along with 95% confidence intervals. The percentages are based on small area estimation (SAE) methods, in which state-level NSDUH data are combined with other data from smaller geographies. The combined data are used to create modeled state estimates of the civilian, noninstitutionalized population ages 12 and older (or adults 18 and older for mental health measures). Most tables cover a single measure by state, region, and age group. A few tables cover multiple measures for just ages 12 to 20.The tables are available as an Excel spreadsheet, a PDF file, or as a zip file containing CSV text files.","title":"2022-2023 NSDUH: Model-Based Estimated Prevalence for States","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2022-2023-nsduh-state-prevalence-estimates","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/vg8q-3gks","issued":"2018-08-16","@type":"dcat:Dataset","modified":"2018-08-16","keyword":["schools","lead","drinking water"],"contactPoint":{"@type":"vcard:Contact","fn":"Willc13","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/vg8q-3gks","description":"Chattaroy Elementary lead in drinking water test results","title":"Chattaroy Elementary School","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/vg8q-3gks/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2gcm-fgw2","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","duck-hepatitis-b","reverse-transcriptase","rnaseh-activity","viral-cores"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2gcm-fgw2","description":"Background\n The hepadnaviral reverse transcriptase can synthesize DNA on its native RNA template within viral cores but it is usually unable to synthesize DNA employing exogenous nucleic acids as a template. The mechanism of this template commitment is unknown. Here we provide evidence that the RNAseH activity of duck hepatitis B virus reverse transcriptase may also be unable to act on exogenous substrates.\n \n \n Results\n RNAseH assays were performed under a wide variety of conditions employing substrate RNAs of Duck Hepatitis B Virus sequence annealed to complementary DNA oligonucleotides and permeabilized intracellular viral core particles. Temperature, pH, cation type, salt concentration, substrate concentration, and the sequences of the cleavage sites were varied, and the effects of ATP and dNTPs on RNAseH activity were examined. duck hepatitis B virus RNAseH activity was not detected under any of these conditions, although E. coli or Avian Myeloblastosis Virus RNAseH activity could be detected under all conditions. Access of the RNA substrate to the enzyme within the viral cores was confirmed.\n \n \n Conclusions\n These results imply that the RNAseH activity of the DHBV reverse transcriptase may not be able to degrade exogenous RNA:DNA heteroduplexes, although it can degrade heteroduplexes of the same sequence generated during reverse transcription of the endogenous RNA template. Therefore, the RNAseH activity appears to be \"substrate committed\" in a manner similar to the template commitment observed for the DNA polymerase activity.","title":"Evidence that the RNAseH activity of the duck hepatitis B virus is unable to act on exogenous substrates","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC37354/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2gd5-gndu","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["service","acf","childr","social","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2gd5-gndu","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"SAC Massachusetts Community Strategic Planning","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/3199","description":"Access the complete SAC Massachusetts Community Strategic Planning on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2gdr-6r3a","bureauCode":["009:38"],"issued":"2017-11-03","@type":"dcat:Dataset","modified":"2026-02-17","keyword":["expenditures","expansion population","cms-64","new adult group","medicaid","viii group","mbes"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:no-reply@data.medicaid.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"00505e90-f8ac-5921-b12f-5e23ba7ffcf3","description":"This dataset reports summary level expenditure data associated with the new adult group established under the Affordable Care Act. These state expenditures are reported through the federal Medicaid Budget and Expenditure System (MBES).\n\nNotes:\n1. “VIII GROUP” is also known as the “New Adult Group.”\n2. The VIII Group is only applicable for states that have expanded their Medicaid programs by adopting the VIII Group. VIII Group expenditure information\nfor the states that have not expanded their Medicaid program is noted as “N/A.”\n3. States that have reported “0” either have no expenditures for that reporting category or have not yet reported expenditures for that category.\n4. MCHIP expenditures are not included in the All Medical Assistance Expenditures.","title":"Medicaid CMS-64 New Adult Group Expenditures","programCode":["009:076"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/medicaid-cms-64-new-adult-group-expenditures-dataset-02172026.csv","mediaType":"text/csv","title":"CSV"}],"license":"https://www.usa.gov/government-works","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2geu-9ng4","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","substance","references","bioactivity","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2geu-9ng4","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865468: MLS000084112","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865468","description":"Access the complete Substance 865468: MLS000084112 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2gff-2uwr","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2024-01-05","keyword":["medicaid","chip","dq atlas","dual enrollment","t-msis analytic files"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"93b36a8e-4dd5-4ff4-9a8b-8c6537684705","description":"This data set presents annual enrollment counts of Medicaid and CHIP beneficiaries by dual eligibility status for Medicaid and Medicare (full dual eligibility, partial dual eligibility, or not dually eligible). There are three metrics presented: (1) the number of beneficiaries ever dually eligible for Medicaid and Medicare over the year (duplicated count); (2) the number of beneficiaries dually eligible for Medicaid and Medicare as of an individual’s last month of enrollment (unduplicated count); and (3) average monthly eligibility for Medicaid and Medicare. \n\nThese metrics are based on data in the T-MSIS Analytic Files (TAF). Some states have serious data quality issues for one or more months, making the data unusable for calculating these measures. To assess data quality, analysts adapted measures featured in the DQ Atlas. Data for a state and month are considered unusable or of high concern based on DQ Atlas thresholds for the topic Dually Enrolled in Medicare. Please refer to the DQ Atlas at http://medicaid.gov/dq-atlas for more information about data quality assessment methods. \n\nSome cells have a value of “DS”. This indicates that data were suppressed for confidentiality reasons because the group included fewer than 11 beneficiaries.","title":"Dual Status Information for Medicaid and CHIP Beneficiaries by Year","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/DualStatus-anul.csv","description":"This data set presents annual enrollment counts of Medicaid and CHIP beneficiaries by dual eligibility status for Medicaid and Medicare (full dual eligibility, partial dual eligibility, or not dually eligible). There are three metrics presented: (1) the number of beneficiaries ever dually eligible for Medicaid and Medicare over the year (duplicated count); (2) the number of beneficiaries dually eligible for Medicaid and Medicare as of an individual’s last month of enrollment (unduplicated count); and (3) average monthly eligibility for Medicaid and Medicare. \n\nThese metrics are based on data in the T-MSIS Analytic Files (TAF). Some states have serious data quality issues for one or more months, making the data unusable for calculating these measures. To assess data quality, analysts adapted measures featured in the DQ Atlas. Data for a state and month are considered unusable or of high concern based on DQ Atlas thresholds for the topic Dually Enrolled in Medicare. Please refer to the DQ Atlas at http://medicaid.gov/dq-atlas for more information about data quality assessment methods. \n\nSome cells have a value of “DS”. This indicates that data were suppressed for confidentiality reasons because the group included fewer than 11 beneficiaries.","@type":"dcat:Distribution","title":"Dual Status Information for Medicaid and CHIP Beneficiaries by Year"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["Enrollment"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/235m-gsry","bureauCode":["009:20"],"issued":"2024-11-15","@type":"dcat:Dataset","modified":"2026-01-14","contactPoint":{"@type":"vcard:Contact","fn":"Pathology and Physiology Branch, Health Effects Laboratory Division","hasEmail":"mailto:sa-cin-webteam@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/235m-gsry","description":"Additive manufacturing (AM) is a broad manufacturing term that encompasses a range of processes that create objects by adding material through a computer-aided design model. Three-dimensional (3D) printing is a form of AM, which builds objects layer-by-layer deposition of feedstock material using a 3D printer machine and computer software. Fused filament fabrication (FFF, also known as Filament Freeform Fabrication) is one 3D printing process in which filaments are melted and extruded from a heated nozzle to deposit material. FFF is an emerging technology and one of the most popular additive manufacturing processes, especially for consumers and small manufacturers. Polycarbonate (PC) is a versatile material and PC filaments are widely used for fused filament fabrication 3D printing. PC filaments are often loaded with additives to achieve different properties of the print objects. These additives range from dyes, organometallic compounds, carbon nanomaterials, nanometal oxides to micrometer-scale particles such as copper, bronze, steel, tungsten, gold, and aluminum nitride (Vance et al., 2017). Several engineered nanomaterials were infused into PC filaments, such as silicon dioxide nanoparticles, titanium nitride nanoparticles (Vidakis et al., 2021), titanium carbide nanopowder (Vidakis et al., 2022a), aluminum nitride nanoparticles (Vidakis et al., 2022b), and carbon nanotubes (Potter et al., 2021).\n\nDuring heating, PC filament undergoes thermal degradation and releases fine particles (0.1 to 2.5 um) and incidental nanoparticles (d < 100 nm) as well as numerous volatile, and semi-volatile organic compounds that are likely derived from PC polymer and additives in the polymer (Azimi et al., 2016; Byrley et al., 2020; Gu et al., 2019; Stefaniak et al., 2017; Stefaniak et al., 2019; Alijagic et al., 2022; Tedla et al., 2022). These emissions could pose a potential hazard to human health. Currently, the potential health hazard of PC filament printing emissions has not been determined.\n\nA NIOSH research group used a condensation nuclei counter to study PC filament emission rates, and determined that the number-based particle emission rates from an industrial-scale material extrusion AM machine were around 2.2 x1011 number/minute and the total volatile organic compound emission rates were around 1.9 x 104 µg/minute (Stefaniak et al., 2019). The same group also found low levels of acetone, benzene, toluene, and m,p-xylene during PC filament printing processes. Potter et al showed that PC filament emissions contained bisphenol A (BPA), phenol, chlorobenzene, DEHP, and di-tert-butylphenol (Potter et al., 2019). In our previous studies on PC filament printer emission-induced cell toxicity (Farcas et al., 2019), emissions from a commercial PC 3D printer were generated in a chamber using a 3D printer and collected in cell culture medium. The number-based size distribution of the particles inside the chamber was between 140-170 nm and the mean particle sizes in cell culture medium were 201±18 nm. Analysis of elemental composition of particles collected in the cell culture medium found C, O, Ca, Na, Si, Ni, Cr, Fe, S, Al, and Cl. The organic compounds in the emission collection cell culture medium were BPA, p-isopropenylphenol, and phenol. At 24 h post-exposure, PC emissions were internalized in human small airway epithelial cells (SAEC) and induced a dose-dependent cytotoxicity, oxidative stress, apoptosis, necrosis, and increases in pro-inflammatory cytokine and chemokine production in SAEC (Farcas et al., 2019). The results demonstrated that PC filament 3D printing emissions induce a cellular toxicity in SAEC.\n\nAlthough cell-based in vitro toxicity analysis is increasingly applied to screen and rank chemicals for prioritizing toxicity studies, as well as to study toxic mechanisms, the toxicological significance of in vitro study-generated data in hazard and risk assessment is limited. In comparison with animal-based in","title":"Pulmonary evaluation of whole-body inhalation exposure of polycarbonate (PC) filament 3D printer emissions in rats","programCode":["009:034"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/download/235m-gsry/application/x-zip-compressed","mediaType":"application/x-zip-compressed"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["National Institute for Occupational Safety and Health"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["medications","drug-manufacturers","drug-information","pharmaceuticals","public-health"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA076736","description":"Fluconazole is an oral antifungal suspension used to treat fungal infections. This prescription drug, with a strength of 40 mg/mL, is manufactured by Zhejiang Poly Pharm. Co., Ltd. and approved under ANDA215738. It belongs to the azole class of antifungals and works by inhibiting fungal growth. This information was generated using AI and is provided for informational and research purposes only.","title":"Fluconazole","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076736","description":"\n Access the FDA dataset for Fluconazole — ANDA 076736 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Fluconazole"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://www.ncbi.nlm.nih.gov/structure/","bureauCode":["009:25"],"issued":"2022-02-08","@type":"dcat:Dataset","modified":"2025-06-18","keyword":["protein","computational biology","tools & utilities","dataset","macromolecules"],"contactPoint":{"@type":"vcard:Contact","fn":"National Library of Medicine","hasEmail":"mailto:custserv@nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Library of Medicine"},"identifier":"https://datadiscovery.nlm.nih.gov/api/views/b58i-eyqq","description":"Three dimensional structures provide a wealth of information on the biological function and the evolutionary history of macromolecules. They can be used to examine sequence-structure-function relationships, interactions, active sites, and more.","title":"Structure - Molecular Modeling Database (MMDB)","programCode":["009:041"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/structure/","description":"Experimentally resolved structures of proteins, RNA, and DNA, derived from the Protein Data Bank (PDB), with value-added features such as explicit chemical graphs, computationally identified 3D domains (compact substructures) that are used to identify similar 3D structures, as well as links to literature, similar sequences, information about chemicals bound to the structures, and more. These connections make it possible, for example, to find 3D structures for homologs of a protein sequence of interest, then interactively view the sequence-structure relationships, active sites, bound chemicals, journal articles, and more.","@type":"dcat:Distribution","title":"Molecular Modeling Database (MMDB) query interface"},{"@type":"dcat:Distribution","downloadURL":"https://ftp.ncbi.nih.gov/mmdb","mediaType":"text/html","title":"Download Molecular Modeling Database (MMDB) Data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Diagnostic Imaging"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2gp9-u99u","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","autoantibody-screening","cryptogenic-fibrosing-alveolitis","idiopathic-pulmonary-fibrosis","immune-response"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2gp9-u99u","description":"The pathogenesis of cryptogenic fibrosing alveolitis (CFA) involves injury, an immune/inflammatory response and fibrosis. The cause of the injury is unknown, but the identification of serum autoantibodies makes an autoimmune aetiology attractive. The core study on which this commentary is based used novel cloning and serum screening technologies in order to identify new public and private autoantibodies in sera from 12 patients with CFA. Largely negative conclusions were drawn from that study. However, we suggest that the prevalence of autoantibodies may have been underestimated, that the study was timely and that this approach is worth pursuing further.","title":"Autoantibodies in cryptogenic fibrosing alveolitis","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59568/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2gps-fqub","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2gps-fqub","description":"Chemical compound data from PubChem database. IUPAC Name: bis[tert-butyl(dimethyl)silyl] 2-[tert-butyl(dimethyl)silyl]oxybutanedioate. Molecular Formula: C22H48O5Si3. Molecular Weight: 476.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528581: Bis[tert-butyl(dimethyl)silyl] 2-([tert-butyl(dimethyl)silyl]oxy)succinate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528581","description":"Access the complete Compound 528581: Bis[tert-butyl(dimethyl)silyl] 2-([tert-butyl(dimethyl)silyl]oxy)succinate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2gqk-jj5s","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["lyme-disease","tick-borne-disease","lyme-arthritis","nih","lyme-vaccine"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2gqk-jj5s","description":"Lyme disease is a tick-borne multisystem disease that affects primarily the skin, nervous system, heart and joints. At least three species of Borrelia burgdorferi sensu lato, namely Borrelia burgdorferi sensu stricto, Borrelia garinii, and Borrelia afzelii, can cause the disease. This review will focus mainly on the pathophysiology of Lyme arthritis, the long-term outcome of Lyme disease, and the recently licensed vaccine against Lyme disease.","title":"Lyme disease and current aspects of immunization","programCode":["009:037"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128914/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2gqy-pvki","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","national-outcome-measures","substance-abuse-treatment","samhsa","block-grant-program"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2gqy-pvki","description":"This is the 2020 Uniform Reporting System (URS) Output Tables for Washington. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2020 Uniform Reporting System (URS) Table For Washington","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2020-uniform-reporting-system-urs-table-washington","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2gtk-58py","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["idiopathic-pulmonary-fibrosis","anti-cytokine-therapy","nih","interferon-gamma","fibrosing-alveolitis"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2gtk-58py","description":"Idiopathic pulmonary fibrosis (IPF) is a condition that has a poor prognosis, with a median survival of 4-5 years irrespective of treatment. Ziesche et al (N Engl J Med 1999, 341: 1264-1269) describe an open randomised trial of 18 patients with IPF, unresponsive to corticosteroid treatment at high dose. Nine patients were treated with continued corticosteroid and nine with prednisolone plus interferon-γ 1b (IFN-γ). Significant benefits in physiological parameters are reported in the IFN-γ-treated group. An analysis of lung tissue by reverse-transcriptase-mediated polymerase chain reaction showed corresponding decreases in the transcription of transforming growth factor-β1 and connective tissue growth factor. This is the first report of treatment showing efficacy in this disease, albeit in a very preliminary study, but the data should be viewed with caution. This study is discussed in the context of other published studies of treatment for IPF and the scientific rationale on which it was based.","title":"Anti-cytokine therapy in fibrosing alveolitis: where are we now?","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59532/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-manufacturers","drug-information","drug","public-health","medications"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA214768","description":"Triamterene is a generic prescription medication used as a potassium-sparing diuretic to help remove excess fluid from the body while maintaining potassium levels. It comes in oral capsules (50 mg and 100 mg strengths) manufactured by Biocon Pharma Inc. under ANDA214768. This information was generated using AI and is provided for informational and research purposes only.","title":"Triamterene","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214768","description":"\n Access the FDA dataset for Triamterene — ANDA 214768 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Triamterene"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2gvj-sypc","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","chemistry","innovation","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2gvj-sypc","description":"A shut-off nozzle for hot runner systems of injection molding machines and a method of controlling the same are disclosed. The shut-off nozzle includes a nozzle body (1) having a resin hole (2), a heater (4), and a thermocouple (3) to sense a temperature of the nozzle body (1); a gate tip (8) having a nozzle gate (7) at which the nozzle body (1) comes into contact with a cavity (10) of a mold; a heating unit (5) provided around the gate tip (8) to heat the gate tip (8) by using electricity; and a cooling unit (6) provided around the gate tip (8) in parallel to the heating unit (5), so that a coolant passes through the cooling unit (6) to cool the gate tip (8). In the control method, the nozzle body (1) is primarily heated to a predetermined high temperature by turning on the heater (4). In addition, the gate tip (8) is heated by turning on the heating unit (5), prior to injecting a molten resin into a cavity (10) of a mold through the nozzle gate (7). The heating unit (5) is, thereafter, turned off after an injection of a predetermined amount of the molten resin into the cavity (10) of the mold is completed, thus allowing the gate tip (8) to start to cool. In addition, the cooling unit (6) is operated to quickly cool the gate tip (8). The mold is opened to remove a molded product from the cavity (10) of the mold.\nThe State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.\n
\n\nIt is a weekly snapshot in time that:\nThe National Child Abuse and Neglect Data System (NCANDS) Child File data set consists of child-specific data of all reports of maltreatment to State child protective service agencies that received an investigation or assessment response. NCANDS is a Federally-sponsored national data collection effort created for the purpose of tracking the volume and nature of child maltreatment reporting each year within the United States. The Child File is the case-level component of the NCANDS. Child File data are collected annually through the voluntary participation of States. Participating States submit their data after going through a process in which the State's administrative system is mapped to the NCANDS data structure. Data elements include the demographics of children and their perpetrators, types of maltreatment, investigation or assessment dispositions, risk factors, and services provided as a result of the investigation or assessment.
","title":"National Child Abuse and Neglect Data System (NCANDS) Child File: Findings from the National Child Abuse and Neglect Data System (NCANDS) – File Contents and Definitions for the Data Tables (updated with FY 2015)","programCode":["009:094"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://healthdata.gov/download/2m45-fv88/application/vnd.openxmlformats-officedocument.wordprocessingml.document","mediaType":"application/vnd.openxmlformats-officedocument.wordprocessingml.document"}],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/"},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2m47-k57c","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","compound","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2m47-k57c","description":"Chemical compound data from PubChem database. IUPAC Name: 1,2,3,7-tetrabromodibenzofuran. Molecular Formula: C12H4Br4O. Molecular Weight: 483.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526233: 1,2,3,7-Tetrabromo-dibenzofuran","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526233","description":"Access the complete Compound 526233: 1,2,3,7-Tetrabromo-dibenzofuran on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2m7c-7vmc","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","compound","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2m7c-7vmc","description":"Chemical compound data from PubChem database. IUPAC Name: 1,2-bis(methylsulfanyl)nonacosane. Molecular Formula: C31H64S2. Molecular Weight: 501.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528996: Nonacosane, 1,2-bis(methylthio)","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528996","description":"Access the complete Compound 528996: Nonacosane, 1,2-bis(methylthio) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2m98-fm2h","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","compound","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2m98-fm2h","description":"Chemical compound data from PubChem database. IUPAC Name: (methyltrisulfanyl)ethane. Molecular Formula: C3H8S3. Molecular Weight: 140.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525358: Ethyl methyl trisulfide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525358","description":"Access the complete Compound 525358: Ethyl methyl trisulfide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2maj-f3mt","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2maj-f3mt","description":"Chemical compound data from PubChem database. IUPAC Name: propyl 4-methylpentanoate. Molecular Formula: C9H18O2. Molecular Weight: 158.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527991: Pentanoic acid, 4-methyl-, propyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527991","description":"Access the complete Compound 527991: Pentanoic acid, 4-methyl-, propyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2man-8tgu","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","substance","references","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2man-8tgu","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864796: MLS000084492","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864796","description":"Access the complete Substance 864796: MLS000084492 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2maw-idyf","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","research","chemistry","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2maw-idyf","description":"Chemical compound data from PubChem database. IUPAC Name: (3-amino-2-oxopropyl) dihydrogen phosphate. Molecular Formula: C3H8NO5P. Molecular Weight: 169.07. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 5: 3-Amino-2-oxopropyl phosphate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/5","description":"Access the complete Compound 5: 3-Amino-2-oxopropyl phosphate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/84hb-ritz","issued":"2019-02-01","@type":"dcat:Dataset","modified":"2019-02-07","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/84hb-ritz","description":"Lead in Drinking Water in Schools Test Results – David Wolfle Elementary School","title":"David Wolfle Elementary School Update","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/84hb-ritz/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mbw-nzvb","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","diabetic-nephropathy","renaal-study","renal-outcomes","losartan-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2mbw-nzvb","description":"The RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan) study is a multinational, double-blind, randomized, placebo controlled trial which was recently published. It was aimed to evaluate the effect of the angiotensin receptor blocker losartan in patients with diabetic nephropathy. The primary efficacy measure was the time to the first event of the composite end point of a doubling of serum creatinine, end-stage renal disease, or death. The conclusion was that losartan led to significant improvement in renal outcomes, that was beyond that attributable to blood pressure control in patients with type 2 diabetes and nephropathy.\n The perusal of the report raises concern, regarding to both the patient population as well as the outcome measures. At randomization, the placebo group included more patients with angina, myocardial infarction and lipid disorders than the losartan group. Information on glucose metabolism was disregarded, and data on antihyperglycemic therapy – which may have undesirable influences on cardiac performance – were not included in a multivariate analysis. In addition, only data on first hospitalization were reported, whilst information on total specific-cause hospitalizations was disregarded, thus potentially masking further unfavorable events. Furthermore, creatinine seems not to be a reliable surrogate end point. Based on its mechanism of action, losartan may possess favorable renoprotective properties. However, due to the methodological flaws and the incomplete data in the RENAAL study, the question of the effectiveness and safety of this drug in diabetic nephropathy remains yet unanswered.","title":"Losartan and diabetic nephropathy: commentaries on the RENAAL study","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC116616/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mc3-73uk","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","health-it","software-adoption","physician-practices","office-automation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2mc3-73uk","description":"Background\n Many physicians are transitioning from paper to electronic formats for billing, scheduling, medical charts, communications, etc. The primary objective of this research was to identify the relationship (if any) between the software selection process and the office staff's perceptions of the software's impact on practice activities.\n \n \n Methods\n A telephone survey was conducted with office representatives of 407 physician practices in Oregon who had purchased information technology. The respondents, usually office managers, answered scripted questions about their selection process and their perceptions of the software after implementation.\n \n \n Results\n Multiple logistic regression revealed that software type, selection steps, and certain factors influencing the purchase were related to whether the respondents felt the software improved the scheduling and financial analysis practice activities. Specifically, practices that selected electronic medical record or practice management software, that made software comparisons, or that considered prior user testimony as important were more likely to have perceived improvements in the scheduling process than were other practices. Practices that considered value important, that did not consider compatibility important, that selected managed care software, that spent less than $10,000, or that provided learning time (most dramatic increase in odds ratio, 8.2) during implementation were more likely to perceive that the software had improved the financial analysis process than were other practices.\n \n \n Conclusion\n Perhaps one of the most important predictors of improvement was providing learning time during implementation, particularly when the software involves several practice activities. Despite this importance, less than half of the practices reported performing this step.","title":"Selecting information technology for physicians' practices: a cross-sectional study","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC102764/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mc6-588a","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","behavioral-health","mental-health","region-6","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2mc6-588a","description":"This is a behavioral health report for HHS Region VI of the United States and utilizes data from the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment (N-SSATS), collected annually. The topics addressed in the reports include youth substance use, youth mental health and treatment, adult mental health, substance use and substance use treatment.","title":"Behavioral Health Barometer: Region 6, Volume 6","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-region-6-volume-6","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mcr-asur","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["child","social","service","acf","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2mcr-asur","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Interoperability Overview","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14295","description":"Access the complete Interoperability Overview on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mer-3t37","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["state-prevalence","adult-mental-illness","samhsa","mental-health","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2mer-3t37","description":"This report provides prevalence estimates and 95% confidence intervals for persons aged 12 or older, 12 to 17, 18 to 25, and 26 or older; also for persons 12 to 20 for two alcohol measures. These are tables of State estimates for 25 measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Results are provided by State by age group.","title":"2010-2011 prevalence estimates for persons aged 18 or older. Also included are 2009-2010 prevalence estimates and p-values from tests of differences between the 2009-2010 and 2010-2011 estimates (26 tables)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2010-2011-prevalence-estimates-persons-aged-18-or-older-also-included-are-2009-2010","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mhg-xxhz","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["abuse","prevention","neglect","grant","assessment"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2mhg-xxhz","description":"The Office on Child Abuse and Neglect seeks to build its capacity for evaluating the programs of its grantees for the prevention of child abuse and neglect. In this webinar, findings discussed in this survey include data that show caregivers high in protective factors have greater physical health.\n\nPresenters: Casandra Firman, from the National Resource Center for CBCAP; Elenor Buffington, Karin Chang-Rios, Jackie Counts, and Heather Rasmussen from the Institute for Educational Research and Public Service, University of Kansas; and Toby Hyman and Jodi Tyson from the Nevada Department of Health and Human Services.\n\nView Webinar (WMV - 69 MB)\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"The Protective Factors Survey: A Tool for Prevention Programs to Measure Change","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/protective-factors-survey-tool-prevention-programs-measure-change","description":"Access the complete The Protective Factors Survey: A Tool for Prevention Programs to Measure Change on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/w4ej-td6g","issued":"2019-02-20","@type":"dcat:Dataset","modified":"2019-02-20","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/w4ej-td6g","description":"Lead in Drinking Water in Schools Test Results – Gregory Heights Elementary School","title":"Gregory Heights Elementary School","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/w4ej-td6g/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/prams/index.htm","bureauCode":["009:20"],"issued":"2023-07-18","@type":"dcat:Dataset","modified":"2023-09-05","references":["https://www.cdc.gov/prams/index.htm","https://www.cdc.gov/prams/pramstat/index.html"],"keyword":["abuse","alcohol use","breastfeeding","contraception","infant health","medicaid","mental health","morbidity","obesity","preconception health","pregnancy history","prenatal care","reproductive health","sleep behavior","smoke exposure","stress","tobacco use","unintended pregnancy","wic"],"contactPoint":{"@type":"vcard:Contact","fn":"DRH Public Inquiries","hasEmail":"mailto:PRAMSProposals@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/4ya2-fkvt","description":"2008. Centers for Disease Control and Prevention (CDC). PRAMS, the Pregnancy Risk Assessment Monitoring System, is a surveillance system collecting state-specific, population-based data on maternal attitudes and experiences before, during, and shortly after pregnancy. It is a collaborative project of the Centers for Disease Control and Prevention (CDC) and state health departments. PRAMS provides data for state health officials to use to improve the health of mothers and infants. PRAMS topics include abuse, alcohol use, contraception, breastfeeding, mental health, morbidity, obesity, preconception health, pregnancy history, prenatal-care, sleep behavior, smoke exposure, stress, tobacco use, WIC, Medicaid, infant health, and unintended pregnancy. Data will be updated annually as it becomes available.","title":"CDC PRAMStat Data for 2008","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/4ya2-fkvt/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/4ya2-fkvt/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/4ya2-fkvt/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/4ya2-fkvt/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/4ya2-fkvt/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/4ya2-fkvt/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"describedBy":"https://chronicdata.cdc.gov/Maternal-Child-Health/CDC-PRAMStat-Data-for-2008/4ya2-fkvt","license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Maternal & Child Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mpb-stq3","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","substance","references","pubchem","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2mpb-stq3","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864935: MLS000084581","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864935","description":"Access the complete Substance 864935: MLS000084581 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mqa-rw3u","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","research","pubchem","patent","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2mqa-rw3u","description":"Chemical patent from PubChem database. Patent Number: AT-E40147-T1. Title: Novel Chemical Entity. Filing Date: 2003-02-03. Inventors: Smith, John A., Johnson, Mary B.. Abstract: The invention relates to a novel chemical entity with unique structural features and biological properties, suitable for development as a therapeutic ... IPC Classifications: C08G, C08K, A61K. This patent covers 13 claims related to 7 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.","title":"Patent AT-E40147-T1: [Translated] AQUEOUS ELECTROCOAT COATING AGENT AND ITS USE FOR COATING OBJECTS.","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E40147-T1","description":"Access the complete Patent AT-E40147-T1: [Translated] AQUEOUS ELECTROCOAT COATING AGENT AND ITS USE FOR COATING OBJECTS. on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mqe-iatp","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["time","neglect","abuse","intervention","real"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2mqe-iatp","description":"Location: Shelby County, Tennessee\n\nHome Visiting Program Selected: Nurse Family Partnership\n\nHome Visiting Target Population: Shelby County residents who meet the overall criteria for Nurse-Family Partnerships: low-income, first-time mothers, 16-28 weeks pregnant. Nearly all participants will be African-American.\n\nProject Overview:\nLe Bonheur Community Outreach will implement a program called Shelby County Nurse Family Partnership Collaborative. The Tennessee Commission for Children and the director of the Le Bonheur Center for Children and Parents will co-chair the Nurse Family Partnership. The program's goals are designed to: 1) utilize the Nurse Family Partnership model to expand and enhance high quality home visitation programs proved to reduce child abuse and deliver other positive outcomes for children and families, 2) develop a replicable local infrastructure model to implement the Nurse Family Partnership, 3) establish a statewide partnership to support local expansion and enhancement of the Nurse Family Partnership and other evidence based home visitation programs in the state, and 4) provide guidance to the Nurse Family Partnership implementations around the country to more effectively serve clients with mental/behavioral health disorders. The proposed evaluation will included an implementation, outcomes and economic cost analysis.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Supporting Evidence-Based Home Visitation Programs to Prevent Child Abuse and Neglect Project: Le Bonheur Community Outreach","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/supporting-evidence-based-home-visitation-programs-prevent-child-abuse-and-8","description":"Access the complete Supporting Evidence-Based Home Visitation Programs to Prevent Child Abuse and Neglect Project: Le Bonheur Community Outreach on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mrv-kaf8","bureauCode":["009:38"],"issued":"2015-11-10","@type":"dcat:Dataset","modified":"2016-08-12","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"Balaji","hasEmail":"mailto:no-reply@data.healthcare.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"wudg-eius","description":"The Service Area PUF (SA-PUF) is one of the seven files that make up the Marketplace PUF. The SA-PUF contains issuer-level data on the geographic coverage or service area (i.e., where the plan is offered) including state, county, and zip code. These data either originate from the Service Area template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).","title":"Service Area PUF - PY2016","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/service-area-puf-2016.wudg-eius.csv","mediaType":"text/csv","title":"CSV"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mw8-f6qs","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","chemistry","pubchem","bioactivity","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2mw8-f6qs","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865689: MLS000083618","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865689","description":"Access the complete Substance 865689: MLS000083618 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mx7-gi6f","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","pubchem","chemistry","bioactivity","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2mx7-gi6f","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864677: MLS000083989","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864677","description":"Access the complete Substance 864677: MLS000083989 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mxf-xbbk","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","cytomegalovirus-infection","autoantibodies","u1-snrnp","systemic-lupus"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2mxf-xbbk","description":"The induction of autoantibodies to U1 small nuclear ribonucleoprotein (U1 snRNP) complexes is not well understood. We present evidence that healthy individuals with cytomegalovirus (CMV) infection have an increased frequency and quantity of antibodies to ribonucleoprotein, directed primarily against the U1-70k protein. A significant association between the presence of antibodies to CMV and antibodies to the total RNP targeted by the immune response to the spliceosome (to both the Sm and RNP; Sm/RNP) was found for patients with systemic lupus erythematosus (SLE) but not those with mixed connective-tissue disease. CMV thus may play a role in inducing autoimmune responses in a subset of patients with systemic lupus erythematosus.","title":"Autoimmune response to U1 small nuclear ribonucleoprotein (U1 snRNP) associated with cytomegalovirus infection","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC34115/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2myz-zpa7","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["drug-abuse","samhsa","suicidal-ideation","substance-use","mental-illness"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2myz-zpa7","description":"This report compares 2006 to 2008 an d2008 to 2010 National Survey on Drug Use and Health (NSDUH) estimates among persons aged 12 or older by 362 substate regions within the 50 States and the District of Columbia. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).","title":"Comparison of 2006-2008 and 2008-2010 NSDUH Substate Region Estimates","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/comparison-2006-2008-and-2008-2010-nsduh-substate-region-estimates","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2mzj-c5em","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","pubchem","bioactivity","chemistry","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2mzj-c5em","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865386: MLS000039568","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865386","description":"Access the complete Substance 865386: MLS000039568 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2n2c-kig5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","chemistry","research","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2n2c-kig5","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 2-hydroxy-6-methoxybenzoate. Molecular Formula: C9H10O4. Molecular Weight: 182.17. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527092: Methyl 2-hydroxy-6-methoxybenzoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527092","description":"Access the complete Compound 527092: Methyl 2-hydroxy-6-methoxybenzoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2n56-eukp","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["drug-overdose","alcohol-related-ed","substance-abuse","samhsa","emergency-department-visits"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2n56-eukp","description":"Excel file with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011 for emergency department visits involving alcohol in the Chicago metropolitan area. For adults aged 21 and older, the alcohol was found in combination with other drugs. For patients under the age of 21, the visit may involve alcohol alone or in combination with other drugs.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol. Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.","title":"Chicago: Drug-Related Emergency Department Visits, 2004-2011 - All Alcohol","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/chicago-drug-related-emergency-department-visits-2004-2011-all-alcohol","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.hcai.ca.gov/","issued":"2018-03-16","temporal":"2005-most recent available","@type":"dcat:Dataset","modified":"2025-10-08","keyword":["hospital","external cause","diagnosis code","pdd","icd-10","icd-9","international classification of diseases","procedure code","morbidity","inpatient","office of statewide health planning and development","injury","oshpd","patient discharge data"],"contactPoint":{"@type":"vcard:Contact","fn":"Department of Health Care Access and Information, Healthcare Analytics Branch","hasEmail":"mailto:dataandreports@hcai.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"d1ac90ad-d583-426f-8012-828743cf4ac1","description":"This dataset contains statewide counts for every diagnosis, procedure, and external cause of injury/morbidity code reported on the hospital inpatient data. Diagnosis codes are reported using ICD-9-CM or ICD-10-CM. Procedure codes are reported using ICD-9-CM or ICD-10-PCS. External cause of injury/morbidity codes are reported using ICD-9-CM or ICD-10-CM. ICD-10 replaced ICD-9, effective October 1, 2015.","title":"Hospital Inpatient - Diagnosis, Procedure, and External Cause Codes","distribution":[{"mediaType":"application/octet-stream","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/b997f885-b5dc-4839-9fd2-d793854afd5b/download/2024_diagnosiscodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2024 Hospital Inpatient – Diagnosis Code Frequency"},{"mediaType":"application/octet-stream","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/ae0766f0-a8e0-407d-b8f6-28cb4e0df01d/download/2024_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2024 Hospital Inpatient – Procedure Code Frequency"},{"mediaType":"application/octet-stream","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/f5ebbecb-caa7-46b6-ba9e-8efb26faa562/download/2024_externalcauseofmorbidityfrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. Up to 12 external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2024 Hospital Inpatient – External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/cd7c3480-e7b1-4724-b385-e7bb3b8e1af4/download/2023_diagnosiscodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2023 Hospital Inpatient – Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/a5756bc8-5f98-4647-845d-54f2de54f6b7/download/2023_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2023 Hospital Inpatient – Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/b03bfb7a-c47d-41c9-96fb-906f8c714079/download/2023_externalcauseofmorbidityfrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. Up to 12 external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2023 Hospital Inpatient – External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/bade0b84-9c2a-49b2-8bf1-01edec1ade71/download/2022_diagnosiscodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2022 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/27daa639-36b1-4cd6-9276-8709f6b8cfbd/download/2022_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2022 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/88116920-bbbb-49e4-afc7-82a0029651dc/download/2022_externalcauseofmorbidityfrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. Up to 12 external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2022 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/c73a6f6b-99e5-4809-8eb9-58aa8ec0f8b5/download/2021_diagnosiscodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2021 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/fdcf637a-f740-4846-b8e8-e8d21a313e8b/download/2021_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2021 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/e611fb7c-0b6f-428b-9d31-75b381f220f7/download/2021_externalcauseofmorbidityfrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. Up to 12 external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2021 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/e15bdc87-520b-4e5c-a260-64cd1b89ffdf/download/2020_diagnosiscodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2020 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/a09c6280-8d93-448e-9d56-ac4e8917d825/download/2020_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2020 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/3c23d914-eea5-41f6-b6fc-b0880f764900/download/2020_externalcauseofmorbidityfrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. Up to 12 external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2020 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/4ba178f4-a8eb-4a47-a18a-27ba4d78a60a/download/2019_diagnosiscodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2019 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/9292c87c-96c2-4154-b244-b77c746533ea/download/2019_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2019 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/b16a49fd-8d42-4dbd-8f9d-814c53f6c14d/download/2019_externalcauseofmorbidityfrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. Up to 12 external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2019 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/600b8009-6bd7-4cf9-8ed1-8722f5fbc29c/download/2018_diagnosiscodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2018 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/f03b2525-f70a-464a-ae55-5233d129d45b/download/2018_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 20 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2018 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/c64d4fdf-fd42-4dd9-b6e2-23bb95a3981e/download/2018_externalcauseofmorbidityfrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2018 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/4250a094-28a0-4015-a3b8-15a9c800ea31/download/2017diagnosiscodefrequenciespdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2017 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/388fae8d-aea5-497c-a89c-1c15d4064c5f/download/2017procedurecodefrequenciespdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 20 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2017 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/b3136aa6-4560-4259-88d3-ac65e1a3f3c8/download/2017externalcauseofmorbidityfrequenciespdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2017 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/909c5223-430d-41d4-92fc-f130e468b8a0/download/2016diagnosiscodefrequenciespdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2016 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/97374dce-c5aa-4ca9-93ec-d93f231ffbf9/download/2016procedurecodefrequenciespdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 20 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2016 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/e2207982-0e39-4c29-b5c9-2b83c2ae8c38/download/2016externalcauseofmorbidityfrequenciespdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2016 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/6e320cac-26ba-42d9-870a-fada82f66600/download/2015-pdd-diagnosis-code-frequencies20160715.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2015 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/ee9e51f2-692e-4265-810d-3478e4c8a1de/download/2015-pdd-procedure-code-frequencies20170406.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 20 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2015 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/57c7ab69-cafe-4599-a8a8-278807a34669/download/2015-pdd-e-code-frequencies20160715.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2015 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/7c0fdd79-21e8-4393-b058-d7933001d3f3/download/2014-pdd-diagnosis-code-frequencies.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2014 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/b308bb0c-5a8d-49c1-aca0-a35c0aa0b5e0/download/2014-pdd-procedure-code-frequencies.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 20 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2014 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/205b624f-0c2e-4c7a-a8b8-bca2ff4a21f7/download/2014-pdd-e-code-frequencies.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2014 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/553cfc6b-6055-45f4-ac30-e5ca43d9ae19/download/2013-pdd-diagnosis-code-frequencies.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2013 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/edd6ec4c-8aae-4ffa-bac9-bb201edae592/download/2013-pdd-procedure-code-frequencies.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 20 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2013 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/bd1a754d-05d8-42ac-ba7a-5007d5daed2e/download/2013-pdd-e-code-frequencies.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2013 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/3965d2e9-4fac-4616-9ab4-057bf1c46da6/download/2012-diagnosis-frequencies.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2012 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/057d38bd-f931-49e6-8323-a0fdef208b1b/download/2012-procedure-frequencies.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM or ICD-10-PCS) reported on the hospital inpatient data. A principal and up to 20 secondary procedure codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2012 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/064f5385-b9d9-4b9a-bcb2-364a2d55b1ae/download/2012-e-code-frequencies.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM or ICD-10-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record. ICD-10 replaced ICD-9, effective October 1, 2015.","@type":"dcat:Distribution","title":"2012 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/0e57da16-8fbb-4ee8-b669-d12c47c4cdca/download/2011_diagnosiscodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2011 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/9ff381c4-695b-4f64-866d-9924d3fd5b21/download/2011_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2011 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/d075a2af-1084-4695-aa20-f0b7e1341b2f/download/2011_externalcausecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2011 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/e8cd8b94-5094-4047-b34d-f34ebf88dbc4/download/2010_diagnosiscodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2010 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/3fb58c2b-6857-4582-96a3-e8668785bf17/download/2010_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2010 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/6e413bc9-1f09-4bf5-a579-4cb064f8e29b/download/2010_externalcausecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2010 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/bedc3f80-2419-48f0-bfbc-f500990c6f4a/download/2009_diagnosiscodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2009 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/7d72bf40-951c-41e8-8a8d-20dd2645a98a/download/2009_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2009 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/f6a1d075-f689-4b9f-adbd-b3b903c9d56e/download/2009_externalcausecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2009 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/11b02b8b-fb4d-49f2-8bea-01c535ab7a84/download/2008_diagnosiscodefrequecies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2008 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/3b826d39-8473-4b42-b62f-34077e6ceb6d/download/2008_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2008 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/056d63e8-4069-42d9-8103-9ae7ffb64309/download/2008_externalcausecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2008 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/171350a9-5b77-433d-bb42-28b3656df9c3/download/2007_diagnosiscodefrequecies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2007 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/068b1b11-bcc6-4eb3-98cf-21e8ecd9e8af/download/2007_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2007 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/69e0aed2-a10a-460f-9ad3-686782b4eb6e/download/2007_externalcausecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2007 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/d2dd1242-e444-4d91-bf2a-d46b2afa73ec/download/2006_diagnosiscodefrequecies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2006 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/56271f87-92a4-4114-879a-dfe89907fcb9/download/2006_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2006 Hospital Inpatient - Procedure Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/5f47566c-088d-44fc-8649-c4e4ee60f3a2/download/2006_externalcausecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every external cause of injury/morbidity code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to four external cause of injury/morbidity codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2006 Hospital Inpatient - External Cause of Injury/Morbidity Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/6f88ea68-2ab3-44e5-b2b2-4a24374906c7/download/2005_diagnosiscodefrequecies_pdd.xlsx","description":"This data table contains statewide counts for every diagnosis code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary diagnosis codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2005 Hospital Inpatient - Diagnosis Code Frequency"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/3586c0a0-f02b-4c6f-aa59-0589845cdc87/download/2005_procedurecodefrequencies_pdd.xlsx","description":"This data table contains statewide counts for every procedure code (ICD-9-CM) reported on the hospital inpatient data. A principal and up to 24 secondary procedure codes may be reported on each inpatient record.","@type":"dcat:Distribution","title":"2005 Hospital Inpatient - Procedure Code Frequency"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/d1ac90ad-d583-426f-8012-828743cf4ac1/resource/fef8fe44-95a5-42e9-b7e5-cdaa6dbb043c/download/hospital-inpatient-diagnosis-procedure-and-external-cause-codes-ng5x90rt.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Healthcare"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/evvy-j9nk","issued":"2019-04-26","@type":"dcat:Dataset","modified":"2019-04-26","keyword":["school","lead","drinking water"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/evvy-j9nk","description":"Lead in Drinking Water in Schools Test Results – Bellevue Christian School - Three Points Elementary","title":"Bellevue Christian School - Three Points Elementary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/evvy-j9nk/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2n8z-pa9w","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","patent","pubchem","research","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2n8z-pa9w","description":"Solid catalyst components and catalysts which comprise (a) a magnesium compound, (b) titanium tetra chloride, and (c) a phthalic acid diester or its derivative represented by a particular formula, can afford polymers of olefins in very high yield. Particularly, propylene polymers can be obtained in very high yield while retaining high stereoregularity. Moreover, they have high responsiveness to hydrogen.Limit state-purchased health care cost growth to 2% less than the projected national health expenditures average every year through 2019.
","title":"Health Care Cost Growth","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.ok.gov/dataset/1d2ce245-2c36-4278-9fe9-b26742135150/resource/00ce6415-28a3-496a-8c38-ff58c1cfd057/download/data-health-care-cost-growth.csv","description":"Limit state-purchased health care cost growth to 2% less than the projected national health expenditures average every year through 2019.
","@type":"dcat:Distribution","title":"Data - Health Care Cost Growth"},{"mediaType":"text/csv","downloadURL":"https://data.ok.gov/dataset/1d2ce245-2c36-4278-9fe9-b26742135150/resource/37c5266b-4b8b-41df-9c05-f158976d6dff/download/c-health-care-cost-growth-column-chart.csv","description":"Limit state-purchased health care cost growth to 2% less than the projected national health expenditures average every year through 2019.
","@type":"dcat:Distribution","title":"(C) - Health Care Cost Growth - Column Chart"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["State"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/m42a-gkda","issued":"2020-09-19","@type":"dcat:Dataset","modified":"2022-05-20","keyword":["prevention agenda","tracking indicator"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/m42a-gkda","description":"There are two datasets related to the State Level Prevention Agenda Tracking Indicators posted on this site. Each dataset consists of 99 state-level health tracking indicators and sub-indicators for the Prevention Agenda 2019-2024: New York State’s Health Improvement Plan. A health tracking indicator is a metric through which progress on a certain area of health improvement can be assessed. The indicators are organized by the Priority Area of the Prevention Agenda as well as the Focus Area under each Priority Area. Priority areas include Prevent Chronic Disease; Promote a Healthy and Safe Environment; Promote Healthy Women, Infants and Children; Promote Well-Being and Prevent Mental and Substance Use Disorders; and Communicable Diseases. The data sets also include indicators about major cross-cutting health outcomes and indicators of health disparities, organized into Health Status and Reduce Health Disparities. The most recent year dataset includes the most recent state level data for all indicators. The trend dataset includes the most recent state level data and historical data, where available. Each dataset also includes the Prevention Agenda 2024 state objectives for the indicators. Sub-indicators are included in these datasets to measure health disparities among racial, ethnic, and socioeconomic groups and persons with disabilities.","title":"Prevention Agenda 2019-2024 Tracking Indicators: State Trend Data","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/m42a-gkda/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/m42a-gkda/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/m42a-gkda/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2pmk-x54z","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","n-ssats","michigan","treatment-facilities","substance-abuse-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2pmk-x54z","description":"This is a National Survey of Substance Abuse Treatment Services (N-SSATS) annual report showing the state profile for Michigan in 2012. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.","title":"2012 State Profile - Michigan","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-state-profile-michigan","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["medications","health-care","drug-safety","fda","prescription-drugs"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA021016","description":"Eletriptan Hydrobromide is a generic prescription medication used to treat migraine headaches. It comes as oral tablets in 20 mg and 40 mg strengths, manufactured by Aurobindo Pharma Limited. As a serotonin receptor agonist, it helps relieve migraine symptoms by narrowing blood vessels in the brain. This information was generated using AI and is provided for informational and research purposes only.","title":"Eletriptan hydrobromide","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021016","description":"\n Access the FDA dataset for Eletriptan hydrobromide — ANDA 021016 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Eletriptan hydrobromide"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["pharmaceuticals","fda","drug","drug-safety","medications"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA218343","description":"Potassium Phosphates is an intravenous prescription solution made by Cipla USA Inc., containing dibasic and monobasic potassium phosphate. It provides essential minerals like potassium and phosphate to treat deficiencies, administered via injection. This information was generated using AI and is provided for informational and research purposes only.","title":"Potassium phosphates","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218343","description":"\n Access the FDA dataset for Potassium phosphates — ANDA 218343 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Potassium phosphates"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2pny-2up8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","chemistry","compound","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2pny-2up8","description":"Chemical compound data from PubChem database. IUPAC Name: 4-ethyl-6-methyl-1,2,3,5-tetrathiane. Molecular Formula: C5H10S4. Molecular Weight: 198.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529756: 4-[Dimethyl(pentadecyloxy)silyl]butanenitrile","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529756","description":"Access the complete Compound 529756: 4-[Dimethyl(pentadecyloxy)silyl]butanenitrile on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ptf-gewz","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","national-outcome-measures","mental-health-services","utilization-measures","evidence-based-practices"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2ptf-gewz","description":"This is the 2016 Uniform Reporting System (URS) Output Tables for New Jersey. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2016 Uniform Reporting System (URS) Table for New Jersey","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2016-uniform-reporting-system-urs-table-new-jersey","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2pvi-g2gk","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","references","pubchem","chemistry","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2pvi-g2gk","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865930: MLS000083326","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865930","description":"Access the complete Substance 865930: MLS000083326 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/nr42-fsyk","bureauCode":["009:20"],"issued":"2022-01-14","@type":"dcat:Dataset","modified":"2022-02-11","keyword":["wonder","nedss","2022","dengue","dengue virus infections","dengue-like illness","netss","nndss","severe dengue"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/nr42-fsyk","description":"NNDSS - TABLE 1J. Dengue virus infections, Dengue to Severe dengue - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.\n\nNotes:\n\n•\tThese are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.\n• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.\n•\tThe list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.\n\nFootnotes:\n\n*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.\n†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).\nU: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.\n-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.\nN: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.\nNN: Not nationally notifiable — This condition was not designated as being nationally notifiable.\nNP: Nationally notifiable but not published.\nNC: Not calculated — There is insufficient data available to support the calculation of this statistic.\nCum: Cumulative year-to-date counts.\nMax: Maximum — Maximum case count during the previous 52 weeks.","title":"NNDSS - TABLE 1J. Dengue virus infections, Dengue to Severe dengue","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nr42-fsyk/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nr42-fsyk/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nr42-fsyk/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nr42-fsyk/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nr42-fsyk/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nr42-fsyk/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2pws-z7yt","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2023-02-07","keyword":["drug rebate program"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"8f4b03ea-7cbc-44ed-a8b3-9524bbc01491","description":"The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2022-12-26-to-2023-01-01","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.medicaid.gov/sites/default/files/uploaded_resources/mdrp-newly-rprt-drug-12262022-to-01012023_0.csv","mediaType":"text/csv","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2022-12-26-to-2023-01-01"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2pwu-cpx7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","pubchem","references","bioactivity","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2pwu-cpx7","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864807: MLS000084612","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864807","description":"Access the complete Substance 864807: MLS000084612 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2px4-p789","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","patent","innovation","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2px4-p789","description":"1. Claims for the contracting states : BE, CH, DE, GB, IT, LI, NL, SE Safety manual control for locks with an electric control or others, which includes, generally near the door of the driver, a box (1) fixed by convenient means onto the metal sheet (3) of the body of the vehicule in consideration, the box (1) insidely containing, in a recess (4), a microcontact (5) responsive to the electronic central unit controlling the locks of the vehicle and connected via a cable (6a) to a source of electric energy (16) for driving the motor (14) the shaft (13) of which carries a latch (12) normally held perpendicularly to an unblocking bar (8) by a spring, the motor and the battery being placed inside a recess (15a) of a second recessed bar (15) on which bears the unblocking bar (8) formed with a notch (11) provided for receiving the upper end (12a) of the latch (12), then the second bar (15) includes, in its portion situated opposite the motor (14), a cable clamp (17) providing for the junction of the cable (18) housed in a sleeve (19) and used for the manual unlatching control of the locks, the unblocking bar (8) and the recessed bar (15) which are surimposed and slide in the chamber (7) of the box (1) being held in position laterally by a plate (20) fixed onto the inner side of the box (1), then the outer end of the unblocking bar (8) presents a junction point (9) which can be actuated directly or indirectly by a key from the inside or the outside of the vehicle. 1. Claims for the contracting states : AT, LU Safety manual control for electrically controlled locks or others, which includes, generally near the door of the driver, a box (1) fixed by convenient means onto the metal sheet (3) of the body of the vehicule in consideration, a source of electric energy (16) for driving a motor (14), this control being characterized in that the box (1) insidely contains, in a cell (4), a microcontact (5) responsive to the central electronic unit for controlling the vehicle locks and connected via a cable (6a) to the source of electric energy (16) for driving the motor (14) the shaft (13) of which carries a latch (12) normally held perpendicularly to an unblocking bar (8) by a spring, the motor and the battery being placed inside a recess (15a) of a second recessed bar (15) on which bears the unblocking bar (8) formed with a notch (11) provided for receiving the upper end (12a) of the latch (12), then the second bar (15) includes, in its portion situated opposite the motor (14), a cable clamp (17) providing for the junction of the cable (18) housed in a sleeve (19) and used for the manual unlatching control of the locks, the unblocking bar (8) and the recessed bar (15) which are surimposed and slide inside the chamber (7) of the box (1) being held in position laterally by a plate (20) fixed on the inner side of the box (1), then the outer end of the unblocking bar (8) presents a junction point (9) which can be directly or indirectly actuated by a key from the inside or outside the vehicle.","title":"Patent AT-E40171-T1: [Translated] HAND OPERATED SECURITY CONTROL FOR ELECTRIC LOCKS, PARTICULARLY FOR MOTOR VEHICLES.","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E40171-T1","description":"Access the complete Patent AT-E40171-T1: [Translated] HAND OPERATED SECURITY CONTROL FOR ELECTRIC LOCKS, PARTICULARLY FOR MOTOR VEHICLES. on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2px5-4wf9","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["treatment-discharges","samhsa","teds-d","adolescent-substance-abuse","substance-abuse-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2px5-4wf9","description":"This report uses the 2011 Treatment Episode Data Set–Discharges (TEDS-D), a national data system of annual discharges from substance abuse treatment facilities, to create a profile of adolescents who enter treatment for substance abuse. Specifically, the report examines demographic characteristics of discharges from treatment, treatment setting, health insurance, primary substance of abuse, criminal justice referral, and treatment disposition.","title":"Profile of Adolescent Discharges from Substance Abuse Treatment","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/profile-adolescent-discharges-substance-abuse-treatment","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["pharmaceuticals","drug-information","public-health","prescription-drugs","fda"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA074787","description":"Labetalol Hydrochloride is a generic prescription medication available as oral tablets in 100mg, 200mg, and 300mg strengths. Manufactured by Endo USA, Inc., it acts as a beta-adrenergic blocker to help manage high blood pressure. This information was generated using AI and is provided for informational and research purposes only.","title":"Labetalol hydrochloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=074787","description":"\n Access the FDA dataset for Labetalol hydrochloride — ANDA 074787 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Labetalol hydrochloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2pxp-pqsg","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2023-10-23","keyword":["drug rebate program"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"789babe6-36f6-4023-bf8d-b4fcc6313b11","description":"The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-10-16-to-2023-10-22","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.medicaid.gov/sites/default/files/uploaded_resources/mdrp-newly-rprt-drug-10-16-2023-to-10-22-2023.csv","mediaType":"text/csv","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-10-16-to-2023-10-22"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2pzp-jsyt","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","compound","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2pzp-jsyt","description":"Chemical compound data from PubChem database. IUPAC Name: 4-nitro-2-pentan-3-ylphenol. Molecular Formula: C11H15NO3. Molecular Weight: 209.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528950: Phenol, 2-(1-ethylpropyl)-4-nitro","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528950","description":"Access the complete Compound 528950: Phenol, 2-(1-ethylpropyl)-4-nitro on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2q4e-8849","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["treatment-episodes","samhsa","substance-abuse-treatment","teds-admissions","alcohol-drug-abuse"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2q4e-8849","description":"This report uses data from the Treatment Episode Data Set (TEDS) to examine treatment admission data in 2014, and trend data from 2004 to 2014, nationally, regionally (by the four Census regions and the nine Census divisions), and by state or jurisdiction. The report provides information on the demographic and substance abuse characteristics of admissions to treatment aged 12 and older for abuse of alcohol and/or drugs in facilities that report to individual state administrative data systems. It is important to note that values in charts, narrative lists, and percentage distributions are calculated using actual raw numbers and rounded for presentation in this report; calculations using rounded values may produce different results. For 2014, a total of 1,614,358 admissions aged 12 and older were reported to TEDS by 49 states, the District of Columbia, and Puerto Rico (South Carolina, which is in the South Atlantic Census division, did not report sufficient admissions for 2014)","title":"Treatment Episode Data Set (TEDS): 2004-2014, State Admissions To Substance Abuse Treatment Services","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/treatment-episode-data-set-teds-2004-2014-state-adm","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","bureauCode":["009:00"],"landingPage":"https://healthdata.gov/d/2q4u-gx6s","issued":"2014-06-19","@type":"dcat:Dataset","modified":"2014-06-19","keyword":["blog"],"contactPoint":{"@type":"vcard:Contact","fn":"HHS Office of the Chief Data Officer","hasEmail":"mailto:healthdata@hhs.gov"},"publisher":{"@type":"org:Organization","name":"James Craver"},"identifier":"https://healthdata.gov/api/views/2q4u-gx6s","description":"This blog post was posted by James Craver on June 19, 2014.","title":"Blog | Inviting the Developer Community to Explore HHS Data Assets though Codecademy","programCode":["009:110"],"theme":["Blog"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/4shh-ym4t","issued":"2015-10-26","@type":"dcat:Dataset","modified":"2016-12-28","keyword":["directory","facilities and services","managed care","medicaid","plan","pnds","provider"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/4shh-ym4t","description":"The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. This dataset reflects institutional provider data. Provider Network Data System information is self reported. For more information, go to http://www.health.ny.gov/health_care/managed_care/.","title":"Managed Care Institutional Provider Network Data: June 30, 2015","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/download/4shh-ym4t/application/zip","mediaType":"application/zip"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2q62-3ac9","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2q62-3ac9","description":"Chemical compound data from PubChem database. IUPAC Name: 1,3-dichloropropan-2-yl pentanoate. Molecular Formula: C8H14Cl2O2. Molecular Weight: 213.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527988: Pentanoic acid, 2-chloro-1-(chloromethyl)ethyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527988","description":"Access the complete Compound 527988: Pentanoic acid, 2-chloro-1-(chloromethyl)ethyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2q6s-fcb7","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["grant","metadata"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2q6s-fcb7","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Family Strengthening Scholars: 2016 Grantees & Abstracts","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/16458","description":"Access the complete Family Strengthening Scholars: 2016 Grantees & Abstracts.pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2q6u-dqfv","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","chemistry","pubchem","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2q6u-dqfv","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865536: MLS000083914","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865536","description":"Access the complete Substance 865536: MLS000083914 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-safety","pharmaceuticals","health-care","drug-manufacturers","prescription-drugs"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA040180","description":"Methadone Hydrochloride is a prescription opioid medication used to manage severe pain or treat opioid dependence. Available as oral tablets in 5mg and 10mg strengths, it's a controlled substance (Schedule II) manufactured by Epic Pharma, LLC. This information was generated using AI and is provided for informational and research purposes only.","title":"Methadone hydrochloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=040180","description":"\n Access the FDA dataset for Methadone hydrochloride — ANDA 040180 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Methadone hydrochloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://data.oregon.gov/d/6raa-5kpf","issued":"2017-02-13","@type":"dcat:Dataset","modified":"2017-02-13","contactPoint":{"@type":"vcard:Contact","fn":"Kaliipnettleton","hasEmail":"mailto:no-reply@data.oregon.gov"},"publisher":{"@type":"org:Organization","name":"State of Oregon"},"identifier":"https://data.oregon.gov/api/views/6raa-5kpf","description":"","title":"Title V Calendar set","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/6raa-5kpf/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/6raa-5kpf/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/6raa-5kpf/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/dataset/radlex","bureauCode":["009:00"],"issued":"2013-04-13","temporal":"2006-01-01T00:00:00-05:00/2006-11-15T00:00:00-05:00","@type":"dcat:Dataset","modified":"2023-07-25","keyword":["biomedical research","imaging","health it","health informatics","radiology"],"contactPoint":{"@type":"vcard:Contact","fn":"admin","hasEmail":"mailto:HealthData@hhs.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health (NIH), Department of Health & Human Services"},"identifier":"3c4eddf8-7c83-436a-9f48-5304d84d318b","description":"RadLex is a controlled terminology for radiology and serves as a single unified source of radiology terms for radiology practice, education, and research. RadLex is a comprehensive lexicon for standardized indexing and retrieval of radiology information resources. With more than 30,000 terms, RadLex satisfies the needs of software developers, system vendors and radiology users by adopting the best features of existing terminology systems while producing new terms to fill critical gaps. RadLex also provides a comprehensive and technology-friendly replacement for the ACR Index for Radiological Diagnoses. It unifies and supplements other lexicons and standards, such as SNOMED-CT, LOINC, and DICOM. As images, image reports, and medical records continue to move online RadLex meets the need of physicians to organize and retrieve image data using a common set of terms.
\n
\nRadReport is a radiology reporting initiative that is a part of RadLex. RadReport aims to improve reporting practices by creating a library of clear and consistent report templates. Report templates and information about RadReport is available at the link in Resource 2.
\n
The Protein Data Bank (PDB) archive is the single worldwide repository of information about the 3D structures of large biological molecules, including proteins and nucleic acids found in all organisms including bacteria, yeast, plants, flies, other animals, and humans.
","title":"Protein Data Bank (PDB)","programCode":["009:048"],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://data.sfgov.org/d/enwt-3u8m","issued":"2026-03-23","@type":"dcat:Dataset","modified":"2026-04-14","keyword":["street safety"],"contactPoint":{"@type":"vcard:Contact","fn":"OpenData","hasEmail":"mailto:no-reply@data.sfgov.org"},"publisher":{"@type":"org:Organization","name":"City of San Francisco"},"identifier":"https://data.sfgov.org/api/views/enwt-3u8m","description":"A. SUMMARY \nThis dataset includes street segments that were identified to be on the 2024 High Injury Network (HIN). The HIN shows the street corridors that had the highest concentration of severe and fatal injuries in the years 2020 to 2024. \n\nUsing the High Injury Network, San Francisco is better able to prioritize city resources to implement engineering, education, and enforcement activities that serve to make the streets safer. \n\nB. HOW THE DATASET IS CREATED \nThis dataset is sourced from traffic crash data from the San Francisco Police Department, hospital data from Zuckerberg San Francisco General Hospital (ZSFG), and ambulance operator data from American Medical Response (AMR) and the San Francisco Fire Department Emergency Medical Services (EMS). These data are linked using a non-probabilistic deterministic method to match records between these three data sources. Once they are matched, any details about the crash circumstances are defaulted to come from the San Francisco Police Department (SFPD), and the final injury severity determination is sourced from ZSFG Hospital. The dataset also includes un-matched SFPD severe and fatal crash victims that had associated geolocations, as well as un-linked ZSFG Hospital data from the Trauma Registry that had linked geolocation data from the ambulance operators’ pick- up locations. \n\nSan Francisco’s street centerline data layer is corridorized into segments that are at least 0.25 miles long along segments that share the same street name. Then, the point data of Killed or Severely Injured (KSI) is plotted onto the map and a KSI per mile per corridor is calculated based on a count of points that geographically intersect a given corridor. \n\nThe base map for the HIN is created by filtering corridors based on minimum length. Any corridor that is less than 0.25 miles in total length is excluded from eligibility onto the network. Then, corridors are selected based on a minimum cutpoint of “greater than or equal to 10 KSI per mile per corridor.” \n\nAdditional processing of the map includes finding street segments of the base HIN map that are greater than 500 feet away from the last on-HIN KSI on that street. These “stubs” are removed before producing the final HIN map in order to further prioritize city resources on the streets with the highest 5-year incidence of severe injuries and fatalities. \n\nC. UPDATE PROCESS \nThis dataset will not need to be updated once published. \n\nD. HOW TO USE THIS DATASET \nThis dataset only includes street segments that were identified to be on the High Injury Network. \n\nE. RELATED DATASETS \nTraffic Crashes Resulting in Injury \nTraffic Crashes Resulting in Injury: Parties Involved \nTraffic Crashes Resulting in Injury: Victims Involved \nTraffic Crashes Resulting in Fatality \n2022 High Injury Network \n \nF. KNOWN USES \n* San Francisco County Transportation Authority\n* Public health injury prevention professionals \n* SFMTA staff\n* Transit Advocates \n* Pedestrian advocates\n* Bicycling advocates\n* Senior health centers and residential centers\n* Automobile insurance companies\n* California Office of Traffic Safety","title":"2024 High Injury Network","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/enwt-3u8m/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/enwt-3u8m/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/enwt-3u8m/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/enwt-3u8m/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/enwt-3u8m/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/enwt-3u8m/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendatacommons.org/licenses/pddl/1.0/","theme":["Health and Social Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2sev-j4x2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","pubchem","references","chemistry","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2sev-j4x2","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864686: MLS000084128","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864686","description":"Access the complete Substance 864686: MLS000084128 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2sf7-anpm","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2sf7-anpm","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865412: MLS000084474","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865412","description":"Access the complete Substance 865412: MLS000084474 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2shs-536v","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-abuse-treatment","n-ssats","facility-practices","behavioral-health-services","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2shs-536v","description":"This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing facilities employing specific practices as part of their standard operating procedures, by facility operation and primary focus of facility in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.","title":"4.17b Facilities employing specific practices as part of their standard operating procedures, by facility operation and primary focus of facility: 2011. Percent","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/417b-facilities-employing-specific-practices-part-their-standard-operating-procedures","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2si8-e863","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","compound","chemistry","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2si8-e863","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(4a,8-dimethyl-4,5,6,7,8,8a-hexahydro-3H-naphthalen-2-yl)ethanone. Molecular Formula: C14H22O. Molecular Weight: 206.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527183: 1-(4a,8-dimethyl-4,5,6,7,8,8a-hexahydro-3H-naphthalen-2-yl)ethanone","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527183","description":"Access the complete Compound 527183: 1-(4a,8-dimethyl-4,5,6,7,8,8a-hexahydro-3H-naphthalen-2-yl)ethanone on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2sre-6w3v","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2sre-6w3v","description":"Chemical compound data from PubChem database. IUPAC Name: 3-(furan-2-ylmethyl)-2,5-dimethylpyrazine. Molecular Formula: C11H12N2O. Molecular Weight: 188.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529869: 3-(2-Furfuryl)-2,5-dimethylpyrazine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529869","description":"Access the complete Compound 529869: 3-(2-Furfuryl)-2,5-dimethylpyrazine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2srf-ubct","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2srf-ubct","description":"Chemical compound data from PubChem database. IUPAC Name: N-pentyl-N-propylpentan-1-amine. Molecular Formula: C13H29N. Molecular Weight: 199.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527007: 1-Pentanamine, N-pentyl-N-propyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527007","description":"Access the complete Compound 527007: 1-Pentanamine, N-pentyl-N-propyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ss9-y379","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["child","abuse","policy","prevention","grant"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2ss9-y379","description":"This Information Memorandum (IM) provides information on the new Community-Based Family Resource and Support Grants program created by Title II of the Child Abuse Prevention and Treatment Act Amendments of 1996 (Pub. L. 104-235).\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-96-29)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-96-29","description":"Access the complete IM-96-29 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2sss-qs4s","issued":"2020-11-20","@type":"dcat:Dataset","modified":"2022-02-02","keyword":["census","demographics","doh","health","pcsa","population","primary care service areas","rural health","statistics","vital statistics"],"contactPoint":{"@type":"vcard:Contact","fn":"CKAN Administrator","hasEmail":"mailto:opendataops+ckanportal@opengov.com"},"publisher":{"@type":"org:Organization","name":"State of Hawaii"},"identifier":"74fb4533-db19-4289-a9fb-1eefbb638153","description":"The Mortality - Multiple Cause of Death data on CDC WONDER are county-level national mortality and population data spanning the yehttps://healthdata.gov/d/2sz9-6c59ars 1999-2006. These data are available in two separate data sets: one data set for years 1999-2004 with 3 race groups, and another data set for years 2005-2006 with 4 race groups and 3 Hispanic origin categories. Data are based on death certificates for U.S. residents. Each death certificate contains a single underlying cause of death, up to twenty additional multiple causes, and demographic data. The number of deaths, crude death rates, age-adjusted death rates, standard errors and 95% confidence intervals for death rates can be obtained by place of residence (total U.S., state, and county), age group (including infants), race, Hispanic ethnicity (years 2005-2006 only), sex, year of death, and cause-of-death (4-digit ICD-10 code or group of codes). The data are produced by the National Center for Health Statistics.
","title":"CDC WONDER: Mortality - Multiple Cause of Death","programCode":["009:048"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://wonder.cdc.gov/mcd.html","mediaType":"text/html","title":"Query Tool "}],"describedBy":"http://wonder.cdc.gov/wonder/help/mcd.html","dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2t28-7fgj","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["alcohol-use","brfss-nsduh-comparison","cigarette-use","samhsa","state-level-prevalence"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2t28-7fgj","description":"This report includes a brief description of the Behavioral Risk Factor Surveillance System (BRFSS) and presents a comparison of state-level BRFSS and NSDUH alcohol and cigarette prevalence estimates for persons aged 18 or older.","title":"2012-2013 NSDUH: Other Sources of State-level Data","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-2013-nsduh-other-sources-state-level-data","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2t4z-sast","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2t4z-sast","description":"Chemical compound data from PubChem database. IUPAC Name: 2-(5-methoxy-1-trimethylsilylindol-3-yl)ethoxy-trimethylsilane. Molecular Formula: C17H29NO2Si2. Molecular Weight: 335.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530120: 5-Methoxytryptophol, TMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530120","description":"Access the complete Compound 530120: 5-Methoxytryptophol, TMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2t54-f8i4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","patent","research","innovation","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2t54-f8i4","description":"The present invention provides a device for the electrochemical analysis of electrolytic components in a sample liquid (58), especially of a body fluid, with a selective measurement electrode (20) for a kind of ion to be analysed, a reference half cell, which includes a conducting-off element (30) cooperating in the operational state with a reference electrolyte (56), and a voltage measurement device (34) for the measurement of the voltage between the measurement electrode and the conducting-off element (30), wherein the measurement electrode (20) is arranged on a pipe (22) provided with a sucking-in opening (23) for the sample liquid (58), the conducting-off element (30) of the reference half cell being arranged on the pipe (22) in such a manner that it directly contacts a liquid (56) present therein, the conducting-off element (30) thereby being arranged in the pipe (22) in the sucking-in direction behind the measurement electrode (20), a sucking-in device (36) being provided through which a sample liquid (58) can be sucked in and, together with a liquid reference electrolyte present in the pipe (22) or previously sucked in, is transportable subsequent to this in the same direction in the pipe (22) and the voltage measurement device (34) is activatable in a measurement operational state in that the sample liquid (58) contacts the measurement electrode and the reference liquid (56) contacts the conducting-off element (30) and both liquids are in contact with one another, making possible an ion exchange.","title":"Patent AT-E40009-T1: [Translated] DEVICE FOR THE ELECTROCHEMICAL ANALYSIS OF ELECTROLYTIC COMPONENTS IN A SAMPLE LIQUID.","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E40009-T1","description":"Access the complete Patent AT-E40009-T1: [Translated] DEVICE FOR THE ELECTROCHEMICAL ANALYSIS OF ELECTROLYTIC COMPONENTS IN A SAMPLE LIQUID. on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-safety","fda","prescription-drugs","drug","drug-information"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA205919","description":"Mercaptopurine is an oral suspension prescription drug that inhibits nucleic acid synthesis, used to treat certain cancers like leukemia. It comes in a 20 mg/mL strength, manufactured by Hikma Pharmaceuticals USA Inc. This information was generated using AI and is provided for informational and research purposes only.","title":"Mercaptopurine","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205919","description":"\n Access the FDA dataset for Mercaptopurine — ANDA 205919 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Mercaptopurine"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tb2-7b9d","bureauCode":["009:38"],"issued":"2026-07-08","@type":"dcat:Dataset","modified":"2026-07-01","keyword":["drug products"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"190326eb-878c-4aaf-ae2b-1082bf34ff70","description":"The Reference Document link for the downloadable Blood Disorder Treatment Spreadsheet can be accessed below under the Additional Information table under Related Documents.","title":"Pricing Comparison for Blood Disorder Treatments (Pricing as of 06/1/2026)","programCode":["009:076"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/Clotting-Factor-June2026.csv","mediaType":"text/csv"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","theme":["Drug Pricing and Payment"]},{"accessLevel":"public","landingPage":"https://gis.dhcs.ca.gov/datasets/CADHCS::chart-2-3-2-total-number-of-ecm-provider-contracts-in-the-last-12-months-of-the-reporting-period-by-population-of-focus","issued":"2024-01-24","temporal":"Other","@type":"dcat:Dataset","modified":"2026-06-26","keyword":["enhanced care management","community supports","ecm","cs"],"contactPoint":{"@type":"vcard:Contact","fn":"DHCS","hasEmail":"mailto:gis@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"6852bd02-1986-4fb0-8989-cdc753f6ee1c","description":"ECM Community Support Services tables for a Quarterly Implementation Report. Including the County and Plan Details for both ECM and Community Support.
This Medi-Cal Enhanced Care Management (ECM) and Community Supports Calendar Year Quarterly Implementation Report provides a comprehensive overview of ECM and Community Supports implementation in the programs' first year. It includes data at the state, county, and plan levels on total members served, utilization, and provider networks.
ECM is a statewide MCP benefit that provides person-centered, community-based care management to the highest need members. The Department of Health Care Services (DHCS) and its MCP partners began implementing ECM in phases by Populations of Focus (POFs), with the first three POFs launching statewide in CY 2022.
Community Supports are services that address members’ health-related social needs and help them avoid higher, costlier levels of care. Although it is optional for MCPs to offer these services, every Medi-Cal MCP offered Community Supports in 2022, and at least two Community Supports services were offered and available in every county by the end of the year.
","title":"Chart 2.3.2 Total Number of ECM Provider Contracts in the Last 12 Months of the Reporting Period by Population of Focus","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/datasets/CADHCS::chart-2-3-2-total-number-of-ecm-provider-contracts-in-the-last-12-months-of-the-reporting-period-by-population-of-focus","mediaType":"text/html","title":"ArcGIS Hub Dataset"},{"@type":"dcat:Distribution","downloadURL":"https://services7.arcgis.com/7MUwsS9z05YumJRZ/arcgis/rest/services/ECM_Community_Support_Data_Tables_for_Quarterly_Implementation_report/FeatureServer/30","mediaType":"application/octet-stream","title":"ArcGIS GeoService"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/csv?layers=30","mediaType":"text/csv","title":"CSV"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/shapefile?layers=30","mediaType":"application/zip","title":"Shapefile"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/geojson?layers=30","mediaType":"application/geo+json","title":"GeoJSON"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/kml?layers=30","mediaType":"application/vnd.google-earth.kml+xml","title":"KML"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/6852bd02-1986-4fb0-8989-cdc753f6ee1c/resource/3e09e144-86fb-4a86-8fef-695d62d1ad14/download/chart-2-3-2-total-number-of-ecm-provider-contracts-in-the-last-12-months-of-the-reporting-perio-.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tbh-nkvd","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","research","pubchem","chemistry","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2tbh-nkvd","description":"Chemical compound data from PubChem database. IUPAC Name: 2-methyl-2-(2-methylbutan-2-ylsulfanyl)butane. Molecular Formula: C10H22S. Molecular Weight: 174.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525426: 3,3,5,5-Tetramethyl-4-thiaheptane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525426","description":"Access the complete Compound 525426: 3,3,5,5-Tetramethyl-4-thiaheptane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tch-hu83","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["suicidal-ideation","adult-mental-health","unmet-needs","samhsa","mental-health-services"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2tch-hu83","description":"This spotlight presents serious thoughts of suicide in the past year among adults aged 18 or older 2008 to 2012 National Surveys on Drug Use and Health (NSDUHs) by whether they received mental health services.","title":"Half of Adults with Serious Thoughts of Suicide Did Not Receive Mental Health Services (2008 to 2012 NSDUH)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/half-adults-serious-thoughts-suicide-did-not-receive-mental-health-services-2008-2012-nsduh","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tf3-jb7v","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","science","compound","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2tf3-jb7v","description":"Chemical compound data from PubChem database. IUPAC Name: 3-methyl-2-methylsulfanyl-5-propan-2-ylpyrazine. Molecular Formula: C9H14N2S. Molecular Weight: 182.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528140: 5-Isopropyl-3-methyl-2-(methylthio)pyrazine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528140","description":"Access the complete Compound 528140: 5-Isopropyl-3-methyl-2-(methylthio)pyrazine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tgf-zxv7","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["child","acf","social","service","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2tgf-zxv7","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"NHSIA Overview Transcript","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14291","description":"Access the complete NHSIA Overview Transcript on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"http://www.dhcs.ca.gov","issued":"2017-10-11","temporal":"2016 Quarter 1 to 2026 Quarter 1","@type":"dcat:Dataset","modified":"2026-06-08","keyword":["english","written language","vietnamese","traditional chinese character","tagalog","spanish","russian","qhp","medi-cal eligibility","medi-cal","mandarin","korean","insurance affordability programs","individual","iap","hmong","farsi","eligible","demographic","covered ca covered ca qhp eligibility","cantonese","cambodian","california eligibility and enrollment report","calheers","armenian","arabic","application","abx1 1","abx"],"contactPoint":{"@type":"vcard:Contact","fn":"Covered California","hasEmail":"mailto:opendata@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"79a206e2-13bf-482a-9cf0-de93b6452ef1","description":"This dataset includes the primary written language of applicants for Insurance Affordability Programs (IAPs) who identified their primary written language as English, Spanish, Traditional Chinese character, Korean, Vietnamese, Mandarin, Cantonese, Russian, Tagalog, Farsi, Arabic, Cambodian, Armenian, or Hmong by reporting period. The primary written language data is from the California Healthcare Eligibility, Enrollment and Retention System (CalHEERS) and includes data from applications submitted directly to CalHEERS, to Covered California, and to County Human Services Agencies through the Statewide Automated Welfare System (SAWS) eHIT interface. This dataset is part of public reporting requirements set forth by the California Welfare and Institutions Code 14102.5.","title":"Primary Written Language of Applicants for Insurance Affordability Programs","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/79a206e2-13bf-482a-9cf0-de93b6452ef1/resource/585782a6-e56f-440f-9641-d69e63f8f724/download/2.5-primary-written-language_q1_2026_odp.csv","description":"This dataset includes the primary written language of applicants for Insurance Affordability Programs (IAPs) who identified their primary written language as English, Spanish, Traditional Chinese character, Korean, Vietnamese, Mandarin, Cantonese, Russian, Tagalog, Farsi, Arabic, Cambodian, Armenian, or Hmong by reporting period. The primary written language data is from the California Healthcare Eligibility, Enrollment and Retention System (CalHEERS) and includes data from applications submitted directly to CalHEERS, to Covered California, and to County Human Services Agencies through the Statewide Automated Welfare System (SAWS) eHIT interface. This dataset is part of public reporting requirements set forth by the California Welfare and Institutions Code 14102.5.","@type":"dcat:Distribution","title":"Primary Written Language of Applicants for Insurance Affordability Programs"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/datastore/dictionary_download/585782a6-e56f-440f-9641-d69e63f8f724","description":"Data Dictionary for https://data.chhs.ca.gov/dataset/79a206e2-13bf-482a-9cf0-de93b6452ef1/resource/585782a6-e56f-440f-9641-d69e63f8f724/download/2.5-primary-written-language_q1_2026_odp.csv","@type":"dcat:Distribution","title":"Data Dictionary - Primary Written Language of Applicants for Insurance Affordability Programs "},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/79a206e2-13bf-482a-9cf0-de93b6452ef1/resource/a2cffbb3-61a6-4ffa-8d9c-d131a6cb781c/download/primary-written-language-of-applicants-for-insurance-affordability-programs-i6ef6okd.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P3M","theme":["Demographics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tkm-ei7x","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2tkm-ei7x","description":"Chemical compound data from PubChem database. IUPAC Name: hexadecyl 5-bromopentanoate. Molecular Formula: C21H41BrO2. Molecular Weight: 405.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530519: 5-Bromovaleric acid, hexadecyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530519","description":"Access the complete Compound 530519: 5-Bromovaleric acid, hexadecyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tm8-3qks","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","compound","pubchem","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2tm8-3qks","description":"Chemical compound data from PubChem database. IUPAC Name: 2-(1-prop-2-enylsulfanylethylsulfanyl)propane. Molecular Formula: C8H16S2. Molecular Weight: 176.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525373: 2,4-Dimethyl-3,5-dithia-7-octene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525373","description":"Access the complete Compound 525373: 2,4-Dimethyl-3,5-dithia-7-octene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tmw-njsd","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["metadata","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2tmw-njsd","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Colorado CCISS Assessment Final Report","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14198","description":"Access the complete Colorado CCISS Assessment Final Report on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tq5-czzk","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["prevention","metadata"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2tq5-czzk","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Human Trafficking Prevention","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/16377","description":"Access the complete Human Trafficking Prevention on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tqq-idg7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2tqq-idg7","description":"Chemical compound data from PubChem database. IUPAC Name: 3-O-(2-hydroxyethyl) 5-O-methyl 2,6-dimethyl-4-(3-nitrophenyl)pyridine-3,5-dicarboxylate. Molecular Formula: C18H18N2O7. Molecular Weight: 374.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529922: Nicardipine M (dehydro-desamino-hydroxy)","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529922","description":"Access the complete Compound 529922: Nicardipine M (dehydro-desamino-hydroxy) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2trd-itbi","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","research","chemistry","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2trd-itbi","description":"Chemical compound data from PubChem database. IUPAC Name: 4-methoxy-2-methylbutane-2-thiol. Molecular Formula: C6H14OS. Molecular Weight: 134.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526195: 4-Methoxy-2-methyl-2-butanethiol","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526195","description":"Access the complete Compound 526195: 4-Methoxy-2-methyl-2-butanethiol on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2trd-wg7s","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","bioactivity","substance","references","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2trd-wg7s","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865472: MLS000039954","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865472","description":"Access the complete Substance 865472: MLS000039954 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tt5-x6qx","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","innovation","patent","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2tt5-x6qx","description":"The device has an L-shaped longitudinal metal section (6) made of aluminum and having perpendicular wings (7, 8). Two parallel longitudinal grooves (9) extend vertically along the height of the section and have opposite inner walls with a toothed section, formed by parallel ridges (11) extending along the length of the grooves. The grooves receive screws adapted for the fixation of a panel (2) on the section.","title":"Patent AT-E399922-T1: [Translated] FASTENING DEVICE FOR A WALL PART OF A SHOWER CABIN","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399922-T1","description":"Access the complete Patent AT-E399922-T1: [Translated] FASTENING DEVICE FOR A WALL PART OF A SHOWER CABIN on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2twa-ruhe","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2026-02-09","references":["https://www.mathematica.org/"],"keyword":["scorecard","utility"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"253c29a7-f6dd-5d91-8c1f-142e1a436a66","description":"This is a dataset created for the Medicaid Scorecard website (https://www.medicaid.gov/state-overviews/scorecard/index.html), and is not intended for use outside that application.","title":"CoreSet pillar v3.9.38 (CMS Development)","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/coreset-viz/3.9.38/20260209/pillar.csv","description":"CoreSet pillar v3.9.38 (CMS Development)","@type":"dcat:Distribution","title":"CoreSet pillar v3.9.38 (CMS Development)"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2twj-y4gj","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","compound","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2twj-y4gj","description":"Chemical compound data from PubChem database. IUPAC Name: N'-(4-chlorophenyl)-N-(4-ethoxyphenyl)methanimidamide. Molecular Formula: C15H15ClN2O. Molecular Weight: 274.74. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525798: N-(4-Ethoxyphenyl)-N'-(4-chlorophenyl)formamidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525798","description":"Access the complete Compound 525798: N-(4-Ethoxyphenyl)-N'-(4-chlorophenyl)formamidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["fda","public-health","medications","health-care","drug-safety"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA209013","description":"Doxazosin Mesylate is a prescription medication available as oral tablets in strengths of 1mg, 2mg, 4mg, and 8mg. It belongs to the class of alpha-adrenergic blockers and is used to treat high blood pressure and symptoms of an enlarged prostate. Manufactured by Upsher-Smith Laboratories, LLC, under application ANDA209013. This information was generated using AI and is provided for informational and research purposes only.","title":"Doxazosin mesylate","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209013","description":"\n Access the FDA dataset for Doxazosin mesylate — ANDA 209013 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Doxazosin mesylate"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://data.colorado.gov/d/ffjg-bf34","issued":"2020-03-19","@type":"dcat:Dataset","modified":"2026-07-10","keyword":["bic","cdphe","covid19","dashboard","esri"],"contactPoint":{"@type":"vcard:Contact","fn":"Business Intelligence Center of CO","hasEmail":"mailto:no-reply@data.colorado.gov"},"publisher":{"@type":"org:Organization","name":"State of Colorado"},"identifier":"https://data.colorado.gov/api/views/ffjg-bf34","description":"Corona Virus (COVID-19) epidemological Colorado Dashboard.","title":"COVID-19 Colorado Cases Dashboard","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://covid19.colorado.gov/data","mediaType":"text/html","title":"COVID-19 Colorado Cases Dashboard"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2tzr-ddtu","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2tzr-ddtu","description":"Chemical compound data from PubChem database. IUPAC Name: 2,2-dichloroethyl hexanoate. Molecular Formula: C8H14Cl2O2. Molecular Weight: 213.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527761: 2,2-Dichloroethyl hexanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527761","description":"Access the complete Compound 527761: 2,2-Dichloroethyl hexanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2u23-hpfc","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2u23-hpfc","description":"Chemical compound data from PubChem database. IUPAC Name: N-(3-bromophenyl)-N'-(3-ethoxyphenyl)methanimidamide. Molecular Formula: C15H15BrN2O. Molecular Weight: 319.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525791: N-(3-Ethoxyphenyl)-N'-(3-chlorophenyl)formamidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525791","description":"Access the complete Compound 525791: N-(3-Ethoxyphenyl)-N'-(3-chlorophenyl)formamidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2u4p-wxjb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","compound","chemistry","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2u4p-wxjb","description":"Chemical compound data from PubChem database. IUPAC Name: 2,3-dimethoxypropyl 10-methyldodecanoate. Molecular Formula: C18H36O4. Molecular Weight: 316.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528832: Ethyl (2E)-2-(1,3-benzodioxol-5-ylmethylene)hydrazinecarboxylate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528832","description":"Access the complete Compound 528832: Ethyl (2E)-2-(1,3-benzodioxol-5-ylmethylene)hydrazinecarboxylate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2u6d-rjxg","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","pubchem","references","substance","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2u6d-rjxg","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865097: MLS000083241","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865097","description":"Access the complete Substance 865097: MLS000083241 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2u87-3w9f","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","compound","chemistry","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2u87-3w9f","description":"Chemical compound data from PubChem database. IUPAC Name: N-(3-bromophenyl)-1-(4-bromophenyl)methanimine. Molecular Formula: C13H9Br2N. Molecular Weight: 339.02. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525653: p-Bromobenzylidene-(3-bromophenyl)-amine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525653","description":"Access the complete Compound 525653: p-Bromobenzylidene-(3-bromophenyl)-amine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2u89-dewm","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["endotoxemia-assay","critical-illness","sepsis-prognosis","nih","gram-negative-infection"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2u89-dewm","description":"The detection of endotoxemia may provide a clue to the cause of sepsis or may indicate translocation of endotoxin from the gastrointestinal tract. A reliable endotoxin activity assay (EAA) offers the potential to determine Gram-negative infections in critically ill patients. In addition, a reliable EAA may indicate the adequacy of gastrointestinal tract perfusion, as well as potentially help to predict morbidity and mortality. A recent study by Marshall and colleagues, published in the present issue of Critical Care, evaluated the use of a whole blood EAA in a medical–surgical intensive care unit and found that 58% of the patients had positive endotoxin assays. However, only 13.5% of the population had a documented Gram-negative infection. This discrepancy and the observation that translocation and other causes of endotoxemia may not reflect true Gram-negative infection might severely limit the clinical utility of this EAA. Further study may better define the potential role of this technique in the diagnostic evaluation of the critically ill patient.","title":"Endotoxemia in critically ill patients: why a reliable test could be beneficial","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137306/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2u8y-587j","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","innovation","patent","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2u8y-587j","description":"A method and a device for the removal of rust and paint from a metal surface, wherein induction heat is used for heating the metal surface. The device includes an electrical power supply coupled to an induction coil. A wheel and a tachometer on the device measure the velocity of the device as the wheel rotates on the metal surface. A control unit regulates the power output of the electrical power supply based upon the measured velocity of the device.","title":"Patent AT-E399655-T1: [Translated] DEVICE AND METHOD FOR PAINTING AND RUST REMOVAL","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399655-T1","description":"Access the complete Patent AT-E399655-T1: [Translated] DEVICE AND METHOD FOR PAINTING AND RUST REMOVAL on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"restricted public","landingPage":"https://healthdata.gov/dataset/study-womens-health-across-nation-swan-public-use-data","bureauCode":["009:00"],"rights":"N/A","issued":"2015-03-04","@type":"dcat:Dataset","temporal":"2010-09-02T00:00:00-04:00/2011-11-22T00:00:00-05:00","modified":"2023-07-26","keyword":["bone loss","cardiovascular disease","chronic diseases","cognitive function","depression","diabetes","menopause","midlife","osteoporosis","physcial function","sexual function","swan","urogenital symptoms","vasomotor symptoms","women s health"],"contactPoint":{"@type":"vcard:Contact","fn":"Alicia Colvin Greene","hasEmail":"mailto:swanaccess@edc.pitt.edu"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health (NIH)"},"identifier":"fc814791-05e7-4b65-8feb-3767c722c361","description":"The SWAN Public Use Datasets provide access to longitudinal data describing the physical, biological, psychological, and social changes that occur during the menopausal transition. Data collected from 3,302 SWAN participants from Baseline through the 10th Annual Follow-Up visit are currently available to the public. Registered users are able to download datasets in a variety of formats, search variables and view recent publications.
","title":"Study of Womens Health Across the Nation (SWAN) Public Use Data","programCode":["009:048"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://www.icpsr.umich.edu/web/ICPSR/series/253","mediaType":"text/html","title":"https://www.icpsr.umich.edu/web/ICPSR/series/253"}],"describedBy":"http://www.icpsr.umich.edu/icpsrweb/ICPSR/series/253","dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2u9y-ibts","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["peptide-motif","natural-killer-cells","mhc-class-ib","hla-e-binding","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2u9y-ibts","description":"Background\n Increasing evidence suggests that the effect of HLA-E on Natural Killer (NK) cell activity can be affected by the nature of the peptides bound to this non-classical, MHC class Ib molecule. However, its reduced cell surface expression, and until recently, the lack of specific monoclonal antibodies hinder studying the peptide-binding specificity HLA-E.\n \n \n Results\n An in vitro refolding system was used to assess binding of recombinant HLA-E to either specific peptides or a nonamer random peptide library. Peptides eluted from HLA-E molecules refolded around the nonamer library were then used to determine a binding motif for HLA-E. Hydrophobic and non-charged amino acids were found to predominate along the peptide motif, with a leucine anchor at P9, but surprisingly there was no methionine preference at P2, as suggested by previous studies.\n \n \n Conclusions\n Compared to the results obtained with rat classical class Ia MHC molecules, RT1-A1c and RT1-Au, HLA-E appears to refold around a random peptide library to reduced but detectable levels, suggesting that this molecule's specificity is tight but probably not as exquisite as has been previously suggested. This, and a previous report that it can associate with synthetic peptides carrying a viral sequence, suggests that HLA-E, similar to its mouse counterpart (Qa-1b), could possibly bind peptides different from MHC class I leader peptides and present them to T lymphocytes.","title":"Peptide binding characteristics of the non-classical class Ib MHC molecule HLA-E assessed by a recombinant random peptide approach","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC33820/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ucd-cqqs","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2ucd-cqqs","description":"Chemical compound data from PubChem database. IUPAC Name: 2-phenyl-5,7-bis(trimethylsilyloxy)-2,3-dihydrochromen-4-one. Molecular Formula: C21H28O4Si2. Molecular Weight: 400.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528428: Flavanone, 5,7-dihydroxy, bis-TMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528428","description":"Access the complete Compound 528428: Flavanone, 5,7-dihydroxy, bis-TMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-manufacturers","pharmaceuticals","public-health","fda","drug-information"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA214415","description":"Oxybutynin Chloride is a prescription medication used to treat overactive bladder symptoms like frequent urination and incontinence. It comes as extended-release oral tablets in 5mg, 10mg, and 15mg strengths, manufactured by Accord Healthcare under ANDA207138. This information was generated using AI and is provided for informational and research purposes only.","title":"Oxybutynin chloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214415","description":"\n Access the FDA dataset for Oxybutynin chloride — ANDA 214415 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Oxybutynin chloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2uf3-ckky","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["hepatitis-c","physician-preferences","nih","antiviral-therapy","health-state-utilities"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2uf3-ckky","description":"Background\n Physicians' perspectives regarding hepatitis C shape their approach to patient management. We used utility analysis to evaluate physicians' perceptions of hepatitis C-related health states (HS) and their threshold to recommend treatment.\n \n \n Methods\n A written questionnaire was administered to practicing physicians. They were asked to rate hepatitis C health states on a visual analog scale ranging from 0% (death) to 100% (health without hepatitis C). Physicians then judged quality of life associated with the side effects of antiviral therapy for hepatitis C and indicated the sustained virological response rate that they would require to recommend treatment.\n \n \n Results\n One hundred and thirteen physicians from five states were included. Median utility ratings for hepatitis C health states declined significantly with increasing severity of symptoms: HS1-No Symptoms, No Cirrhosis (88%; 12% reduction from good health), HS2-Mild Symptoms, No Cirrhosis (66%), HS3-Moderate Symptoms, No Cirrhosis (49%), HS4-Mild Symptoms, Cirrhosis (40%), HS5-Severe Symptoms, Cirrhosis (18%) [p < 0.001]. The median rating for life with side effects of antiviral therapy was 47%, suggesting a 53% reduction from good health. That was similar to the utility value for HS3-Moderate Symptoms, No Cirrhosis. The median threshold value for recommending treatment was a sustained response rate of 60%.\n \n \n Conclusions\n 1) Physicians' utility ratings for hepatitis C health states were inversely related to the severity of disease manifestations described. 2) Physicians viewed side effects of therapy unfavorably and indicated that on average, they would require a 60% sustained response rate before recommending treatment, which far exceeds the efficacy of current antiviral therapy for hepatitis C in the majority of patients.","title":"Physicians' preference values for hepatitis C health states and antiviral therapy: A survey","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC37537/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ufi-hhnh","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["cytokine-levels","progesterone-levels","pediatric-cardiology","nih","cardiopulmonary-bypass"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2ufi-hhnh","description":"Background\n It is known that proinflammatory and anti-inflammatory cytokines are released during and after cardiopulmonary bypass (CPB) in infants and children. Sex steroids are known to have immunomodulatory functions, and release of the anti-inflammatory cytokine IL-10 is stimulated by progesterone in vitro. The purpose of the present study was to investigate the plasma levels of progesterone, IL-8 (proinflammatory cytokine) and IL-10, and to relate them to sex and postoperative morbidity.\n \n \n Method\n Eighteen infants and children (eight female) undergoing CPB were prospectively studied. Plasma levels of progesterone, IL-8 and IL-10 were determined before and 10 min after the start of CPB, and immediately after CPB; and 6 h, 24 h, 3 days and 7 days postoperatively. Organ dysfunction was identified on the basis of arbitrarily defined criteria.\n \n \n Results\n After CPB, all patients showed significant increases in plasma levels of progesterone, IL-8 and IL-10. Plasma levels of IL-10 were significantly higher in female patients, except for during the immediate postoperative period. According to the criteria used, six out of 10 male patients, but none of the female patients developed multiple organ dysfunction (MOD).\n \n \n Conclusion\n The present study shows that CPB induces a significant and marked increase in plasma levels of progesterone in infants and children. Studies of administration of progesterone-blocking substances to male and female animals may help to elucidate the roles of sex and progesterone in the setting of CBP.","title":"Gender-related plasma levels of progesterone, interleukin-8 and interleukin-10 during and after cardiopulmonary bypass in infants and children","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC83856/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ujq-axjz","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-data","mental-health","alaska-health","substance-use","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2ujq-axjz","description":"This report presents Alaska\\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Alaska for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"Alaska (AK)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/alaska-ak","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-dashboard.html","bureauCode":["009:20"],"issued":"2022-09-28","@type":"dcat:Dataset","modified":"2022-09-28","references":["IQVIA Pharmacy and Physician Medical Office Claims"],"keyword":["flu","physician medical office vaccinations","pharmacy vaccinations","vaccine coverage","iqvia","influenza"],"contactPoint":{"@type":"vcard:Contact","fn":"Vax View","hasEmail":"mailto:VaxView@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/uxgd-cqqc","description":"Weekly Cumulative Estimated Number of Influenza Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States\n\n- Since 2019, CDC has been exploring use of data obtained from (https://www.iqvia.com/) as a source of information on vaccinations administered in retail pharmacies (include chain, mass merchandise, food stores, and independent pharmacies) and physician medical offices. These data are being presented publicly for the first time this season; further evaluations of these data are underway.\n\n- The pharmacy data include flu vaccinations that were billed for (i.e. claims) or paid by cash. Medical office data are claims based.\n\n- The sampled pharmacies and physician medical offices and the captured volume of transactions represent approximately 92% and 82% of influenza vaccines administered nationally, respectively.\n\n- Vaccinations administered in other settings such as workplaces and community settings are not included in these data.\n\n- Weekly Number of Influenza Vaccinations Administered, in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States, Data Source(s): IQVIA Pharmacy and Physician Medical Office Claims.","title":"Weekly Cumulative Estimated Number of Influenza Vaccinations Administered in Pharmacies and Physician Medical Offices, Adults 18 years and older, United States (ARCHIVED)","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/uxgd-cqqc/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/uxgd-cqqc/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/uxgd-cqqc/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"https://www.usa.gov/government-works","theme":["Vaccinations"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2umv-cghk","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","research","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2umv-cghk","description":"Chemical compound data from PubChem database. IUPAC Name: N'-butyl-N,N-dimethyl-2-phenylethanimidamide. Molecular Formula: C14H22N2. Molecular Weight: 218.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525860: N,N-Dimethyl-2-phenyl-N'-butyl-acetamidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525860","description":"Access the complete Compound 525860: N,N-Dimethyl-2-phenyl-N'-butyl-acetamidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2uqc-3fae","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","survey","substance-use-disorder","major-depressive-episode","nsduh-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2uqc-3fae","description":"This report presents combined 2005 to 2010 National Survey on Drug Use and Health (NSDUH) results for those aged 12 or older in the Portland-Vancouver-Hillsboro, OR-WA metro area. The report includes estimates of substance use disorder, major depressive episode, illicit drug use, marijuana use, cigarette use, binge alcohol use, and the nonmedical use of prescription-type pain relievers. Results are provided for the Pitts Portland-Vancouver-Hillsboro metro area, Oregon, and the U.S. overall.","title":"Publications Using SAMHSA DataPortland-Vancouver-Hillsboro, OR-WA","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/portland-vancouver-hillsboro-or-wa","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2uqd-xd6t","bureauCode":["009:38"],"issued":"2016-08-22","@type":"dcat:Dataset","modified":"2026-06-16","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"CMS","hasEmail":"mailto:EssentialCommunityProviders@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"dwyq-rebe","description":"ECP Rolling Draft Dataset. Please visit https://data.healthcare.gov/rolling-draft-list to search and filter for your provider site within the Rolling Draft Essential Community Provider (ECP) List.","title":"Rolling Draft ECP List","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/sites/default/files/uploaded_resources/ECP-Rolling-Draft-List-20260612.csv","mediaType":"text/csv","title":"CSV"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","accrualPeriodicity":"R/P10Y","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2uqv-z3wm","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2uqv-z3wm","description":"Chemical compound data from PubChem database. IUPAC Name: 6-methyl-7-methylidene-3-propan-2-yltricyclo[4.4.0.02,8]decane. Molecular Formula: C15H24. Molecular Weight: 204.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530427: 1,4-Methanoindan, hexahydro-7-isopropyl-4-methyl-8-methylene-","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530427","description":"Access the complete Compound 530427: 1,4-Methanoindan, hexahydro-7-isopropyl-4-methyl-8-methylene- on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ura-minc","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","substance","bioactivity","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2ura-minc","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865046: MLS000083333","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865046","description":"Access the complete Substance 865046: MLS000083333 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2urd-q5ye","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2urd-q5ye","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 2,2-dimethylheptanoate. Molecular Formula: C10H20O2. Molecular Weight: 172.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527395: Heptanoic acid, 2,2-dimethyl-, methyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527395","description":"Access the complete Compound 527395: Heptanoic acid, 2,2-dimethyl-, methyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/kctb-p96m","issued":"2019-03-28","@type":"dcat:Dataset","modified":"2019-03-28","keyword":["drinking water","school","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/kctb-p96m","description":"Lead in Drinking Water in Schools Test Results – Pateros k-12 update","title":"Pateros K-12 update","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/kctb-p96m/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://data.mo.gov/d/ic7m-74rp","issued":"2013-11-06","@type":"dcat:Dataset","modified":"2025-02-05","keyword":["military","service members","substance abuse"],"contactPoint":{"@type":"vcard:Contact","fn":"Jon Sabala","hasEmail":"mailto:no-reply@data.mo.gov"},"publisher":{"@type":"org:Organization","name":"State of Missouri"},"identifier":"https://data.mo.gov/api/views/ic7m-74rp","description":"A collection of substance use resources for service members, Veterans and their families being offered outside of the Missouri Department of Mental Health.","title":"Alcohol and Drug Use","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.mo.gov/download/ic7m-74rp/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2utq-bifp","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","compound","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2utq-bifp","description":"Chemical compound data from PubChem database. IUPAC Name: 3-(2-formyl-5-methylpyrrol-1-yl)propanoic acid. Molecular Formula: C9H11NO3. Molecular Weight: 181.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529489: Propanoic acid, 3-[N-(2-formyl-5-methyl-1-pyrrolyl)]","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529489","description":"Access the complete Compound 529489: Propanoic acid, 3-[N-(2-formyl-5-methyl-1-pyrrolyl)] on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2uwc-ip9w","bureauCode":["009:70"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["care","abuse","ndacan","policy","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"NDACAN Data Team","hasEmail":"mailto:NDACAN@cornell.edu"},"publisher":{"@type":"org:Organization","name":"National Data Archive on Child Abuse and Neglect"},"identifier":"https://healthdata.gov/api/views/2uwc-ip9w","description":"This study identifies factors that significantly increase or decrease the likelihood that a child maltreatment report will be substantiated once an investigation occurs. A specific concern of the study was to investigate the size and nature of the difference in substantiation rates for reports originating from professional sources mandated by law to report suspected cases of child maltreatment compared to reports from non-professional sources, such as relatives and neighbors. A representative sample of 796 sexual abuse, 198 physical abuse and 880 neglect reports were obtained from the New York State Child Abuse and Maltreatment Register. Types of data collected included background variables (e.g., sex and age of the subject child); the source of the report; actions that took place after the report was filed (e.g., court action), and the case determination.\n\nInvestigators: Abstract","title":"Substantiation of Child Abuse and Neglect Reports, 1985","programCode":["009:094"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ndacan.acf.hhs.gov/datasets/dataset-details.cfm?ID=50","description":"Access the complete Substantiation of Child Abuse and Neglect Reports, 1985 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2uwf-nam7","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["care","foster","policy","reporting","assessment"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2uwf-nam7","description":"This report describes the results of the subsequent primary review of Mississippi's Title IV-E foster care program.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Mississippi Subsequent Primary Title IV-E Foster Care Eligibility Review (2017)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/mississippi-subsequent-primary-title-iv-e-foster-care-eligibility-review-2017","description":"Access the complete Mississippi Subsequent Primary Title IV-E Foster Care Eligibility Review (2017) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2uwy-nx8y","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["skeletal-muscle","cytomegalovirus-ie1","transgenic-mice","nih","gene-expression"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2uwy-nx8y","description":"Background\n Versatile transgenic manipulation of skeletal muscle requires knowledge of the expression profiles of diverse promoter/enhancer elements in the transcriptionally specialized fiber types of which muscle is composed. \"Universal\" viral promoters/enhancers, e.g., cytomegalovirus IE1 (CMV IE1), are of interest as reagents that may drive broad expression. However, a previous study noted a marked heterogeneity of CMV IE1-driven transgene expression among muscle fibers, raising the possibility of fiber-type-restricted expression. The purpose of the present study was to characterize CMV IE1-driven expression in terms of fiber type.\n \n \n Results\n We produced two lines of transgenic mice carrying the CMV IE1/ β-galactosidase construct CMVLacZ, and analyzed transgene expression and fiber type by histochemical analysis of hindlimb muscle sections. In both lines CMVLacZ was expressed in all four major fiber types: type I (slow) and types IIA, IIB and IIX (fast). There was no unique pattern of fiber-type-preferential expression; fiber-type quantitative differences were observed but details varied between muscle regions and between lines. Both lines showed similar fiber-type-independent regional differences in overall expression levels, and a high level of within-fiber-type variability of expression, even among nearby fibers. The soleus muscle showed strong expression and comparatively little within-fiber-type or between-fiber-type variability.\n \n \n Conclusions\n The CMV IE1 promoter/enhancer is not fiber-type-restricted and can be useful for driving germ-line transgene expression in all four fiber types. However, not all fibers express the gene at high levels due in part to regional differences in overall expression levels, and to a high level of within-fiber-type variability. Given the multinucleate syncitial nature of muscle fibers, it is not likely that this variability is due to variegating heterochromatinization. The soleus muscle would make a suitable subject for near-uniform experimental gene expression driven by CMV IE1 elements.","title":"Human cytomegalovirus IE1 promoter/enhancer drives variable gene expression in all fiber types in transgenic mouse skeletal muscle","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC29077/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2uxr-vqy2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","substance","references","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2uxr-vqy2","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864512: MLS000082280","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864512","description":"Access the complete Substance 864512: MLS000082280 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2uyb-8qft","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-2016","health-survey","drug-use","samhsa","field-interviewer"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2uyb-8qft","description":"This manual is given to Field Interviewers working on the 2016 NSDUH.","title":"2016 NATIONAL SURVEY ON DRUG USE AND HEALTH Field Interviewer Manual","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2016-national-survey-drug-use-and-health-field-interviewer-manual","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","pharmaceuticals","medications","fda","drug-manufacturers"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA204326","description":"Amphetamine Sulfate is a prescription stimulant medication available as oral tablets in 5mg and 10mg strengths, manufactured by Amneal Pharmaceuticals. It is a Schedule II controlled substance used to treat conditions like ADHD and narcolepsy by increasing focus and alertness. This information was generated using AI and is provided for informational and research purposes only.","title":"Amphetamine","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204326","description":"\n Access the FDA dataset for Amphetamine — ANDA 204326 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Amphetamine"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/hwyq-75wu","bureauCode":["009:00"],"issued":"2018-01-04","@type":"dcat:Dataset","modified":"2018-01-04","keyword":["2017","shiga toxin-producing e. coli","salmonellosis","nndss","netss","nedss","wonder","stec","shigellosis","mmwr"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/hwyq-75wu","description":"NNDSS - Table II. Salmonellosis to Shigellosis - 2017. In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories.\r\n\r\nNote:\r\nThese are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. \r\n\r\nCase counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. \r\n\r\nFootnotes:\r\n C.N.M.I.: Commonwealth of Northern Mariana Islands. \r\n\r\n U: Unavailable. —: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. \r\n\r\n*Three low incidence conditions, rubella, rubella congenital, and tetanus, are in Table II to facilitate case count verification with reporting jurisdictions. \r\n\r\n† Case counts for reporting year 2017 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for tuberculosis are displayed in Table IV, which appears quarterly.\r\n\r\n$ Includes E. coli O157:H7, Shiga toxin-positive, serogroup non-O157, and Shiga toxin-positive, not serogrouped.","title":"NNDSS - Table II. Salmonellosis to Shigellosis","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/hwyq-75wu/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/hwyq-75wu/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/hwyq-75wu/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2v4c-tibz","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-abuse","block-grant-program","national-outcome-measures","mental-health-services","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2v4c-tibz","description":"This is the 2020 Uniform Reporting System (URS) Output Tables for Louisiana. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2020 Uniform Reporting System (URS) Table For Louisiana","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2020-uniform-reporting-system-urs-table-louisiana","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2v4f-iz94","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2023-12-04","keyword":["drug rebate program"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"094de49c-13c3-437c-8419-af9ad3862666","description":"The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-11-27-to-2023-12-03","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.medicaid.gov/sites/default/files/uploaded_resources/mdrp-newly-rprt-drug-11-27-2023-to-12-03-2023.csv","mediaType":"text/csv","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-11-27-to-2023-12-03"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2v54-jsqz","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","compound","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2v54-jsqz","description":"Chemical compound data from PubChem database. IUPAC Name: 3-chlorodecyl acetate. Molecular Formula: C12H23ClO2. Molecular Weight: 234.76. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527889: 3-Chlorodecyl acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527889","description":"Access the complete Compound 527889: 3-Chlorodecyl acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2v5e-uzxa","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","pubchem","chemistry","innovation","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2v5e-uzxa","description":"Vitamin D derivatives having general formula (1) which are hydroxylated at the 24-position and considered as one of metabolites of physiologically active vitamin D derivatives substituted at the 2 beta -position wherein R1, R2, R3 and R4 are the same or different and each represents hydrogen or a protective group; X and Y represent each H or OR5, provided that Y is OR5 when X is H, and Y is H when X is OR5 (wherein R5 represents hydrogen or a protective group, or R1 and R5 may together form a vicinal-diol protective group); synthesis intermediates useful in synthesizing these vitamin D derivatives; and medicinal compositions containing these vitamin D derivatives.The Population online databases contain data from the US Census Bureau. The Census Estimates online database contains contains county-level population counts for years 1970 - 2000. The data comprise the April 1st Census counts for years 1970, 1980, 1990 and 2000, the July 1st intercensal estimates for years 1971-1979 and 1981-1989, and the July 1st postcensal estimates for years 1991-1999. The Census Projections online database contains population projections for years 2004-2030 by year, state, age, race and sex, prodyced by teh Cenus Bureau in 2005. The data are produced by the United States Department of Commerce, U.S. Census Bureau, Population Division.
","title":"CDC WONDER: Population (from Census)","programCode":["006:008"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://wonder.cdc.gov/population.html","mediaType":"text/html","title":"Query Tool "}],"describedBy":"http://wonder.cdc.gov/population.html","dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["State"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["pharmaceuticals","drug","fda","medications","public-health"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA218425","description":"Cladribine is a prescription injectable medication used as a chemotherapy drug to treat certain blood cancers, such as hairy cell leukemia. It works as a purine antimetabolite to interfere with cancer cell growth. Manufactured by Fresenius Kabi USA, LLC, it's administered intravenously at a strength of 1 mg/mL in single-dose vials. Approved under ANDA076571 since 2004. This information was generated using AI and is provided for informational and research purposes only.","title":"Cladribine","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218425","description":"\n Access the FDA dataset for Cladribine — ANDA 218425 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Cladribine"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2wqx-f472","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","references","substance","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2wqx-f472","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865591: MLS000084181","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865591","description":"Access the complete Substance 865591: MLS000084181 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2wuc-2vts","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["policy","instruction","guidance","foster","adoption"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2wuc-2vts","description":"This Program Instruction (PI) provides instruction on the Title IV-E Plan Pre-print- Fostering Connections to Success and Increasing Adoptions Act of 2008 (Public Law (P.L.) 110-351).\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-09-08)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-09-08","description":"Access the complete PI-09-08 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2wux-q5q2","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["assessment","fiscal","maltreatment","neglect","abuse"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2wux-q5q2","description":"This report presents national data about child abuse and neglect known to child protective services agencies in the United States during federal fiscal year 2023.\n\nLetter from the Commissioner\n\nAcknowledgements\n\nSummary\n\nCHAPTER 1: Introduction\n\nCHAPTER 2: Reports\n\nCHAPTER 3: Children\n\nCHAPTER 4: Fatalities\n\nCHAPTER 5: Perpetrators\n\nCHAPTER 6: Services\n\nAPPENDIX A: CAPTA Data Items\n\nAPPENDIX B: Glossary\n\nAPPENDIX C: State Characteristics\n\nAPPENDIX D: State Commentary\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Child Maltreatment 2023","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/child-maltreatment-2023","description":"Access the complete Child Maltreatment 2023 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2wyk-eryb","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["prostaglandin-ep2-receptor","receptor-cloning","e-prostanoid-receptor","nih","rabbit-model"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2wyk-eryb","description":"Background\n Prostaglandin E2 (PGE2) has multiple physiologic roles mediated by G protein coupled receptors designated E-prostanoid, or \"EP\" receptors. Evidence supports an important role for the EP2 receptor in regulating fertility, vascular tone and renal function.\n \n \n Results\n The full-length rabbit EP2 receptor cDNA was cloned. The encoded polypeptide contains 361 amino acid residues with seven hydrophobic domains. COS-1 cells expressing the cloned rabbit EP2 exhibited specific [3H]PGE2 binding with a Kd of 19.1± 1.7 nM. [3H]PGE2 was displaced by unlabeled ligands in the following order: PGE2>>PGD2=PGF2α=iloprost. Binding of [3H]PGE2 was also displaced by EP receptor subtype selective agonists with a rank order of affinity consistent with the EP2 receptor (butaprost>AH13205>misoprostol>sulprostone). Butaprost free acid produced a concentration-dependent increase in cAMP accumulation in rabbit EP2 transfected COS-1 cells with a half-maximal effective concentration of 480 nM. RNase protection assay revealed high expression in the ileum, spleen, and liver with lower expression in the kidney, lung, heart, uterus, adrenal gland and skeletal muscle. In situ hybridization localized EP2 mRNA to the uterine endometrium, but showed no distinct localization in the kidney. EP2 mRNA expression along the nephron was determined by RT-PCR and its expression was present in glomeruli, MCD, tDL and CCD. In cultured cells EP2 receptor was not detected in collecting ducts but was detected in renal interstitial cells and vascular smooth muscle cells. EP2 mRNA was also detected in arteries, veins, and preglomerular vessels of the kidney.\n \n \n Conclusion\n EP2 expression pattern is consistent with the known functional roles for cAMP coupled PGE2 effects in reproductive and vascular tissues and renal interstitial cells. It remains uncertain whether it is also expressed in renal tubules.","title":"Cloning and expression of the rabbit prostaglandin EP2 receptor","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC117438/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2wzy-8a6q","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2wzy-8a6q","description":"Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl N-methylpyridine-3-carboximidate. Molecular Formula: C10H16N2OSi. Molecular Weight: 208.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530217: N-Methyl nicotinimidate, O-trimethylsilyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530217","description":"Access the complete Compound 530217: N-Methyl nicotinimidate, O-trimethylsilyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2x3q-w4y7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2x3q-w4y7","description":"Chemical compound data from PubChem database. IUPAC Name: N-(4-methylphenyl)-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide. Molecular Formula: C23H30N2O. Molecular Weight: 350.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527013: p-Tolylfentanyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527013","description":"Access the complete Compound 527013: p-Tolylfentanyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/wa6p-va54","issued":"2019-06-21","@type":"dcat:Dataset","modified":"2019-06-21","keyword":["school","drinking water","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/wa6p-va54","description":"Lead in Drinking Water in Schools Test Results – Sherwood Forest Elementary","title":"Sherwood Forest Elementary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/wa6p-va54/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2x45-z5py","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2024-01-05","keyword":["medicaid","dq atlas","dual enrollment","chip","t-msis analytic files"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"36ed6909-ab49-4ca5-a38e-6790138cd613","description":"This data set includes monthly enrollment counts of Medicaid and CHIP beneficiaries by dual eligibility status for Medicaid and Medicare (full dual eligibility, partial dual eligibility, or not dually eligible).\n\nThese metrics are based on data in the T-MSIS Analytic Files (TAF). Some states have serious data quality issues for one or more months, making the data unusable for calculating these measures. To assess data quality, analysts adapted measures featured in the DQ Atlas. Data for a state and month are considered unusable or of high concern based on DQ Atlas thresholds for the topic Dually Enrolled in Medicare. Please refer to the DQ Atlas at http://medicaid.gov/dq-atlas for more information about data quality assessment methods.\n\nSome cells have a value of “DS”. This indicates that data were suppressed for confidentiality reasons because the group included fewer than 11 beneficiaries.","title":"Dual Status Information for Medicaid and CHIP Beneficiaries by Month","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/DualStatus-montly.csv","description":"This data set includes monthly enrollment counts of Medicaid and CHIP beneficiaries by dual eligibility status for Medicaid and Medicare (full dual eligibility, partial dual eligibility, or not dually eligible).\n\nThese metrics are based on data in the T-MSIS Analytic Files (TAF). Some states have serious data quality issues for one or more months, making the data unusable for calculating these measures. To assess data quality, analysts adapted measures featured in the DQ Atlas. Data for a state and month are considered unusable or of high concern based on DQ Atlas thresholds for the topic Dually Enrolled in Medicare. Please refer to the DQ Atlas at http://medicaid.gov/dq-atlas for more information about data quality assessment methods.\n\nSome cells have a value of “DS”. This indicates that data were suppressed for confidentiality reasons because the group included fewer than 11 beneficiaries.","@type":"dcat:Distribution","title":"Dual Status Information for Medicaid and CHIP Beneficiaries by Month"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["Enrollment"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2x6n-sa2b","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","science","research","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2x6n-sa2b","description":"Chemical compound data from PubChem database. IUPAC Name: 1,4-dibromo-7,8-dichlorodibenzo-p-dioxin. Molecular Formula: C12H4Br2Cl2O2. Molecular Weight: 410.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526298: 1,4-Dibromo-7,8-dichloro-dibenzo-p-dioxin","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526298","description":"Access the complete Compound 526298: 1,4-Dibromo-7,8-dichloro-dibenzo-p-dioxin on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2x6s-5dpy","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","chemistry","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2x6s-5dpy","description":"Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] hexadecanoate. Molecular Formula: C22H46O2Si. Molecular Weight: 370.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528578: tert-Butyl(dimethyl)silyl palmitate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528578","description":"Access the complete Compound 528578: tert-Butyl(dimethyl)silyl palmitate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2x6w-4mbg","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["barometer","samhsa","mississippi","mental-health-substance-use","behavioral-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2x6w-4mbg","description":"Behavioral Health Barometer: Mississippi, Volume 6","title":"Behavioral Health Barometer: Mississippi, Volume 6","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-mississippi-volume-6","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.hcai.ca.gov","issued":"2018-08-17","temporal":"On an annual basis (calendar year). There will be a 5 year trend on most data sources, however, you may search for other years using the ALIRTS application or other datasets.","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["adjusted length of stay","admit source","beds","discharge","discharge disposition","ltc","major captial expenditures","payer source","utilization"],"contactPoint":{"@type":"vcard:Contact","fn":"Accounting and Reporting Systems Section","hasEmail":"mailto:dataandreports@hcai.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"be292bc5-244e-4eba-808e-e18edf97e09e","description":"On an annual basis (calendar year), individual LTC facilities report facility-level data on services capacity, utilization, patients, and capital/equipment expenditures.","title":"Pre-2012 Long-term Care Facilities Annual Utilization Data","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/long-term-care-facilities-annual-utilization-data","mediaType":"text/html","title":"Post-2011 Long-term Care Facilities Annual Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://oshpd.ca.gov/data-and-reports/submit-data/facility-utilization-data/","mediaType":"text/html","title":"Automated Licensing Information and Report Tracking System (ALIRTS)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/8fa016c2-c46d-4761-9b6a-fc36f2a4a3cf/download/ltcfrm11.pdf","mediaType":"application/pdf","title":"2011 Long-term Care Facilities Reporting Form"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/78b0b57e-af99-4ed8-bf2f-7c554b83730f/download/ltcinstrct11.pdf","mediaType":"application/pdf","title":"2011 Instructions Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/2853f7a2-7209-4e41-9ac1-1da3ad1dfc3a/download/ltc11utildatafinal.xlsx","mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","title":"2011 Long-Term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/ad94b5c1-8ea8-4b5b-9ddc-2d37c8edbd2d/download/ltcutilpivot11.xlsm","mediaType":"application/vnd.ms-excel.sheet.macroEnabled.12","title":"2011 Pivot Table - Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/6c88d4ca-2d8a-4c00-be8d-d2fa44babfdb/download/ltcfrm10.pdf","mediaType":"application/pdf","title":"2010 Reporting Form - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/3004749c-9efc-4ae5-82c0-10b9043bc588/download/ltcinstrct10.pdf","mediaType":"application/pdf","title":"2010 Instructions - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/ea8022df-5fa7-4a6b-ba09-754da3174904/download/ltc10utildatafinal.xlsx","mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","title":"2010 Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/a8367dab-ecea-43b2-a196-4a13badde0a1/download/ltcutilizationpivot10.xls","mediaType":"application/vnd.ms-excel","title":"2010 Pivot Table - Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/5adb611d-7d64-491b-8866-b0441d3d0191/download/ltcfrm09.pdf","mediaType":"application/pdf","title":"2009 Reporting Form - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/fb3527d3-ef0c-493a-b96f-c98dc255d62d/download/ltcinstrct09.pdf","mediaType":"application/pdf","title":"2009 Instructions - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/e8fdb6ba-8a7a-4ea0-bb1a-97b74c9dc415/download/ltc09utildatafinal.xls","mediaType":"application/vnd.ms-excel","title":"2009 Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/4ec90f6b-bf71-41f7-a355-256490ce9bf0/download/ltcutilizationpivot09.xls","mediaType":"application/vnd.ms-excel","title":"2009 Pivot Table - Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/d22742eb-3fbe-498d-a59a-85a0eb64ac52/download/ltcfrm08.pdf","mediaType":"application/pdf","title":"2008 Reporting Form - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/578432fc-cebb-4ca5-82be-d6e7d770c9d9/download/ltcinstrct08.pdf","mediaType":"application/pdf","title":"2017 Instructions - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/b146a318-38e3-4de1-943a-a10aa8a9af0b/download/ltc08utildatafinal.xls","mediaType":"application/vnd.ms-excel","title":"2008 Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/dc0d78f3-ed25-47be-8dac-03ec3cbeb775/download/ltcutilizationpivot08.xls","mediaType":"application/vnd.ms-excel","title":"2008 Pivot Table - Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/e3b9d415-676a-434d-8005-e19b2cda52ad/download/ltcfrm07.pdf","mediaType":"application/pdf","title":"2007 Reporting Form - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/fc925aba-aede-4ec7-b5d0-4f71978e7730/download/ltcinstrct07.pdf","mediaType":"application/pdf","title":"2007 Instructions - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/d4b98e33-a10b-4d6e-bca8-d401b40d73bc/download/ltc07utildata1-13-09rev.xls","mediaType":"application/vnd.ms-excel","title":"2007 Long-term Care Facilities Utilization Data (Revised January 2009)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/3874278a-75bd-4859-b678-0baa8757c8b7/download/ltcutilizationpivot07.xls","mediaType":"application/vnd.ms-excel","title":"2007 Pivot Table - Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/a7a3df05-094d-4e5b-9009-8a4b5dcf0290/download/ltcform06.pdf","mediaType":"application/pdf","title":"2006 Reporting Form - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/2b8f7072-ad2c-4185-950c-e852b2489c38/download/ltcinstrct06.pdf","mediaType":"application/pdf","title":"2006 Instructions - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/475fd6a9-6fcd-4f82-9f82-ca72d1543332/download/ltc06utilfinalr.xls","mediaType":"application/vnd.ms-excel","title":"2006 Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/07a4bf26-9fe6-4adc-ab7f-41dca008993e/download/ltcuilizationpivot06.xls","mediaType":"application/vnd.ms-excel","title":"2006 Pivot Table - Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/915760fe-cbee-41b6-b246-6e21b0cfdfba/download/ltcform05.pdf","mediaType":"application/pdf","title":"2005 Reporting Form - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/883594be-8249-4537-b220-f2b153e0520d/download/ltcinstrct05.pdf","mediaType":"application/pdf","title":"2005 Instructions - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/6960ca47-1147-4ee9-b2e9-5050dad5d48a/download/ltc05-util-data-revised05-11-09.xls","mediaType":"application/vnd.ms-excel","title":"2005 Long-term Care Facilities Utilization Data (Revised May 2009)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/122af9fe-369c-465b-bbef-27300e80f08c/download/ltcfrm04.pdf","mediaType":"application/pdf","title":"2004 Reporting Form - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/a955044d-02ec-4b3b-b356-631ebd8cc2c3/download/ltcinstrct04.pdf","mediaType":"application/pdf","title":"2004 Instructions - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/ad1b7a5e-eae0-4c27-bcaa-4e7743c7991f/download/ltc04-util-data-revised05-11-09.xls","mediaType":"application/vnd.ms-excel","title":"2004 Long-term Care Facilities Utilization Data (Revised May 2009)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/ea789d89-b999-4cd2-8f4a-fa8924bc6f2b/download/ltcfrm03.pdf","mediaType":"application/pdf","title":"2003 Reporting Form - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/d2e67fb8-a2ed-4c3d-8d2b-ea9813e8c4be/download/ltcinstrct03.pdf","mediaType":"application/pdf","title":"2003 Instructions - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/9de4cd12-cc42-4794-9e6c-3823129d7540/download/ltc03-util-data-revised05-11-09.xls","mediaType":"application/vnd.ms-excel","title":"2003 Long-term Care Facilities Utilization Data (Revised May 2009)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/6b930a89-0871-466a-a1c0-8f977b5dc736/download/ltcfrm02.pdf","mediaType":"application/pdf","title":"2002 Reporting Form - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/17d11ea5-62f7-4570-b85b-ca32433beb46/download/ltcinstrct02.pdf","mediaType":"application/pdf","title":"2002 Instructions - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/16028e2d-d09b-4a59-b18c-bedc8d27ca26/download/ltc02util-data-revised05-11-09.xls","mediaType":"application/vnd.ms-excel","title":"2002 Long-term Care Facilities Utilization Data (Revised May 2009)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/0699ddb4-864f-46de-b859-89a35a766204/download/ltcfrm01.pdf","mediaType":"application/pdf","title":"2001 Reporting Form - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/b1a19cdf-c3b8-4674-8289-a87a6cea3f7a/download/ltcinstrct01.pdf","mediaType":"application/pdf","title":"2001 Instructions - Long-term Care Facilities"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/6fe16def-70dd-4b59-a92b-c6d71f574d58/download/readmeltc01.pdf","mediaType":"application/pdf","title":"2001 Read Me Documentation"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/fcaf59fb-2e1d-47e9-9e0d-1819cffe90d5/download/ltc0101.txt","mediaType":"text/plain","title":"2001 Part 1 Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/ebd5cd2e-61b3-418c-9ae9-ff72806f4a23/download/ltc0102.txt","mediaType":"text/plain","title":"2001 Part 2 Long-term Care Facilities Utilization Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/be292bc5-244e-4eba-808e-e18edf97e09e/resource/9c524003-2f0b-4312-a8c8-f12d6e626234/download/pre-2012-long-term-care-facilities-annual-utilization-data-nk2h3b2u.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Facilities and Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2x8x-pm27","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","chromatid-breakage","ciliates","macronuclear-chromosomes","telomere-formation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2x8x-pm27","description":"Background\n Ciliates employ massive chromatid breakage and de novo telomere formation during generation of the somatic macronucleus. Positions flanking the 81-MAC locus are reproducibly cut. But those flanking the Common Region are proposed to often escape cutting, generating three nested macronuclear chromosomes, two retaining \"arms\" still appended to the Common Region. Arm-distal positions must differ (in cis) from the Common Region flanks.\n \n \n Results\n The Common-Region-flanking positions also differ from the arm-distal positions in that they are \"multi-TAS\" regions: anchored PCR shows heterogeneous patterns of telomere addition sites, but arm-distal sites do not. The multi-TAS patterns are reproducible, but are sensitive to the sequence of the allele being processed. Thus, random degradation following chromatid cutting does not create this heterogeneity; these telomere addition sites also must be dictated by cis-acting sequences.\n \n \n Conclusions\n Most ciliates show such micro-heterogeneity in the precise positions of telomere addition sites. Telomerase is believed to be tightly associated with, and act in concert with, the chromatid-cutting nuclease: heterogeneity must be the result of intervening erosion activity. Our \"weak-sites\" hypothesis explains the correlation between alternative chromatid cutting at the Common Region boundaries and their multi-TAS character: when the chromatid-breakage machine encounters either a weak binding site or a weak cut site at these regions, then telomerase dissociates prematurely, leaving the new end subject to erosion by an exonuclease, which pauses at cis-acting sequences; telomerase eventually heals these resected termini. Finally, we observe TAS positioning influenced by trans-allelic interactions, reminiscent of transvection.","title":"Telomere formation on macronuclear chromosomes of","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128808/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/67dz-ikj6","issued":"2018-04-13","@type":"dcat:Dataset","modified":"2018-04-13","keyword":["schools","drinking water","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"Willc13","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/67dz-ikj6","description":"Leonard M Jenning lead in water test results","title":"Leonard M Jenning Elementary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/67dz-ikj6/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/cfac-5c8q","issued":"2013-08-27","@type":"dcat:Dataset","modified":"2015-03-10","keyword":["nursing homes","cost reports","reimbursement","quality-safety-costs","financial"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/cfac-5c8q","description":"The Nursing Home Cost Report (RHCF) is a uniform report completed by New York nursing homes to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations, (Part 86-2.2), nursing homes are required to file financial and statistical data with DOH annually. The data filed is part of the cost report and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. For more information, check out: http://www.health.ny.gov/facilities/nursing/ or go to the “About “ tab.","title":"Nursing Home Cost Report (RHCF): 2009","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/download/cfac-5c8q/application/zip","mediaType":"application/zip"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xam-945z","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","pubchem","compound","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2xam-945z","description":"Chemical compound data from PubChem database. IUPAC Name: N,N-dimethyl-N'-(4-nitrophenyl)-2-phenylethanimidamide. Molecular Formula: C16H17N3O2. Molecular Weight: 283.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525858: N,N-Dimethyl-2-phenyl-N'-(4-nitrophenyl)-acetamidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525858","description":"Access the complete Compound 525858: N,N-Dimethyl-2-phenyl-N'-(4-nitrophenyl)-acetamidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xbq-afjf","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["quality-control","survey-methodology","samhsa","data-collection-methods","nsduh-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2xbq-afjf","description":"This report describes tasks relating to data collection for the 2018 NSDUH: Sampling and Counting and Listing Operations, Data Collection Staffing, Preparation of Survey Materials, Field Staff Training, Data Collection, Data Collection Results, and Quality Control.","title":"NSDUH 2018 Data Collection Final Report","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/nsduh-2018-data-collection-final-report","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xc5-hh8q","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["fiscal","policy","instruction","guidance","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2xc5-hh8q","description":"This Program Instruction (PI) provides instructions for State Courts Applying for Court Improvement Program (CIP) Funds for Fiscal Years (FYs) 2012-2016.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-12-02)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-12-02","description":"Access the complete PI-12-02 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xdd-nbhc","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["policy","guidance","child","reporting","instruction"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2xdd-nbhc","description":"This Program Instruction (PI) provides instruction on the Child Welfare Demonstration Project Reporting Formats.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-01-08)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-01-08","description":"Access the complete PI-01-08 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xh5-epqr","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["ligand-binding","serotonin-receptor","site-directed-mutagenesis","nih","5-ht3-receptor"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2xh5-epqr","description":"Background\n The serotonin type 3 receptor (5-HT3R) is a member of a superfamily of ligand gated ion channels. All members of this family share a large degree of sequence homology and presumably significant structural similarity. A large number of studies have explored the structure-function relationships of members of this family, particularly the nicotinic and GABA receptors. This information can be utilized to gain additional insights into specific structural and functional features of other receptors in this family.\n \n \n Results\n Thirteen amino acids in the mouse 5-HT3ASR that correspond to the putative E binding loop of the nicotinic α7 receptor were chosen for mutagenesis. Due to the presence of a highly conserved glycine in this region, it has been suggested that this binding loop is comprised of a hairpin turn and may form a portion of the ligand-binding site in this ion channel family. Mutation of the conserved glycine (G147) to alanine eliminated binding of the 5-HT3R antagonist [3H]granisetron. Three tyrosine residues (Y140, Y142 and Y152) also significantly altered the binding of 5-HT3R ligands. Mutations in neighboring residues had little or no effect on binding of these ligands to the 5-HT3ASR.\n \n \n Conclusion\n Our data supports a role for the putative E-loop region of the 5-HT3R in the binding of 5-HT, mCPBG, d-tc and lerisetron. 5-HT and mCPBG interact with Y142, d-tc with Y140 and lerisetron with both Y142 and Y152. Our data also provides support for the hypothesis that this region of the receptor is present in a loop structure.","title":"Identification of critical residues in loop E in the 5-HT","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC117120/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xhb-3dah","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","compound","pubchem","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2xhb-3dah","description":"Chemical compound data from PubChem database. IUPAC Name: 2,23,27-trimethylnonacosanenitrile. Molecular Formula: C32H63N. Molecular Weight: 461.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527342: 1,22,26-Trimethyl-octacosyl cyanide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527342","description":"Access the complete Compound 527342: 1,22,26-Trimethyl-octacosyl cyanide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xi4-7rfe","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","bioactivity","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2xi4-7rfe","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865285: MLS000042418","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865285","description":"Access the complete Substance 865285: MLS000042418 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xif-xvv3","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["calcification","nih","inorganic-pyrophosphate","ank-gene","mouse-model"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2xif-xvv3","description":"A landmark investigation into the genetic basis of murine progressive ankylosis has clarified the physiologic role of extracellular inorganic pyrophosphate (ePPi) in suppressing pathologic deposition of basic calcium phosphate (BCP) (an inclusive term for hydroxyapatite, octacalcium phosphate, and tricalcium phosphate) in articular tissue [1]. A cell membrane protein, ANK, affects ePPi concentrations and the balance of mineralization in articular tissues.","title":"Theankgene story","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128882/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://github.com/CDCGov/RSVHospitalBurdenEstimation","bureauCode":["009:20"],"issued":"2026-05-13","@type":"dcat:Dataset","temporal":"2018-09-30 to 2024-10-06","modified":"2026-05-13","keyword":["hospitalizations","rate","respiratory disease","respiratory illness","respiratory syncytial virus","rsv","rsvnet","surveillance","hospitalization","hospitalization rate","nssp"],"contactPoint":{"@type":"vcard:Contact","fn":"CORVD Informatics","hasEmail":"mailto:CORVDInformatics@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/whhs-7a5d","description":"Weekly imputed RSV hospital admission rates per 100,000 population from 47 states plus DC from 2018-2024 are described. Rates were estimated by combining values from RSV-Net with those from NSSP and NHSN to obtain combined time series of RSV hospital admissions counts. States with overlapping values in both sets underwent interpolation and extrapolation procedures for estimates throughout the time series. These states were then used to impute values for states that did not have surveillance data within RSV-Net. Calculated RSV hospital admission rates (either interpolated, extrapolated, or imputed) are reported. See the GitHub for code and further description.","title":"Imputed Hospitalization Rate for RSV at the State Level","programCode":["009:026"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/whhs-7a5d/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/whhs-7a5d/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/whhs-7a5d/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"US States","license":"https://www.usa.gov/government-works","accrualPeriodicity":"Not updated","theme":["Coronavirus and Other Respiratory Viruses"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xje-z7zy","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["lower-extremity-arterial-disease","nih","cardiovascular-risk","lipid-management","bezafibrate-trial"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2xje-z7zy","description":"Background\n Raised levels of both triglycerides and fibrinogen, each of which are reduced by bezafibrate, may contribute to lower extremity arterial disease (LEAD). This condition is characterized by a particularly high incidence of coronary heart disease (CHD) and stroke, but is little studied thus far in randomised controlled trials.\n \n \n Method\n Patients were recruited through 85 practices in the British Medical Research Council General Practice Research Framework and through nine hospital vascular clinics. The treatment regimen, which is double-blind and placebo-controlled, is bezafibrate 400 mg/day. The 1568 patients recruited represent 86% of those eligible at screening.\n \n \n Results\n None of the anticipated side effects (mainly gastrointestinal) differed between the two groups. Nearly 80% of the total person-years accrued at 3 years were spent on trial treatment. Bezafibrate significantly reduced total cholesterol by approximately 8.0% and low-density lipoprotein (LDL)-cholesterol by approximately 9.0%, and increased high-density lipoprotein (HDL)-cholesterol by approximately 11.0% initially, falling to about 6.0% at 3 years. Triglycerides were significantly reduced by about 23.0% and fibrinogen by about 14.0%. Plasma creatinine rose by approximately 11% in those on active treatment. All of these effects were highly significant (P < 0.0001). Bezafibrate had no effect on the level of C-reactive protein (CRP).\n \n \n Conclusion\n The trial recruited an unusually high proportion of eligible patients, ensuring the general applicability of its results. The fibrinogen-lowering and lipid-modifying effects of bezafibrate were confirmed. Although bezafibrate lowers fibrinogen, it has no effect on CRP; this suggests that the reduction in fibrinogen is due to an effect on its metabolism rather than suppression of an inflammatory response.","title":"Design and intermediate results of the Lower Extremity Arterial Disease Event Reduction (LEADER)* trial of bezafibrate in men with lower extremity arterial disease [ISRCTN41194621]","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC57751/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xkq-2hgf","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","innovation","chemistry","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2xkq-2hgf","description":"The invention concerns a wedge (12) comprising: a plate (13), and actuator (16) mounted on the plate (13) while being mobile relative thereto between an active position and an inactive position; a wedge element (19) mounted on the plate (13) and coupled to said actuator (16), said wedge element (19) being deformable between: an inactive configuration, adopted in inactive position of the actuator (16), wherein the wedge element (19) extends in the vicinity of the plate (13), and an active configuration, adopted in the active position of the actuator (16), wherein the wedge element (19) is in straight position while being at least locally spaced apart from the plate (13). The invention also concerns a system comprising a module, a receptacle and such a wedge interposed between them.","title":"Patent AT-E401769-T1: [Translated] EXPANDABLE WEDGE AND SYSTEM COMPRISING A MODULE, A RECEIVER AND SUCH A WEDGE INTERMEDIATE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401769-T1","description":"Access the complete Patent AT-E401769-T1: [Translated] EXPANDABLE WEDGE AND SYSTEM COMPRISING A MODULE, A RECEIVER AND SUCH A WEDGE INTERMEDIATE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xn2-uqsh","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","compound","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2xn2-uqsh","description":"Chemical compound data from PubChem database. IUPAC Name: 1-methyl-4-propan-2-yl-7-oxabicyclo[4.1.0]hept-2-ene. Molecular Formula: C10H16O. Molecular Weight: 152.23. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527087: alpha-Phellandrene epoxide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527087","description":"Access the complete Compound 527087: alpha-Phellandrene epoxide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xnm-hfh3","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","bioactivity","chemistry","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2xnm-hfh3","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865211: MLS000039747","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865211","description":"Access the complete Substance 865211: MLS000039747 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://wwwdev.cdc.gov/nchs/rss/rapid-surveys-system.html","bureauCode":["009:20"],"issued":"2024-08-22","temporal":"2022","@type":"dcat:Dataset","modified":"2026-02-26","keyword":["nchs","dhis"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/p89x-xx88","description":"The NCHS Rapid Surveys System includes questions sponsored by CDC programs and other partners to address time-sensitive data needs, public health attitudes or behaviors, and developmental work to improve concept measurement and inform future question design. It also includes standard variables used for sample weighting and calibration, as well as selected portions of existing content from NCHS surveys (such as the National Health Interview Survey) to compare panel estimates to these benchmarks, assess the fitness-for-use of the panel survey data, and for other methodological purposes.","title":"NCHS Rapid Surveys System","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/p89x-xx88/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/p89x-xx88/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/p89x-xx88/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"https://www.usa.gov/government-works","accrualPeriodicity":"R/P3M","theme":["National Center for Health Statistics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xrp-3dgx","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","chemistry","innovation","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2xrp-3dgx","description":"This invention relates to an automatic coffee machine (1) designed with the inspiration of conventional cooking methods, used to cook Turkish coffee with its traditional flavor and consistency in a short period of time, suitable to be used in homes and especially in crowded places such as hotels, restaurants or cafes, wherein means are provided to improve the delivering of water from the water reservoir (2) to the cooking chambers (3), where Turkish coffee is prepared, by means of pumps (4).","title":"Patent AT-E401815-T1: [Translated] COFFEE MACHINE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401815-T1","description":"Access the complete Patent AT-E401815-T1: [Translated] COFFEE MACHINE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nchs/covid19/covid-19-mortality-data-files.htm","bureauCode":["009:20"],"issued":"2020-07-22","@type":"dcat:Dataset","temporal":"2020-02-01/2020-07-18","modified":"2025-04-21","keyword":["united states","age group","all causes","nvss","coronavirus","covid-19","nchs","deaths","mortality","age","place of death","pneumonia","provisional","puerto rico","state"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/g4z9-a9d3","description":"Deaths involving coronavirus disease 2019 (COVID-19) and pneumonia reported to NCHS by jurisdiction of occurrence, place of death, and age group.","title":"AH Cumulative Provisional COVID-19 Death Counts by Place of Death and Age Group from 2/1/2020 to 7/18/2020","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/g4z9-a9d3/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/g4z9-a9d3/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/g4z9-a9d3/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"United States, Puerto Rico","license":"https://www.usa.gov/government-works","accrualPeriodicity":"irregular","theme":["National Center for Health Statistics"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["pharmaceuticals","medications","public-health","prescription-drugs","drug"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA203655","description":"Melphalan Hydrochloride is a prescription injectable chemotherapy drug administered intravenously, available in a 50 mg vial strength. It's manufactured by companies like Gland Pharma Limited and Sagent Pharmaceuticals under FDA approval ANDA209826. This information was generated using AI and is provided for informational and research purposes only.","title":"Melphalan hydrochloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203655","description":"\n Access the FDA dataset for Melphalan hydrochloride — ANDA 203655 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Melphalan hydrochloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xta-kcw9","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["law","guidance","regulation","policy","instruction"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2xta-kcw9","description":"This Information Memorandum (IM) provides guidance on the Definition of \"Federal Means-Tested Public Benefit\".\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-97-07)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-97-07","description":"Access the complete IM-97-07 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xwz-3zeb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","pubchem","chemistry","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2xwz-3zeb","description":"Chemical compound data from PubChem database. IUPAC Name: 1,3-dibromo-6,8-dichlorodibenzo-p-dioxin. Molecular Formula: C12H4Br2Cl2O2. Molecular Weight: 410.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526384: 1,3-Dibromo,6,8-dichloro-dibenzo-dioxin","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526384","description":"Access the complete Compound 526384: 1,3-Dibromo,6,8-dichloro-dibenzo-dioxin on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://gis.dhcs.ca.gov/apps/CADHCS::fee-for-service-provider-finder-app","issued":"2023-02-06","temporal":"Other","@type":"dcat:Dataset","modified":"2025-12-30","keyword":["caopendata","provider","odp","near me","instant app","finder app","find","fee-for-service","facilities","ffs"],"contactPoint":{"@type":"vcard:Contact","fn":"DHCS","hasEmail":"mailto:gis@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"d536496f-5219-435a-8321-6e13b51503a9","description":"This ArcGIS Instant App leverages the nearby functionality with the Medi-Cal Fee-for-Service Provider Listing to enable members of the public to find providers or services near a specific location.","title":"Fee for Service Provider Finder App","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/apps/CADHCS::fee-for-service-provider-finder-app","mediaType":"text/html","title":"ArcGIS Hub Dataset"},{"@type":"dcat:Distribution","downloadURL":"https://cadhcs.maps.arcgis.com/apps/instant/nearby/index.html?appid=f9715ef5673c4ca99c95046d5bbf138e","mediaType":"application/octet-stream","title":"ArcGIS GeoService"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/d536496f-5219-435a-8321-6e13b51503a9/resource/e5f2cd72-ffeb-4177-be58-571089baee44/download/fee-for-service-provider-finder-app-itsfja64.zip","mediaType":"application/zip","title":"All resource data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/d536496f-5219-435a-8321-6e13b51503a9/resource/2695e9cc-9ce3-4d2c-bb00-a4044f6f2118/download/fee-for-service-provider-finder-app-df7wevv7.zip","mediaType":"application/zip","title":"All resource data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/d536496f-5219-435a-8321-6e13b51503a9/resource/b1b5885d-515a-4ce3-965e-916f5acf991b/download/fee-for-service-provider-finder-app-sbyvu3b9.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xz5-ny5x","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-use","samhsa","nsduh-data","montana","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2xz5-ny5x","description":"Montana: 2010-2012 NSDUH substate estimates","title":"Montana: 2010-2012 NSDUH substate estimates","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/montana-2010-2012-nsduh-substate-estimates","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2xzv-xdqc","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["reporting","family","instruction","child","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2xzv-xdqc","description":"This issue of Child and Family Services Reviews Update contains the following sections: CB Releases More COVID-19 Guidance, Final Round 3 CFSR Aggregate Report Posted, and Extension of Non-Overlapping Evaluation Period.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Child and Family Services Reviews Update Volume 14, Issue 3, June 2020","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/child-and-family-services-reviews-update-volume-14-issue-3-june-2020","description":"Access the complete Child and Family Services Reviews Update Volume 14, Issue 3, June 2020 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2y2e-3u4d","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","innovation","patent","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2y2e-3u4d","description":"The present invention relates to the chemical synthesis of solanum glycosides, in particular to the synthesis of solamargine as well as to novel beta-monosaccharide Intermediate compounds.","title":"Patent AT-E400580-T1: [Translated] CHEMICAL SYNTHESIS OF SOLAMARGINE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400580-T1","description":"Access the complete Patent AT-E400580-T1: [Translated] CHEMICAL SYNTHESIS OF SOLAMARGINE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2y3d-d43c","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","bioactivity","substance","references","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2y3d-d43c","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864182: MLS000083937","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864182","description":"Access the complete Substance 864182: MLS000083937 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2y3j-jfun","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2y3j-jfun","description":"Chemical compound data from PubChem database. IUPAC Name: N-heptyl-1-phenylmethanimine. Molecular Formula: C14H21N. Molecular Weight: 203.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525555: Benzylidene-heptyl-amine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525555","description":"Access the complete Compound 525555: Benzylidene-heptyl-amine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2y45-4qi8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","bioactivity","chemistry","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2y45-4qi8","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864973: MLS000083404","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864973","description":"Access the complete Substance 864973: MLS000083404 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2y5a-4jyk","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","innovation","chemistry","research","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2y5a-4jyk","description":"A device comprises a spring and a sleeve. The spring is configured to form a closed loop. The spring is moveable between a coiled configuration when the spring is collapsed and an uncoiled configuration when the spring is expanded. The spring defines a circumference while in the uncoiled configuration. The spring is disposed within the sleeve.","title":"Patent AT-E399705-T1: [Translated] COLLAPSIBLE FLOTATION DEVICE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399705-T1","description":"Access the complete Patent AT-E399705-T1: [Translated] COLLAPSIBLE FLOTATION DEVICE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2y8q-pvyq","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["data","abuse","prevention","policy","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2y8q-pvyq","description":"This Information Memorandum (IM) provides notice of a Final Rule on the Child Abuse Prevention and Treatment Act (CAPTA).\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-15-03)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-15-03","description":"Access the complete IM-15-03 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2y9g-th3y","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","innovation","patent","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2y9g-th3y","description":"The invention relates to the identification of a new protein that binds to the cytoplasmic domain of syndecan. This new protein, denominated as \"syntenin\", contains 298 amino acids and is characterized by a tandem repeat of PDZ-domains that reacts with the C-terminal amino acid sequence of syndecans. The amino-terminal region of syntenin further comprises five tyrosine residues whereas no tyrosine residues are present in the remaining part of the protein. The present invention further discloses a nucleic acid encoding syntenin, a method to screen for components interfering with the syndecan-syntenin interaction, a method for diagnosing Alzheimer's disease, inflammatory diseases, and malignancies and a pharmaceutical composition for healing the latter diseases.","title":"Patent AT-E401402-T1: [Translated] PROTEINS INTERACTING WITH SYNDEKAN AND THEIR USE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401402-T1","description":"Access the complete Patent AT-E401402-T1: [Translated] PROTEINS INTERACTING WITH SYNDEKAN AND THEIR USE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://gis.dhcs.ca.gov/datasets/CADHCS::chart-2-1-total-number-of-provider-contracts-for-ecm-in-each-quarter","issued":"2024-01-24","temporal":"Other","@type":"dcat:Dataset","modified":"2026-06-26","keyword":["cs","community supports","ecm","enhanced care management"],"contactPoint":{"@type":"vcard:Contact","fn":"DHCS","hasEmail":"mailto:gis@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"5380f610-8ecc-46df-806a-236783187d96","description":"ECM Community Support Services tables for a Quarterly Implementation Report. Including the County and Plan Details for both ECM and Community Support.
This Medi-Cal Enhanced Care Management (ECM) and Community Supports Calendar Year Quarterly Implementation Report provides a comprehensive overview of ECM and Community Supports implementation in the programs' first year. It includes data at the state, county, and plan levels on total members served, utilization, and provider networks.
ECM is a statewide MCP benefit that provides person-centered, community-based care management to the highest need members. The Department of Health Care Services (DHCS) and its MCP partners began implementing ECM in phases by Populations of Focus (POFs), with the first three POFs launching statewide in CY 2022.
Community Supports are services that address members’ health-related social needs and help them avoid higher, costlier levels of care. Although it is optional for MCPs to offer these services, every Medi-Cal MCP offered Community Supports in 2022, and at least two Community Supports services were offered and available in every county by the end of the year.
","title":"Chart 2.1 Total Number of Provider Contracts for ECM in Each Quarter","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/datasets/CADHCS::chart-2-1-total-number-of-provider-contracts-for-ecm-in-each-quarter","mediaType":"text/html","title":"ArcGIS Hub Dataset"},{"@type":"dcat:Distribution","downloadURL":"https://services7.arcgis.com/7MUwsS9z05YumJRZ/arcgis/rest/services/ECM_Community_Support_Data_Tables_for_Quarterly_Implementation_report/FeatureServer/27","mediaType":"application/octet-stream","title":"ArcGIS GeoService"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/csv?layers=27","mediaType":"text/csv","title":"CSV"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/shapefile?layers=27","mediaType":"application/zip","title":"Shapefile"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/geojson?layers=27","mediaType":"application/geo+json","title":"GeoJSON"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/kml?layers=27","mediaType":"application/vnd.google-earth.kml+xml","title":"KML"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/5380f610-8ecc-46df-806a-236783187d96/resource/b0c0b121-6466-42ac-bfb6-d66de30237ea/download/chart-2-1-total-number-of-provider-contracts-for-ecm-in-each-quarter-1xru1ijv.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2yas-6rz8","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["outcome-measures","american-samoa","block-grant-data","mental-health-services","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2yas-6rz8","description":"This is the 2021 Uniform Reporting System (URS) Output Tables for American Samoa. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2021 Uniform Reporting System (URS) Table For American Samoa","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2021-uniform-reporting-system-urs-table-american-samoa","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2yav-p5ag","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","references","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2yav-p5ag","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864328: MLS000041769","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864328","description":"Access the complete Substance 864328: MLS000041769 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ybf-iw4g","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["social","childr","child","acf","service"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2ybf-iw4g","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Appendix III: Definitions of WEI Categories and Work Activities (March 2011)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/11650","description":"Access the complete Appendix III: Definitions of WEI Categories and Work Activities (March 2011) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ye6-mpqx","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2ye6-mpqx","description":"Chemical compound data from PubChem database. IUPAC Name: 2-ethylthieno[2,3-c]thiophene. Molecular Formula: C8H8S2. Molecular Weight: 168.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526932: 2-Ethylthienothiophene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526932","description":"Access the complete Compound 526932: 2-Ethylthienothiophene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ygm-cev2","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["breast-cancer-guidelines","guideline-quality","consensus-based-guidelines","nih","evidence-based-guidelines"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2ygm-cev2","description":"Background\n It is not known whether there are differences in the quality and recommendations between evidence-based (EB) and consensus-based (CB) guidelines. We used breast cancer guidelines as a case study to assess for these differences.\n \n \n Methods\n Five different instruments to evaluate the quality of guidelines were identified by a literature search. We also searched MEDLINE and the Internet to locate 8 breast cancer guidelines. These guidelines were classified in three categories: evidence based, consensus based and consensus based with no explicit consideration of evidence (CB-EB). Each guideline was evaluated by three of the authors using each of the instruments. For each guideline we assessed the agreement among 14 decision points which were selected from the NCCN (National Cancer Comprehensive Network) guidelines algorithm. For each decision point we recorded the level of the quality of the information used to support it. A regression analysis was performed to assess if the percentage of high quality evidence used in the guidelines development was related to the overall quality of the guidelines.\n \n \n Results\n Three guidelines were classified as EB, three as CB-EB and two as CB. The EB guidelines scored better than CB, with the CB-EB scoring in the middle among all instruments for guidelines quality assessment. No major disagreement in recommendations was detected among the guidelines regardless of the method used for development, but the EB guidelines had a better agreement with the benchmark guideline for any decision point. When the source of evidence used to support decision were of high quality, we found a higher level of full agreement among the guidelines' recommendations. Up to 94% of variation in the quality score among guidelines could be explained by the quality of evidence used for guidelines development.\n \n \n Conclusion\n EB guidelines have a better quality than CB guidelines and CB-EB guidelines. Explicit use of high quality evidence can lead to a better agreement among recommendations. However, no major disagreement among guidelines was noted regardless of the method for their development.","title":"Quality and methods of developing practice guidelines","programCode":["009:035"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC65517/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ykf-evpi","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["splanchnic-ischemia","nih","liver-perfusion","intestinal-ischemia","gut-blood-flow"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2ykf-evpi","description":"Inadequate splanchnic perfusion is associated with increased morbidity and mortality, particularly if liver dysfunction coexists. Heart failure, increased intra-abdominal pressure, haemodialysis and the presence of obstructive sleep apnoea are among the multiple clinical conditions that are associated with impaired splanchnic perfusion in critically ill patients. Total liver blood flow is believed to be relatively protected when gut blood flow decreases, because hepatic arterial flow increases when portal venous flow decreases (the hepatic arterial buffer response [HABR]). However, there is evidence that the HABR is diminished or even abolished during endotoxaemia and when gut blood flow becomes very low. Unfortunately, no drugs are yet available that increase total hepato-splanchnic blood flow selectively and to a clinically relevant extent. The present review discusses old and new concepts of splanchnic vasoregulation from both experimental and clinical viewpoints. Recently published trials in this field are discussed.","title":"Clinical review: Splanchnic ischaemia","programCode":["009:037"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137310/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ypt-pbuu","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pain-reliever-misuse","substance-use-prevalence","nsduh-survey","prescription-drug-abuse","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2ypt-pbuu","description":"Table 8. Nonmedical Use of Pain Relievers in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2013 and 2014 NSDUHs","title":"Table 8. Nonmedical Use of Pain Relievers in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2013 and 2014 NSDUHs","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/table-8-nonmedical-use-pain-relievers-past-year-age-group-and-state-percentages-annual-0","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://hcai.ca.gov/data-and-reports/cost-transparency/hospital-supplier-diversity/","issued":"2021-07-20","temporal":"Point in time, year over year.","@type":"dcat:Dataset","modified":"2025-12-16","keyword":["hospital supplier diversity report","health care","women","disabled veteran","equity","supplier diversity","minority","lgbt"],"contactPoint":{"@type":"vcard:Contact","fn":"Department of Health Care Access and Information","hasEmail":"mailto:Supplier.Diversity@hcai.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"ac3d8ad8-1e76-4893-b08a-301ec32c1bee","description":"This dataset contains Hospital Supplier Diversity Plans. \r\n\r\nAs outlined in [Health and Safety Code Section 1339.85-1339.87](https://leginfo.legislature.ca.gov/faces/codes_displayText.xhtml?division=2.&chapter=2.17.&lawCode=HSC), licensed hospitals with operating expenses of fifty million dollars ($50,000,000) or more, and each licensed hospital with operating expenses of twenty-five million dollars ($25,000,000) or more that is part of a hospital system, shall submit an annual report to the department on its minority, women, LGBT, and disabled veteran business enterprise procurement efforts during the previous year. \r\n\r\nDetails on reporting requirements can be found in [Section 1339.87](https://leginfo.legislature.ca.gov/faces/codes_displaySection.xhtml?sectionNum=1339.87&lawCode=HSC).\r\n\r\nFor more on [Hospital Supplier Diversity Plans](https://hcai.ca.gov/data-and-reports/cost-transparency/hospital-supplier-diversity/). \r\n\r\nData notes: \r\nThe information contained in a hospital’s plan on minority, women, LGBT, and disabled veteran business enterprises is provided for informational purposes only.\r\n\r\nSuppliers are not required to disclose the above information to hospitals, and therefore not all diverse spending will be accurately identified.","title":"Hospital Supplier Diversity Plans","distribution":[{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/a5d07fb2-0416-4067-bda4-55375223fd56/download/2024-hsd-odp-upload-cover-sheet.pdf","description":"Includes coversheet, individual and system/regional blank templates.","@type":"dcat:Distribution","title":"2024 Hospital Supplier Diversity Plan Document"},{"mediaType":"application/vnd.ms-excel","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/b874ad93-9f4e-4e8c-82fc-32b26d4ca8d4/download/supplier-diversity-plan-2024-extract_09222025.xlsx","description":"Excel format of individual plan responses as of 9.22.2025 431KB","@type":"dcat:Distribution","title":"2024 Hospital Supplier Diversity Individual Plans Extract"},{"mediaType":"application/vnd.ms-excel","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/49740ab8-71ec-421e-b26a-7755f0b1cdde/download/supplier-diversity-regional-plan-2024-extract-1.xlsx","description":"Excel format of system/regional plan responses as of 9.19.25 70.4 KB","@type":"dcat:Distribution","title":"2024 Hospital Supplier Diversity System/Regional Plans Extract"},{"mediaType":"application/zip","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/05b90a91-3d07-4773-934e-8b24209a51fa/download/supplier-diversity-plan-2024-1.zip","description":"PDF versions of the 2024 Supplier Diversity Individual Plans as of 9.22.25","@type":"dcat:Distribution","title":"2024 Supplier Diversity Individual Plans"},{"mediaType":"application/zip","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/7a2121a8-00ac-4f81-8843-df3940cb4cfd/download/system-regional-plan-2024-1.zip","description":"PDF versions of the 2024 System/Regional Plans as of 9.19.25","@type":"dcat:Distribution","title":"2024 System Regional Plans"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/d451b754-986d-4cf7-a98b-ba970de2b07b/download/supplier-diversity-reporting-2022-2024-pivot-table_updated.xlsx","description":"The Supplier Diversity Reporting Pivot table was created to provide the public and stakeholders with a clear, interactive view of California's Hospitals procurement data over the last three reporting periods (2022-2024). The data is illustrated through charts and graphs can be broken down by specific categories and filters, allowing for a more comprehensive view of California's Hospitals.","@type":"dcat:Distribution","title":"Supplier Diversity Reporting 2022-2024 Pivot table"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/2c673389-aa91-49d1-b391-978f7baca7ec/download/supplier-diversity-in-california-hospital-procurements-2021-2023-dashboard-data.xlsx","description":"The underlying data for the Supplier Diversity in California Hospital Procurements, 2021-2023 dashboard.","@type":"dcat:Distribution","title":"Supplier Diversity in California Hospital Procurements, 2021-2023 Dashboard Data"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/8d2a600f-8952-405f-8742-d38b65fb07bb/download/supplier-diversity-in-california-hospital-procurements-2021-2023-data-dictionary.xlsx","description":"The data dictionary for the Supplier Diversity in California Hospital Procurements, 2021-2023 dashboard data.","@type":"dcat:Distribution","title":"Supplier Diversity in California Hospital Procurements, 2021-2023 Data Dictionary"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/05fc7584-6c6d-415f-8624-6be9a01c6b0b/download/hospital-supplier-diversity-reporting-pivot-table-2021-2023-.xlsx","description":"The Supplier Diversity Reporting Pivot table was created to provide the public and stakeholders with a clear, interactive view of California's Hospitals procurement data over the last three reporting periods (2021-2023). The data is illustrated through charts and graphs can be broken down by specific categories and filters, allowing for a more comprehensive view of California's Hospitals.","@type":"dcat:Distribution","title":"Supplier Diversity Reporting 2021-2023 Pivot table"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/8c89d70e-e856-4552-a8c5-dc59b309724d/download/2023-hsd-odp-upload-cover-sheet.pdf","description":"Includes coversheet, individual and system/regional blank templates.","@type":"dcat:Distribution","title":"2023 Hospital Supplier Diversity Plan Document"},{"mediaType":"application/vnd.ms-excel","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/ae617185-833a-4c71-9486-0f3ff8a589ab/download/supplier-diversity-plan-2023-extract_12162025.xlsx","description":"Excel format of individual plan responses as of 12.16.2025 268 KB","@type":"dcat:Distribution","title":"2023 Hospital Supplier Diversity Individual Plans Extract"},{"mediaType":"application/vnd.ms-excel","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/e8f74860-265f-438c-aba4-d4db325065d3/download/supplier-diversity-regional-plan-2023_10202025.xlsx","description":"Excel format of system/regional plan responses as of 10.20.2025 18.0KB","@type":"dcat:Distribution","title":"2023 Hospital Supplier Diversity System/Regional Plans Extract"},{"mediaType":"application/zip","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/5a0b8f5d-5fe2-467c-a49e-7ca6cbc9606d/download/supplier-diversity-plan-2023-12162025.zip","description":"PDF versions of the 2023 Supplier Diversity Individual Plans as of 12.16.2025","@type":"dcat:Distribution","title":"2023 Supplier Diversity Individual Plans"},{"mediaType":"application/zip","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/74914891-3e29-476c-9c10-9fc235cd4586/download/system-regional-plan-2023.zip","description":"PDF versions of the 2023 System/Regional Plans as of 10.20.2025","@type":"dcat:Distribution","title":"2023 System Regional Plans"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/5c46cbf6-df03-493b-8cf7-b4cb41a12331/download/2022-hsd-odp-upload-cover-sheet.pdf","description":"Includes coversheet, individual and system/regional blank templates.","@type":"dcat:Distribution","title":"2022 Hospital Supplier Diversity Plan Document"},{"mediaType":"application/vnd.ms-excel","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/91ad173b-8fde-4115-bf75-79790d551cbb/download/supplier-diversity-plan-2022-extract.xlsx","description":"Excel format of individual plan responses.","@type":"dcat:Distribution","title":"2022 Hospital Supplier Diversity Individual Plans Extract"},{"mediaType":"application/vnd.ms-excel","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/dc32ee77-81cc-4fda-ba10-fc3979c43488/download/supplier-diversity-regional-report-2022-extract-4.xlsx","description":"Excel format of system/regional plan responses.","@type":"dcat:Distribution","title":"2022 Hospital Supplier Diversity System/Regional Plans Extract"},{"mediaType":"application/zip","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/5b0dd7db-09fb-489f-8422-57d95631f417/download/supplier-diversity-report-2022.zip","description":"PDF versions of the 2022 Supplier Diversity Individual Plans.","@type":"dcat:Distribution","title":"2022 Supplier Diversity Individual Plans"},{"mediaType":"application/zip","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/47640c27-6fd2-4a2e-8f1a-94587966696b/download/system-regional-report-2022-2.zip","description":"PDF versions of the 2022 System Regional Plans.","@type":"dcat:Distribution","title":"2022 System Regional Plans"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/3e1040a8-280b-403e-a022-7eb3450c119c/download/2021-hsd-odp-upload-coversheet-2.pdf","description":"Includes coversheet, individual and system/regional blank templates, and individual and system/regional data dictionaries.","@type":"dcat:Distribution","title":"2021 Hospital Supplier Diversity Plan Document"},{"mediaType":"application/vnd.ms-excel","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/2f883b66-37fe-493c-999b-af4ab848c677/download/supplier-diversity-plan-2021-extract.xlsx","description":"Excel format of individual plan responses.","@type":"dcat:Distribution","title":"2021 Hospital Supplier Diversity Individual Plans Extract"},{"mediaType":"application/vnd.ms-excel","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/0cb31ab3-9ff7-47bc-a856-ef1c46de9aa1/download/supplier-diversity-regional-report-2021-extract-8.xlsx","description":"Excel format of system/regional plan responses.","@type":"dcat:Distribution","title":"2021 Hospital Supplier Diversity System/Regional Plans Extract"},{"mediaType":"application/octet-stream","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/96d7f69e-b8b0-41aa-98c9-36e52597d5b5/download/supplier-diversity-report-2021.zip","description":"PDF versions of the 2021 Supplier Diversity Individual Plans.","@type":"dcat:Distribution","title":"2021 Supplier Diversity Individual Plans"},{"mediaType":"application/zip","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/72737f0c-7745-4a14-b22e-78a560a75f53/download/system-regional-report-2021.zip","description":"PDF versions of the 2021 System Regional Plans.","@type":"dcat:Distribution","title":"2021 System Regional Plans"},{"mediaType":"application/zip","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/bd8dae12-dea0-422b-a025-f80bc40d9b32/download/2020_hospital_supplier_diversity_reports.zip","description":"Dataset for Hospital Supplier Diversity Plans from 2020. \r\n(File Size: 264 MB)\r\nUpdated 06/10/2022: Updated system report received.","@type":"dcat:Distribution","title":"2020 Hospital Supplier Diversity Plans"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/af231a09-a429-4c8e-bcf3-b74c40892bdc/download/hospital-supplier-diversity-reports-8xi4t67e.zip","mediaType":"application/zip","title":"All resource data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/ac3d8ad8-1e76-4893-b08a-301ec32c1bee/resource/a0798cc9-3c54-4a01-ba27-912c7fe9ffbb/download/2024-hsd-odp-upload-cover-sheet.pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Demographics","Facilities and Services","Workforce"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2yqy-j4vt","bureauCode":["009:38"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-07-23","keyword":["cms","medicare-payments","drg-payment","hospital-incentives","value-based-payment"],"contactPoint":{"@type":"vcard:Contact","fn":"CMS","hasEmail":"mailto:pfs@cms.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services (CMS)"},"identifier":"https://healthdata.gov/api/views/2yqy-j4vt","description":"Net Change in Base Operating DRG Payment Amount shows number of hospitals for specified ranges of value-based incentive payment amounts after subtracting the amount by which their Medicare payments per discharge were reduced.","title":"Table 1: FY2021 Net Change in Base Operating DRG Payment Amount","programCode":["009:078"],"distribution":[{"mediaType":"text/html","downloadURL":"https://data.cms.gov/provider-data/sites/default/files/resources/794aef5e642b10af5e5b0502025c1ce0_1720656688/FY2021_Net_Change_in_Base_Op_DRG_Payment_Amt.csv","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ytf-k83g","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","bioactivity","chemistry","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2ytf-k83g","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865862: MLS000039581","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865862","description":"Access the complete Substance 865862: MLS000039581 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ytm-24qe","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2024-12-23","keyword":["nadac","drug acquisition cost"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"99315a95-37ac-4eee-946a-3c523b4c481e","description":"National Average Drug Acquisition Cost (NADAC) weekly reference data for the calendar year.","title":"NADAC (National Average Drug Acquisition Cost) 2024","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/nadac-national-average-drug-acquisition-cost-12-25-2024.csv","mediaType":"text/csv"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["National Average Drug Acquisition Cost","Drug Pricing and Payment"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2yu5-tchd","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","pubchem","chemistry","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2yu5-tchd","description":"Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3-(2-sulfanylideneimidazol-4-yl)-2-(trimethylsilylamino)propanoate. Molecular Formula: C12H23N3O2SSi2. Molecular Weight: 329.57. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530095: 2-Thiohistidine, TMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530095","description":"Access the complete Compound 530095: 2-Thiohistidine, TMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["prescription-drugs","health-care","drug-information","drug-manufacturers","public-health"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA200797","description":"Valsartan is a generic prescription medication that blocks angiotensin II receptors to help lower blood pressure and treat heart failure. Available as oral tablets in strengths of 40mg, 80mg, 160mg, and 320mg, it's manufactured by Jubilant Cadista Pharmaceuticals Inc. under ANDA203536. This information was generated using AI and is provided for informational and research purposes only.","title":"Valsartan","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=200797","description":"\n Access the FDA dataset for Valsartan — ANDA 200797 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Valsartan"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2z29-bq4h","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["fiscal","data","policy","reporting","adoption"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2z29-bq4h","description":"This report provides state-specific data from fiscal year 2010 about the sex of children adopted through public agencies.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Sex of Public Agency Children Adopted: 10/1/2009 - 9/30/2010","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/sex-public-agency-children-adopted-10/1/2009-9/30/2010","description":"Access the complete Sex of Public Agency Children Adopted: 10/1/2009 - 9/30/2010 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2z2i-jf67","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["alcohol-drug-abuse","substance-abuse-treatment","samhsa","treatment-facilities","new-hampshire"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2z2i-jf67","description":"This is a National Survey of Substance Abuse Treatment Services (N-SSATS) annual report showing the state profile for New Hampshire in 2012. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.","title":"2012 State Profile - New Hampshire","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-state-profile-new-hampshire","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nchs/nhis/index.htm","bureauCode":["009:20"],"issued":"2023-09-06","temporal":"2021-2022","@type":"dcat:Dataset","modified":"2025-04-21","keyword":["summary health statistics","nhis"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/5pqj-rvh4","description":"Interactive Summary Health Statistics for Teens provide estimates of selected health topics for youth aged 12-17 years based on final data from the National Health Interview Survey— Teen.","title":"NHIS Teen","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/5pqj-rvh4/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/5pqj-rvh4/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/5pqj-rvh4/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"https://www.usa.gov/government-works","theme":["National Center for Health Statistics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2z2x-ijtz","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","innovation","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2z2x-ijtz","description":"Chemical patent from PubChem database. Patent Number: AT-E400943-T1. Title: Improved Chemical Process. Filing Date: 1995-03-17. Inventors: Smith, John A., Johnson, Mary B.. Abstract: An improved chemical process is disclosed, featuring enhanced yield, reduced reaction time, and improved environmental profile compared to conventiona... IPC Classifications: C12N, C12P, A61K. This patent covers 27 claims related to 7 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.","title":"Patent AT-E400943-T1: [Translated] BINARY TREE METHOD AND SYSTEM FOR MULTIPLEX SCHEDULE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400943-T1","description":"Access the complete Patent AT-E400943-T1: [Translated] BINARY TREE METHOD AND SYSTEM FOR MULTIPLEX SCHEDULE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2z4i-rpp9","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["adoption","child","grant","policy","social"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2z4i-rpp9","description":"On October 17, 2000 the U.S. Congress, under Public Law 103-310, amended the Public Health Services Act to authorize specific activities pertaining to Infant Adoption Awareness (title XII, Subtitle A). The legislation requires the Secretary of the Department of Health and Human Services (DHHS) to award grants to adoption organizations to develop and implement programs to train the designated staff of eligible health centers in providing adoption information and referral to pregnant women on an equal basis with all other courses of action included in nondirective counseling for pregnant women. The term \"eligible health centers\" means public and nonprofit private entities that provide health services to pregnant women. The legislation also requires the Secretary to establish a set of best-practice guidelines to which the DHHS-funded training programs will adhere in providing training to staff of eligible health centers.\n\nIn response to these legislative requirements, the Department of Health and Human Services has developed the following \"best-practice\" guidelines to be followed by recipients of cooperative agreements in developing curriculum and providing training to implement the Infant Adoption Awareness Training Program (IAATP). This \"best-practice\" guideline is critical for attaining the primary IAATP goal- enhancing the ability of health center personnel to provide adoption information and referral on an equal basis with all other courses of action included in nondirective counseling for pregnant women.\n\nConsistent with the intent of the legislation, these guidelines were developed in consultation with 29 experts in the fields of adoption, child welfare, health services, medicine, law, and adoption counseling, as well as adoptive parents.\n\nTraining Goals\n\nBasic Skills\n\nCurriculum\n\nTraining Structure\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Infant Adoption Awareness Training Program","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/infant-adoption-awareness-training-program","description":"Access the complete Infant Adoption Awareness Training Program on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/nf22-99pv","bureauCode":["009:00"],"issued":"2016-01-07","@type":"dcat:Dataset","modified":"2016-01-07","keyword":["tetanus","nndss","netss","mmwr","wonder","vibriosis","varicella","2015","nedss"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/nf22-99pv","description":"NNDSS - Table II. Tetanus to Vibriosis - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. �� Any species of the family Vibrionaceae, other than toxigenic Vibrio cholerae O1 or O139.","title":"NNDSS - Table II. Tetanus to Vibriosis","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nf22-99pv/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nf22-99pv/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/nf22-99pv/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zbr-q335","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-statistics","state-level-data","serious-mental-illness","adult-smi-estimates","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2zbr-q335","description":"This is a Uniform Reporting System (URS) series of tables that details the number of adults with serious mental illness (SMI), ages 18 and older, by State, from 2018.","title":"Instructions To Update The SAMHSA SMI And SED Estimates URS Table 1: Number Of Adults With Serious Mental Illness, Age 18 And Older, By State, 2018","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/instructions-update-samhsa-smi-and-sed-estimates-2018","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-manufacturers","health-care","medications","pharmaceuticals","public-health"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA020898","description":"Thyrogen (thyrotropin alfa) is a prescription medication that mimics thyroid-stimulating hormone to help diagnose or treat thyroid conditions, such as in thyroid cancer patients preparing for radioactive iodine therapy. It's administered as an intramuscular injection, available as a lyophilized powder for solution. Manufactured by Genzyme Corporation. This information was generated using AI and is provided for informational and research purposes only.","title":"Thyrotropin alfa","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020898","description":"\n Access the FDA dataset for Thyrotropin alfa — ANDA 020898 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Thyrotropin alfa"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zdj-9wx2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2zdj-9wx2","description":"Chemical compound data from PubChem database. IUPAC Name: 6-propyldodecane. Molecular Formula: C15H32. Molecular Weight: 212.41. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529959: Dodecane, 6-propyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529959","description":"Access the complete Compound 529959: Dodecane, 6-propyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zdy-zt4g","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","chemistry","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2zdy-zt4g","description":"Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-[2-[2-(2,3-diacetyloxypropoxy)propoxy]propoxy]propoxy]propoxy]propyl acetate. Molecular Formula: C24H44O11. Molecular Weight: 508.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525156: Glycerol-pentapropylene glycol ether, triacetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525156","description":"Access the complete Compound 525156: Glycerol-pentapropylene glycol ether, triacetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ze6-agkm","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2ze6-agkm","description":"Chemical compound data from PubChem database. IUPAC Name: 9-ethylheptadecane. Molecular Formula: C19H40. Molecular Weight: 268.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529995: Heptadecane, 9-ethyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529995","description":"Access the complete Compound 529995: Heptadecane, 9-ethyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zg3-kw57","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","science","chemistry","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2zg3-kw57","description":"Chemical compound data from PubChem database. IUPAC Name: pent-4-en-2-yl benzoate. Molecular Formula: C12H14O2. Molecular Weight: 190.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527782: 4-Penten-2-ol, benzoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527782","description":"Access the complete Compound 527782: 4-Penten-2-ol, benzoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zge-92dx","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-withdrawal","samhsa","drug-related-ed-visits","detoxification-seeking","denver-metro-area"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2zge-92dx","description":"Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving patients seeking detox in the Denver metropolitan area, covering 2004-2011. This includes nonemergency requests made through the ED for admission to detoxification unit, visits to obtain medical clearance before being incarcerated, and acute emergencies where an individual is experiencing withdrawal symptoms and requests detox. These estimates do not include patients who seek or enter the hospital\\'s detox unit through other avenues.","title":"Denver: Drug-Related Emergency Department Visits, 2004-2011 - Seeking Detox","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/denver-drug-related-emergency-department-visits-2004-2011-seeking-detox","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"http://www.icpsr.umich.edu/icpsrweb/NAHDAP/index.jsp","bureauCode":["009:00"],"issued":"2016-07-17","@type":"dcat:Dataset","modified":"2023-07-26","keyword":["national-institutes-of-health-nih"],"contactPoint":{"@type":"vcard:Contact","fn":"Etz, Kathy","hasEmail":"mailto:ketz@nida.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health (NIH)"},"identifier":"d2073e47-2472-417c-9431-0797be6d35a8","description":"NAHDAP acquires, preserves and disseminates data relevant to drug addiction and HIV research. By preserving and making available an easily accessible library of electronic data on drug addiction and HIV infection in the United States, NAHDAP offers scholars the opportunity to conduct secondary analysis on major issues of social and behavioral sciences and public policy.
","title":"National Addiction & HIV Data Archive Program (NAHDAP)","programCode":["009:027"],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zin-72cb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","innovation","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2zin-72cb","description":"An animal water trough having a cover structure which fits within the trough and preferably adapted to float on the surface of trough water to substantially cover the whole water surface area. Receptacles or channels are provided in the cover. Apertures, which communicate with the water trough, are provided in the channel walls to convey water from the trough into the receptacle or channel. Preferably, a substance dispenser is located in the cover, which feeds substances into the trough water.","title":"Patent AT-E401785-T1: [Translated] DRINKING DEVICE FOR ANIMALS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401785-T1","description":"Access the complete Patent AT-E401785-T1: [Translated] DRINKING DEVICE FOR ANIMALS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ziw-4fmr","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["pubchem","chemistry","compound","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2ziw-4fmr","description":"Chemical compound data from PubChem database. IUPAC Name: N-hexyl-1-phenylmethanimine. Molecular Formula: C13H19N. Molecular Weight: 189.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525556: Hexylamine, N-benzylidene-","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525556","description":"Access the complete Compound 525556: Hexylamine, N-benzylidene- on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zk9-ksrg","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2zk9-ksrg","description":"Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3-methyl-2-trimethylsilyloxypentanoate. Molecular Formula: C12H28O3Si2. Molecular Weight: 276.52. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528641: Trimethylsilyl 3-methyl-2-[(trimethylsilyl)oxy]pentanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528641","description":"Access the complete Compound 528641: Trimethylsilyl 3-methyl-2-[(trimethylsilyl)oxy]pentanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/km4m-vcsb","bureauCode":["009:20"],"issued":"2022-11-23","@type":"dcat:Dataset","temporal":"2020-12-13/2023-05-12","modified":"2023-05-12","references":["https://www.cdc.gov/coronavirus/2019-ncov/vaccines/distributing/about-vaccine-data.html"],"keyword":["administration","vaccination","sex","race","izdl","immunization","ethnicity","demographics","covid-19","coronavirus","age"],"contactPoint":{"@type":"vcard:Contact","fn":"NCIRD","hasEmail":"mailto:iisinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/km4m-vcsb","description":"Overall Demographic Characteristics of People Receiving COVID-19 Vaccinations in the United States at national level. Data represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities. ","title":"COVID-19 Vaccination Demographics in the United States,National","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/km4m-vcsb/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/km4m-vcsb/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/km4m-vcsb/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"US","license":"https://www.usa.gov/government-works","accrualPeriodicity":"R/P1D","theme":["Vaccinations"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zpd-8k8m","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["cow-milk-allergy","nih","pediatric-allergy","hydrolyzed-formula","double-blind-study"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2zpd-8k8m","description":"Background\n Formulae for infants with cow's milk protein allergy (CMA) should be based on extensively hydrolysed protein. 'Extensively' however is not strictly defined. Differences in molecular weight and peptide chain length may affect its clinical outcome. We studied the safety of a new extensively hydrolysed casein based formula (Frisolac Allergycare®: FAC) for children with IgE mediated CMA.\n \n \n Methods\n Thirty children, aged 1.5 – 14.8 years old (median 4.9 years) with persistent CMA were enrolled in this double-blind reference product (Nutramigen®: NUT) controlled crossover study. All had positive skin prick tests (SPT) and IgE mediated allergy, showing immediate reactions after ingestion of small amounts of milk. Twenty-five children also had positive radio allergen sorbent tests (RAST) to cow's milk. Formulae provided consisted of 80% elementary formula in combination with 20% reference or test product. Crossover periods lasted for two weeks. From both products molecular weight (MALDI-TOF method and HPLC) and peptide chain length distribution (adapted Edman degradation) were determined.\n \n \n Results\n Maximum molecular weights of NUT and FAC are 2.1 and 2.56 kDa, respectively. The contribution of free amino acids and small peptides <0.5 kDa is 46% for FAC and 53% for NUT. About 50% of the protein fraction of both products consists of peptides longer than four amino acids. Three children did not complete the study. The other children all tolerated FAC very well; no adverse reactions were reported.\n \n \n Conclusions\n The new extensively hydrolysed casein-based formula (FAC) can safely be used in children with IgE mediated cow's milk allergy.","title":"Safety of a new extensively hydrolysed formula in children with cow's milk protein allergy: a double blind crossover study","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC130212/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zq6-ixny","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["skills-training","nih","armenia","obstetric-emergencies","maternal-mortality"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/2zq6-ixny","description":"Background\n Mortality rates in Western Europe have fallen significantly over the last 50 years. Maternal mortality now averages 10 maternal deaths per 100,000 live births but in some of the Newly Independent States of the former Soviet Union, the ratio is nearly 4 times higher. The availability of skilled attendants to prevent, detect and manage major obstetric complications may be the single most important factor in preventing maternal deaths. A modern, multidisciplinary, scenario and model based training programme has been established in the UK (Managing Obstetric Emergencies and Trauma (MOET)) and allows specialist obstetricians to learn or revise the undertaking of procedures using models, and to have their skills tested in scenarios.\n \n \n Methods\n Given the success of the MOET course in the UK, the organisers were keen to evaluate it in another setting (Armenia). Pre-course knowledge and practice questionnaires were administered. In an exploratory analysis, post-course results were compared to pre-course answers obtained by the same interviewer.\n \n \n Results\n All candidates showed an improvement in post-course scores. The range was far narrower afterwards (167–188) than before (85–129.5). In the individual score analysis only two scenarios showed a non-significant change (cord prolapse and breech delivery).\n \n \n Conclusion\n This paper demonstrates the reliability of the model based scenarios, with a highly significant improvement in obstetric emergency management. However, clinical audit will be required to measure the full impact of training by longer term follow up. Audit of delays, specific obstetric complications, referrals and near misses may all be amenable to review.","title":"Managing Obstetric Emergencies and Trauma (MOET) structured skills training in Armenia, utilising models and reality based scenarios","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC116574/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdph.ca.gov/Programs/CFH/DMCAH/Pages/Data/Adolescent-Health-Data.aspx","issued":"2017-06-16","temporal":"Aggregated 2014-2016","@type":"dcat:Dataset","modified":"2026-02-12","keyword":["cfh","adolescent births","teen births","repeat births","prb","poverty","pbhp","mcah","maternal child adolescent health","birth rates","adolescent health","abr"],"contactPoint":{"@type":"vcard:Contact","fn":"Maternal, Child and Adolescent Health Division","hasEmail":"mailto:opendata@cdph.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"165e1016-991f-487c-bdd0-84dd1c0a6fe8","description":"This dataset contains California’s adolescent birth rate (ABR) by county, age group and race/ethnicity using aggregated years 2014-2016. The ABR is calculated as the number of live births to females aged 15-19 divided by the female population aged 15-19, multiplied by 1,000. Births to females under age 15 are uncommon and thus added to the numerator (total number of births aged 15-19) in calculating the ABR for aged 15-19. The categories by age group are aged 18-19 and aged 15-17; births occurring to females under aged 15 are added to the numerator for aged 15-17 in calculating the ABR for this age group. The race and ethnic groups in this table utilized five mutually exclusive race and ethnicity categories. These categories are Hispanic and the following Non-Hispanic categories of Multi-Race, Black, American Indian (includes Eskimo and Aleut), Asian and Pacific Islander (includes Hawaiian) combined, and White. Note that there are birth records with missing race/ethnicity or categorized as “Other” and not shown in the dataset but included in the ABR calculation overall.","title":"Adolescent Births","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/165e1016-991f-487c-bdd0-84dd1c0a6fe8/resource/0e5a7fea-2efa-48c6-a1bf-7b68f77f8a72/download/abr1416-by-county-opendataportal-ver4.csv","description":"This dataset contains California’s adolescent birth rate (ABR) by county, age group and race/ethnicity using aggregated years 2014-2016. The ABR is calculated as the number of live births to females aged 15-19 divided by the female population aged 15-19, multiplied by 1,000. Births to females under age 15 are uncommon and thus added to the numerator (total number of births aged 15-19) in calculating the ABR for aged 15-19. The categories by age group are aged 18-19 and aged 15-17; births occurring to females under aged 15 are added to the numerator for aged 15-17 in calculating the ABR for this age group. The race and ethnic groups in this table utilized five mutually exclusive race and ethnicity categories. These categories are Hispanic and the following Non-Hispanic categories of Multi-Race, Black, American Indian (includes Eskimo and Aleut), Asian and Pacific Islander (includes Hawaiian) combined, and White. Note that there are birth records with missing race/ethnicity or categorized as “Other” and not shown in the dataset but included in the ABR calculation overall.","@type":"dcat:Distribution","title":"Adolescent Births 2014-2016 (CSV)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/165e1016-991f-487c-bdd0-84dd1c0a6fe8/resource/07a613f2-fb1f-4970-9f00-2e7b371788c8/download/adolescent-births-_9c2_e4g.zip","mediaType":"application/zip","title":"All resource data"},{"mediaType":"text/html","downloadURL":"https://www.cdph.ca.gov/Programs/CFH/DMCAH/surveillance/Pages/adolescent-births.aspx","description":"_https://www.cdph.ca.gov/Programs/CFH/DMCAH/surveillance/Pages/adolescent-births.aspx_","@type":"dcat:Distribution","title":"Adolescent Births Dashboard"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["Demographics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2ztc-siah","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["data","policy","scope","fiscal","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2ztc-siah","description":"This report provides state-specific data from fiscal year 2006 about the race and ethnicity of children who were adopted through public agencies.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Race/Ethnicity of Public Agency Children Adopted: 10/1/2005 - 9/30/2006","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/race/ethnicity-public-agency-children-adopted-10/1/2005-9/30/2006","description":"Access the complete Race/Ethnicity of Public Agency Children Adopted: 10/1/2005 - 9/30/2006 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zth-824s","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["youth-mental-health","samhsa","mde-prevalence","mental-health-services","substance-use-disorders"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2zth-824s","description":"These detailed tables present totals and prevalence estimates of mental health related issues among adolescents aged 12 to 17 from the 2012 National Survey on Drug Use and Health (NSDUH). Tables with data on ayouths include measures on mental health service utilization, MDE, treatment for depression (among youths with MDE), and co-occurrence of mental disorders with substance use or with substance use disorders. Results are provided by age group, gender, race/ethnicity, education level, county type, poverty level, insurance status, overal health, and geographic area. Comparisons are made between 2012 and 2011.","title":"Youth Mental Health Tables (Prevalence Estimates) - 2.1 to 2.14","programCode":["009:062"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/youth-mental-health-tables-prevalence-estimates-21-214-1","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zu6-ii3i","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["assessment","metadata"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2zu6-ii3i","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Background Paper: Child and Family Services Reviews National","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/5463","description":"Access the complete Background Paper: Child and Family Services Reviews National.pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zun-7sum","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["childr","service","social","child","acf"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/2zun-7sum","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Alabama PIP (FY 2004)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/9896","description":"Access the complete Alabama PIP (FY 2004).pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zur-3s4c","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","bioactivity","references","substance","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2zur-3s4c","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864197: MLS000083574","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864197","description":"Access the complete Substance 864197: MLS000083574 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zv4-vm3q","bureauCode":["009:38"],"issued":"2014-11-07","temporal":"2016-01-01T00:00:00+00:00/2017-01-01T00:00:00+00:00","@type":"dcat:Dataset","modified":"2021-08-23","keyword":["nadac","drug acquisition cost"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"7656fc17-f1b4-566b-9a2d-c4a4f2ac7ae1","description":"National Average Drug Acquisition Cost (NADAC) weekly reference data for the calendar year.","title":"NADAC (National Average Drug Acquisition Cost) 2016","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/nadac-national-average-drug-acquisition-cost.a4y5-998d.7656fc17-f1b4-566b-9a2d-c4a4f2ac7ae1.csv","mediaType":"text/csv","title":"CSV"}],"license":"https://www.usa.gov/government-works","theme":["National Average Drug Acquisition Cost","Drug Pricing and Payment"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zxr-7mhq","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","pubchem","chemistry","compound","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/2zxr-7mhq","description":"Chemical compound data from PubChem database. IUPAC Name: 2,2-dichloroethyl propanoate. Molecular Formula: C5H8Cl2O2. Molecular Weight: 171.02. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527768: 2,2-Dichloroethyl propionate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527768","description":"Access the complete Compound 527768: 2,2-Dichloroethyl propionate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zyw-mwv2","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","treatment-services","substance-abuse","facility-characteristics","opioid-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/2zyw-mwv2","description":"This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing the type of care offered in facilities with Opioid Treatment Programs (OTPs), by facility operation and primary focus of facility in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.","title":"4.21b Type of care offered in facilities with Opioid Treatment Programs (OTPs), by facility operation and primary focus of facility: 2011. Percent","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/421b-type-care-offered-facilities-opioid-treatment-programs-otps-facility-operation-and","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/2zz2-zxju","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2023-06-07","references":["https://www.mathematica.org/"],"keyword":["scorecard","utility"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"10ebe487-2deb-5e03-88bc-9d847fca5d76","description":"This is a dataset created for the Medicaid Scorecard website (https://www.medicaid.gov/state-overviews/scorecard/index.html), and is not intended for use outside that application.","title":"Scorecard TAG v0.3.1-1 (etl_test)","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/scorecard/0.3.1-1/TAG.csv","description":"Scorecard TAG v0.3.1-1 (etl_test)","@type":"dcat:Distribution","title":"Scorecard TAG v0.3.1-1 (etl_test)"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/324c-ghve","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","compound","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/324c-ghve","description":"Chemical compound data from PubChem database. IUPAC Name: N-trimethylsilylheptadecan-1-amine. Molecular Formula: C20H45NSi. Molecular Weight: 327.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529150: 1-Heptadecanol, TMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529150","description":"Access the complete Compound 529150: 1-Heptadecanol, TMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3254-67ar","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["instruction","policy","response","guidance","19"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3254-67ar","description":"This letter from the Children’s Bureau advises child welfare leaders of the flexibility of certain requirements regarding fingerprint-based criminal records checks and caseworker visits to a child’s home due to the COVID-19 pandemic.\n\nBrowse ALL COVID-19 Resources\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Guidance Regarding Fingerprint and Caseworker Visit Requirements During COVID-19 Response","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/guidance-regarding-fingerprint-and-caseworker-visit-requirements-during-covid-19","description":"Access the complete Guidance Regarding Fingerprint and Caseworker Visit Requirements During COVID-19 Response on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/325p-i54r","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["social","childr","child","acf","service"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/325p-i54r","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Family and Youth Services Bureau Fact Sheet, April 2017","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/4743","description":"Access the complete Family and Youth Services Bureau Fact Sheet, April 2017 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3262-bshe","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","substance-abuse","national-outcome-measures","samhsa","community-mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3262-bshe","description":"2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Indiana. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2015 CMHS Uniform Reporting System (URS) Table for Indiana","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2015-cmhs-uniform-reporting-system-urs-table-indiana","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/327g-3iqb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","chemistry","research","pubchem","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/327g-3iqb","description":"The present invention discloses compounds of formula: (I) (II) where Ar 1 , Ar 2 , X, R 1 , R 2 , R 3 , m, and n are disclosed herein or a pharmaceutically acceptable salt thereof (a \"Phenylene Compound\"); compositions comprising an effective amount of a Phenylene Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof an effective amount of a Phenylene Compound.","title":"Patent AT-E399782-T1: [Translated] PHENYLCARBOXYRAMIDE COMPOUNDS SUITABLE FOR THE TREATMENT OF PAIN","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399782-T1","description":"Access the complete Patent AT-E399782-T1: [Translated] PHENYLCARBOXYRAMIDE COMPOUNDS SUITABLE FOR THE TREATMENT OF PAIN on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/329f-h2fc","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["lexa-gfp-fusion","peptide-libraries","gene-expression","transcriptional-transactivation","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/329f-h2fc","description":"Background\n Transcriptional transactivation is a process with remarkable tolerance for sequence diversity and structural geometry. In studies of the features that constitute transactivating functions, acidity has remained one of the most common characteristics observed among native activation domains and activator peptides.\n \n \n Results\n We performed a deliberate search of random peptide libraries for peptides capable of conferring transcriptional transactivation on the lexA DNA binding domain. Two libraries, one composed of C-terminal fusions, the other of peptide insertions within the green fluorescent protein structure, were used. We show that (i) peptide sequences other than C-terminal fusions can confer transactivation; (ii) though acidic activator peptides are more common, charge neutral and basic peptides can function as activators; and (iii) peptides as short as 11 amino acids behave in a modular fashion.\n \n \n Conclusions\n These results support the recruitment model of transcriptional activation and, combined with other studies, suggest the possibility of using activator peptides in a variety of applications, including drug development work.","title":"Transcriptional transactivation by selected short random peptides attached to lexA-GFP fusion proteins","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC56998/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/329j-99zs","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","research","pubchem","compound","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/329j-99zs","description":"Chemical compound data from PubChem database. IUPAC Name: 2-iodoethyl 4-methylpentanoate. Molecular Formula: C8H15IO2. Molecular Weight: 270.11. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527277: Pentanoic acid, 4-methyl, 2-iodoethyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527277","description":"Access the complete Compound 527277: Pentanoic acid, 4-methyl, 2-iodoethyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32ag-t9tv","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","science","chemistry","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/32ag-t9tv","description":"Chemical compound data from PubChem database. IUPAC Name: 3-methylbutan-2-yl butanoate. Molecular Formula: C9H18O2. Molecular Weight: 158.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527668: Butanoic acid, 1,2-dimethylpropyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527668","description":"Access the complete Compound 527668: Butanoic acid, 1,2-dimethylpropyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.sfgov.org/d/bw5r-gd57","issued":"2022-06-14","@type":"dcat:Dataset","modified":"2025-01-07","keyword":["vaccination"],"contactPoint":{"@type":"vcard:Contact","fn":"OpenData","hasEmail":"mailto:no-reply@data.sfgov.org"},"publisher":{"@type":"org:Organization","name":"City of San Francisco"},"identifier":"https://data.sfgov.org/api/views/bw5r-gd57","description":"Update Jan 26, 2023: This dataset is no longer being updated. Please visit https://sf.gov/get-vaccinated-against-covid-19 for information on vaccine locations. \n\nA. SUMMARY\nDataset contains Vaccine Access points in City and County of San Francisco as listed on https://sf.gov/vaccine-sites. \nThis site list is not inclusive of all City Sites, as some mobile sites and other providers may not be included.\n\nB. HOW THE DATASET IS CREATED\nMaintained by City staff.\n\nC. UPDATE PROCESS\nUpdated daily via automated process","title":"ARCHIVED: San Francisco Vaccine Access Points","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/bw5r-gd57/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/bw5r-gd57/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/bw5r-gd57/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/bw5r-gd57/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/bw5r-gd57/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/bw5r-gd57/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendatacommons.org/licenses/pddl/1.0/","theme":["Health and Social Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32c8-pm4x","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","research","chemistry","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/32c8-pm4x","description":"Chemical compound data from PubChem database. IUPAC Name: 3-methyl-2-pentylquinazolin-4-one. Molecular Formula: C14H18N2O. Molecular Weight: 230.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529121: 4-Quinazolone, 3-methyl-2-pentyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529121","description":"Access the complete Compound 529121: 4-Quinazolone, 3-methyl-2-pentyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32dw-thh8","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["fiscal","metadata"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/32dw-thh8","description":"ACF Children Bureau resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Is this funding opportunity open to public and state institutions of higher education?","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/faq/funding-opportunity-open-public-and-state-institutions-higher-education","description":"Access the complete Is this funding opportunity open to public and state institutions of higher education? on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["medications","drug","drug-manufacturers","fda","public-health"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA218952","description":"Dicyclomine Hydrochloride is a prescription anticholinergic medication used to treat symptoms of irritable bowel syndrome, such as abdominal pain and cramping. It comes as 10 mg oral capsules, manufactured by Upsher-Smith Laboratories, LLC. This information was generated using AI and is provided for informational and research purposes only.","title":"Dicyclomine hydrochloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218952","description":"\n Access the FDA dataset for Dicyclomine hydrochloride — ANDA 218952 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Dicyclomine hydrochloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32gm-v69r","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-abuse","mental-health-services","national-outcome-measures","samhsa","urs-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/32gm-v69r","description":"These are the 2019 Uniform Reporting System (URS) Output Tables for Indiana. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2019 Uniform Reporting System (URS) Table for Indiana","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2019-uniform-reporting-system-urs-table-indiana","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32hf-x9k5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","research","science","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/32hf-x9k5","description":"Chemical compound data from PubChem database. IUPAC Name: 2-hexan-2-yl-6-nitrophenol. Molecular Formula: C12H17NO3. Molecular Weight: 223.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528958: Phenol, 2-(1-methylpentyl)-6-nitro","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528958","description":"Access the complete Compound 528958: Phenol, 2-(1-methylpentyl)-6-nitro on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32i5-qkdm","bureauCode":["009:38"],"issued":"2019-10-22","@type":"dcat:Dataset","modified":"2020-10-23","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"Ashley Van Scyoc","hasEmail":"mailto:CMS_FEPS@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"8kxw-8r6g","description":"The Service Area PUF (SA-PUF) is one of the files that make up the Marketplace PUF. The SA-PUF contains issuer-level data on the geographic coverage or service area (i.e., where the plan is offered) including state, county, and zip code. These data either originate from the Service Area template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).","title":"Service Area PUF - PY2020","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/service-area-puf-2020.8kxw-8r6g.csv","mediaType":"text/csv","title":"CSV"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32j3-vvf4","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-use-disorders","samhsa","nsduh-data","workplace-drug-testing","employee-assistance-programs"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/32j3-vvf4","description":"This short report uses 2008 to 2012 National Survey on Drug Use and Health (NSDUH) to assess receipt of workplace policies and programs regarding substance use among full-time employed workers aged 18 to 64 by past month illicit drug use or heavy alcohol use status.","title":"Workplace Policies and Programs Concerning Alcohol and Drug Use","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/workplace-policies-and-programs-concerning-alcohol-and-drug-use","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32jn-t84u","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["gene-therapy","heart-failure","intimal-hyperplasia","nih","adrenergic-receptors"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/32jn-t84u","description":"Gene therapy using in vivo recombinant adenovirus-mediated gene transfer is an effective technique that offers great potential to improve existing drug treatments for the complex cardiovascular diseases of heart failure and vascular smooth muscle intimal hyperplasia. Cardiac-specific adenovirus-mediated transfer of the carboxyl-terminus of the β-adrenergic receptor kinase (βARKct), acting as a Gβγ-β-adrenergic receptor kinase (βARK)1 inhibitor, improves basal and agonist-induced cardiac performance in both normal and failing rabbit hearts. In addition, βARKct adenovirus infection of vascular smooth muscle is capable of significantly diminishing neointimal proliferation after angioplasty. Therefore, further investigation is warranted to determine whether inhibition of βARK1 activity and sequestration of Gβγ via an adenovirus that encodes the βARKct transgene might be a useful clinical tool for the treatment of cardiovascular pathologies.","title":"Beta-Adrenergic gene therapy for cardiovascular disease","programCode":["009:037"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59618/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32md-mndu","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/32md-mndu","description":"Chemical compound data from PubChem database. IUPAC Name: prop-2-ynyl 2-bromoacetate. Molecular Formula: C5H5BrO2. Molecular Weight: 177.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527585: 2-Propy1-ol, bromoacetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527585","description":"Access the complete Compound 527585: 2-Propy1-ol, bromoacetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32qb-8tm2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","innovation","research","pubchem","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/32qb-8tm2","description":"Preparation of an acrolein comprises dehydration of glycerol in gas phase, in the presence of a solid, strong acid catalyst having Hammett acidity Ho of -9 to -18.","title":"Patent AT-E399751-T1: [Translated] PROCESS FOR DEHYDRATION OF GLYCEROL TO ACROLEIN","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399751-T1","description":"Access the complete Patent AT-E399751-T1: [Translated] PROCESS FOR DEHYDRATION OF GLYCEROL TO ACROLEIN on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32r8-uqj4","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","block-grant-program","community-mental-health","mental-health-services","outcome-measures"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/32r8-uqj4","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2012 Uniform Reporting System (URS) Tables for Virginia","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-uniform-reporting-system-urs-tables-virginia","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32vw-85w7","bureauCode":["009:38"],"issued":"2015-10-29","@type":"dcat:Dataset","modified":"2015-12-03","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"Felix","hasEmail":"mailto:no-reply@data.healthcare.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"ia68-8jye","description":"Dataset.","title":"QHP Landscape PY2016 NV Individual Dental","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/2016-qhp-landscape-nv-individual-market-dental.ia68-8jye.csv","mediaType":"text/csv","title":"CSV"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","accrualPeriodicity":"R/P10Y","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/32z7-m6uh","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["national-outcome-measures","substance-abuse","samhsa","mental-health-services","block-grant-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/32z7-m6uh","description":"This is the 2018 Uniform Reporting System (URS) Output Tables for Arkansas. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2018 Uniform Reporting System (URS) Table for Arkansas","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2018-uniform-reporting-system-urs-table-arkansas","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/uny6-e3dx","bureauCode":["009:20"],"issued":"2022-06-16","@type":"dcat:Dataset","temporal":"July 2022-June 2023","modified":"2024-01-24","keyword":["immunization","covid-19 vaccination","vaccination coverage","vaccination","vaccine confidence","covid-19","vaxviews","nis-ccm"],"contactPoint":{"@type":"vcard:Contact","fn":"VaxView Team","hasEmail":"mailto:VaxView@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/uny6-e3dx","description":"National Immunization Survey Child COVID Module (NIS-CCM): CDC is providing information on COVID-19 vaccine confidence to supplement vaccine administration data. These data represent trends in vaccination status and intent, and other behavioral indicators, by demographics and other characteristics.","title":"National Immunization Survey Child COVID Module (NIS-CCM): COVIDVaxViews| Data | Centers for Disease Control and Prevention (cdc.gov)-Archived","programCode":["009:026"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/uny6-e3dx/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/uny6-e3dx/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/uny6-e3dx/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"National","license":"https://www.usa.gov/government-works","accrualPeriodicity":"Monthly","theme":["Vaccinations"],"language":["English"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/338b-dvbi","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["pubchem","science","chemistry","research","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/338b-dvbi","description":"Chemical compound data from PubChem database. IUPAC Name: 2-tert-butylsulfanylbutane. Molecular Formula: C8H18S. Molecular Weight: 146.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525433: 3,5,5-Trimethyl-4-thiahexane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525433","description":"Access the complete Compound 525433: 3,5,5-Trimethyl-4-thiahexane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-dashboard.html","bureauCode":["009:20"],"issued":"2021-01-28","@type":"dcat:Dataset","modified":"2022-04-01","references":["IPSOS Knowledge Panel Omnibus and NORC AmeriSpeak Omnibus Surveys"],"keyword":["ethnicity","vaccination","race","age group","adults","flu","flu vaccination"],"contactPoint":{"@type":"vcard:Contact","fn":"Vax Views","hasEmail":"mailto:VaxView@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/kmap-fsfn","description":"Cumulative Influenza Vaccination Coverage, Adults 18 years and older, by Age Group and Race/Ethnicity, United States, 2020-21, IPSOS Knowledge Panel Omnibus and NORC AmeriSpeak Omnibus Surveys","title":"Cumulative Influenza Vaccination Coverage, Adults 18 years and older, by Age Group and Race/Ethnicity, United States","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/kmap-fsfn/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/kmap-fsfn/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/kmap-fsfn/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"https://www.usa.gov/government-works","theme":["Vaccinations"],"language":["English"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/339m-pp2x","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","innovation","patent","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/339m-pp2x","description":"Furniture drive for displacing parts of a piece of furniture relative to one another, includes a linearly displaceable drive element for pivoting a pivot shaft that, when furniture drive is in a mounted position, is operatively connected to a part of the piece of furniture to be displaced, and drive element is connected in the manner of a crank mechanism via a rod-like power transmission element to pivot shaft, one end of which is connected to drive element in an articulated manner, however without displacing in the longitudinal direction of power transmission element, and other end of which is connected in an articulated manner to a crank pin of pivot shaft, the position and distance of coupling points of power transmission element on drive element and pivot shaft being selected such that power transmission element, during displacing movement, changes the angular position by more than 20°, preferably more than 40°.","title":"Patent AT-E401022-T1: [Translated] ADJUSTABLE SEATING","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401022-T1","description":"Access the complete Patent AT-E401022-T1: [Translated] ADJUSTABLE SEATING on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/339w-e6sw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","pubchem","patent","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/339w-e6sw","description":"A digital frequency sender comprises a generator which supplies multi-frequency codes by cyclically scanning a table under the control of a time base (BT). The sender comprises a logarithmic generator (GL) which delivers single-frequency signals, a logarithmic adder (AL) which sums two single-frequency signals in compressed form, and a frequency output unit (DF) controlled by a computer (CAL). The invention is particularly applicable to time division telecommunication exchange division.","title":"Patent AT-E4016-T1: [Translated] DIGITAL FREQUENCY TRANSMITTER.","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E4016-T1","description":"Access the complete Patent AT-E4016-T1: [Translated] DIGITAL FREQUENCY TRANSMITTER. on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/cndj-vxkf","bureauCode":["009:20"],"issued":"2025-03-21","@type":"dcat:Dataset","modified":"2025-03-21","keyword":["care cascade","tuberculosis (tb)","patient perspective","latent tuberculosis infection (ltbi)","cascade of care"],"contactPoint":{"@type":"vcard:Contact","fn":"Tuberculosis Epidemiologic Studies Consortium","hasEmail":"mailto:tbesc3@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/cndj-vxkf","description":"This was a sub study of a larger study that had a mixed methods approach focused on identifying barriers and facilitators to increasing testing and treatment of latent tuberculosis infection at community health clinics and tuberculosis (TB) clinics. This sub study focuses on the patient perspective on the barriers and facilitators to TB prevention and care.","title":"Tuberculosis Epidemiologic Studies Consortium (TBESC) II Part C Sub Study: Assessing Patient Barriers and Facilitators to TB Prevention and Care at Community Health Clinics and TB Clinics","programCode":["009:027"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/download/cndj-vxkf/application/x-zip-compressed","mediaType":"application/x-zip-compressed"}],"license":"https://www.usa.gov/government-works","theme":["National Center for HIV","Viral Hepatitis","STD","and TB Prevention"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33hf-g5d4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/33hf-g5d4","description":"Chemical compound data from PubChem database. IUPAC Name: hexadecan-4-yl 4-cyanobenzoate. Molecular Formula: C24H37NO2. Molecular Weight: 371.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530600: 4-Cyanobenzoic acid, 4-hexadecyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530600","description":"Access the complete Compound 530600: 4-Cyanobenzoic acid, 4-hexadecyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33iv-62tb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","science","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/33iv-62tb","description":"Chemical compound data from PubChem database. IUPAC Name: [3,5-dimethoxy-2-(methoxymethyl)oxan-4-yl] acetate. Molecular Formula: C11H20O6. Molecular Weight: 248.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526607: 4-O-Acetyl-2,6-anhydro-1,3,5-tri-O-methylhexitol","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526607","description":"Access the complete Compound 526607: 4-O-Acetyl-2,6-anhydro-1,3,5-tri-O-methylhexitol on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33j3-c4jq","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["ceramide-signaling","gene-expression","cell-death","nih","neuronal-apoptosis"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/33j3-c4jq","description":"A cell-culture model was used to establish a profile of gene expression during the effector phase of ceramide-mediated cell death. Of the 239 genes that met the criteria for differential hybridization, 10 correspond to genes previously involved in C2-ceramide or TNF-α signaling pathways and 20 in neuronal disorders, oncogenesis or more broadly in the regulation of proliferation.","title":"Identification of genes involved in ceramide-dependent neuronal apoptosis using cDNA arrays","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC126236/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33km-w4nu","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-abuse","samhsa","nsduh-data","drug-abuse","alcohol-dependence"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/33km-w4nu","description":"This report presents State estimates for measures of past year illicit drug or alcohol dependence or abuse based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Resuts are provided by age group.","title":"Table 20. Dependence or Abuse of Illicit Drugs or Alcohol in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2010 and 2011 NSDUHs","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/table-20-dependence-or-abuse-illicit-drugs-or-alcohol-past-year-age-group-and-state","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33ku-w2jz","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","chemistry","bioactivity","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/33ku-w2jz","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864461: MLS000041756","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864461","description":"Access the complete Substance 864461: MLS000041756 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33kz-gmvg","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["colorado-health","samhsa","substance-use","nsduh-data","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/33kz-gmvg","description":"This report presents Colorado\\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Colorado for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"Colorado (CO)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/colorado-co","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/7pvw-pdbr","bureauCode":["009:20"],"issued":"2022-05-18","@type":"dcat:Dataset","temporal":"2020-01-22/2023-05-10","modified":"2025-02-23","keyword":["coronavirus","aggregate county data","cases","covid-19"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC-INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/7pvw-pdbr","description":"The Public Health Emergency (PHE) declaration for COVID-19 expired on May 11, 2023. As a result, the Aggregate Case and Death Surveillance System will be discontinued. Although these data will continue to be publicly available, this dataset will no longer be updated.\n\nOn October 20, 2022, CDC began retrieving aggregate case and death data from jurisdictional and state partners weekly instead of daily. \n\nThis dataset includes the URLs that were used by the aggregate county data collection process that compiled aggregate case and death counts by county. Within this file, each of the states (plus select jurisdictions and territories) are listed along with the county web sources which were used for pulling these numbers. Some states had a single statewide source for collecting the county data, while other states and local health jurisdictions may have had standalone sources for individual counties. In the cases where both local and state web sources were listed, a composite approach was taken so that the maximum value reported for a location from either source was used. The initial raw data were sourced from these links and ingested into the CDC aggregate county dataset before being published on the COVID Data Tracker.","title":"United States COVID-19 County Level Data Sources - ARCHIVED","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/7pvw-pdbr/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/7pvw-pdbr/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/7pvw-pdbr/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"US","license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"No longer updated (dataset archived)","theme":["Public Health Surveillance"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33p6-y3qz","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental","metadata"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/33p6-y3qz","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Intergovernmental Personnel Act (IPA) Ethics FAQs","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/faq/intergovernmental-personnel-act-ipa-ethics-regulations","description":"Access the complete Intergovernmental Personnel Act (IPA) Ethics FAQs on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33pf-c9e8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","chemistry","compound","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/33pf-c9e8","description":"Chemical compound data from PubChem database. IUPAC Name: 2,2,4,4,6,6,8,8,10,10,12,12,14,14,16,16,18,18,20,20,22,22,24,24,26,26,28,28,30,30,32,32,34,34-tetratriacontamethyl-1,3,5,7,9,11,13,15,17,19,21,23,25,27,29,31,33-heptadecaoxa-2,4,6,8,10,12,14,16,18,20,22,24,26,28,30,32,34-heptadecasilacyclotetratriacontane. Molecular Formula: C34H102O17Si17. Molecular Weight: 1260.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528777: Cycloheptadecasiloxane, tetratriacontamethyl-","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528777","description":"Access the complete Compound 528777: Cycloheptadecasiloxane, tetratriacontamethyl- on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/a57z-zecw","issued":"2018-04-03","@type":"dcat:Dataset","modified":"2018-04-09","keyword":["lead","drinking water","school"],"contactPoint":{"@type":"vcard:Contact","fn":"Elizabeth Kimball","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/a57z-zecw","description":"Lead in Drinking Water in Schools Testing Results - Kahlotus Elementary","title":"Kahlotus Elementary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/a57z-zecw/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33qp-nvk4","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["capgras-syndrome","nih","cerebral-infarct","neuropsychiatric-disorder","ecmo-complications"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/33qp-nvk4","description":"Ischaemic cerebral accidents are frequent following extracorporeal membrane oxygenation (ECMO), especially after fixing the reinjection cannula in the right primitive carotid artery, which leads to an interruption in downstream flow. We describe a rare and unusual symptom of cerebral ischaemic accident that is known as Capgras syndrome. This feature is interesting because it may be documented by computed tomography (CT) scan and particular electroencephalography signals. It appears that our observation represents the first documented case of Capgras syndrome complicating ECMO. This incident emphasizes the potential hazards associated with right common artery ligature for venoarterial extracorporeal membrane oxygenation (VAECMO). In addition, it shows that this psychiatric symptom (that has been interpreted psychodynamically for many years) can have an organic basis, which should be studied.","title":"Capgras syndrome: a clinical manifestation of watershed cerebral infarct complicating the use of extracorporeal membrane oxygenation","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC37410/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33rj-2dvy","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","compound","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/33rj-2dvy","description":"Chemical compound data from PubChem database. IUPAC Name: pent-4-en-2-yl 2,2-dichloroacetate. Molecular Formula: C7H10Cl2O2. Molecular Weight: 197.06. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527607: 4-Penten-2-ol, dichloroacetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527607","description":"Access the complete Compound 527607: 4-Penten-2-ol, dichloroacetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33ua-gqmr","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["glucose-tolerance","insulin-resistance","nih","caucasian-population","fabp2-polymorphism"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/33ua-gqmr","description":"Background\n An A54T polymorphism at the fatty acid binding protein 2 (FABP2) locus was found to be associated with insulin resistance in non-diabetic Pima Indians. To see whether this association is present in other populations, we performed a cross sectional study to examine the role of this polymorphism on insulin resistance in 55 healthy and normotensive Caucasian subjects with normal glucose tolerance. Insulin sensitivity (%S) and beta cell function (%B) were assessed using the Homeostasis Model Assessment (HOMA). Their genotypes were determined using a polymerase chain reaction-restriction fragment length polymorphism assay. The relationship between the genotypes and the phenotypes was examined.\n \n \n Results\n After genotyping, we identified 24 AA, 27 AT and 4 TT subjects. The TT subjects were combined with the AT subjects during the analysis due to its small sample size. No differences were noted in gender distribution, clinical features, and fasting lipid profile between the two genotypic groups (AA vs. AT/TT). The AT/TT group had a higher fasting plasma insulin concentration and a lower %S than the AA group (p = 0.0444 and p = 0.0461, respectively). However, no differences were noted in plasma glucose concentrations and %B. Univariate analysis revealed that this polymorphism explained 7.3% of the variation in %S. Multivariate analysis revealed that the polymorphism was an independent determinant for %S (p = 0.0434) and with body mass index accounted for 28.7% of the variation in %S. In contrast, this polymorphism had no impact on %B.\n \n \n Conclusions\n The A54T polymorphism at the FABP2 locus is a risk factor for insulin resistance in a Caucasian population.","title":"The A54T polymorphism at the intestinal fatty acid binding protein 2 is associated with insulin resistance in glucose tolerant Caucasians","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC31346/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdph.ca.gov/Programs/CFH/DWICSN/Pages/Program-Landing1.aspx","issued":"2025-09-30","temporal":"2010 and after\r\n2010-2018 WIC Food Instrument System;\r\n2019-2024 WIC Electronic Benefits System","@type":"dcat:Dataset","modified":"2025-12-03","keyword":["electronic benefit transfer","ebt","fi","wic","wic participants","food instrument"],"contactPoint":{"@type":"vcard:Contact","fn":"Women, Infants and Children Program","hasEmail":"mailto:opendata@cdph.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"890afa4a-fc77-4d1a-a09f-52a7f0e3a490","description":"**WIC Program Overview**\r\n\r\nThe Women, Infants and Children (WIC) Program is a federally funded health and nutrition program that provides assistance to pregnant and postpartum individuals, infants, and children up to age five. WIC supports California families by offering: \r\n\r\n- Food benefits based on individual participants’ nutritional needs and risk assessment;\r\n- Nutritional education and breastfeeding support;\r\n- Healthcare referrals and other community services.\r\n\r\nParticipants must also meet income guidelines and other criteria. Currently, 84 WIC local agencies provide services monthly to approximately one million participants at 500 sites in local communities throughout the State. The food benefits can be used to purchase healthy supplemental foods from WIC authorized vendor stores throughout the State (about 3,700 in 2024). Certified WIC participants are individuals who have completed the eligibility and enrollment process and are approved to receive benefits and services. Participating WIC clients refer to certified individuals who are actively issued benefits during a specific reporting period.\r\n\r\n**Report File Overview**\r\n\r\nThere are two reports providing detailed information about WIC participants by year and month in California, including: \r\n\r\nReport 1: WIC Participants by County of Residence and by WIC Category\r\n\r\nThis report counts the number of certified WIC participants, participants issued benefits, and participants redeeming benefits (only for Food Instrument [FI] benefits) in each county in California by WIC Category for each year and month. Category in the report is defined as Breastfeeding, Child Aged 1-4, Infant, Non-Breastfeeding, and Prenatal. Statewide totals are included. \r\n\r\nReport 2: WIC Participants by County of Residence and by Race/Ethnicity\r\n\r\nThis report counts the number of certified WIC participants (those who met eligibility criteria), participants issued food benefits, and participants redeeming benefits (only for FI benefits) in each county in California by race/ethnicity and for each year and month. Race/ethnicity in the report is defined as Hispanic, Non-Hispanic African American, Non-Hispanic Asian, Non-Hispanic White, and Non-Hispanic Other. Statewide totals are included. \r\nFor definitions and coding structure for County of Residence, WIC Category, race/ethnicity; certified participants, issued participants, and redeemed participants please see the Data Dictionary file. \r\n\r\n**Note regarding transition to Electronic Benefit Transfer**\r\n\r\nEach report listed above is split into two files: 1) 2010-2018 data and 2) 2019 data onward. This is due to the transition to electronic benefit transfer in June 2019. Prior to June 2019, WIC issued paper food instruments (FIs {i.e., WIC checks}) to individual participants for purchasing supplemental, nutritious foods. Between June 2019 and March 2020, California WIC transitioned from the FI delivery system to a new Electronic Benefit Transfer (EBT) system. With the new system, each family’s WIC food benefits are loaded to its EBT account and accessed by its California WIC card, which works like a debit card. As a result of the change, the benefit redemptions (i.e., purchases) are no longer recorded at the individual level, but at the family level; which results in the 2019 and later data file not including a “Number of Redeemed Participants” column.\r\n\r\nNote on small sample sizes\r\n\r\nTo ensure WIC participant anonymity, small cells are suppressed when the number of WIC participants is fewer than 11. The suppressed cells are annotated as “. “. Due to consistently small numbers, data for Alpine and Sierra counties are not shared, although they are included in the Statewide records. Statewide records are provided under the Category of “County of Residence”.","title":"WIC Participants by County","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/890afa4a-fc77-4d1a-a09f-52a7f0e3a490/resource/369f0cfe-2ad1-441b-8251-b8a92d73801f/download/report1_wic-participants-by-county-of-residence-by-wic-category_2010-2018.csv","description":"This report counts the number of certified WIC participants, participants issued benefits, and participants redeeming benefits (only for Food Instrument [FI] benefits) in each county in California by WIC Category for each year and month. Category in the report is defined as Breastfeeding, Child Aged 1-4, Infant, Non-Breastfeeding, and Prenatal. Statewide totals are included.","@type":"dcat:Distribution","title":"WIC Participants by County of Residence and by WIC Category, 2010-2018"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/890afa4a-fc77-4d1a-a09f-52a7f0e3a490/resource/d17babd7-815e-4bad-a1a9-55b70540e944/download/report1_wic-participants-by-county-of-residence-by-wic-category_2019-2024.csv","description":"This report counts the number of certified WIC participants, participants issued benefits, and participants redeeming benefits (only for Food Instrument [FI] benefits) in each county in California by WIC Category for each year and month. Category in the report is defined as Breastfeeding, Child Aged 1-4, Infant, Non-Breastfeeding, and Prenatal. Statewide totals are included.","@type":"dcat:Distribution","title":"WIC Participants by County of Residence and by WIC Category, 2019 Onwards"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/890afa4a-fc77-4d1a-a09f-52a7f0e3a490/resource/ea2df040-e9fb-4b8b-b66b-ac623dba701a/download/report2_wic-participants-by-county-of-residence-by-race-ethnicity_2010-2018.csv","description":"This report counts the number of certified WIC participants (those who met eligibility criteria), participants issued food benefits, and participants redeeming benefits (only for FI benefits) in each county in California by race/ethnicity and for each year and month. Race/ethnicity in the report is defined as Hispanic, Non-Hispanic African American, Non-Hispanic Asian, Non-Hispanic White, and Non-Hispanic Other. Statewide totals are included.","@type":"dcat:Distribution","title":"WIC Participants by County of Residence and by Race/Ethnicity 2010-2018"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/890afa4a-fc77-4d1a-a09f-52a7f0e3a490/resource/8a27dc3e-1789-4c55-832d-0d6d8720e3da/download/report2_wic-participants-by-county-of-residence-by-race-ethnicity_2019-2024.csv","description":"This report counts the number of certified WIC participants (those who met eligibility criteria), participants issued food benefits, and participants redeeming benefits (only for FI benefits) in each county in California by race/ethnicity and for each year and month. Race/ethnicity in the report is defined as Hispanic, Non-Hispanic African American, Non-Hispanic Asian, Non-Hispanic White, and Non-Hispanic Other. Statewide totals are included.","@type":"dcat:Distribution","title":"WIC Participants by County of Residence and by Race/Ethnicity, 2019 Onwards"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/890afa4a-fc77-4d1a-a09f-52a7f0e3a490/resource/f36b0e10-04ea-4483-a865-a6b57d1349f2/download/cdph-wic-participants-by-county-1xi205en.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/33zq-xf3w","bureauCode":["009:00"],"issued":"2023-09-29","@type":"dcat:Dataset","modified":"2024-12-27","keyword":["program enrollment","medicaid","enrollment","applications","child enrollment","chip","eligibility determinations"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"d30cfc7c-4b32-4df1-b2bf-e0a850befd77","description":"This historic dataset with total enrollment in separate CHIP programs by month and state was created to fulfill reporting requirements under section 1902(tt)(1) of the Social Security Act, which was added by section 5131(b) of subtitle D of title V of division FF of the Consolidated Appropriations Act, 2023 (P.L. 117-328) (CAA, 2023). For each month from April 1, 2023, through June 30, 2024, states were required to submit to CMS (on a timely basis), and CMS was required to make public, certain monthly data, including the total number of beneficiaries who were enrolled in a separate CHIP program. Accordingly, this historic dataset contains separate CHIP enrollment by month and state between April 2023 and June 2024.
\r\nCMS will continue to publicly report separate CHIP enrollment by month and state (beyond the historic CAA/Unwinding period) in a new dataset, which is available at [link]. Please note that the methods used to count separate CHIP enrollees differ slightly between the two datasets; as a result, data users should exercise caution if comparing separate CHIP enrollment across the two datasets.
\r\nSources: T-MSIS Analytic Files (TAF) and state-submitted enrollment totals. The data notes indicate when a state’s monthly total was a state-submitted value, rather than from T-MSIS.
TAF data were pulled as follows:
April 2023 enrollment - TAF as of August 2023
May 2023 enrollment - TAF as of August 2023
June 2023 enrollment - TAF as of September 2023
July 2023 enrollment - TAF as of October 2023
August 2023 enrollment - TAF as of November 2023
September 2023 enrollment - TAF as of December 2023
October 2023 enrollment - TAF as of January 2024
November 2023 enrollment - TAF as of February 2024
December 2023 enrollment - TAF as of March 2024
January 2024 enrollment - TAF as of April 2024
February 2024 enrollment - TAF as of May 2024
March 2024 enrollment - TAF as of June 2024
April 2024 enrollment – TAF as of July 2024
May 2024 enrollment – TAF as of August 2024
June 2024 enrollment – TAF as of September 2024
TAF are produced one month after the T-MSIS submission month. For example, TAF as of August 2023 is based on July T-MSIS submissions.
\r\nNotes: The separate CHIP enrollment in this report is not inclusive of enrollees covered by Medicaid expansion CHIP. Enrollment includes individuals enrolled in separate CHIP at any point during the month but excludes those enrolled in both Medicaid and separate CHIP during the month. See the Data Sources and Metrics Definitions Overview document for a full description of the data sources, metric definitions, and general data limitations.
Alaska, District of Columbia, Hawaii, New Hampshire, New Mexico, North Carolina, North Dakota, Ohio, South Carolina, Vermont, and Wyoming do not have separate CHIP Programs. Maryland has a separate CHIP program that began in July 2023; April 2023 - June 2023 data for Maryland represents retroactive coverage.
This document includes separate CHIP data submitted to CMS by states via T-MSIS or a separate collection form. These data include reporting metrics consistent with section 1902(tt)(1) of the Social Security Act.
CHIP: Children's Health Insurance Program
Data notes: \r\n(a) State-submitted value; data not from T-MSIS
(b1) May 2023 enrollment pulled from TAF as of September 2023
(b2) Data was restated using TAF as of October 2023
(b3) Data was restated using TAF as of April 2024
(b4) Data was restated using TAF as of July 2024
(b5) Data was restated using TAF as of August 2024
(c) Enrollment counts include postpartum women with coverage funded via a Health Services Initiative
ECM Community Support Services tables for a Quarterly Implementation Report. Including the County and Plan Details for both ECM and Community Support.
This Medi-Cal Enhanced Care Management (ECM) and Community Supports Calendar Year Quarterly Implementation Report provides a comprehensive overview of ECM and Community Supports implementation in the programs' first year. It includes data at the state, county, and plan levels on total members served, utilization, and provider networks.
ECM is a statewide MCP benefit that provides person-centered, community-based care management to the highest need members. The Department of Health Care Services (DHCS) and its MCP partners began implementing ECM in phases by Populations of Focus (POFs), with the first three POFs launching statewide in CY 2022.
Community Supports are services that address members’ health-related social needs and help them avoid higher, costlier levels of care. Although it is optional for MCPs to offer these services, every Medi-Cal MCP offered Community Supports in 2022, and at least two Community Supports services were offered and available in every county by the end of the year.
","title":"Chart 3.0.7 Total Number of Members who utilzed CS in the quarter 12-months prior to the last quarter of data","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/datasets/CADHCS::chart-3-0-7-total-number-of-members-who-utilzed-cs-in-the-quarter-12-months-prior-to-the-last-quarter-of-data","mediaType":"text/html","title":"ArcGIS Hub Dataset"},{"@type":"dcat:Distribution","downloadURL":"https://services7.arcgis.com/7MUwsS9z05YumJRZ/arcgis/rest/services/ECM_Community_Support_Data_Tables_for_Quarterly_Implementation_report/FeatureServer/10","mediaType":"application/octet-stream","title":"ArcGIS GeoService"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/csv?layers=10","mediaType":"text/csv","title":"CSV"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/shapefile?layers=10","mediaType":"application/zip","title":"Shapefile"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/geojson?layers=10","mediaType":"application/geo+json","title":"GeoJSON"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/kml?layers=10","mediaType":"application/vnd.google-earth.kml+xml","title":"KML"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/f79e3230-fd04-4292-a407-072b9ec88110/resource/310a039a-8fec-47e8-8fef-afa8b669c102/download/chart-3-0-7-total-number-of-members-who-utilzed-cs-in-the-quarter-12-months-prior-to-the-last-q-.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34br-psvh","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","chemistry","research","innovation","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/34br-psvh","description":"The nozzles (12) are arranged in comb fingers (14) introduced into the interspace between the fins (10). Each finger has one or more nozzles. The fingers are so designed, that on placing the nozzle head (13) on the end face of the fins, the nozzles align with the interspaces. The nozzles are arranged in at least one row. Their spacing is uniform, amounting to 1-6 mm. Nozzles on one finger, are set at various angles with respect to each other. The head includes a handle.","title":"Patent AT-E400786-T1: [Translated] METHOD FOR CLEANING HEAT EXCHANGERS HAVING LANES IN INDOOR AIR CONDITIONING SYSTEMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400786-T1","description":"Access the complete Patent AT-E400786-T1: [Translated] METHOD FOR CLEANING HEAT EXCHANGERS HAVING LANES IN INDOOR AIR CONDITIONING SYSTEMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34cf-spne","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","references","chemistry","substance","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/34cf-spne","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 1: MOLI000002","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/1","description":"Access the complete Substance 1: MOLI000002 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34hr-wvtm","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","references","substance","bioactivity","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/34hr-wvtm","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865500: MLS000084565","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865500","description":"Access the complete Substance 865500: MLS000084565 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["fda","public-health","prescription-drugs","medications","drug"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA219910","description":"EPIOXA CROSS-LINKING is a prescription ophthalmic solution containing riboflavin 5-phosphate (0.239%) used in corneal cross-linking procedures to strengthen the cornea and treat conditions like keratoconus. It comes as a kit with syringes for eye application. Manufactured by Glaukos Corporation. This information was generated using AI and is provided for informational and research purposes only.","title":"Riboflavin 5-phosphate ophthalmic","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=219910","description":"\n Access the FDA dataset for Riboflavin 5-phosphate ophthalmic — ANDA 219910 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Riboflavin 5-phosphate ophthalmic"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34iq-bgq5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/34iq-bgq5","description":"Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-(2-pentoxyethoxy)ethoxy]ethoxy]ethyl 2,2,2-trifluoroacetate. Molecular Formula: C15H27F3O6. Molecular Weight: 360.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526887: 2-(2-(2-Pentoxy-ethoxy)-ethoxy)-ethoxy)-ethyl trifluoroacetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526887","description":"Access the complete Compound 526887: 2-(2-(2-Pentoxy-ethoxy)-ethoxy)-ethoxy)-ethyl trifluoroacetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34is-a2zd","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-hawaii","hawaii-behavioral-health","youth-mental-health","substance-use-trends","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/34is-a2zd","description":"This is a behavioral health report for the state of Hawaii. It uses the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use, youth mental health and treatment, adult mental health and treatment, substance use, and substance use treatment for the years 2009 to 2013.","title":"Behavioral Health Barometer: Hawaii, 2014","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-hawaii-2014","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34mj-i2mz","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","mental-health-services","missouri-mental-health","national-outcome-measures","urs-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/34mj-i2mz","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2011 CMHS Uniform Reporting System (URS) Output Tables for Missouri","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2011-cmhs-uniform-reporting-system-urs-output-tables-missouri","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34pu-uah7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","compound","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/34pu-uah7","description":"Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 13-methyltetradecanoate. Molecular Formula: C18H38O2Si. Molecular Weight: 314.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526095: Tetradecanoic acid, 13-methyl, trimethylsilyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526095","description":"Access the complete Compound 526095: Tetradecanoic acid, 13-methyl, trimethylsilyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34sj-9xpf","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","patent","innovation","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/34sj-9xpf","description":"A liquid composition for a thin-film polymer fluorescent information layer is disclosed that comprises a polymerizable substance (PS), a polymerization photoinitiator, a fluorescent dye (FD) and an organic solvent, comprising one or more ketones having a boiling temperature in the range of about 98-120 DEG C mixed with another solvent having a boiling temperature not higher than about 80 DEG C.","title":"Patent AT-E400053-T1: [Translated] METHOD FOR PRODUCING A THIN FLUORESCENT INFORMATION LAYER ON THE RELIEF SURFACE OF A SUPPORT","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400053-T1","description":"Access the complete Patent AT-E400053-T1: [Translated] METHOD FOR PRODUCING A THIN FLUORESCENT INFORMATION LAYER ON THE RELIEF SURFACE OF A SUPPORT on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34u3-e96t","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","substance","references","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/34u3-e96t","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865761: MLS000042810","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865761","description":"Access the complete Substance 865761: MLS000042810 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34u4-2x8e","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","chemistry","pubchem","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/34u4-2x8e","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864956: MLS000042257","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864956","description":"Access the complete Substance 864956: MLS000042257 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34v8-9hvt","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["metadata","time","real"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/34v8-9hvt","description":"ACF Children Bureau resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"How do I change my current child custody/visitation arrangement?","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/faq/custody1","description":"Access the complete How do I change my current child custody/visitation arrangement? on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://www.cdph.ca.gov/Programs/OHE/Pages/HCI-Search.aspx","issued":"2017-06-16","temporal":"2001, 2005-2007, 2007-2011, 2008-2010, 2009","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["hci","walking","bicycle","active transportation","commuting","transportation","healthy community indicator","social determinants of health"],"contactPoint":{"@type":"vcard:Contact","fn":"Office of Health Equity, Healthy Places Team","hasEmail":"mailto:opendata@cdph.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"775b88dc-4d37-42f9-9873-be0eb9b55dd4","description":"This table contains data on the percent of population aged 16 years or older whose commute to work is 10 or more minutes/day by walking or biking for California, its regions, counties, and cities/towns. Data is from the U.S. Census Bureau, American Community Survey, and from the U.S. Department of Transportation, Federal Highway Administration, and National Household Travel Survey. The table is part of a series of indicators in the Healthy Communities Data and Indicators Project of the Office of Health Equity. Active modes of transport, bicycling and walking alone and in combination with public transit, offer opportunities to incorporate physical activity into the daily routine. Physical activity is associated with lowering rates of heart disease and stroke, diabetes, colon and breast cancer, dementia and depression. Automobile commuting is associated with health hazards, such as air pollution, motor vehicle crashes, pedestrian injuries and fatalities, and sedentary lifestyles. Consequently the transition from automobile-focused transport to public and active transport offers environmental health benefits, including reductions in air pollution, greenhouse gases and noise pollution, and may lead to greater overall safety in transportation. More information about the data table and a data dictionary can be found in the About/Attachments section.","title":"Time Walk Bike to Work","distribution":[{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/775b88dc-4d37-42f9-9873-be0eb9b55dd4/resource/f20b8ec7-fdfc-45c2-8e16-8a83e441f0c7/download/hciwalkbicycle778narrativeandexamples3-26-14.pdf","description":"This table contains data on the percent of population aged 16 years or older whose commute to work is 10 or more minutes/day by walking or biking for California, its regions, counties, and cities/towns. Data is from the U.S. Census Bureau, American Community Survey, and from the U.S. Department of Transportation, Federal Highway Administration, and National Household Travel Survey. The table is part of a series of indicators in the [Healthy Communities Data and Indicators Project of the Office of Health Equity](https://www.cdph.ca.gov/Programs/OHE/Pages/Healthy-Communities-Data-and-Indicators-Project-(HCI).aspx). Active modes of transport, bicycling and walking alone and in combination with public transit, offer opportunities to incorporate physical activity into the daily routine. Physical activity is associated with lowering rates of heart disease and stroke, diabetes, colon and breast cancer, dementia and depression. Automobile commuting is associated with health hazards, such as air pollution, motor vehicle crashes, pedestrian injuries and fatalities, and sedentary lifestyles. Consequently the transition from automobile-focused transport to public and active transport offers environmental health benefits, including reductions in air pollution, greenhouse gases and noise pollution, and may lead to greater overall safety in transportation. More information about the data table and a data dictionary can be found in the About/Attachments section.","@type":"dcat:Distribution","title":"Time Walk Bike Narrative and Examples"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/775b88dc-4d37-42f9-9873-be0eb9b55dd4/resource/e152f540-9d63-4619-84e1-735c0ebb558f/download/hci_walk_bicycle_778_ct_pl_co_re_st_10-23-13-ada.xls","description":"This table contains data on the percent of population aged 16 years or older whose commute to work is 10 or more minutes/day by walking or biking for California, its regions, counties, and cities/towns. Data is from the U.S. Census Bureau, American Community Survey, and from the U.S. Department of Transportation, Federal Highway Administration, and National Household Travel Survey. The table is part of a series of indicators in the [Healthy Communities Data and Indicators Project of the Office of Health Equity](https://www.cdph.ca.gov/Programs/OHE/Pages/Healthy-Communities-Data-and-Indicators-Project-(HCI).aspx). Active modes of transport, bicycling and walking alone and in combination with public transit, offer opportunities to incorporate physical activity into the daily routine. Physical activity is associated with lowering rates of heart disease and stroke, diabetes, colon and breast cancer, dementia and depression. Automobile commuting is associated with health hazards, such as air pollution, motor vehicle crashes, pedestrian injuries and fatalities, and sedentary lifestyles. Consequently the transition from automobile-focused transport to public and active transport offers environmental health benefits, including reductions in air pollution, greenhouse gases and noise pollution, and may lead to greater overall safety in transportation. More information about the data table and a data dictionary can be found in the About/Attachments section.","@type":"dcat:Distribution","title":"Time Walk Bike to Work, 2001-2011"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/775b88dc-4d37-42f9-9873-be0eb9b55dd4/resource/fdcdf77d-52bb-4518-a8f8-be47c8f12d23/download/time-walk-bike-to-work-dd.xlsx","description":"This table contains data on the percent of population aged 16 years or older whose commute to work is 10 or more minutes/day by walking or biking for California, its regions, counties, and cities/towns. Data is from the U.S. Census Bureau, American Community Survey, and from the U.S. Department of Transportation, Federal Highway Administration, and National Household Travel Survey. The table is part of a series of indicators in the [Healthy Communities Data and Indicators Project of the Office of Health Equity](https://www.cdph.ca.gov/Programs/OHE/Pages/Healthy-Communities-Data-and-Indicators-Project-(HCI).aspx). Active modes of transport, bicycling and walking alone and in combination with public transit, offer opportunities to incorporate physical activity into the daily routine. Physical activity is associated with lowering rates of heart disease and stroke, diabetes, colon and breast cancer, dementia and depression. Automobile commuting is associated with health hazards, such as air pollution, motor vehicle crashes, pedestrian injuries and fatalities, and sedentary lifestyles. Consequently the transition from automobile-focused transport to public and active transport offers environmental health benefits, including reductions in air pollution, greenhouse gases and noise pollution, and may lead to greater overall safety in transportation. More information about the data table and a data dictionary can be found in the About/Attachments section.","@type":"dcat:Distribution","title":"Time Bike Walk to Work Data Dictionary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/775b88dc-4d37-42f9-9873-be0eb9b55dd4/resource/2c3be3bf-5555-410c-bbff-03bd8c701896/download/time-walk-bike-to-work-2001-2011-gzvrzls_.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["Environment"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34xf-6szw","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["schizophrenia-genetics","notch4-gene","case-control-study","japanese-population","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/34xf-6szw","description":"Background\n The human NOTCH4 gene is a candidate gene for schizophrenia due to its chromosomal location and neurobiological roles. In a British linkage study, NOTCH4 gene polymorphisms were highly associated with schizophrenia. In a Japanese case-control association study, however, these polymorphisms did not show significant associations with schizophrenia. We conducted a case-control study with Japanese subjects to explore an association between the triplet repeat polymorphism in the NOTCH4 gene and schizophrenia, including subtypes of schizophrenia, longitudinal disease course characteristics, and a positive family history for psychoses.\n \n \n Methods\n We examined the (CTG)n repeat polymorphism in the NOTCH4 gene among 100 healthy Japanese individuals and 102 patients with schizophrenia (22 paranoid, 38 disorganized, 29 residual, 64 episodic, 31 continuous, 42 with prominent negative symptoms, and 46 with positive family histories) using a polymerase chain reaction-based, single-strand conformational polymorphism analysis.\n \n \n Results\n Five different alleles consisting of 6, 9, 10, 11, and 13 repeats of CTG (Leu) in patients with schizophrenia, and 4 alleles consisting of 6, 9, 10, and 11 repeats in controls were found. No significant differences in genotype or allele frequencies of repeat numbers were found between controls and patients. In addition, there were no associations between the polymorphism and schizophrenia subtypes, longitudinal disease course characteristics, or positive family history of the patients.\n \n \n Conclusions\n Our data suggest a lack of association between the NOTCH4 gene triplet repeat polymorphism and schizophrenia in Japanese individuals.","title":"The (CTG)n polymorphism in the NOTCH4 gene is not associated with schizophrenia in Japanese individuals","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC32311/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/34zk-tzxx","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["care","policy","grant","foster","fiscal"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/34zk-tzxx","description":"The California Partners for Permanency (CAPP) goal in its five years of federal funding is to improve permanency outcomes for African-American and American Indian children in foster care by implementing a Child and Family Practice Model that addresses systemic bias and includes culturally-sensitive engagement; empowerment of family, Tribal and community networks; and use of culturally-based healing practices and practice adaptations.\n\nVisit the Child and Family Policy Institute of California (formerly California Partners for Permanency) Webpage\n \n \n\n.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"California Partners for Permanency (CAPP) Permanency Innovations Initiative (PII) Grantee Profile","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/california-partners-permanency-capp-permanency-innovations-initiative-pii-grantee","description":"Access the complete California Partners for Permanency (CAPP) Permanency Innovations Initiative (PII) Grantee Profile on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/353j-9j5y","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["testicular-blood-flow","testicular-microlithiasis","doppler-ultrasound","case-study","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/353j-9j5y","description":"Background\n Testicular microlithiasis is a rare, usually asymptomatic, non-progressive disease of the testes associated with various genetic anomalies, infertility and testicular tumors. According to our literature search, there is no specific data about Doppler findings in this disease.\n \n \n Case presentation\n Doppler findings of three cases of testicular microlithiasis during last two years in our institution are presented.\n \n \n Conclusions\n Although our hypothesis was to find increased Doppler parameters due to intratesticular arterial compression, our findings suggest that there are no Doppler findings specific to testicular microlithiasis.","title":"Effects of testicular microlithiasis on Doppler parameters: report of three cases","programCode":["009:035"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC65702/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["pharmaceuticals","public-health","drug-manufacturers","medications","drug-information"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA076455","description":"Desogestrel and Ethinyl Estradiol is a prescription oral contraceptive pill containing 0.15 mg desogestrel and 0.03 mg ethinyl estradiol per tablet. It's used to prevent pregnancy by inhibiting ovulation and altering cervical mucus. Available as a 28-day kit from Mayne Pharma Inc. under ANDA091234. This information was generated using AI and is provided for informational and research purposes only.","title":"Desogestrel and ethinyl estradiol","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076455","description":"\n Access the FDA dataset for Desogestrel and ethinyl estradiol — ANDA 076455 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Desogestrel and ethinyl estradiol"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/359u-i9vr","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["prescription-painkillers","substance-use","racial-ethnic-differences","samhsa","nonmedical-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/359u-i9vr","description":"This spotlight uses 2013 National Survey on Drug Use and Health to assess race/ethnic differences in the past year nonmedical use of prescription pain relievers among those aged 12 or older.","title":"Nonmedical Use of Prescription Pain Relievers Varies by Race and Ethnicity","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/nonmedical-use-prescription-pain-relievers-varies-race-and-ethnicity","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35a8-bghw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/35a8-bghw","description":"Chemical compound data from PubChem database. IUPAC Name: 4,6-dimethyl-1,2,3,5-tetrathiane. Molecular Formula: C4H8S4. Molecular Weight: 184.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526622: 4,6-Dimethyl-1,2,3,5-tetrathiane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526622","description":"Access the complete Compound 526622: 4,6-Dimethyl-1,2,3,5-tetrathiane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35ae-uswk","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","pubchem","research","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/35ae-uswk","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(ethylsulfanylmethyl)cyclopenta-1,3-diene. Molecular Formula: C8H12S. Molecular Weight: 140.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528326: Ethylfurfuryl sulfide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528326","description":"Access the complete Compound 528326: Ethylfurfuryl sulfide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35as-dmjf","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","nsduh-data","substate-data","tobacco-use","adolescent-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/35as-dmjf","description":"Table 14. Tobacco Use in the Past Month among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs","title":"Table 14. Tobacco Use in the Past Month among Persons Aged 12 or Older, by State and Substate Regions: Percentages, Annual Averages Based on 2010, 2011, and 2012 NSDUHs","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/table-14-tobacco-use-past-month-among-persons-aged-12-or-older-state-and-substate-regions","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/dataset/child-welfare-outcomes-data-portal","bureauCode":["009:00"],"issued":"2012-05-30","temporal":"2004-01-01T00:00:00-05:00/2007-12-31T00:00:00-05:00","@type":"dcat:Dataset","modified":"2023-07-26","keyword":["department-of-health-human-services","children's health"],"contactPoint":{"@type":"vcard:Contact","fn":"admin","hasEmail":"mailto:HealthData@hhs.gov"},"publisher":{"@type":"org:Organization","name":"Department of Health & Human Services"},"identifier":"f7707293-3a86-4f71-9e8c-6ca27c4c4eca","description":"The most current Child Welfare Outcomes data is featured on this site. Through the site, you can view the data before the full report is published. The most recently published full report is Child Welfare Outcomes 2004-2007: Report to Congress.
","title":"Child Welfare Outcomes Data Portal","programCode":["009:048"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://cwoutcomes.acf.hhs.gov/data/","mediaType":"text/html","title":"Query Tool "}],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/"},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35d3-9aud","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["grant","real","time","policy","fiscal"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/35d3-9aud","description":"The following are Children's Bureau discretionary grants awarded in fiscal year (FY) 2020. When available, each grant award will include a link to the expired Funding Opportunity Announcement (FOA), a brief description, the grant recipients, and a link to their project abstracts.\n\nHHS-2020-ACF-ACYF-CZ-1840\n\nThe purpose of this FOA is to create, through cooperative agreement, a National Child Welfare Capacity Building Center for Courts (Center). The Center will serve as the focal point for national child welfare expertise, evidence-informed training and technical assistance services, and workforce development support for State Court Improvement Programs (CIP), Tribal Court Improvement Programs (TCIP), courts, child welfare attorneys, and the Children's Bureau's State and Tribal Indian Child Welfare Act (ICWA) Implementation Partnership Grantees. These services and supports are designed to build the capacity of state and tribal courts, CIPs, TCIPs and child welfare judges and attorneys to meet federal requirements, to participate in federal monitoring and related state and tribal child welfare program improvement planning activities, to implement national child welfare policies and programs, to improve practice and service delivery, and to achieve prevention, safety, permanency, and well-being outcomes for children, youth, and families.\n\nThe first-year award amount is up to $3,000,000, with a project period up to 48 months. The grant was awarded to the following:\n\nHHS-2020-ACF-ACYF-CZ-1839\n\nThe purpose of this FOA is to establish, through cooperative agreement, one Quality Improvement Center (QIC) to develop a model program to assess and address the array of individual and collective needs of birth families to support timely, stable, and lasting family reunification and family well-being. The QIC will install, implement, and evaluate the model program in 4-6 local sites. The QIC will incorporate information learned through a literature review, a pool of technical assistance (TA) experts, and the input of birth parents, foster parents, youth, courts, and community service providers/support organizations throughout development and implementation of project activities.\n\nThe first-year award amount is up to $2,000,000, with a project period up to 60 months. The grant was awarded to the following:\n\nHHS-2019-ACF-ACYF-CS-1561\n\nThe purpose of this FOA is to award one-time grants to tribes, tribal organizations, or tribal consortia that are seeking to develop a plan to implement a title IV-E foster care; adoption assistance; and, at tribal option, a title IV-E plan under section 471 of the Social Security Act. The grant may be used for costs relating to the development of data-collection systems, a cost-allocation methodology, agency and tribal court procedures necessary to meet the case review system requirements under section 475(5) of the Act, or any other costs attributable to meeting any other requirement necessary for approval of a title IV-E plan.\n\nThe award amount is up to $300,000 for one 24-month project and budget period. The grants were awarded to the following:\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"FY 2020 Children's Bureau Discretionary Grant Awards","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/fy-2020-childrens-bureau-discretionary-grant-awards","description":"Access the complete FY 2020 Children's Bureau Discretionary Grant Awards on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35en-xg9w","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","chemistry","compound","science","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/35en-xg9w","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(methylsulfanylmethylsulfanyl)propane. Molecular Formula: C5H12S2. Molecular Weight: 136.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525376: 2,4-Dithiaheptane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525376","description":"Access the complete Compound 525376: 2,4-Dithiaheptane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35ey-yzyg","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["social","acf","child","service","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/35ey-yzyg","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Overview Viewpoint Description","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14286","description":"Access the complete Overview Viewpoint Description on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35gz-uem8","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2025-10-17","keyword":["drug rebate program"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"ae0d720a-eafc-44dc-88ab-65da83917ec2","description":"The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-12-11-to-2023-12-17","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/mdrp-newly-rprt-drug-12112023-to-12172023-10172025.csv","mediaType":"text/csv","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-12-11-to-2023-12-17"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35hi-r6db","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","science","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/35hi-r6db","description":"Chemical compound data from PubChem database. IUPAC Name: N-propyloctan-2-amine. Molecular Formula: C11H25N. Molecular Weight: 171.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525054: 1-Heptanamine, 1-methyl, N-propyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525054","description":"Access the complete Compound 525054: 1-Heptanamine, 1-methyl, N-propyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35hj-y5va","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","pubchem","references","chemistry","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/35hj-y5va","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 866048: MLS000080672","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/866048","description":"Access the complete Substance 866048: MLS000080672 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35iz-mdbi","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","substance","pubchem","chemistry","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/35iz-mdbi","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865772: MLS000084263","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865772","description":"Access the complete Substance 865772: MLS000084263 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35jj-v86q","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","innovation","patent","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/35jj-v86q","description":"This invention relates to a fuel cell system comprising an outer tubular solid oxide fuel cell, a solid phase porous matrix located inside the outer fuel cell, and at least one inner tubular solid oxide fuel cell embedded in the matrix. The outer fuel cell has an inner electrode layer configured to receive a first reactant fluid, an outer electrode layer configured to receive a second reactant fluid, and an electrolyte layer sandwiched between the electrode layers. The inner fuel cell has an outer electrode layer configured to receive the first reactant fluid, and an inner electrolyte layer sandwiched between the inner and outer electrode layers. The matrix has sufficient mechanical strength to support the inner fuel cell and sufficient porosity to enable the first reactant fluid to flow through the matrix to the inner and outer fuel cell respectively.","title":"Patent AT-E400069-T1: [Translated] SOLID OXIDE FUEL CELL SYSTEM","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400069-T1","description":"Access the complete Patent AT-E400069-T1: [Translated] SOLID OXIDE FUEL CELL SYSTEM on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35ni-42pb","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","bioactivity","chemistry","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/35ni-42pb","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 4: MOLI000006","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/4","description":"Access the complete Substance 4: MOLI000006 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdph.ca.gov/Programs/OHE/Pages/OfficeHealthEquity.aspx","issued":"2017-08-28","temporal":"2015","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["childcare","children","day care","day care center","hci","child","child care","daycare center","daycare","healthy community indicators","infant","infant center","social determinates of health"],"contactPoint":{"@type":"vcard:Contact","fn":"CDPH Office of Health Equity, Health Research and Statistics Unit","hasEmail":"mailto:opendata@cdph.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"e5095eba-b0f3-4050-a971-cf5c17f5ede3","description":"This table contains data on the number of licensed day care center slots (facility capacity) per 1,000 children aged 0-5 years in California, its regions, counties, cities, towns, and census tracts. The table contains 2015 data, and includes type of facility (day care center or infant center). Access to child care has become a critical support for working families. Many working families find high-quality child care unaffordable, and the increasing cost of child care can be crippling for low-income families and single parents. These barriers can impact parental choices of child care. Increased availability of child care facilities can positively impact families by providing more choices of child care in terms of price and quality. Estimates for this indicator are provided for the total population, and are not available by race/ethnicity. More information on the data table and a data dictionary can be found in the Data and Resources section.\r\nThe licensed day care centers table is part of a series of indicators in the Healthy Communities Data and Indicators Project (HCI) of the Office of Health Equity. The goal of HCI is to enhance public health by providing data, a standardized set of statistical measures, and tools that a broad array of sectors can use for planning healthy communities and evaluating the impact of plans, projects, policy, and environmental changes on community health. The creation of healthy social, economic, and physical environments that promote healthy behaviors and healthy outcomes requires coordination and collaboration across multiple sectors, including transportation, housing, education, agriculture and others. Statistical metrics, or indicators, are needed to help local, regional, and state public health and partner agencies assess community environments and plan for healthy communities that optimize public health. More information on HCI can be found here: https://www.cdph.ca.gov/Programs/OHE/CDPH%20Document%20Library/Accessible%202%20CDPH_Healthy_Community_Indicators1pager5-16-12.pdf\r\n\r\nThe format of the licensed day care centers table is based on the standardized data format for all HCI indicators. As a result, this data table contains certain variables used in the HCI project (e.g., indicator ID, and indicator definition). Some of these variables may contain the same value for all observations.","title":"Number of licensed day care center slots per 1,000 children aged 0-5 years","distribution":[{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/e5095eba-b0f3-4050-a971-cf5c17f5ede3/resource/956ec024-dea4-4495-b89e-3d14aced344a/download/hcilicensed-daycare-center760narrative11-13-15.pdf","description":"Healthy communities indicators project licensed day care center slots narrative report","@type":"dcat:Distribution","title":"HCI_Licensed Day Care Center Slots-Report"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/e5095eba-b0f3-4050-a971-cf5c17f5ede3/resource/48772b13-65c3-4140-8985-b48fc279de48/download/hci_licensed_daycare_centers_760_ca_re_co_cd_pl_ct_110215-ada2.xlsx","description":"The licensed day care centers table contains data on the number of licensed day care center slots per 1,000 children aged 0-5 years in California, its regions, counties, cities, towns, and Census tracts. The table contains 2015 data, and includes type of facility (day care center or infant center).","@type":"dcat:Distribution","title":"Number of licensed day care center slots per 1,000 children aged 0-5 years-Data"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/e5095eba-b0f3-4050-a971-cf5c17f5ede3/resource/30f4de45-a7c6-4b7c-9158-60408529758c/download/licensed-daycare-centers-data-dictionary.xlsx","description":"Data dictionary for licensed day care center slots data file.","@type":"dcat:Distribution","title":"Licensed Day Care Center Slots-Data Dictionary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/e5095eba-b0f3-4050-a971-cf5c17f5ede3/resource/2fe8f320-948b-43d2-b566-62e258cc7cdc/download/test-cdph-number-of-licensed-daycare-center-slots-per-1-000-children-aged-0-5-years-6se6pidg.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["Facilities and Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35rw-dem5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","research","science","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/35rw-dem5","description":"Chemical compound data from PubChem database. IUPAC Name: 1,2,4,7,8-pentabromodibenzofuran. Molecular Formula: C12H3Br5O. Molecular Weight: 562.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526242: 1,2,4,7,8-Pentabromo-dibenzofuran","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526242","description":"Access the complete Compound 526242: 1,2,4,7,8-Pentabromo-dibenzofuran on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.colorado.gov/d/7jcr-yuy9","issued":"2015-04-24","@type":"dcat:Dataset","modified":"2026-02-19","keyword":["behavioral health","cdphe","colorado","covid19","facilities","gis","gocodecolorado","health"],"contactPoint":{"@type":"vcard:Contact","fn":"CDPHE_spatial_data","hasEmail":"mailto:no-reply@data.colorado.gov"},"publisher":{"@type":"org:Organization","name":"State of Colorado"},"identifier":"https://data.colorado.gov/api/views/7jcr-yuy9","description":"Point geometry feature class representing Community Behavioral Health Centers and Resource locations, developed directly from address information obtained directly from the Office of Emergency Preparedness and Response, Colorado Department of Public Health and Environment, in 2017. Coordinate locations (latitude/longitude) were derived from the known street addresses of health facilities using a combination of Centrus MapMarker geocoding software and Google Earth imagery locations. This file was developed for use in activities and exercises within the Colorado Department of Public Health and Environment.","title":"CDPHE Community Behavioral Health Centers","distribution":[{"mediaType":"text/html","downloadURL":"http://data-cdphe.opendata.arcgis.com/datasets/cdphe-community-behavioral-health-centers","description":"Point geometry feature class representing Community Behavioral Health Centers and Resource locations, developed directly from address information obtained directly from the Office of Emergency Preparedness and Response, Colorado Department of Public Health and Environment, in 2017. Coordinate locations (latitude/longitude) were derived from the known street addresses of health facilities using a combination of Centrus MapMarker geocoding software and Google Earth imagery locations. This file was developed for use in activities and exercises within the Colorado Department of Public Health and Environment.","@type":"dcat:Distribution","title":"CDPHE Community Behavioral Health Centers"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35tp-ep76","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","substance-abuse-treatment","alcoholism-treatment","behavioral-health-services","treatment-facility-census"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/35tp-ep76","description":"This report presents results from the 2006 National Survey of Substance Abuse Treatment Services (N-SSATS), an annual census of facilities providing substance abuse treatment. Conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA), the N-SSATS is designed to collect data on the location, characteristics, and use of alcoholism and drug abuse treatment facilities and services throughout the 50 states, the District of Columbia, and other U.S. jurisdictions.","title":"National Survey of Substance Abuse Treatment Services (N-SSATS): 2006 Data on Substance Abuse Treatment Facilities","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2006-nssats-substance-abuse-treatment-facilities-data","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35u9-8zgh","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","compound","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/35u9-8zgh","description":"Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-(trimethylsilylamino)benzoate. Molecular Formula: C13H23NO2Si2. Molecular Weight: 281.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530151: Anthranilic acid, N-(trimethylsilyl)-, trimethylsilyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530151","description":"Access the complete Compound 530151: Anthranilic acid, N-(trimethylsilyl)-, trimethylsilyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35uv-2rzq","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-use","wyoming","samhsa","behavioral-health","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/35uv-2rzq","description":"Behavioral Health Barometer: Wyoming, Volume 4","title":"Behavioral Health Barometer: Wyoming, Volume 4","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-wyoming-volume-4","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/35wn-96s6","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","arkansas","mental-health-services","noms","urs-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/35wn-96s6","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for Arkansas for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2013 CMHS Uniform Reporting System (URS) Tables for Arkansas","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2013-cmhs-uniform-reporting-system-urs-tables-arkansas","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/ucm135419.htm","bureauCode":["009:10"],"issued":"2021-02-25","@type":"dcat:Dataset","modified":"2025-07-16","references":["http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/ucm135419.htm#zip","http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfAssem/assembler.cfm"],"keyword":["cdrh"],"contactPoint":{"@type":"vcard:Contact","fn":"openFDA","hasEmail":"mailto:open@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"aae3533d-6b69-4648-833c-a73700e51f51","description":"Federal regulations require that an assembler who installs one or more certified components of a diagnostic x-ray system submit a report of assembly. This database contains the releasable information submitted including Equipment Location, General Information and Component Information. Note: Data does not include dental system installations.","title":"X-Ray Assembler Data","programCode":["009:005"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Databases/ucm135419.htm","mediaType":"application/zip"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"http://www.cdc.gov/nccdphp/dph/","bureauCode":["009:20"],"issued":"2017-12-04","@type":"dcat:Dataset","modified":"2023-11-14","references":["https://academic.oup.com/aje/article/179/8/1025/109078","https://academic.oup.com/aje/article/182/2/127/93984","https://www.cdc.gov/pcd/issues/2017/17_0281.htm","https://www.cdc.gov/pcd/issues/2018/18_0313.htm"],"keyword":["cities","500cities","behaviors","census","outcomes","unhealthy","tract","prevalence","gis","prevention"],"contactPoint":{"@type":"vcard:Contact","fn":"500 Cities Public Inquiries","hasEmail":"mailto:places@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/k86t-wghb","description":"2017, 2016. Data were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. The project was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. 500 cities project census tract-level data in GIS-friendly format can be joined with census tract spatial data (https://chronicdata.cdc.gov/500-Cities/500-Cities-Census-Tract-Boundaries/x7zy-2xmx) in a geographic information system (GIS) to produce maps of 27 measures at the census tract level. There are 7 measures (all teeth lost, dental visits, mammograms, Pap tests, colorectal cancer screening, core preventive services among older adults, and sleep less than 7 hours) in this 2019 release from the 2016 BRFSS that were the same as the 2018 release.","title":"500 Cities: Census Tract-level Data (GIS Friendly Format), 2019 release","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/k86t-wghb/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/k86t-wghb/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/k86t-wghb/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"describedBy":"https://chronicdata.cdc.gov/500-Cities/500-Cities-Census-Tract-level-Data-GIS-Friendly-Fo/k86t-wghb","license":"http://opendefinition.org/licenses/odc-odbl/","theme":["500 Cities & Places"]},{"accessLevel":"public","landingPage":"http://www.hcai.ca.gov/HID/Find-Data.html","issued":"2017-06-16","temporal":"2011-2015","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["skilled nursing","ltc","profitability","net income","hcai","department of health care access and information"],"contactPoint":{"@type":"vcard:Contact","fn":"Department of Health Care Access and Information, Healthcare Information Division/Accounting and Reporting Systems Section","hasEmail":"mailto:opendata@hcai.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"4327ea61-c69b-4f43-a0eb-a354476880bb","description":"This dataset provides Long-Term Care Facility Income Statement Data.","title":"Long-Term Care Facility Profitability","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/4327ea61-c69b-4f43-a0eb-a354476880bb/resource/1510e857-a2cf-4b40-b4c3-829fe72851e1/download/long-term-care-facility-profitability.csv","description":"This dataset provides Long-Term Care Facility Income Statement Data.","@type":"dcat:Distribution","title":"Long-Term Care Facility Profitability (CSV)"},{"mediaType":"application/vnd.openxmlformats-officedocument.wordprocessingml.document","downloadURL":"https://data.chhs.ca.gov/dataset/4327ea61-c69b-4f43-a0eb-a354476880bb/resource/c89224f9-1b17-4967-a1b3-26285f9adf28/download/hid-datadictionaryltcprofitability.docx","description":"This dataset provides Long-Term Care Facility Income Statement Data.","@type":"dcat:Distribution","title":"hid-data-dictionary-ltcprofitability"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/4327ea61-c69b-4f43-a0eb-a354476880bb/resource/5fd9d08e-106d-444a-bedc-bb73e6474934/download/long-term-care-facility-profitability-sas9b2lt.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Facilities and Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/366z-7ck3","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["age-groups","mental-health","samhsa","state-estimates","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/366z-7ck3","description":"This table shows the boundaries used to create the maps shown in \\\"2012-2013 NSDUH National Maps of State Estimates.\\\"","title":"2012-2013 NSDUH State Estimates Categorized into Five Groups by Age Group","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-2013-nsduh-state-estimates-categorized-five-groups-age-group","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.dhcs.ca.gov/","issued":"2025-09-15","temporal":"SFY 2019-2020 to SFY 2022-2023","@type":"dcat:Dataset","modified":"2026-05-15","keyword":["adults","ab 470","youth","age","mhpd","children","ocw","race","open child welfare","performance outcome system","smhs","behavioral health","demographics","fc","language","faster care","dhcs","nsmhs","sex","utilization","tsd","snapshot"],"contactPoint":{"@type":"vcard:Contact","fn":"Program Data Reporting Division","hasEmail":"mailto:opendata@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"380ed3e6-3cef-4aa1-813e-ddad3dd6bb98","description":"The Behavioral Health Program Performance Data provides underlying data for the Mental Health Performance Dashboard covering state fiscal years 2019-2020 to 2023-2024. The California Department of Health Care Services (DHCS) oversees Mental Health Services derived from Medi-Cal claims, encounter, and eligibility systems in accordance with California Welfare and Institutions Code (WIC) § 14707.5 (added as part of Assembly Bill 470 on 10/7/17), and also Specialty Mental Health Services (SMHS) for Medi-Cal members through County Mental Health Plans (MHPs). These services support individuals with serious mental health conditions, helping them manage symptoms and progress toward recovery. DHCS also contracts with Medi-Cal Managed Care Plans (MCPs) for primary, preventive, specialty, and non-specialty mental health services (NSMHS).","title":"Behavioral Health Program Performance Data","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/aeb088b1-3904-47c3-b5c4-de564ff1426c/download/all_demo_data_new_3.csv","description":"Provides demographic data for SMHS, NSMHS, Adults, Children and Youth, Foster Care Youth, and Open Child Welfare Case Youth.","@type":"dcat:Distribution","title":"Demographic Data for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/d7c5e57e-d8b5-4cea-a9fe-cfd1feb78967/download/all_asce_data_new_3.csv","description":"Provides information on member movement within the mental health system for a FY for SMHS, MHS, Adults, Children and Youth, Foster Care Youth, and Open Child Welfare Case Youth.","@type":"dcat:Distribution","title":"Snapshot Data for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/01c445fe-0669-421d-ac82-d8e252841d16/download/all_tsd_data_new_3.csv","description":"Provides information on time to first SMHS appointment following an inpatient discharge for Adults, Children and Youth, Foster Care Youth, and Open Child Welfare Case Youth.","@type":"dcat:Distribution","title":"Time to Step-Down Data for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/a2b06d8f-3b62-4713-87b9-39a14afe82c6/download/ocw_utilization.csv","description":"SMHS, MHS service utilization for Open Child Welfare Case Youth.","@type":"dcat:Distribution","title":"OCW SMHS and MHS Service Utilization Data for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/95865313-13b0-4042-aefa-caa290216145/download/fc_utilization.csv","description":"SMHS, MHS service utilization for Foster Care Youth.","@type":"dcat:Distribution","title":"FC SMHS and MHS Service Utilization Data for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/ff0fe5a7-5e7b-45c1-b45f-7503874a03c2/download/adult_utilization_by_age.csv","description":"SMHS, MHS service utilization data for adult broken out by age.","@type":"dcat:Distribution","title":"Adult SMHS and MHS Service Utilization Data by Age for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/1bc987e7-2609-45de-9997-de650218b12f/download/adult_utilization_by_language.csv","description":"SMHS, MHS service utilization data for adult broken out by written language.","@type":"dcat:Distribution","title":"Adult SMHS and MHS Service Utilization Data by Written Language for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/0cb64eab-52c6-4f2e-a831-9836b75e6069/download/adult_utilization_by_race.csv","description":"SMHS, MHS service utilization data for adult broken out by race.","@type":"dcat:Distribution","title":"Adult SMHS and MHS Service Utilization Data by Race for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/4a7fa3df-e3cb-49bc-a56c-dc0a65d5c422/download/adult_utilization_by_sex.csv","description":"SMHS, MHS service utilization data for adults broken out by sex.","@type":"dcat:Distribution","title":"Adult SMHS and MHS Service Utilization Data by Sex for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/767b198a-2981-42d4-8794-49b44e04c439/download/children_and_youth_utilization_by_age.csv","description":"SMHS, MHS service utilization data for youth broken out by age.","@type":"dcat:Distribution","title":"Youth SMHS and MHS Service Utilization Data by Age for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/0bd09ce8-dd93-4e15-a689-639a155958d5/download/children_and_youth_utilization_by_language.csv","description":"SMHS, MHS service utilization data for youth broken out by written language.","@type":"dcat:Distribution","title":"Youth SMHS and MHS Service Utilization Data by Written Language for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/8d402c80-0ed0-4501-954b-8d379544d7eb/download/children_and_youth_utilization_by_race.csv","description":"SMHS, MHS service utilization data for youth broken out by race.","@type":"dcat:Distribution","title":"Youth SMHS and MHS Service Utilization Data by Race for FY's 2020-2023"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/d69ad255-c1f4-49c7-9524-60c76b432dc7/download/children-_and_youth_utilization_by_sex.csv","description":"SMHS, MHS service utilization data for youth broken out by sex.","@type":"dcat:Distribution","title":"Youth SMHS and MHS Service Utilization Data by Sex for FY's 2020-2023"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/380ed3e6-3cef-4aa1-813e-ddad3dd6bb98/resource/f00fcffa-cef6-4ff8-a056-031fe36f244d/download/behavioral-health-program-performance-data-863_rb3h.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["State"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm","bureauCode":["009:20"],"issued":"2015-12-02","@type":"dcat:Dataset","temporal":"1940/2018","modified":"2025-04-21","keyword":["nchs","united states","age of mother","birth rates"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:births@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/yt7u-eiyg","description":"This dataset includes birth rates for females by age group in the United States since 1940.\n\nThe number of states in the reporting area differ historically. In 1915 (when the birth registration area was established), 10 states and the District of Columbia reported births; by 1933, 48 states and the District of Columbia were reporting births, with the last two states, Alaska and Hawaii, added to the registration area in 1959 and 1960, when these regions gained statehood. Reporting area information is detailed in references 1 and 2 below. Trend lines for 1909–1958 are based on live births adjusted for under-registration; beginning with 1959, trend lines are based on registered live births.","title":"NCHS - Birth Rates for Females by Age Group: United States","isPartOf":"NCHS - Birth Rates for Females by Age Group: United States","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/yt7u-eiyg/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/yt7u-eiyg/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/yt7u-eiyg/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"50 states and District of Columbia","describedBy":"https://www.cdc.gov/nchs/data_access/vitalstatsonline.htm","license":"https://www.usa.gov/government-works","theme":["National Center for Health Statistics"],"language":["English"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","fda","prescription-drugs","health-care","drug-manufacturers"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA075742","description":"Ranitidine is a generic over-the-counter medication used to relieve heartburn, acid indigestion, and sour stomach. It contains 150 mg of ranitidine hydrochloride per tablet and works by reducing stomach acid production. Manufactured by Dr. Reddy's Laboratories Limited, it's available in various tablet pack sizes. This information was generated using AI and is provided for informational and research purposes only.","title":"Ranitidine","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075742","description":"\n Access the FDA dataset for Ranitidine — ANDA 075742 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Ranitidine"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36ak-ymxg","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","brfss-survey","incidence-rates","hysterectomy-prevalence","uterine-cancer"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/36ak-ymxg","description":"Background\n Two methods are presented for obtaining hysterectomy prevalence corrected estimates of invasive cancer incidence rates and probabilities of the corpus uterine.\n \n \n Methods\n The first method involves cross-sectional hysterectomy data from the Utah Hospital Discharge Data Base and mortality data applied to life-table methods. The second involves hysterectomy prevalence estimates obtained directly from the Utah Behavior Risk Factor Surveillance System (BRFSS) survey.\n \n \n Results\n Hysterectomy prevalence estimates based on the first method are lower than those obtained from the second method through age 74, but higher in the remaining ages. Correction for hysterectomy prevalence is greatest among women ages 75–79. In this age group, the uncorrected rate is 125 (per 100,000) and the corrected rate based on the life-table method is 223 using 1995–97 data, 243 using 1992–94 data, and 228 from the survey method. The uncorrected lifetime probability of developing corpus uterine cancer is 2.6%; the corrected probability from the life-table method using 1995–97 data is 4.2%, using 1992–94 data is 4.5%; and based on prevalence data from the survey method is 4.6%.\n \n \n Conclusions\n Both methods provide reasonable hysterectomy prevalence estimates for correcting corpus uterine cancer rates and probabilities. Because of declining trends in hysterectomy in recent decades, corrected estimates from the life-table method are less pronounced than those based on the survey method. These methods may be useful for obtaining corrected uterine cancer rates and probabilities in areas of the world that do not have sufficient years of hysterectomy data to directly compute prevalence.","title":"Comparison of two methods based on cross-sectional data for correcting corpus uterine cancer incidence and probabilities","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC58835/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36fa-6du2","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["suicide-attempts","seattle-metro","samhsa","emergency-department","drug-overdose"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/36fa-6du2","description":"Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving suicide attempts in the Seattle metropolitan area, covering 2004-2011. Drug-related suicide attempts include visits for drug overdoses and for suicide attempts by other means (e.g., using a firearm) if drugs were involved or related to the suicide attempt.","title":"Seattle: Drug-Related Emergency Department Visits, 2004-2011 - Suicide Attempts","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/seattle-drug-related-emergency-department-visits-2004-2011-suicide-attempts","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36hn-ih62","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["exercise-tolerance","cardiac-rehabilitation","exercise-training","nih","heart-failure"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/36hn-ih62","description":"Chronic heart failure (CHF) is a common condition with a poor prognosis. It is associated with poor exercise tolerance and debilitating symptoms. These symptoms appear to be associated with pathophysiological changes that occur systemically in the patient with CHF. Exercise training in carefully selected patients has been shown to be safe and to improve exercise capacity. Many of the pathophysiological abnormalities of CHF are improved by training. Some studies have suggested a possible improvement in morbidity and mortality with training. This review analyzes the controlled clinical trials of exercise training in CHF published to date.","title":"Exercise training in heart failure","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59617/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36hz-6ntf","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","compound","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/36hz-6ntf","description":"Chemical compound data from PubChem database. IUPAC Name: 2-bromo-3-methylbutane. Molecular Formula: C5H11Br. Molecular Weight: 151.04. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529978: 2-Bromo-3-methylbutane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529978","description":"Access the complete Compound 529978: 2-Bromo-3-methylbutane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["pharmaceuticals","health-care","drug-safety","drug-information","medications"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA761133","description":"Entyvio (vedolizumab) is a prescription biologic medication that blocks certain immune cells from entering the gut, reducing inflammation. It's used to treat moderate to severe ulcerative colitis or Crohn's disease in adults who haven't responded well to other therapies. Available as an intravenous infusion (300 mg) or subcutaneous injection pen (108 mg/0.68 mL). This information was generated using AI and is provided for informational and research purposes only.","title":"Vedolizumab","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761133","description":"\n Access the FDA dataset for Vedolizumab — ANDA 761133 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Vedolizumab"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36kj-68gx","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","science","chemistry","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/36kj-68gx","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 2-(3-nitrophenyl)-2-(4-nitrophenyl)acetate. Molecular Formula: C15H12N2O6. Molecular Weight: 316.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526959: 3-Nitrophenyl-4-nitrophenylacetic acid, methyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526959","description":"Access the complete Compound 526959: 3-Nitrophenyl-4-nitrophenylacetic acid, methyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36kp-xydu","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["metadata","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/36kp-xydu","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"ACF No Fear Act EEO FY 2018 Data","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/650","description":"Access the complete ACF No Fear Act EEO FY 2018 Data on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36kw-8h8z","bureauCode":["009:38"],"issued":"2017-01-04","@type":"dcat:Dataset","modified":"2017-08-25","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"Andrew Jennings","hasEmail":"mailto:no-reply@data.healthcare.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"nbg4-75xg","description":"The Service Area PUF (SA-PUF) is one of the files that make up the Marketplace PUF. The SA-PUF contains issuer-level data on the geographic coverage or service area (i.e., where the plan is offered) including state, county, and zip code. These data either originate from the Service Area template (i.e., template field), an Excel based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).","title":"Service Area PUF - PY2017","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/service-area-puf-2017.nbg4-75xg.csv","mediaType":"text/csv","title":"CSV"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36m9-q78t","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","compound","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/36m9-q78t","description":"Chemical compound data from PubChem database. IUPAC Name: 2-(2-methylbutan-2-yl)-4-nitrophenol. Molecular Formula: C11H15NO3. Molecular Weight: 209.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528945: Phenol, 2-(1,1-dimethylpropyl)-4-nitro","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528945","description":"Access the complete Compound 528945: Phenol, 2-(1,1-dimethylpropyl)-4-nitro on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36pu-kcva","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","mental-health-services","block-grant","outcome-measures","oklahoma"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/36pu-kcva","description":"This is the 2023 Uniform Reporting System (URS) Output Tables for Oklahoma. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2023 Uniform Reporting System (URS) Table For Oklahoma","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2023-uniform-reporting-system-urs-table-oklahoma","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36q7-7mu2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","science","research","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/36q7-7mu2","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(1-adamantyl)-3-methylbutan-1-one. Molecular Formula: C15H24O. Molecular Weight: 220.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526925: iso-Butyladamantyl ketone","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526925","description":"Access the complete Compound 526925: iso-Butyladamantyl ketone on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36qk-k7q5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","pubchem","references","substance","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/36qk-k7q5","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865093: MLS000042457","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865093","description":"Access the complete Substance 865093: MLS000042457 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36rb-gten","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["child","tribal","welfare","podcast","law"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/36rb-gten","description":"This Child Welfare Information Gateway Podcast is available on Apple Podcasts\n \n \n\n, GooglePlay\n \n \n\n, Spotify\n \n \n\n, Stitcher\n \n \n\n, SoundCloud\n \n \n\n, and the Child Welfare Information Gateway\n \n \n\n website. Subscribe to receive new episodes as they are released.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Tribal Courts and Child Welfare: Building Relationships With State Counterparts","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/podcast/tribal-courts-and-child-welfare-building-relationships-state-counterparts","description":"Access the complete Tribal Courts and Child Welfare: Building Relationships With State Counterparts on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36si-ye2g","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","pubchem","chemistry","research","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/36si-ye2g","description":"Boiler has many round pipes through which heating medium flows and head pieces (3) at both ends of the round pipes, by means of which the pipes are technically flow-connected to each other. To create a boiler with a sealing connection between the pipes on one hand and the head pieces on the other, each round pipe has an adjustable extension (5) on the head piece side running around the inside of the pipe, pointing in the direction of the respective head piece. Head pieces each have many pipe connections (4) of circular diameter. The end of each connection facing the pipe has an enlarged inner diameter (DISe). A reduced outer diameter (DARr) of each round pipe corresponds to the enlarged inner diameter of the attached pipe connection.","title":"Patent AT-E401544-T1: [Translated] RADIATORS, ESPECIALLY MULTI-COLUMN RADIATORS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401544-T1","description":"Access the complete Patent AT-E401544-T1: [Translated] RADIATORS, ESPECIALLY MULTI-COLUMN RADIATORS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36sp-w9pn","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","chemistry","pubchem","research","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/36sp-w9pn","description":"The invention relates to a method for preparing a polymer conjugate, in which a water-soluble polymer employed, the polymer having a linear or branched water-soluble polymer backbone and, at one end of the backbone, a branched moiety linked with two free reactive groups capable of covalent bonding to another molecule. Most specificly, it relates to an activated, substantially water soluble poly(ethylene glycol) having a linear or branched poly(ethylene glycol) backbone and at least one terminus linked to the backbone through a hydrolytically stable linkage, wherein the terminus is branched and has proximal reactive groups is reacted with active moieties in a biologically active agent such as a protein or peptide thus forming conjugates between the activated poly(ethylene glycol) and the biologically active agent.","title":"Patent AT-E399809-T1: [Translated] METHOD FOR PRODUCING POLYMER CONJUGATES","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399809-T1","description":"Access the complete Patent AT-E399809-T1: [Translated] METHOD FOR PRODUCING POLYMER CONJUGATES on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36xc-abcf","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["airway-afferent-nerves","pulmonary-pharmacology","respiratory-nerve-activity","vagus-nerve-stimulation","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/36xc-abcf","description":"Afferent nerves in the airways serve to regulate breathing pattern, cough, and airway autonomic neural tone. Pharmacologic agents that influence afferent nerve activity can be subclassified into compounds that modulate activity by indirect means (e.g. bronchial smooth muscle spasmogens) and those that act directly on the nerves. Directly acting agents affect afferent nerve activity by interacting with various ion channels and receptors within the membrane of the afferent terminals. Whether by direct or indirect means, most compounds that enter the airspace will modify afferent nerve activity, and through this action alter airway physiology.","title":"Pharmacology of airway afferent nerve activity","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59581/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36xm-ny9u","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","patent","research","innovation","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/36xm-ny9u","description":"An ink composition comprising a dispersion medium and a charged particle, wherein the charged particle comprises a colorant, a compound having pKb of 16 or less in water and containing a proton-acceptive neutral functional group, and a charge controlling agent having pKa of 16 or less in water and containing a proton-donative group.","title":"Patent AT-E399823-T1: [Translated] INK COMPOSITION AND INKJET RECORDING METHOD","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399823-T1","description":"Access the complete Patent AT-E399823-T1: [Translated] INK COMPOSITION AND INKJET RECORDING METHOD on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/36za-n73h","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["missouri","mental-health-indicators","substance-use-disorder","samhsa","nsduh-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/36za-n73h","description":"This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for Missouri overall and for substate regions within Missouri. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).","title":"Missouri (MO)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/missouri-mo-1","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/2bpn-4v8c","issued":"2018-07-03","@type":"dcat:Dataset","modified":"2018-07-03","keyword":["drinking water","schools","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"Willc13","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/2bpn-4v8c","description":"Miller Junior High lead in drinking water test results","title":"Miller Junior High","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/2bpn-4v8c/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/fluvaxview/dashboard/pregnant-women-coverage.html","bureauCode":["009:20"],"issued":"2024-09-25","@type":"dcat:Dataset","temporal":"2025-2026","modified":"2026-05-20","keyword":["vsd","nis-acm","iqvia","iis","flu vaccination","nis-flu"],"contactPoint":{"@type":"vcard:Contact","fn":"VaxView Team","hasEmail":"mailto:VaxView@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/8fbp-accd","description":"Weekly Influenza Vaccination Coverage, Pregnant Women 18-49 Years Old by Race and Ethnicity\n \nWeekly influenza vaccination coverage estimates for pregnant women 18–49 years are based on electronic health record (EHR) data from the Vaccine Safety Datalink (VSD) (https://www.cdc.gov/vaccine-safety-systems/vsd/), a collaboration between CDC’s Immunization Safety Office and multiple integrated health care organizations.","title":"Weekly Influenza Vaccination Coverage Among Pregnant Women 18-49 Years, by Race and Ethnicity","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/8fbp-accd/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/8fbp-accd/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/8fbp-accd/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"United States","license":"https://www.usa.gov/government-works","accrualPeriodicity":"Weekly","theme":["Pregnancy & Vaccination"],"language":["English"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","public-health","medications","prescription-drugs","drug-safety"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA216941","description":"Mesalamine, sold as Rowasa and sfRowasa (sulfite-free), is a rectal enema medication used to treat inflammation in the colon, such as in ulcerative colitis. It works by reducing swelling and irritation in the intestines. Administer as directed by a doctor, typically once daily at bedtime. This information was generated using AI and is provided for informational and research purposes only.","title":"Mesalamine","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216941","description":"\n Access the FDA dataset for Mesalamine — ANDA 216941 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Mesalamine"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/37df-pvnm","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","chemistry","research","science","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/37df-pvnm","description":"Chemical compound data from PubChem database. IUPAC Name: 2-[2-[2-(2-acetyloxypropoxy)propoxy]propoxy]propyl acetate. Molecular Formula: C16H30O7. Molecular Weight: 334.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525184: Tetrapropylene glycol, diacetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525184","description":"Access the complete Compound 525184: Tetrapropylene glycol, diacetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/37fq-eybh","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2024-01-05","keyword":["chip","integrated care","medicaid","behavioral health care"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"905e5046-5351-44e4-b65b-204bf684805c","description":"This table presents three populations of beneficiaries who could benefit from different levels of integrated care, 2017-2021: (1) beneficiaries who received services for a behavioral health (BH) condition; (2) beneficiaries who received services for a behavioral health condition who also received services for at least one of a number of select physical health (PH) conditions (a subset of population 1); and (3) beneficiaries prescribed medications for substance use disorders who do not have a medical claim for a behavioral health condition (a subset of population 1).\n\nSome states have serious data quality issues, making the data unusable for identifying this population. To assess data quality, analysts used measures featured in the DQ Atlas. Data for a state are considered unusable based on DQ Atlas thresholds for the following topics: Total Medicaid and CHIP Enrollment, Claims Volume - IP, Claims Volume - OT, Claims Volume - IP, Diagnosis Code - IP, Diagnosis Code - OT, Procedure Codes - OT Professional, Gender, Age, Zip code, Race and ethnicity, Eligibility group code, Enrollment in CMC Plans. \n\nData from Maryland, Tennessee, and Utah are omitted for the tables due to data quality concerns. Maryland was excluded in 2017 due to unusable diagnosis codes in the IP file and the OT file. Tennessee was excluded due to unusable diagnosis codes in the IP file in 2017 - 2019. Utah was excluded due to unusable procedure codes on OT professional claims in 2017 - 2020. In addition, states with a high data quality concern on one or more measures are noted in the table in the \"Data Quality\" column. Please refer to the DQ Atlas at http://medicaid.gov/dq-atlas for more information about data quality assessment methods.","title":"Beneficiaries who could benefit from integrated care, 2017-2021","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/benf-benft-frm-integr-care-2017-2021.csv","mediaType":"text/csv","title":"Beneficiaries who could benefit from integrated care, 2017-2021"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/37g2-jihx","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","research","pubchem","patent","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/37g2-jihx","description":"Starch sugar compositions comprising a plurality of nigerooligosaccharide alcohols may be added to food and drink as at least part of its sweeteners, whereby various advantages can be provided, eg not only a sweetness can be imparted, but also the quality of sweetness can be improved, and the moisture retention of foods can be improved. The nigerooligosaccharide alcohols may be prepared by allowing at least one enzyme selected from a -amylase of various types, an oligosaccharide-forming amylase, a beta -amylase and a debranching enzyme and an enzyme capable of forming nigerooligosaccharide by transglycosylation and/or condensation reaction to act successively or simultaneously on a material comprised of at least one selected from i) starch, ii) a maltooligosaccharide with a degree of polymerization not lower than maltose and iii) a dextrin, to form nigerooligosaccharide, which is thereafter reduced to obtain a starch sugar composition containing the nigerooligosaccharide alcohol(s).","title":"Patent AT-E401414-T1: [Translated] FOODS AND BEVERAGES CONTAINING NIGEROOLIGOSACCHARIDE ALCOHOL.","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401414-T1","description":"Access the complete Patent AT-E401414-T1: [Translated] FOODS AND BEVERAGES CONTAINING NIGEROOLIGOSACCHARIDE ALCOHOL. on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/a779-hxc5","issued":"2018-06-19","@type":"dcat:Dataset","modified":"2018-06-19","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"Elizabeth Kimball","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/a779-hxc5","description":"Lead in drinking water in schools test results","title":"Phil Snowdon","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/a779-hxc5/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/37ih-mf5i","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["ohio","samhsa","substance-abuse","mental-health","behavioral-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/37ih-mf5i","description":"Publications Using SAMHSA DataBehavioral Health Barometer: Ohio, Volume 4","title":"Publications Using SAMHSA DataBehavioral Health Barometer: Ohio, Volume 4","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-ohio-volume-4","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/37k6-vp6g","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","research","chemistry","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/37k6-vp6g","description":"Chemical compound data from PubChem database. IUPAC Name: N'-(2-hydroxyphenyl)-N,N-dimethylmethanimidamide. Molecular Formula: C9H12N2O. Molecular Weight: 164.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525990: N1N1-dimethyl-N2-ortho-hydroxyphenylformamidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525990","description":"Access the complete Compound 525990: N1N1-dimethyl-N2-ortho-hydroxyphenylformamidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/37mr-64u9","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/37mr-64u9","description":"Chemical compound data from PubChem database. IUPAC Name: 2,3-dimethyl-5-propylthiophene. Molecular Formula: C9H14S. Molecular Weight: 154.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528242: 2,3-Dimethyl-5-propylthiophene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528242","description":"Access the complete Compound 528242: 2,3-Dimethyl-5-propylthiophene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/37nh-h3vb","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["child","scope","policy","response","emergency"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/37nh-h3vb","description":"This letter from the Deputy Secretary of the U.S. Department of Health and Human Services urges state Governors to classify child welfare workers and service providers as level 1 emergency responders to allow them greater access to personal protective equipment.\n\nBrowse All COVID-19 Resources\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Letter to Governors Regarding Personal Protective Equipment for Child Welfare Workers","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/letter-governors-regarding-personal-protective-equipment-child-welfare-workers","description":"Access the complete Letter to Governors Regarding Personal Protective Equipment for Child Welfare Workers on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/37nv-69gi","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["n-ssats","facility-characteristics","samhsa","behavioral-health","substance-abuse-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/37nv-69gi","description":"This a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing type of care offered, by facility operation and primary focus of facility in 2011.","title":"4.2b Type of care offered, by facility operation and primary focus of facility: 2011. Percent","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/42b-type-care-offered-facility-operation-and-primary-focus-facility-2011-percent","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/37qq-9qkv","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","icu-nutrition","enteral-parenteral","critical-illness","metabolic-support"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/37qq-9qkv","description":"Nutritional support has become a routine part of the care of the critically ill patient. It is an adjunctive therapy, the main goal of which is to attenuate the development of malnutrition, yet the effectiveness of nutritional support is often thwarted by an underlying hostile metabolic milieu. This requires that these metabolic changes be taken into consideration when designing nutritional regimens for such patients. There is also a need to conduct large, multi-center studies to acquire more knowledge of the cost-benefit and cost effectiveness of nutritional support in the critically ill.","title":"Nutrition in the intensive care unit","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137235/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/37vi-c7y4","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["state-prevalence","mental-health-services","samhsa","age-group","service-utilization"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/37vi-c7y4","description":"Received Mental Health Services in the Past Year, by Age Group and State - Excel and CSV file","title":"2014-2015 NSDUH State Prevalence Estimates Additional Outcomes","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2014-2015-nsduh-state-prevalence-estimates-additional-outcomes-0","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/37yi-kt5f","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","bioactivity","substance","references","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/37yi-kt5f","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 866122: MLS000042631","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/866122","description":"Access the complete Substance 866122: MLS000042631 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3834-kk9x","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["pubchem","research","chemistry","science","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3834-kk9x","description":"Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2-[tert-butyl(dimethyl)silyl]oxy-2-phenylacetate. Molecular Formula: C20H36O3Si2. Molecular Weight: 380.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528583: Benzeneacetic acid, alpha-[(tert-butyldimethylsilyl)oxy]-, tert-butyldimethylsilyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528583","description":"Access the complete Compound 528583: Benzeneacetic acid, alpha-[(tert-butyldimethylsilyl)oxy]-, tert-butyldimethylsilyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://opendata.maryland.gov/d/e3du-cv4i","issued":"2019-04-25","@type":"dcat:Dataset","modified":"2024-08-14","keyword":["heart disease","mortality","ship","state health improvement process","vital stats","vsa","mdh"],"contactPoint":{"@type":"vcard:Contact","fn":"Tiffanie.Powell@maryland.gov","hasEmail":"mailto:no-reply@opendata.maryland.gov"},"publisher":{"@type":"org:Organization","name":"State of Maryland"},"identifier":"https://opendata.maryland.gov/api/views/e3du-cv4i","description":"This is historical data. The update frequency has been set to \"Static Data\" and is here for historic value. Updated on 8/14/2024\n\nAge-Adjusted Mortality Rate From Heart Disease - This indicator shows the age-adjusted mortality rate from heart disease (per 100,000 population). Heart disease is the leading cause of death in Maryland accounting for 25% of all deaths. Between 2012-2014, over 30,000 people died of heart disease in Maryland. Link to Data Details ","title":"SHIP Age-Adjusted Mortality Rate From Heart Disease 2009-2021","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/e3du-cv4i/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/e3du-cv4i/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/e3du-cv4i/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health and Human Services"]},{"accessLevel":"public","landingPage":"https://data.cityofchicago.org/d/cs4s-nsna","issued":"2011-04-17","@type":"dcat:Dataset","modified":"2019-04-18","keyword":["workforce","human services","gis","family and support services","facilities"],"contactPoint":{"@type":"vcard:Contact","fn":"cocadmin","hasEmail":"mailto:no-reply@data.cityofchicago.org"},"publisher":{"@type":"org:Organization","name":"City of Chicago"},"identifier":"https://data.cityofchicago.org/api/views/cs4s-nsna","description":"City of Chicago's Workforce Center locations, hours of operation and contact information.","title":"Workforce Centers","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cs4s-nsna/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cs4s-nsna/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cs4s-nsna/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cs4s-nsna/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cs4s-nsna/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cs4s-nsna/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/388b-pjtk","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/388b-pjtk","description":"Chemical compound data from PubChem database. IUPAC Name: trimethyl-[3,5,6-tris(trimethylsilyloxy)oxepan-4-yl]oxysilane. Molecular Formula: C18H44O5Si4. Molecular Weight: 452.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529477: 1,6-Anhydroiditol, TMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529477","description":"Access the complete Compound 529477: 1,6-Anhydroiditol, TMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38a9-7sdg","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-use","cocaine-use","samhsa","state-estimates","young-adults"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/38a9-7sdg","description":"This report provides estimates of past year cocaine use among young adults aged 18 to 25 using combined 2014-2015 National Survey on Drug Use and Health data. Estimates are provided for the nation as a whole and for each state. Comparisons are made to estimates from 2013–2014.","title":"State Estimates of Past Year Cocaine Use among Young Adults: 2014 and 2015","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/state-estimates-past-year-cocaine-use-among-young-adults-2014-and-2015","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38cu-hid3","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","compound","chemistry","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/38cu-hid3","description":"Chemical compound data from PubChem database. IUPAC Name: pentadecyl 2-chloropropanoate. Molecular Formula: C18H35ClO2. Molecular Weight: 318.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530591: 2-Chloropropionic acid, pentadecyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530591","description":"Access the complete Compound 530591: 2-Chloropropionic acid, pentadecyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38ds-pjrc","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","chemistry","bioactivity","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/38ds-pjrc","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 866013: MLS000039611","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/866013","description":"Access the complete Substance 866013: MLS000039611 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38fh-fy8h","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["major-depressive-episode","prescription-pain-reliever","florida-metro-area","samhsa","substance-use-disorder"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/38fh-fy8h","description":"This report presents combined 2005 to 2010 National Survey on Drug Use and Health (NSDUH) results for those aged 12 or older in the Tampa-St. Petersburg-Clearwater, FL metro area. The report includes estimates of substance use disorder, major depressive episode, illicit drug use, marijuana use, cigarette use, binge alcohol use, and the nonmedical use of prescription-type pain relievers. Results are provided for the Tampa-St. Petersburg-Clearwater metro area, Florida, and the U.S. overall.","title":"Tampa-St. Petersburg-Clearwater, FL","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/tampa-st-petersburg-clearwater-fl","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38hm-6bcc","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","compound","science","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/38hm-6bcc","description":"Chemical compound data from PubChem database. IUPAC Name: 2,3-dimethoxypropyl 13-methyltetradecanoate. Molecular Formula: C20H40O4. Molecular Weight: 344.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528837: Methyl 2-hydroxy-4-([(E)-(2-hydroxy-1-naphthyl)methylidene]amino)benzoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528837","description":"Access the complete Compound 528837: Methyl 2-hydroxy-4-([(E)-(2-hydroxy-1-naphthyl)methylidene]amino)benzoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38ht-9hxd","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/38ht-9hxd","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865973: MLS000084620","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865973","description":"Access the complete Substance 865973: MLS000084620 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38i5-4w6h","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","innovation","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/38i5-4w6h","description":"Chemical patent from PubChem database. Patent Number: AT-E399542-T1. Title: Novel Pharmaceutical Composition. Filing Date: 1999-11-21. Inventors: Smith, John A., Johnson, Mary B.. Abstract: The present invention relates to a novel pharmaceutical composition comprising one or more active pharmaceutical ingredients and pharmaceutically acce... IPC Classifications: C07D, C07F, A61K. This patent covers 17 claims related to 4 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.","title":"Patent AT-E399542-T1: [Translated] ALFAVBETA3 AND ALFAVBETA6 INTEGRIN ANTAGONISTS AS ANTIFIBROTIC AGENTS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399542-T1","description":"Access the complete Patent AT-E399542-T1: [Translated] ALFAVBETA3 AND ALFAVBETA6 INTEGRIN ANTAGONISTS AS ANTIFIBROTIC AGENTS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://hcai.ca.gov/data/healthcare-quality/coronary-artery-bypass-graft-outcomes-reports/","issued":"2017-06-16","temporal":"2011-2023","@type":"dcat:Dataset","modified":"2025-09-09","keyword":["patient","performance rating","post-operative stroke","risk-adjusted rate","hospital quality","heart bypass","healthcare quality","healthcare","deaths","coronary artery bypass graft","cardiac surgery","cardiac bypass","30-day readmission rate","hospital readmission","measures","mortality rate","outcome"],"contactPoint":{"@type":"vcard:Contact","fn":"Department of Health Care Access and Information, Information Services Division, Healthcare Analytics Branch, Quality and Performance Section","hasEmail":"mailto:dataandreports@hcai.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"cdfbe77b-abdc-4e2f-b1da-db47b2064b74","description":"This dataset contains the location of hospitals that performed Coronary Artery Bypass Graft (CABG) surgery in California from 2011 to 2022. It also provides performance ratings for the following risk-adjusted outcome measures related to the CABG surgery: operative mortality for isolated CABG and CABG plus valve, post-operative stroke, and 30-day all cause readmission. The dataset also includes the number of cases and adverse events for each CABG outcome measure. The methodology, including risk models that generated the rates and performance ratings differed among years. Users should exercise caution when comparing trends of rates over time (see metadata for more information).","title":"California Hospital Performance Ratings for Coronary Artery Bypass Graft (CABG) Surgery","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/3855214d-a9da-4802-ba92-c3880f36d1a3/download/2018-2023-california-hospital-performance-ratings-for-coronary-artery-bypass-graft-surgery.csv","mediaType":"text/csv","title":"2018-2023 California Hospital Performance Ratings for Coronary Artery Bypass Graft (CABG) Surgery"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/d01574ee-04cc-422e-8280-ca88987f2582/download/data-dictionary.pdf","mediaType":"application/pdf","title":"Data Dictionary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/53597ded-1c92-43fb-9689-c13fa091a52f/download/2023_executive_summary.pdf","mediaType":"application/pdf","title":"2023 Executive Summary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/f6a96c0e-99ab-4528-a6a7-3dedca8543a2/download/2023-hospital-results.pdf","mediaType":"application/pdf","title":"2023 Hospital Results"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/7e06bcdc-f786-4a14-8580-d121c0246d8d/download/2023-technical-note.pdf","mediaType":"application/pdf","title":"2023 Technical Note"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/86773748-705f-4d8c-b862-4d7b76a8f8e7/download/2022-executive-summary.pdf","mediaType":"application/pdf","title":"2022 Executive Summary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/e0a47519-3c69-44be-a26f-f355e2e4ce56/download/2022-hospital-results.pdf","mediaType":"application/pdf","title":"2022 Hospital Results"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/f837b9bf-88f6-4277-9a59-b72f2ed71cd7/download/2022-technical-note.pdf","mediaType":"application/pdf","title":"2022 Technical Note"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/889abc39-43dc-4d15-bd44-e8ae0dc7d2a3/download/2021_executive_summary.pdf","mediaType":"application/pdf","title":"2021 Executive Summary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/3a7bf4bf-7488-4649-851a-cac77f1da98e/download/2021_hospital_results.pdf","mediaType":"application/pdf","title":"2021 Hospital Results"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/42677cf5-3b12-4f67-bc2b-1d6e3e939f3b/download/2021_technical_note.pdf","mediaType":"application/pdf","title":"2021 Technical Note"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/463973d8-86ce-4b54-9c53-49d1e30dd355/download/2020_executive_summary.pdf","mediaType":"application/pdf","title":"2020 Executive Summary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/a56efbca-2e24-4df9-b816-3e4ec05475cb/download/2020_hospital_results.pdf","mediaType":"application/pdf","title":"2020 Hospital Results"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/e4bc88c3-a00f-4065-9dff-3806f94406ae/download/2020_technical_note.pdf","mediaType":"application/pdf","title":"2020 Technical Note"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/303a9eb4-5667-4e88-852d-a19b6a8fa9b6/download/2019_executive_summary.pdf","mediaType":"application/pdf","title":"2019 Executive Summary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/83ffe33f-651f-44be-876c-b1d04a1e992b/download/2019_hospital_results.pdf","mediaType":"application/pdf","title":"2019 Hospital Results"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/38d91387-5097-4b1e-a3c3-d4defe062540/download/2019_hospital_statement.pdf","mediaType":"application/pdf","title":"2019 Hospital Statement"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/b5b811d0-b991-46b0-b5d0-4efd58cc2bcf/download/2019_technical_note.pdf","mediaType":"application/pdf","title":"2019 Technical Note"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/ce4bdc8d-0473-4959-bb2d-6b22260ae1be/download/california-hospital-performance-ratings-for-coronary-artery-bypass-graft-cabg-surgery-2011-2018.csv","description":"This dataset contains the location of hospitals that performed Coronary Artery Bypass Graft (CABG) surgery in California from 2011 to 2018. It also provides performance ratings for the following outcome measures related to the CABG surgery: risk-adjusted operative mortality, post-operative stroke, and 30-day readmission; and number of adverse events and cases for each CABG outcome measure. The methodology, including risk models that generated the rates and performance ratings differed among years. Users should exercise caution when comparing trends of rates over time (see metadata for more information).","@type":"dcat:Distribution","title":"2011-2018 California Hospital Performance Ratings for Coronary Artery Bypass Graft (CABG) Surgery"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/f9588337-dd46-45cb-9218-32faede8c220/download/data-dictionary-cabg-report-hospital-summary-.pdf","description":"This dataset contains the location of hospitals that performed Coronary Artery Bypass Graft (CABG) surgery in California from 2011 to 2018. It also provides performance ratings for the following outcome measures related to the CABG surgery: risk-adjusted operative mortality, post-operative stroke, and 30-day readmission; and number of adverse events and cases for each CABG outcome measure. The methodology, including risk models that generated the rates and performance ratings differed among years. Users should exercise caution when comparing trends of rates over time (see metadata for more information).","@type":"dcat:Distribution","title":"2011-2018 Data Dictionary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/e5e63934-91ad-4b39-846e-1a672ca797b4/download/2017-2018-executive-summary.pdf","mediaType":"application/pdf","title":"2017-2018 Executive Summary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/db5a6180-5931-4805-947c-6a194143f784/download/2017-2018-hospital-results.pdf","mediaType":"application/pdf","title":"2017-2018 Hospital Results"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/ba529ef6-c4ef-4b56-8bf4-a7618e3ae6aa/download/2017-2018-surgeon-results.pdf","mediaType":"application/pdf","title":"2017-2018 Surgeon Results"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/59516b69-16ee-44f7-8ae9-8f82018472f1/download/2017-2018-technical-note.pdf","mediaType":"application/pdf","title":"2017-2018 Technical Note"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/1b9006da-ae93-4348-921f-fe70b7055770/download/2017-executive-summary.pdf","mediaType":"application/pdf","title":"2017 Executive Summary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/51e78126-5217-49ab-bf4a-9d96767ce073/download/2017-hospital-results.pdf","mediaType":"application/pdf","title":"2017 Hospital Results"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/24a34f0e-9695-424e-a54d-57ddfb6e710b/download/2017-hospital-statement.pdf","mediaType":"application/pdf","title":"2017 Hospital Statement"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/9694f676-5bd4-41a3-ab5b-888ddf11e6e7/download/2017-technical-note.pdf","mediaType":"application/pdf","title":"2017 Technical Note"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/ea47ca6b-829b-4136-8fff-a505fc0a7779/download/2016-executive-summary.pdf","mediaType":"application/pdf","title":"2015-2016 Executive Summary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/cc84d7da-8ed3-4a6d-a843-6371d6b04a81/download/2016-hospital-results.pdf","mediaType":"application/pdf","title":"2015-2016 Hospital Results"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/3c320b0d-1183-4d79-bb12-474c26b80c94/download/2016-hospital-statements.pdf","mediaType":"application/pdf","title":"2015-2016 Hospital Statements"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/fe7918e1-ebe5-4256-b108-ba78661303ee/download/2015-2016-surgeon-results.pdf","mediaType":"application/pdf","title":"2015-2016 Surgeon Results"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/aa0aca1b-d66c-47d0-b7f5-374f97d7821a/download/cabg-2016-ccorp_tech-note-final.pdf","mediaType":"application/pdf","title":"2015-2016 Technical Note"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/e2127f3a-e712-412a-b931-ea151c053c03/download/2015-executive-summary.pdf","description":"2015 CABG Executive Summary","@type":"dcat:Distribution","title":"2015 Executive Summary"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/233851b6-0acf-4c0e-83e3-5865073be7a7/download/2015-hospital-results.pdf","description":"2015 Hospitals Results","@type":"dcat:Distribution","title":"2015 Hospital Results"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/f0e5ef98-18df-4f05-bff0-0d1d3d32bb14/download/2015-hospital-statements.pdf","description":"2015 Hospital Statements","@type":"dcat:Distribution","title":"2015 Hospital Statements"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/7603cead-8181-4063-bd4b-054d256bf750/download/2015-technical-note.pdf","description":"2015 Technical Note","@type":"dcat:Distribution","title":"2015 Technical Note"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/22a144e0-9915-4b21-967c-bf166d408c2b/download/2013-2014-executive-summary.pdf","description":"2013-2014 Executive Summary","@type":"dcat:Distribution","title":"2013-2014 Executive Summary"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/5c08b432-daec-4f03-b344-2adb35029384/download/2013-2014-hospital-results.pdf","description":"2013-2014 Hospital Results","@type":"dcat:Distribution","title":"2013-2014 Hospital Results"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/e14f435d-eb6d-4506-9080-a514d5c8eb8f/download/2013-2014-surgeon-results.pdf","description":"2013-2014 Surgeon Results","@type":"dcat:Distribution","title":"2013-2014 Surgeon Results"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/183f4cbe-0e24-4b11-ab3f-7e33853cb06a/download/2013-2014-hospital-statements.pdf","description":"2013-2014 Hospital Statements","@type":"dcat:Distribution","title":"2013-2014 Hospital Statements"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/3a543a63-2ae6-414b-a4f9-3b0ee84f2ec0/download/2013-2014-technical-note.pdf","description":"2013-2014 Technical Note","@type":"dcat:Distribution","title":"2013-2014 Technical Note"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/f8bcb448-2aec-4b09-863f-28d58a31a725/download/2013-executive-summary.pdf","description":"2013 Executive Summary","@type":"dcat:Distribution","title":"2013 Executive Summary"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/50c7d7dd-efe0-416d-836a-db9160fd174a/download/2013-hospital-results.pdf","description":"2013 Hospital Results","@type":"dcat:Distribution","title":"2013 Hospital Results"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/7a088360-ce74-46d7-84d0-9ef09089b55f/download/2013-hospital-statements.pdf","description":"2013 Hospital Statements","@type":"dcat:Distribution","title":"2013 Hospital Statements"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/e8d8950f-e6d8-44da-9bf2-ea34a6b69f64/download/2013-technical-notes.pdf","description":"2013 Technical Note","@type":"dcat:Distribution","title":"2013 Technical Note"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/e27bb64c-31ab-41d2-ba5d-68f108df0a19/download/2011-2012-executive-summary.pdf","description":"2011-2012 Executive Summary","@type":"dcat:Distribution","title":"2011-2012 Executive Summary"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/8657d0fa-3746-4b2b-849a-56ba869da405/download/2011-2012-hospital-results.pdf","description":"2011-2012 Hospital Results","@type":"dcat:Distribution","title":"2011-2012 Hospital Results"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/f9f7f4e9-54a2-4f1f-8ee4-7772dc11e34e/download/2011-2012-surgeons-results.pdf","description":"2011-2012 Surgeon Results","@type":"dcat:Distribution","title":"2011-2012 Surgeon Results"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/4b6d1edc-4f84-4837-9460-37d68bb1f52d/download/2011-2012-hospital-statements.pdf","description":"2011-2012 Hospital Statements","@type":"dcat:Distribution","title":"2011-2012 Hospital Statements"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/303ede06-bba1-4c3a-9054-8c608222262e/download/2011-2012-technical-note.pdf","description":"2011-2012 Technical Note","@type":"dcat:Distribution","title":"2011-2012 Technical Note"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/5acfd7f3-e121-4d53-906f-85027ceaaf8a/download/2011-hospital-full-report.pdf","description":"2011 Hospital Report (full report)","@type":"dcat:Distribution","title":"2011 Hospital Report (full report)"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/9b16d53f-d70d-4f28-96ae-1dd07edcc84e/download/2009-2010-hospital-and-surgeon-report.pdf","description":"2009-2010 Hospital and Surgeon Report (full report)","@type":"dcat:Distribution","title":"2009-2010 Hospital and Surgeon Report (full report)"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/d63e347e-c49d-4789-b729-78930deb72cc/download/2009-hospital-report-full-report.pdf","description":"2009 Hospital Report (full report)","@type":"dcat:Distribution","title":"2009 Hospital Report (full report)"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/03c0ee69-4b8c-424b-bc06-f996bdf1985e/download/2007-2008-hospital-and-surgeon-report-full-report.pdf","description":"2007-2008 Hospital and Surgeon Report (full report)","@type":"dcat:Distribution","title":"2007-2008 Hospital and Surgeon Report (full report)"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/30d408ba-c924-45c3-ae09-1960a2803b20/download/2007-hospital-report-full-report.pdf","description":"2007 Hospital Report (full report)","@type":"dcat:Distribution","title":"2007 Hospital Report (full report)"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/1bd7d07b-e593-43ce-818a-5624736d2c36/download/2005-2006-hospital-and-surgeon-report-full-report.pdf","description":"2005-2006 Hospital and Surgeon Report (full report)","@type":"dcat:Distribution","title":"2005-2006 Hospital and Surgeon Report (full report)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/cdfbe77b-abdc-4e2f-b1da-db47b2064b74/resource/be2b5581-c75a-4373-be19-f4225faa5ffc/download/california-hospital-performance-ratings-for-coronary-artery-bypass-graft-cabg-surgery-a3dkr0tc.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Diseases and Conditions","Healthcare"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38j7-aa84","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","inflammation-regulation","synovial-cells","rheumatoid-arthritis","nf-kb-pathway"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/38j7-aa84","description":"The transcription factor NF-κB has been well recognized as a pivotal regulator of inflammation in rheumatoid arthritis (RA), but recent developments revealed a broad involvement of NF-κB in other aspects of RA pathology, including development of T helper 1 responses, activation, abnormal apoptosis and proliferation of RA fibroblast-like synovial cells, and differentiation and activation of bone resorbing activity of osteoclasts. In agreement with this, studies in animal models of RA have demonstrated the high therapeutic efficacy of specific inhibitors of NF-κB pathway, indicating the feasibility of anti-NF-κB therapy for human disease.","title":"NF-kappaB in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128895/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38n7-4bq7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","pubchem","compound","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/38n7-4bq7","description":"Chemical compound data from PubChem database. IUPAC Name: 12-methylpentacosane. Molecular Formula: C26H54. Molecular Weight: 366.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526108: 12-Methylpentacosane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526108","description":"Access the complete Compound 526108: 12-Methylpentacosane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38pk-pfrh","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["community-mental-health","national-outcome-measures","samhsa","urs-data","mental-health-services"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/38pk-pfrh","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for Kansas for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2013 CMHS Uniform Reporting System (URS) Tables for Kansas","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2013-cmhs-uniform-reporting-system-urs-tables-kansas","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38qg-c725","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","science","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/38qg-c725","description":"Chemical compound data from PubChem database. IUPAC Name: methyl docosa-4,7,10,13,16,19-hexaenoate. Molecular Formula: C23H34O2. Molecular Weight: 342.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530333: Methyl 4,7,10,13,16,19-docosahexaenoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530333","description":"Access the complete Compound 530333: Methyl 4,7,10,13,16,19-docosahexaenoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38qi-yk2q","bureauCode":["009:00"],"issued":"2023-07-31","@type":"dcat:Dataset","modified":"2025-07-03","keyword":["vaccination","covid-19","demography","geographic","hhs","maps","primary series","public education campaign","sae maps","small area estimations","statistical models","u.s. adults"],"contactPoint":{"@type":"vcard:Contact","fn":"Kelley Smith","hasEmail":"mailto:content@hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Department of Health and Human Services"},"identifier":"https://healthdata.gov/api/views/38qi-yk2q","description":"The goal of the Monthly Outcome Survey (MOS) Small Area Estimations (SAE) is to generate estimates of the proportions of adults, by county and month, who were in the population of interest for the U.S. Department of Health and Human Services’ (HHS) We Can Do This COVID-19 Public Education Campaign. These data are designed to be used by practitioners and researchers to understand how county-level COVID-19 vaccination hesitancy changed over time in the United States.","title":"HHS COVID-19 Small Area Estimations Survey - Primary Vaccine Series - Wave 01","primaryITInvestmentUII":"009-000005797","programCode":["009:028"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://healthdata.gov/api/v3/views/38qi-yk2q/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"mediaType":"application/json","downloadURL":"https://healthdata.gov/api/v3/views/38qi-yk2q/query.json?accessType=DOWNLOAD","describedBy":"https://healthdata.gov/api/views/38qi-yk2q/columns.json","describedByType":"application/json","@type":"dcat:Distribution"},{"mediaType":"application/xml","downloadURL":"https://healthdata.gov/api/v3/views/38qi-yk2q/export.xml?accessType=DOWNLOAD","describedBy":"https://healthdata.gov/api/views/38qi-yk2q/columns.xml","describedByType":"application/xml","@type":"dcat:Distribution"}],"spatial":"U.S.","dataQuality":true,"license":"https://www.usa.gov/government-works","theme":["Health"],"language":["English"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/x7xw-nitb","bureauCode":["009:20"],"issued":"2024-11-15","@type":"dcat:Dataset","modified":"2026-01-14","contactPoint":{"@type":"vcard:Contact","fn":"Allergy and Clinical Immunology Branch (ACIB), Health Effects Laboratory Division (HELD)","hasEmail":"mailto:sa-cin-webteam@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/x7xw-nitb","description":"Perfluoroheptaoinc acid (PFHpA), perfluorohexanoic acid (PFHxA), and perfluoropentanoic acid (PFPeA) are synthetic chemicals belonging to the per- and polyfluoroalkyl substances (PFAS) group that includes over 5,000 chemicals. PFHpA, PFHxA, and PFPeA are short-chain PFAS (C7, C6, C5, respectively) that have been labeled as a safer alternative to the legacy PFAS perfluorooctanoic acid (PFOA) and perfluorooctane sulfate (PFOS) which have been linked to numerous health effects. This class of chemicals are incorporated into consumer products such as stain resistant carpeting and textiles, nanosprays, medical devices, and fire-fighting foams. There is a high potential for occupational exposure and in the environment, short-chain PFAS have been detected in a variety of water sources leading to concerns for dermal exposure, however, these studies are lacking. In previous studies from our lab, PFOA was demonstrated to be absorbed via the skin and immunomodulatory. Also, the short-chain PFAS, PFBA, was found to have systemic toxic effects on mice with dermal exposure. In the present study, the systemic toxicity of a 28-day dermal PFHpA, PFHxA, and PFPeA (1.25-5% w/v or v/v, or 31.25-125 mg/kg/dose) exposure was evaluated in a murine model.","title":"Systemic toxicity induced by topical application of perfluoroheptanoic acid (PFHpA), perfluorohexanoic acid (PFHxA), and perfluoropentanoic acid (PFPeA) in a murine model","programCode":["009:034"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/download/x7xw-nitb/application/x-zip-compressed","mediaType":"application/x-zip-compressed"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["National Institute for Occupational Safety and Health"]},{"accessLevel":"public","landingPage":"https://nhsc.hrsa.gov/","bureauCode":["009:15"],"issued":"2012-05-30","temporal":"2009-01-01T00:00:00-05:00/2009-01-01T00:00:00-05:00","@type":"dcat:Dataset","modified":"2023-07-26","keyword":["clinician","shortage","underserved","service","scholarship","recruitment","nhsc","national health service corps","vacancy","mental health","medical","volunteer","health care providers","loan repayor","job","high-need","find jobs","dental","community health"],"contactPoint":{"@type":"vcard:Contact","fn":"HRSA Contact Center","hasEmail":"mailto:nhscsp@hrsa.gov"},"publisher":{"@type":"org:Organization","name":"Health Resources and Services Administration"},"identifier":"96140022-54b5-4e69-a7b9-0dbea290b5e0","description":"The National Health Service Corps (NHSC) Jobs Center helps doctors and nurses who are interested in working at areas where there is the highest need find out more about opportunities in a particular area or healthcare discipline. The Job Center provides information on the work locations and area. Job opportunities can be searched and identified by a combination of search parameters. The user views the search results on a map and as text and both views provide links to get more detailed information for each returned opportunity.
","title":"NHSC Jobs Center for Primary Care Medical, Dental and Mental Health Providers","programCode":["009:014"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://connector.hrsa.gov/connector/","mediaType":"text/html","title":"Query Tool "}],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Community","Health","National"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38tg-vttp","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","research","science","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/38tg-vttp","description":"Chemical compound data from PubChem database. IUPAC Name: 1,2,6,9-tetrabromodibenzo-p-dioxin. Molecular Formula: C12H4Br4O2. Molecular Weight: 499.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526373: 1,2,6,9-Tetrabromo-dibenzo-dioxin","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526373","description":"Access the complete Compound 526373: 1,2,6,9-Tetrabromo-dibenzo-dioxin on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/38vg-trtb","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","bioactivity","substance","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/38vg-trtb","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 866136: MLS000042811","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/866136","description":"Access the complete Substance 866136: MLS000042811 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nchs/covid19/covid-19-mortality-data-files.htm","bureauCode":["009:20"],"issued":"2019-06-26","@type":"dcat:Dataset","modified":"2025-04-21","keyword":["all causes","coronavirus","nchs","nvss","provisional","united states","covid-19","yearly","deaths","health service area","mortality"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/7873-6w4v","description":"Provisional count of deaths involving coronavirus disease 2019 (COVID-19) in the United States by health service area. Health service area is determined by the decedent's county of residence.","title":"AH Provisional COVID-19 Deaths Counts by Health Service Area","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/7873-6w4v/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/7873-6w4v/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/7873-6w4v/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"United States","license":"https://www.usa.gov/government-works","accrualPeriodicity":"irregular","theme":["National Center for Health Statistics"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/j2w5-q37a","issued":"2018-05-22","@type":"dcat:Dataset","modified":"2018-05-22","keyword":["school","lead","drinking water"],"contactPoint":{"@type":"vcard:Contact","fn":"Elizabeth Kimball","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/j2w5-q37a","description":"Lead in drinking water in schools test results","title":"Garfield Elementary And Middle","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/j2w5-q37a/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/394m-6zdr","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["antioxidant-enzymes","oxidative-stress","nih","gene-polymorphism","diabetic-neuropathy"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/394m-6zdr","description":"Background\n Oxidative stress, resulting in a marked increase in the level of oxygen free radicals (OFR), has been implicated in the etiology of diabetic neuropathy (DN). Antioxidant enzymes may protect against the rapid onset and progression of DN, by reducing the excess of OFR and peroxide. Mutations and polymorphisms in the genes encoding such enzymes may therefore result in predisposition to DN. We investigated the role of genes encoding two antioxidant enzymes, mitochondrial (Mn-SOD) and extracellular (EC-SOD) superoxide dismutase, in DN pathogenesis in a Russian population. We studied Ala(-9)Val and Ile58Thr polymorphisms of the Mn-SOD gene and Arg213Gly dimorphism of the EC-SOD gene in type 1 diabetic patients with (n = 82) and without DN (n = 84).\n \n \n Results\n We developed and used a new polymerase chain reaction (PCR) assays for rapid detection of polymorphisms. These assays involved the use of mismatch PCR primers to create restriction sites in the amplified product only in presence of the polymorphic base. The PCR product was than digested with BshTI, Eco32I or Eco52I to detect Ala(-9)Val, Ile58Thr or Arg213Gly polymorphic site respectively. The frequencies of the Ala allele (50.6% vs. 68.5%, p < 0.002) and the Ala/Ala genotype (17.1% vs. 39.3%, p < 0.005) of the Mn-SOD gene were significantly lower in DN patients than in diabetic subjects without DN. In contrast, the Val allele (49.4% vs. 31.5%, p < 0.002) and the Val/Val genotype (15.9% vs. 2.4%, p < 0.01) were significantly more frequent in the DN patients than in the control group.\n \n \n Conclusions\n Ala(-9)Val substitution in the Mn-SOD gene was associated with DN in a Russian population","title":"Polymorphisms in the","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC31388/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/dataset/medicaid-fraud-control-units-mfcu-annual-spending-and-performance-statistics-0","bureauCode":["009:00"],"issued":"2012-05-30","@type":"dcat:Dataset","modified":"2023-07-25","keyword":["medicaid","state spending","fraud"],"contactPoint":{"@type":"vcard:Contact","fn":"admin","hasEmail":"mailto:HealthData@hhs.gov"},"publisher":{"@type":"org:Organization","name":"Department of Health & Human Services"},"identifier":"b4a62bb8-24ad-4da3-9ac4-81b41aa9105a","description":"Medicaid Fraud Control Units (MFCU or Unit) investigate and prosecute Medicaid fraud as well as patient abuse and neglect in health care facilities. OIG certifies, and annually recertifies, each MFCU. OIG collects information about MFCU operations and assesses whether they comply with statutes, regulations, and OIG policy. OIG also analyzes MFCU performance based on 12 published performance standards and recommends program improvements where appropriate.
","title":"Medicaid Fraud Control Units (MFCUs)","programCode":["009:076"],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/396w-93ku","bureauCode":["009:38"],"issued":"2020-06-12","@type":"dcat:Dataset","modified":"2025-10-17","keyword":["medicaid"],"contactPoint":{"@type":"vcard:Contact","fn":"Chris Vaughn","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"b7cf4576-a930-59b4-86c8-c8685aaa5c2c","description":"Dataset.","title":"2018 Managed Care Programs By State","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/2018-manged-care-programs-by-state_310172025.csv","mediaType":"text/csv","title":"CSV"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-safety","public-health","prescription-drugs","pharmaceuticals","fda"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA204447","description":"Trintellix is a prescription brand name for vortioxetine, an oral tablet medication manufactured by Takeda Pharmaceuticals America, Inc. It is available in strengths of 5 mg, 10 mg, and 20 mg (15 mg discontinued). This information was generated using AI and is provided for informational and research purposes only.","title":"Vortioxetine","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204447","description":"\n Access the FDA dataset for Vortioxetine — ANDA 204447 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Vortioxetine"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39bh-f6x7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","research","pubchem","patent","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/39bh-f6x7","description":"Blends of quercetin and isoflavones from the group consisting of genestein, daidzein and glycetin display synergistic effects when applied as anti-inflammatory agent or as skin agent in particular for anti ageing purposes.","title":"Patent AT-E400285-T1: [Translated] MIXTURES OF ISOFLAVONES AND FLAVONES","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400285-T1","description":"Access the complete Patent AT-E400285-T1: [Translated] MIXTURES OF ISOFLAVONES AND FLAVONES on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39cd-ir6g","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["metadata","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/39cd-ir6g","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"ACF Policy for Requesting an Exemption from Required Electronic Application Submission","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14163","description":"Access the complete ACF Policy for Requesting an Exemption from Required Electronic Application Submission on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39ce-ze8s","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","innovation","chemistry","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/39ce-ze8s","description":"The heat exchanger has a collector (18) receiving the ends of multiple tubes (12,14). A collector box (20) covers the collector, and has a longitudinal wall (40) in contact with the collector defining first (50) and second (52) compartments into which the tubes open. The collector has a hollow region (56) facing the wall (40) to allow communication between the first and second compartments.","title":"Patent AT-E400783-T1: [Translated] MULTIPLE PASSAGE HEAT EXCHANGER, ESPECIALLY FOR MOTOR VEHICLES","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400783-T1","description":"Access the complete Patent AT-E400783-T1: [Translated] MULTIPLE PASSAGE HEAT EXCHANGER, ESPECIALLY FOR MOTOR VEHICLES on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/w6ed-sctw","issued":"2021-11-12","@type":"dcat:Dataset","modified":"2026-07-08","keyword":["sars-cov2","covid","covid-19","novel coronavirus"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/w6ed-sctw","description":"This dataset includes nursing home and adult care facility reported information about COVID-19 testing and infections for residents and staff for each facility by week. The information in this dataset is updated weekly.","title":"New York State Statewide Nursing Home and Adult Care Facility Resident and Staff COVID-19 Infections","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/w6ed-sctw/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/w6ed-sctw/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/w6ed-sctw/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39dx-s33r","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","science","chemistry","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/39dx-s33r","description":"Chemical compound data from PubChem database. IUPAC Name: tridec-2-ynyl 4-ethylbenzoate. Molecular Formula: C22H32O2. Molecular Weight: 328.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530689: 4-Ethylbenzoic acid, tridec-2-ynyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530689","description":"Access the complete Compound 530689: 4-Ethylbenzoic acid, tridec-2-ynyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39f4-upgr","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["state-level-estimates","mental-health","samhsa","substance-use","small-area-estimation"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/39f4-upgr","description":"Browse population estimates based on the 2022-2023 National Surveys on Drug Use and Health (NSDUH) for each state and region. There are four tables for each geographic area, which present population estimates and percentages for 38 measures of substance use and mental health by age group. These estimates are based on small area estimation (SAE) methods in which state-level NSDUH data are combined with other data from smaller geographies. The combined data are used to create modeled state estimates of the civilian, noninstitutionalized population ages 12 and older (or adults 18 and older for mental health measures).The tables are available in a zip file of PDFs or as an HTML file. There is also a table of contents which contains links to specific state files in HTML or PDF.Tables labeled with an A include measures of substance use and perceptions of substance use. Tables labeled with a B include measures of substance use disorder and treatment, and mental health measures.","title":"2022-2023 NSDUH: State-Specific Tables","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2022-2023-nsduh-state-specific-tables","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39hd-ik8j","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","compound","pubchem","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/39hd-ik8j","description":"Chemical compound data from PubChem database. IUPAC Name: (5-bromo-2-trimethylsilyloxypyrimidin-4-yl)oxy-trimethylsilane. Molecular Formula: C10H19BrN2O2Si2. Molecular Weight: 335.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529009: 5-Bromouracil, TMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529009","description":"Access the complete Compound 529009: 5-Bromouracil, TMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39hy-jcth","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health","substance-use","indiana","behavioral-health","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/39hy-jcth","description":"Behavioral Health Barometer: Indiana, Volume 6","title":"Publications Using SAMHSA DataBehavioral Health Barometer: Indiana, Volume 6","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-indiana-volume-6","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39hz-gukh","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["breast-cancer","organochlorines","case-control-study","estrogen-receptor","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/39hz-gukh","description":"Background\n The relationship between breast cancer and organochlorine exposure is controversial and complex. As estrogen receptor positive and negative breast cancer may represent different entities of the disease, this study was undertaken to evaluate organochlorines influence on breast cancer risk and survival according to receptor status.\n \n \n Methods\n The background material stems from the Copenhagen City Heart Study (Denmark 1976-78). The breast cancer risk was investigated in a cohort nested case-control design including 161 cases and twice as many breast cancer free controls. The cases served as a cohort in the survival analysis. Serum organochlorine concentrations were determined by gaschromotography.\n \n \n Results\n The observed increased breast cancer risk associated with exposure to dieldrin derived from women who developed an estrogen receptor negative (ERN) tumor (Odds ratio [OR] I vs. IV quartile, 7.6, 95% confidence interval [95% CI] 1.4-46.1, p-value for linear trend 0.01). Tumors in women with the highest dieldrin serum level were larger and more often spread at the time of diagnosis than ERP tumors. The risk of dying was for the remaining evaluated compounds higher among patients with ERP breast cancer when compared to those with ERN. In the highest quartile of polychlorinated biphenyls (ΣPCB) it was more than 2-fold increased (Relative risk [RR] I vs. IV quartile, 2.5, 95% CI 1.1-5.7), but no dose-response relation was apparent.\n \n \n Conclusion\n The results do not suggest that exposure to potential estrogenic organochlorines leads to development of an ERP breast cancer. A possible adverse effect on prognosis of hormone-responsive breast cancers needs to be clarified.","title":"Organochlorine exposures influence on breast cancer risk and survival according to estrogen receptor status: a Danish cohort-nested case-control study","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC37543/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39is-v9ph","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","bioactivity","substance","chemistry","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/39is-v9ph","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865633: MLS000039627","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865633","description":"Access the complete Substance 865633: MLS000039627 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39iw-e6ih","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["myocardial-infarction","blood-donation","coronary-angiography","myocardial-bridging","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/39iw-e6ih","description":"Background\n Systolic compression of a coronary artery by overlying myocardial tissue is termed myocardial bridging. Myocardial bridging usually has a benign prognosis, but some cases resulting in myocardial ischemia, infarction and sudden cardiac death have been reported. We are reporting a case of myocardial bridging which was complicated with acute myocardial infarction associated with inappropriate blood donation.\n \n \n Case presentation\n A 33 year-old-man was admitted to our emergency with acute anteroseptal myocardial infarction after a blood donation. The electrocardiography showed sinus rhythm and was consistent with an acute anteroseptal myocardial infarction. We decided to perform primary percutanous intervention (PCI). Myocardial bridging was observed in the mid segment of the left anterior descending coronary artery on coronary angiogram. PCI was canceled and medical follow up was decided. Blood transfusion was made because he had a deep anemia. A normal hemaglobin level and clinical reperfusion was achieved after ten hours by blood transfusion. At the one year follow up visit, our patient was healthy and had no cardiac complaints.\n \n \n Conclusions\n Myocardial bridging may cause acute myocardial infarction in various clinical conditions. Although the condition in this case caused profound anemia related acute myocardial infarction, its treatment and management was unusual.","title":"Myocardial bridging as a cause of acute myocardial infarction: a case report","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128836/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39kt-4dqb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","chemistry","references","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/39kt-4dqb","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864519: MLS000083872","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864519","description":"Access the complete Substance 864519: MLS000083872 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39m2-ha54","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","block-grant-program","samhsa","national-outcome-measures","substance-abuse"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/39m2-ha54","description":"This is the 2020 Uniform Reporting System (URS) Output Tables for New Hampshire. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2020 Uniform Reporting System (URS) Table For New Hampshire","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2020-uniform-reporting-system-urs-table-new-hampshire","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39qz-zaui","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["emergency-department","drug-overdose","miami-fort-lauderdale","samhsa","suicide-attempts"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/39qz-zaui","description":"Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving suicide attempts in the Fort Lauderdale division of the Miami metropolitan area, covering 2008-2011. Drug-related suicide attempts include visits for drug overdoses and for suicide attempts by other means (e.g., using a firearm) if drugs were involved or related to the suicide attempt.","title":"Miami - Fort Lauderdale Div: Drug-Related Emergency Department Visits, 2008-2011 - Suicide Attempts","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/miami-fort-lauderdale-div-drug-related-emergency-department-visits-2008-2011-suicide","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39ry-7d6n","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["adoption","data","policy","fiscal","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/39ry-7d6n","description":"This report provides state-specific data from fiscal year 2013 about the sex of children adopted through public agencies.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Sex of Public Agency Children Adopted: 10/1/2012 - 9/30/2013","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/sex-public-agency-children-adopted-10/1/2012-9/30/2013","description":"Access the complete Sex of Public Agency Children Adopted: 10/1/2012 - 9/30/2013 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39sk-86vy","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health","behavioral-health-survey","samhsa","nsduh-questionnaire","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/39sk-86vy","description":"Browse the English in-person and web interview questionnaires for the 2022 National Survey on Drug Use and Health (NSDUH). The documents provide the exact questions given to respondents in their full context, along with the skip patterns that determined whether a person was asked a question or not. There is also information on which sections were interviewer administered when conducted in-person, and a section that summarizes changes made to the questionnaire for 2022.","title":"NSDUH 2022 Questionnaire","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/nsduh-2022-questionnaire","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39sq-6cns","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["data","aid","affair","policy","fiscal"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/39sq-6cns","description":"This report provides information for determining tribes’ Federal Medical Assistance Percentages (FMAPs) for fiscal year 2024.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Tribal Federal Medical Assistance Percentage Look-Up Table for FY 2024","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/tribal-lookup-table-fy-2024","description":"Access the complete Tribal Federal Medical Assistance Percentage Look-Up Table for FY 2024 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39tk-iwz3","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2024-01-05","keyword":["medicaid","dental","dq atlas","service use","t-msis analytic files","chip"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"2aa0ed3d-6ef8-47a8-90b0-06b6d2fa3953","description":"This data set includes monthly counts and rates (per 1,000 beneficiaries) of dental services provided to Medicaid and CHIP beneficiaries under the age of 19 (as of the first day of the month), by state. \n\nThese metrics are based on data in the T-MSIS Analytic Files (TAF). Some states have serious data quality issues for one or more months, making the data unusable for calculating dental services measures. To assess data quality, analysts adapted measures featured in the DQ Atlas. Data for a state and month are considered unusable if at least one of the following topics meets the DQ Atlas threshold for unusable: Total Medicaid and CHIP Enrollment, Procedure Codes - OT Professional, Claims Volume - OT. Please refer to the DQ Atlas at http://medicaid.gov/dq-atlas for more information about data quality assessment methods. Cells with a value of “DQ” indicate that data were suppressed due to unusable data. \n\nSome cells have a value of “DS”. This indicates that data were suppressed for confidentiality reasons because the group included fewer than 11 beneficiaries.","title":"Dental Services Provided to Medicaid and CHIP Beneficiaries Under Age 19","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/Dental-Services-Provided-to-MedicaidCHIP-Beneficiaries-Under-Age-19.csv","description":"This data set includes monthly counts and rates (per 1,000 beneficiaries) of dental services provided to Medicaid and CHIP beneficiaries under the age of 19 (as of the first day of the month), by state. \n\nThese metrics are based on data in the T-MSIS Analytic Files (TAF). Some states have serious data quality issues for one or more months, making the data unusable for calculating dental services measures. To assess data quality, analysts adapted measures featured in the DQ Atlas. Data for a state and month are considered unusable if at least one of the following topics meets the DQ Atlas threshold for unusable: Total Medicaid and CHIP Enrollment, Procedure Codes - OT Professional, Claims Volume - OT. Please refer to the DQ Atlas at http://medicaid.gov/dq-atlas for more information about data quality assessment methods. Cells with a value of “DQ” indicate that data were suppressed due to unusable data. \n\nSome cells have a value of “DS”. This indicates that data were suppressed for confidentiality reasons because the group included fewer than 11 beneficiaries.","@type":"dcat:Distribution","title":"Dental Services Provided to Medicaid and CHIP Beneficiaries Under Age 19"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39up-i4uw","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["child","data","policy","prevention","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/39up-i4uw","description":"On February 3, 2022 the Children’s Bureau hosted a webinar on Title IV-E Program Data Submission which demonstrated using the National Child Welfare Data Management System (NCWDMS). The Webinar and Presentation slides may be accessed through the links below.\n\nDescriptive Audio Version\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Title IV-E Prevention Program Data Submission Spring 2022 Webinar","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/program-data-submission-spring-2022","description":"Access the complete Title IV-E Prevention Program Data Submission Spring 2022 Webinar on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39vm-h4nf","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["suicide-mortality","suicidal-ideation","middle-aged-adults","nsuhd-data","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/39vm-h4nf","description":"This report uses 2009 to 2014 NSDUH data, and 1999 and 2009 to 2014 data from the National Vital Statistics System to examine the percentages of suicidal thoughts and behaviors versus suicidal death rates among the middle-aged.","title":"Suicidality and Death by Suicide Among Middle-aged Adults in the United States","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/suicidality-and-death-suicide-among-middle-aged-adults-united-states","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39wi-c4bt","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-data","mental-illness-prevalence","mental-health-estimates","smi-ami","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/39wi-c4bt","description":"This report presents current and prior methodological approaches for estimating the prevalence of serious mental illness (SMI) and any mental illness (AMI) among adults aged 18 or older using 2008 to 2012 National Survey on Drug Use and Health (NSDUH) data. Revised SMI and AMI estimates for 2012 are presented by by age group, gender, race/ethnicity, education level, employment status, region, county type, receipt of mental health treatment, federal poverty level and insurance status.","title":"A Revised Strategy for Estimating the Prevalence of Mental Illness","programCode":["009:062"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/revised-strategy-estimating-prevalence-mental-illness","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39wy-7v83","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","science","research","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/39wy-7v83","description":"Chemical compound data from PubChem database. IUPAC Name: 3-ethylsulfanylthiophene. Molecular Formula: C6H8S2. Molecular Weight: 144.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528920: Thiophene, 3-ethylthio","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528920","description":"Access the complete Compound 528920: Thiophene, 3-ethylthio on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/39x5-spbc","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","compound","chemistry","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/39x5-spbc","description":"Chemical compound data from PubChem database. IUPAC Name: 2-hexyl-3-methoxypyrazine. Molecular Formula: C11H18N2O. Molecular Weight: 194.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528305: Pyrazine, 2-hexyl-3-methoxy","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528305","description":"Access the complete Compound 528305: Pyrazine, 2-hexyl-3-methoxy on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3a3x-8aed","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["reverse-transcriptase","nih","retrotransposons","drosophila-melanogaster","mobile-genetic-elements"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3a3x-8aed","description":"Background:\n Non-long terminal repeat (non-LTR) retrotransposons are eukaryotic mobile genetic elements that transpose by reverse transcription of an RNA intermediate. We have performed a systematic search for sequences matching the characteristic reverse transcriptase domain of non-LTR retrotransposons in the sequenced regions of the Drosophila melanogaster genome.\n \n \n Results:\n In addition to previously characterized BS, Doc, F, G, I and Jockey elements, we have identified new non-LTR retrotransposons: Waldo, You and JuanDm. Waldo elements are related to mosquito RTI elements. You to the Drosophila I factor, and JuanDm to mosquito Juan-A and Juan-C. Interestingly, all JuanDm elements are highly homogeneous in sequence, suggesting that they are recent components of the Drosophila genome.\n \n \n Conclusions:\n The genome of D. melanogaster contains at least ten families of non-site-specific non-LTR retrotransposons representing three distinct clades. Many of these families contain potentially active members. Fine evolutionary analyses must await the more accurate sequences that are expected in the next future.","title":"A search for reverse transcriptase-coding sequences reveals new non-LTR retrotransposons in the genome of","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC16141/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3a5b-zqzj","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","chemistry","science","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3a5b-zqzj","description":"Chemical compound data from PubChem database. IUPAC Name: trideca-1,3-dien-5,7,9,11-tetrayne. Molecular Formula: C13H8. Molecular Weight: 164.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528755: Tridec-1,3-diene-5,7,9,11-tetrayne","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528755","description":"Access the complete Compound 528755: Tridec-1,3-diene-5,7,9,11-tetrayne on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3a65-pvv6","bureauCode":["009:00"],"issued":"2023-08-01","@type":"dcat:Dataset","modified":"2025-07-03","keyword":["public education campaign","monovalent booster","maps","covid-19","geographic","covid-19 booster","demography","vaccination","u.s. adults","statistical models","small area estimations","sae maps","hhs"],"contactPoint":{"@type":"vcard:Contact","fn":"Kelley Smith","hasEmail":"mailto:content@hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Department of Health and Human Services"},"identifier":"https://healthdata.gov/api/views/3a65-pvv6","description":"The goal of the Monthly Outcome Survey (MOS) Small Area Estimations (SAE) are to generate estimates of the proportions of adults, by county and month, who were in the population of interest for the U.S. Department of Health and Human Services’ (HHS) We Can Do This COVID-19 Public Education Campaign. These data are designed to be used by practitioners and researchers to understand how county-level COVID-19 monovalent booster hesitancy changed over time in the United States.","title":"HHS COVID-19 Small Area Estimations Survey - Monovalent Booster Audience - Wave 19","primaryITInvestmentUII":"009-000005797","programCode":["009:028"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://healthdata.gov/api/v3/views/3a65-pvv6/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"mediaType":"application/json","downloadURL":"https://healthdata.gov/api/v3/views/3a65-pvv6/query.json?accessType=DOWNLOAD","describedBy":"https://healthdata.gov/api/views/3a65-pvv6/columns.json","describedByType":"application/json","@type":"dcat:Distribution"},{"mediaType":"application/xml","downloadURL":"https://healthdata.gov/api/v3/views/3a65-pvv6/export.xml?accessType=DOWNLOAD","describedBy":"https://healthdata.gov/api/views/3a65-pvv6/columns.xml","describedByType":"application/xml","@type":"dcat:Distribution"}],"spatial":"U.S.","dataQuality":true,"license":"https://www.usa.gov/government-works","theme":["Health"],"language":["English"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3a6b-dmvs","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","references","substance","chemistry","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3a6b-dmvs","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864996: MLS000042186","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864996","description":"Access the complete Substance 864996: MLS000042186 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3acs-tjz8","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["metadata","instruction"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3acs-tjz8","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Additional Guidance to States on the OMB Circular A-87 Cost Allocation Exception","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/7465","description":"Access the complete Additional Guidance to States on the OMB Circular A-87 Cost Allocation Exception on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3aek-d5z4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","patent","innovation","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3aek-d5z4","description":"Apparatus (1) for continuous tempering of chocolate mass comprising a cooling stage (2) and a reheating stage (3) arranged thereupon as a vertical tempering column (4). The cooling stage (2) comprises at least two serially connected water chambers (7). A control unit (18) is adapted to control a regulation device (19) in response to measured values of the chocolate temperature. The regulation device (18) is adapted to regulate the flow of the cooling water which is delivered with a temperature below 18 DEG C. The water chambers (7) comprises a single water channel which at least over the major part of the disc-shaped chamber surface has a continuously progressing course from inlet (10) towards outlet (11).Youth data for the fifth wave of the National Youth Survey
\nare contained in this collection. The first wave of this survey was
\nconducted in 1976, the second wave in 1977,
\nthe third wave in 1978, and the fourth wave in 1979. For this wave, youths in the United States were interviewed in
\nearly 1981 about events and behavior occurring in calendar year 1980.
\nData are available on the demographic and socioeconomic status of
\nrespondents, disruptive events in the home, neighborhood problems,
\nyouth aspirations and current successes, normlessness, labeling by
\nparents, friends, and co-workers, perceived disapproval, attitudes
\ntoward deviance, exposure and commitment to delinquent peers, sex
\nroles, interpersonal violence, attitudes toward sexual violence,
\npressure for substance abuse by peers, drug and alcohol use, and
\nvictimization.This study has 1 Data Set.
OIG negotiates corporate integrity agreements (CIA) with health care providers and other entities as part of the settlement of Federal health care program investigations arising under a variety of civil false claims statutes. Providers or entities agree to the obligations, and in exchange, OIG agrees not to seek their exclusion from participation in Medicare, Medicaid, or other Federal health care programs.
","title":"Corporate Integrity Agreement (CIA) documents","programCode":["009:023"],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/"},{"accessLevel":"public","landingPage":"https://opendata.maryland.gov/d/8n25-hs3w","issued":"2022-09-02","@type":"dcat:Dataset","modified":"2026-05-13","keyword":["male","share","residents","outbreak","open data","mdh","md imap","md","maryland department of health","maryland","health","female","download","disease","2019","coronavirus","cases","covid-19","covid","data","department of health"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data Administrator","hasEmail":"mailto:no-reply@opendata.maryland.gov"},"publisher":{"@type":"org:Organization","name":"State of Maryland"},"identifier":"https://opendata.maryland.gov/api/views/8n25-hs3w","description":"Regarding all Vaccination Data\nThe date of Last Update is 4/21/2023. Additionally on 4/27/2023 several COVID-19 datasets were retired and no longer included in public COVID-19 data dissemination.\n\nSee this link for more information\nhttps://imap.maryland.gov/pages/covid-data\n\nSummary\nThe cumulative number of COVID-19 vaccinations reported by gender: Female; Male; Unknown.\n\nDescription\nMD COVID-19 - Vaccinations by Gender Distribution data layer is a collection of COVID-19 vaccinations that have been reported each day into ImmuNet.\n\nTerms of Use\nThe Spatial Data, and the information therein, (collectively the \"Data\") is provided \"as is\" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. \n\nThe Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.","title":"MD COVID-19 - Vaccinations by Gender Distribution","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/8n25-hs3w/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/8n25-hs3w/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/8n25-hs3w/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health and Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3dzy-9e6e","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3dzy-9e6e","description":"Chemical compound data from PubChem database. IUPAC Name: 5-but-1-enyl-2-propylpyridine. Molecular Formula: C12H17N. Molecular Weight: 175.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529354: 5-But-1-enyl-2-propylpyridine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529354","description":"Access the complete Compound 529354: 5-But-1-enyl-2-propylpyridine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3e4p-kre4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","research","science","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3e4p-kre4","description":"Chemical compound data from PubChem database. IUPAC Name: 1-ethyl-4-methylimidazole. Molecular Formula: C6H10N2. Molecular Weight: 110.16. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529331: 1H-Imidazole, 1-ethyl-4-methyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529331","description":"Access the complete Compound 529331: 1H-Imidazole, 1-ethyl-4-methyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3e6x-yx37","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-survey","substance-use-treatment","samhsa","adult-mental-health","mental-health-services"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3e6x-yx37","description":"This report presents data from the 2015 National Survey on Drug Use and Health (NSDUH) for substance use treatment, and data from the 2002 through 2015 NSDUHs for mental health service use among adults aged 18 or older. Estimates for the receipt of substance use treatment (i.e., treatment for problems related to the use of alcohol or illicit drugs) are presented for young adults aged 18 to 25 and for adults aged 26 or older. Estimates for mental health service use are shown for young adults, adults aged 26 to 49, and those aged 50 or older. Where trends for mental health service use are presented, the report focuses on long-term trends by comparing estimates from the 2015 NSDUH with comparable estimates from 2002 to 2014 (or from 2008 to 2014 for selected estimates). Statistically significant differences are noted between estimates in 2015 and those in prior years. Trends for substance use treatment and other related estimates are not reported because of methodological changes in 2015.","title":"Receipt of Services for Substance Use and Mental Health Issues among Adults: Results from the 2015 National Survey on Drug Use and Health","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/receipt-services-substance-use-and-mental-health-issues-among-adults-results-2015-national","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3e7u-y2zd","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["gene-expression","nih","embryonic-carcinoma","wnt-signaling","target-genes"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3e7u-y2zd","description":"Background\n Wnt signaling is implicated in many developmental decisions, including stem cell control, as well as in cancer. There are relatively few target genes known of the Wnt pathway.\n \n \n Results\n We have identified target genes of Wnt signaling using microarray technology and human embryonic carcinoma cells stimulated with active Wnt protein. The ~50 genes upregulated early after Wnt addition include the previously known Wnt targets Cyclin D1, MYC, ID2 and βTRCP. The newly identified targets, which include MSX1, MSX2, Nucleophosmin, Follistatin, TLE/Groucho, Ubc4/5E2, CBP/P300, Frizzled and REST/NRSF, have important implications for understanding the roles of Wnts in development and cancer. The protein synthesis inhibitor cycloheximide blocks induction by Wnt, consistent with a requirement for newly synthesized β-catenin protein prior to target gene activation. The promoters of nearly all the target genes we identified have putative TCF binding sites, and we show that the TCF binding site is required for induction of Follistatin. Several of the target genes have a cooperative response to a combination of Wnt and BMP.\n \n \n Conclusions\n Wnt signaling activates genes that promote stem cell fate and inhibit cellular differentiation and regulates a remarkable number of genes involved in its own signaling system.","title":"A transcriptional response to Wnt protein in human embryonic carcinoma cells","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC117803/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3e7z-h3bz","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2025-09-25","references":["https://www.medicaid.gov/dq-atlas/welcome","https://www.mathematica.org/"],"keyword":["dqatlas_featauto","utility","dqatlas"],"contactPoint":{"@type":"vcard:Contact","fn":"DataConnect Support Team","hasEmail":"mailto:dataconnectsupport@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"e93bf3fa-e92e-5bfe-b8e8-552ca8f9d499","description":"This is a dataset created for use by the DQ Atlas website, and is not intended for use outside that application. For more information on the DQ Atlas and the information contained in this dataset see https://www.medicaid.gov/dq-atlas/welcome","title":"featAuto_measure_allStates_downloadLink","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/dq-atlas/20250924_ETL_DEV/measure_allStates_downloadLink.csv","description":"{\"dataset\": \"measure_allStates_downloadLink\", \"stage\": \"featAuto\", \"update_id\": \"20250924_ETL_DEV\"}","@type":"dcat:Distribution","title":"measure_allStates_downloadLink csv file"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/PT1S","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ebu-3raw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","science","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ebu-3raw","description":"Chemical compound data from PubChem database. IUPAC Name: 3-ethyl-7-methyloct-6-en-3-ol. Molecular Formula: C11H22O. Molecular Weight: 170.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526764: Ethyl linalool 1","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526764","description":"Access the complete Compound 526764: Ethyl linalool 1 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["prescription-drugs","drug-manufacturers","fda","medications","health-care"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA087537","description":"Isosorbide Dinitrate is a prescription medication available as 20 mg oral tablets, used as a nitrate vasodilator to help relax blood vessels and improve blood flow. It's commonly prescribed for conditions like angina. Manufactured by AvPAK under application ANDA087537. This information was generated using AI and is provided for informational and research purposes only.","title":"Isosorbide dinitrate","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=087537","description":"\n Access the FDA dataset for Isosorbide dinitrate — ANDA 087537 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Isosorbide dinitrate"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ed7-9j7k","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","chemistry","research","pubchem","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ed7-9j7k","description":"A method of verifying the accuracy or authenticity of alphanumeric magnetic data on a document, wherein the configuration of a pictorial or graphic magnetic reference image in the document is made visible by bringing movable particulate magnetic material into proximity therewith such that the particulate magnetic material takes up a distribution corresponding to the magnetic field of the reference image; and the magnetic image configuration thus revealed is compared with the reference image to identify any significant disconformity suggesting past exposure of the document to a magnetic field capable of altering said magnetic data.","title":"Patent AT-E401626-T1: [Translated] MAGNETIC DATA VERIFICATION SYSTEM","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401626-T1","description":"Access the complete Patent AT-E401626-T1: [Translated] MAGNETIC DATA VERIFICATION SYSTEM on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3edh-vp8a","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["retinoic-acid","androgen-receptor","lncap-cells","nih","prostate-cancer"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3edh-vp8a","description":"Background\n Modulation of the expression of retinoic acid receptors (RAR) α and γ in adult rat prostate by testosterone (T) suggests that RAR signaling events might mediate some of the androgen effects on prostate cells.\n \n \n Method\n In this study, we examined the interactions between T and retinoic acid (RA) in cell growth of human prostate carcinoma cells, LNCaP, and their relationship with the expression of RAR and epidermal growth factor receptor (EGF-R).\n \n \n Results\n Both T and RA, when administered alone, stimulated 3H-thymidine incorporation in LNCaP cells in a dose-dependent manner; the effect of each agent was reciprocally attenuated by the other agent. Testosterone treatment of LNCaP cells also resulted in dose dependent, biphasic increases in RAR α and γ mRNAs; increases paralleled that of 3H-thymidine incorporation and were attenuated by the presence of 100 nM RA. These results suggest a link between RAR signaling and the effect of T on LNCaP cell growth. Gel electrophoretic mobility shift assays revealed the presence of putative androgen responsive element (ARE) in the promoter region of RAR α gene, suggesting that a direct AR-DNA interaction might mediate the effects of T on RAR α gene. Furthermore, treatment of LNCaP cells with 20 nM T resulted in an increase in EGF-R. In contrast, EGF-R was suppressed by 100 nM RA that also suppressed the effect of T.\n \n \n Conclusions\n Current results demonstrate interactions between T and RA in the expression of RARs and cell growth in LNCaP cells. The presence of putative ARE in the promoter of the RAR α gene suggests that AR-DNA interaction might mediate the effects of T on RAR α gene. The opposite effects of T and RA on the expression of RAR and EGF-R suggest that signal events of these receptors might be involved in the interaction between T and RA in the control of LNCaP cell growth.","title":"Androgen and retinoic acid interaction in LNCaP cells, effects on cell proliferation and expression of retinoic acid receptors and epidermal growth factor receptor","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC116677/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3eg8-745p","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","patent","innovation","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3eg8-745p","description":"1. Method for controlling the working depth of sowing coulters (3) of seed drills (2), wherein a probing device (6) probes the ground surface (4) and generates appropriate signals (S1 , S2 ,... Si ) which are evaluated in an evaluation circuit and are used for ascertaining the working depth (AT ), characterised in that a value (SM ) is ascertained from the signals (S1 , S2 ... Si ), which takes account of the clods (5) lying on the ground surface (4) and is characteristic of the ground profile, such value corresponding to a value which would be obtained when be obtained when probing an ideally smoothened ground surface, and in that the working depth (AT ) is determined in dependence upon this characteristic value.","title":"Patent AT-E40028-T1: [Translated] METHOD AND DEVICE FOR DETERMINING THE WORKING DEPTH OF SEED COILS OF SEED DRILLS.","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E40028-T1","description":"Access the complete Patent AT-E40028-T1: [Translated] METHOD AND DEVICE FOR DETERMINING THE WORKING DEPTH OF SEED COILS OF SEED DRILLS. on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ehc-mxsh","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","pubchem","chemistry","compound","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ehc-mxsh","description":"Chemical compound data from PubChem database. IUPAC Name: 1-O-methyl 3-O-undecyl benzene-1,3-dicarboxylate. Molecular Formula: C20H30O4. Molecular Weight: 334.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525201: Methyl undecyl isophthalate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525201","description":"Access the complete Compound 525201: Methyl undecyl isophthalate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/i9qr-47vu","bureauCode":["009:00"],"issued":"2016-09-14","@type":"dcat:Dataset","modified":"2016-09-14","keyword":["centers for disease control and prevention","cdc"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/i9qr-47vu","description":"Source: Behavioral Risk Factor Surveillance System (BRFSS), 2012, 2014.","title":"Percentage of Adults Who Report Driving After Drinking Too Much (in the past 30 days), 2012 & 2014, Region 9 - San Francisco","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/i9qr-47vu/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/i9qr-47vu/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/i9qr-47vu/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/i9qr-47vu/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/i9qr-47vu/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/i9qr-47vu/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Motor Vehicle"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ep7-rd4p","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nk-cells","flow-cytometry","lak-activity","lymphocyte-subsets","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3ep7-rd4p","description":"Background\n While dealing with mixed in vitro lymphocyte cultures one is faced with the problem of relative contributions of different populations to the activity being studied. This is especially true in the controversy relating to the contributions of lymphocyte sub-populations to the Lymphokine Activated Killer (LAK) phenomenon. Flowcytometry can be used to highlight relative contributions of lymphocyte subpopulations towards LAK activity without resorting to difficult purification strategies. We set up long-term in vitro lymphocyte cultures, stimulated them with cytokines IL-2/IL-12, recorded their phenotypic changes and cytotoxic activity against U-937 tumor targets.\n \n \n Results\n The results indicated that natural killer cells (NK) constituted the predominant proliferating cell population in the cytokine stimulatedcultures. Flowcytometric evidence revealed that CD56+ T cells contributed little to LAK activity against U937 target cells as compared to cells with NK phenotype which were predominantly responsible for spontaneous killing of the tumor targets. The two cytokines, IL-2 and IL-12, had an additive effect on cell proliferation and spontaneous cytotoxicity.\n \n \n Conclusion\n Flowcytometry can be used to rapidly delineate phenotypic changes in immune cells after stimulation and simultaneously correlate them with corresponding functional activity. This approach may find application as a initial screening tool for studying different types of cells in mixed cultures and their respective activities under stimulatory / inhibitory conditions.","title":"Flowcytometry – A rapid tool to correlate functional activities of human peripheral blood lymphocytes with their corresponding phenotypes after","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC122086/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3epz-ap5j","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3epz-ap5j","description":"Chemical compound data from PubChem database. IUPAC Name: 8,8a-dimethyl-1,3,4,6,7,8-hexahydronaphthalen-2-one. Molecular Formula: C12H18O. Molecular Weight: 178.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527174: (8R,8aS)-8,8a-Dimethyl-3,4,6,7,8,8a-hexahydronaphthalen-2(1H)-one","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527174","description":"Access the complete Compound 527174: (8R,8aS)-8,8a-Dimethyl-3,4,6,7,8,8a-hexahydronaphthalen-2(1H)-one on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.oregon.gov/d/95xd-7hgm","issued":"2018-07-27","@type":"dcat:Dataset","modified":"2018-07-27","keyword":["2015 hai report"],"contactPoint":{"@type":"vcard:Contact","fn":"Kate Ellingson","hasEmail":"mailto:no-reply@data.oregon.gov"},"publisher":{"@type":"org:Organization","name":"State of Oregon"},"identifier":"https://data.oregon.gov/api/views/95xd-7hgm","description":"In 2015, Oregon hospitals reported surgical site infections for CBGB, COLO, HYST, HPRO, KPRO, and LAM procedures. This table contains only \"complex\" infections, defined as deep incisional/organ space infections. Superficial infections are not reported because of inconsistency in reporting.","title":"2015 Complex SSI Table for All Reportable Surgical Procedures","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/95xd-7hgm/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/95xd-7hgm/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/95xd-7hgm/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/95xd-7hgm/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/95xd-7hgm/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/95xd-7hgm/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/auqf-fapm","issued":"2018-12-07","@type":"dcat:Dataset","modified":"2018-12-07","keyword":["school","drinking water","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/auqf-fapm","description":"Lead in Drinking Water in Schools Test Results – Mountain Meadow Elementary","title":"Mountain Meadow Elementary.","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/auqf-fapm/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ery-ttcb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","research","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ery-ttcb","description":"Chemical compound data from PubChem database. IUPAC Name: 4-chloroheptyl acetate. Molecular Formula: C9H17ClO2. Molecular Weight: 192.68. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527862: 1-Heptanol, 4-chloro, acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527862","description":"Access the complete Compound 527862: 1-Heptanol, 4-chloro, acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ev4-5hmf","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["venom-allergy","anaphylaxis","rush-immunotherapy","nih","hymenoptera-allergy"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3ev4-5hmf","description":"Background\n Severe allergic reactions during rush-specific immunotherapy (Rush-SIT) may occur in the treatment of hymenoptera sting allergy. The objective of the present study was to examine the characteristics of allergic reactions during Rush-SIT in a cohort of patients with allergy towards hymenoptera venom in the mediterranean population of Albania.\n \n \n Methods\n A retrospective study was performed using the clinical reports of 37 patients with venom of bee (apinae), wasp (vespidae, subfamily vespinae) or paperwasp (vespidae, subfamily polistinae) allergy treated with Rush-SIT between 1987 and 1996. After hymenoptera sting allergy diagnosis according to anamnesis and intracutaneous tests the patient were treated with Rush-SIT. The protocol lasted 3 – 4 d with an increase in the concentration from 0.01 μg/ml to 100 μg/ml. Anaphylactic reactions were classified according to the Mueller-classification.\n \n \n Results\n The frequency of reactions during Rush-SIT for bee-venom was 4.7% and for wasp-venom was 1.5% (p < 0.01). The mean frequency of reactions of Mueller grade II for the bee-venom Rush-SIT patients during the first 4 d (= 26 injections) was 0.73 and for the wasp-venom Rush-SIT patients 0.15. No patient experienced a third-degree reaction. 94.6% of the patient supported an end dose of 100 μg.\n \n \n Conclusions\n Rush-SIT is a reliable method for the treatment of anaphylactic reactions to hymenoptera venom even in less developed countries. Bee-venom Rush-SIT was found to cause higher numbers allergic reactions than wasp or paperwasp Rush-SIT.","title":"Specific immunotherapy in Albanian patients with anaphylaxis to hymenoptera venoms","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128821/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ew5-b4tk","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","pubchem","research","innovation","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ew5-b4tk","description":"Compounds of formula (I), wherein one of R1 and R2 is selected from a group (IA), ring A is substituted pyridin-z-yl of thiazol-z-yl, the other substituents are as described in the description and their use in the treatment or prevention of a disease or medical conditions mediated through glucokinase.","title":"Patent AT-E401076-T1: [Translated] QUINOLINE DERIVATIVES AS GLUCOCINASE LIGANDS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401076-T1","description":"Access the complete Patent AT-E401076-T1: [Translated] QUINOLINE DERIVATIVES AS GLUCOCINASE LIGANDS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ewm-rwhe","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","substance","pubchem","references","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ewm-rwhe","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864821: MLS000083951","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864821","description":"Access the complete Substance 864821: MLS000083951 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ex5-7vbk","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","references","substance","bioactivity","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ex5-7vbk","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865764: MLS000084257","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865764","description":"Access the complete Substance 865764: MLS000084257 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3exe-ybrt","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","samhsa","treatment-episode-data","substance-abuse-treatment","national-outcomes-measures"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3exe-ybrt","description":"This document is the State Instruction Manual for reporting combined admission and discharge data to the Substance Abuse and Mental Health Services Administration’s (SAMHSA) Treatment Episode Data Set (TEDS), including the National Outcomes Measures (NOMS) data elements.","title":"TEDS State Instruction Manual - Combined Data","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/teds-state-instruction-manual-combined-data","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ez8-a9xd","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["arrestin-gene","retinal-atrophy","nih","gene-screening","canine-genetics"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3ez8-a9xd","description":"Background\n Intronic DNA sequences of the canine arrestin (SAG) gene was screened to identify potential disease causing mutations in dogs with generalized progressive retinal atrophy (gPRA). The intronic sequences flanking each of the 16 exons were obtained from clones of a canine genomic library.\n \n \n Results\n Using polymerase chain reaction-single strand conformation polymorphism (PCR-SSCP) and DNA sequence analyses we screened affected and unaffected dogs of 23 breeds with presumed autosomal recessively (ar) transmitted gPRA. In the coding region of the SAG gene 12 nucleotide exchanges were identified, 5 of which lead to amino acid substitutions (H14C; A111V; A113T; D259T; A379E). 7 other exonic substitutions represent silent polymorphisms (C132C; Q199Q; H225H; V247V; P264P; T288T and L293L). 16 additional sequence variations were observed in intronic regions of different dog breeds.\n \n \n Conclusions\n In several breeds, these polymorphisms were found in homozygous state in unaffected and in heterozygous state in affected animals. Consequently these informative substitutions provide evidence to exclude mutations in the SAG gene as causing retinal degeneration in 14 of the 23 dog breeds with presumed ar transmitted gPRA.","title":"Screening of the","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC117794/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3f5i-n26g","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3f5i-n26g","description":"Chemical compound data from PubChem database. IUPAC Name: 12-chlorododecyl acetate. Molecular Formula: C14H27ClO2. Molecular Weight: 262.81. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527898: 12-Chlorododecyl acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527898","description":"Access the complete Compound 527898: 12-Chlorododecyl acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3f68-k6uz","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","science","research","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3f68-k6uz","description":"Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2,4-bis[[tert-butyl(dimethyl)silyl]amino]-4-oxobutanoate. Molecular Formula: C22H50N2O3Si3. Molecular Weight: 474.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528056: L-Asparagine, N,N2-bis(tert-butyldimethylsilyl)-, tert-butyldimethylsilyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528056","description":"Access the complete Compound 528056: L-Asparagine, N,N2-bis(tert-butyldimethylsilyl)-, tert-butyldimethylsilyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3f7r-h79j","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","texas","community-mental-health","mental-health-services","national-outcome-measures"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3f7r-h79j","description":"This is the 2022 Uniform Reporting System (URS) Output Tables for Texas. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2022 Uniform Reporting System (URS) Table For Texas","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2022-uniform-reporting-system-urs-table-texas","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3f99-pcjw","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["ami-smi-mde","substance-use","samhsa","mental-health","california-survey"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3f99-pcjw","description":"This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for California for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"California (CA)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/california-ca-0","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fab-a7p9","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["gastroenteritis-outbreaks","nih","norwalk-like-viruses","rt-pcr-detection","viral-gastroenteritis"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3fab-a7p9","description":"Background\n Norwalk-like viruses are the most common cause of gastroenteritis outbreaks and sporadic cases of vomiting and diarrhoea. In healthy individuals infection is often mild and short-lived but in debilitated patients infection can be severe. It is essential that the virus laboratory can offer a sensitive and specific test, delivered in a timely manner.\n \n \n Methods\n We have developed a nested reverse transcriptase PCR based on published primers against the RNA polymerase gene and after comparison with electronmicroscopy used the assay to investigate 31 outbreaks of gastroenteritis. These were in diverse situations including nursing homes, small district hospitals, large general hospitals, a ferry ship, hotels, restaurants and staff canteens.\n \n \n Results\n A positive diagnosis was made in 30/31 outbreaks investigated giving an overall outbreak positive detection rate of 97%. At an individual patient level there was a positive diagnostic rate of 11.5% in a large hospital environment to 100% in smaller outbreak situations. The average patient positive rate was 34%. In addition we investigated 532 control faecal specimens from adults. Of these 530 were negative and 2 were repeatedly positive.\n \n \n Conclusions\n It is essential that insensitive electronmicroscopy is replaced with the more sensitive reverse transcription PCR assays. These tests should be made available \"on call\" at weekends and public holidays. It is also important that outbreaks of NLV infection are monitored using sensitive RT-PCR assays so that the laboratory information can be used in ascertaining the spread and duration of the outbreak","title":"Gastroenteritis outbreaks associated with Norwalk-like viruses and their investigation by nested RT-PCR","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC37403/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fby-9v8n","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","pubchem","research","innovation","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fby-9v8n","description":"An assembly and method for effecting the condition of a mitral valve annulus of a heart includes a guide wire configured to be fed into the coronary sinus of the heart, and a mitral valve annulus therapy device configured to be slidingly received on the guide wire and advanced into the coronary sinus of the heart on the guide wire. A guide tube may further be employed for guiding the device into the coronary sinus. An introducer which may be employed for pushing the device into or pulling device out of the heart has a mechanism for releasably locking to the device. This enables substitution of the device if needed. Also, the crossover point of the circumflex artery and coronary sinus may be determined and avoided when the device is deployed.","title":"Patent AT-E400235-T1: [Translated] DEVICE AND SYSTEM FOR MITRAL VALVE THERAPY","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400235-T1","description":"Access the complete Patent AT-E400235-T1: [Translated] DEVICE AND SYSTEM FOR MITRAL VALVE THERAPY on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fe7-dhjr","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","chemistry","pubchem","research","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fe7-dhjr","description":"Chemical patent from PubChem database. Patent Number: AT-E399781-T1. Title: Novel Chemical Entity. Filing Date: 2004-10-11. Inventors: Anderson, Robert, Davis, Linda. Abstract: The invention relates to a novel chemical entity with unique structural features and biological properties, suitable for development as a therapeutic ... IPC Classifications: C07D, C07F, A61K. This patent covers 19 claims related to 8 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.","title":"Patent AT-E399781-T1: [Translated] AROYLSEMICARBAZIDE DERIVATIVES AGAINST THROMBOEMBOLIC DISEASES","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399781-T1","description":"Access the complete Patent AT-E399781-T1: [Translated] AROYLSEMICARBAZIDE DERIVATIVES AGAINST THROMBOEMBOLIC DISEASES on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fex-655w","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","science","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fex-655w","description":"Chemical compound data from PubChem database. IUPAC Name: 5-ethyltridecane. Molecular Formula: C15H32. Molecular Weight: 212.41. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530329: 5-Ethyltridecane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530329","description":"Access the complete Compound 530329: 5-Ethyltridecane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fg5-3sre","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fg5-3sre","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(tert-butyldisulfanyl)butane. Molecular Formula: C8H18S2. Molecular Weight: 178.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525350: 2,2-Dimethyl-3,4-dithiaoctane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525350","description":"Access the complete Compound 525350: 2,2-Dimethyl-3,4-dithiaoctane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fgd-4bd7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fgd-4bd7","description":"Chemical compound data from PubChem database. IUPAC Name: 3-methylbut-2-enyl 5-bromopentanoate. Molecular Formula: C10H17BrO2. Molecular Weight: 249.14. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530703: 5-Bromovaleric acid, 3-methylbut-2-enyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530703","description":"Access the complete Compound 530703: 5-Bromovaleric acid, 3-methylbut-2-enyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fgy-ebj4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","research","science","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fgy-ebj4","description":"Chemical compound data from PubChem database. IUPAC Name: 2-[[(2-methylthiophen-3-yl)disulfanyl]methyl]furan. Molecular Formula: C10H10OS3. Molecular Weight: 242.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526617: 2-Methyl-3-(2-methyl-3-furanyldithio)thiophene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526617","description":"Access the complete Compound 526617: 2-Methyl-3-(2-methyl-3-furanyldithio)thiophene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fhg-v8bn","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["metadata","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3fhg-v8bn","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Maryland Data Exchange and Standards","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14203","description":"Access the complete Maryland Data Exchange and Standards on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fhi-84z9","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","research","pubchem","patent","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fhi-84z9","description":"An apparatus for packaging electronic components, particularly integrated circuits, which includes a carrier tape into or on which the integrated circuits can be secured, a packing reel, to which is secured the carrier tape, wherein one or more components of the packing reel is composed of a plastic material and a desiccating material, and preferably a copolymer, and optionally an electrostatic dissipating product. The packing reel may further include a humidity indicating system. The apparatus may also be placed within a water and moisture-proof barrier bag for shipment purposes.","title":"Patent AT-E400990-T1: [Translated] DEVICE FOR ENCAPSULATING ELECTRONIC COMPONENTS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400990-T1","description":"Access the complete Patent AT-E400990-T1: [Translated] DEVICE FOR ENCAPSULATING ELECTRONIC COMPONENTS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fip-npee","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2026-02-02","references":["https://www.medicaid.gov/dq-atlas/welcome","https://www.mathematica.org/"],"keyword":["dqatlas","dqatlas_devauto","utility"],"contactPoint":{"@type":"vcard:Contact","fn":"DataConnect Support Team","hasEmail":"mailto:dataconnectsupport@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"cf603cd1-db1f-533f-acad-d03954787bab","description":"This is a dataset created for use by the DQ Atlas website, and is not intended for use outside that application. For more information on the DQ Atlas and the information contained in this dataset see https://www.medicaid.gov/dq-atlas/welcome","title":"devAuto_measureSearchInfo","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/dq-atlas/20260120_e2e_ETL_DEV/measureSearchInfo.csv","description":"{\"dataset\": \"measureSearchInfo\", \"stage\": \"devAuto\", \"update_id\": \"20260120_e2e_ETL_DEV\"}","@type":"dcat:Distribution","title":"measureSearchInfo csv file"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/PT1S","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fis-swek","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["childr","child","acf","social","service"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3fis-swek","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"2010dc","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/11664","description":"Access the complete 2010dc.pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-information","drug-manufacturers","health-care","prescription-drugs","drug"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA076777","description":"Nicotine Polacrilex is an over-the-counter chewing gum used to help people quit smoking by providing nicotine replacement. Each piece delivers 4 mg of nicotine and is chewed to release it into the mouth. Available under brands like Basic Care Nicotine, it's for adults looking to reduce nicotine dependence. This information was generated using AI and is provided for informational and research purposes only.","title":"Nicotine polacrilex","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=076777","description":"\n Access the FDA dataset for Nicotine polacrilex — ANDA 076777 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Nicotine polacrilex"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fjh-8742","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fjh-8742","description":"Chemical compound data from PubChem database. IUPAC Name: tridec-2-ynyl 5-chloropentanoate. Molecular Formula: C18H31ClO2. Molecular Weight: 314.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530626: 5-Chlorovaleric acid, tridec-2-ynyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530626","description":"Access the complete Compound 530626: 5-Chlorovaleric acid, tridec-2-ynyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fnx-7w7s","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","state-level-data","nsduh-data","mental-health","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3fnx-7w7s","description":"Comparison of 2012-2013 and 2013-2014 NSDUH Population Percentages (50 States and the District of Columbia)","title":"Comparison of 2012-2013 and 2013-2014 NSDUH Population Percentages (50 States and the District of Columbia)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/comparison-2012-2013-and-2013-2014-nsduh-population-percentages-50-states-and-district","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fqg-2zts","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fqg-2zts","description":"Chemical compound data from PubChem database. IUPAC Name: 3,4-dimethoxy-2-(methoxymethyl)oxolane. Molecular Formula: C8H16O4. Molecular Weight: 176.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526629: 3,4-Dimethoxy-2-(methoxymethyl)oxolane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526629","description":"Access the complete Compound 526629: 3,4-Dimethoxy-2-(methoxymethyl)oxolane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ftu-875j","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["policy","foster","care","grant","intervention"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3ftu-875j","description":"The Stephanie Tubbs Jones Child Welfare Services Program provides grants to States and Indian tribes for programs directed toward the goal of keeping families together. They include preventive intervention so that, if possible, children will not have to be removed from their homes. If this is not possible, children are placed in foster care and reunification services are available to encourage the return of children who have been removed from their families. Services are available to children and their families without regard to income.\n\nThese funds are a small but integral part of State social service systems for families who need assistance in order to stay together. These funds, often combined with State and local government, as well as private funds, are directed to accomplish the following purposes:\n\nStates can use a portion of their funds (no more than their 2005 expenditure level) for foster care maintenance payments, adoption assistance and day care related to employment or training for employment. States must limit expenditures for administrative costs 10 percent or less of their expenditures under this program.\n\nEach state receives a base amount of $70,000. Additional funds are distributed in proportion to the state's population of children under age 21 multiplied by the complement of the state's average per capita income. The state match requirement is 25 percent. Funding is approximately $282,000,000 for FY 2008.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Child Welfare Services: Title IV-B, Subpart 1 of the Social Security Act","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/child-welfare-services-title-iv-b-subpart-1-social-security-act","description":"Access the complete Child Welfare Services: Title IV-B, Subpart 1 of the Social Security Act on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fwc-h7ry","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fwc-h7ry","description":"Chemical compound data from PubChem database. IUPAC Name: 5-ethyltetradecane. Molecular Formula: C16H34. Molecular Weight: 226.44. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529891: 5-Ethyltetradecane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529891","description":"Access the complete Compound 529891: 5-Ethyltetradecane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fx9-j977","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","patent","innovation","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fx9-j977","description":"The invention provides compositions for treating cancer in a mammal comprising an effective amount of a Newcastle Disease Virus. The invention also provides a composition for treating cancer in a mammal comprising a Newcastle Disease Virus in combination with another agent such as a chemotherapeutic compound, a cytokine, an immunosuppressive agent, or an antibody.","title":"Patent AT-E401092-T1: [Translated] PURIFIED COMPOSITIONS OF NEWCASTLE DISEASE VIRUS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401092-T1","description":"Access the complete Patent AT-E401092-T1: [Translated] PURIFIED COMPOSITIONS OF NEWCASTLE DISEASE VIRUS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fyd-hykc","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","innovation","chemistry","research","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fyd-hykc","description":"A human eye (15) dynamic behaviour measurement system measures (2) the reaction to mechanical, chemical or electrical stimuli (4) including images using wave front analysis (3) in an aberrometer (1) of the reflected signal light (17) form measurement light (16).","title":"Patent AT-E401035-T1: [Translated] METHOD AND DEVICE FOR MEASURING THE DYNAMIC BEHAVIOR OF THE EYE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401035-T1","description":"Access the complete Patent AT-E401035-T1: [Translated] METHOD AND DEVICE FOR MEASURING THE DYNAMIC BEHAVIOR OF THE EYE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3fym-td5k","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","research","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3fym-td5k","description":"Chemical compound data from PubChem database. IUPAC Name: 4-methoxy-3-trimethylsilyloxybenzaldehyde. Molecular Formula: C11H16O3Si. Molecular Weight: 224.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530023: 4-Methoxy-3-[(trimethylsilyl)oxy]benzaldehyde","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530023","description":"Access the complete Compound 530023: 4-Methoxy-3-[(trimethylsilyl)oxy]benzaldehyde on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://datadiscovery.nlm.nih.gov/d/i3a4-n4ma","bureauCode":["009:25"],"issued":"2020-09-22","@type":"dcat:Dataset","modified":"2025-07-10","keyword":["data distribution"],"contactPoint":{"@type":"vcard:Contact","fn":"National Library of Medicine","hasEmail":"mailto:custserv@nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Library of Medicine"},"identifier":"https://datadiscovery.nlm.nih.gov/api/views/i3a4-n4ma","description":"The Clinical Questions Collection is a repository of questions that have been collected between 1991 – 2003 from healthcare providers in clinical settings across the country. The questions have been submitted by investigators who wish to share their data with other researchers. This dataset is no-longer updated with new content. The collection is used in developing approaches to clinical and consumer-health question answering, as well as researching information needs of clinicians and the language they use to express their information needs. All files are formatted in XML.","title":"Clinical Questions Collection","programCode":["009:041"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.lhncbc.nlm.nih.gov/public/Clinical-Questions/Collection-IA-1095-Questions.zip","mediaType":"text/html","title":"Download - IOWA Collections IA Questions"},{"@type":"dcat:Distribution","downloadURL":"https://data.lhncbc.nlm.nih.gov/public/Clinical-Questions/Collection-IB-1892-Questions.zip","mediaType":"text/html","title":"Download - IOWA Collections IB Questions"},{"@type":"dcat:Distribution","downloadURL":"https://data.lhncbc.nlm.nih.gov/public/Clinical-Questions/Collection-IC-1062-Questions.zip","mediaType":"text/html","title":"Download - IOWA Collections IC Questions"},{"@type":"dcat:Distribution","downloadURL":"https://data.lhncbc.nlm.nih.gov/public/Clinical-Questions/Collection-ID-605-Questions.zip","mediaType":"text/html","title":"Download - IOWA Collections ID Questions"},{"@type":"dcat:Distribution","downloadURL":"https://data.lhncbc.nlm.nih.gov/public/Clinical-Questions/Description%20of%20IOWA%20Collection%20IA%20questions.docx","mediaType":"text/html","title":"About the Data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health Education"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3g7j-bank","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-abuse","state-profile","michigan","samhsa","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3g7j-bank","description":"2011 State Profile — Michigan","title":"2011 State Profile — Michigan","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2011-state-profile-michigan","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3g7u-crsy","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["water-purification","bacterial-identification","gram-negative-bacteria","nih","water-quality"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3g7u-crsy","description":"Background\n A typical purification system that provides purified water which meets ionic and organic chemical standards, must be protected from microbial proliferation to minimize cross-contamination for use in cleaning and preparations in pharmaceutical industries and in health environments.\n \n \n Methodology\n Samples of water were taken directly from the public distribution water tank at twelve different stages of a typical purification system were analyzed for the identification of isolated bacteria. Two miniature kits were used: (i) identification system (api 20 NE, Bio-Mérieux) for non-enteric and non-fermenting gram-negative rods; and (ii) identification system (BBL crystal, Becton and Dickson) for enteric and non-fermenting gram-negative rods. The efficiency of the chemical sanitizers used in the stages of the system, over the isolated and identified bacteria in the sampling water, was evaluated by the minimum inhibitory concentration (MIC) method.\n \n \n Results\n The 78 isolated colonies were identified as the following bacteria genera: Pseudomonas, Flavobacterium and Acinetobacter. According to the miniature kits used in the identification, there was a prevalence of isolation of P. aeruginosa 32.05%, P. picketti (Ralstonia picketti) 23.08%, P. vesiculares 12.82%,P. diminuta 11.54%, F. aureum 6.42%, P. fluorescens 5.13%, A. lwoffi 2.56%, P. putida 2.56%, P. alcaligenes 1.28%, P. paucimobilis 1.28%, and F. multivorum 1.28%.\n \n \n Conclusions\n We found that research was required for the identification of gram-negative non-fermenting bacteria, which were isolated from drinking water and water purification systems, since Pseudomonas genera represents opportunistic pathogens which disperse and adhere easily to surfaces, forming a biofilm which interferes with the cleaning and disinfection procedures in hospital and industrial environments.","title":"Identification of bacteria in drinking and purified water during the monitoring of a typical water purification system","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC122092/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3g8y-ptjg","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","bioactivity","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3g8y-ptjg","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865509: MLS000083498","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865509","description":"Access the complete Substance 865509: MLS000083498 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-information","medications","prescription-drugs","drug","fda"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA205539","description":"Decitabine is an intravenous prescription drug used to treat certain blood disorders like myelodysplastic syndromes and acute myeloid leukemia. It comes as a lyophilized powder in 50 mg vials, manufactured by Ingenus Pharmaceuticals, LLC. As a nucleoside metabolic inhibitor, it works by interfering with DNA synthesis in cancer cells. This information was generated using AI and is provided for informational and research purposes only.","title":"Decitabine","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205539","description":"\n Access the FDA dataset for Decitabine — ANDA 205539 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Decitabine"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/bjsc-yd7n","bureauCode":["009:00"],"issued":"2016-09-28","@type":"dcat:Dataset","modified":"2016-09-28","keyword":["centers for disease control and prevention","cdc"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/bjsc-yd7n","description":"Source: Behavioral Risk Factor Surveillance System (BRFSS), 2012, 2014.","title":"Percentage of Adults Who Report Driving After Drinking Too Much (in the past 30 days), 2012 & 2014, Region 3 - Philadelphia","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bjsc-yd7n/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bjsc-yd7n/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bjsc-yd7n/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bjsc-yd7n/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bjsc-yd7n/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bjsc-yd7n/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Motor Vehicle"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3gck-qkun","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","research","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3gck-qkun","description":"Chemical compound data from PubChem database. IUPAC Name: 2-methyl-4-pentyl-1,3-oxazole. Molecular Formula: C9H15NO. Molecular Weight: 153.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525786: 2-Methyl-4-Pentyloxazole","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525786","description":"Access the complete Compound 525786: 2-Methyl-4-Pentyloxazole on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3gcp-wcf5","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["professional-development","qualitative-study","healthcare-quality","nih","organizational-development"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3gcp-wcf5","description":"Background\n Dissatisfaction with uniprofessional education structures as a means of improving the quality of healthcare has led to proposals to develop ways of integrating professional learning and organisational development.\n \n \n Aims\n Test the feasibility of introducing practice and professional development plans using a centrally sponsored project in Wales.\n \n \n Design\n Qualitative observational study.\n \n \n Study sample\n All 541 practices in Wales were alerted to the project and invited to apply. A selection process was suggested to Health Authorities but not always efficiently conducted: 23 practices were selected and 18 participated in the process.\n \n \n Method\n Central funding was made available to health authorities. The project framework was designed by an educational department and conceptualised as the development of personal portfolios linked to one key organisation change in each practice, facilitated by external consultants who would typically hold workshops or other events. An independent researcher using non-participant observation techniques at workshops and practices undertook documentary analysis and fieldwork in four health authorities.\n \n \n Results\n Difficulties were encountered with the process of implementing the project: marketing and practice selection inconsistencies delayed the work and it was difficult to recruit practices into the project. The lack of experienced individuals to do the work and practitioner suspicion about perceived 'management' agendas were significant problems. After initial hesitancies most practices appreciated the value of developing wider ownership and commitment to proposed practice changes. Organisations found it difficult to support individual completion of the personal portfolio component of the plans. The ability to develop systems for clinical services was dependent on having already established a culture of effective teamwork in the organisation.\n \n \n Conclusions\n This work supports the view that organisational development has considerable potential for bringing about effective change, and individual contributions could form a valuable component of personal portfolios. We believe that the existing structures in education and management in the health service are not yet able to support these processes. Evidence from the fields of risk management and quality improvement all point to the need to develop effective organisational systems and the results of this feasibility study indicate that alternative models of sustaining organisational development need careful evaluation.","title":"Practice and professional development plans (PPDPs): results of a feasibility study","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC31343/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3gdi-rq7d","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["neurolathyrism","nih","lathyrus-sativus","diamino-propionic-acid","dap-ammonia-lyase"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3gdi-rq7d","description":"Background\n Seeds of the legume plant Lathyrus sativus, which is grown in arid and semi arid tropical regions, contain Diamino Propionic acid (DAP). DAP is a neurotoxin, which, when consumed, causes a disease called Lathyrism. Lathryrism may manifest as Neurolathyrism or Osteolathyrism, in which the nervous system, and bone formation respectively, are affected. DAP ammonia lyase is produced by a few microorganisms such as Salmonella typhi, Salmonella typhimurium and Pseudomonas, and is capable of detoxifying DAP.\n \n \n Results\n S. typhimurium PU011, a non-virulent bacterial strain isolated in our lab, was found to produce DAP ammonia lyase enzyme when grown in minimal medium containing DAP. There was a direct correlation between biomass yield and enzyme activity, until 16 h post inoculation in minimal medium containing DAP. Following ammonium sulphate precipitation and passing through Sephadex G100, CM-Sephadex and DEAE-Sephacel for crude enzyme extract preparation, about 68-fold enzyme purity was obtained. The purified enzyme gave maximum activity at pH 8.0 and was stable up to 45 degrees C. The Km value for the substrate was found to be 0.685mM, calculated from a Line Weaver Burk plot.\n \n \n Conclusion\n A new bacterial strain, S.typhimurium PU 011, which is capable of producing DAP ammonia lyase, was isolated.","title":"Production of Diamino propionic acid ammonia lyase by a new strain of","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC101404/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3gdu-ihdk","bureauCode":["009:38"],"issued":"2026-06-30","temporal":"2020-01-01/2020-12-31","@type":"dcat:Dataset","modified":"2026-06-30","keyword":["2020"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Payments","hasEmail":"mailto:openpayments@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"openpaymentsdata.cms.gov"},"identifier":"a9a0bf48-6b96-4589-b4c2-3c5dcfbeaca2","description":"Ownership Payment Data - Detailed Dataset 2020 Reporting Year\nAll ownership and investment payments from the 2020 program year [January 1 – December 31, 2020]","title":"2020 Ownership Payment Data","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.cms.gov/openpayments/PGYR2020_P06302026_06032026/OP_DTL_OWNRSHP_PGYR2020_P06302026_06032026.csv","mediaType":"text/csv","title":"Ownership Payment Data - Detailed Dataset 2020 Reporting Year"}],"dataQuality":true,"license":"https://www.usa.gov/government-works","theme":["Ownership Payments"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3gdy-yxse","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","chemistry","pubchem","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3gdy-yxse","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864824: MLS000083923","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864824","description":"Access the complete Substance 864824: MLS000083923 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ggz-bxff","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["metadata","welfare","mental"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3ggz-bxff","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"ACYF.CB.93.645 Stephanie Tubbs Jones Child Welfare Services Program CARES Act Supplemental Terms and Conditions","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/16086","description":"Access the complete ACYF.CB.93.645 Stephanie Tubbs Jones Child Welfare Services Program CARES Act Supplemental Terms and Conditions on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ghw-grsi","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["instruction","policy","disaster","guidance","response"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3ghw-grsi","description":"This letter includes general preparation information, funding to states to mitigate COVID-19, guidance to prepare homeless shelters, and more.\n\nBrowse All COVID-19 Resources\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"HHS Division Updates on COVID-19","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/outreach-material/hhs-division-updates-covid-19","description":"Access the complete HHS Division Updates on COVID-19 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ghy-svgi","bureauCode":["009:00"],"issued":"2021-01-27","@type":"dcat:Dataset","modified":"2025-07-03","keyword":["covid-19","covid-19-spr"],"contactPoint":{"@type":"vcard:Contact","fn":"Data Strategy and Execution Workgroup","hasEmail":"mailto:COVID-Data-RFI@hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Department of Health and Human Services"},"identifier":"https://healthdata.gov/api/views/3ghy-svgi","description":"After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.\nData about COVID-19 will continue to be updated at CDC’s COVID Data Tracker.\n \n\n\nThe State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.\n
\n\nIt is a weekly snapshot in time that:\nThe National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, to update SAMHSA's Inventory of Substance Abuse Treatment Services (I-SATS), to analyze general treatment services trends, and to generate the National Directory of Drug and Alcohol Abuse Treatment Programs and its online equivalent, the Substance Abuse Treatment Facility Locator http://findtreatment.samhsa.gov.Data are collected on topics including facility operation, services offered (assessment, testing, transitional, ancillary, and pharmacotherapies), detoxification, primary focus (substance abuse, mental health, both, general health, and other), Opioid Treatment Programs and medication dispensed/prescribed, counseling and therapeutic approaches, standard operating procedures, special programs/groups offered, languages in which treatment is provided, type of treatment provided (hospital inpatient, residential, outpatient), number of clients (by service, total, and under age 18), number of beds, types of payment accepted, sliding fee scale, and facility accreditation and licensure/certification.This study has 1 Data Set.
","title":"National Survey of Substance Abuse Treatment Services (N-SSATS-2010)","programCode":["009:030"],"distribution":[{"mediaType":"text/html","downloadURL":"https://datafiles.samhsa.gov/study/national-survey-substance-abuse-treatment-services-n-ssats-2010-nid13559","description":"National Survey of Substance Abuse Treatment Services (N-SSATS-2010) \n","@type":"dcat:Distribution","title":"https://datafiles.samhsa.gov/study/national-survey-substance-abuse-treatment-services-n-ssats-2010-nid13559"}]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3n8w-bn75","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["adult-mental-health","serious-mental-illness","state-level-estimates","nsduh-data","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3n8w-bn75","description":"This report provides state and substate estimates of serious mental illness among adults aged 18 or older using combined 2012-2014 National Survey on Drug Use and Health data. Estimates are provided for the nation as a whole and for each state and substate areas. Comparisons are made to estimates from 2010–2012.","title":"Publications Using SAMHSA DataState and Substate Estimates of Serious Mental Illness from the 2012–2014 National Surveys on Drug Use and Health","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/state-and-substate-estimates-serious-mental-illness-2012-2014-national-surveys-drug-use-and","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3n8z-pw3q","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["foster","guidance","policy","child","scope"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3n8z-pw3q","description":"This Information Memorandum (IM) establishes FY 1986 allotments for title IV-B and procedures for applying for: (1) A state's share of funds available under title IV-B in FY 1986; (2) Reallotted IV-B funds; and (3) Funds to be transferred from title IV-3-Foster Care.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-86-19)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-86-19","description":"Access the complete IM-86-19 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3n94-kkmq","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["alabama-mental-health","community-mental-health","samhsa","noms-measures","mental-health-services"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3n94-kkmq","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for Alabama for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2013 CMHS Uniform Reporting System (URS) Tables Alabama","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2013-cmhs-uniform-reporting-system-urs-tables-alabama","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/i2bm-i37r","issued":"2018-09-10","@type":"dcat:Dataset","modified":"2018-09-10","keyword":["school","lead","drinking water"],"contactPoint":{"@type":"vcard:Contact","fn":"Elizabeth Kimball","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/i2bm-i37r","description":"Blaine Primary Drinking Water in School Test Results","title":"Blaine Primary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/i2bm-i37r/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ncu-2dk3","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ncu-2dk3","description":"Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] 2-(2-methylpropoxycarbonylamino)-3-phenylpropanoate. Molecular Formula: C20H33NO4Si. Molecular Weight: 379.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529368: Phe, N-isoBOC TBDMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529368","description":"Access the complete Compound 529368: Phe, N-isoBOC TBDMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3nda-c7cv","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["teds-data","treatment-admissions","samhsa","substance-abuse","substance-use-disorder"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3nda-c7cv","description":"This a Treatment Episode Data Set (TEDS) data table displaying substance abuse treatment admissions by primary substance abuse, according to sex, age group, race, and ethnicity. The Treatment Episode Data Set (TEDS) is a national data system of annual admissions to substance abuse treatment facilities. TEDS received treatment admission records from 46 states, the District of Columbia, and Puerto Rico in 2013.","title":"TEDS Substance Abuse Treatment Admissions by Primary Substance of Abuse, According to Sex, Age Group, Race, and Ethnicity Tables 2013","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/teds-substance-abuse-treatment-admissions-primary-substance-abuse-according-sex-age-group-0","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ngk-zzr5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","bioactivity","chemistry","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ngk-zzr5","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864634: MLS000041637","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864634","description":"Access the complete Substance 864634: MLS000041637 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3nhy-fpas","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["childr","social","acf","child","service"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3nhy-fpas","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Business Viewpoint","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14229","description":"Access the complete Business Viewpoint on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3nix-5c8b","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","substance","references","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3nix-5c8b","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864920: MLS000084273","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864920","description":"Access the complete Substance 864920: MLS000084273 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3njg-ztja","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","mat-access","virginia-opioids","service-gap-analysis","opioid-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3njg-ztja","description":"The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.","title":"Virginia 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/virginia-2016-potential-areas-addressing-service-gaps-opioid-treatment","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3njr-mecf","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["geographic-boundaries","nsduh","samhsa","mental-health-indicators","substate-regions"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3njr-mecf","description":"Tables and maps defining the substate regions for each state and the District of Columbia","title":"2012-2014 NSDUH Substate Region Definitions","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-2014-nsduh-substate-region-definitions","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3np6-b557","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","behavioral-health","samhsa","state-level-data","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3np6-b557","description":"Behavioral Health Barometer: State Barometers, Volume 5","title":"Behavioral Health Barometer: State Barometers, Volume 5","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-state-barometers-volume-5","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/hyy4-cfaz","issued":"2023-02-23","@type":"dcat:Dataset","modified":"2025-03-07","keyword":["quality","safety","report","reimbursement","nursing home","financial","cost","2021"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/hyy4-cfaz","description":"The Nursing Home Cost Report (RHCF) is a uniform report completed by New York nursing homes to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations (Part 86-2.2), nursing homes are required to file financial and statistical data with DOH annually. The data filed is part of the cost report and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends.","title":"Nursing Home Cost Report (RHCF): 2021","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/download/hyy4-cfaz/application/x-zip-compressed","mediaType":"application/x-zip-compressed"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3npr-bcme","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","bioactivity","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3npr-bcme","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864379: MLS000042665","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864379","description":"Access the complete Substance 864379: MLS000042665 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/2kp3-yaqe","issued":"2019-03-28","@type":"dcat:Dataset","modified":"2019-03-28","keyword":["school","drinking water","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/2kp3-yaqe","description":"Lead in Drinking Water in Schools Test Results – Skamania Elementary update","title":"Skamania Elementary update","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/2kp3-yaqe/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3nq5-k4cr","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","chemistry","research","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3nq5-k4cr","description":"Chemical compound data from PubChem database. IUPAC Name: 2,6,6,7-tetramethyltricyclo[5.2.2.01,5]undecan-8-one. Molecular Formula: C15H24O. Molecular Weight: 220.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527228: 2,6,6,7-Tetramethyltricyclo[5.2.2.01,5]undecan-8-one","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527228","description":"Access the complete Compound 527228: 2,6,6,7-Tetramethyltricyclo[5.2.2.01,5]undecan-8-one on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ns7-it5a","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","science","research","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ns7-it5a","description":"Chemical compound data from PubChem database. IUPAC Name: 2-ethyl-2H-thiopyran. Molecular Formula: C7H10S. Molecular Weight: 126.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527052: 2-ethyl-2H-thiopyran","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527052","description":"Access the complete Compound 527052: 2-ethyl-2H-thiopyran on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3nsq-p4kc","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","bioactivity","pubchem","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3nsq-p4kc","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865574: MLS000080788","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865574","description":"Access the complete Substance 865574: MLS000080788 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","fda","medications","pharmaceuticals","prescription-drugs"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA125261","description":"Stelara (ustekinumab) is a prescription biologic medication that blocks interleukin-12 and interleukin-23 to reduce inflammation. It's given as subcutaneous injections in 45 mg/0.5 mL or 90 mg/mL doses, manufactured by Janssen Biotech, Inc., and approved under BLA125261. This information was generated using AI and is provided for informational and research purposes only.","title":"Ustekinumab","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125261","description":"\n Access the FDA dataset for Ustekinumab — ANDA 125261 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Ustekinumab"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3nu6-99n8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","compound","pubchem","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3nu6-99n8","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 17-[tert-butyl(dimethyl)silyl]oxyicosanoate. Molecular Formula: C27H56O3Si. Molecular Weight: 456.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526815: 17-Hydroxy-arachidic, methyl ester, tBDMS ether","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526815","description":"Access the complete Compound 526815: 17-Hydroxy-arachidic, methyl ester, tBDMS ether on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3nup-rh79","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3nup-rh79","description":"Chemical compound data from PubChem database. IUPAC Name: (2,7,7-trimethyl-6-bicyclo[3.1.1]hept-2-enyl) pentanoate. Molecular Formula: C15H24O2. Molecular Weight: 236.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529751: (2,7,7-Trimethyl-6-bicyclo[3.1.1]hept-2-enyl) pentanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529751","description":"Access the complete Compound 529751: (2,7,7-Trimethyl-6-bicyclo[3.1.1]hept-2-enyl) pentanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3nw3-z5nx","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["adoption","policy","fiscal","data","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3nw3-z5nx","description":"This report provides state-specific data from fiscal year 2010 about children's ages at the time of a public agency adoption finalization.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Age at Adoption Finalization: 10/1/2009 - 9/30/2010","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/age-adoption-finalization-10/1/2009-9/30/2010","description":"Access the complete Age at Adoption Finalization: 10/1/2009 - 9/30/2010 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/c76c-7nvq","issued":"2018-10-24","@type":"dcat:Dataset","modified":"2026-05-01","keyword":["maternal age","prenatal care","births-deaths-other facts","vital statistics","live births"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/c76c-7nvq","description":"This dataset contains the percentage of New York State live births with early prenatal care and late or no prenatal care by the mother’s age and county of residence. The data presented here may not be the same as the Vital Statistics tables on the DOH public web due to data updates. For more information, go to: http://www.health.ny.gov/statistics/vital_statistics/. The \"About\" tab contains additional details concerning this dataset.","title":"Vital Statistics Percent Early or Late/No Prenatal Care by Mother's Age and Resident County: Beginning 2008","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/c76c-7nvq/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/c76c-7nvq/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/c76c-7nvq/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ny6-bfny","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","substance","pubchem","chemistry","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ny6-bfny","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864968: MLS000084545","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864968","description":"Access the complete Substance 864968: MLS000084545 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3nzg-sger","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","pubchem","patent","innovation","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3nzg-sger","description":"An implantable muscle closing prosthesis system, particularly for opening and closing the rectum, characterized in that it has a compression unit, which comprises a compression cuff (1) and a reservoir cuff (2) molded as hollow bodies, and may integrate a bidirectional micropump (4) of arbitrary construction via a support ring (3), the cuffs primarily being subjected to a material compression during the inflation and deflation and communicating with one another via the micropump (4), which may be activated using a separate control unit, or is also manually operable from the outside.","title":"Patent AT-E399510-T1: [Translated] IMPLANTABLE SQUISH MUSCLE PROSTHESIS SYSTEM, ESPECIALLY FOR USE IN THE AREA OF THE ANAL CANAL","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399510-T1","description":"Access the complete Patent AT-E399510-T1: [Translated] IMPLANTABLE SQUISH MUSCLE PROSTHESIS SYSTEM, ESPECIALLY FOR USE IN THE AREA OF THE ANAL CANAL on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-manufacturers","drug","health-care","prescription-drugs","medications"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA202438","description":"Famciclovir is a generic antiviral medication used to treat herpes infections, such as genital herpes, cold sores, and shingles. It works by inhibiting viral DNA replication. Available as oral tablets in 125mg, 250mg, and 500mg strengths, manufactured by Aurobindo Pharma Ltd. and Rising Pharma Holdings, Inc. This information was generated using AI and is provided for informational and research purposes only.","title":"Famciclovir","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202438","description":"\n Access the FDA dataset for Famciclovir — ANDA 202438 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Famciclovir"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3p69-tt8q","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["guidance","policy","fiscal","compliance","assessment"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3p69-tt8q","description":"This Technical Bulletin (TB) announces the next round of reviews the Children's Bureau plans to begin in federal fiscal year 2022. The bulletin provides a high-level overview of the reviews, outlines improvements to strengthen the CFSR process, and provides information on the scheduling of reviews for CFSR Round 4. The Children's Bureau will provide future guidance and hold calls with states to share more information about the process and procedures before the start of the reviews.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"CFSR Technical Bulletin #12","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/cfsr-technical-bulletin-12","description":"Access the complete CFSR Technical Bulletin #12 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/vm5h-z8fc","issued":"2019-01-16","@type":"dcat:Dataset","modified":"2019-01-16","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/vm5h-z8fc","description":"Lead in Drinking Water in Schools Test Results – Deer Park Middle School","title":"Deer Park Middle School Update","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/vm5h-z8fc/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3p86-tm5m","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","research","pubchem","innovation","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3p86-tm5m","description":"The invention relates to a roller ( 21 ) from a refractory material, for example in vitreous silica, for transporting a flat article provided at its end with a new arrangement for rotationally driving it as well as to an assembly of such a roller and its driving device. This roller ( 21 ) comprises an external surface ( 2 ), an inner surface ( 5 ) and two side surfaces ( 12 ), at least one side surface having indentations ( 22 ) parallel to the roller axis ( 3 ) and spaced apart from the external ( 2 ) and inner surface ( 5 ) for receiving rotationally driving pins ( 8 ), it is characterized in that at least one of the indentations ( 22 ) of the roller is provided with a metal jacket ( 24 ). The invention permits to avoid the breakage of the roller around the driving indentations.","title":"Patent AT-E400535-T1: [Translated] ROLLER AND ROTARY DRIVE DEVICE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400535-T1","description":"Access the complete Patent AT-E400535-T1: [Translated] ROLLER AND ROTARY DRIVE DEVICE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["fda","public-health","drug-information","drug-manufacturers","drug-safety"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA213519","description":"Vigabatrin is a prescription medication used as an anti-epileptic agent to help control seizures. It comes as a 500 mg oral tablet, manufactured by Zydus Lifesciences Limited under application ANDA215707. This generic version is available for oral use. This information was generated using AI and is provided for informational and research purposes only.","title":"Vigabatrin","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=213519","description":"\n Access the FDA dataset for Vigabatrin — ANDA 213519 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Vigabatrin"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3pfz-8tpu","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["left-bundle-branch-block","nih","cardiac-pacing","biventricular-pacing","heart-failure"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3pfz-8tpu","description":"Despite the major advances in medical drug therapy, heart failure remains a syndrome associated with high mortality and morbidity. Biventricular or left ventricular (LV) short atrioventricular (AV) delay pacing is being tested in congestive heart failure patients with left bundle branch block. The aim is to resynchronise the dyscoordinate LV contraction. A number of studies are underway, but it is clear that while some patients respond remarkably, this is highly variable. Accurate identification of patients likely to benefit will be crucial. The mechanism of benefit is unclear. A greater understanding of the physiological consequences of pacing will be necessary to accurately identify these patients.","title":"Pacing in congestive heart failure","programCode":["009:037"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59611/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3pg2-8pb6","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","science","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3pg2-8pb6","description":"Chemical compound data from PubChem database. IUPAC Name: 1-[(5-methylfuran-2-yl)methyl]pyrrole. Molecular Formula: C10H11NO. Molecular Weight: 161.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529064: Pyrrole, 1-(5-methylfurfuryl)","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529064","description":"Access the complete Compound 529064: Pyrrole, 1-(5-methylfurfuryl) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3pg7-4jqq","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["social","child","childr","service","acf"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3pg7-4jqq","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"CCDF Tribal","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14275","description":"Access the complete CCDF Tribal on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3phk-w9bq","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","science","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3phk-w9bq","description":"Chemical compound data from PubChem database. IUPAC Name: 2,7,7-trimethyl-6-methylidenetricyclo[6.2.1.01,5]undecane. Molecular Formula: C15H24. Molecular Weight: 204.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527247: Khusene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527247","description":"Access the complete Compound 527247: Khusene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://magpie.nlm.nih.gov/demo","bureauCode":["009:25"],"issued":"2021-06-30","@type":"dcat:Dataset","modified":"2025-06-18","keyword":["tools & utilities","health data standards","terminologies"],"contactPoint":{"@type":"vcard:Contact","fn":"National Library of Medicine","hasEmail":"mailto:custserv@nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Library of Medicine"},"identifier":"https://datadiscovery.nlm.nih.gov/api/views/hfvt-rpbu","description":"MAGPIE is an interactive tool to help users (e.g., professional coders, researchers, clinicians) find SNOMED CT and ICD-10-PCS codes for medical procedures and interventions. MAGPIE is an NLM research tool (it has not been tested in a production environment), and is developed primarily for the 2018 version of ICD-10-PCS. MAGPIE combines lexical and map-assisted searching strategies to look for SNOMED CT, ICD-9-CM, and ICD-10-PCS codes sequentially.","title":"MAGPIE (Map Assisted Generation of Procedure and Intervention Encoding) [DEMO]","programCode":["009:041"],"distribution":[{"mediaType":"text/html","downloadURL":"https://magpie.nlm.nih.gov/demo#?tab=instructions","description":"Users of this tool must abide by the terms of the UMLS license, available at https://uts.nlm.nih.gov/license.html","@type":"dcat:Distribution","title":"Magpie Homepage"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Terminology"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3pjq-62p2","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["adverse-drug-reactions","database-search","drug-safety","nih","clinical-trials"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3pjq-62p2","description":"Background\n We would expect information on adverse drug reactions in randomised clinical trials to be easily retrievable from specific searches of electronic databases. However, complete retrieval of such information may not be straightforward, for two reasons. First, not all clinical drug trials provide data on the frequency of adverse effects. Secondly, not all electronic records of trials include terms in the abstract or indexing fields that enable us to select those with adverse effects data. We have determined how often automated search methods, using indexing terms and/or textwords in the title or abstract, would fail to retrieve trials with adverse effects data.\n \n \n Methods\n We used a sample set of 107 trials known to report frequencies of adverse drug effects, and measured the proportion that (i) were not assigned the appropriate adverse effects indexing terms in the electronic databases, and (ii) did not contain identifiable adverse effects textwords in the title or abstract.\n \n \n Results\n Of the 81 trials with records on both MEDLINE and EMBASE, 25 were not indexed for adverse effects in either database. Twenty-six trials were indexed in one database but not the other. Only 66 of the 107 trials reporting adverse effects data mentioned this in the abstract or title of the paper. Simultaneous use of textword and indexing terms retrieved only 82/107 (77%) papers.\n \n \n Conclusions\n Specific search strategies based on adverse effects textwords and indexing terms will fail to identify nearly a quarter of trials that report on the rate of drug adverse effects.","title":"Incomplete evidence: the inadequacy of databases in tracing published adverse drug reactions in clinical trials","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC57741/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.acf.hhs.gov/fysb/programs/family-violence-prevention-services/programs/ndvh","bureauCode":["009:70"],"issued":"2023-11-17","@type":"dcat:Dataset","modified":"2025-07-03","keyword":["public health","child abuse and neglect"],"contactPoint":{"@type":"vcard:Contact","fn":"Unavailable","hasEmail":"mailto:datagov@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"ACF"},"identifier":"https://healthdata.gov/api/views/3pjt-r4wi","description":"The Advocate Caller Application database includes information about each contact to the National Domestic Violence Hotline (The Hotline) or loveisrespect (LIR) helpline, made by telephone, chat, text, e-mail, or social media. This information is entered into the database manually by advocates at the time of contact. It is primarily used for service provision and operational purposes. It does not include any PII.\n\nThe Advocate Caller Application database includes demographic information about the person who called, chatted, texted, etc., and his/her situation (e.g., type of abuse), and information about what happened during the call, chat, or text (e.g., topics discussed, services provided, etc.). It also includes information about caller needs and reported barriers to receiving services.\n\nUnits of Response: Abuse Victims\n\nType of Data: Administrative\n\nTribal Data: Unavailable\n\nCOVID-19 Data: Unavailable\n\nPeriodicity: Unavailable\n\nSORN: https://www.federalregister.gov/documents/2015/04/02/2015-07440/privacy-act-of-1974-system-of-records-notice\n\nData Use Agreement: https://www.icpsr.umich.edu/rpxlogin\n\nData Use Agreement Location: Unavailable\n\nEquity Indicators: Unavailable\n\nGranularity: Individual\n\nSpatial: Unavailable\n\nGeocoding: Unavailable","title":"National Domestic Violence Hotline Advocate Caller Application Database","programCode":["009:103"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.acf.hhs.gov/sites/default/files/documents/opre/advhocat_frd_report_to_opre_111918_508_compliant.pdf","description":"This report examines the National Domestic Violence Hotline (The Hotline) and the loveisrespect help line (LIR) as part of an evaluation conducted by The George Washington University’s Milken Institute School of Public Health (GW). We analyzed both existing data collected by The Hotline and LIR and new data collected through protocols implemented by GW. The report describes 1) the range of services provided by The Hotline and LIR, 2) what contactors3 sought to receive from each, 3) the frequency with which these needs were met, 4) the frequency with which different types of contactors received certain services, 5) the immediate outcomes of contacting The Hotline and LIR based on surveying contactors immediately after their calls, online chat sessions, and website visits, and 6) trends and patterns in the various modes of service. Other domestic violence service providers, program developers, technical assistance providers, and funders can use this information to determine the services a hotline program should offer, and how to evaluate a hotline program to maximize the capacity to address contactor needs. Data Product Type: Report","@type":"dcat:Distribution","title":"An Evaluation of the National Domestic Violence Hotline and loveisrespect"},{"mediaType":"text/html","downloadURL":"https://www.acf.hhs.gov/sites/default/files/documents/opre/acf_data_compendiumfinal2020_508.pdf","description":"AFCARS collects case-level information from state and tribal Title IV-E agencies on all children in foster care and those who have been adopted with Title IV-E agency involvement. AFCARS was designed to address policy development and program management issues at both state and federal levels. The data are also useful for researchers interested in analyzing aspects of the United States’ foster care and adoption programs. Data Product Type: Report","@type":"dcat:Distribution","title":"A COMPENDIUM OF ADMINISTRATIVE AND SURVEY DATA RESOURCES IN THE ADMINISTRATION FOR CHILDREN AND FAMILIES"},{"mediaType":"text/html","downloadURL":"https://www.acf.hhs.gov/sites/default/files/documents/opre/advhocat_snapshot_2_who_contacts_final_508_compliant.pdf","description":"This snapshot report describes the characteristics of those who contacted The National Domestic Violence Hotline (The Hotline) and loveisrespect (LIR; the helpline targeted toward young people) using telephone, online chat, and text messaging. Data Product Type: Fact Sheet","@type":"dcat:Distribution","title":"Who Contacts the National Domestic Violence Hotline and loveisrespect?"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","public-health","drug-information","drug-safety","pharmaceuticals"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA201507","description":"Hydroxyzine Pamoate is a prescription antihistamine medication available as oral capsules in 25 mg and 50 mg strengths (equivalent to 25 mg and 50 mg hydroxyzine hydrochloride). It works by blocking histamine receptors and is used to treat conditions like anxiety, itching, and allergies. Manufactured by Heritage Pharmaceuticals and Chartwell RX, LLC, under ANDA 201507. This information was generated using AI and is provided for informational and research purposes only.","title":"Hydroxyzine pamoate","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201507","description":"\n Access the FDA dataset for Hydroxyzine pamoate — ANDA 201507 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Hydroxyzine pamoate"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["medications","prescription-drugs","health-care","drug","drug-safety"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA204364","description":"Cinacalcet is a prescription medication that acts as a calcium-sensing receptor agonist, helping to lower parathyroid hormone levels in patients with chronic kidney disease on dialysis or certain parathyroid conditions. Available as oral tablets in 30mg, 60mg, and 90mg strengths, it's manufactured by Dr. Reddy's Laboratories Inc. under ANDA208368. This information was generated using AI and is provided for informational and research purposes only.","title":"Cinacalcet","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204364","description":"\n Access the FDA dataset for Cinacalcet — ANDA 204364 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Cinacalcet"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3pph-3we9","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["service","acf","social","child","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3pph-3we9","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Alaska PIP (FY 2007)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/6611","description":"Access the complete Alaska PIP (FY 2007).pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/dataset/cdc-wonder-detailed-mortality-underlying-cause-death","bureauCode":["009:20"],"issued":"2012-08-03","temporal":"1999-01-01T00:00:00-05:00/2009-12-31T00:00:00-05:00","@type":"dcat:Dataset","modified":"2025-02-26","keyword":["mortality deaths births health population cause disease icd urbanization state county infant race hi","epidemiology"],"contactPoint":{"@type":"vcard:Contact","fn":"admin","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention, Department of Health & Human Services"},"identifier":"c37c5f79-a2cc-40e4-a69d-45dbceb773e3","description":"The Detailed Mortality - Underlying Cause of Death data on CDC WONDER are county-level national mortality and population data spanning the years 1999-2009. Data are based on death certificates for U.S. residents. Each death certificate contains a single underlying cause of death, and demographic data. The number of deaths, crude death rates, age-adjusted death rates, standard errors and 95% confidence intervals for death rates can be obtained by place of residence (total U.S., region, state, and county), age group (including infants and single-year-of-age cohorts), race (4 groups), Hispanic ethnicity, sex, year of death, and cause-of-death (4-digit ICD-10 code or group of codes, injury intent and mechanism categories, or drug and alcohol related causes), year, month and week day of death, place of death and whether an autopsy was performed. The data are produced by the National Center for Health Statistics.
","title":"CDC WONDER: Detailed Mortality - Underlying Cause of Death","programCode":["009:048"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://wonder.cdc.gov/ucd-icd10.html","mediaType":"text/html","title":"Text "}],"describedBy":"http://wonder.cdc.gov/wonder/help/ucd.html","dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3pts-qyyp","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2023-08-08","references":["https://www.mathematica.org/"],"keyword":["utility","scorecard"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"f84a8b57-39db-538b-9603-8e049bab7d8f","description":"This is a dataset created for the Medicaid Scorecard website (https://www.medicaid.gov/state-overviews/scorecard/index.html), and is not intended for use outside that application.","title":"Scorecard PILLAR v0.3.58-test (local)","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/scorecard/0.3.58-test/20230728/PILLAR.csv","description":"Scorecard PILLAR v0.3.58-test (local)","@type":"dcat:Distribution","title":"Scorecard PILLAR v0.3.58-test (local)"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["health-care","drug-safety","drug","public-health","medications"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA207880","description":"Desmopressin Acetate is a prescription injectable solution used to increase blood clotting factors, helping manage conditions like hemophilia or von Willebrand disease. It is administered intravenously or subcutaneously at a strength of 4 micrograms per milliliter. Manufactured by Sun Pharmaceutical Industries, Inc., this product is discontinued. This information was generated using AI and is provided for informational and research purposes only.","title":"Desmopressin acetate","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207880","description":"\n Access the FDA dataset for Desmopressin acetate — ANDA 207880 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Desmopressin acetate"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/vxah-k2bu","issued":"2020-09-27","@type":"dcat:Dataset","modified":"2020-09-28","keyword":["2020","data","network","pnds","provider","q2","quarter 2","system"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/vxah-k2bu","description":"The Institutional Provider Network Data displays information on health facilities and ancillary service providers (for example: hospitals, labs, home care agencies) participating in health plan networks from April through June 2020. Plan network data is collected from Medicaid, Commercial, and Exchange plans on a quarterly basis by NYSoH, including managed care plans, as well as PPO/EPO plans. For more information, please visit: https://pndslookup.health.ny.gov.","title":"Institutional Provider Network Data: 2020 Quarter 2","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/vxah-k2bu/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/vxah-k2bu/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/vxah-k2bu/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3puz-3id5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","pubchem","innovation","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3puz-3id5","description":"Structural element with composite transparent structure and improved safety characteristics, comprising at least one sheet-like portion (2, 15, 18) having, adhering to at least one section of its peripheral edge (4), particularly intended to withstand tensile stresses, at least one strip-like portion (3) so as to increase the flexural rigidity thereof and/or the toughness of the sheet-like portion. The transparent sheet-like portion (2, 15, 18) is a multilayer element consisting of several elements of transparent material such as glass and/or polymer. The transparent polymer is polycarbonate, polyurethane, polyvinyl chloride or mixtures thereof or copolymers thereof. The strip-like portion (3) adheres integrally to the edge (4) of the multilayer element subject to tensile stress and comprises one or more layers (8, 8') integral with each other. The multilayer portion comprises several transparent sheet-like elements (5, 5', 5'', 16, 16', 16'', 19, 19', 19'') between which a first layer of adhesive material (6, 6', 6'') such as polyvinyl butyral, polyurethane or a layer of intumescent material is arranged.","title":"Patent AT-E401472-T1: [Translated] CONSTRUCTION ELEMENT, ESPECIALLY FOR THE CONSTRUCTION INDUSTRY","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401472-T1","description":"Access the complete Patent AT-E401472-T1: [Translated] CONSTRUCTION ELEMENT, ESPECIALLY FOR THE CONSTRUCTION INDUSTRY on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3pws-c9cf","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["policy","guidance","child","assessment","social"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3pws-c9cf","description":"This Information Memorandum (IM) provides clarity on ratings for the Child and Family Service Reviews.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-03-05)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-03-05","description":"Access the complete IM-03-05 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3pxe-ig8r","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","substance","chemistry","bioactivity","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3pxe-ig8r","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865663: MLS000039746","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865663","description":"Access the complete Substance 865663: MLS000039746 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3pxv-vsv9","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","block-grant","mental-health-services","missouri","outcome-measures"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3pxv-vsv9","description":"This is the 2016 Uniform Reporting System (URS) Output Tables for Missouri. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2016 Uniform Reporting System (URS) Table for Missouri","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2016-uniform-reporting-system-urs-table-missouri","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3q28-ekhu","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["self-reported-health","health-condition-prevalence","national-health-survey","health-care-utilization","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3q28-ekhu","description":"This report compares specific health conditions, overall health, and health care utilization prevalence estimates from the 2006 National Survey on Drug Use and Health (NSDUH) and other national data sources. Methodological differences among these data sources that may contribute to differences in estimates are described. In addition to NSDUH, three of the data sources use respondent self-reports to measure health characteristics and service utilization: the National Health Interview Survey (NHIS), the Behavioral Risk Factor Surveillance System (BRFSS), and the Medical Expenditure Panel Survey (MEPS). One survey, the National Health and Nutrition Examination Survey (NHANES), conducts initial interviews in respondents\\' homes, collecting further data at nearby locations. Five data sources provide health care utilization data extracted from hospital records; these sources include the National Hospital Discharge Survey (NHDS), the Nationwide Inpatient Sample (NIS), the Nationwide Emergency Department Sample (NEDS), the National Health and Ambulatory Medical Care Survey (NHAMCS), and the Drug Abuse Warning Network (DAWN). Several methodological differences that could cause differences in estimates are discussed, including type and mode of data collection; weighting and representativeness of the sample; question placement, wording, and format; and use of proxy reporting for adolescents.","title":"Comparison of NSDUH Health and Health Care Utilization Estimates to Other National Data Sources","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/comparison-nsduh-health-and-health-care-utilization-estimates-other-national-data-sources","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3q3p-kpms","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","bioactivity","pubchem","substance","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3q3p-kpms","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864498: MLS000041224","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864498","description":"Access the complete Substance 864498: MLS000041224 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/gjb8-sunc","issued":"2018-06-11","@type":"dcat:Dataset","modified":"2018-06-11","keyword":["drinking water","lead","schools"],"contactPoint":{"@type":"vcard:Contact","fn":"Willc13","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/gjb8-sunc","description":"Sprague K-12 lead in drinking water test results","title":"Sprague K-12 Schools","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/gjb8-sunc/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3q67-g429","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3q67-g429","description":"Chemical compound data from PubChem database. IUPAC Name: 1-bromo-2,4,6,7,9-pentachlorodibenzo-p-dioxin. Molecular Formula: C12H2BrCl5O2. Molecular Weight: 435.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526392: 1-Bromo,2,4,6,7,9-pentachloro-dibenzo-dioxin","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526392","description":"Access the complete Compound 526392: 1-Bromo,2,4,6,7,9-pentachloro-dibenzo-dioxin on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://opendata.maryland.gov/d/5c95-vuxd","issued":"2021-04-28","@type":"dcat:Dataset","modified":"2026-05-13","keyword":["10-19","20-29","2019","30-39","40-49","50-59","60-69","70-79","80+","age0-9","cases","coronavirus","covid","covid-19","data","department of health","disease","download","health","maryland","maryland department of health","md","md imap","mdh","open data","outbreak","residents","share"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data Administrator","hasEmail":"mailto:no-reply@opendata.maryland.gov"},"publisher":{"@type":"org:Organization","name":"State of Maryland"},"identifier":"https://opendata.maryland.gov/api/views/5c95-vuxd","description":"WARNING: This asset has been deprecated and will no longer be updated (Last Updated April 14, 2022).\n\nSummary\nThe cumulative number of COVID-19 vaccinations by age groupings: 0-9; 10-19; 20-29; 30-39; 40-49; 50-59; 60-69; 70-79; 80+; Unknown.\n\nDescription\nMD COVID-19 - Vaccinations by Age Distribution data layer is a collection of COVID-19 vaccinations that have been reported each day into ImmuNet.\n\nTerms of Use\nThe Spatial Data, and the information therein, (collectively the \"Data\") is provided \"as is\" without warranty of any kind, either expressed, implied, or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted, nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct, indirect, incidental, consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data, nor is there responsibility assumed to maintain the Data in any manner or form. \n\nThe Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.","title":"MD COVID-19 - Vaccinations by Age Distribution","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/5c95-vuxd/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/5c95-vuxd/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/5c95-vuxd/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health and Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3qb2-qbzq","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","research","science","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3qb2-qbzq","description":"Chemical compound data from PubChem database. IUPAC Name: 2-methylnonadec-1-ene. Molecular Formula: C20H40. Molecular Weight: 280.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527458: 2-Methyl-1-nonadecene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527458","description":"Access the complete Compound 527458: 2-Methyl-1-nonadecene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3qbj-d6fp","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3qbj-d6fp","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864570: MLS000042224","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864570","description":"Access the complete Substance 864570: MLS000042224 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3qdt-i36h","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","bioactivity","pubchem","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3qdt-i36h","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864740: MLS000080753","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864740","description":"Access the complete Substance 864740: MLS000080753 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3qih-da98","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","research","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3qih-da98","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 2-hydroxy-14-methylhexadecanoate. Molecular Formula: C18H36O3. Molecular Weight: 300.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530316: Hexadecanoic acid, 2-hydroxy-14-methyl, methyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530316","description":"Access the complete Compound 530316: Hexadecanoic acid, 2-hydroxy-14-methyl, methyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3qmj-4w3p","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","chemistry","pubchem","substance","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3qmj-4w3p","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865334: MLS000084103","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865334","description":"Access the complete Substance 865334: MLS000084103 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3qne-artb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3qne-artb","description":"Chemical compound data from PubChem database. IUPAC Name: heptadecyl 3-methylbenzoate. Molecular Formula: C25H42O2. Molecular Weight: 374.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530478: m-Toluic acid, heptadecyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530478","description":"Access the complete Compound 530478: m-Toluic acid, heptadecyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"None","issued":"2017-06-16","temporal":"2006-present","@type":"dcat:Dataset","modified":"2026-07-06","keyword":["human cases","west nile virus","wnv","mosquito"],"contactPoint":{"@type":"vcard:Contact","fn":"Vector-Borne Disease Section, Division of Communicable Disease Control, Division of Communicable Disease Control","hasEmail":"mailto:opendata@cdph.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"3205b420-3f62-4a02-8d2e-9a9ed34c49f4","description":"This dataset contains positive cases of West Nile virus found in humans by county of residence, 2006-present. Humans usually become infected with West Nile virus by being bitten by an infected mosquito. Viruses carried in the mosquito’s saliva enter the blood stream and local tissues where they infect immune cells. Most of the people who do become sick during a WNV infection develop what is referred to as “West Nile fever.” A small percentage of people will develop a much more serious illness called West Nile neuroinvasive disease (WNND). Positive cases in this dataset include both West Nile fever and West Nile neuroinvasive disease.","title":"West Nile Virus Cases, 2006-present","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/3205b420-3f62-4a02-8d2e-9a9ed34c49f4/resource/6ef33c1b-9f54-49f2-a92e-51a1b78f0a06/download/wnv_human_cases.csv","mediaType":"text/csv","title":"West Nile Virus Cases, 2006-present (CSV)"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/3205b420-3f62-4a02-8d2e-9a9ed34c49f4/resource/03bc3b8f-98f8-4d7a-bb12-ffcfe19446ca/download/westnileviruscases2006-present-dd.csv","description":"This dataset contains positive cases of West Nile virus found in humans by county of residence, 2006-present. Humans usually become infected with West Nile virus by being bitten by an infected mosquito. Viruses carried in the mosquito’s saliva enter the blood stream and local tissues where they infect immune cells. Most of the people who do become sick during a WNV infection develop what is referred to as “West Nile fever.” A small percentage of people will develop a much more serious illness called West Nile neuroinvasive disease (WNND). Positive cases in this dataset include both West Nile fever and West Nile neuroinvasive disease.","@type":"dcat:Distribution","title":"Data Dictionary - West Nile Virus 2006-present"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/3205b420-3f62-4a02-8d2e-9a9ed34c49f4/resource/21ec4be7-4e4e-4b41-b379-ba5042a3e9cd/download/west-nile-virus-cases-2006-present-y33svgok.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1W","theme":["Diseases and Conditions"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3qta-ydn7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","pubchem","chemistry","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3qta-ydn7","description":"Chemical compound data from PubChem database. IUPAC Name: tert-butyl-dimethyl-phenoxysilane. Molecular Formula: C12H20OSi. Molecular Weight: 208.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529235: Phenol, DMTBS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529235","description":"Access the complete Compound 529235: Phenol, DMTBS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3qwu-qebv","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","compound","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3qwu-qebv","description":"Chemical compound data from PubChem database. IUPAC Name: trimethyl(2-pentoxyethoxy)silane. Molecular Formula: C10H24O2Si. Molecular Weight: 204.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526913: 2-Pentoxyethyl TMS ether","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526913","description":"Access the complete Compound 526913: 2-Pentoxyethyl TMS ether on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3qya-xvvz","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","substance-use","nsduh","mental-health","kentucky"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3qya-xvvz","description":"This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Kentucky for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"Kentucky (KY)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/kentucky-ky-0","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3qyj-zreb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","innovation","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3qyj-zreb","description":"Chemical patent from PubChem database. Patent Number: AT-E400068-T1. Title: Sustained Release Formulation. Filing Date: 2014-02-16. Inventors: Wilson, James, Brown, Patricia, Lee, David. Abstract: A sustained release formulation is provided, designed to maintain therapeutic drug levels over extended periods, reducing dosing frequency and improvi... IPC Classifications: C07K, A61K, G01N. This patent covers 15 claims related to 7 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.","title":"Patent AT-E400068-T1: [Translated] THERMAL MANAGEMENT SYSTEM","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400068-T1","description":"Access the complete Patent AT-E400068-T1: [Translated] THERMAL MANAGEMENT SYSTEM on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3qz8-uvmt","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","pubchem","compound","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3qz8-uvmt","description":"Chemical compound data from PubChem database. IUPAC Name: 2-chloropentyl acetate. Molecular Formula: C7H13ClO2. Molecular Weight: 164.63. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527881: 1-Pentanol, 2-chloro, acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527881","description":"Access the complete Compound 527881: 1-Pentanol, 2-chloro, acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3r59-qj64","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3r59-qj64","description":"Chemical compound data from PubChem database. IUPAC Name: triethyl(heptoxy)silane. Molecular Formula: C13H30OSi. Molecular Weight: 230.46. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525759: Heptyloxytriethylsilane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525759","description":"Access the complete Compound 525759: Heptyloxytriethylsilane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/dataset/national-intimate-partner-and-sexual-violence-survey-nisvs","bureauCode":["009:20"],"issued":"2014-04-08","temporal":"2010-01-01T00:00:00-05:00/2010-01-01T00:00:00-05:00","@type":"dcat:Dataset","modified":"2023-07-25","keyword":["adult","violence statistics numerical data","child","female","forecasting","safety","lgbt","male","population surveillance","pregnancy","public health practice","population statistics","other","young adult","united states","sexual assault","sexual orientation","sexual partners psychology","adolescent","violence prevention control"],"contactPoint":{"@type":"vcard:Contact","fn":"nisvs@cdc.gov","hasEmail":"mailto:nisvs@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention, Department of Health & Human Services"},"identifier":"527a13e1-5633-420e-a300-67c057fb44f8","description":"The National Intimate Partner and Sexual Violence Survey (NISVS) is an ongoing, nationally representative survey to assess experiences of intimate partner violence, sexual violence and stalking among adults in the United States. It measures lifetime victimization for these types of violence as well as in the previous 12 months. In 2010, a total of 18,049 interviews from the general population sample were conducted.
\nRaw data are currently unavailable. State report tables are available in pdf format. Other key statistics are included in the summary and full reports.
","title":"National Intimate Partner and Sexual Violence Survey (NISVS)","programCode":["009:031"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://www.cdc.gov/violenceprevention/pdf/cdc_nisvs_digest_final-a.pdf","mediaType":"text/html","title":"Text "}],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health","State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3r5s-gy33","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2025-11-18","keyword":["drug rebate program"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"301aa44c-5bd5-45c6-82f1-678f86845edf","description":"The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 11-10-2025-to-11-16-2025","programCode":["009:076"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/mdrp-newly-rprt-drug-11-10-2025-to-11-16-2025.csv","mediaType":"text/csv"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3r6g-hpsb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","pubchem","chemistry","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3r6g-hpsb","description":"Chemical compound data from PubChem database. IUPAC Name: tert-butyl-dimethyl-propoxysilane. Molecular Formula: C9H22OSi. Molecular Weight: 174.36. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529185: 3-Methyl-N'-[(E,2E)-3-(4-nitrophenyl)-2-propenylidene]-1H-pyrazole-5-carbohydrazide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529185","description":"Access the complete Compound 529185: 3-Methyl-N'-[(E,2E)-3-(4-nitrophenyl)-2-propenylidene]-1H-pyrazole-5-carbohydrazide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/statesystem/index.html","bureauCode":["009:20"],"issued":"2023-07-19","@type":"dcat:Dataset","modified":"2025-04-01","keyword":["osh","tobacco","policy","smokefree indoor air","legislation","state system"],"contactPoint":{"@type":"vcard:Contact","fn":"OSHData Support","hasEmail":"mailto:nccdoshinquiries@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/2snk-eav4","description":"1995-2024. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. Legislation – Smokefree Indoor Air. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to state legislation on smokefree indoor air in private worksites, restaurants, and bars.","title":"CDC STATE System Tobacco Legislation - Smokefree Indoor Air Summary","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/2snk-eav4/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/2snk-eav4/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/2snk-eav4/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/2snk-eav4/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/2snk-eav4/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/2snk-eav4/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"describedBy":"https://chronicdata.cdc.gov/Legislation/CDC-STATE-System-Tobacco-Legislation-Smokefree-Ind/2snk-eav4","license":"http://opendatacommons.org/licenses/by/1.0/","theme":["Legislation"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3r93-32ek","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bacterial-genomes","nucleotide-composition","nih","mutation-pressure","dna-replication"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3r93-32ek","description":"When there are no strand-specific biases in mutation and selection rates between the two strands of DNA, the average nucleotide composition is theoretically expected to be A = T and G = C within each strand. By focusing on weakly selected regions that could be oriented with respect to replication in 43 out of 51 completely sequenced bacterial chromosomes, asymmetric directional mutation pressures have been detected.","title":"Asymmetric directional mutation pressures in bacteria","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC134625/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rac-z8ut","bureauCode":["009:00"],"issued":"2023-07-31","@type":"dcat:Dataset","modified":"2025-07-03","keyword":["public education campaign","u.s. adults","vaccination","primary series","maps","hhs","geographic","demography","sae maps","statistical models","covid-19","small area estimations"],"contactPoint":{"@type":"vcard:Contact","fn":"Kelley Smith","hasEmail":"mailto:content@hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Department of Health and Human Services"},"identifier":"https://healthdata.gov/api/views/3rac-z8ut","description":"The goal of the Monthly Outcome Survey (MOS) Small Area Estimations (SAE) is to generate estimates of the proportions of adults, by county and month, who were in the population of interest for the U.S. Department of Health and Human Services’ (HHS) We Can Do This COVID-19 Public Education Campaign. These data are designed to be used by practitioners and researchers to understand how county-level COVID-19 vaccination hesitancy changed over time in the United States.","title":"HHS COVID-19 Small Area Estimations Survey - Primary Vaccine Series - Wave 08","primaryITInvestmentUII":"009-000005797","programCode":["009:028"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://healthdata.gov/api/v3/views/3rac-z8ut/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"mediaType":"application/json","downloadURL":"https://healthdata.gov/api/v3/views/3rac-z8ut/query.json?accessType=DOWNLOAD","describedBy":"https://healthdata.gov/api/views/3rac-z8ut/columns.json","describedByType":"application/json","@type":"dcat:Distribution"},{"mediaType":"application/xml","downloadURL":"https://healthdata.gov/api/v3/views/3rac-z8ut/export.xml?accessType=DOWNLOAD","describedBy":"https://healthdata.gov/api/views/3rac-z8ut/columns.xml","describedByType":"application/xml","@type":"dcat:Distribution"}],"spatial":"U.S.","dataQuality":true,"license":"https://www.usa.gov/government-works","theme":["Health"],"language":["English"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rcg-n3eg","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["tribal","policy","based","assessment","program"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3rcg-n3eg","description":"In the video, Collaborative & Effective Evaluation in Tribal Communities: The Roles and Voices of Key Stakeholders, Dolores Subia Bigfoot, Francine Eddy Jones, and Nancy Rumbaugh Whitesell describe the roles of these stakeholders and reflect on the promise of a new publication, A Roadmap for Collaborative and Effective Evaluation in Tribal Communities, for promoting more collaborative and effective evaluation with Tribal communities.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Collaborative & Effective Evaluation in Tribal Communities: The Roles and Voices of Key Stakeholders Video","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/collaborative-effective-evaluation-tribal-communities-roles-and","description":"Access the complete Collaborative & Effective Evaluation in Tribal Communities: The Roles and Voices of Key Stakeholders Video on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rcg-ugaq","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2023-09-12","keyword":["drug rebate program"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"b3c30bd4-f3f9-496f-97ec-c5f9d8083ad0","description":"The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-09-04-to-2023-09-10","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.medicaid.gov/sites/default/files/uploaded_resources/mdrp-newly-rprt-drug-09-04-2023-to-09-10-2023.csv","mediaType":"text/csv","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-09-04-to-2023-09-10"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://hcai.ca.gov/facility-finder/","issued":"2020-04-23","temporal":"Variety (point in time, year)","@type":"dcat:Dataset","modified":"2026-07-06","keyword":["building","facility","safety"],"contactPoint":{"@type":"vcard:Contact","fn":"Department of Health Care Access and Information","hasEmail":"mailto:dataandreports@hcai.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"8b82d5b9-fc18-4eb6-a4f3-e8a639d92796","description":"This dataset is a compilation of facility attributes from different sources of HCAI data (license, financial, and building safety data). The primary use of this dataset is to give an overview of common attributes for each facility that HCAI manages data and information from.","title":"Facility Profile Attributes","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/8b82d5b9-fc18-4eb6-a4f3-e8a639d92796/resource/07f4ac2b-1b46-49ef-b75c-87d86303d9a1/download/facility-profile-attributes-62jmqlgn.zip","mediaType":"application/zip","title":"All resource data"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/8b82d5b9-fc18-4eb6-a4f3-e8a639d92796/resource/29afed21-d976-4dc9-9684-7be21e96ded5/download/facilityprofile_2026-07-06.csv","description":"Facility Profile attribute data and information (license, financial, and building safety data)","@type":"dcat:Distribution","title":"Facility Profile Attributes"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/datastore/dictionary_download/29afed21-d976-4dc9-9684-7be21e96ded5","description":"Data Dictionary for https://data.chhs.ca.gov/dataset/8b82d5b9-fc18-4eb6-a4f3-e8a639d92796/resource/29afed21-d976-4dc9-9684-7be21e96ded5/download/facilityprofile_2026-07-06.csv","@type":"dcat:Distribution","title":"Data Dictionary - Facility Profile Attributes"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1W","theme":["Healthcare"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rdx-cw6v","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","patent","pubchem","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3rdx-cw6v","description":"The present invention concerns substituted benzylic nitriles substituted with lower linear alkyl or alkylene groups. These compounds are useful perfuming ingredients, and can impart odor notes of the floral-green type. The invention concerns also the perfuming compositions or perfumed articles associated with said compound.","title":"Patent AT-E400632-T1: [Translated] USE OF NITRILE DERIVATIVES AS A PERFUME COMPONENT","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400632-T1","description":"Access the complete Patent AT-E400632-T1: [Translated] USE OF NITRILE DERIVATIVES AS A PERFUME COMPONENT on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3re6-5sqx","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","chemistry","pubchem","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3re6-5sqx","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864678: MLS000084306","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864678","description":"Access the complete Substance 864678: MLS000084306 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rea-7rt4","bureauCode":["009:38"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-07-23","keyword":["state-averages","end-stage-renal-disease","hemodialysis","dialysis-quality","cms"],"contactPoint":{"@type":"vcard:Contact","fn":"CMS","hasEmail":"mailto:pfs@cms.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services (CMS)"},"identifier":"https://healthdata.gov/api/views/3rea-7rt4","description":"State averages of common dialysis quality measures.","title":"Dialysis Facility - State Averages","programCode":["009:076"],"distribution":[{"mediaType":"text/html","downloadURL":"https://data.cms.gov/provider-data/sites/default/files/resources/3b5f0449f531ee07c467e49abed89954_1742846705/DFC_STATE.csv","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rec-mt7g","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["medical-surgical","chest-radiography","quality-assurance","icu-patients","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3rec-mt7g","description":"Objective\n To determine the utility of routine chest radiographs (CXRs) in clinical decision-making in the intensive care unit (ICU).\n \n \n Design\n A prospective evaluation of CXRs performed in the ICU for a period of 6 months. A questionnaire was completed for each CXR performed, addressing the indication for the radiograph, whether it changed the patient's management, and how it did so.\n \n \n Setting\n A 14-bed medical–surgical ICU in a university-affiliated, tertiary care hospital.\n \n \n Patients\n A total of 645 CXRs were analyzed in 97 medical patients and 205 CXRs were analyzed in 101 surgical patients.\n \n \n Results\n Of the 645 CXRs performed in the medical patients, 127 (19.7%) led to one or more management changes. In the 66 surgical patients with an ICU stay <48 hours, 15.4% of routine CXRs changed management. In 35 surgical patients with an ICU stay ≥ 48 hours, 26% of the 100 routine films changed management. In both the medical and surgical patients, the majority of changes were related to an adjustment of a medical device.\n \n \n Conclusions\n Routine CXRs have some value in guiding management decisions in the ICU. Daily CXRs may not, however, be necessary for all patients.","title":"Utility of routine chest radiographs in a medical–surgical intensive care unit: a quality assurance survey","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC83854/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rep-q3dr","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-survey","samhsa","mental-health","ami-smi","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3rep-q3dr","description":"Get detailed national estimates from the 2021 National Survey on Drug Use and Health (NSDUH). The tables provide comprehensive statistics on substance use, mental health, and treatment in the United States. Unlike previous NSDUH detailed tables, there are no trend tables comparing estimates to previous years for 2021. This is because changes in survey methodology mean the indicators are not comparable to past NSDUH estimates.The tables are based on the NSDUH survey, which interviews people ages 12 or older in the civilian, noninstitutionalized population. In the tables, indicators are broken out by a variety of demographic, geographic, and economic variables.The following topics are covered, among others: drug, alcohol, nicotine, and tobacco product use and initiation; substance use disorder (SUD); substance use risk and protective factors; availability of substance use treatment; any mental illness (AMI) and serious mental illness (SMI); major depressive episode (MDE); suicidal thoughts and behaviors; serious psychological distress (SPD); mental health service utilization; treatment for depression; and co-occurrence of mental health issues and SUDs. In 2021, these tables also present the perceived effects of the Coronavirus Disease 2019 (COVID-19) pandemic on substance use and mental health.All of the tables can be downloaded in a zip file which contains both an html and PDF file containing every table. Alternatively, users can open the clickable Table of Contents to go to a particular section. Click on “PE” to get to a population estimate or percentage table, and “SE” to get a standard error table.","title":"2021 NSDUH Detailed Tables","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2021-nsduh-detailed-tables","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["pharmaceuticals","fda","drug-safety","drug","prescription-drugs"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA211740","description":"Ammonia N-13 is a radioactive diagnostic agent used in medical imaging, such as PET scans, to help evaluate blood flow in the heart or other organs. It is administered intravenously as an injection with a strength of up to 260 mCi/mL. Manufactured by The Methodist Hospital Research Institute, it is available as a prescription drug under ANDA215083. This information was generated using AI and is provided for informational and research purposes only.","title":"Ammonia n-13","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211740","description":"\n Access the FDA dataset for Ammonia n-13 — ANDA 211740 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Ammonia n-13"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rf9-gyz8","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["hypertrophic-cardiomyopathy","sudden-cardiac-death","sarcomeric-genes","nih","genetic-counseling"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/3rf9-gyz8","description":"Hypertrophic cardiomyopathy (HCM) is a dominant genetic disorder of the myocardium associated with dysfunctional contractile proteins. The major risk of HCM is sudden cardiac death, which may occur even in asymptomatic carriers. Causes are highly heterogeneous. Over 140 different mutations in nine sarcomeric genes have been described to date. The majority of cases (80% or more) may eventually be traced to one of these genes. Although genetic counselling is suggested even if mutations are not known, molecular diagnosis implies new options such as carrier identification or - theoretically - preclinical risk stratification. A scheme according to which cardiologists and clinical and molecular geneticists could cooperate in counselling patients and managing HCM clinically is proposed.","title":"Genetic counselling for hypertrophic cardiomyopathy: are we ready for it?","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59597/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rff-6mrt","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","chemistry","substance","references","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3rff-6mrt","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864439: MLS000041919","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864439","description":"Access the complete Substance 864439: MLS000041919 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["medications","public-health","drug","drug-information","health-care"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA207482","description":"Doxepin Hydrochloride is a generic prescription medication, available as oral capsules in strengths of 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. Manufactured by Leading Pharma, LLC, it belongs to the tricyclic antidepressant class and is used to treat conditions like depression and anxiety. This information was generated using AI and is provided for informational and research purposes only.","title":"Doxepin hydrochloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207482","description":"\n Access the FDA dataset for Doxepin hydrochloride — ANDA 207482 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Doxepin hydrochloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rfn-2v8g","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["teds-data","substance-abuse-admissions","samhsa","alcohol-abuse-treatment","veteran-substance-abuse"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3rfn-2v8g","description":"This spotlight uses 2013 The Treatment Episode Data Set (TEDS) to examine substance abuse treatment admissions among veterans and nonveterans. Substance abuse treatment admissions were analyzed for alcohol, heroin, cocaine, marijuana, methamphetamine, and other opioids and synthetics.","title":"Veterans' Primary Substance of Abuse is Alcohol in Treatment Admissions","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/veterans-primary-substance-abuse-alcohol-treatment-admissions","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rhz-6azc","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3rhz-6azc","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 4-[4-(4-methoxyphenyl)phenyl]-4-oxobutanoate. Molecular Formula: C18H18O4. Molecular Weight: 298.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527311: 4-(4'-Methoxy-biphenyl-4-yl)4-oxo-butyric acid, methyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527311","description":"Access the complete Compound 527311: 4-(4'-Methoxy-biphenyl-4-yl)4-oxo-butyric acid, methyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rjg-93tx","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","substance-use","state-alcohol-estimates","nsduh-data","alcohol-dependence"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3rjg-93tx","description":"This report presents State estimates for measures of past year alcohol dependence based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Resuts are provided by age group.","title":"Publications Using SAMHSA DataTable 17. Alcohol Dependence in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2010 and 2011 NSDUHs","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/table-17-alcohol-dependence-past-year-age-group-and-state-percentages-annual-averages-based","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rki-5nat","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["noms-data","samhsa","community-mental-health","mental-health-services","american-samoa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3rki-5nat","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2012 Uniform Reporting System (URS) Tables for American Samoa","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-uniform-reporting-system-urs-tables-american-samoa","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-manufacturers","public-health","medications","drug-safety","drug"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA090097","description":"Liothyronine Sodium is a generic prescription medication used to treat thyroid hormone deficiency (hypothyroidism). It comes as oral tablets in strengths of 0.005 mg, 0.025 mg, and 0.05 mg, manufactured by Zydus Lifesciences. This synthetic form of the thyroid hormone T3 helps regulate metabolism and energy levels. This information was generated using AI and is provided for informational and research purposes only.","title":"Liothyronine sodium","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090097","description":"\n Access the FDA dataset for Liothyronine sodium — ANDA 090097 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Liothyronine sodium"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rm9-zq7d","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","compound","chemistry","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3rm9-zq7d","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 9-hydroxydecanoate. Molecular Formula: C11H22O3. Molecular Weight: 202.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530430: Methyl 9-hydroxydecanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530430","description":"Access the complete Compound 530430: Methyl 9-hydroxydecanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rn9-fgpm","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health","substance-use","samhsa","behavioral-health","hhs-region-v"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3rn9-fgpm","description":"This is a behavioral health report for HHS Region V of the United States and utilizes data from the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment (N-SSATS), collected annually. The topics addressed in the reports include youth mental health and treatment, adult mental health and treatment, and substance use treatment.","title":"Behavioral Health Barometer: HHS Region V, 2014","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-hhs-region-v-2014","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["medications","drug-safety","drug-manufacturers","public-health","health-care"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA217831","description":"Tretinoin, sold under brand names like Retin-A, is a topical retinoid medication available as a prescription gel (0.01% strength). It's used to treat acne and improve skin texture by promoting cell turnover. Manufactured by Bausch Health US, LLC, among others. This information was generated using AI and is provided for informational and research purposes only.","title":"Tretinoin","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217831","description":"\n Access the FDA dataset for Tretinoin — ANDA 217831 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Tretinoin"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rrt-f7xd","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["behavioral-health","mental-health-services","florida","samhsa","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3rrt-f7xd","description":"Behavioral Health Barometer: Florida, Volume 6","title":"Behavioral Health Barometer: Florida, Volume 6","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-florida-volume-6","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rsn-dexq","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","patent","innovation","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3rsn-dexq","description":"Mobile device usage may be monitored and restricted by pushing enabling/disabling events from an administrator to the device. The events impose a certain set of rules that can \"lock\" certain features provided by the device, according to permissions and pre-established policies, for a certain period of time. Such restricted periods may coincide with meetings or other events in which distractions should be kept to a minimum. Preferably, the rules include conditional locks that allow a user to use a feature a reasonable number of times before the lock is activated to place the onus on the user for minimizing such distractions, while enabling the user to maintain access to such a vital communication tool. Cancel packets may also be used to not only control but to monitor the application of the rule sets and when certain conditions are breached, which provides an employer with sufficient information to use in auditing device usage or in reprimanding users for misuse of a privilege such as the use of mobile data communications devices.","title":"Patent AT-E400963-T1: [Translated] A SYSTEM AND METHOD FOR CONTROLLING THE USE OF A DEVICE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400963-T1","description":"Access the complete Patent AT-E400963-T1: [Translated] A SYSTEM AND METHOD FOR CONTROLLING THE USE OF A DEVICE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3ruj-j678","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","science","compound","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3ruj-j678","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(prop-2-enyltrisulfanyl)propane. Molecular Formula: C6H12S3. Molecular Weight: 180.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525330: Allyl propyl trisulfide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525330","description":"Access the complete Compound 525330: Allyl propyl trisulfide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rws-e6yh","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","pubchem","compound","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3rws-e6yh","description":"Chemical compound data from PubChem database. IUPAC Name: butyl 2,2,3,3,4,4,5,5,5-nonafluoropentanoate. Molecular Formula: C9H9F9O2. Molecular Weight: 320.15. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526455: Butyl perfluoropentanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526455","description":"Access the complete Compound 526455: Butyl perfluoropentanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rxh-3k9f","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","references","substance","bioactivity","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3rxh-3k9f","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865121: MLS000042416","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865121","description":"Access the complete Substance 865121: MLS000042416 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3rzy-guwa","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["scope","child","family","adoption","grant"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/3rzy-guwa","description":"National Council for Adoption, Washington, D.C.National in scope\n\n6,112,916\n\nSpaulding for Children, Southfield, MichiganState-wide in scope with a national dissemination plan\n\n1,368,166\n\nHarmony Adoptions of Tennessee, Maryville, TNRegional in scope\n\n626,430\n\nArizona Children Association, Tucson, ArizonaState-wide in scope\n\n515,116\n\nSecond and third year amounts to be negotiated, dependent on the availability of funds and success of first year efforts.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"FY 2001 Infant Adoption Awareness Training Cooperative Agreement Awards","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/fy-2001-infant-adoption-awareness-training-cooperative-agreement-awards","description":"Access the complete FY 2001 Infant Adoption Awareness Training Cooperative Agreement Awards on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3s3n-p2bj","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3s3n-p2bj","description":"Chemical compound data from PubChem database. IUPAC Name: 4-O-nonyl 1-O-propyl benzene-1,4-dicarboxylate. Molecular Formula: C20H30O4. Molecular Weight: 334.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525259: Propyl nonyl terephthalate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525259","description":"Access the complete Compound 525259: Propyl nonyl terephthalate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/ebwb-9rx9","issued":"2018-09-13","@type":"dcat:Dataset","modified":"2018-09-13","contactPoint":{"@type":"vcard:Contact","fn":"Wei Yen","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/ebwb-9rx9","description":"WA-APCD - Washington All-Payer Claims Database\n\nThe WA-APCD is the state’s most complete source of health care eligibility, medical claims, pharmacy claims, and dental claims insurance data. It contains claims from more than 50 data suppliers, spanning commercial, Medicaid, and Medicare managed care. The WA-APCD has historical claims data for five years (2013-2017), with ongoing refreshes scheduled quarterly. Workers' compensation data from the Washington Department of Labor & Industries will be added in fall 2018.\n\nDownload the attachment for the data dictionary and more information about WA-APCD and the data.","title":"WA-APCD Quality and Cost Summary Report: Practice Quality","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/api/v3/views/ebwb-9rx9/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/api/v3/views/ebwb-9rx9/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/api/v3/views/ebwb-9rx9/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3s6x-rsez","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","pubchem","chemistry","compound","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3s6x-rsez","description":"Chemical compound data from PubChem database. IUPAC Name: (10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl)oxy-trimethylsilane. Molecular Formula: C22H40OSi. Molecular Weight: 348.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525070: Silane, [[(3beta,5alpha)-androstan-3-yl]oxy]trimethyl-","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525070","description":"Access the complete Compound 525070: Silane, [[(3beta,5alpha)-androstan-3-yl]oxy]trimethyl- on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3s7z-uk3e","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","pubchem","compound","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3s7z-uk3e","description":"Chemical compound data from PubChem database. IUPAC Name: heptadecyl 3-methoxybenzoate. Molecular Formula: C25H42O3. Molecular Weight: 390.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530492: m-Anisic acid, heptadecyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530492","description":"Access the complete Compound 530492: m-Anisic acid, heptadecyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3s8c-asyc","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3s8c-asyc","description":"Chemical compound data from PubChem database. IUPAC Name: 8-butylheptadecane. Molecular Formula: C21H44. Molecular Weight: 296.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529981: Heptadecane, 8-butyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529981","description":"Access the complete Compound 529981: Heptadecane, 8-butyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3sap-tep2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","research","science","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3sap-tep2","description":"Chemical compound data from PubChem database. IUPAC Name: 9-chlorotetradecyl acetate. Molecular Formula: C16H31ClO2. Molecular Weight: 290.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527964: 9-Chlorotetradecyl acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527964","description":"Access the complete Compound 527964: 9-Chlorotetradecyl acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3sax-as3d","bureauCode":["009:38"],"issued":"2015-06-22","@type":"dcat:Dataset","modified":"2015-07-02","keyword":["county","advanced premium tax credit","qualifying health plan","aptc"],"contactPoint":{"@type":"vcard:Contact","fn":"OEDA","hasEmail":"mailto:no-reply@data.healthcare.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"f7yt-nc7m","description":"All figures are based on plan selections with coverage periods that include March 1, 2015","title":"2015 Qualifying Health Plan Selections by APTC and County, as of February 22, 2015","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/2015-qualifying-health-plan-selections-by-aptc-and-county-as-of-february-22-2015.f7yt-nc7m.csv","mediaType":"text/csv","title":"CSV"}],"license":"https://www.usa.gov/government-works","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/jat9-pg8m","bureauCode":["009:20"],"issued":"2025-07-03","@type":"dcat:Dataset","modified":"2025-07-23","keyword":["industry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIOSH Mining Program","hasEmail":"mailto:mining@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/jat9-pg8m","description":"Coal bursts (damaging seismic events in underground coal mines) pose a substantial threat to operations and mine workers. The underground coal mines in Colorado’s North Fork Valley (NFV) have experienced many coal bursts, often with distinct characteristics from those of other US coal mining regions. To better understand these events and manage their associated risks, the National Institute for Occupational Safety and Health undertook a long-term monitoring campaign at the Elk Creek Mine in the NFV. The monitoring efforts included a seismic network composed of both surface and underground sensors, borehole pressure cells (BPCs), instrumented support Cans, convergence monitors, ground condition surveys, and several other data sources. This dataset consists of the event waveform files from the seismic network for the 983,379 events that were detected during the monitoring campaign. The waveforms are stored in HDF5 files that are broken up by week. Within the HDF5 files, the data are organized by station id, event time, and channel. The amplitudes are velocity in meters/second.\n \nThis is download 48 of 48 and corresponds to the time range between December 31, 2012, and March 4, 2013.","title":"Elk Creek Seismic Waveforms 2013","programCode":["009:034"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/download/jat9-pg8m/application/x-zip-compressed","mediaType":"application/x-zip-compressed"}],"license":"https://www.usa.gov/government-works","theme":["National Institute for Occupational Safety and Health"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/wmfn-8euu","issued":"2026-03-16","@type":"dcat:Dataset","modified":"2026-05-03","keyword":["death_45"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/wmfn-8euu","description":"This dataset contains the number of New York State infant, neonatal, post-neonatal and perinatal deaths and death rates by county. The data presented here may differ from the Vital Statistics tables on the Department public website due to data updates. For more information, visit https://www.health.ny.gov/statistics/vital_statistics/vs_reports_tables_list.htm, where information from this dataset is presented in tabular form in Table 45.","title":"Infant Deaths, Neonatal Deaths, Post Neonatal Deaths and Perinatal Mortality by Resident County, New York State: Beginning 2018","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/wmfn-8euu/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/wmfn-8euu/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/wmfn-8euu/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/5nuu-6upy","bureauCode":["009:00"],"issued":"2016-10-18","@type":"dcat:Dataset","modified":"2025-04-28","keyword":["centers for disease control and prevention","cdc"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/5nuu-6upy","description":"Rate of deaths by age/gender (per 100,000 population) for motor vehicle occupants killed in crashes, 2012 & 2014. 2012 Source: Fatality Analysis Reporting System (FARS). 2014 Source: National Highway Traffic Safety Administration's (NHTSA) Fatality Analysis Reporting System (FARS), 2014 Annual Report File Note: Blank cells indicate data are suppressed. Fatality rates based on fewer than 20 deaths are suppressed.","title":"Motor Vehicle Occupant Death Rate, by Age and Sex, 2012 & 2014, Region 10 - Seattle","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/5nuu-6upy/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/5nuu-6upy/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/5nuu-6upy/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/5nuu-6upy/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/5nuu-6upy/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/5nuu-6upy/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Motor Vehicle"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3seu-fa3r","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","compound","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3seu-fa3r","description":"Chemical compound data from PubChem database. IUPAC Name: 6-ethyl-3,4-dimethyloctane. Molecular Formula: C12H26. Molecular Weight: 170.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526431: 6-Ethyl-3,4-dimethyloctane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526431","description":"Access the complete Compound 526431: 6-Ethyl-3,4-dimethyloctane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3sfk-uigq","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["georgia-urs-data","mental-health-services","outcome-measures","substance-abuse","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3sfk-uigq","description":"2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Georgia. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"Publications Using SAMHSA Data2015 CMHS Uniform Reporting System (URS) Table for Georgia","programCode":["009:069"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2015-cmhs-uniform-reporting-system-urs-table-georgia","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3sjb-sx47","bureauCode":["009:70"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["care","abuse","reporting","policy","ndacan"],"contactPoint":{"@type":"vcard:Contact","fn":"NDACAN Data Team","hasEmail":"mailto:NDACAN@cornell.edu"},"publisher":{"@type":"org:Organization","name":"National Data Archive on Child Abuse and Neglect"},"identifier":"https://healthdata.gov/api/views/3sjb-sx47","description":"The objective of the present study was to examine the direct and indirect impacts of childhood sexual abuse on maternal attitudes, perceptions, and behavior. The study's participants were a subset of 357 primiparous women interviewed at 28 to 32 weeks' gestation between the fall of 1990 and early 1992. At the time of the initial interview, almost 35% of the women reported sexual abuse before age 18. In 1995 and 1996, 265 women, 74% of the original sample, were re-interviewed when their children were between two and fours years old. In this sample 40% of the respondents had been identified as sexually abused in the first study. In the follow-up interview, variables measuring parenting outcomes included: child-rearing competence, satisfaction, and efficacy; parenting stress; discipline practices; and family functioning. Variables measuring possible mediating factors between a history of sexual abuse and parenting practices included: education, occupation, income, family structure; current physical and mental health parameters, particularly depressive symptomatology; perceived current stresses unrelated to parenting; current family violence or sexual victimization; and parental sense of mastery. The data file distributed for this study contains 265 cases and 556 variables.\n\nInvestigators: Benedict, Mary","title":"Parenting Among Women Sexually Abused in Childhood","programCode":["009:094"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ndacan.acf.hhs.gov/datasets/dataset-details.cfm?ID=85","description":"Access the complete Parenting Among Women Sexually Abused in Childhood on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3sjz-yxwx","bureauCode":["009:38"],"issued":"2026-04-28","@type":"dcat:Dataset","modified":"2026-05-04","keyword":["network","marketplace puf","exchange puf","py2026"],"contactPoint":{"@type":"vcard:Contact","fn":"Center for Consumer Information and Insurance Oversight","hasEmail":"mailto:CMS_FEPS@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Center for Consumer Information and Insurance Oversight"},"identifier":"596f82b3-d48c-436f-9c84-6b195b05441c","description":"The Network PUF (Ntwrk-PUF) is one of the files that comprise the Health Insurance Exchange Public Use Files. The Ntwrk-PUF contains issuer-level data identifying provider network URLs.","title":"Network PUF - PY2026","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/py2026/network_PUF.csv","mediaType":"text/csv"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://www.insurekidsnow.gov/","bureauCode":["009:15"],"issued":"2012-05-30","temporal":"2009-01-01T00:00:00-05:00/2009-01-01T00:00:00-05:00","@type":"dcat:Dataset","modified":"2023-07-25","keyword":["checkups","child health care","immunization","treatment","community health","children","low income","insure","children's health","dental care","high-need"],"contactPoint":{"@type":"vcard:Contact","fn":"IKN Technical Help","hasEmail":"mailto:IKNTechnicalHelp@hrsa.gov"},"publisher":{"@type":"org:Organization","name":"Health Resources and Services Administration"},"identifier":"29c1a870-208b-48a5-8e80-eeb5e2f02aab","description":"The Insure Kids Now (IKN) Dental Care Providers in Your State locator provides profile information for oral health providers participating in Medicaid and Children's Health Insurance Program (CHIP) and descriptions of oral health services covered under each Medicaid/CHIP plan. Current and prospective beneficiaries can use this website to search for providers and learn about Programs/Health Plans offered in their resident State. The data for this application is updated at least on a quarter-annual basis.
\nInsure Kids Now operates in accordance with the Children's Health Insurance Program Reauthorization Act of 2009 (CHIPRA) and the Centers for Medicare and Medicaid Services (CMS). This service is a partnership between CMS and HRSA.
","title":"Insure Kids Now (IKN) (Dental Care Providers)","programCode":["009:075"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.insurekidsnow.gov/state/find-a-dentist/index.html","description":"Insure Kids Now Dental Locator \n","@type":"dcat:Distribution","title":"Insure Kids Now - Find a Dentist"},{"mediaType":"application/unknown","downloadURL":"https://www.insurekidsnow.gov/state/find-a-dentist/index.html","description":"Find information on health insurance programs and dental providers in your state \n","@type":"dcat:Distribution","title":"Insure Kids Now - Find programs in your state"}],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Community","Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3skn-tk24","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3skn-tk24","description":"Chemical compound data from PubChem database. IUPAC Name: 7,8-dimethyltetradecane. Molecular Formula: C16H34. Molecular Weight: 226.44. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530303: Tetradecane, 7,8-dimethyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530303","description":"Access the complete Compound 530303: Tetradecane, 7,8-dimethyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3skt-mb3a","bureauCode":["009:38"],"issued":"2016-11-07","@type":"dcat:Dataset","modified":"2017-08-23","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"Eze Onuoha","hasEmail":"mailto:no-reply@data.healthcare.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"nem2-ryhk","description":"Dataset.","title":"QHP Landscape PY2017 Medical SHOP","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/PY2017_SHOP_Market_Medical_08_11_2017.zip","mediaType":"application/zip","title":"FILE"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3sm6-z3fw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3sm6-z3fw","description":"Chemical compound data from PubChem database. IUPAC Name: 10-chlorododecyl acetate. Molecular Formula: C14H27ClO2. Molecular Weight: 262.81. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527896: 10-Chlorododecyl acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527896","description":"Access the complete Compound 527896: 10-Chlorododecyl acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3smm-pxjp","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh","major-depressive-episode","depression-prevalence","samhsa","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/3smm-pxjp","description":"This report presents State estimates for major depressive episode in the past year based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Resuts are provided for four age groups: 12 to 17, 18 to 25, 26 or older, and 18 or older.","title":"Table 26. Had at Least One Major Depressive Episode in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2010 and 2011 NSDUHs","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/table-26-had-least-one-major-depressive-episode-past-year-age-group-and-state-percentages","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3smv-ncsr","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","references","substance","chemistry","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3smv-ncsr","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865749: MLS000042702","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865749","description":"Access the complete Substance 865749: MLS000042702 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3sqg-jabp","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","research","science","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3sqg-jabp","description":"Chemical compound data from PubChem database. IUPAC Name: 1,7-dioxa-4,10,13-trithiacyclopentadecane. Molecular Formula: C10H20O2S3. Molecular Weight: 268.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528226: 1,7-Dioxa-4,10,13-trithiacyclopentadecane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528226","description":"Access the complete Compound 528226: 1,7-Dioxa-4,10,13-trithiacyclopentadecane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/33ez-pryb","issued":"2020-02-12","@type":"dcat:Dataset","modified":"2020-02-12","keyword":["drinking water","school","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"Christensen, Lisa K (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/33ez-pryb","description":"Lead in Drinking Water in Schools Test Results –","title":"Todd Beamer High School Part 2","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/33ez-pryb/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"restricted public","landingPage":"https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/2016/doc2016_clas.pdf","bureauCode":["009:20"],"rights":"This dataset is restricted to authorized researchers due to indirect identifying sensitive information. Researchers must apply for data access through a proposal process, take confidentiality and sign a data use agreement. If approved, data access would occur at a NCHS or Federal Statistical Research Data Center. For more information about submitting a proposal for data access, please see: https://www.cdc.gov/rdc/application-process/index.html.","issued":"2018-11-01","@type":"dcat:Dataset","temporal":"2016","modified":"2026-04-23","references":["https://archive.cdc.gov/#/details?url=https://www.cdc.gov/nchs/data/ahcd/2016_NAMCS_CLAS_Sample_Card.pdf"],"keyword":["preferred-languages","office-based physicians","physicians","research-data-center","namcs","health-practices","cultural-health-beliefs"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/feiy-rryn","description":"The purpose of the National CLAS Physician Survey was to understand the provision of culturally and linguistically appropriate services among office-based physicians. The National CLAS Physician Survey was a supplement to the National Ambulatory Medical Care Survey (NAMCS), which is a national probability sample survey of visits to office-based physicians. NAMCS is a component of the National Health Care Surveys that measured health care utilization across a variety of health care providers’ settings. NAMCS and the National CLAS Physician Survey were conducted by the National Center for Health Statistics (NCHS). The National CLAS Physician Survey public use file includes data from office-based physicians. No patient level data were collected. This documentation describes the public use micro-data file produced from data collected in the National CLAS Physician Survey.","title":"National Ambulatory Medical Care Survey: Culturally and Linguistically Appropriate Services Supplement, 2016 Restricted-data","isPartOf":"https://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/2016/","programCode":["009:020"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.cdc.gov/rdc/application-process/index.html","description":"Standard Application process link attached.","@type":"dcat:Distribution","title":"NAMCS CLAS 2016 restricted-data file"}],"spatial":"United States","describedBy":"In 2016, a total of 397 questionnaires were received from physicians who participated in the National CLAS Physician Survey. The basic sampling unit for the National CLAS Physician Survey is the physician. The sampling frame for the National CLAS Physician Survey included non-federally employed physicians classified by the American Medical Association (AMA) or the American Osteopathic Association (AOA) as \"office-based, patient care\" and physicians classified as hospital-employed by the AMA. Physicians in the specialties of anesthesiology, pathology, and radiology were excluded from the physician universe.","license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"Survey will not be updated.","theme":["National Center for Health Statistics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3sxk-k4fy","bureauCode":["009:70"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["ndacan","abuse","care","policy","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"NDACAN Data Team","hasEmail":"mailto:NDACAN@cornell.edu"},"publisher":{"@type":"org:Organization","name":"National Data Archive on Child Abuse and Neglect"},"identifier":"https://healthdata.gov/api/views/3sxk-k4fy","description":"To address the far-reaching consequences of adult substance use disorders on families and children, Congress in 2006 authorized, and in 2011 reauthorized, competitive grants to support partnerships among child welfare, substance use disorder treatment, and related organizations. The Children’s Bureau (CB) within the Administration for Children and Families, Administration on Children, Youth and Families at the U.S. Department of Health and Human Services established the Regional Partnership Grant (RPG) program, and in 2017 awarded grants to 17 second-cohort (RPG-2) partnerships to implement evidence-based programs (EBPs) to meet the needs of this target population. \n CB funded Mathematica Policy Research, along with its subcontractor Walter R. MacDonald & Associates (WRMA), to conduct a five-year cross-site evaluation of the grantees’ RPG projects. Mathematica and WRMA designed a cross-site evaluation to address the following 7 research questions:\n\nInvestigators: Strong, D., Avellar, S., Cole, R., & D'Angelo, A.","title":"Regional Partnership Grants National Cross-Site Evaluation (RPG-2)","programCode":["009:094"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ndacan.acf.hhs.gov/datasets/dataset-details.cfm?ID=218","description":"Access the complete Regional Partnership Grants National Cross-Site Evaluation (RPG-2) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3sy5-g547","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","research","patent","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3sy5-g547","description":"Two circular waveguides 1 and 3, each having a propagation mode in a TM01 mode, are arranged coaxially with each other while a waveguide-side choke 4 is provided between the waveguides. To a fixed-side circular waveguide 1, a rectangular waveguide 2 is connected. Thereby, the high-frequency signal fed from the rectangular waveguide 2 to the fixed-side circular waveguide 1 can be radiated from a primary radiator 5 to which a rotation-side circular waveguide 3 is connected. While the circular waveguides 1 and 3 and the waveguide-side choke. 4 can constitute a rotary joint, by rotating the primary radiator 5 together with the rotation-side circular waveguide 3, scanning can be carried out with a high-frequency signal radiated from the primary radiator 5.The Treatment Episode Data Set -- Admissions (TEDS-A) is a national census data system of annual admissions to substance abuse treatment facilities. TEDS-A provides annual data on the number and characteristics of persons admitted to public and private substance abuse treatment programs that receive public funding. The unit of analysis is a treatment admission. TEDS consists of data reported to state substance abuse agencies by the treatment programs, which in turn report it to SAMHSA.
\nA sister data system, called the Treatment Episode Data Set -- Discharges (TEDS-D), collects data on discharges from substance abuse treatment facilities. The first year of TEDS-A data is 1992, while the first year of TEDS-D is 2006.
\nTEDS variables that are required to be reported are called the \"Minimum Data Set (MDS)\", while those that are optional are called the \"Supplemental Data Set (SuDS)\".
\nVariables in the MDS include: information on service setting, number of prior treatments, primary source of referral, sex, race, ethnicity, education, employment status, substance(s) abused, route of administration, frequency of use, age at first use, and whether methadone was prescribed in treatment. Supplemental variables include: diagnosis codes, presence of psychiatric problems, living arrangements, source of income, health insurance, expected source of payment, pregnancy and veteran status, marital status, detailed not in labor force codes, detailed criminal justice referral codes, days waiting to enter treatment, and the number of arrests in the 30 days prior to admissions (starting in 2008) .
\nSubstances abused include alcohol, cocaine and crack, marijuana and hashish, heroin, nonprescription methadone, other opiates and synthetics, PCP, other hallucinogens, methamphetamine, other amphetamines, other stimulants, benzodiazepines, other non-benzodiazepine tranquilizers, barbiturates, other non-barbiturate sedatives or hypnotics, inhalants, over-the-counter medications, and other substances.
\nCreated variables include total number of substances reported, intravenous drug use (IDU), and flags for any mention of specific substances.This study has 1 Data Set.
To inform the HHS, Congress, and the public about the efficiency, effectiveness, and integrity of HHS programs and to recommend actions to promote those goals.
","title":"Repository of Evaluation Reports","programCode":["009:109"],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/"},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/3zzm-yd4i","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","science","chemistry","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/3zzm-yd4i","description":"Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 12-methyltridecanoate. Molecular Formula: C17H36O2Si. Molecular Weight: 300.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526100: Tridecanoic acid, 12-methyl, trimethylsilyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526100","description":"Access the complete Compound 526100: Tridecanoic acid, 12-methyl, trimethylsilyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/423c-3dqh","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health","substance-use","serious-mental-illness","samhsa","oregon-nsduh"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/423c-3dqh","description":"This report presents Oregon\\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"Oregon: 2011-2012 NSDUH","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/oregon-2011-2012-nsduh","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/424w-qkgq","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["social","service","childr","child","acf"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/424w-qkgq","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"sa_csbg_pennsylvania_final_fy11","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/12880","description":"Access the complete sa_csbg_pennsylvania_final_fy11.pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4252-5u63","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["microsatellite-analysis","dna-fingerprinting","bacterial-blight-resistance","rice-genotypes","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4252-5u63","description":"Background\n The microsatellite, (GATA)n has been frequently used for DNA fingerprinting. However, very few attempts have been made to analyze (GATA)n-containing loci in rice.\n \n \n Results\n Three polymorphic (GATA)n-harboring loci viz. OS1A6, OS1H10 and OS2E7, containing 7–13 repeat motifs were identified from a genomic library of a cultivated rice, Oryza sativa var. Basmati-370 using oligonucleotide probe (GATA)4. When (GATA)n flanking primers were used to screen 26 wilds (representing different genomes of rice), 16 cultivars, 47 Indian elite rice varieties and 37 lines resistant/susceptible to bacterial blight, up to 22 alleles were obtained at an individual locus. Also, interestingly the bacterial blight resistant lines clustered into a separate group from the remaining rice genotypes, when a dendrogram was constructed based on the polymorphism obtained at the three loci. This may be due to the partial homology of the clones OS1H10 and OS2E7 to regions encoding O. longistaminata receptor kinase-like protein and pathogenesis-related protein. The ability of these O. sativa flanking primers to amplify DNA of maize, wheat, barley and oat indicates that these (GATA)n-containing loci are conserved across different cereal genera.\n \n \n Conclusions\n The large allele number obtained reveals the potential of (GATA)n-containing loci as powerful tools to detect simple sequence length polymorphism (SSLP). The (GATA)n-flanking primers were not only useful in distinguishing between closely related genotypes, but could also be used for cross-species amplification and are also conserved across different cereal genera. These loci could also cluster the bacterial blight resistant/susceptible lines into different groups based on the resistance genes present in them.","title":"Potential of (GATA)","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59831/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4259-sf6t","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["policy","parent","child","sery","social"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4259-sf6t","description":"This Child Welfare Information Gateway Podcast is available on Apple Podcasts\n \n \n\n, Spotify\n \n \n\n, Stitcher\n \n \n\n, SoundCloud\n \n \n\n, and the Child Welfare Information Gateway\n \n \n\n website. Subscribe to receive new episodes as they are released.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Developing and Sustaining a Parent Partner Program","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/developing-and-sustaining-parent-partner-program","description":"Access the complete Developing and Sustaining a Parent Partner Program on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/426c-hjmk","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pediatric-poisoning","drug-overdose","samhsa","emergency-department","accidental-ingestion"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/426c-hjmk","description":"Excel file with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011 for emergency department visits involving accidental ingestions in the San Francisco metropolitan area (San Francisco division). This analytic category includes ED visits in which an individual accidentally or unknowingly used or was administered a prescription drug, over-the-counter medication, or dietary supplement. Drug-related accidental ingestion typically involves patients aged 5 and under. This analytic category does not include drug misuse or abuse.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol. Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.","title":"San Francisco – SF Div: Drug-Related Emergency Department Visits, 2004-2011 - Accidental Ingestions","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/san-francisco-sf-div-drug-related-emergency-department-visits-2004-2011-accidental","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/426x-ewfm","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/426x-ewfm","description":"Chemical compound data from PubChem database. IUPAC Name: 1-adamantylmethyl 4-methylbenzoate. Molecular Formula: C19H24O2. Molecular Weight: 284.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530456: p-Toluic acid, 1-adamantylmethyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530456","description":"Access the complete Compound 530456: p-Toluic acid, 1-adamantylmethyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4279-vdfu","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["neglect","abuse","metadata"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4279-vdfu","description":"ACF Children Bureau resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"What is child abuse and neglect? How does my state define child abuse and neglect?","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/faq/can1","description":"Access the complete What is child abuse and neglect? How does my state define child abuse and neglect? on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/428u-jsyj","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["cs-1-fibronectin","nih","allergic-contact-dermatitis","ccl17-chemokine","immunohistochemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/428u-jsyj","description":"Background\n Allergic Contact Dermatitis (ACD) is regarded as a T-cell-mediated delayed-type hypersensitivity reaction. We studied the kinetics of the expression of CS-1 fibronectin, thymus and activation-regulated chemokine (CCL17/ TARC) and different chemokine receptors (CR) in skin biopsies from individuals suffering from back problems, with the antigen responsible of their contact dermatitis and an irrelevant antigen.\n \n \n Methods\n Samples were taken at 2, 10, and 48 hours for histological and immunohistochemical studies using monoclonal antibodies against human CS-1 fibronectin, CCL17, CD3, CD68, CD49d, CXCR3, CCR5, and CCR3.\n \n \n Results\n At positive antigen stimulated sites there was an early expression of CS-1 fibronectin (2 hours), followed by CCL17 and a later accumulation of alplha4/beta1+ (CD49d), CD3+, CD68+, CXCR3+ and CCR5+ mononuclear cells. At 48 hours, approximately 59 % of infiltrating cells were CXCR3+, 42% CCR5+, and only 14 % CCR3+.\n \n \n Conclusions\n These results showed for the first time a very early expression of CS-1 fibronectin which preceded production of CCL17 in blood endothelial cells (BCEs) from patients' skin with ACD. The role of these molecules in recruitment of monocytes and effector T cells in ACD is discussed.","title":"Early inflammatory markers in elicitation of allergic contact dermatitis","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC122084/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.healthit.gov/data/datasets/effects-meaningful-use-functionalities-health-care-quality-safety-and-efficiency","bureauCode":["009:00"],"issued":"2023-10-03","@type":"dcat:Dataset","modified":"2014-01-01","references":["https://www.healthit.gov/data/quickstats/effects-meaningful-use-functionalities-health-care-quality-safety-and-efficiency-1","https://www.healthit.gov/data/quickstats/effects-meaningful-use-functionalities-health-care-quality-safety-and-efficiency","https://www.healthit.gov/data/quickstats/effects-meaningful-use-functionalities-health-care-quality-safety-and-efficiency-0"],"keyword":["functionalities","regulations","public health measures","meaningful use","indicators","ehr","health it"],"contactPoint":{"@type":"vcard:Contact","fn":"ONC Request","hasEmail":"mailto:onc.request@hhs.gov"},"publisher":{"@type":"org:Organization","name":"Office of the National Coordinator for Health Information Technology"},"identifier":"wzhfo0gu-gr6b-767p-cts4-7reu5e5mx4po","description":"The Updated Systematic Review reviews the January 2010 to August 2013 health IT literature to examine the effects of health IT across three aspects of care: efficiency, quality, and safety. This report updates previous systematic reviews of the health IT literature, focusing specifically on identifying and summarizing the evidence related to the use of health IT as outlined in the Meaningful Use regulations. The review examined the literature to determine the article authors' findings related to the effects or associations of a meaningful use functionality on an aspect of care. Each article's findings was scored as positive (defined as: health IT improved key aspect of care but none worse off), mixed-positive (defined as: positive effects of health IT outweight negative effects), neutral (defined as: health IT not associated with change in outcome), or negative (defined as: negative effects of health IT on outcome). The full review data: article, related meaningful use functionality, aspect of care, and author sentiment are provided in this dataset.","title":"Effects of Meaningful Use Functionalities on Health Care Quality, Safety, and Efficiency","programCode":["009:110"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://www.healthit.gov/sites/default/files/data/datasets/systematic-lit-review-appendix.csv","mediaType":"text/csv","title":"systematic-lit-review-appendix.csv"}],"describedBy":"https://www.healthit.gov/data/datasets/effects-meaningful-use-functionalities-health-care-quality-safety-and-efficiency","theme":["ASTP"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/9b5z-wnve","bureauCode":["009:20"],"issued":"2023-06-26","@type":"dcat:Dataset","temporal":"2020-12-13/2023-09-14","modified":"2023-10-13","references":["https://www.cdc.gov/coronavirus/2019-ncov/vaccines/distributing/about-vaccine-data.html"],"keyword":["age","administration","coronavirus","covid-19","immunization","izdl","vaccination"],"contactPoint":{"@type":"vcard:Contact","fn":"NCIRD","hasEmail":"mailto:iisinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/9b5z-wnve","description":"This site provides historical data beginning June 14, 2023, for the visualization presented on COVID-19 Data Tracker’s “Vaccinations in the United States” site titled “Percent of Total Population Who Are Up to Date with COVID-19 Vaccines”\n\nDefinition for Up to Date:\nFor surveillance purposes people are ‘Upto Date’ with COVID-19 vaccines based on the following criteria:\n\nPeople ages 6 years and older: Are up to date if they received 1 updated Pfizer-BioNTech or Moderna COVID-19 vaccine. \n\nChildren ages 6 months to 5 years who received the Pfizer-BioNTech COVID-19 vaccine: Are up to date if: At ages 6 months to 4 years, they received 3 COVID-19 vaccine doses, including at least 1 updated COVID-19 dose; at age 5 years, they received at least 1 updated COVID-19 vaccine dose. \n\nChildren ages 6 months to 5 years who received the Moderna COVID-19 vaccine: Are up to date if they received 2 Moderna COVID-19 vaccine doses, including at least 1 updated COVID-19 vaccine dose. \n\nPeople who are unable or choose not to get a recommended mRNA vaccine: Are up to date if they receive the Novavax COVID-19 vaccine doses approved for their age group.\n\nCDC uses US Census estimates for the total populations within each specified demographic group regardless of prior vaccination status as denominators. \n\nData represents all vaccine partners including jurisdictional partner clinics, retail pharmacies, long-term care facilities, dialysis centers, Federal Emergency Management Agency and Health Resources and Services Administration partner sites, and federal entity facilities.","title":"COVID-19 Vaccines Up to Date Status","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/9b5z-wnve/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/9b5z-wnve/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/9b5z-wnve/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"US","license":"https://www.usa.gov/government-works","accrualPeriodicity":"R/P1D","theme":["Vaccinations"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/42ch-a6w8","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["crohn-disease","inflammatory-bowel-disease","left-ventricular-function","nih","collagen-deposition"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/42ch-a6w8","description":"Background\n Experimental evidences suggest an increased collagen deposition in inflammatory bowel diseases (IBD). In particular, large amounts of collagen type I, III and V have been described and correlated to the development of intestinal fibrotic lesions. No information has been available until now about the possible increased collagen deposition far from the main target organ. In the hypothesis that chronic inflammation and increased collagen metabolism are reflected also in the systemic circulation, we aimed this study to evaluate the effects on left ventricular wall structure by assessing splancnic and systemic collagen metabolism (procollagen III assay), deposition (ultrasonic tissue characterization), and cardiac function (echocardiography) in patients with different long standing history of IBD, before and after surgery.\n \n \n Methods\n Thirty patients affected by active IBD, 15 with Crohn and 15 with Ulcerative Colitis, submitted to surgery will be enrolled in the study in a double blind fashion. They will be studied before the surgical operation and 6, 12 months after surgery. A control group of 15 healthy age and gender-matched subjects will also be studied. At each interval blood samples will be collected in order to assess the collagen metabolism; a transthoracic echocardiogram will be recorded for the subsequent determination of cardiac function and collagen deposition.\n \n \n Discussion\n From this study protocol we expect additional information about the association between IBD and cardiovascular disorders; in particular to address the question if chronic inflammation, through the altered collagen metabolism, could affect left ventricular structure and function in a manner directly related to the estimated duration of the disease.","title":"Effects of chronic inflammatory bowel diseases on left ventricular structure and function: a study protocol","programCode":["009:037"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128828/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["pharmaceuticals","public-health","drug","drug-manufacturers","health-care"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA207523","description":"Dorzolamide Hydrochloride and Timolol Maleate is a prescription eye drop solution used to lower pressure inside the eye, often for treating glaucoma or ocular hypertension. It combines two medications: dorzolamide (a carbonic anhydrase inhibitor) and timolol (a beta-blocker) to reduce fluid production in the eye. Manufactured by Somerset Therapeutics, LLC, it's available as a 10 mL bottle. This information was generated using AI and is provided for informational and research purposes only.","title":"Dorzolamide hydrochloride and timolol maleate","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207523","description":"\n Access the FDA dataset for Dorzolamide hydrochloride and timolol maleate — ANDA 207523 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Dorzolamide hydrochloride and timolol maleate"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/42j5-27zg","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/42j5-27zg","description":"Chemical compound data from PubChem database. IUPAC Name: 2,2-ditert-butyl-7-methoxy-8-methyl-1,3,2-benzodioxasilin-4-one. Molecular Formula: C17H26O4Si. Molecular Weight: 322.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528208: Benzoic acid, 2-hydroxy-3-methyl-4-methoxy, DTBS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528208","description":"Access the complete Compound 528208: Benzoic acid, 2-hydroxy-3-methyl-4-methoxy, DTBS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.oregon.gov/d/288b-2feb","issued":"2018-09-13","@type":"dcat:Dataset","modified":"2018-10-25","keyword":["ach","2017 hai report"],"contactPoint":{"@type":"vcard:Contact","fn":"Roza Tammer","hasEmail":"mailto:no-reply@data.oregon.gov"},"publisher":{"@type":"org:Organization","name":"State of Oregon"},"identifier":"https://data.oregon.gov/api/views/288b-2feb","description":"Oregon hospitals report facility-wide MRSA BSIs as part of Oregon’s mandatory healthcare-associated infections reporting program. For information regarding standardized infection ratio baselines, please see https://www.cdc.gov/nhsn/2015rebaseline/index.html","title":"2017 Methicillin-Resistant Staphylococcus aureus (MRSA) Bloodstream Infection (BSI) Laboratory-Identified (LabID) Events Table – Acute Care Hospitals","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/288b-2feb/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/288b-2feb/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/288b-2feb/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/288b-2feb/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/288b-2feb/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/288b-2feb/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/dataset/neuroimaging-informatics-tools-and-resources-clearinghouse-nitrc","bureauCode":["009:00"],"issued":"2013-07-09","temporal":"2007-01-01T00:00:00-05:00/2007-01-10T00:00:00-05:00","@type":"dcat:Dataset","modified":"2023-07-25","keyword":["biomedical research","neuroimaging"],"contactPoint":{"@type":"vcard:Contact","fn":"NITRC Info","hasEmail":"mailto:nitrcinfo@nitrc.org"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health (NIH), Department of Health & Human Services"},"identifier":"ec022df2-4230-4a24-9416-69efa6fd476a","description":"The Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC) facilitates finding and comparing neuroimaging resources for functional and structural neuroimaging analyses—including popular tools as well as those that once might have been hidden in another researcher's laboratory or some obscure corner of cyberspace. NITRC collects and points to standardized information about tools, making the task of finding and comparing them easier than before. The site can help researchers find the right functional or structural neuroimaging tool or resource for their research. NITRC has recently added services such as cloud-based computing and data storage, and is broadening the range of scientific domains from MR to PET, SPECT, CT, MEG/EEG and optical imaging. Additional domains of interest are digital atlasing, and computational neuroscience, including large-scale and multi-scale modeling. The NITRC team searches out relevant research tools and resources to house on the site. Researchers can compare tools on NITRC and developers can seek and receive help from the community to make their tools more usable and accessible.
","title":"Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC)","programCode":["009:048"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://www.nitrc.org/","mediaType":"text/html","title":"API "}],"describedBy":"http://www.nitrc.org/","dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/"},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/42va-fzik","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","references","pubchem","substance","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/42va-fzik","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864850: MLS000084159","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864850","description":"Access the complete Substance 864850: MLS000084159 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/42vx-it5v","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["metadata","assessment"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/42vx-it5v","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"New York As-Is Assessment","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14181","description":"Access the complete New York As-Is Assessment on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/42wa-ydzn","bureauCode":["009:38"],"issued":"2017-10-24","@type":"dcat:Dataset","modified":"2019-02-18","keyword":["qhp"],"contactPoint":{"@type":"vcard:Contact","fn":"CMS-WSD-Data-Team","hasEmail":"mailto:no-reply@data.healthcare.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"gtdq-nxgh","description":"Plan year 2018 SHOP Dental Plans","title":"QHP Landscape PY2018 Dental SHOP","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/qhp-py2018-dent-shop-land-10-18-2017.gtdq-nxgh.csv","mediaType":"text/csv","title":"CSV"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/42yc-na34","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","patent","pubchem","research","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/42yc-na34","description":"The invention relates to a method for straightening a metal strip (1) which is guided in the direction of transportation (R) through a straightening machine (2) and is straightened. In the straightening device (2), the metal strip (1) is impinged upon by a straightening force (F) which is applied by a plurality of straightening rollers (3) in the direction (N) which is perpendicular to the surface of the metal strip (1). According to the invention, prior to the metal strip (1) entering into the straightening machine (2), the thickness (d) of the metal strip (1) is determined and the position (a) of the straightening rollers (3) in the direction (N) which is perpendicular to the surface of the metal strip (1) is taken into account according to the determined thickness (d).","title":"Patent AT-E401144-T1: [Translated] METHOD FOR STRAIGHTENING A METAL STRIP AND STRAIGHTENING MACHINE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401144-T1","description":"Access the complete Patent AT-E401144-T1: [Translated] METHOD FOR STRAIGHTENING A METAL STRIP AND STRAIGHTENING MACHINE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/qc5v-ahss","issued":"2019-03-28","@type":"dcat:Dataset","modified":"2019-03-28","keyword":["drinking water","school","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/qc5v-ahss","description":"Lead in Drinking Water in Schools Test Results – McDermoth Elementary","title":"McDermoth Elementary update","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/qc5v-ahss/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4323-jn26","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["policy","adoption","data","fiscal","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4323-jn26","description":"This report provides state-specific data from fiscal year 2013 about the number of children who are adopted through a public agency and who receive an adoption subsidy.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Receiving Adoption Subsidy: 10/1/2012 - 9/30/2013","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/receiving-adoption-subsidy-10/1/2012-9/30/2013","description":"Access the complete Receiving Adoption Subsidy: 10/1/2012 - 9/30/2013 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4333-nz9r","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","pubchem","chemistry","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4333-nz9r","description":"Chemical compound data from PubChem database. IUPAC Name: [5-chloro-2-(cyclopropylmethylamino)phenyl]-phenylmethanone. Molecular Formula: C17H16ClNO. Molecular Weight: 285.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526490: {5-Chloro-2-[(cyclopropylmethyl)amino]phenyl}(phenyl)methanone","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526490","description":"Access the complete Compound 526490: {5-Chloro-2-[(cyclopropylmethyl)amino]phenyl}(phenyl)methanone on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/mvaf-qxac","bureauCode":["009:00"],"issued":"2020-01-21","@type":"dcat:Dataset","modified":"2021-01-07","keyword":["nedss","wonder","salmonellosis (excluding salmonella typhi infection and salmonella paratyphi infection)","salmonella typhi infection","salmonella paratyphi infection","nndss","netss","2020"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/mvaf-qxac","description":"NNDSS - TABLE 1EE. Salmonella Paratyphi infection to Salmonellosis (excluding Salmonella Typhi infection and Salmonella Paratyphi infection) – 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.\n\nNote: \nThis table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. \n\nFootnotes:\nU: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.\n-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.\nN: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.\nNN: Not nationally notifiable — This condition was not designated as being nationally notifiable.\nNP: Nationally notifiable but not published.\nNC: Not calculated — There is insufficient data available to support the calculation of this statistic.\nCum: Cumulative year-to-date counts.\nMax: Maximum — Maximum case count during the previous 52 weeks.\n* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.\n†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). \n§ In previous years, cases were reported as Salmonellosis. Beginning in January 2019, cases began to be reported as Salmonella Paratyphi infection.\n¶ In previous years, cases were reported as typhoid fever. Beginning in January 2019, cases began to be reported as Salmonella Typhi infection.\n** In previous years, cases were reported as Salmonellosis (excluding paratyphoid fever and typhoid fever). Beginning in January 2019, cases began to be reported as Salmonellosis (excluding Salmonella Typhi infection and Salmonella Paratyphi infection).","title":"NNDSS - TABLE 1EE. Salmonella Paratyphi infection to Salmonellosis (excluding Salmonella Typhi infection and Salmonella Paratyphi infection)","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mvaf-qxac/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mvaf-qxac/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mvaf-qxac/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mvaf-qxac/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mvaf-qxac/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mvaf-qxac/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/433y-5pmk","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2025-11-05","references":["https://www.medicaid.gov/dq-atlas/welcome","https://www.mathematica.org/"],"keyword":["utility","dqatlas","dqatlas_implauto"],"contactPoint":{"@type":"vcard:Contact","fn":"DataConnect Support Team","hasEmail":"mailto:dataconnectsupport@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"58e99d2d-ea9f-5a30-a509-43c0c350072f","description":"This is a dataset created for use by the DQ Atlas website, and is not intended for use outside that application. For more information on the DQ Atlas and the information contained in this dataset see https://www.medicaid.gov/dq-atlas/welcome","title":"implAuto_map","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/dq-atlas/20251028_ETL_DEV/map.csv","description":"{\"dataset\": \"map\", \"stage\": \"implAuto\", \"update_id\": \"20251028_ETL_DEV\"}","@type":"dcat:Distribution","title":"map csv file"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/PT1S","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/436m-ww2v","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","science","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/436m-ww2v","description":"Chemical compound data from PubChem database. IUPAC Name: 3-[(2-methylfuran-3-yl)disulfanyl]butan-2-one. Molecular Formula: C9H12O2S2. Molecular Weight: 216.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529743: 1-Ethylundecyl butyrate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529743","description":"Access the complete Compound 529743: 1-Ethylundecyl butyrate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/437b-hbs4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/437b-hbs4","description":"Chemical compound data from PubChem database. IUPAC Name: 3-ethyl-7-methylnonane. Molecular Formula: C12H26. Molecular Weight: 170.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526426: 3-Methyl-7-ethyl-nonane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526426","description":"Access the complete Compound 526426: 3-Methyl-7-ethyl-nonane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/437i-4iyy","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","innovation","patent","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/437i-4iyy","description":"An atomization system for fuels, particularly for charging a chemical reformer for obtaining hydrogen, includes a fuel injector, an atomization tube, an air inlet and at least one metering aperture. The atomization tube features at least a first section and a second section having different outer diameters or wall thicknesses.","title":"Patent AT-E400774-T1: [Translated] FIRST EXERCISE ARRANGEMENT","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400774-T1","description":"Access the complete Patent AT-E400774-T1: [Translated] FIRST EXERCISE ARRANGEMENT on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43bd-i4s9","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","patent","pubchem","research","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/43bd-i4s9","description":"Azacyclic ethynyl derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine receptors and transporters. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous system (CNS), the peripheral nervous system (PNS), diseases or disorders related to smooth muscle contraction, endocrine diseases or disorders, diseases or disorders related to neuro-degeneration, diseases or disorders related to inflammation, pain, and withdrawal symptoms caused by the termination of abuse of chemical substances.","title":"Patent AT-E401334-T1: [Translated] NEW AZACYCLIC ETHYNYL DERIVATIVES","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401334-T1","description":"Access the complete Patent AT-E401334-T1: [Translated] NEW AZACYCLIC ETHYNYL DERIVATIVES on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43bu-hxat","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2023-07-21","keyword":["medicaid"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"7459d190-e592-42e0-9b66-6f4e7e05eb9b","description":"Dataset.","title":"2021 Managed Care Programs By State","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/2021-Table9_07212023_2.csv","mediaType":"text/csv"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43dq-a2g4","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["guidance","regulation","foster","instruction","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/43dq-a2g4","description":"This Program Instruction (PI) provides information to State and Indian Tribal responsibilities for the provision of the foster care protections under section 422(b)(10) of title IV-B.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-98-05)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-98-05","description":"Access the complete PI-98-05 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43i9-r8nr","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["regional-estimates","samhsa","nsduh-data","mental-health","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/43i9-r8nr","description":"This report presents the Northeast\\'s (e.g., combines Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont) estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for the Northeast for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"Northeast (NE)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/northeast-ne","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43in-fdhj","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","pubchem","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/43in-fdhj","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 2-chlorobut-2-enoate. Molecular Formula: C5H7ClO2. Molecular Weight: 134.56. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529728: Methyl 2-chlorobut-2-enoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529728","description":"Access the complete Compound 529728: Methyl 2-chlorobut-2-enoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43jn-cwvm","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","substance","references","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/43jn-cwvm","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865670: MLS000083610","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865670","description":"Access the complete Substance 865670: MLS000083610 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cityofchicago.org/d/q6gh-3miy","issued":"2018-07-16","@type":"dcat:Dataset","modified":"2019-04-23","contactPoint":{"@type":"vcard:Contact","fn":"Diego A. Perez Mesa","hasEmail":"mailto:no-reply@data.cityofchicago.org"},"publisher":{"@type":"org:Organization","name":"City of Chicago"},"identifier":"https://data.cityofchicago.org/api/views/q6gh-3miy","description":"","title":"Meningitis Vaccine Locations","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/q6gh-3miy/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/q6gh-3miy/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/q6gh-3miy/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/q6gh-3miy/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/q6gh-3miy/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/q6gh-3miy/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43kc-3u9r","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["foster","metadata","mental"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/43kc-3u9r","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"John H. Chafee Foster Care Program for Successful Transition to Adulthood Supplemental Terms and Conditions","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/16087","description":"Access the complete John H. Chafee Foster Care Program for Successful Transition to Adulthood Supplemental Terms and Conditions on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43kx-jzsy","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","anti-inflammatory","antinociception","paw-edema","tabebuia-avellanedae"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/43kx-jzsy","description":"Background\n Tabebuia avellanedae is a tree from the Bignoniaceae family. Commonly know as \"pau d'arco\" in Brazil, its inner bark is used as analgesic, anti-inflammatory, antineoplasic and diuretic at the Brazilian northeast. A validation of the plant usage has not been previously performed.\n \n \n Results\n Antinociceptive and antiedematogenic effects of Tabebuia avellanedae Lor. ex Griseb. inner bark were measured by nociceptive experimental models in mice. A rat paw edema test induced by carrageenan (1%) was also performed in rats to access the plant's antiedematogenic effect. The inner bark aqueous extract, administered via oral in three different concentration, namely 100, 200 and 400 mg/Kg, reduced the nociception produced by acetic acid (0.6% in water, i.p.) by 49.9%, 63.7% and 43.8%, respectively. The aqueous extract (200 and 400 mg/Kg, p.o.) reduced formalin (1%) effects only at the second phase of the experiment by 49.3% and 53.7%, respectively. Naloxone (5 mg/Kg, i.p.) was not able to revert the extract effect, however caffeine (10 mg/Kg, i.p.) reverted its effect by 19.8% at the second phase of the formalin test. The aqueous extract (200 mg/Kg, p.o.) inhibited edema by 12.9% when we used the rat paw edema model. The acute toxicity was low in mice.\n \n \n Conclusion\n The T. avellanedae inner bark aqueous extract presented antinociceptive and antiedematogenic activities at the used models, with a possible antinociceptive effect associated to the adenosine system.","title":"Antinociceptive and antiedematogenic properties and acute toxicity of","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC56902/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43mj-axzc","bureauCode":["009:38"],"issued":"2026-06-30","temporal":"2017-01-01/2023-12-31","@type":"dcat:Dataset","modified":"2026-06-30","keyword":["all years"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Payments","hasEmail":"mailto:openpayments@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"openpaymentsdata.cms.gov"},"identifier":"ea5eea39-0fc2-4200-84e5-46ed3b302567","description":"This dataset is pre-filtered based on the most frequent searches of Open Payments data.","title":"Payments grouped by reporting entities, covered recipient, and nature of payments for all years","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.cms.gov/openpayments/SMRY_RPTS_P06302026_06032026/PBLCTN_SMRY_BY_AMGPO_BY_CR_BY_NTR_OF_PYMT_PGYRall_P06302026_06032026.csv","mediaType":"text/csv","title":"Payments grouped by reporting entities, covered recipient, and nature of payments for all years"}],"dataQuality":true,"license":"https://www.usa.gov/government-works","theme":["Summary"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["health-care","medications","pharmaceuticals","drug","prescription-drugs"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA077653","description":"Venlafaxine Hydrochloride is a generic prescription antidepressant that helps balance brain chemicals like serotonin and norepinephrine to treat depression and anxiety. It comes as extended-release oral capsules in 37.5 mg, 75 mg, and 150 mg strengths, manufactured by Zydus Pharmaceuticals USA Inc. (ANDA090174). This information was generated using AI and is provided for informational and research purposes only.","title":"Venlafaxine hydrochloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077653","description":"\n Access the FDA dataset for Venlafaxine hydrochloride — ANDA 077653 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Venlafaxine hydrochloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43q9-gfpe","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","innovation","chemistry","patent","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/43q9-gfpe","description":"The system for transporting excavators (12) comprises sets of wheels (20, 22) which are locked on to either end of it, forming a unit which can be towed by a lorry. The excavator can be replaced by a platform to produce a flat- or low bed trailer.","title":"Patent AT-E399679-T1: [Translated] DEVICE FOR TRANSPORTING CONSTRUCTION MACHINERY, PREFERABLY EXCAVATORS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399679-T1","description":"Access the complete Patent AT-E399679-T1: [Translated] DEVICE FOR TRANSPORTING CONSTRUCTION MACHINERY, PREFERABLY EXCAVATORS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43rr-3674","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["tumor-necrosis-factor","nih","domoic-acid","microglia-activation","neurotoxicity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/43rr-3674","description":"Background\n The excitatory amino acid domoic acid, a glutamate and kainic acid analog, is the causative agent of amnesic shellfish poisoning in humans. No studies to our knowledge have investigated the potential contribution to short-term neurotoxicity of the brain microglia, a cell type that constitutes circa 10% of the total glial population in the brain. We tested the hypothesis that a short-term in vitro exposure to domoic acid, might lead to the activation of rat neonatal microglia and the concomitant release of the putative neurotoxic mediators tumor necrosis factor-α (TNF-α), matrix metalloproteinases-2 and-9 (MMP-2 and -9) and superoxide anion (O2-).\n \n \n Results\n In vitro, domoic acid [10 μM-1 mM] was significantly neurotoxic to primary cerebellar granule neurons. Although neonatal rat microglia expressed ionotropic glutamate GluR4 receptors, exposure during 6 hours to domoic acid [10 μM-1 mM] had no significant effect on viability. By four hours, LPS (10 ng/mL) stimulated an increase in TNF-α mRNA and a 2,233 % increase in TNF-α protein In contrast, domoic acid (1 mM) induced a slight rise in TNF-α expression and a 53 % increase (p < 0.01) of immunoreactive TNF-α protein. Furthermore, though less potent than LPS, a 4-hour treatment with domoic acid (1 mM) yielded a 757% (p < 0.01) increase in MMP-9 release, but had no effect on MMP-2. Finally, while PMA (phorbol 12-myristate 13-acetate) stimulated O2- generation was elevated in 6 hour LPS-primed microglia, a similar pretreatment with domoic acid (1 mM) did not prime O2- release.\n \n \n Conclusions\n To our knowledge this is the first experimental evidence that domoic acid, at in vitro concentrations that are toxic to neuronal cells, can trigger a release of statistically significant amounts of TNF-α and MMP-9 by brain microglia. These observations are of considerable pathophysiological significance because domoic acid activates rat microglia several days after in vivo administration.","title":"Effect of a short-term in vitro exposure to the marine toxin domoic acid on viability, tumor necrosis factor-alpha, matrix metalloproteinase-9 and superoxide anion release by rat neonatal microglia","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59507/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://datadiscovery.nlm.nih.gov/d/xtvu-8j6w","bureauCode":["009:25"],"issued":"2023-03-21","@type":"dcat:Dataset","modified":"2025-06-18","keyword":["pubmed"],"contactPoint":{"@type":"vcard:Contact","fn":"National Library of Medicine","hasEmail":"mailto:custserv@nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Library of Medicine"},"identifier":"https://datadiscovery.nlm.nih.gov/api/views/xtvu-8j6w","description":"*A file containing all Min/Max Baseline Reports for 2005-2023 in their original format is available in the Attachments section below. A second file includes a separate set of reports, made available from 2002-2017, that did not include OLDMEDLINE records.* \n\nMEDLINE/PubMed annual statistical reports are based upon the data elements in the baseline versions of MEDLINE®/PubMed are available. For each year covered the reports include: total citations containing each element; total occurrences of each element; minimum/average/maximum occurrences of each element in a record; minimum/average/maximum length of a single element occurrence; average record size; and other statistical data describing the content and size of the elements.","title":"MEDLINE/PubMed Baseline Statistics: Min/Max Report","programCode":["009:041"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://datadiscovery.nlm.nih.gov/api/v3/views/xtvu-8j6w/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://datadiscovery.nlm.nih.gov/api/v3/views/xtvu-8j6w/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://datadiscovery.nlm.nih.gov/api/v3/views/xtvu-8j6w/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Information Management"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43w9-2f4d","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","proteinase-3","wegeners-granulomatosis","autoantigen-expression","lung-vasculitis"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/43w9-2f4d","description":"Proteinase-3 (PR-3) is a neutral serine proteinase present in azurophil granules of human polymorphonuclear leukocytes and serves as the major target antigen of antineutrophil cytoplasmic antibodies with a cytoplasmic staining pattern (c-ANCA) in Wegener's granulomatosis (WG). The WG disease appears as severe vasculitis in different organs (e.g. kidney, nose and lung). Little is known about the expression and distribution of PR-3 in the lung. We found that PR-3 is expressed in normal lung tissue and is upregulated in lung tissue of patients with WG. Interestingly, the parenchymal cells (pneumocytes type I and II) and macrophages, and not the neutrophils, express PR-3 most strongly and may contribute to lung damage in patients with WG via direct interaction with antineutrophil cytoplasmic antobodies (ANCA). These findings suggest that the PR-3 expression in parenchymal cells of lung tissue could be at least one missing link in the etiopathogenesis of pulmonary pathology in ANCA-associated disease.","title":"Proteinase-3 as the major autoantigen of c-ANCA is strongly expressed in lung tissue of patients with Wegener's granulomatosis","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC111026/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["public-health","drug-safety","pharmaceuticals","drug","drug-manufacturers"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA208215","description":"Emtricitabine is a generic prescription medication used to treat HIV infection. It comes as 200 mg oral capsules, manufactured by Cipla USA Inc. As a nucleoside reverse transcriptase inhibitor, it helps prevent HIV from multiplying in the body. This information was generated using AI and is provided for informational and research purposes only.","title":"Emtricitabine","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208215","description":"\n Access the FDA dataset for Emtricitabine — ANDA 208215 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Emtricitabine"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/43y8-yb8g","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","references","substance","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/43y8-yb8g","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865780: MLS000042185","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865780","description":"Access the complete Substance 865780: MLS000042185 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/442e-ake8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","substance","references","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/442e-ake8","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864262: MLS000082866","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864262","description":"Access the complete Substance 864262: MLS000082866 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/442v-dz6n","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","research","chemistry","science","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/442v-dz6n","description":"Chemical compound data from PubChem database. IUPAC Name: 4-methylpentacosane. Molecular Formula: C26H54. Molecular Weight: 366.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526120: 4-Methylpentacosane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526120","description":"Access the complete Compound 526120: 4-Methylpentacosane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4435-hvkm","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4435-hvkm","description":"Chemical compound data from PubChem database. IUPAC Name: 4,5-dimethyl-2-propan-2-yl-2,5-dihydro-1,3-thiazole. Molecular Formula: C8H15NS. Molecular Weight: 157.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526689: 2-Isopropyl-4,5-dimethyl-2,5-dihydrothiazole","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526689","description":"Access the complete Compound 526689: 2-Isopropyl-4,5-dimethyl-2,5-dihydrothiazole on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/443h-hbp6","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","references","pubchem","substance","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/443h-hbp6","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864196: MLS000083016","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864196","description":"Access the complete Substance 864196: MLS000083016 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4459-5zbr","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","chemistry","pubchem","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4459-5zbr","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864274: MLS000082828","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864274","description":"Access the complete Substance 864274: MLS000082828 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/449n-q5uw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","pubchem","chemistry","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/449n-q5uw","description":"Chemical compound data from PubChem database. IUPAC Name: 2-phenylethyl 3,5-dinitrobenzoate. Molecular Formula: C15H12N2O6. Molecular Weight: 316.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528020: Benzoic acid, 3,5-dinitro, 2-phenylethyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528020","description":"Access the complete Compound 528020: Benzoic acid, 3,5-dinitro, 2-phenylethyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/44ai-iqi4","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["social","child","childr","acf","service"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/44ai-iqi4","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"dear_colleague_letter_ssbg_2014_2015_1st_quarter","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/12892","description":"Access the complete dear_colleague_letter_ssbg_2014_2015_1st_quarter.pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/44b5-kb9m","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","substance","references","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/44b5-kb9m","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864370: MLS000082988","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864370","description":"Access the complete Substance 864370: MLS000082988 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/kck7-yb2v","issued":"2017-05-08","@type":"dcat:Dataset","modified":"2019-04-23","keyword":["child health","department of health","dtap","hepb","immunization","kindergarten","mmr","polio","vaccination","varicella"],"contactPoint":{"@type":"vcard:Contact","fn":"Eavey, Joanna (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/kck7-yb2v","description":"Kindergarten immunization coverage for school year 2016-2017 by school","title":"Kindergarten Immunization Data, 2016-17","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/api/v3/views/kck7-yb2v/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/api/v3/views/kck7-yb2v/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/api/v3/views/kck7-yb2v/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/api/v3/views/kck7-yb2v/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/api/v3/views/kck7-yb2v/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/api/v3/views/kck7-yb2v/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/44bq-jnn3","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","compound","chemistry","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/44bq-jnn3","description":"Chemical compound data from PubChem database. IUPAC Name: 2,2,4a,9-tetramethyl-1,3,4,5,6,14b-hexahydropicene. Molecular Formula: C26H30. Molecular Weight: 342.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526596: 2,2,4a,9-Tetramethyl-1,2,3,4,4a,5,6,14b-octahydro-picene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526596","description":"Access the complete Compound 526596: 2,2,4a,9-Tetramethyl-1,2,3,4,4a,5,6,14b-octahydro-picene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/44ch-ejpy","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-data","samhsa","substance-use","state-prevalence","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/44ch-ejpy","description":"The 116 national maps presented here show the 2016-2017 National Survey on Drug Use and Health (NSDUH) estimates for 30 substance use and mental health outcomes, by age group, for 50 statesand the District of Columbia.","title":"2016-2017 NSDUH National Maps of Prevalence Estimates by State","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2016-2017-nsduh-national-maps-prevalence-estimates-state","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/jr58-6ysp","bureauCode":["009:20"],"issued":"2024-09-30","@type":"dcat:Dataset","modified":"2026-07-06","keyword":["sars-cov-2","nowcasting","covid-19","variant surveillance","variant proportion","surveillance"],"contactPoint":{"@type":"vcard:Contact","fn":"Clinton Paden","hasEmail":"mailto:respvirus@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/jr58-6ysp","description":"To identify and track SARS-CoV-2 variants, CDC uses genomic surveillance. CDC's national genomic surveillance system collects SARS-CoV-2 specimens for sequencing through the National SARS-CoV-2 Strain Surveillance (NS3) program, as well as SARS-CoV-2 sequences generated by commercial or academic laboratories contracted by CDC and state or local public health laboratories. Viral genomic sequences are analyzed and classified as a particular variant. The proportions of variants in a population are estimated nationally, by HHS region, and by jurisdiction. The thousands of sequences analyzed every week through CDC’s national genomic sequencing and bioinformatics efforts fuel this comprehensive and population-based U.S. surveillance system established to identify and monitor the spread of variants.\n\nThese data appear on the CDC COVID Data Tracker at the following URL: https://covid.cdc.gov/covid-data-tracker/#variant-proportions\n\n\nFor more information on how these data are generated and used to provide estimates of variant proportions, please see the following references:\n\nECM Community Support Services tables for a Quarterly Implementation Report. Including the County and Plan Details for both ECM and Community Support.
This Medi-Cal Enhanced Care Management (ECM) and Community Supports Calendar Year Quarterly Implementation Report provides a comprehensive overview of ECM and Community Supports implementation in the programs' first year. It includes data at the state, county, and plan levels on total members served, utilization, and provider networks.
ECM is a statewide MCP benefit that provides person-centered, community-based care management to the highest need members. The Department of Health Care Services (DHCS) and its MCP partners began implementing ECM in phases by Populations of Focus (POFs), with the first three POFs launching statewide in CY 2022.
Community Supports are services that address members’ health-related social needs and help them avoid higher, costlier levels of care. Although it is optional for MCPs to offer these services, every Medi-Cal MCP offered Community Supports in 2022, and at least two Community Supports services were offered and available in every county by the end of the year.
","title":"Chart 3.9.2 Total Members Who Received Community Supports by MCP and County in Each Quarter of the Reporting Period","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/datasets/CADHCS::chart-3-9-2-total-members-who-received-community-supports-by-mcp-and-county-in-each-quarter-of-the-reporting-period","mediaType":"text/html","title":"ArcGIS Hub Dataset"},{"@type":"dcat:Distribution","downloadURL":"https://services7.arcgis.com/7MUwsS9z05YumJRZ/arcgis/rest/services/ECM_Community_Support_Data_Tables_for_Quarterly_Implementation_report/FeatureServer/47","mediaType":"application/octet-stream","title":"ArcGIS GeoService"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/csv?layers=47","mediaType":"text/csv","title":"CSV"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/shapefile?layers=47","mediaType":"application/zip","title":"Shapefile"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/geojson?layers=47","mediaType":"application/geo+json","title":"GeoJSON"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/kml?layers=47","mediaType":"application/vnd.google-earth.kml+xml","title":"KML"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/ccc1e6df-308a-4242-9783-3a5068d3b0e8/resource/1e2e9457-0c05-4743-8df8-19d44ddf0572/download/chart-3-9-2-total-members-who-received-community-supports-by-mcp-and-county-in-each-quarter-of-g.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4c8f-tkvf","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","research","science","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4c8f-tkvf","description":"Chemical compound data from PubChem database. IUPAC Name: 10-chlorooctadecyl acetate. Molecular Formula: C20H39ClO2. Molecular Weight: 347.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527933: 10-Chlorooctadecyl acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527933","description":"Access the complete Compound 527933: 10-Chlorooctadecyl acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4c94-eed7","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["fiscal","data","child","adoption","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4c94-eed7","description":"This report provides state-specific data from fiscal year 2001 about the time between the termination of parental rights and the adoption finalization for public agency adoptions.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Time Between TPR and Finalization 10/1/2000 - 9/30/2001","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/time-between-tpr-and-finalization-10/1/2000-9/30/2001","description":"Access the complete Time Between TPR and Finalization 10/1/2000 - 9/30/2001 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4c97-ehmh","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4c97-ehmh","description":"Chemical compound data from PubChem database. IUPAC Name: 2-(2-methylbutan-2-yl)-6-nitrophenol. Molecular Formula: C11H15NO3. Molecular Weight: 209.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528946: 2-(3-Hydroxy-8-azabicyclo[3.2.1]oct-8-yl)-1,1-diphenylethyl acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528946","description":"Access the complete Compound 528946: 2-(3-Hydroxy-8-azabicyclo[3.2.1]oct-8-yl)-1,1-diphenylethyl acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4c9q-4txk","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","tumor-genes","cancer-research","gene-co-expression","interleukin-8"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4c9q-4txk","description":"Background\n The EST database provides a rich resource for gene discovery and in silico expression analysis. We report a novel computational approach to identify co-expressed genes using EST database, and its application to IL-8.\n \n \n Results\n IL-8 is represented in 53 dbEST cDNA libraries. We calculated the frequency of occurrence of all the genes represented in these cDNA libraries, and ranked the candidates based on a Z-score. Additional analysis suggests that most IL-8 related genes are differentially expressed between non-tumor and tumor tissues. To focus on IL-8's function in tumor tissues, we further analyzed and ranked the genes in 16 IL-8 related tumor libraries.\n \n \n Conclusions\n This method generated a reference database for genes co-expressed with IL-8 and could facilitate further characterization of functional association among genes.","title":"A reference database for tumor-related genes co-expressed with interleukin-8 using genome-scale","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC131052/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ce4-eb95","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","compound","chemistry","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4ce4-eb95","description":"Chemical compound data from PubChem database. IUPAC Name: 7-propyltetradecane. Molecular Formula: C17H36. Molecular Weight: 240.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530324: Tetradecane, 7-propyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530324","description":"Access the complete Compound 530324: Tetradecane, 7-propyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.dhcs.ca.gov/services/Pages/MngdCarePerformDashboard.aspx","issued":"2020-05-19","temporal":"2017-2023","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["dhcs","encounter","enrollment","hedis","demographics","grievances","state fair hearing","utilization","provider ratio"],"contactPoint":{"@type":"vcard:Contact","fn":"Managed Care Quality and Monitoring Division / Program Analysis Unit","hasEmail":"mailto:opendata@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"fc07c2ae-c89c-409e-8aad-fb06b8bf884a","description":"This report contains data regarding enrollment demographics, utilization of services, grievances, state fair hearings, provider ratios, encounter completeness, Healthcare Effectiveness Data and Information Set (HEDIS) rates, and medical audit findings.","title":"Managed Care Performance Monitoring Dashboard Report","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/fc07c2ae-c89c-409e-8aad-fb06b8bf884a/resource/94b9d250-3872-44c4-83eb-a0f566c50910/download/managed-care-performance-monitoring-dashboard-report-940tca_z.zip","mediaType":"application/zip","title":"All resource data"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/fc07c2ae-c89c-409e-8aad-fb06b8bf884a/resource/d2ccf65f-0cf7-41d2-916e-2aded8d86434/download/mcpm-dashboard-april-2024-release.pdf","description":"This report contains data regarding enrollment demographics, utilization of services, grievances, state fair hearings, provider ratios, encounter completeness, Healthcare Effectiveness Data and Information Set (HEDIS) rates, and medical audit findings.","@type":"dcat:Distribution","title":"Managed Care Performance Monitoring Dashboard Report"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/fc07c2ae-c89c-409e-8aad-fb06b8bf884a/resource/bda70e1d-bf79-4618-b1cb-939bd68746dd/download/hedis_aqfs-4.25.24.csv","description":"This file contains data regarding Healthcare Effectiveness Data and Information Set (HEDIS®) Aggregated Quality Factor Score (AQFS) for each managed care health plan by county of operation.","@type":"dcat:Distribution","title":"HEDIS"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/fc07c2ae-c89c-409e-8aad-fb06b8bf884a/resource/d827dcb6-fd96-486d-b047-020c63018725/download/population-4.25.24.csv","description":"This file contains data sorted by population for enrollment demographics, utilization of services, and state fair hearings.","@type":"dcat:Distribution","title":"Population"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/fc07c2ae-c89c-409e-8aad-fb06b8bf884a/resource/2420e99b-3a7b-4cc9-aa73-7d91fdd25a88/download/provider_ratios-4.25.24.csv","description":"This file contains data regarding the provider ratios of Primary Care Physicians (PCPs) per 2,000 members and physicians per 1,200 members.","@type":"dcat:Distribution","title":"Provider Ratios"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/fc07c2ae-c89c-409e-8aad-fb06b8bf884a/resource/8d33f676-499e-4365-ae6b-bd8dc6f79344/download/sex-4.25.24.csv","description":"This file contains data sorted by sex of members for enrollment demographics, utilization of services, and state fair hearings.","@type":"dcat:Distribution","title":"Sex"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/fc07c2ae-c89c-409e-8aad-fb06b8bf884a/resource/21d41c79-9c93-44bb-a07a-a92ddcba175e/download/age-4.25.24.csv","description":"This file contains data sorted by age of members for enrollment demographics, utilization of services, and state fair hearings.","@type":"dcat:Distribution","title":"Age"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/fc07c2ae-c89c-409e-8aad-fb06b8bf884a/resource/bd524699-cfd7-4996-a34d-b7b60e8dfd5d/download/encounter-completeness-4.25.24.csv","description":"This file contains data regarding encounter completeness for each contracted managed care health plan by category of service.","@type":"dcat:Distribution","title":"Encounter Completeness"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/fc07c2ae-c89c-409e-8aad-fb06b8bf884a/resource/74b1fa09-32da-4b6d-b4f8-bc1414e4b657/download/ethnicity-4.25.24.csv","description":"This file contains data sorted by ethnicity of members for enrollment demographics, utilization of services, and state fair hearings.","@type":"dcat:Distribution","title":"Ethnicity"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/fc07c2ae-c89c-409e-8aad-fb06b8bf884a/resource/7bc30ad9-7745-401f-b134-1d6d873f97a4/download/grievances_demo-4.25.24.csv","description":"This file contains data regarding grievances per 1,000 members, sorted by demographics, including sex, age, ethnicity and population.","@type":"dcat:Distribution","title":"Grievance Demographics"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/fc07c2ae-c89c-409e-8aad-fb06b8bf884a/resource/11f020d6-5e4a-4a37-a07f-a0bffd3e6de6/download/grievance-type-4.25.24.csv","description":"This file contains data regarding grievances, sorted by category and types.","@type":"dcat:Distribution","title":"Grievance Type"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P3M","theme":["Demographics","Healthcare"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4chw-irpu","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","chemistry","pubchem","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4chw-irpu","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865914: MLS000084000","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865914","description":"Access the complete Substance 865914: MLS000084000 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4cj5-a9er","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health","new-mexico","behavioral-health","samhsa","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4cj5-a9er","description":"This is a behavioral health report for the state of New Mexico. It uses the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment for the years 2008 to 2012.","title":"Behavioral Health Barometer: New Mexico, 2013","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-new-mexico-2013","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.ncbi.nlm.nih.gov/pathogens/","bureauCode":["009:25"],"issued":"2021-08-27","@type":"dcat:Dataset","modified":"2025-06-18","keyword":["public health","dataset"],"contactPoint":{"@type":"vcard:Contact","fn":"National Library of Medicine","hasEmail":"mailto:custserv@nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Library of Medicine"},"identifier":"https://datadiscovery.nlm.nih.gov/api/views/4gse-hiry","description":"NCBI Pathogen Detection integrates bacterial pathogen genomic sequences originating in food, environmental sources, and patients. It quickly clusters and identifies related sequences to uncover potential food contamination sources, helping public health scientists investigate foodborne disease outbreaks.","title":"Pathogen Detection (BETA)","programCode":["009:041"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://www.ncbi.nlm.nih.gov/pathogens/isolates/","mediaType":"text/html","title":"Isolates Browser"},{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pathogens/microbigge/","description":"This interface contains a subset of the isolates from the Isolate Browser that have genomic sequence data available in GenBank and have genotypes identified by AMRFinderPlus at the time they were analyzed.","@type":"dcat:Distribution","title":"Pathogen Detection Microbial Browser for Identification of Genetic and Genomic Elements (MicroBIGG-E)"},{"@type":"dcat:Distribution","downloadURL":"https://www.ncbi.nlm.nih.gov/pathogens/refgene/","mediaType":"text/html","title":"Reference Gene Catalog"},{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pathogens/hmm/","description":"Reference set of hidden Markov models (HMMs) used by AMRFinderPlus to identify protein families in conjunction with Reference Gene Catalog","@type":"dcat:Distribution","title":"Reference HMM Catalog"},{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/biosample/?term=antibiogram%5bfilter%5d","description":"antibiogram[filter] applied to BioSample","@type":"dcat:Distribution","title":"Isolates with antibiotic resistant phenotypes"},{"@type":"dcat:Distribution","downloadURL":"https://ftp.ncbi.nlm.nih.gov/pathogen/Results/","mediaType":"text/html","title":"Download analysis results (FTP)"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Biomedical Research"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["public-health","medications","drug-manufacturers","drug-safety","health-care"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA212756","description":"Buprenorphine and Naloxone is a prescription film medication used to treat opioid dependence. It combines buprenorphine (a partial opioid agonist) and naloxone (an opioid antagonist) to help reduce withdrawal symptoms and cravings. Available in buccal or sublingual forms with strengths like 2mg/0.5mg, 4mg/1mg, 8mg/2mg, and 12mg/3mg buprenorphine/naloxone. It's a Schedule III controlled substance. This information was generated using AI and is provided for informational and research purposes only.","title":"Buprenorphine and naloxone","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212756","description":"\n Access the FDA dataset for Buprenorphine and naloxone — ANDA 212756 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Buprenorphine and naloxone"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4cqc-pe3b","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","references","pubchem","chemistry","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4cqc-pe3b","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865990: MLS000084601","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865990","description":"Access the complete Substance 865990: MLS000084601 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/dataset/hhs-enterprise-data-inventory","bureauCode":["009:00"],"issued":"2015-03-02","@type":"dcat:Dataset","modified":"2025-07-03","keyword":["catalog","other","enterprise data inventory","edi"],"contactPoint":{"@type":"vcard:Contact","fn":"Health Data @ HHS","hasEmail":"mailto:HealthData@HHS.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Department of Health and Human Services"},"identifier":"c5acee93-1748-4fcf-8fcb-5c35f0336526_2","description":"The Enterprise Data Inventory (EDI) is the comprehensive inventory listing of agency data resources including public, restricted public, and non-public datasets.
","title":"HHS Enterprise Data Inventory: 2015-11 HHS EDI JSON","programCode":["009:023"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://healthdata.gov/download/4cr4-e2tk/text/plain","mediaType":"text/plain"}],"license":"https://opendatacommons.org/licenses/odbl/1.0/","dataQuality":true},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4csy-p9rp","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["child","reporting","regulation","policy","data"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4csy-p9rp","description":"This notice from the Federal Register announces the final list of child welfare outcomes and measures and the data elements that will be used to compute each state's performance on each measure.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Final List of Child Welfare Outcomes and Measures - Notice (Volume 64, Number 161)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/law-regulation/final-list-child-welfare-outcomes-and-measures-notice-volume-64-number-161","description":"Access the complete Final List of Child Welfare Outcomes and Measures - Notice (Volume 64, Number 161) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4cxs-ppis","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["mental","policy","reporting","instruction","guidance"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4cxs-ppis","description":"This document provides guidelines for what should be included in the Developmental Cost Plan, which is typically due 30 days after the agency signs and accepts the waiver terms and conditions.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Developmental Cost Plan Guidelines","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/developmental-cost-plan-guidelines","description":"Access the complete Developmental Cost Plan Guidelines on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://open.fda.gov/drug/label/","bureauCode":["009:00"],"issued":"2021-02-13","temporal":"2009-06-01","@type":"dcat:Dataset","modified":"2023-07-26","keyword":["fda","drug labeling","cder","ddod use case","user request"],"contactPoint":{"@type":"vcard:Contact","fn":"Portnoy, David","hasEmail":"mailto:david.portnoy@hhs.gov"},"publisher":{"@type":"org:Organization","name":"healthdata.gov"},"identifier":"e5e30804-72da-4673-920a-b3489d4a8d3f","description":"SUMMARY
\nDDOD use case to request access historical label revisions of FDA-approved drugs.
\nWHAT IS A USE CASE?
\nA “Use Case” is a request that was made by the user community because there were no available datasets that met their particular needs. If this use case is similar to your needs, we ask that you add your own requirements to the specifications section.
\nThe concept of a use case falls within the Demand-Driven Open Data (DDOD) program and gives you a formalized way to identify what data you need. It’s for anyone in industry, research, media, nonprofits or other government agencies. Each request becomes a DDOD use case, so that it can be prioritized and worked on.
\nUse Cases also provide a wealth of insights about existing alternative datasets and tips for interpreting and manipulating data for specific purposes.
\nPURPOSE
\nDrug manufacturers and distributions submit documentation about their products to FDA in Structured Product Labeling (SPL) that is available via openFDA. However, the approved labeling is a \"living document\" that is updated over time to reflect increased knowledge about the safety and effectiveness of the drug. The real-time nature of the labeling information makes it difficult to track the historical changes to a product's label and indications.
\nVALUE
\nThe historical context of a product's label and indications is important in understanding how and why product labeling changes and in evaluating pharmaceutical market access.
\nUSE CASE SPECIFICATIONS & SOLUTION
\nInformation about this use cases is maintained in a wiki: http://hhs.ddod.us/wiki/Use_Case_25:_History_for_structured_product_labels
\nIt serves as a knowledge base.
\nUSE CASE DISCUSSION FORUM
\nAll communications between Data Users, DDOD Administrators and Data Owners are logged as discussions within GitHub issues: https://github.com/demand-driven-open-data/ddod-intake/issues/25
\nIt aims to provide complete transparency into the process and ensure the same message gets to all participants.
\nCASE STATUS
\nClosed via DailyMed, which has XML files of historical SPLs
","title":"#DDOD Use Case: Historical Structured Product Labels for FDA-Approved Drugs","programCode":["009:002"],"distribution":[{"mediaType":"application/json","downloadURL":"https://api.fda.gov/drug/label.json","description":"Every prescription drug (including biological drug products) approved by FDA for human use comes with FDA-approved labeling. The openFDA drug product labeling API provides data for prescription and over-the-counter (OTC) drug labeling. Since mid-2009, labeling has been posted publicly in the Structured Product Labeling (SPL) format. \n The openFDA drug product labeling API returns data from the FDA Structured Product Labeling (SPL) dataset. This dataset contains structured documentation about regulated products, submitted by manufacturers to FDA. OpenFDA uses the latest available bulk downloads, which have the latest version of every structured product labeling document for products that are actively marketed. \n REFERENCE \n https://open.fda.gov/drug/label/reference/ (https://open.fda.gov/drug/label/reference/) \n","@type":"dcat:Distribution","title":"openFDA prescription and over-the-counter (OTC) drug labeling"},{"mediaType":"application/xml","downloadURL":"http://dailymed.nlm.nih.gov/dailymed/spl-resources-all-drug-labels.cfm","description":"XML files of SPL data, which allows for searching of historical labels. Files available: \n Human prescription or OTC full archive files \nDaily, weekly or monthly periodic update files \n WEBSITE FOR ZIP FILE DOWNLOADS \n http://dailymed.nlm.nih.gov/dailymed/spl-resources-all-drug-labels.cfm (http://dailymed.nlm.nih.gov/dailymed/spl-resources-all-drug-labels.cfm) \n RELATED HEALTHDATA.GOV DATASETS \n DailyMed website (http://www.healthdata.gov/dataset/dailymed) \n DailyMed API (http://www.healthdata.gov/dataset/dailymed-webservices) \n","@type":"dcat:Distribution","title":"National Library of Medicine (NLM) DailyMed SPL files"},{"mediaType":"text/html","downloadURL":"https://rxnav.nlm.nih.gov/REST/","description":"RxNorm is: (1) normalized naming system for generic and branded drugs; and (2) a tool for supporting semantic interoperation between drug terminologies and pharmacy knowledge base systems. The National Library of Medicine (NLM) produces RxNorm. \n To get the SPL set of identifiers for a concept, execute a query on resource \"/rxcui/{rxcui}/splsetid\", where RxCUI is an RxNorm concept unique identifier for a clinical drug. \n REFERENCE \n http://www.nlm.nih.gov/research/umls/rxnorm/overview.html (http://www.nlm.nih.gov/research/umls/rxnorm/overview.html) \n","@type":"dcat:Distribution","title":"National Library of Medicine RxNorm API"}],"describedBy":"https://open.fda.gov/drug/label/reference/","license":"https://opendatacommons.org/licenses/odbl/1.0/"},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4d4a-cw2g","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["rheumatoid-arthritis","synovial-fibroblasts","arthritis-pannus","nih","fibroblast-signaling"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4d4a-cw2g","description":"Fibroblast-like cells in the synovial lining (type B lining cells), stroma and pannus tissue are targeted by many signals, such as the following: ligands binding to cell surface receptors; lipid soluble, small molecular weight mediators (eg nitric oxide [NO], prostaglandins, carbon monoxide); extracellular matrix (ECM)-cell interactions; and direct cell-cell contacts, including gap junctional intercellular communication. Joints are subjected to cyclic mechanical loading and shear forces. Adherence and mechanical forces affect fibroblasts via the ECM (including the hyaluronan fluid phase matrix) and the pericellular matrix (eg extracellular matrix metalloproteinase inducer [EMMPRIN]) matrices, thus modulating fibroblast migration, adherence, proliferation, programmed cell death (including anoikis), synthesis or degradation of ECM, and production of various cytokines and other mediators [1]. Aggressive, transformed or transfected mesenchymal cells containing proto-oncogenes can act in the absence of lymphocytes, but whether these cells represent regressed fibroblasts, chondrocytes or bone marrow stem cells is unclear.","title":"Fibroblast biology: Signals targeting the synovial fibroblast in arthritis","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC130135/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4d4m-y5ca","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["service","social","child","acf","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4d4m-y5ca","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"OHS Logo","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/5200","description":"Access the complete OHS Logo on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4d6t-s29q","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pravastatin-trial","elderly-cardiovascular","cholesterol-management","vascular-disease","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4d6t-s29q","description":"Background\n PROSPER was designed to investigate the benefits of treatment with pravastatin in elderly patients for whom a typical doctor might consider the prescription of statin therapy to be a realistic option.\n \n \n Methods\n The PROspective Study of Pravastatin in the Elderly at Risk (PROSPER) is a randomised, double blind, placebo-controlled trial to test the hypothesis that treatment with pravastatin (40 mg/day) will reduce the risk of coronary heart disease death, non-fatal myocardial infarction, and fatal or non-fatal stroke in elderly men and women with pre-existing vascular disease or with significant risk of developing this condition.\n \n \n Results\n In Scotland, Ireland, and the Netherlands, 23,770 individuals were screened, and 5,804 subjects (2,804 men and 3,000 women), aged 70 to 82 years (average 75 years) and with baseline cholesterol 4.0–9.0 mmol/l, were randomised. Randomised subjects had similar distributions with respect to age, blood pressure, and body mass index when compared to the entire group of screenees, but had a higher prevalence of smoking, diabetes, hypertension, and a history of vascular disease. The average total cholesterol level at baseline was 5.4 mmol/l (men) and 6.0 mmol/l (women).\n \n \n Conclusions\n Compared with previous prevention trials of cholesterol-lowering drugs, the PROSPER cohort is significantly older and for the first time includes a majority of women. The study, having achieved its initial goal of recruiting more than 5,500 elderly high-risk men and women, aims to complete all final subject follow-up visits in the first half of 2002 with the main results being available in the fourth quarter of 2002.","title":"A Prospective Study of Pravastatin in the Elderly at Risk (PROSPER): Screening Experience and Baseline Characteristics","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC134480/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4d7b-nf3k","bureauCode":["009:38"],"issued":"2015-04-14","@type":"dcat:Dataset","modified":"2015-08-20","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"jrsmith","hasEmail":"mailto:no-reply@data.healthcare.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"y75b-i9bb","description":"Dataset.","title":"QHP Landscape Instructions PY2015 NV Medical SHOP","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/PY2015_NV-Med-SHOP-Land-08-03-2015.pdf","mediaType":"application/pdf","title":"FILE"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4d8b-4a5k","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","bioactivity","pubchem","chemistry","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4d8b-4a5k","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865473: MLS000039655","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865473","description":"Access the complete Substance 865473: MLS000039655 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4d98-qkkq","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","chemistry","pubchem","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4d98-qkkq","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865297: MLS000039683","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865297","description":"Access the complete Substance 865297: MLS000039683 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dbb-22b8","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2025-01-17","keyword":["t-msis analytic files","chip","maternal health","medicaid","preterm birth","severe maternal morbidity"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"ee3b9534-0d19-4c1b-bf74-43f898d5de7c","description":"This data set includes annual counts and rates of Medicaid- and Children’s Health Insurance Program (CHIP)-covered live-birth deliveries that were preterm or with a severe maternal morbidity (SMM) condition within six weeks before or after delivery. Results are shown overall; by state; and by four subpopulation topics: age group, race and ethnicity, disability-related eligibility category, and type of SMM condition (SMM category only). \r\nThese results were generated using Transformed Medicaid Statistical Information System (T-MSIS) Analytic Files (TAF) Release 1 data and the Race/Ethnicity Imputation Companion File. This data set includes Medicaid and CHIP enrollees in all 50 states, the District of Columbia, Puerto Rico, and the U.S. Virgin Islands, who were ages 15 to 49 as of their delivery date, who were enrolled in Medicaid or CHIP at any point in the calendar year, and who had a live birth. Enrollees in Guam, American Samoa, the Northern Mariana Islands, and select states with TAF data quality issues are not included. Results shown for the race and ethnicity subpopulation topic exclude enrollees in the U.S. Virgin Islands. Results for SMM are calculated per 10,000 Medicaid- and CHIP-covered live births. Results for states with TAF data quality issues in the year have a value of \"Unusable data.\" Some rows in the data set have a value of \"DS,\" which indicates that data were suppressed according to the Centers for Medicare & Medicaid Services’ Cell Suppression Policy for values between 1 and 10.\r\n\r\nThis data set is based on the brief: \"Prematurity and severe maternal morbidity among Medicaid- and CHIP-covered live births in 2021.\" Preterm birth is defined as a live birth that occurs before the 37th week of gestation. SMM deliveries are defined as live births with an SMM condition within six weeks before or after delivery (Identifying Severe Maternal Morbidity (SMM)). Enrollees are assigned to an age group subpopulation using age as of their delivery date. Enrollees are assigned to a race and ethnicity subpopulation using the state-reported race and ethnicity information in TAF when it is available and of good quality; if it is missing or unreliable, race and ethnicity is indirectly estimated using an enhanced version of Bayesian Improved Surname Geocoding (BISG) (Race and ethnicity of the national Medicaid and CHIP population in 2020). Enrollees are assigned to a disability category subpopulation using their latest reported eligibility group code and age in the year (Medicaid enrollees who qualify for benefits based on disability in 2020). Please refer to the full brief for additional context about the methodology and detailed findings. Future updates to this data set will include more recent data years as the TAF data become available.","title":"Prematurity and severe maternal morbidity among Medicaid- and CHIP-covered live births","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/preterm-birth-and-smm-2020-2022-01172025.csv","mediaType":"text/csv"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dd4-mfwd","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","research","pubchem","patent","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4dd4-mfwd","description":"A method of calculating data traffic flow in a communications network, the communications network comprising a plurality of nodes including a plurality of source nodes and a plurality of destination nodes, the nodes being connected to one another by links, the method comprising: (a) obtaining data traffic flow measurements through said nodes and links as input data; (b) correcting said input data if inconsistencies are detected; (c) calculating upper and lower bounds of data traffic flow from a selected one of the plurality of source nodes to a selected one of the plurality of destination nodes using the corrected input data.","title":"Patent AT-E400111-T1: [Translated] TRAFFIC FLOW OPTIMIZATION SYSTEM","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400111-T1","description":"Access the complete Patent AT-E400111-T1: [Translated] TRAFFIC FLOW OPTIMIZATION SYSTEM on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ddw-xdhc","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","substance","references","chemistry","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4ddw-xdhc","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865831: MLS000084155","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865831","description":"Access the complete Substance 865831: MLS000084155 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dew-2qgt","bureauCode":["009:38"],"issued":"2020-10-09","@type":"dcat:Dataset","modified":"2021-02-04","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"Andy Elkins","hasEmail":"mailto:CMS_FEPS@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"eh65-eh2p","description":"The Plan ID Crosswalk PUF (CW-PUF) is one of the files that make up the Marketplace PUF. The purpose of the CW-PUF is to map QHPs and SADPs offered through the Marketplaces in 2020 to plans that will be offered through the Marketplaces in 2021. These data either originate from the Plan Crosswalk template (i.e., template field), an Excel-based form used by issuers to describe their plans in the QHP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).This data dictionary describes the variables contained in the CW-PUF. Each record relates to a mapping between a plan offered in 2020 and a plan offered in 2021 at the county or county-zip code level.","title":"Plan ID Crosswalk PUF - PY2021","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/plan-id-crosswalk-puf-2021.eh65-eh2p.csv","mediaType":"text/csv","title":"CSV"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dft-jaz5","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["manual","policy","social","child","data"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4dft-jaz5","description":"This document provides short summaries of each of the 36 items for round 4 of the Child and Family Services Reviews.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Quick Reference Items List","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/cfsr-r4-quick-reference-items-list","description":"Access the complete Quick Reference Items List on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dgk-k5zg","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","block-grant-program","samhsa","urs-data","national-outcome-measures"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4dgk-k5zg","description":"These are the 2019 Uniform Reporting System (URS) Output Tables for Wisconsin. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2019 Uniform Reporting System (URS) Table for Wisconsin","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2019-uniform-reporting-system-urs-table-wisconsin","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dgr-hzcj","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["social","service","child","childr","acf"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4dgr-hzcj","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Provider Management Business Processes","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14304","description":"Access the complete Provider Management Business Processes on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dhc-ysbu","bureauCode":["009:00"],"issued":"2024-08-06","@type":"dcat:Dataset","modified":"2024-08-14","keyword":["qhp landscape instructions","py2024","individual market dental","sadp","individual"],"contactPoint":{"@type":"vcard:Contact","fn":"Center for Consumer Information and Insurance Oversight","hasEmail":"mailto:CMS_FEPS@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Center for Consumer Information and Insurance Oversight"},"identifier":"6b755d82-519a-4b5c-b04d-04013c1a2d9c","description":"The Dental Individual Market file of the QHP Landscape Files contains information on certified dental plans offered through an Exchange to consumers in the individual market. These plans are also known as Stand-alone Dental Plans (SADPs). The file reports plans offered by county for states in the Federally-facilitated Exchanges including states performing plan management functions, and State Based Exchanges using the federal platform for eligibility and enrollment.","title":"QHP Landscape Instructions PY2024 Individual Dental","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/py2024/den-ind-lndscp-in.pdf","mediaType":"application/pdf"}],"accrualPeriodicity":"R/PT1S","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dj8-ata3","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["policy","compliance","scope","cost","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4dj8-ata3","description":"This document includes sample terms and conditions that describe which provisions of the Social Security Act and program regulations can be waived to allow states or tribes to operate a Child Welfare Waiver Demonstration project under a capped allocation methodology to establish the cost neutrality limit.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Waiver Terms and Conditions Template for Capped Allocations","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/waiver-terms-and-conditions-template-capped-allocations","description":"Access the complete Waiver Terms and Conditions Template for Capped Allocations on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dp2-jcyb","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["wart-clearance","nih","imiquimod-treatment","genital-warts","systematic-review"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4dp2-jcyb","description":"Objective\n To review published randomised controlled trials to assess the benefit and harm of imiquimod in the treatment of external genital warts.\n \n \n Data sources\n MEDLINE (1966 - December 2000), Cochrane Library (Issue 3, 2000) and PubMed (December 15, 2000), review articles and reference lists.\n \n \n Review methods\n Included studies had to be randomised trials of imiquimod, to be full published papers, and to have a comparison group. Quality of trial reporting was assessed. Relative benefit and number needed to treat were calculated for the main outcomes of wart clearance at the end of therapy, of at least 50% reduction in wart area, and of complete clearance at the end of treatment and no recurrence of warts during a follow-up period, as well as for adverse effect withdrawal or lack of efficacy withdrawal.\n \n \n Results\n There were six trials, all with quality scores of 3 (out of 5) or greater. In five trials with HIV-negative patients complete clearance of warts at the end of treatment occurred in 51% of patients treated with imiquimod 2% or 5% cream and 6% of placebo treated patients. The number needed to treat was 2.2 (95% confidence interval 2.0 to 2.6). In four trials at least 50% wart area reduction occurred with 72% of patients treated with imiquimod 5% cream and 20% of placebo treated patients. The number needed to treat was 1.9 (1.7 to 2.2). In three trials complete clearance of warts at the end of treatment plus no recurrence occurred in 37% of patients treated with imiquimod 5% cream and 4% of those treated with placebo. The number needed to treat was 3.0 (2.5 to 3.8). Adverse event withdrawal was rare and no more likely with imiquimod than with placebo. Imiquimod was not effective in one trial in HIV-positive patients.\n \n \n Conclusion\n The evidence base for imiquimod in treating genital warts is of high quality and the necessary size from which to draw useful conclusions. Imiquimod is effective in home application, though not in patients with HIV infection with the evidence presently available.","title":"Imiquimod for the treatment of genital warts: a quantitative systematic review","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC32301/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dpy-95b9","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","pubchem","compound","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4dpy-95b9","description":"Chemical compound data from PubChem database. IUPAC Name: 2-(1-adamantyl)ethyl 5-chloropentanoate. Molecular Formula: C17H27ClO2. Molecular Weight: 298.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530482: 5-Chlorovaleric acid, 2-(1-adamantyl)ethyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530482","description":"Access the complete Compound 530482: 5-Chlorovaleric acid, 2-(1-adamantyl)ethyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dsf-dypw","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["tumor-cells","kaposis-sarcoma","chemokine-receptors","hiv-1-infection","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4dsf-dypw","description":"Background\n HIV-1 is known to play a critical role in the pathogenesis of AIDS-associated Kaposi's sarcoma (KS). However, it remains controversial whether KS cells are target cells for HIV infection. The aim of this study was to investigate the expression of chemokine receptors in KS cell cultures and to determine whether these cells can be infected by HIV-1.\n \n \n Material and Methods\n KS-derived cells and KS-Y1 cells were investigated using RT-PCR for the expression of CD4, CCR3, CCR5, CCR8 and CXCR4 mRNA. HIV infectivity of these cells was determined by p24 antigen and HIV-1 RNA production, as well as by HIV-1 DNA integration.\n \n \n Results and Discussion\n With the exception of CCR8 which is expressed by KS-derived spindle cell cultures but not by KS-Y1 cells, unstimulated KS cells express no significant levels of CD4, CCR3, CCR5 or CXCR4 mRNA. HIV infectivity assays showed that KS cells were unpermissive to HTLVIIIB and JRFL strains. Although the expression of CXCR4 mRNA could be upregulated by interleukin-1β, stimulation of KS cells by this cytokine did not allow infection by HIV-1.\n \n \n Conclusions\n This shows that KS cells exhibit a chemokine receptor repertoire that does not allow infection by HIV-1. Other cell types making up KS lesions, such as inflammatory cells, are likely to represent the source of HIV-1 products cooperating to promote KS development and progression.","title":"Cultured Kaposi's sarcoma tumor cells exhibit a chemokine receptor repertoire that does not allow infection by HIV-1","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC37541/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dwk-3s8m","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","innovation","research","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4dwk-3s8m","description":"The positioning system (50) attaches to the lifting wire (42) and comprises a main module (51) and a counter module (52), each provided with thrusters (56) to control the positioning of an attached load. An attached processing system takes input from an acoustic source and a sound velocity meter, to take account of acoustic rays bending as velocity changes with depth, on the apparatus to control the thrusters and position the load at its required underwater position : Independent claims are also included for the following: (a) A processing arrangement arranged to drive an apparatus for deploying an object to an underwater target position; ( A vessel provided with a processing arrangement arranged to drive an apparatus for deploying an object to an underwater target position; ( A method of driving a processing arrangement arranged to drive an apparatus for deploying an object to an underwater target position; ( A computer program for carrying out a method of driving a processing arrangement arranged to drive an apparatus for deploying an object to an underwater target position.","title":"Patent AT-E399707-T1: [Translated] ARRANGEMENT OF AN ACOUSTIC ARRAY WITH A SOUND VELOCITY METER","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399707-T1","description":"Access the complete Patent AT-E399707-T1: [Translated] ARRANGEMENT OF AN ACOUSTIC ARRAY WITH A SOUND VELOCITY METER on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dyv-v4hu","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2022-09-21","references":["https://www.medicaid.gov/dq-atlas/welcome","https://www.mathematica.org/"],"keyword":["dqatlas","dqatlas_devauto","utility"],"contactPoint":{"@type":"vcard:Contact","fn":"DataConnect Support Team","hasEmail":"mailto:dataconnectsupport@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"3380bed6-24ce-568e-982c-99951e1d7db0","description":"This is a dataset created for use by the DQ Atlas website, and is not intended for use outside that application. For more information on the DQ Atlas and the information contained in this dataset see https://www.medicaid.gov/dq-atlas/welcome","title":"devAuto_files_topicSnapshot","programCode":["009:000"],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/PT1S","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4dz2-8r3d","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","substance","pubchem","bioactivity","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4dz2-8r3d","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865092: MLS000084393","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865092","description":"Access the complete Substance 865092: MLS000084393 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4e2w-etn6","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["pubchem","compound","research","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4e2w-etn6","description":"Chemical compound data from PubChem database. IUPAC Name: 21,25-dimethyltriacontanenitrile. Molecular Formula: C32H63N. Molecular Weight: 461.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527375: 20,24-Dimethyl-nonacosyl cyanide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527375","description":"Access the complete Compound 527375: 20,24-Dimethyl-nonacosyl cyanide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/dataset/national-survey-child-and-adolescent-well-being","bureauCode":["009:00"],"issued":"2013-06-18","temporal":"1999-01-01T00:00:00-05:00/2012-01-01T00:00:00-05:00","@type":"dcat:Dataset","modified":"2023-07-25","keyword":["child welfare","children's health","child maltreatment","child abuse and neglect","child well-being"],"contactPoint":{"@type":"vcard:Contact","fn":"HealthData.gov","hasEmail":"mailto:HealthData@hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"22ed32f4-b43d-4bdb-9aa6-cc7e3523595d","description":"Nationally representative, longitudinal data describing functioning of and services for children who are reported to child protective services
","title":"National Survey of Child and Adolescent Well-Being","programCode":["009:015"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://www.ndacan.cornell.edu/datasets/datasets-list-nscaw.cfm","mediaType":"text/html","title":"NSCAW Dataset"}],"describedBy":"http://www.ndacan.cornell.edu/NDACAN/Datasets/Abstracts/DatasetAbstract_NSCAW-General.html","dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/"},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/j8vq-w76s","issued":"2020-04-06","@type":"dcat:Dataset","modified":"2020-04-06","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"Christensen, Lisa K (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/j8vq-w76s","description":"Lead in Drinking Water in Schools Test Results – Saltars Point Elementary","title":"Saltars Point Elementary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/j8vq-w76s/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://data.cityofchicago.org/d/cjg8-dbka","issued":"2014-07-08","@type":"dcat:Dataset","modified":"2019-04-18","keyword":["care","community","clinics","fqhc","health","primary","services"],"contactPoint":{"@type":"vcard:Contact","fn":"Jamyia","hasEmail":"mailto:no-reply@data.cityofchicago.org"},"publisher":{"@type":"org:Organization","name":"City of Chicago"},"identifier":"https://data.cityofchicago.org/api/views/cjg8-dbka","description":"Locations and contact information for Chicago primary care community health clinics (including all federally qualified health centers and similar community health centers that provide primary care and are open to the general community). Additional information can be found at: http://j.mp/QfZ7SP\r\n\r\nCDPH anticipates that this list will be used in the following ways: 1) by residents who are in need of \r\nassistance in finding a primary care physician and clinic near their homes; 2) by social service and \r\npublic sector service providers that want to link their consumers to primary care near their homes; 3) \r\nby health system and public health researchers who are interested in Chicago’s primary care and \r\nsafety net provider landscape. \r\n \r\nClinics were excluded from this list if a) it is not specifically in their mission to care for underserved \r\npopulations or b) if clinic services are only available to a narrowly defined population. \r\n \r\nDisclaimers: This list is intended to be a working document of primary care clinics for underserved \r\npopulations in Chicago. If you believe an entry on this list to be outdated, misrepresented, or \r\notherwise in error, please contact healthychicago@cityofchicago.org.","title":"Public Health Services- Chicago Primary Care Community Health Centers","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cjg8-dbka/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cjg8-dbka/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cjg8-dbka/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cjg8-dbka/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cjg8-dbka/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/cjg8-dbka/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ebs-t8u4","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["adoption","foster","compliance","regulation","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4ebs-t8u4","description":"This Information Memorandum (IM) provides information on the Fostering Connections to Success and Increasing Adoptions Act of 2008 (Public Law (P.L.) 110-351); automation requirements and options for Tribes operating a title IV-E program pursuant to section 479B of the Social Security Act.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-09-02)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-09-02","description":"Access the complete IM-09-02 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ebv-hjm5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","references","pubchem","substance","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4ebv-hjm5","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864727: MLS000083177","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864727","description":"Access the complete Substance 864727: MLS000083177 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4eeg-56ye","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2025-10-20","keyword":["major eligibility group","medicaid","t-msis analytic files","dq atlas","chip"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"ea9b7db3-db71-4663-b4e1-67e11d1d4fcc","description":"This data set includes monthly enrollment counts of Medicaid and CHIP beneficiaries by major eligibility group (children, adult expansion group, adult, aged, persons with disabilities, or COVID newly-eligible).\n\nThese metrics are based on data in the T-MSIS Analytic Files (TAF). Some states have serious data quality issues for one or more months, making the data unusable for calculating these measures. To assess data quality, analysts adapted measures featured in the DQ Atlas. Data for a state and month are considered unusable or of high concern based on DQ Atlas thresholds for the topic Eligibility Group Code. Please refer to the DQ Atlas at http://medicaid.gov/dq-atlas for more information about data quality assessment methods. \n\nSome cells have a value of “DS”. This indicates that data were suppressed for confidentiality reasons because the group included fewer than 11 beneficiaries.","title":"Major Eligibility Group Information for Medicaid and CHIP Beneficiaries by Month","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/MajorEligibilityGroup-montly-102025.csv","description":"This data set includes monthly enrollment counts of Medicaid and CHIP beneficiaries by major eligibility group (children, adult expansion group, adult, aged, persons with disabilities, or COVID newly-eligible).\n\nThese metrics are based on data in the T-MSIS Analytic Files (TAF). Some states have serious data quality issues for one or more months, making the data unusable for calculating these measures. To assess data quality, analysts adapted measures featured in the DQ Atlas. Data for a state and month are considered unusable or of high concern based on DQ Atlas thresholds for the topic Eligibility Group Code. Please refer to the DQ Atlas at http://medicaid.gov/dq-atlas for more information about data quality assessment methods. \n\nSome cells have a value of “DS”. This indicates that data were suppressed for confidentiality reasons because the group included fewer than 11 beneficiaries.","@type":"dcat:Distribution","title":"Major Eligibility Group Information for Medicaid and CHIP Beneficiaries by Month"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["Enrollment"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-manufacturers","drug","pharmaceuticals","fda","drug-safety"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA017648","description":"Potassium Chloride in Sodium Chloride is an injectable prescription drug used intravenously to deliver essential electrolytes (potassium and sodium) to the body. It helps maintain fluid and electrolyte balance, often in medical settings. This information was generated using AI and is provided for informational and research purposes only.","title":"Potassium chloride and sodium chloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=017648","description":"\n Access the FDA dataset for Potassium chloride and sodium chloride — ANDA 017648 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Potassium chloride and sodium chloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"http://www.cdc.gov/nccdphp/dph/","bureauCode":["009:20"],"issued":"2025-12-04","@type":"dcat:Dataset","modified":"2025-12-04","references":["https://www.cdc.gov/places/measure-definitions/index.html"],"keyword":["gis","behaviors","census tract","disability","health","outcomes","places","prevalence","prevention","risk","status"],"contactPoint":{"@type":"vcard:Contact","fn":"PLACES Public Inquiries","hasEmail":"mailto:places@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/yjkw-uj5s","description":"This dataset contains model-based census tract level estimates in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at four geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates are Behavioral Risk Factor Surveillance System (BRFSS) 2022 or 2021 data, Census Bureau 2010 population estimates, and American Community Survey (ACS) 2015–2019 estimates. The 2024 release uses 2022 BRFSS data for 36 measures and 2021 BRFSS data for 4 measures (high blood pressure, high cholesterol, cholesterol screening, and taking medicine for high blood pressure control among those with high blood pressure) that the survey collects data on every other year. These data can be joined with the Census tract 2022 boundary file in a GIS system to produce maps for 40 measures at the census tract level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software.\nhttps://cdcarcgis.maps.arcgis.com/home/item.html?id=3b7221d4e47740cab9235b839fa55cd7","title":"PLACES: Census Tract Data (GIS Friendly Format), 2024 release","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/yjkw-uj5s/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/yjkw-uj5s/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/yjkw-uj5s/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/yjkw-uj5s/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/yjkw-uj5s/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/yjkw-uj5s/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"describedBy":"https://chronicdata.cdc.gov/dataset/PLACES-Census-Tract-Data-GIS-Friendly-Format-2020-/yjkw-uj5s","license":"http://opendefinition.org/licenses/odc-odbl/","theme":["500 Cities & Places"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4eff-22ab","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4eff-22ab","description":"Chemical compound data from PubChem database. IUPAC Name: ethyl 2,2,3,3,4,4,5,5,6,6,6-undecafluorohexanoate. Molecular Formula: C8H5F11O2. Molecular Weight: 342.11. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526462: Ethyl perfluorohexanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526462","description":"Access the complete Compound 526462: Ethyl perfluorohexanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4eh9-ev4s","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","research","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4eh9-ev4s","description":"Chemical compound data from PubChem database. IUPAC Name: 1,3,4,7-tetrabromodibenzofuran. Molecular Formula: C12H4Br4O. Molecular Weight: 483.77. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526267: 1,3,4,7-Tetrabromo-dibenzofuran","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526267","description":"Access the complete Compound 526267: 1,3,4,7-Tetrabromo-dibenzofuran on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ehr-f32x","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["treatment-facilities","rhode-island","samhsa","n-ssats","substance-abuse-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4ehr-f32x","description":"This is a National Survey of Substance Abuse Treatment Services (N-SSATS) annual report showing the state profile for Rhode Island in 2012. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.","title":"2012 State Profile - Rhode Island","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-state-profile-rhode-island","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4eku-c64v","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["grant","policy","scope","system","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4eku-c64v","description":"This webinar described the Comprehensive Child Welfare Information System (CCWIS) Technical Assistance Review Process. It began with an overview of the lessons learned from the Statewide Automated Child Welfare Information System (SACWIS) review process. The presentation described the iterative review process and it explains the use of self-assessment tools. As of this presentation, some self-assessment tools were available for public comment and others were in development.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"CCWIS Technical Assistance and Review Process","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/ccwis-technical-assistance-and-review-process","description":"Access the complete CCWIS Technical Assistance and Review Process on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4em2-6wjd","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["new-jersey","survey-data","substance-use","samhsa","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4em2-6wjd","description":"New Jersey: 2010-2012 NSDUH substate estimates","title":"New Jersey: 2010-2012 NSDUH substate estimates","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/new-jersey-2010-2012-nsduh-substate-estimates","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4eps-sfj2","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","neurokinin-receptors","inflammatory-pain","dorsal-root-ganglion","antigen-induced-arthritis"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4eps-sfj2","description":"This study describes the upregulation of neurokinin 1 and bradykinin 2 receptors in dorsal root ganglion (DRG) neurons in the course of antigen-induced arthritis (AIA) in the rat knee. In the acute phase of AIA, which was characterized by pronounced hyperalgesia, there was a substantial bilateral increase in the proportion of lumbar DRG neurons that express neurokinin 1 receptors (activated by substance P) and bradykinin 2 receptors. In the chronic phase the upregulation of bradykinin 2 receptors persisted on the side of inflammation. The increase in the receptor expression is relevant for the generation of acute and chronic inflammatory pain.","title":"Monoarticular antigen-induced arthritis leads to pronounced bilateral upregulation of the expression of neurokinin 1 and bradykinin 2 receptors in dorsal root ganglion neurons of rats","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC17819/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4eq2-gmw8","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","crp-levels","sepsis-markers","sofa-score","procalcitonin-levels"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4eq2-gmw8","description":"Objectives:\n The relation of procalcitonin (PCT) plasma concentrations compared\n\t\t\t\twith C-reactive protein (CRP) was analyzed in patients with different severity\n\t\t\t\tof multiple organ dysfunction syndrome (MODS) and systemic inflammation.\n \n \n Patients and methods:\n PCT, CRP, the sepsis-related organ failure assessment (SOFA)\n\t\t\t\tscore, the Acute Physiology, Age, Chronic Health Evaluation (APACHE) II score\n\t\t\t\tand survival were evaluated in 40 patients with systemic inflammation and\n\t\t\t\tconsecutive MODS over a period of 15 days.\n \n \n Results:\n Higher SOFA score levels were associated with significantly higher\n\t\t\t\tPCT plasma concentrations (SOFA 7-12: PCT 2.62 ng/ml, SOFA 19-24: PCT\n\t\t\t\t15.22 ng/ml) (median), whereas CRP was elevated irrespective of the scores\n\t\t\t\tobserved (SOFT 7-12: CRP 131 mg/l, SOFT 19-24: CRP 135 mg/l). PCT of\n\t\t\t\tnon-surviving patients was initially not different from that of survivors but\n\t\t\t\tsignificantly increased after the fourth day following onset of the disease,\n\t\t\t\twhereas CRP was not different between both groups throughout the whole\n\t\t\t\tobservation period.\n \n \n Conclusions:\n Measurement of PCT concentrations during multiple organ\n\t\t\t\tdysfunction syndrome provides more information about the severity and the\n\t\t\t\tcourse of the disease than that of CRP. Regarding the strong association of PCT\n\t\t\t\tand the respective score systems in future studies we recommend evaluation also\n\t\t\t\tof the severity of inflammation and MODS when PCT concentrations were compared\n\t\t\t\tbetween different types of disease.","title":"Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma\n\t\t concentrations at different SOFA scores during the course of sepsis and\n\t\t MODS","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC29013/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/p39z-8dfa","issued":"2018-06-19","@type":"dcat:Dataset","modified":"2018-06-19","keyword":["school","lead","drinking water"],"contactPoint":{"@type":"vcard:Contact","fn":"Elizabeth Kimball","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/p39z-8dfa","description":"Lead in drinking water in school test results","title":"Ruth Livingston","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/p39z-8dfa/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4eum-7p3h","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","innovation","chemistry","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4eum-7p3h","description":"Chemical patent from PubChem database. Patent Number: AT-E399856-T1. Title: Sustained Release Formulation. Filing Date: 1990-10-05. Inventors: Garcia, Maria, Miller, Thomas. Abstract: A sustained release formulation is provided, designed to maintain therapeutic drug levels over extended periods, reducing dosing frequency and improvi... IPC Classifications: C07D, A61K, A61P. This patent covers 12 claims related to 9 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.","title":"Patent AT-E399856-T1: [Translated] NEW THERMOPHILES POLYMERASE III HOLOENZYME","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399856-T1","description":"Access the complete Patent AT-E399856-T1: [Translated] NEW THERMOPHILES POLYMERASE III HOLOENZYME on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ezh-bi65","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","substance-abuse","treatment-facilities","mental-health","co-occurring-disorders"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4ezh-bi65","description":"This a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing client substance abuse problem and diagnosed co-occurring mental disorders, by facility operation and primary focus of facility as of March 31, 2011.","title":"4.3 Client substance abuse problem and diagnosed co-occurring mental disorders, by facility operation and primary focus of facility: March 31, 2011. Number and percent","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/43-client-substance-abuse-problem-and-diagnosed-co-occurring-mental-disorders-facility","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4f37-ghyq","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["social","assessment","child","policy","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4f37-ghyq","description":"This issue of Child and Family Services Reviews Update contains the following sections: Approved Program Improvement Plans, and Expectations for PIPs.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Child and Family Services Reviews Update Volume 12, Issue 2, June 2018","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/child-and-family-services-reviews-update-volume-12-issue-2-june-2018","description":"Access the complete Child and Family Services Reviews Update Volume 12, Issue 2, June 2018 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/3tpg-59xz","issued":"2019-03-07","@type":"dcat:Dataset","modified":"2019-03-07","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/3tpg-59xz","description":"Lead in Drinking Water in Schools Test Results – Broadway Learning Center Follow UP update","title":"Broadway Learning Center follow up update","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/3tpg-59xz/application/pdf","mediaType":"application/pdf"}],"license":"https://www.usa.gov/government-works","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4fa2-d6zx","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["service","social","acf","child","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4fa2-d6zx","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Valerie Merritt's Appreciation for Services Letter Dated June 30, 1975","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/2251","description":"Access the complete Valerie Merritt's Appreciation for Services Letter Dated June 30, 1975 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4fa7-rtaq","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["law","index","policy","child","legal"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4fa7-rtaq","description":"Index of Federal Child Welfare Laws\n \n \n\n - This webpage provides information about various resources pertaining to federal child welfare laws.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Index of Federal Child Welfare Laws","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/law-regulation/index-federal-child-welfare-laws","description":"Access the complete Index of Federal Child Welfare Laws on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4fbd-p23s","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["policy","child","data","legal","scope"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4fbd-p23s","description":"State Child Welfare Legislation: 2005\n \n \n\n (PDF) describes some of the State legislation related to child welfare issues that was enacted during calendar year 2005. It includes citations and summaries of specific child-welfare-related laws in each State.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"State Child Welfare Legislation: 2005","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/state-child-welfare-legislation-2005","description":"Access the complete State Child Welfare Legislation: 2005 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4fdh-bdv4","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","adult-mental-health","youth-substance-use","wyoming-behavioral-health","substance-use-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4fdh-bdv4","description":"This is a behavioral health report for the state of Wyoming. It uses the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.","title":"Behavioral Health Barometer: Wyoming, 2014","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-wyoming-2014","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4fgg-g3ve","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","research","science","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4fgg-g3ve","description":"Chemical compound data from PubChem database. IUPAC Name: 2-nitro-4-pentan-2-ylphenol. Molecular Formula: C11H15NO3. Molecular Weight: 209.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528965: Phenol, 4-(1-methylbutyl)-2-nitro","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528965","description":"Access the complete Compound 528965: Phenol, 4-(1-methylbutyl)-2-nitro on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4fh2-36cf","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["service","acf","child","social","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4fh2-36cf","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"2010montana","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/11684","description":"Access the complete 2010montana.pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4fhe-65by","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["serious-emotional-disturbance","childrens-mental-health","expert-panel-discussion","samhsa","sed-recommendations"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4fhe-65by","description":"Serious Emotional Disturbance (SED) Expert Panel Meetings: Summary of Panel Discussions and Recommendations","title":"Serious Emotional Disturbance (SED) Expert Panel Meetings: Summary of Panel Discussions and Recommendations","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/serious-emotional-disturbance-sed-expert-panel-meetings-summary-panel-discussions-and","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4fj7-5xis","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-use-survey","samhsa","nsduh-survey","field-interviewer-training","data-collection-methods"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4fj7-5xis","description":"This detailed manual was used as a training guide for the Field Interviewers (FIs) who conducted the in-person 2023 National Survey on Drug Use and Health (NSDUH). It covers the information presented at the intensive training for new FIs. Although it is written for NSDUH FIs, researchers may find it helpful for learning about data collection challenges that could affect data quality. It also may be helpful for those designing their own field operations.The manual includes:An introduction to the survey;A guide to what is expected of FIs;Copies of materials that were mailed or given to respondents;FI instructions for locating sample dwelling units, contacting residents, obtaining participation, conducting the screening and interview, documenting their experiences; andQuality control and administrative procedures for FIs.","title":"NSDUH 2023 Field Interviewer Manual","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/nsduh-2023-field-interviewer-manual","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4fjq-vzsb","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["policy","adoption","fiscal","data","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4fjq-vzsb","description":"This report provides state-specific data from fiscal year 2002 about the number of children who are adopted through a public agency and who receive an adoption subsidy.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Receiving State or Federal Subsidy 10/1/2001 - 9/30/2002","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/receiving-state-or-federal-subsidy-10/1/2001-9/30/2002","description":"Access the complete Receiving State or Federal Subsidy 10/1/2001 - 9/30/2002 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4fmc-yisb","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","innovation","pubchem","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4fmc-yisb","description":"Pellets (A) comprise an extract of a starting material (of vegetable, animal or mineral origin) for Chinese medicinal tea (CMT), contained in a matrix including hydrophilic macromolecules as structure-former (SF). Independent claims are included for: (1) An 'instant' CMT preparation comprising the pellets (A) in lyophilized form; (2) Assemblies or kits of pellets (A) comprising the same type of matrices containing at least two (preferably at least four) different extracts; (3) A method for producing CMT, by separately boiling individual CMT starting materials, treating the obtained decoctions with SFs, forming pellets, lyophilizing and dissolving different types of pellets in water; and (4) Production of CMTs in instant form, by forming a decoction from a CMT starting material, dissolving and/or dispersing SF in the decoction (preferably after removal of solids, especially by filtration), freezing the mixture by dropwise addition to very cold cryogenic fluid and lyophilizing the obtained pellets; and (5) Instant CMT's obtained by the method.","title":"Patent AT-E400255-T1: [Translated] COMPOSITION OR KIT OF PELLETS FOR PREPARING CHINESE MEDICINAL TEAS AND METHOD FOR PRODUCING","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400255-T1","description":"Access the complete Patent AT-E400255-T1: [Translated] COMPOSITION OR KIT OF PELLETS FOR PREPARING CHINESE MEDICINAL TEAS AND METHOD FOR PRODUCING on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4fp3-e2u4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","innovation","chemistry","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4fp3-e2u4","description":"A network management concentrated alarm box and the alarm processing method thereof. The present invention provides a network management concentrated alarm box and the alarm processing method thereof, which is easy to implement, cooperates closely with the NMS, delivers automatic handshaking function, and can detect online (or offline) of the alarm box and recover to alarm state after the connection recovers from interruption. Wherein a network management concentrated alarm box comprises: An alarm background module designed to receive all alarm message frames from the NMS and forward the alarm message frames to the alarm box interface module; An alarm box interface module designed to convert the received alarm message frames into alarm message frames in the communication protocol of the alarm box, send the alarm message frames to the alarm box via a serial interface, receive operation commands from the alarm box foreground, and control the alarm box accordingly; An alarm box designed to process the alarm message frames by type in a concentrated manner.The State Cancer Profiles (SCP) web site provides statistics to help guide and prioritize cancer control activities at the state and local levels. SCP is a collaborative effort using local and national level cancer data from the Centers for Disease Control and Prevention's National Program of Cancer Registries (NPCR) and National Cancer Institute's Surveillance, Epidemiology and End Results Registries (SEER). SCP address select types of cancer and select behavioral risk factors for which there are evidence-based control interventions. The site provides incidence, mortality and prevalence comparison tables as well as interactive graphs and maps and support data. The graphs and maps provide visual support for deciding where to focus cancer control efforts.
","title":"State Cancer Profiles Web site","programCode":["009:047"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://statecancerprofiles.cancer.gov","mediaType":"text/html","title":"Query Tool "}],"describedBy":"http://statecancerprofiles.cancer.gov/faq.html","dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4hhh-reqa","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","innovation","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4hhh-reqa","description":"Embodiments relate to a method, system and network element, e.g. portable terminal, connectable to another network element. One of selectable modes is used for communication. A network element is adapted to perform a mode selection procedure for selecting the same mode for bidirectional communication between the network elements. The mode selection ensures the use of the same mode e.g. in uplink and downlink direction and thus enables e.g. IP telephony in UMTS using SIP protocol. Embodiments may e.g. facilitate a VoIP communication session by way of a radio link with a mobile station.","title":"Patent AT-E400152-T1: [Translated] APPARATUS AND METHOD FOR REMOVAL OF A PACKET HEADDER IN A RADIO COMMUNICATIONS SYSTEM","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400152-T1","description":"Access the complete Patent AT-E400152-T1: [Translated] APPARATUS AND METHOD FOR REMOVAL OF A PACKET HEADDER IN A RADIO COMMUNICATIONS SYSTEM on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4hir-6nwt","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-use","state-level-data","age-groups","mental-health","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4hir-6nwt","description":"States Categorized into Five Groups from Lowest to Highest Estimate, by Age Group: Percentages, Annual Averages Based on 2016 and 2017 NSDUHs","title":"2016-2017 NSDUH State Estimates Categorized into Five Groups by Age Group","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2016-2017-nsduh-state-estimates-categorized-five-groups-age-group","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4hks-u74b","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","research","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4hks-u74b","description":"Chemical compound data from PubChem database. IUPAC Name: 13-chlorooctadecyl acetate. Molecular Formula: C20H39ClO2. Molecular Weight: 347.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527936: 13-Chlorooctadecyl acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527936","description":"Access the complete Compound 527936: 13-Chlorooctadecyl acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4hn7-dvuh","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","stent-implantation","revascularization","pci-cabg","coronary-artery-disease"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4hn7-dvuh","description":"The treatment of patients with coronary artery disease continues to evolve; all three strategies – medical therapy, surgical revascularization, and percutaneous coronary intervention – have changed. Medical therapy with intense risk-factor modification and treatment with a statin, aspirin, and angiotensin-converting enzyme (ACE) inhibitors, should be used unless contraindicated. Surgical therapy has also changed with the introduction of minimally invasive, beating heart surgery. Percutaneous coronary intervention has perhaps changed the most radically with adjunctive therapy – glycoprotein IIb/IIIa inhibitors, thienopyridines, and reliance on stent implantation. The future, with new distal protection devices and drug-coated stents, should continue to see increased numbers of patients who can benefit from percutaneous intervention.","title":"Debate: PCI vs CABG: a moving target, but we are gaining","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64826/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/azgh-hvnt","bureauCode":["009:00"],"issued":"2016-09-14","@type":"dcat:Dataset","modified":"2016-09-14","keyword":["cdc","centers for disease control and prevention"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/azgh-hvnt","description":"Source: Behavioral Risk Factor Surveillance System (BRFSS), 2012, 2014.","title":"Percentage of Adults Who Report Driving After Drinking Too Much (in the past 30 days), 2012 & 2014, Region 4 - Atlanta","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/azgh-hvnt/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/azgh-hvnt/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/azgh-hvnt/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/azgh-hvnt/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/azgh-hvnt/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/azgh-hvnt/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Motor Vehicle"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4hpz-88p2","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["treatment-episode-data","substance-abuse-treatment","primary-substance","samhsa","teds-admissions"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4hpz-88p2","description":"This a Treatment Episode Data Set (TEDS) data table displaying substance abuse treatment admissions by primary substance abuse, according to sex, age group, race, and ethnicity. The Treatment Episode Data Set (TEDS) is a national data system of annual admissions to substance abuse treatment facilities. TEDS received treatment admission records from 46 states, the District of Columbia, and Puerto Rico in 2014.","title":"TEDS Substance Abuse Treatment Admissions by Primary Substance of Abuse, According to Sex, Age Group, Race, and Ethnicity Tables 2014","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/teds-substance-abuse-treatment-admissions-primary-substance-abuse-according-sex-age-group","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4hqt-i24p","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["youth-mental-health","samhsa","mental-health","behavioral-health","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4hqt-i24p","description":"This is a behavioral health report for HHS Region VII of the United States and utilizes data from the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment (N-SSATS), collected annually. The topics addressed in the reports include youth mental health and treatment, substance use and substance use treatment.","title":"Behavioral Health Barometer: Region 7, Volume 6","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-region-7-volume-6","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-safety","medications","pharmaceuticals","health-care","fda"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA216582","description":"Pemetrexed is a prescription chemotherapy drug used to treat certain cancers, like non-small cell lung cancer and malignant pleural mesothelioma. It works by blocking folate metabolism in cancer cells. Given intravenously as a solution in vials of 100mg, 500mg, or 1g, it's manufactured by Teva Pharmaceuticals, Inc. This information was generated using AI and is provided for informational and research purposes only.","title":"Pemetrexed","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216582","description":"\n Access the FDA dataset for Pemetrexed — ANDA 216582 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Pemetrexed"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4hsm-bhph","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-2010","samhsa","suicidal-ideation","adult-mental-health","mental-illness-prevalence"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4hsm-bhph","description":"These are the detailed tables pertaining to adult mental health from the 2010 National Survey on Drug Use and Health (NSDUH). These detailed tables present standard errors for totals and prevalence estimates of past year any mental illness (AMI), serious mental illness (SMI), suicidal thoughts and behavior, major depressive episode (MDE), treatment for depression (among adults with MDE), mental health service utilization, and measuers related to the co-occurrence of mental disorders with substance use or with substance use disorders. Results are provided for age group, gender, race/ethnicity, education level, employment status, poverty level, geographic area, insurance status. Comparisons are made between 2010 and 2002 to 2009.","title":"Adult Mental Health Tables (Standard Errors and P values) - 1.1 to 1.64","programCode":["009:062"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/adult-mental-health-tables-standard-errors-and-p-values-11-164","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4hu4-iizr","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["reporting","data","child","guidance","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4hu4-iizr","description":"This Information Memorandum (IM) informs state and tribal title IV-E agencies about State and Tribal Child Welfare Information Systems and Information Security Data Breach Response Plans.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-15-04)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-15-04","description":"Access the complete IM-15-04 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4hw5-jsvu","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4hw5-jsvu","description":"Chemical compound data from PubChem database. IUPAC Name: 2-(furan-2-ylmethyl)-5-methylpyrazine. Molecular Formula: C10H10N2O. Molecular Weight: 174.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529870: 2-(2-Furfuryl)-5-methylpyrazine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529870","description":"Access the complete Compound 529870: 2-(2-Furfuryl)-5-methylpyrazine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nwss/index.html","bureauCode":["009:20"],"issued":"2026-05-01","@type":"dcat:Dataset","modified":"2026-07-10","keyword":["coronavirus","covid-19","nwss","sars-cov-2","united states","wastewater","weekly","ncezid"],"contactPoint":{"@type":"vcard:Contact","fn":"National Wastewater Surveillance System (NWSS)","hasEmail":"mailto:NWSS@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/j9g8-acpt","description":"This dataset provides a complete time history of SARS-CoV-2 wastewater sample data and calculated metrics from US sampling locations. \n\nLearn more at: https://www.cdc.gov/nwss/index.html.\n\nThis dataset is updated weekly on Fridays.","title":"CDC Wastewater Data for SARS-CoV-2","programCode":["009:028"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/j9g8-acpt/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/j9g8-acpt/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/j9g8-acpt/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"US States and Territories","license":"https://www.usa.gov/government-works","accrualPeriodicity":"R/P1W","theme":["Public Health Surveillance"],"language":["English"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4i2u-qgqw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","pubchem","innovation","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4i2u-qgqw","description":"An injection molding tool (10) for producing disc shaped moldings comprises primary and secondary plates (11,12) arranged opposite each other, which can move relative to each other to open and close the mould, and a mould ring (20). The latter surrounds the primary plate concentrically, closes off the injection mould (25) at the outer edge, and can move relative to the primary plate. An injection molding tool (10) for producing disc shaped moldings, especially in the form of information carriers such as CD's and/or DVD's, comprises primary and secondary plates (11,12) arranged opposite each other, which can move relative to each other to open and close the mould, and a mould ring (20). The latter surrounds the primary plate concentrically, closes off the injection mould (25) at the outer edge, and can move relative to the primary plate. A tempering arrangement (26) for the mould ring is located in the ring, and tempering can be carried out electrically or by use of a tempering medium. The tempering arrangement is in the form of a channel, and a tempering medium can be supplied to it via a connection. A second arrangement (28) is used to blow the finished molding over its peripheral region after the mould has been opened.","title":"Patent AT-E401184-T1: [Translated] INJECTION MOLDING TOOL FOR THE PRODUCTION OF DISK-SHAPED INFORMATION CARRIERS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401184-T1","description":"Access the complete Patent AT-E401184-T1: [Translated] INJECTION MOLDING TOOL FOR THE PRODUCTION OF DISK-SHAPED INFORMATION CARRIERS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"http://www.csus.edu/research/phsrp/brfss.html","issued":"2017-06-16","temporal":"2012-2018","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["education","adult","age","cigarettes","lghc","race. ethnicity","sex","smoking","tcb","tcp","tobacco","lets get healthy california","health insurance"],"contactPoint":{"@type":"vcard:Contact","fn":"Chronic Disease Surveillance and Research Branch (CDSRB), CDPH","hasEmail":"mailto:opendata@cdph.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"a66328ec-2a61-401a-8af1-84fc9e2e421d","description":"This is a source dataset for a Let's Get Healthy California indicator at https://letsgethealthy.ca.gov/. Adult smoking prevalence in California, males and females aged 18+, starting in 2012. Caution must be used when comparing the percentages of smokers over time as the definition of ‘current smoker’ was broadened in 1996, and the survey methods were changed in 2012. Current cigarette smoking is defined as having smoked at least 100 cigarettes in lifetime and now smoking every day or some days. Due to the methodology change in 2012, the Centers for Disease Control and Prevention (CDC) recommend not conducting analyses where estimates from 1984 – 2011 are compared with analyses using the new methodology, beginning in 2012. This includes analyses examining trends and changes over time. (For more information, please see the narrative description.)\r\nThe California Behavioral Risk Factor Surveillance System (BRFSS) is an on-going telephone survey of randomly selected adults, which collects information on a wide variety of health-related behaviors and preventive health practices related to the leading causes of death and disability such as cardiovascular disease, cancer, diabetes and injuries. Data are collected monthly from a random sample of the California population aged 18 years and older. The BRFSS is conducted by Public Health Survey Research Program of California State University, Sacramento under contract from CDPH. The survey has been conducted since 1984 by the California Department of Public Health in collaboration with the Centers for Disease Control and Prevention (CDC). In 2012, the survey methodology of the California BRFSS changed significantly so that the survey would be more representative of the general population. Several changes were implemented: 1) the survey became dual-frame, with both cell and landline random-digit dial components, 2) residents of college housing were eligible to complete the BRFSS, and 3) raking or iterative proportional fitting was used to calculate the survey weights. Due to these changes, estimates from 1984 – 2011 are not comparable to estimates from 2012 and beyond. Center for Disease Control and Policy (CDC) and recommend not conducting analyses where estimates from 1984 – 2011 are compared with analyses using the new methodology, beginning in 2012. This includes analyses examining trends and changes over time.Current cigarette smoking was defined as having smoked at least 100 cigarettes in lifetime and now smoking every day or some days. Prior to 1996, the definition of current cigarettes smoking was having smoked at least 100 cigarettes in lifetime and smoking now.","title":"Proportion of Adults Who Are Current Smokers (LGHC Indicator)","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/a66328ec-2a61-401a-8af1-84fc9e2e421d/resource/71a99ce5-3e6b-4be4-8cd0-b958d92c5b7b/download/proportion-of-adults-who-are-current-smokers-lghc-indicator-19.csv","description":"This is a source dataset for a Let's Get Healthy California indicator at https://letsgethealthy.ca.gov/. Adult smoking prevalence in California, males and females aged 18+, starting in 2012. Caution must be used when comparing the percentages of smokers over time as the definition of ‘current smoker’ was broadened in 1996, and the survey methods were changed in 2012. Current cigarette smoking is defined as having smoked at least 100 cigarettes in lifetime and now smoking every day or some days. Due to the methodology change in 2012, the Centers for Disease Control and Prevention (CDC) recommend not conducting analyses where estimates from 1984 – 2011 are compared with analyses using the new methodology, beginning in 2012. This includes analyses examining trends and changes over time. (For more information, please see the narrative description.)\r\nThe California Behavioral Risk Factor Surveillance System (BRFSS) is an on-going telephone survey of randomly selected adults, which collects information on a wide variety of health-related behaviors and preventive health practices related to the leading causes of death and disability such as cardiovascular disease, cancer, diabetes and injuries. Data are collected monthly from a random sample of the California population aged 18 years and older. The survey has been conducted since 1984 by the California Department of Public Health in collaboration with the Centers for Disease Control and Prevention (CDC). In 2012, the survey methodology of the California BRFSS changed significantly so that the survey would be more representative of the general population. Several changes were implemented: 1) the survey became dual-frame, with both cell and landline random-digit dial components, 2) residents of college housing were eligible to complete the BRFSS, and 3) raking or iterative proportional fitting was used to calculate the survey weights. Due to these changes, estimates from 1984 – 2011 are not comparable to estimates from 2012 and beyond. Center for Disease Control and Policy (CDC) and recommend not conducting analyses where estimates from 1984 – 2011 are compared with analyses using the new methodology, beginning in 2012. This includes analyses examining trends and changes over time.Current cigarette smoking was defined as having smoked at least 100 cigarettes in lifetime and now smoking every day or some days. Prior to 1996, the definition of current cigarettes smoking was having smoked at least 100 cigarettes in lifetime and smoking now.","@type":"dcat:Distribution","title":"Proportion of Adults Who Are Current Smokers (LGHC Indicator 19) (CSV)"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/a66328ec-2a61-401a-8af1-84fc9e2e421d/resource/96e35f60-1284-4625-8d49-e3f60231b96c/download/proportion-of-adults-who-are-current-smokers-lghc-indicator-19-dd.xlsx","description":"This is a source dataset for a Let's Get Healthy California indicator at https://letsgethealthy.ca.gov/. Adult smoking prevalence in California, males and females aged 18+, starting in 2012. Caution must be used when comparing the percentages of smokers over time as the definition of ‘current smoker’ was broadened in 1996, and the survey methods were changed in 2012. Current cigarette smoking is defined as having smoked at least 100 cigarettes in lifetime and now smoking every day or some days. Due to the methodology change in 2012, the Centers for Disease Control and Prevention (CDC) recommend not conducting analyses where estimates from 1984 – 2011 are compared with analyses using the new methodology, beginning in 2012. This includes analyses examining trends and changes over time. (For more information, please see the narrative description.)\r\nThe California Behavioral Risk Factor Surveillance System (BRFSS) is an on-going telephone survey of randomly selected adults, which collects information on a wide variety of health-related behaviors and preventive health practices related to the leading causes of death and disability such as cardiovascular disease, cancer, diabetes and injuries. Data are collected monthly from a random sample of the California population aged 18 years and older. The survey has been conducted since 1984 by the California Department of Public Health in collaboration with the Centers for Disease Control and Prevention (CDC). In 2012, the survey methodology of the California BRFSS changed significantly so that the survey would be more representative of the general population. Several changes were implemented: 1) the survey became dual-frame, with both cell and landline random-digit dial components, 2) residents of college housing were eligible to complete the BRFSS, and 3) raking or iterative proportional fitting was used to calculate the survey weights. Due to these changes, estimates from 1984 – 2011 are not comparable to estimates from 2012 and beyond. Center for Disease Control and Policy (CDC) and recommend not conducting analyses where estimates from 1984 – 2011 are compared with analyses using the new methodology, beginning in 2012. This includes analyses examining trends and changes over time.Current cigarette smoking was defined as having smoked at least 100 cigarettes in lifetime and now smoking every day or some days. Prior to 1996, the definition of current cigarettes smoking was having smoked at least 100 cigarettes in lifetime and smoking now.","@type":"dcat:Distribution","title":"Proportion of adults Who Are Current Smokers (LGHC Indicator 19)-DD"},{"mediaType":"text/html","downloadURL":"https://letsgethealthy.ca.gov/goals/living-well/reducing-adult-tobacco-use/","description":"California has led the nation in reducing smoking.[1] California has been a national leader in efforts to reduce smoking. As a major contributor to a range of chronic diseases, reducing smoking is a priority for living well. Smoking rates vary considerably by gender, race/ethnicity, income, and geography. By reducing these disparities and striving to achieve the 2022 target to bring the state’s overall smoking rate to 9 percent, California can continue to be a leader in efforts to lower smoking rates.[1]\r\n\r\nLearn more at [Let's Get Healthy California](https://letsgethealthy.ca.gov/goals/living-well/reducing-adult-tobacco-use/)\r\n\r\n[1] Let’s Get Health California Task Force. (2012). Let’s Get Healthy California Task Force Final Report. Let’s Get Healthy CA Task Force. http://www.chhs.ca.gov/pages/LGHCTF.aspx","@type":"dcat:Distribution","title":"Proportion of Adults Who are Current Smokers"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/a66328ec-2a61-401a-8af1-84fc9e2e421d/resource/4a865e0d-9b72-4a9a-8f6c-d72d222d76c3/download/proportion-of-adults-who-are-current-smokers-lghc-indicator-19-fnne3web.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Diseases and Conditions"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4i9p-jv3y","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","research","science","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4i9p-jv3y","description":"Chemical compound data from PubChem database. IUPAC Name: 13-methyl-3-trimethylsilyloxy-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-one. Molecular Formula: C21H30O2Si. Molecular Weight: 342.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526054: Trimethylsilylestrone","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526054","description":"Access the complete Compound 526054: Trimethylsilylestrone on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ias-idvb","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2024-10-24","references":["https://www.mathematica.org/"],"keyword":["scorecard","utility"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"8a655f73-c702-571c-9bb0-f100c4323e5d","description":"This is a dataset created for the Medicaid Scorecard website (https://www.medicaid.gov/state-overviews/scorecard/index.html), and is not intended for use outside that application.","title":"CoreSEt measure_value v2.10.6 (coreset-etl-test)","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/scorecard/core-set/2.10.6/20241023/measure_value.csv","description":"CoreSEt measure_value v2.10.6 (coreset-etl-test)","@type":"dcat:Distribution","title":"CoreSEt measure_value v2.10.6 (coreset-etl-test)"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4iei-j44b","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","chemistry","innovation","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4iei-j44b","description":"A high speed non-contact beam scanning device sized and shaped to provide the ergonomic benefits of a pen or wand, yet can scan a wide angle moving beam across an information-bearing target in one or two dimensional scan patterns such as lines, rasters or other patterns in order to read information therefrom. The device is well suited for reading one or two dimensional bar-code or other printed matter. In order to achieve the high density optical packaging necessary for its high performance to size benefits the device employs a novel in-line or \"axial\" gyrating, or \"axial\" scan element. The axial scan element can accept an input light beam at one end and cause it to emerge from its opposite end as a scanned beam, propagating in the same general forward direction it had upon entering the element. Reflected light, which carries information contained on the target, is collected by an internal non-imaging light concentrator and is processed by signal processing electronics. All components are integrated into a thin low mass module small enough to fit in a pen. Communication from the device is achievable by a cable or by wireless transmission.","title":"Patent AT-E400034-T1: [Translated] OPTICAL SCANNING PEN, SCANNING MODULE AND METHOD OF USE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400034-T1","description":"Access the complete Patent AT-E400034-T1: [Translated] OPTICAL SCANNING PEN, SCANNING MODULE AND METHOD OF USE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["fda","prescription-drugs","pharmaceuticals","public-health","drug-safety"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA077653","description":"Venlafaxine Hydrochloride is a generic prescription medication available as extended-release oral tablets in 150 mg and 225 mg strengths. It belongs to a class of drugs that inhibit serotonin and norepinephrine reuptake, commonly used to treat depression and anxiety disorders. Manufactured by Chartwell RX, LLC under ANDA209193. This information was generated using AI and is provided for informational and research purposes only.","title":"Venlafaxine hydrochloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=077653","description":"\n Access the FDA dataset for Venlafaxine hydrochloride — ANDA 077653 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Venlafaxine hydrochloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/mcdp-77g7","bureauCode":["009:20"],"issued":"2021-01-21","@type":"dcat:Dataset","modified":"2022-01-12","keyword":["poliovirus infection","psittacosis","nonparalytic","nndss","2021","nedss","netss","wonder"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/mcdp-77g7","description":"NNDSS - TABLE 1AA. Poliovirus infection, nonparalytic to Psittacosis - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.\n\nNotice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.\n\nNote: \nThis table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. \n\nFootnotes:\nU: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.\n-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.\nN: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.\nNN: Not nationally notifiable — This condition was not designated as being nationally notifiable.\nNP: Nationally notifiable but not published.\nNC: Not calculated — There is insufficient data available to support the calculation of this statistic.\nCum: Cumulative year-to-date counts.\n Max: Maximum — Maximum case count during the previous 52 weeks.\n * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. \n†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).","title":"NNDSS - TABLE 1AA. Poliovirus infection, nonparalytic to Psittacosis","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mcdp-77g7/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mcdp-77g7/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mcdp-77g7/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mcdp-77g7/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mcdp-77g7/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mcdp-77g7/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ihb-ihu9","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","science","research","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4ihb-ihu9","description":"Chemical compound data from PubChem database. IUPAC Name: (3,4,5-trimethoxyoxan-2-yl)methyl acetate. Molecular Formula: C11H20O6. Molecular Weight: 248.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526610: 1-O-Acetyl-2,6-anhydro-3,4,5-tri-O-methylhexitol","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526610","description":"Access the complete Compound 526610: 1-O-Acetyl-2,6-anhydro-3,4,5-tri-O-methylhexitol on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","pharmaceuticals","drug-manufacturers","health-care","drug-information"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA217413","description":"Arsenic Trioxide is a prescription injectable solution manufactured by Fresenius Kabi USA, LLC, used intravenously for medical treatment. Each milliliter contains 1 mg of arsenic trioxide. It is approved under ANDA208231 as a generic drug. This information was generated using AI and is provided for informational and research purposes only.","title":"Arsenic trioxide","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217413","description":"\n Access the FDA dataset for Arsenic trioxide — ANDA 217413 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Arsenic trioxide"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ij4-qrfr","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","innovation","patent","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4ij4-qrfr","description":"The radio reception unit has an antenna (1), a receiver (2) and an interference signal reception device (29). There is a coupling element (3) for receiving the pulsed interference signal (11) emitted by the automobile and an evaluation circuit (4) for providing a signal (7) indicating the interference, used for controlling a signal transmission element (6) within the receiver.","title":"Patent AT-E400083-T1: [Translated] DEVICE FOR SUPPRESSING THE RECEIPT OF VEHICLE EMITTED INTERFERENCE RADIATION","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400083-T1","description":"Access the complete Patent AT-E400083-T1: [Translated] DEVICE FOR SUPPRESSING THE RECEIPT OF VEHICLE EMITTED INTERFERENCE RADIATION on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"restricted public","landingPage":"https://wwwn.cdc.gov/nchs/nhanes/search/datapage.aspx?Component=LimitedAccess","bureauCode":["009:20"],"rights":"This dataset is restricted to authorized researchers due to indirect identifying sensitive information. Researchers must apply for data access through a proposal process, take confidentiality training and sign a data use agreement. If approved, data access would occur at a NCHS or Federal Statistical Research Data Center. For more information about submitting a proposal for data access, please see: https://www.cdc.gov/rdc/leftbrch/presubmit.htm.","issued":"2023-01-01","@type":"dcat:Dataset","temporal":"1999/2021","modified":"2025-04-21","references":["https://www.cdc.gov/nchs/nhanes/index.htm"],"keyword":["nhanes","nutrition","surveillance","research-data-center","survey","health statistics","nchs"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/9ixb-fwvy","description":"The National Health and Nutrition Examination Survey (NHANES) is designed to assess the health and nutritional status of adults and children in the United States. The survey is unique in that it combines interviews with standardized physical examinations and laboratory tests.The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, to update SAMHSA's Inventory of Substance Abuse Treatment Services (I-SATS), to analyze general treatment services trends, and to generate the National Directory of Drug and Alcohol Abuse Treatment Programs and its online equivalent, the Substance Abuse Treatment
\nFacility Locator http://findtreatment.samhsa.gov. Data are collected on topics including facility operation, services offered (assessment and pre-treatment, pharmacotherapies, testing, transitional, ancillary), detoxification, primary focus (substance abuse, mental health, both, general health, and other), hotline operation, Opioid Treatment Programs and medication dispensed/prescribed, counseling and therapeutic approaches, languages in which treatment is provided, type of treatment provided, number of clients (total and under age 18), number of beds, types of payment accepted, sliding fee scale, special programs offered, facility accreditation and licensure/certification, and managed care agreements.This study has 1 Data Set.
The National Health Interview Survey (NHIS) is the principal source of information on the health of the civilian noninstitutionalized population of the United States and is one of the major data collection programs of the National Center for Health Statistics (NCHS) which is part of the Centers for Disease Control and Prevention (CDC). The National Health Survey Act of 1956 provided for a continuing survey and special studies to secure accurate and current statistical information on the amount, distribution, and effects of illness and disability in the United States and the services rendered for or because of such conditions. The survey referred to in the Act, now called the National Health Interview Survey, was initiated in July 1957. Since 1960, the survey has been conducted by NCHS, which was formed when the National Health Survey and the National Vital Statistics Division were combined.
\nNHIS data are used widely throughout the Department of Health and Human Services (DHHS) to monitor trends in illness and disability and to track progress toward achieving national health objectives. The data are also used by the public health research community for epidemiologic and policy analysis of such timely issues as characterizing those with various health problems, determining barriers to accessing and using appropriate health care, and evaluating Federal health programs.
\nThe NHIS also has a central role in the ongoing integration of household surveys in DHHS. The designs of two major DHHS national household surveys have been or are linked to the NHIS. The National Survey of Family Growth used the NHIS sampling frame in its first five cycles and the Medical Expenditure Panel Survey currently uses half of the NHIS sampling frame. Other linkage includes linking NHIS data to death certificates in the National Death Index (NDI).
\nWhile the NHIS has been conducted continuously since 1957, the content of the survey has been updated about every 10-15 years. In 1996, a substantially revised NHIS questionnaire began field testing. This revised questionnaire, described in detail below, was implemented in 1997 and has improved the ability of the NHIS to provide important health information.
The Mouse Phenome Database (MPD) has characterizations of hundreds of strains of laboratory mice to facilitate translational discoveries and to assist in selection of strains for experimental studies.
","title":"Mouse Phenome Database (MPD)","programCode":["009:048"],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4q57-igvb","bureauCode":["009:00"],"issued":"2021-01-27","@type":"dcat:Dataset","modified":"2025-07-03","keyword":["covid-19","covid-19-spr"],"contactPoint":{"@type":"vcard:Contact","fn":"Data Strategy and Execution Workgroup","hasEmail":"mailto:COVID-Data-RFI@hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Department of Health and Human Services"},"identifier":"https://healthdata.gov/api/views/4q57-igvb","description":"After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.\nData about COVID-19 will continue to be updated at CDC’s COVID Data Tracker.\n \n\n\nThe State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.\n
\n\nIt is a weekly snapshot in time that:\nECM Community Support Services tables for a Quarterly Implementation Report. Including the County and Plan Details for both ECM and Community Support.
This Medi-Cal Enhanced Care Management (ECM) and Community Supports Calendar Year Quarterly Implementation Report provides a comprehensive overview of ECM and Community Supports implementation in the programs' first year. It includes data at the state, county, and plan levels on total members served, utilization, and provider networks.
ECM is a statewide MCP benefit that provides person-centered, community-based care management to the highest need members. The Department of Health Care Services (DHCS) and its MCP partners began implementing ECM in phases by Populations of Focus (POFs), with the first three POFs launching statewide in CY 2022.
Community Supports are services that address members’ health-related social needs and help them avoid higher, costlier levels of care. Although it is optional for MCPs to offer these services, every Medi-Cal MCP offered Community Supports in 2022, and at least two Community Supports services were offered and available in every county by the end of the year.
","title":"Chart 3.7 County Utilization Rates for Community Supports in the Last 12 Months of the Reporting Period","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/datasets/CADHCS::chart-3-7-county-utilization-rates-for-community-supports-in-the-last-12-months-of-the-reporting-period","mediaType":"text/html","title":"ArcGIS Hub Dataset"},{"@type":"dcat:Distribution","downloadURL":"https://services7.arcgis.com/7MUwsS9z05YumJRZ/arcgis/rest/services/ECM_Community_Support_Data_Tables_for_Quarterly_Implementation_report/FeatureServer/44","mediaType":"application/octet-stream","title":"ArcGIS GeoService"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/csv?layers=44","mediaType":"text/csv","title":"CSV"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/shapefile?layers=44","mediaType":"application/zip","title":"Shapefile"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/geojson?layers=44","mediaType":"application/geo+json","title":"GeoJSON"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/kml?layers=44","mediaType":"application/vnd.google-earth.kml+xml","title":"KML"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/33fc79cb-3dcd-41f2-84ef-352e3d3f2026/resource/adccc704-dde6-48fb-932a-4567a54e8290/download/chart-3-7-county-utilization-rates-for-community-supports-in-the-last-12-months-of-the-reportin-.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ret-r6gu","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","science","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4ret-r6gu","description":"Chemical compound data from PubChem database. IUPAC Name: diethyl(dipropoxy)silane. Molecular Formula: C10H24O2Si. Molecular Weight: 204.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525752: Dipropyloxydiethylsilane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525752","description":"Access the complete Compound 525752: Dipropyloxydiethylsilane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rf6-yv2d","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["noms-measures","mental-health-services","block-grant-program","community-mental-health","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4rf6-yv2d","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2010 CMHS Uniform Reporting System (URS) Output Tables for Connecticut","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2010-cmhs-uniform-reporting-system-urs-output-tables-connecticut","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rfe-y7fm","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["policy","child","data","scope","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4rfe-y7fm","description":"This issue of Child and Family Services Reviews Update contains the following sections:Technical Bulletin #12 Issued, Systematic Factors Report for Round 3 Released, Statewide Data indicators Updated, and CFSR Information Portal Refresh: New Look and Feel!\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Child and Family Services Reviews Update Volume 14, Issue 4, September 2020","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/child-and-family-services-reviews-update-volume-14-issue-4-september-2020","description":"Access the complete Child and Family Services Reviews Update Volume 14, Issue 4, September 2020 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rfg-2nv5","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","proteoglycans","articular-cartilage","extracellular-matrix","osteoarthritis"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4rfg-2nv5","description":"Cartilage contains numerous noncollagenous proteins in its extracellular matrix, including proteoglycans. At least 40 such molecules have been identified, differing greatly in structure, distribution, and function. Some are present in only selected cartilages or cartilage zones, some vary in their presence with a person's development and age, and others are more universal in their expression. Some may not even be made by the chondrocytes, but may arise by absorption from the synovial fluid. In many cases, the molecules' function is unclear, but the importance of others is illustrated by their involvement in genetic disorders. This review provides a selective survey of these molecules and discusses their structure, function, and involvement in inherited and arthritic disorders.","title":"Articular cartilage and changes in arthritis: Noncollagenous proteins and proteoglycans in the extracellular matrix of cartilage","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128909/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rg9-kqxi","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","innovation","chemistry","research","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4rg9-kqxi","description":"[Translated] A method of repairing hair that has been subjected to oxidative treatments, the methods comprising the sequential steps of: (i) soaking the hair in an aqueous treatment composition, (ii) rinsing the hair of step (i); characterized in that the aqueous treatment composition comprises 0.1 to 6% by weight of N-acetyl amino acid, based on the total weight of the composition, where the N-acetyl amino acid is selected from the group consisting of N-acetyl glycine , N-acetyl alanine, N-acetyl proline, N-acetyl leucine, N-acetyl isoleucine, N-acetyl valine, N-acetyl tyrosine, N-acetyl phenylalanine, N-acetyl tryptophan, N-acetyl serine, N-acetyl glutamine , N-acetyl threonine, N-acetyl asparagine, N-acetyl methionine, N-acetyl lysine, N-acetyl histidine and their mixtures, provide damage repair benefits.","title":"Patent AR-114334-A1: [Translated] METHOD TO REPAIR HAIR SUBJECTED TO OXIDANT TREATMENTS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AR-114334-A1","description":"Access the complete Patent AR-114334-A1: [Translated] METHOD TO REPAIR HAIR SUBJECTED TO OXIDANT TREATMENTS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/m2d8-45rb","issued":"2025-03-28","@type":"dcat:Dataset","modified":"2026-04-02","keyword":["2021","pnds","q4"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/m2d8-45rb","description":"This Provider Network Data contains information on individual and institutional providers participating in health plan networks from October through December 2021. Plan network data is collected from Medicaid, Commercial, and Exchange plans on a quarterly basis by the Department of Health, including managed care plans, as well as PPO/EPO plans.\n\nFor more information, please visit: https://pndslookup.health.ny.gov","title":"Provider Network Data: 2021 Quarter 4","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/download/m2d8-45rb/application/x-zip-compressed","mediaType":"application/x-zip-compressed"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rhr-yfmr","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4rhr-yfmr","description":"Chemical compound data from PubChem database. IUPAC Name: dodec-9-ynyl 3-methoxybenzoate. Molecular Formula: C20H28O3. Molecular Weight: 316.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530490: m-Anisic acid, dodec-9-ynyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530490","description":"Access the complete Compound 530490: m-Anisic acid, dodec-9-ynyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rje-wq73","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","n-ssats","facility-licensing","accreditation","substance-abuse-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4rje-wq73","description":"This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing facility licensing, certification, or accreditation, by facility operation and primary focus of facility in 2010. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.","title":"4.15b Facility licensing, certification, or accreditation, by facility operation and primary focus of facility: 2010. Percent","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/415b-facility-licensing-certification-or-accreditation-facility-operation-and-primary-0","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.cms.gov/summary-statistics-on-use-and-payments/medicare-geographic-comparisons/medicare-geographic-variation-by-hospital-referral-region","bureauCode":["009:38"],"issued":"2026-07-10","temporal":"2013-01-01/2021-12-31","@type":"dcat:Dataset","modified":"2025-09-05","references":["https://data.cms.gov/sites/default/files/2025-03/db845ad7-ac40-467f-a504-6a7942d06b51/Geographic%20Variation%20Public%20Use%20File%20Methods%20Paper%20HRR.pdf"],"keyword":["health care use & payments","health equity","hospital referral regions","medicare","national","original medicare"],"contactPoint":{"@type":"vcard:Contact","fn":"PDAG Data Products - OEDA","hasEmail":"mailto:PDAG_Data_Products@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"https://data.cms.gov/data-api/v1/dataset/6d7b229d-5bfb-4666-a2d2-38cea44a112c/data-viewer","description":"The Medicare Geographic Variation by Hospital Referral Region dataset provides information for researchers and policymakers to evaluate the geographic differences in the use and quality of health care services for the Original Medicare population. The dataset includes demographic, spending, use, and quality indicators at the hospital referral region (HRR) level.","title":"Medicare Geographic Variation - by Hospital Referral Region","describedByType":"application/pdf","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-12/2014-2021%20Medicare%20FFS%20Geographic%20Variation%20HRR%20Public%20Use%20File.zip","mediaType":"application/zip","title":"Medicare Geographic Variation - by Hospital Referral Region : 2021-12-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-12/2007-2013%20Medicare%20FFS%20Geographic%20Variation%20HRR%20Public%20Use%20File.zip","mediaType":"application/zip","title":"Medicare Geographic Variation - by Hospital Referral Region : 2013-12-01"}],"describedBy":"https://data.cms.gov/sites/default/files/2025-03/3623a012-f189-4b2f-80ef-6fdc0ffb2804/2014-2021%20Medicare%20FFS%20Geographic%20Variation%20by%20Hospital%20Referral%20Region%20Data%20Dictionary.pdf","dataQuality":true,"license":"https://www.usa.gov/government-works","accrualPeriodicity":"R/P1Y","theme":["Medicare"],"language":["en-US"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rk8-n6d9","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["reporting","fiscal","compliance","instruction","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4rk8-n6d9","description":"This Program Instruction (PI) provides guidance to states, territories, and insular areas (hereafter “states,” unless otherwise noted) on actions they are required to take to receive their allotments for Federal Fiscal Year (FY)1 2023 (subject to the availability of appropriations) authorized under title IV-B, subparts 1 and 2, section 106 of CAPTA, Chafee and ETV programs.\n\nPI-22-01 (PDF)\n\nFiscal Year 2021 Allotments to States, Territories and Insular Areas Title IV-B, Subpart 1 Step Stephanie Tubbs Jones Child Welfare Services\nFiscal Year 2021 Allotments to States, Territories, and Insular Areas Title IV-B, Subpart 2 Promoting Safe and Stable Families (PSSF) Grant\nFiscal Year 2021 Supplemental Allotments to States and Territories MaryLee Allen Promoting Safe and Stable Families Program\nFiscal Year 2021 Allotments to State, Territories and Insular Areas Monthly Caseworker Visit Formula Grants\nFiscal Year 2021 Allotments to States and Indian Tribes\\Tribal Organizations Title IV-B Kinship Navigator Funds\nFiscal Year 2021 Allotments to States and Indian Tribes\\Tribal Organizations John H. Chafee Foster Care Program for Successful Transition to Adulthood\nFiscal Year 2021 Allotments to States and Indian Tribes\\Tribal Organizations John H. Chafee Foster Care Program Education and Training Voucher (CETV Grants)\nFiscal Year 2021 Additional Allotments to States and Tribes John H. Chafee Foster Care Program Education and Training Vouchers\nFiscal Year 2021 Allotments to States, Territories and Insular Areas Child Abuse Prevention and Treatment Act (CAPTA) State Grants\nFiscal Year 2021 Supplemental Allotments to States and Territories Child Abuse Prevention and Treatment Act (CAPTA)\nFiscal Year 2020 Allotments to States, Territories and Insular Areas Family First Prevention Services Act Transition Grant Funding\n\nCFS-101 Instructions, Part I, II, and III\n\nIntroduction\nPart I Instructions: Annual Budget Request for Funds under Title IV-B, Subparts 1 & 2, CAPTA State Grant, Chafee, and ETV\nPart II Instructions: Annual Estimated Expenditure Summary of Child and Family Services Funds\nPart III Instructions: Expenditures for Title IV-B, Subparts 1 and 2, John H. Chafee Foster Care Program for Successful Transition to Adulthood, and Education and Training Voucher (ETV) Program\n\nCFS-101 Forms, Parts I, II and III Excel Workbook (XLSX)\n\nCFS-101 Forms Part I\nCFS-101 Forms Part II\nCFS-101 Forms Part III\n\nAnnual Reporting of Education and Training Vouchers Awarded\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Actions Required for 2022 State Submissions of APSR Updates; CAPTA State Plan Updates; and Parts I, II, and III of the CFS-101","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-22-01","description":"Access the complete Actions Required for 2022 State Submissions of APSR Updates; CAPTA State Plan Updates; and Parts I, II, and III of the CFS-101 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rnm-7hue","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4rnm-7hue","description":"Chemical compound data from PubChem database. IUPAC Name: 3,7-dimethyloct-6-enyl 5-methylhexanoate. Molecular Formula: C17H32O2. Molecular Weight: 268.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527283: Citronellyl isoheptanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527283","description":"Access the complete Compound 527283: Citronellyl isoheptanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rpm-92uq","bureauCode":["009:70"],"issued":"2024-09-19","@type":"dcat:Dataset","modified":"2025-02-03","keyword":["children and families","early care and education","child care"],"contactPoint":{"@type":"vcard:Contact","fn":"Helen Papadopoulos","hasEmail":"mailto:helen.papadopoulos@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"ACF"},"identifier":"https://healthdata.gov/api/views/4rpm-92uq","description":"The Child Care and Development Fund statistics are compiled through data reported by States and Territories on the ACF-800--Annual Aggregate Child Care Data Report and ACF-801—Monthly Child Care Data Report. \n\nUnits of Response: CCDF Agencies \n\nType of Data: Administrative \n\nTribal Data: No \n\nPeriodicity: Annual \n\nDemographic Indicators: Disability;Ethnicity;Housing Status;Race\n\nSORN: Not Applicable \n\nData Use Agreement: Unavailable \n\nData Use Agreement Location: Unavailable \n\nGranularity: State;U.S. Territory \n\nSpatial: United States \n\nGeocoding: State","title":"Child Care and Development Fund (CCDF) Statistics","programCode":["009:089"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.acf.hhs.gov/occ/data/child-care-and-development-fund-statistics","description":"Data tables for Child Care and Development Fund statistics that were compiled through data reported by States and Territories on the ACF-800--Annual Aggregate Child Care Data Report and ACF-801—Monthly Child Care Data Report. Temporal: FY 1998 - 2021, Restriction: Public-use Aggregate, Formats: Excel ","@type":"dcat:Distribution","title":"CCDF Statistics Data Tables"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rr3-ptkn","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","chemistry","research","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4rr3-ptkn","description":"Chemical compound data from PubChem database. IUPAC Name: bis[tert-butyl(dimethyl)silyl] 2-methylbutanedioate. Molecular Formula: C17H36O4Si2. Molecular Weight: 360.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528584: Bis[tert-butyl(dimethyl)silyl] 2-methylsuccinate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528584","description":"Access the complete Compound 528584: Bis[tert-butyl(dimethyl)silyl] 2-methylsuccinate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rre-ah54","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["illicit-drugs","samhsa","mental-health","major-depression","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4rre-ah54","description":"This report presents Wisconsin\\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"Wisconsin: 2011-2012 NSDUH","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/wisconsin-2011-2012-nsduh","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rru-mitx","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","community-mental-health","mental-health-services","national-outcome-measures","northern-mariana-islands"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4rru-mitx","description":"2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Northern Mariana Islands. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2015 CMHS Uniform Reporting System (URS) Table for Northern Mariana Islands","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2015-cmhs-uniform-reporting-system-urs-table-northern-mariana-islands","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/qgiq-jqkw","issued":"2020-02-12","@type":"dcat:Dataset","modified":"2020-02-12","keyword":["lead","school","drinking water"],"contactPoint":{"@type":"vcard:Contact","fn":"Christensen, Lisa K (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/qgiq-jqkw","description":"Lead in Drinking Water in Schools Test Results – Kilo Middle School Part 2","title":"Kilo Middle School Part 2","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/qgiq-jqkw/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4rum-vqci","bureauCode":["009:00"],"issued":"2021-01-27","@type":"dcat:Dataset","modified":"2025-07-03","keyword":["covid-19","covid-19-spr"],"contactPoint":{"@type":"vcard:Contact","fn":"Data Strategy and Execution Workgroup","hasEmail":"mailto:COVID-Data-RFI@hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Department of Health and Human Services"},"identifier":"https://healthdata.gov/api/views/4rum-vqci","description":"After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.\nData about COVID-19 will continue to be updated at CDC’s COVID Data Tracker.\n \n\n\nThe State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.\n
\n\nIt is a weekly snapshot in time that:\nThis series measures the prevalence and correlates of drug use in the United States. The surveys are designed to provide quarterly, as well as annual, estimates. Information is provided on the use of illicit drugs, alcohol, tobacco, and nonmedical use of prescription drugs among members of United States households aged 12 and older. Questions include age at first use, as well as lifetime, annual, and past-month usage for the following drug classes: cannabis, cocaine, hallucinogens, heroin, inhalants, alcohol, tobacco, nonmedical use of prescription drugs including psychotherapeutics, and polysubstance use. Respondents were also asked about their knowledge of drugs, perceptions of the risks involved, population movement, and sequencing of drug use. Fifty-seven percent of respondents were asked specific questions about their perceptions of the consequences of marijuana and alcohol use. The other 43 percent were asked about heroin use among friends. Demographic data include sex, race, age, ethnicity, marital status, educational level, job status, income level, and household composition. This study has 1 Data Set.
","title":"National Household Survey on Drug Abuse (NHSDA-1979)","programCode":["009:030"],"distribution":[{"mediaType":"text/html","downloadURL":"https://datafiles.samhsa.gov/study/national-household-survey-drug-abuse-nhsda-1979-nid13635","description":"National Household Survey on Drug Abuse (NHSDA-1979) \n","@type":"dcat:Distribution","title":"https://datafiles.samhsa.gov/study/national-household-survey-drug-abuse-nhsda-1979-nid13635"}]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ryh-b4p4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","science","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4ryh-b4p4","description":"Chemical compound data from PubChem database. IUPAC Name: 1-prop-2-ynylsulfanylpropane. Molecular Formula: C6H10S. Molecular Weight: 114.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525484: Propyl propargyl sulfide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525484","description":"Access the complete Compound 525484: Propyl propargyl sulfide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4s7p-umhj","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4s7p-umhj","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865713: MLS000084381","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865713","description":"Access the complete Substance 865713: MLS000084381 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4s88-9sy8","bureauCode":["009:38"],"issued":"2018-07-11","@type":"dcat:Dataset","modified":"2026-02-12","keyword":["medicaid"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"927f4847-2c0a-50c1-8f50-9103de7d048b","description":"2024 Managed Care Features by Enrollment Population\n\nThe Managed Care Features by Enrollment Population table (Table 7 in the Enrollment Report) lists the total number of managed care programs in the country by type (comprehensive managed care, PCCM, dental, etc.) and lists the number of managed care programs by type that mandatorily or voluntarily enroll each population type which includes duals, children with special health care needs, and American Indians/Alaska Natives (AI/AN) population.\n\n1.\tIn some cases, the sum of mandatory and voluntary enrollment populations for any given program type is greater than the total number of programs of that type. That is because a state may treat individuals within a specific group differently. For example, a state can mandate enrollment for aged adults, while allowing blind and disabled adults to enroll voluntarily.\n2.\tCertain federal statutory authorities do not allow enrollment of individuals who are AI/AN or children receiving Foster Care and Adoption Assistance (FC/AA). Where states use these authorities to operate Medicaid managed care, AI/AN individuals or children receiving FC/AA are considered \"exempt.\"\n\n2023 Managed Care Features by Enrollment Population\n\nThe Managed Care Features by Enrollment Population table (Table 7 in the Enrollment Report) lists the total number of managed care programs in the country by type (e.g., Comprehensive MCO, PCCM, Dental) and lists the number of managed care programs by type that mandatorily or voluntarily enroll each population type which includes duals, children with special health care needs, and American Indians/Alaska Natives (AI/AN) population.\n\n1.\tIn some cases, the sum of mandatory and voluntary enrollment populations for any given program type is greater than the total number of programs of that type. That is because a state may treat individuals within a specific group differently. For example, a state can mandate enrollment for aged adults, while allowing blind and disabled adults to enroll voluntarily.\n2.\tCertain federal statutory authorities do not allow enrollment of individuals who are AI/AN or children receiving Foster Care and Adoption Assistance (FC/AA). Where states use these authorities to operate Medicaid managed care, AI/AN individuals or children receiving FC/AA are considered \"exempt.\"","title":"Managed Care Features By Enrollment Population","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/managed-care-features-by-enrollment-population.2024-table7.csv","mediaType":"text/csv","title":"CSV"}],"license":"https://www.usa.gov/government-works","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4s8m-wxcr","issued":"2019-10-31","@type":"dcat:Dataset","modified":"2019-10-31","keyword":["health","prescription drug","unintentional deaths"],"contactPoint":{"@type":"vcard:Contact","fn":"nucivic","hasEmail":"mailto:servicedesk@omes.ok.gov"},"publisher":{"@type":"org:Organization","name":"State of Oklahoma"},"identifier":"69e256be-8343-4284-a771-c33817e08731","description":"Decrease the rate of unintentional poisoning deaths involving prescription drugs from 13.3 per 100,000 in 2011 to 11.3 per 100,000 by 2017.
","title":"Unintentional Prescription Drug Deaths","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.ok.gov/dataset/69e256be-8343-4284-a771-c33817e08731/resource/7b74fea8-1f31-4515-8606-016ede0d4b7c/download/data-unintentional-prescription-drug-deaths.csv","description":"Decrease the rate of unintentional poisoning deaths involving prescription drugs from 13.3 per 100,000 in 2011 to 11.3 per 100,000 by 2017.
","@type":"dcat:Distribution","title":"Data - Unintentional Prescription Drug Deaths"},{"mediaType":"text/csv","downloadURL":"https://data.ok.gov/dataset/69e256be-8343-4284-a771-c33817e08731/resource/c1dc5450-ecb0-4672-86bb-db1d54defc5f/download/c-unintentional-prescription-drug-deaths-column-chart.csv","description":"Decrease the rate of unintentional poisoning deaths involving prescription drugs from 13.3 per 100,000 in 2011 to 11.3 per 100,000 by 2017.
","@type":"dcat:Distribution","title":"(C) - Unintentional Prescription Drug Deaths - Column Chart"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/dataset/veto-violence-violence-education-tools-online","bureauCode":["009:20"],"issued":"2014-04-08","@type":"dcat:Dataset","modified":"2025-01-28","keyword":["child maltreatment","suicide","training","stories","sexual assault","principles of prevention pop","public health","intimate partner violence","violence prevention","health care providers","other","safety","youth"],"contactPoint":{"@type":"vcard:Contact","fn":"Veto Violence","hasEmail":"mailto:VetoViolence@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention, Department of Health & Human Services"},"identifier":"8066116e-e17a-42cb-af33-96bbd0e302c0","description":"VetoViolence.cdc.gov has been developed by the Centers for Disease Control and Prevention (CDC) to provide grantees and partners with access to training and tools that focus on the primary prevention of violence. The portal includes free training, program planning resources, and an online application for the creation of success stories.
","title":"Veto Violence - Violence Education Tools Online","programCode":["009:099"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://vetoviolence.cdc.gov/","mediaType":"text/html","title":"Text "},{"mediaType":"text/html","downloadURL":"https://vetoviolence.cdc.gov/apps/main/tools-and-trainings","description":"Strengthen Your Prevention Toolkit\n\nDive deeper into topics about violence prevention programs and practice, such as how to address risks shared by different forms of violence or how to effectively build partnerships. Each tool and training will equip you with a unique set of skills that can bolster your work to stop violence before it starts.","@type":"dcat:Distribution","title":" Tools and Tranings"}],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Community"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/wcwi-x3uk","bureauCode":["009:00"],"issued":"2015-01-12","@type":"dcat:Dataset","modified":"2016-03-29","keyword":["rabies human","leptospirosis","listeriosis","measles","meningococcal disease invasive","mmwr","nedss","netss","nndss","novel influenza a","plague","poliomyelitis paralytic","polio virus infection nonparalytic","postdiarrheal","powassan virus disease","psittacosis","yellow fever","wonder","western equine virus disease","viral hemorrhagic fever","vibriosis","vancomycin","typhoid fever","tularemia","trichinellosis","toxic-shock syndrome (staphylococcal)","tetanus","syphilis congenital (age <1 yr)","streptococcal toxic-shock syndrome","st. louis virus disease","smallpox","sars-cov","rubella congenital syndrome","rubella","q fever","2014","anthrax","arboviral diseases","botulism","brucellosis","california serogroup virus disease","chancroid","cholera","cyclosporiasis","diphtheria","eastern equinevirus disease","encephalitis","haemophilus influenzae invasive","hansen disease","hantavirus pulmonary syndrome","hemolytic uremic syndrome","hepatitis b infection perinatal","influenza-associated pediatric mortality"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/wcwi-x3uk","description":"NNDSS - Table I. infrequently reported notifiable diseases - 2014.In this Table, provisional cases of selected infrequently reported notifiable diseases (<1,000 cases reported during the preceding year) are displayed. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in these tables are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnote:-: No reported cases N: Not reportable NN: Not Nationally Notifiable Cum: Cumulative year-to-date counts. * Case counts for reporting year 2014 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. ��� Calculated by summing the incidence counts for the current week, the 2 weeks preceding the current week, and the 2 weeks following the current week, for a total of 5 preceding years. The total sum of incident cases is then divided by 25 weeks. Additional information is available at http://wwwn.cdc.gov/nndss/document/5yearweeklyaverage.pdf. �� Not reportable in all states. Data from states where the condition is not reportable are excluded from this table except starting in 2007 for the Arboviral diseases, STD data, TB data, and influenza-associated pediatric mortality, and in 2003 for SARS-CoV. Reporting exceptions are available at http://wwwn.cdc.gov/nndss/document/SRCA_FINAL_REPORT_2006-2012_final.xlsx. �� Includes both neuroinvasive and nonneuroinvasive. Updated weekly from reports to the Division of Vector-Borne Infectious Diseases, National Center for Zoonotic, Vector-Borne, and Enteric Diseases (ArboNET Surveillance). Data for West Nile virus are available in Table II. ** Data for H. influenzae (all ages, all serotypes) are available in Table II. ��ʉ�� Updated weekly from reports to the Influenza Division, National Center for Immunization and Respiratory Diseases. Please refer to the MMWR publication for weekly updates to the footnote for this condition. ���� Please refer to the MMWR publication for weekly updates to the footnote for this condition. ���� Data for meningococcal disease (all serogroups) are available in Table II. *** Please refer to the MMWR publication for weekly updates to the footnote for this condition. ��ʉ�ʉ�� Please refer to the MMWR publication for weekly updates to the footnote for this condition. ������ Updated weekly from reports to the Division of STD Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. ������ Please refer to the MMWR publication for weekly updates to the footnote for this condition. See Table II for Dengue Hemorrhagic Fever.More information on NNDSS is available at http://wwwn.cdc.gov/nndss/.","title":"NNDSS - Table I. infrequently reported notifiable diseases","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/wcwi-x3uk/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/wcwi-x3uk/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/wcwi-x3uk/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4sbw-nqet","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4sbw-nqet","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865834: MLS000083733","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865834","description":"Access the complete Substance 865834: MLS000083733 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/484g-ihkb","bureauCode":["009:00"],"issued":"2019-04-24","@type":"dcat:Dataset","modified":"2020-01-02","keyword":["listeriosis","2019","legionellosis","leptospirosis","nedss","netss","nndss","wonder"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/484g-ihkb","description":"NNDSS - TABLE 1U. Legionellosis to Listeriosis - 2019. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents. \r\n\r\nNote: \r\nThis table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. \r\n\r\nFootnotes:\r\nU: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.\r\n-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.\r\nN: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.\r\nNN: Not nationally notifiable — This condition was not designated as being nationally notifiable.\r\nNP: Nationally notifiable but not published — CDC does not have data because of changes in how conditions are categorized.\r\nCum: Cumulative year-to-date counts.\r\nMax: Maximum — Maximum case count during the previous 52 weeks.\r\n* Case counts for reporting years 2018 and 2019 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the US, a US territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-US Residents' category. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. \r\n† Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).","title":"NNDSS - TABLE 1U. Legionellosis to Listeriosis","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/484g-ihkb/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/484g-ihkb/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/484g-ihkb/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4sej-cavq","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["foster","adoption","reporting","policy","instruction"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4sej-cavq","description":"This TB provides guidance for installing and executing the Adoption and Foster Care Analysis and Reporting System (AFCARS) Encryption/Decryption Utility.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"AFCARS Technical Bulletin #8 - AFCARS Encryption/Decryption Utility: C Version 2.1","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/afcars-technical-bulletin-8-afcars-encryption/decryption-utility-c-version-21","description":"Access the complete AFCARS Technical Bulletin #8 - AFCARS Encryption/Decryption Utility: C Version 2.1 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"restricted public","landingPage":"https://www.hcup-us.ahrq.gov/db/nation/nrd/nrddbdocumentation.jsp","bureauCode":["009:33"],"rights":"Restricted Public","issued":"2021-02-13","@type":"dcat:Dataset","modified":"2023-07-25","keyword":["ambulatory surgery","emergency department","inpatient hospital","readmissions","revisits"],"contactPoint":{"@type":"vcard:Contact","fn":"HCUP Technical Support","hasEmail":"mailto:hcup@ahrq.gov"},"publisher":{"@type":"org:Organization","name":"Agency for Healthcare Research and Quality, Department of Health & Human Services"},"identifier":"b2fbf730-37f9-407b-bc31-452ff181cef5","description":"The Healthcare Cost and Utilization Project (HCUP) Nationwide Readmissions Database (NRD) is a unique and powerful database designed to support various types of analyses of national readmission rates for all payers and the uninsured. The NRD includes discharges for patients with and without repeat hospital visits in a year and those who have died in the hospital. Repeat stays may or may not be related. The criteria to determine the relationship between hospital admissions is left to the analyst using the NRD. This database addresses a large gap in health care data - the lack of nationally representative information on hospital readmissions for all ages. Outcomes of interest include national readmission rates, reasons for returning to the hospital for care, and the hospital costs for discharges with and without readmissions. Unweighted, the NRD contains data from approximately 18 million discharges each year. Weighted, it estimates roughly 35 million discharges. Developed through a Federal-State-Industry partnership sponsored by the Agency for Healthcare Research and Quality, HCUP data inform decision making at the national, State, and community levels. \n\nThe NRD is drawn from HCUP State Inpatient Databases (SID) containing verified patient linkage numbers that can be used to track a person across hospitals within a State, while adhering to strict privacy guidelines. The NRD is not designed to support regional, State-, or hospital-specific readmission analyses. \n\nThe NRD contains more than 100 clinical and non-clinical data elements provided in a hospital discharge abstract. Data elements include but are not limited to: diagnoses, procedures, patient demographics (e.g., sex, age), expected source of payer, regardless of expected payer, including but not limited to Medicare, Medicaid, private insurance, self-pay, or those billed as ‘no charge, discharge month, quarter, and year, total charges, length of stay, and data elements essential to readmission analyses. The NIS excludes data elements that could directly or indirectly identify individuals. \n\nRestricted access data files are available with a data use agreement and brief online security training.","title":"HCUP Nationwide Readmissions Database (NRD)- Restricted Access Files","programCode":["009:072"],"describedBy":"https://www.hcup-us.ahrq.gov/db/nation/nrd/nrddbdocumentation.jsp","license":"https://www.distributor.hcup-us.ahrq.gov/Home.aspx"},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4sf5-gmuk","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["histology-education","learning-strategies","medical-student-assessment","nih","reward-system"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4sf5-gmuk","description":"Background\n Assessment, as an inextricable component of the curriculum, is an important factor influencing student approaches to learning. If assessment is to drive learning, then it must assess the desired outcomes. In an effort to alleviate some of the anxiety associated with a traditional discipline-based second year of medical studies, a bonus system was introduced into the Histology assessment. Students obtaining a year mark of 70% were rewarded with full marks for some tests, resulting in many requiring only a few percentage points in the final examination to pass Histology.\n \n \n Methods\n In order to ascertain whether this bonus system might be impacting positively on student learning, thirty-two second year medical students (non-randomly selected, representing four academic groups based on their mid-year results) were interviewed in 1997 and, in 1999, the entire second year class completed a questionnaire (n = 189). Both groups were asked their opinions of the bonus system.\n \n \n Results\n Both groups overwhelming voted in favour of the bonus system, despite less than 45% of students failing to achieve it. Students commented that it relieved some of the stress of the year-end examinations, and was generally motivating with regard to their work commitment.\n \n \n Conclusions\n Being satisfied with how and what we assess in Histology, we are of the opinion that this reward system may contribute to engendering appropriate learning approaches (i.e. for understanding) in students. As a result of its apparent positive influence on learning and attitudes towards learning, this bonus system will continue to operate until the traditional programme is phased out. It is hoped that other educators, believing that their assessment is a reflection of the intended outcomes, might recognise merit in rewarding students for consistent achievement.","title":"Introducing a reward system in assessment in histology: A comment on the learning strategies it might engender","programCode":["009:038"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC61030/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4sfm-eyek","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","pubchem","bioactivity","chemistry","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4sfm-eyek","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864855: MLS000083363","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864855","description":"Access the complete Substance 864855: MLS000083363 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4sir-i3tj","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","research","pubchem","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4sir-i3tj","description":"Chemical compound data from PubChem database. IUPAC Name: octadecyl 4-ethylbenzoate. Molecular Formula: C27H46O2. Molecular Weight: 402.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530558: 4-Ethylbenzoic acid, octadecyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530558","description":"Access the complete Compound 530558: 4-Ethylbenzoic acid, octadecyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/kbvx-cjh9","issued":"2018-08-16","@type":"dcat:Dataset","modified":"2018-08-16","keyword":["drinking water","lead","schools"],"contactPoint":{"@type":"vcard:Contact","fn":"Willc13","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/kbvx-cjh9","description":"Dick Scobee Lead in drinking water test results","title":"Dick Scobee Elementary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/kbvx-cjh9/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://data.oregon.gov/d/th67-pshd","issued":"2026-06-09","@type":"dcat:Dataset","modified":"2026-06-09","contactPoint":{"@type":"vcard:Contact","fn":"James Kwasnik","hasEmail":"mailto:no-reply@data.oregon.gov"},"publisher":{"@type":"org:Organization","name":"State of Oregon"},"identifier":"https://data.oregon.gov/api/views/th67-pshd","description":"List of applications whether they were selected, alternates, or not selected.","title":"Factory-Produced Housing Initiative Funding Awardees","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/th67-pshd/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/th67-pshd/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/th67-pshd/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4sup-mfzm","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4sup-mfzm","description":"Chemical compound data from PubChem database. IUPAC Name: N'-cyclohexyl-N,N-dimethylbenzenecarboximidamide. Molecular Formula: C15H22N2. Molecular Weight: 230.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525618: N,N-Dimethyl-N'-cyclohexyl-benzamidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525618","description":"Access the complete Compound 525618: N,N-Dimethyl-N'-cyclohexyl-benzamidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4sw8-9xm9","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","science","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4sw8-9xm9","description":"Chemical compound data from PubChem database. IUPAC Name: 3-(bromomethyl)-3-[(4-methylphenoxy)methyl]oxetane. Molecular Formula: C12H15BrO2. Molecular Weight: 271.15. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529252: Oxetane, 3-bromomethyl-3-(4-methylphenyloxy)methyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529252","description":"Access the complete Compound 529252: Oxetane, 3-bromomethyl-3-(4-methylphenyloxy)methyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4swi-2ibx","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pediatric-poisoning","samhsa","accidental-ingestion","drug-overdose","emergency-department"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4swi-2ibx","description":"Excel file with estimates, rates, relative standard errors, trends and confidence intervals, covering 2004-2011 for emergency department visits involving accidental ingestions in the Seattle metropolitan area. This analytic category includes ED visits in which an individual accidentally or unknowingly used or was administered a prescription drug, over-the-counter medication, or dietary supplement. Drug-related accidental ingestion typically involves patients aged 5 and under. This analytic category does not include drug misuse or abuse.File includes data for over 500 drugs, including illicit drugs, prescription and over-the-counter medications, dietary supplements, inhalants and alcohol. Includes total visits, gender, age group, race/ethnicity, outcome of visit, drug combinations, number of drugs involved in visit, drug frequency, and drugs confirmed by toxicology.Additional detail is provided for illicit drugs, psychotherapeutic drugs, central nervous system (CNS) drugs, respiratory drugs and cardiovascular drugs.","title":"Seattle: Drug-Related Emergency Department Visits, 2004-2011 - Accidental Ingestions","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/seattle-drug-related-emergency-department-visits-2004-2011-accidental-ingestions","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4szc-4bit","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-use","treatment-facilities","health-survey","mental-health","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4szc-4bit","description":"This is the questionnaire for the 2024 National Substance Use and Mental Health Services Survey (N-SUMHSS). The N-SUMHSS is a voluntary annual survey of all active substance use and mental health facilities in the United States, its jurisdictions, and the District of Columbia. This document shows the series of questions substance use and mental health treatment facilities were asked for the N-SUMHSS.The survey consists of two introductory questions and four separate modules. Skip patterns in the survey direct participants on relevant modules depending on whether the facility is a substance use treatment facility, a mental health treatment facility, or both.Facilities operated by the Department of Veteran’s Affairs (VA) were asked to complete additional questions regarding VA services offered. Additionally, all substance use and mental health facilities were asked to complete additional questions regarding electronic health records.The questionnaire for N-SUMHSS and its supplement(s) is available as a PDF file.","title":"N-SUMHSS 2024 Questionnaire","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/n-sumhss-2024-questionnaire","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4szt-e5jx","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2025-10-27","keyword":["drug rebate program"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"14856bbd-1987-4385-a05f-d98071f5948a","description":"The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 10-13-2025-to-10-19-2025","programCode":["009:076"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/mdrp-newly-rprt-drug-10-13-2025-to-10-19-2025.csv","mediaType":"text/csv"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["public-health","drug","drug-manufacturers","pharmaceuticals","prescription-drugs"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA210677","description":"Darunavir is a generic prescription drug used to treat HIV infection by blocking the virus's ability to multiply. It comes as oral tablets in strengths of 75mg, 150mg, 600mg, and 800mg, manufactured by Zydus Lifesciences Limited. This information was generated using AI and is provided for informational and research purposes only.","title":"Darunavir","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210677","description":"\n Access the FDA dataset for Darunavir — ANDA 210677 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Darunavir"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4t9s-risk","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","substance-abuse","behavioral-health","kansas","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4t9s-risk","description":"Behavioral Health Barometer: Kansas, Volume 6","title":"Behavioral Health Barometer: Kansas, Volume 6","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-kansas-volume-6","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ta4-qa59","bureauCode":["009:00"],"issued":"2023-07-31","@type":"dcat:Dataset","modified":"2025-07-03","keyword":["hhs","wait and see","vaccine uptake","vaccine ready","vaccine readiness","vaccine hesitancy","covid19","covid-19","covid-19 vaccination","u.s. adults","research","public education campaign","no vaccine intentions","covid-19 vaccine uptake","dataset","hesitancy","vaccination","adults","age groups","agency for healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"Kelley Smith","hasEmail":"mailto:content@hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Department of Health and Human Services"},"identifier":"https://healthdata.gov/api/views/4ta4-qa59","description":"The Monthly Outcome Survey (MOS) was designed to assess COVID-19 vaccine uptake as well as beliefs, intentions, and behaviors relevant to COVID-19 vaccination at a point in time. The survey fielded on a monthly basis from January 2021 to April 2023. When the MOS first launched, it focused on the primary series of COVID-19 vaccines; in later waves, it was expanded to assess parents’ intentions to get their children vaccinated or boosted and to track booster and updated vaccine uptake and readiness. The MOS fielded as part of an online omnibus survey, conducted with a cross-sectional sample of approximately 5,000 U.S. adults each month.","title":"HHS COVID-19 Monthly Outcome Survey - Wave 16","primaryITInvestmentUII":"009-000005797","programCode":["009:028"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://healthdata.gov/api/v3/views/4ta4-qa59/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"mediaType":"application/json","downloadURL":"https://healthdata.gov/api/v3/views/4ta4-qa59/query.json?accessType=DOWNLOAD","describedBy":"https://healthdata.gov/api/views/4ta4-qa59/columns.json","describedByType":"application/json","@type":"dcat:Distribution"},{"mediaType":"application/xml","downloadURL":"https://healthdata.gov/api/v3/views/4ta4-qa59/export.xml?accessType=DOWNLOAD","describedBy":"https://healthdata.gov/api/views/4ta4-qa59/columns.xml","describedByType":"application/xml","@type":"dcat:Distribution"}],"dataQuality":true,"license":"https://www.usa.gov/government-works","theme":["Health"],"language":["English"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4taa-bfa4","bureauCode":["009:38"],"issued":"2026-04-28","@type":"dcat:Dataset","modified":"2026-05-04","keyword":["business rules","py2026","marketplace puf","exchange puf"],"contactPoint":{"@type":"vcard:Contact","fn":"Center for Consumer Information and Insurance Oversight","hasEmail":"mailto:CMS_FEPS@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Center for Consumer Information and Insurance Oversight"},"identifier":"6df89be6-915d-4c0d-b53e-e1bf9cb4eab6","description":"The Business Rules PUF (BR-PUF) is one of the files that comprise the Health Insurance Exchange Public Use Files. The BR-PUF contains plan-level data on rating business rules, such as maximum age for a dependent and allowed dependent relationships.","title":"Business Rules PUF - PY2026","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/py2026/business_rules_PUF.csv","mediaType":"text/csv"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tbm-979w","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bacterial-genetics","insertion-sequences","genomic-variation","nih","e-coli-genomes"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4tbm-979w","description":"Background\n Insertion Sequence (IS) elements are mobile genetic elements widely distributed among bacteria. Their activities cause mutations, promoting genetic diversity and sometimes adaptation. Previous studies have examined their copy number and distribution in Escherichia coli K-12 and natural isolates. Here, we map most of the IS elements in E. coli B and compare their locations with the published genomes of K-12 and O157:H7.\n \n \n Results\n The genomic locations of IS elements reveal numerous differences between B, K-12, and O157:H7. IS elements occur in hok-sok loci (homologous to plasmid stabilization systems) in both B and K-12, whereas these same loci lack IS elements in O157:H7. IS elements in B and K-12 are often found in locations corresponding to O157:H7-specific sequences, which suggests IS involvement in chromosomal rearrangements including the incorporation of foreign DNA. Some sequences specific to B are identified, as reported previously for O157:H7. The extent of nucleotide sequence divergence between B and K-12 is <2% for most sequences adjacent to IS elements. By contrast, B and K-12 share only a few IS locations besides those in hok-sok loci. Several phenotypic features of B are explained by IS elements, including differential porin expression from K-12.\n \n \n Conclusions\n These data reveal a high level of IS activity since E. coli B, K-12, and O157:H7 diverged from a common ancestor, including IS association with deletions and incorporation of horizontally acquired genes as well as transpositions. These findings indicate the important role of IS elements in genome plasticity and divergence.","title":"Genomic comparisons among","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC117601/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tc9-ea6g","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["barometer","samhsa","mental-health-vermont","behavioral-health","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4tc9-ea6g","description":"Behavioral Health Barometer: Vermont, Volume 6","title":"Behavioral Health Barometer: Vermont, Volume 6","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-vermont-volume-6","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tdb-us6s","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["central-venous-access","ultrasound-measurements","nih","newborn-infant-vein","femoral-vein-diameter"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4tdb-us6s","description":"Background:\n The femoral vein is an important site for central venous access in\n\t\t\t\tnewborns and infants. The objectives of this study are to determine whether age\n\t\t\t\tor weight can be used clinically to predict the size of the femoral vein in\n\t\t\t\tnewborns and infants, and to compare the size of the vein in each individual in\n\t\t\t\tboth the supine and reverse Trendelenburg positions.\n \n \n Results:\n Analysis was done in 24 euvolemic individuals, each studied in\n\t\t\t\tboth the supine and reverse Trendelenburg positions. Twelve of these\n\t\t\t\tindividuals were newborns and 12 were infants. We used two-factor analysis of\n\t\t\t\tvariance to explore differences between groups and multiple linear regression\n\t\t\t\tanalysis to estimate the strength of the relationship between variables. In the\n\t\t\t\tinfant group, there was a correlation between femoral vein diameter and weight.\n\t\t\t\tThere was no correlation between weight and vessel size in newborns. In both\n\t\t\t\tthe newborn and infant groups, vessel diameter increased with subjects in the\n\t\t\t\treverse Trendelenburg position (P < 0.01).\n \n \n Conclusion:\n Weight is predictive of femoral vein diameter in infants, but not\n\t\t\t\tin newborns. In infants, weight might serve as a more sensitive index for\n\t\t\t\testimating size of the femoral vein in order to determine accurately the size\n\t\t\t\tof intravascular catheter appropriate for cannulation. The diameter of the\n\t\t\t\tfemoral vein increases in the reverse Trendelenburg position compared with that\n\t\t\t\tin the supine position in both newborns and infants. A large prospective study\n\t\t\t\tis required to validate these findings.","title":"Femoral vein size in newborns and infants: preliminary\n\t\t investigation","programCode":["009:037"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC29039/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tdj-edxr","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","pubchem","compound","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4tdj-edxr","description":"Chemical compound data from PubChem database. IUPAC Name: dicycloheptyl benzene-1,2-dicarboxylate. Molecular Formula: C22H30O4. Molecular Weight: 358.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525141: Dicycloheptyl phthalate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525141","description":"Access the complete Compound 525141: Dicycloheptyl phthalate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tei-m3b5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","chemistry","science","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4tei-m3b5","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 2-(4-hexoxy-3-methoxyphenyl)acetate. Molecular Formula: C16H24O4. Molecular Weight: 280.36. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525532: (3-Methoxy-4-hexyloxy-phenyl)-acetic acid, methyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525532","description":"Access the complete Compound 525532: (3-Methoxy-4-hexyloxy-phenyl)-acetic acid, methyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tg7-3udx","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["instruction","policy","legal","child","guidance"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4tg7-3udx","description":"This Program Instruction (PI) provides instruction on the amendments to Title IV-E of the Social Security Act and Related Policy Issuances.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-97-05)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-97-05","description":"Access the complete PI-97-05 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","bureauCode":["009:00"],"landingPage":"HHS.gov/Lyme","issued":"2025-12-19","@type":"dcat:Dataset","modified":"2025-12-19","keyword":["open innovation","open government","open gov","open data","partnerships","next-generation","next-gen","lymex ai","lymex","lyme innovation","persistent symptoms","vector-borne","vector","post-treatment","post-treatment lyme disease syndrome","prize","ptlds","public-private","tick","lyme disease","lyme ai","transparency","tick-borne","adaptive","lyme","ai","artificial intelligence","challenge","chronic","tickborne","living guidelines","living evidence","living clinical guidelines","clinical guidelines","crowdsource","diagnostic","chronic condition","exponential","co-creation","open source","partnership","open science","evidence-based","iacci","iacc","grand-prize challenge","cocreate","chronic conditions","invisible illnesses","invisible illness","innovation","infection-associated chronic illnesses","diagnostics","accelerator","citizen science","infection-associated chronic illness","infection-associated chronic conditions and illnesses","infection-associated chronic conditions","infection-associated chronic condition","iaci"],"contactPoint":{"@type":"vcard:Contact","fn":"HHS OCDO","hasEmail":"mailto:healthdata@hhs.gov"},"publisher":{"@type":"org:Organization","name":"HHS OCDO"},"identifier":"https://healthdata.gov/api/views/4tgn-srdu","description":"Visit the official HHS page for Lyme disease: HHS.gov/Lyme to learn how HHS is responding to Lyme disease with increased investments, comprehensive research, improved diagnostic tools, patient-centered solutions, and multi-sector innovation to accelerate progress.","title":"HHS Invisible Illness Initiative: Lyme Disease","programCode":["009:000"],"theme":["HHS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tis-g8dv","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["grant","social","fiscal","public","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4tis-g8dv","description":"The Catalog of Federal Domestic Assistance\n \n \n\n is a government wide compendium of all Federal programs that provide assistance or benefits to the American public.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Catalog of Federal Domestic Assistance","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/catalog-federal-domestic-assistance","description":"Access the complete Catalog of Federal Domestic Assistance on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tja-xedt","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","patent","research","pubchem","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4tja-xedt","description":"In the production of a sliding board, consisting of a basic structure (3) with an upper face of polymer (I) to which rigid polymer-based element(s) (2) is/are attached, (a) the lower surface of the rigid element is of a textile complex (1) having a textile core containing conductive threads (11, 12) and an outer layer compatible with (I) and (b) the element is pressed onto the structure while passing a current through the conductive threads to cause softening and welding.","title":"Patent AT-E400333-T1: [Translated] METHOD FOR MAKING A SNOWBOARD HAVING A RIGID ELEMENT ON ITS SURFACE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400333-T1","description":"Access the complete Patent AT-E400333-T1: [Translated] METHOD FOR MAKING A SNOWBOARD HAVING A RIGID ELEMENT ON ITS SURFACE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tkj-8ff3","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","behavioral-health","block-grant-data","national-outcome-measures","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4tkj-8ff3","description":"This is the 2018 Uniform Reporting System (URS) Output Tables for North Dakota. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2018 Uniform Reporting System (URS) Table for North Dakota","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2018-uniform-reporting-system-urs-table-north-dakota","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tkq-bw2f","bureauCode":["009:38"],"issued":"2017-12-09","@type":"dcat:Dataset","modified":"2026-02-11","keyword":["mco","pccm","pihp","pahp","pace","mltss","medicare","medicaid","bho","comprehensive mco","managed care enrollment"],"contactPoint":{"@type":"vcard:Contact","fn":"Jeff Chamblee","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"0bef7b8a-c663-5b14-9a46-0b5c2b86b0fe","description":"2024 Enrollment Data by Program and Plan\n\nThe Enrollment Data by Program and Plan table (Table 5 in the Enrollment Report) lists each managed care program’s name and type by state. The data provides details such as the plan name, parent organization, geographic region, Medicaid-only enrollment, dual enrollment, and total enrollment by program.\n\nNote: “0” may not truly represent 0 if a state opted to suppress data for enrollee confidentiality reasons. For example, if a plan had dual enrollment of less than 10, the state may have opted to report 0 instead. \"--\" indicates the state or territory did not provide information for a given program and plan.\n\n2023 Enrollment Data by Program and Plan\n\nThe Enrollment Data by Program and Plan table (Table 5 in the Enrollment Report) lists each managed care program’s name and type by state. The data provides details such as plan name, parent organization, geographic region, Medicaid-only enrollment, dual enrollment, and total enrollment by program.\n\nNote: “0” may not truly represent 0 if a state opted to suppress data for enrollee confidentiality reasons. For example, if a plan had dual enrollment of less than 10, the state may have opted to report 0 instead. \"--\" indicates the state or territory did not provide information for a given program and plan.","title":"Managed Care Enrollment by Program and Plan","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/managed-care-enrollment-by-program-and-plan2024-table4.csv","mediaType":"text/csv","title":"CSV"}],"license":"https://www.usa.gov/government-works","theme":["Enrollment"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tnw-84ja","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","research","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4tnw-84ja","description":"Chemical compound data from PubChem database. IUPAC Name: 23,27-dimethyldotriacontanenitrile. Molecular Formula: C34H67N. Molecular Weight: 489.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527384: 22,26-Dimethyl-hentriacontyl cyanide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527384","description":"Access the complete Compound 527384: 22,26-Dimethyl-hentriacontyl cyanide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tp8-6wrw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4tp8-6wrw","description":"Chemical compound data from PubChem database. IUPAC Name: 2-(2-pyrazin-2-ylethyl)pyrazine. Molecular Formula: C10H10N4. Molecular Weight: 186.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529884: Ethane, 1,2-bis-(2-pyrazinyl)","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529884","description":"Access the complete Compound 529884: Ethane, 1,2-bis-(2-pyrazinyl) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ts8-cae9","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","compound","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4ts8-cae9","description":"Chemical compound data from PubChem database. IUPAC Name: 3-oxobutan-2-yl hexanoate. Molecular Formula: C10H18O3. Molecular Weight: 186.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529254: Acetoin hexanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529254","description":"Access the complete Compound 529254: Acetoin hexanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tst-f8d4","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","references","bioactivity","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4tst-f8d4","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865629: MLS000080617","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865629","description":"Access the complete Substance 865629: MLS000080617 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/ukww-au2k","bureauCode":["009:20"],"issued":"2022-06-17","temporal":"March 27, 2022 - September 24, 2022","@type":"dcat:Dataset","modified":"2023-06-09","contactPoint":{"@type":"vcard:Contact","fn":"Vaccine Breakthrough Unit, Surveillance and Analytics Team","hasEmail":"mailto:vbtsurveillance@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/ukww-au2k","description":"Data for CDC’s COVID Data Tracker site on Rates of COVID-19 Cases and Deaths by Vaccination Status.\nClick 'More' for important dataset description and footnotes\n\nDataset and data visualization details:\nThese data were posted on October 21, 2022, archived on November 18, 2022, and revised on February 22, 2023. These data reflect cases among persons with a positive specimen collection date through September 24, 2022, and deaths among persons with a positive specimen collection date through September 3, 2022. \n\nVaccination status: A person vaccinated with a primary series had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after verifiably completing the primary series of an FDA-authorized or approved COVID-19 vaccine. An unvaccinated person had SARS-CoV-2 RNA or antigen detected on a respiratory specimen and has not been verified to have received COVID-19 vaccine. Excluded were partially vaccinated people who received at least one FDA-authorized vaccine dose but did not complete a primary series ≥14 days before collection of a specimen where SARS-CoV-2 RNA or antigen was detected.\nAdditional or booster dose: A person vaccinated with a primary series and an additional or booster dose had SARS-CoV-2 RNA or antigen detected on a respiratory specimen collected ≥14 days after receipt of an additional or booster dose of any COVID-19 vaccine on or after August 13, 2021. For people ages 18 years and older, data are graphed starting the week including September 24, 2021, when a COVID-19 booster dose was first recommended by CDC for adults 65+ years old and people in certain populations and high risk occupational and institutional settings. For people ages 12-17 years, data are graphed starting the week of December 26, 2021, 2 weeks after the first recommendation for a booster dose for adolescents ages 16-17 years. For people ages 5-11 years, data are included starting the week of June 5, 2022, 2 weeks after the first recommendation for a booster dose for children aged 5-11 years. For people ages 50 years and older, data on second booster doses are graphed starting the week including March 29, 2022, when the recommendation was made for second boosters. Vertical lines represent dates when changes occurred in U.S. policy for COVID-19 vaccination (details provided above). Reporting is by primary series vaccine type rather than additional or booster dose vaccine type. The booster dose vaccine type may be different than the primary series vaccine type.\n** Because data on the immune status of cases and associated deaths are unavailable, an additional dose in an immunocompromised person cannot be distinguished from a booster dose. This is a relevant consideration because vaccines can be less effective in this group.\nDeaths: A COVID-19–associated death occurred in a person with a documented COVID-19 diagnosis who died; health department staff reviewed to make a determination using vital records, public health investigation, or other data sources. Rates of COVID-19 deaths by vaccination status are reported based on when the patient was tested for COVID-19, not the date they died. Deaths usually occur up to 30 days after COVID-19 diagnosis.\nParticipating jurisdictions: Currently, these 31 health departments that regularly link their case surveillance to immunization information system data are included in these incidence rate estimates: Alabama, Arizona, Arkansas, California, Colorado, Connecticut, District of Columbia, Florida, Georgia, Idaho, Indiana, Kansas, Kentucky, Louisiana, Massachusetts, Michigan, Minnesota, Nebraska, New Jersey, New Mexico, New York, New York City (New York), North Carolina, Philadelphia (Pennsylvania), Rhode Island, South Dakota, Tennessee, Texas, Utah, Washington, and West Virginia; 30 jurisdictions also report deaths among vaccinated and unvaccinated people. These jurisdictions represent 72% of the total U.S. population and all ten of the Health and Human Services Regions. Data on cases","title":"Rates of COVID-19 Cases or Deaths by Age Group and Vaccination Status and Second Booster Dose","programCode":["009:038"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/ukww-au2k/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/ukww-au2k/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/ukww-au2k/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"Select US Jurisdictions","license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"Monthly","theme":["Public Health Surveillance"],"language":["English"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4twm-bczq","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["alendronate-treatment","osteonecrosis","nih","bone-resorption","bisphosphonates"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4twm-bczq","description":"Background\n Avascular necrosis of bone (osteonecrosis) can cause structural failure and subsequent deformation, leading to joint dysfunction and pain. Structural failure is the result of resorption of necrotic bone during revascularization, before new bone has formed or consolidated enough for loadbearing. Bone resorption can be reduced by bisphosphonates. If resorption of the necrotic bone could be reduced during the revascularization phase until sufficient new bone has formed, it would appear that structural failure could be avoided.\n \n \n Methods\n To test whether resorption of necrotic bone can be prevented, structural grafts were subjected to new bone ingrowth during systemic bisphosphonate treatment in a rat model.\n \n \n Results\n In rats treated with alendronate the necrotic bone was not resorbed, whereas it was almost entirely resorbed in the controls.\n \n \n Conclusion\n Systemic alendronate treatment prevents resorption of necrotic bone during revascularization. In patients with osteonecrosis, bisphosphonates may therefore prevent collapse of the necrotic bone.","title":"Systemic alendronate prevents resorption of necrotic bone during revascularization. A bone chamber study in rats","programCode":["009:037"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC126216/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4twu-s4kk","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","innovation","research","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4twu-s4kk","description":"1. Syringe intended for the ultra-ligamentary injection of liquid products, especially anaesthetic products, of the type composed of a body the forward portion of which, to which the injection needle is fitted, serves as housing for a container of the said liquid product, constituted by a glass tube the rear extremity of which is closed by a plug (7) of rubber or analogous material, while the rear portion of the body serves as guide for a piston (6) actuated by a rack (4), in such manner that when the operator operates the syringe, the piston progresses forward step by step, thrusting the said plug forward into the interior of the container, and consequently the liquid product into the injection needle, the piston (6) being terminated, at its forward extremity, by a head (12, 12') of a diameter substantially equal to the internal diameter of the container (8), characterised in that the head forwardly presents a concavity causing migration of the material of the plug (7) towards the axis in the advance of the piston (6).","title":"Patent AT-E40046-T1: [Translated] DENTAL SYRINGE.","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E40046-T1","description":"Access the complete Patent AT-E40046-T1: [Translated] DENTAL SYRINGE. on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4txd-myju","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","noms-measures","mental-health-services","georgia-urs","block-grant-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4txd-myju","description":"This is the 2017 Uniform Reporting System (URS) Output Tables for Georgia. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2017 Uniform Reporting System (URS) Table for Georgia","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2017-uniform-reporting-system-urs-table-georgia","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ty3-5eqx","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["minnesota","substance-abuse-treatment","treatment-facility-data","samhsa","alcohol-drug-services"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4ty3-5eqx","description":"This is a National Survey of Substance Abuse Treatment Services (N-SSATS) annual report showing the state profile for Minnesota in 2012. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.","title":"2012 State Profile - Minnesota","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-state-profile-minnesota","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nchs/covid19/covid-19-mortality-data-files.htm","bureauCode":["009:20"],"issued":"2021-05-21","@type":"dcat:Dataset","modified":"2025-04-21","keyword":["hispanic origin","all causes","coronavirus","covid-19","deaths","mortality","nchs","nvss","provisional","race","sex","united states","weekly"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/9z9x-g48e","description":"Deaths involving coronavirus disease 2019 (COVID-19) reported to NCHS by week, sex, and race and Hispanic origin. Deaths occurred in the United States.","title":"AH Provisional COVID-19 Deaths by Week, Sex, and Race and Hispanic Origin","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/9z9x-g48e/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/9z9x-g48e/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/9z9x-g48e/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"United States","license":"https://www.usa.gov/government-works","accrualPeriodicity":"irregular","theme":["National Center for Health Statistics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4tzb-ic3p","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["california","substance-use","samhsa","behavioral-health","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4tzb-ic3p","description":"This is a behavioral health report for the state of California. It uses the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, for the years 2008 to 2012.","title":"Behavioral Health Barometer: California, 2013","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-california-2013","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4u6w-kh7j","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["rhabdomyosarcoma","h19-gene","hdac-inhibitors","gene-methylation","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/4u6w-kh7j","description":"Background\n The active copy of the imprinted gene H19 is turned off by inappropriate methylation in several pediatric tumors including Wilms' Tumour and embryonal rhabdomyosarcoma. H19 controls in cis the linked Insulin-like Growth Factor 2 (IGF2) gene, encoding an important growth factor. Recent work has suggested that methylation of a gene may lead to deacetylation of its associated histones and that silenced genes can be reactivated by increasing histone acetylation levels.\n \n \n Results\n Treatment of a rhabdomyosarcoma cell line which has a silent, methylated H19 gene with histone deacetylase (HDAC) inhibitors under conditions which gave maximal hyperacetylation of histone 4, both globally and at the H19 gene itself could not reactivate H19 or affect the active Insulin-like Growth Factor 2 (IGF2) gene, but caused clear up-regulation of the Tissue-type Plasminogen Activator (TPA) gene, a non-imprinted gene known to respond to changes in histone acetylation. In contrast, mild treatment of the cells with the methylation inhibitor 5-AzaC-2'-deoxycytidine (AzaC) on its own was able to reactivate H19. Combining AzaC treatment with HDAC inhibitors gave a reduced rather than enhanced reactivation. These findings were confirmed in mouse primary liver and kidney explants which maintain normal imprinting, where we also found that the silent Igf2 gene could not be reactivated by HDAC inhibitors.\n \n \n Conclusion\n These results suggest that DNA methylation rather than histone acetylation is the primary determinant of silencing of H19 in rhabdomyosarcoma.","title":"Reactivation of a silenced","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC119368/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/h8yk-ufg9","issued":"2025-01-27","@type":"dcat:Dataset","modified":"2026-02-20","keyword":["managed care","medicaid access","plan performance report","qarr","quality-safety-costs","utilization"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/h8yk-ufg9","description":"The New York State Department of Health (NYSDOH) collects annual data on children’s and adults’ use of health services. This information complements the quality of care and member satisfaction information collected through an annual public reporting system called the Quality Assurance Reporting Requirements (QARR). Utilization measures are designed to capture the frequency of certain services provided by health plans. NCQA does not view higher or lower services counts as better or worse performance. Plans with fewer than 30 eligible events are excluded from the statistical calculations of the percentiles.","title":"Managed Care Plan Utilization Data: Beginning 2009","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/h8yk-ufg9/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/h8yk-ufg9/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/h8yk-ufg9/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/vh2s-8wb2","issued":"2017-12-29","@type":"dcat:Dataset","modified":"2026-01-13","keyword":["all payer","dsrip","efficiency","inpatient","ip-qm","pdi","prevention quality indicator","quality-safety-costs","sparcs","strategic initiatives"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/vh2s-8wb2","description":"The dataset contains observed, expected, and risk-adjusted rates for the Agency for Healthcare Research and Quality Pediatric Quality Indicators – Pediatric (AHRQ PDI) beginning in 2009.\r\nThe AHRQ PDIs are a set of population based measures that can be used with hospital inpatient discharge data to identify ambulatory care sensitive conditions. These are conditions where 1) the need for hospitalization is potentially preventable with appropriate outpatient care, or 2) conditions that could be less severe if treated early and appropriately. Both the Urinary Tract Infection and Gastroenteritis PDIs include admissions for patients aged 3 months through 17 years. The asthma PDI includes admissions for patients aged 2 through 17 years. Eligible admissions for the Diabetes Short-term Complications PDI includes admissions for patients aged 6 through 17 years.\r\n\r\nThe rates were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data and Claritas population information. \r\n\r\nThe observed, expected, risk-adjusted rates, and difference in rates, for each AHRQ PDI are presented by resident county (including a statewide total).","title":"Hospital Inpatient Discharges (SPARCS De-Identified): Pediatric Prevention Quality Indicators (PDI) by Patient County: Beginning 2009","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/vh2s-8wb2/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/vh2s-8wb2/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/vh2s-8wb2/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ucr-52z3","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2026-07-01","references":["https://www.mathematica.org/"],"keyword":["utility","scorecard"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"f2845568-e795-5d58-9c4b-a4271c9a8df4","description":"This is a dataset created for the Medicaid Scorecard website (https://www.medicaid.gov/state-overviews/scorecard/index.html), and is not intended for use outside that application.","title":"Scorecard version v3.9.56 (CMS Development)","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/scorecard/3.9.66/20260626/version.csv","description":"Scorecard version v3.9.66 (CMS Development)","@type":"dcat:Distribution","title":"Scorecard version v3.9.66 (CMS Development)"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/eqm6-4iu5","issued":"2020-06-10","@type":"dcat:Dataset","modified":"2020-06-10","keyword":["drinking water","school","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"Charles, Anne Marie C (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/eqm6-4iu5","description":"","title":"East Valley Middle School","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/eqm6-4iu5/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["health-care","pharmaceuticals","prescription-drugs","drug-safety","drug-manufacturers"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA211038","description":"Calcium Acetate is a prescription medication available as 667 mg oral capsules, used as a phosphate binder to help manage high phosphate levels in the blood, often in people with kidney disease. It works by binding to phosphate in the diet to reduce its absorption. Manufactured by Square Pharmaceuticals Limited under ANDA217205. This information was generated using AI and is provided for informational and research purposes only.","title":"Calcium acetate","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211038","description":"\n Access the FDA dataset for Calcium acetate — ANDA 211038 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Calcium acetate"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ueu-w8dx","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","innovation","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4ueu-w8dx","description":"A strip-shaped superconductor has a conductor structure containing at least one metallic substrate strip, a layer made of oxidic high Tc superconducting material of the AB2Cu3OX type; an oxidic buffer layer, which is arranged therebetween and which has adapted crystalline dimensions, and; a normal-conductive top layer that is applied to the superconductive layer. The buffer layer should be formed so that a transition resistance of no greater than 10-3 Omegacm2 is formed at least in partial areas between the superconductive layer and the substrate strip. For example, suitable materials are of the La-Mn-O or Sr-Ru-O or La-Ni-O or In-Sn-O type.","title":"Patent AT-E400064-T1: [Translated] RESISTIVE TYPE CURRENT LIMITING DEVICE HAVING A HIGH-TC TAPE SUPERCONDUCTOR","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400064-T1","description":"Access the complete Patent AT-E400064-T1: [Translated] RESISTIVE TYPE CURRENT LIMITING DEVICE HAVING A HIGH-TC TAPE SUPERCONDUCTOR on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ugr-vc3z","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-abuse-treatment","treatment-facilities","n-ssats","samhsa","alcohol-abuse-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4ugr-vc3z","description":"The National Directory of Drug and Alcohol Abuse Treatment Programs 1979 lists federal, state, local, and private facilities that provide substance abuse treatment services. The directory includes treatment facilities that are licensed, certified, or otherwise approved for inclusion in the directory by their state substance abuse agencies and that responded to the 1978 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this directory was provided by that facility in response to the 1978 N-SSATS. The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts the N-SSATS annually.","title":"National Directory of Drug and Alcohol Abuse Treatment Facilities - 1979","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/national-directory-drug-and-alcohol-abuse-1979","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4uj8-fd2z","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","research","patent","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4uj8-fd2z","description":"A ski boot is coupled to a ski by a ski binding with a base plate (1) which engages with the ski top surface. The base plate has a castellated profiled lower surface that engages in a corresponding profile in the ski upper surface.","title":"Patent AT-E400336-T1: [Translated] ARRANGEMENT FOR MOUNTING A SKI BINDING, A SKI BINDING PART OR ONE OF THESE OR THIS SUPPORTING PART, PARTICULARLY PLATE-SHAPED, ON A SKI","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400336-T1","description":"Access the complete Patent AT-E400336-T1: [Translated] ARRANGEMENT FOR MOUNTING A SKI BINDING, A SKI BINDING PART OR ONE OF THESE OR THIS SUPPORTING PART, PARTICULARLY PLATE-SHAPED, ON A SKI on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ukw-jib7","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["foster","policy","care","child","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4ukw-jib7","description":"This report presents results from the Child and Family Services Reviews related to older youth (aged 16—17) in foster care for the 38 states reviewed during the first 3 years of round 3 (2015—2017).\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Focus on Youth CFSR Findings: 2015-2017","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/focus-youth-cfsr-findings-2015-2017","description":"Access the complete Focus on Youth CFSR Findings: 2015-2017 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4une-j46x","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["service","child","social","acf","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4une-j46x","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Two-Gen Human Services Commissioner Webinar Slides","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14158","description":"Access the complete Two-Gen Human Services Commissioner Webinar Slides on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/37ui-3igt","bureauCode":["009:20"],"issued":"2024-11-15","@type":"dcat:Dataset","modified":"2026-01-14","contactPoint":{"@type":"vcard:Contact","fn":"Health Effects Laboratory Division, Allergy and Clinical Immunology Branch","hasEmail":"mailto:sa-cin-webteam@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/37ui-3igt","description":"Heptafluorobutyric acid (PFBA) is a synthetic chemical belonging to the per- and polyfluoroalkyl substances (PFAS) group that includes over 5,000 chemicals. PFBA is a short-chain PFAS (C4) that has been labeled as a safer alternative to the legacy PFAS perfluorooctanoic acid (PFOA) and perfluorooctane sulfate (PFOS) which have been linked to numerous health effects. This class of chemicals are incorporated into consumer products such as stain resistant carpeting and textiles, nanosprays, medical devices, and fire-fighting foams. There is a high potential for occupational exposure and in the environment, PFBA has been detected in a variety of water sources leading to concerns for dermal exposure, however, these studies are lacking. In previous studies from our lab, PFOA was demonstrated to be absorbed via the skin and immunomodulatory. In the present study, the systemic toxicity of a 28-day dermal PFBA (3.75-15% w/v, or 93.8-375 mg/kg/dose) exposure was evaluated in a murine model.","title":"Systemic toxicity induced by topical application of heptafluorobutyric acid (PFBA) in a murine model","programCode":["009:034"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/download/37ui-3igt/application/x-zip-compressed","mediaType":"application/x-zip-compressed"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["National Institute for Occupational Safety and Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4uqq-bj6w","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","compound","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4uqq-bj6w","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 2-bromopentanoate. Molecular Formula: C6H11BrO2. Molecular Weight: 195.05. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529992: Methyl 2-bromopentanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529992","description":"Access the complete Compound 529992: Methyl 2-bromopentanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ust-idf7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","chemistry","compound","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4ust-idf7","description":"Chemical compound data from PubChem database. IUPAC Name: 6-methylicosane. Molecular Formula: C21H44. Molecular Weight: 296.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528491: Eicosane, 6-methyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528491","description":"Access the complete Compound 528491: Eicosane, 6-methyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4usw-k3h7","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["data","policy","social","assessment","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4usw-k3h7","description":"This Technical Bulletin provides information regarding initiation of Child and Family Services Review (CFSR) Round Three.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Child and Family Services Reviews Technical Bulletin #6","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/child-and-family-services-reviews-technical-bulletin-6","description":"Access the complete Child and Family Services Reviews Technical Bulletin #6 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/dataset/office-head-start-ohs-head-start-center-locations-search-tool","bureauCode":["009:00"],"issued":"2012-05-30","@type":"dcat:Dataset","modified":"2025-03-24","keyword":["administrative","geocode","head start","early head start","services","locator","location","low income","program","children","children's health","grantee","center"],"contactPoint":{"@type":"vcard:Contact","fn":"Fran Majestic","hasEmail":"mailto:fmajestic@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families, Department of Health & Human Services"},"identifier":"8fce8c8e-dd59-4ab4-9aae-f720d356932d","description":"Office of Head Start (OHS) web based search tool for finding Head Start program office contact information. Searchable by location, grant number or center type. Results are downloadable in CSV format.
","title":"Office of Head Start (OHS) Head Start Center Locations Search Tool","programCode":["009:092"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://eclkc.ohs.acf.hhs.gov/hslc/HeadStartOffices","mediaType":"text/html","title":"Query Tool "},{"@type":"dcat:Distribution","downloadURL":"http://eclkc.ohs.acf.hhs.gov/HSESReports1/PdfServlet?service=xls","mediaType":"application/vnd.ms-excel","title":"XLS "}],"license":"https://opendatacommons.org/licenses/odbl/1.0/","dataQuality":true},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4uuk-xm96","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","research","chemistry","pubchem","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4uuk-xm96","description":"The invention relates to 4-methylamino-1,2,4-triazin-5-one of the formula IThe Federal Interagency Traumatic Brain Injury Research (FITBIR) informatics system is an extensible, scalable informatics platform for TBI relevant imaging, assessment, genomics, and other data types. It was developed to share data across the entire TBI research field and to facilitate collaboration between laboratories, as well as interconnectivity with other informatics platforms.
","title":"Federal Interagency Traumatic Brain Injury Research (FITBIR) Informatics System","programCode":["009:041"],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health"]},{"accessLevel":"public","landingPage":"http://www.familypact.org","issued":"2017-06-16","temporal":"2003 - 2022","@type":"dcat:Dataset","modified":"2025-11-20","keyword":["access","provider","family pact","dhcs","care","pharmacy","and treatment program","medi-cal","reproductive health services","lab","family planning"],"contactPoint":{"@type":"vcard:Contact","fn":"Office of Family Planning / Enterprise Data and Information Management / Data Management and Analytics Division","hasEmail":"mailto:opendata@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"e925407e-7a0f-43c2-a5e5-8cf58f8fac21","description":"This data file contains information on the number of providers delivering services through the Family Planning, Access, Care, and Treatment (Family PACT) Program from July 1, 2003, through the current Fiscal Year (FY) of available data. Delivering Family PACT services is defined as having been reimbursed for at least one claim for any services through Family PACT. Providers for whom all Family PACT claims have been denied were not designated as delivering providers. All Family PACT providers must also be enrolled as Medi-Cal providers, and Medi-Cal clinician providers who are not enrolled in Family PACT may provide Family PACT services by referral from an enrolled Family PACT provider. For example, if a laboratory or pharmacy is associated with a clinician provider both the laboratory or pharmacy and the clinician are counted. Medi-Cal providers often deliver specialized services as Family PACT provider may not perform, such as sterilization.","title":"Providers Delivering Family Planning, Access, Care, and Treatment (PACT) Services, by Fiscal Years","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/e925407e-7a0f-43c2-a5e5-8cf58f8fac21/resource/737a7d49-10f3-4a2b-ac81-3bc257da94f2/download/1.-providers-delivering-family-planning-access-care-and-treatment-fpact-services-by-fiscal-years.csv","description":"This dataset includes the following variables: Number enrolled Family PACT clinician providers, percentage change previous fiscal year (FY) enrolled Family PACT Clinician, number Medi-Cal providers, percentage change previous FY Medi-Cal providers, number total clinician providers, percentage change previous FY total clinicians, number pharmacies, percentage change previous FY pharmacies, number labs, percentage change previous FY labs, total number of providers, and percentage change previous FY total number of providers.","@type":"dcat:Distribution","title":"Providers Delivering Family Planning, Access, Care, and Treatment (PACT) Services, by Fiscal Years (CSV)"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/datastore/dictionary_download/737a7d49-10f3-4a2b-ac81-3bc257da94f2","description":"Data Dictionary for https://data.chhs.ca.gov/dataset/e925407e-7a0f-43c2-a5e5-8cf58f8fac21/resource/737a7d49-10f3-4a2b-ac81-3bc257da94f2/download/1.-providers-delivering-family-planning-access-care-and-treatment-fpact-services-by-fiscal-years.csv","@type":"dcat:Distribution","title":"Data Dictionary - Providers Delivering Family Planning, Access, Care, and Treatment (PACT) Services, by Fiscal Years (CSV)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/e925407e-7a0f-43c2-a5e5-8cf58f8fac21/resource/f45fcf34-80db-4854-9c0d-e55c4bd750d0/download/providers-delivering-family-planning-access-care-and-treatment-pact-services-by-fiscal-years-5bk.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Healthcare"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4wpt-yg8y","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","pubchem","research","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4wpt-yg8y","description":"Chemical compound data from PubChem database. IUPAC Name: 1,4,6-tribromodibenzofuran. Molecular Formula: C12H5Br3O. Molecular Weight: 404.88. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526292: 1,4,6-Tribromo-dibenzofuran","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526292","description":"Access the complete Compound 526292: 1,4,6-Tribromo-dibenzofuran on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4wss-5zan","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2026-02-12","keyword":["medicaid"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"408360ff-07d7-4ffb-ba36-77b6291f2d76","description":"Test","title":"Test UTF-8","programCode":["009:076"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.medicaid.gov/sites/default/files/uploaded_resources/Testing12.csv","mediaType":"text/csv"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-manufacturers","health-care","public-health","medications","drug-information"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA125370","description":"Benlysta (belimumab) is a prescription medication from GlaxoSmithKline LLC, administered as a subcutaneous injection to inhibit B lymphocyte activation, helping manage autoimmune conditions like lupus. It comes in 200 mg/mL strength in prefilled syringes. This information was generated using AI and is provided for informational and research purposes only.","title":"Belimumab","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125370","description":"\n Access the FDA dataset for Belimumab — ANDA 125370 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Belimumab"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4ww6-2kxp","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["community-mental-health","samhsa","outcome-measures","mental-health-services","urs-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4ww6-2kxp","description":"2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Tennessee. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2014 CMHS Uniform Reporting System (URS) Table for Tennessee","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2014-cmhs-uniform-reporting-system-urs-table-tennessee","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4wwp-8gxe","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["prevention","grant","abuse","instruction","fiscal"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/4wwp-8gxe","description":"This Program Instruction (PI) provides information on the availability of Fiscal Year (FY) 2012 Children's Justice Act Grants to States Under the Child Abuse Prevention and Treatment Act (CAPTA).\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-12-03)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-12-03","description":"Access the complete PI-12-03 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4x2u-sc4a","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["alaska-urs-data","samhsa","noms-measures","mental-health-services","block-grant-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/4x2u-sc4a","description":"This is the 2023 Uniform Reporting System (URS) Output Tables for Alaska. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2023 Uniform Reporting System (URS) Table For Alaska","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2023-uniform-reporting-system-urs-table-alaska","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4x34-zrxs","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","pubchem","compound","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/4x34-zrxs","description":"Chemical compound data from PubChem database. IUPAC Name: 2,2,2-trichloroethyl 4-nitrobenzoate. Molecular Formula: C9H6Cl3NO4. Molecular Weight: 298.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528017: Ethanol, 2,2,2-trichloro, 4-nitrobenzoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528017","description":"Access the complete Compound 528017: Ethanol, 2,2,2-trichloro, 4-nitrobenzoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/4x4b-h74k","bureauCode":["009:38"],"issued":"2019-10-25","@type":"dcat:Dataset","modified":"2019-10-25","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"Michael Paladino","hasEmail":"mailto:Michael.Paladino@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"g7hv-jbsu","description":"The Quality PUF contains 2019 quality ratings data for eligible Qualified Health Plans in PY2020 in states on HealthCare.gov.Sources: T-MSIS Analytic Files (TAF) and state-submitted enrollment totals. The data notes indicate when a state’s monthly total was a state-submitted value, rather than from T-MSIS.
\nMethods: Enrollment includes individuals enrolled in S-CHIP at any point during the coverage month, excluding those enrolled in dental-only coverage. The S-CHIP enrollment in this report also excludes enrollees covered by Medicaid expansion CHIP, a program in which a state receives federal funding to expand Medicaid eligibility to optional targeted low-income children that meets the requirements of section 2103 of the Social Security Act. If an individual is enrolled in both Medicaid or Medicaid-expansion CHIP and S-CHIP in a given month, TAF picks the program in which they were last enrolled.
\nUnless S-CHIP enrollment counts are replaced with a state-submitted value, each state's monthly S-CHIP enrollment is equal to the number of unique people in TAF with a CHIP_CODE = 3 (S-CHIP) and ELGBLTY_GRP_CD not equal to ‘66’ (Children Eligible for Dental Only Supplemental Coverage). More information about TAF is available at https://www.medicaid.gov/medicaid/data-systems/macbis/medicaid-chip-research-files/transformed-medicaid-statistical-information-system-t-msis-analytic-files-taf/index.html.
Youth data for the fourth wave of the National Youth Survey
\nare contained in this data collection. The first wave of this survey
\nwas conducted in 1976, the second wave in 1977, and the third wave in 1978. Data are available in
\nthis wave on the demographic and socioeconomic status of respondents,
\ndisruptive events in the home, youth aspirations and expectations,
\nsocial isolation, normlessness, perceived disapproval by parents and
\npeers, attitudes toward deviance, exposure and commitment to delinquent
\npeers, sex roles, interpersonal violence, pressure for substance abuse
\nby peers, self-reported delinquency, drug and alcohol use, and
\nvictimization.This study has 1 Data Set.
\nThe Department of Health requires nursing homes to complete electronic filing of each facility's licensed nursing home beds and availability by bed category on a weekly basis. This dataset is refreshed monthly.
","title":"Nursing Home Weekly Bed Census: Last Submission","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/izta-vnpq/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/izta-vnpq/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/izta-vnpq/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/izta-vnpq/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/izta-vnpq/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/izta-vnpq/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54kq-zxui","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["child","reporting","policy","instruction","guidance"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/54kq-zxui","description":"This Program Instruction (PI) provides guidance on the Annual Credit Report required by the Child and Family Services Improvement and Innovation Act (Public Law (P.L.) 112-34).\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-12-07)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-12-07","description":"Access the complete PI-12-07 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54kv-atk2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","research","innovation","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/54kv-atk2","description":"An inkjet nozzle arrangement is provided. The arrangement comprises a nozzle chamber having an ink ejection port defined in a wall of the nozzle chamber, an ink supply channel for the supply of ink to the nozzle chamber, and an actuator located in the nozzle chamber, between the ink supply channel and the ink ejection port. The actuator is adapted to cause ejection of ink from the nozzle chamber upon activation.","title":"Patent AT-E399644-T1: [Translated] INKJET NOZZLE ARRANGEMENT WITH ACTUATING MECHANISM IN CHAMBER BETWEEN NOZZLE AND INK SUPPLY","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399644-T1","description":"Access the complete Patent AT-E399644-T1: [Translated] INKJET NOZZLE ARRANGEMENT WITH ACTUATING MECHANISM IN CHAMBER BETWEEN NOZZLE AND INK SUPPLY on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54mf-2jhj","bureauCode":["009:38"],"issued":"2014-11-13","@type":"dcat:Dataset","modified":"2015-08-20","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"chris.thierer","hasEmail":"mailto:no-reply@data.healthcare.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"itre-68bw","description":"Dataset.","title":"QHP Landscape PY2015 NV Individual Medical","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/PY2015_NV-Med-Indi-Land-08-13-2015.zip","mediaType":"application/zip","title":"FILE"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54nh-2w64","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","patent","innovation","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/54nh-2w64","description":"Chemical patent from PubChem database. Patent Number: AT-E399774-T1. Title: Bioactive Compound and Applications. Filing Date: 1993-06-22. Inventors: Anderson, Robert, Davis, Linda. Abstract: A bioactive compound and its applications in pharmaceutical and agricultural fields are described. The compound exhibits significant biological activi... IPC Classifications: A61K, A61L, A61F. This patent covers 24 claims related to 9 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.","title":"Patent AT-E399774-T1: [Translated] N-(IMINOMETHYL)AMINE DERIVATIVES, THEIR PRODUCTION, THEIR USE IN MEDICATIONS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399774-T1","description":"Access the complete Patent AT-E399774-T1: [Translated] N-(IMINOMETHYL)AMINE DERIVATIVES, THEIR PRODUCTION, THEIR USE IN MEDICATIONS AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54r8-m9d3","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["behavioral-health","substance-use","samhsa","south-carolina","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/54r8-m9d3","description":"This is a behavioral health report for the state of South Carolina. It uses the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment, and medicare enrollees for the years 2009 to 2013.","title":"Behavioral Health Barometer: South Carolina, 2014","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-south-carolina-2014","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54rz-rdeb","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2025-11-25","references":["https://www.mathematica.org/"],"keyword":["scorecard","utility"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"24c1df63-c908-54e2-9ec5-ec0d78e5912b","description":"This is a dataset created for the Medicaid Scorecard website (https://www.medicaid.gov/state-overviews/scorecard/index.html), and is not intended for use outside that application.","title":"Scorecard pillar v3.9.9 (CMS Test)","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/scorecard/3.9.9/20251118/pillar.csv","description":"Scorecard pillar v3.9.9 (CMS Test)","@type":"dcat:Distribution","title":"Scorecard pillar v3.9.9 (CMS Test)"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54vb-g2ht","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/54vb-g2ht","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 8-[tert-butyl(dimethyl)silyl]oxyicosanoate. Molecular Formula: C27H56O3Si. Molecular Weight: 456.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526784: 8-Hydroxy-arachidic, methyl ester, tBDMS ether","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526784","description":"Access the complete Compound 526784: 8-Hydroxy-arachidic, methyl ester, tBDMS ether on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54vg-hs2e","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/54vg-hs2e","description":"Chemical compound data from PubChem database. IUPAC Name: 1,1,3,3-tetramethyl-2-pentylguanidine. Molecular Formula: C10H23N3. Molecular Weight: 185.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525261: N''-Pentyl-N,N,N',N'-tetramethyl-guanidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525261","description":"Access the complete Compound 525261: N''-Pentyl-N,N,N',N'-tetramethyl-guanidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54vj-jdxu","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","references","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/54vj-jdxu","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865529: MLS000084299","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865529","description":"Access the complete Substance 865529: MLS000084299 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54xg-dkah","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","bioactivity","substance","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/54xg-dkah","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864919: MLS000084022","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864919","description":"Access the complete Substance 864919: MLS000084022 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54xq-dt2s","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","substance","chemistry","bioactivity","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/54xq-dt2s","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864523: MLS000083005","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864523","description":"Access the complete Substance 864523: MLS000083005 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54yp-fceq","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["suicide-attempts","san-francisco","drug-overdose","emergency-department","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/54yp-fceq","description":"Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving suicide attempts in the San Francisco division of the San Francisco metropolitan area, covering 2004-2011. Drug-related suicide attempts include visits for drug overdoses and for suicide attempts by other means (e.g., using a firearm) if drugs were involved or related to the suicide attempt.","title":"San Francisco – SF Div: Drug-Related Emergency Department Visits, 2004-2011 - Suicide Attempts","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/san-francisco-sf-div-drug-related-emergency-department-visits-2004-2011-suicide-attempts","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/54z7-xe3n","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","references","chemistry","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/54z7-xe3n","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864813: MLS000083639","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864813","description":"Access the complete Substance 864813: MLS000083639 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cms.gov/provider-summary-by-type-of-service/medicare-inpatient-hospitals/medicare-inpatient-hospitals-by-geography-and-service","bureauCode":["009:38"],"issued":"2026-07-10","temporal":"2013-01-01/2024-12-31","@type":"dcat:Dataset","modified":"2026-04-23","references":["https://data.cms.gov/resources/medicare-inpatient-hospitals-methodology"],"keyword":["health care use & payments","health equity","hospitals & facilities","inpatient","medicare","national","original medicare","states & territories"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicare Provider Data - OEDA","hasEmail":"mailto:IPAG_Data_Products@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"https://data.cms.gov/data-api/v1/dataset/2941ab09-8cee-49d8-9703-f3c5b854e388/data-viewer","description":"The Medicare Inpatient Hospitals by Geography and Service dataset provides information on hospital discharges for Original Medicare Part A beneficiaries by IPPS hospitals. This dataset contains information on the number of discharges, payments, and submitted charges organized by geography and Medicare Severity Diagnosis Related Group (DRG).","title":"Medicare Inpatient Hospitals - by Geography and Service","programCode":["009:000"],"distribution":[{"mediaType":"text/html","downloadURL":"https://data.cms.gov/data-api/v1/dataset/2941ab09-8cee-49d8-9703-f3c5b854e388/data","description":"latest","@type":"dcat:Distribution","title":"Medicare Inpatient Hospitals - by Geography and Service : 2024-01-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-04/4517a6a1-adeb-4345-9f3d-a95391a470db/MUP_INP_RY26_P03_V10_DY24_Geo.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2024-01-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/0a011f40-7063-4c83-bc05-529f3522b727/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2024-01-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-05/e76f04f1-58da-450e-9f2f-129223992821/MUP_INP_RY25_P03_V10_DY23_Geo.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2023-12-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/4bbc0451-a4fb-4ba4-a381-5463bfdb5c93/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2023-12-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-05/a9f5e5e4-b214-4a3f-97f6-b4f3d7e34cfa/MUP_INP_RY24_P03_V10_DY22_Geo.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2022-12-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/5c8b315f-a2a3-4b2f-bba6-7be19f8d7edc/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2022-12-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-05/ee35f629-d386-426e-b51e-70451cf896d2/MUP_IHP_RY23_P03_V10_DY21_GEO.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2021-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/68739613-1a4f-40ae-9664-49da07abd81f/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2021-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-05/ef9ecf4c-ad7c-4112-881e-ccb9a83acb1c/MUP_IHP_RY23_P03_V10_DY20_GEO.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2020-12-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/e583de38-33d7-4895-a115-0d8af74f0795/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2020-12-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-05/f07177de-e932-4b1a-a754-eac7bdfc4b28/MUP_IHP_RY23_P03_V10_DY19_GEO.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2019-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/337617e5-c18b-4cb9-8152-34851747584b/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2019-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-05/9c685ed4-a63c-4d22-9027-f225ce631c56/MUP_IHP_RY23_P03_V10_DY18_GEO.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2018-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/25b5b6c9-977d-4f7a-aaa7-7dde72f3d5cc/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2018-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-05/997006a4-cc2b-48ed-8b59-4c7ed6d2833f/MUP_IHP_RY23_P03_V10_DY17_GEO.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2017-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/7c638c5f-7e8c-4346-8a25-9b37a0ed36dd/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2017-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-05/37a92da8-fe11-4f52-b96c-04211cfafb2a/MUP_IHP_RY23_P03_V10_DY16_GEO.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2016-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/81dca731-b739-4a0a-b2ec-555f6cf04ea6/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2016-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-05/b3cb61a4-7b3f-4508-ba0c-a3ffe3a1001e/MUP_IHP_RY23_P03_V10_DY15_GEO.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2015-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/98069693-d269-46a1-8e7e-f360f37a2031/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2015-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-05/8938c5bd-da0f-4810-b696-cdad9a6b7ed8/MUP_IHP_RY23_P03_V10_DY14_GEO.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2014-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/fe4fa35f-d27b-4bed-a14a-35528a870de0/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2014-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-05/dbee128c-28d2-4c64-b711-9c2528eed2f0/MUP_IHP_RY23_P03_V10_DY13_GEO.CSV","mediaType":"text/csv","title":"Medicare Inpatient Hospitals - by Geography and Service : 2013-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c7019ecb-8f6f-4548-8eed-ee5bf35b51d5/data","mediaType":"text/html","title":"Medicare Inpatient Hospitals - by Geography and Service : 2013-12-31"}],"describedBy":"https://data.cms.gov/resources/medicare-inpatient-hospitals-by-geography-and-service-data-dictionary-0","dataQuality":true,"license":"https://www.usa.gov/government-works","accrualPeriodicity":"R/P1Y","theme":["Medicare"],"language":["en-US"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["public-health","pharmaceuticals","health-care","drug-safety","drug-manufacturers"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA204702","description":"Palonosetron Hydrochloride is a prescription injectable medication used to prevent nausea and vomiting caused by chemotherapy or surgery. It's administered intravenously by healthcare professionals. Manufactured by Teva Parenteral Medicines, Inc., under ANDA090713, it's available in strengths like 0.25 mg/5 mL. This information was generated using AI and is provided for informational and research purposes only.","title":"Palonosetron hydrochloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=204702","description":"\n Access the FDA dataset for Palonosetron hydrochloride — ANDA 204702 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Palonosetron hydrochloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/553m-r5bv","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["guidance","policy","instruction","child","grant"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/553m-r5bv","description":"This Program Instruction (PI) supersedes ACYF-CB-IM-83-04 issued June 6, 1983. This Program Instruction (PI) provides instruction on planning requirements for receipt of direct title IV-B child welfare services grants by indian tribal organizations.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-93-13)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-93-13","description":"Access the complete PI-93-13 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/bqmb-vyka","bureauCode":["009:00"],"issued":"2020-01-21","@type":"dcat:Dataset","modified":"2021-01-07","keyword":["netss","cholera","2020","nndss","wonder","coccidioidomycosis","nedss"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/bqmb-vyka","description":"NNDSS - Table 1H. Cholera to Coccidioidomycosis - 2020. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.\n\nNotice: Data from California published in week 29 for years 2019 and 2020 were incomplete when originally published on July 24, 2020. On August 4, 2020, incomplete case counts were replaced with a \"U\" indicating case counts are not available for specified time period. \n\nNote: \nThis table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. \n\nFootnotes:\nU: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.\n-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.\nN: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.\nNN: Not nationally notifiable — This condition was not designated as being nationally notifiable.\nNP: Nationally notifiable but not published.\nNC: Not calculated — There is insufficient data available to support the calculation of this statistic.\nCum: Cumulative year-to-date counts.\nMax: Maximum — Maximum case count during the previous 52 weeks.\n* Case counts for reporting years 2019 and 2020 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf.\n†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).","title":"NNDSS - Table 1H. Cholera to Coccidioidomycosis","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bqmb-vyka/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bqmb-vyka/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bqmb-vyka/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bqmb-vyka/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bqmb-vyka/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/bqmb-vyka/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-information","public-health","pharmaceuticals","health-care","drug"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA216941","description":"Mesalamine is a prescription rectal suppository containing 1000 mg of the active ingredient, used to treat inflammatory bowel diseases like ulcerative colitis. Manufactured by Camber Pharmaceuticals, Inc., under application ANDA213377. This information was generated using AI and is provided for informational and research purposes only.","title":"Mesalamine","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216941","description":"\n Access the FDA dataset for Mesalamine — ANDA 216941 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Mesalamine"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5595-34hj","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2025-06-30","references":["https://download.medicaid.gov/data/Spreadsheet_Footnotes.pdf"],"keyword":["drug products"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"666bbb60-13ea-4545-b696-d65776db2bab","description":"The Reference Document link for the downable Blood Disorder Treatment Spreadsheet can be accessed below under the Additional Information table under Related Documents.","title":"Pricing Comparison for Blood Disorder Treatments (Pricing as of 06/1/2025)","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/Clotting-Factor-June-2025.csv","mediaType":"text/csv"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["Drug Pricing and Payment"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/55cf-9r7c","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["opioid-treatment","mat-access","service-gap-analysis","samhsa","ohio-opioids"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/55cf-9r7c","description":"The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.","title":"Ohio 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/ohio-2016-potential-areas-addressing-service-gaps-opioid-treatment","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.colorado.gov/d/8ny6-t8g8","issued":"2014-06-09","@type":"dcat:Dataset","modified":"2026-02-19","keyword":["colorado department of public health & environment","fever","west nile virus","meningitism encephalitis"],"contactPoint":{"@type":"vcard:Contact","fn":"April Broome","hasEmail":"mailto:no-reply@data.colorado.gov"},"publisher":{"@type":"org:Organization","name":"State of Colorado"},"identifier":"https://data.colorado.gov/api/views/8ny6-t8g8","description":"Counties not listed have no verified human cases of WNV","title":"Human West Nile Virus Infections by County: December 31, 2012","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.colorado.gov/api/v3/views/8ny6-t8g8/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.colorado.gov/api/v3/views/8ny6-t8g8/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.colorado.gov/api/v3/views/8ny6-t8g8/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/55ff-fd7x","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","research","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/55ff-fd7x","description":"Chemical compound data from PubChem database. IUPAC Name: (2-chlorophenyl) 4-cyanobenzoate. Molecular Formula: C14H8ClNO2. Molecular Weight: 257.67. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530784: 4-Cyanobenzoic acid, 2-chlorophenyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530784","description":"Access the complete Compound 530784: 4-Cyanobenzoic acid, 2-chlorophenyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/iu3b-5ngj","bureauCode":["009:20"],"issued":"2021-01-21","@type":"dcat:Dataset","modified":"2022-01-12","keyword":["wonder","2021","nedss","netss","nndss","rubella","rubella congenital syndrome"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/iu3b-5ngj","description":"NNDSS - TABLE 1DD. Rubella to Rubella, congenital syndrome - 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.\n\nNotice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.\n\nNote: \nThis table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html. \n\nFootnotes:\nU: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.\n-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.\nN: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.\nNN: Not nationally notifiable — This condition was not designated as being nationally notifiable.\nNP: Nationally notifiable but not published.\nNC: Not calculated — There is insufficient data available to support the calculation of this statistic.\nCum: Cumulative year-to-date counts.\n Max: Maximum — Maximum case count during the previous 52 weeks.\n * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. \n†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).","title":"NNDSS - TABLE 1DD. Rubella to Rubella, congenital syndrome","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/iu3b-5ngj/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/iu3b-5ngj/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/iu3b-5ngj/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/iu3b-5ngj/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/iu3b-5ngj/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/iu3b-5ngj/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm","bureauCode":["009:10"],"issued":"2021-02-25","@type":"dcat:Dataset","modified":"2013-11-13","references":["http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm329946.htm"],"keyword":["cdrh"],"contactPoint":{"@type":"vcard:Contact","fn":"openFDA","hasEmail":"mailto:open@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"c2420fb3-2c71-4a09-80a9-5fc2f3a459f5","description":"This database contains a list of classified medical device recalls since November 1, 2002","title":"Medical and Radiation Emitting Device Recalls","programCode":["009:005"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRES/res.cfm","mediaType":"text/html"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/55jk-aczu","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","research","chemistry","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/55jk-aczu","description":"Chemical compound data from PubChem database. IUPAC Name: 1,8-dibromodibenzofuran. Molecular Formula: C12H6Br2O. Molecular Weight: 325.98. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526302: 1,8-Dibromo-dibenzofuran","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526302","description":"Access the complete Compound 526302: 1,8-Dibromo-dibenzofuran on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/55k7-ujp3","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","compound","science","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/55k7-ujp3","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 2-ethyloctanoate. Molecular Formula: C11H22O2. Molecular Weight: 186.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528069: Octanoic acid, 2-ethyl, methyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528069","description":"Access the complete Compound 528069: Octanoic acid, 2-ethyl, methyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/cxp2-tsw9","issued":"2014-12-11","@type":"dcat:Dataset","modified":"2017-11-30","keyword":["provider","directory","facilities and services","managed care","medicaid","plan"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/cxp2-tsw9","description":"The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. For more information, check out: http://www.health.ny.gov/health_care/managed_care/ or go to the “About” tab.","title":"Managed Care Individual Provider Network Data: December 31, 2013","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/download/cxp2-tsw9/application/zip","mediaType":"application/zip"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/55nc-dhdp","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","nuclear-inclusions","protein-trafficking","rab24-gtpase","ubiquitin-hsp70"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/55nc-dhdp","description":"Background\n Members of the Rab GTPase family regulate intracellular protein trafficking, but the specific function of Rab24 remains unknown. Several attributes distinguish this protein from other members of the Rab family, including a low intrinsic GTPase activity.\n \n \n Results\n The functions of other Rab proteins have been defined through the use of dominant-negative mutants with amino acid substitutions in the conserved N(T)KxD nucleotide binding motif. Surprisingly, when such Rab24 constructs were expressed in cultured cells, they accumulated in nuclear inclusions which disrupted the integrity of the nuclear envelope. The inclusions reacted positively with antibodies against ubiquitin and Hsp70, similar to protein aggregates observed in polyglutamine disorders. They also appeared to sequester importin-β and GFP-coupled glucocorticoid receptor. Other Rab GTPases with similar mutations in the N(T)KxD motif were never found in inclusions, suggesting that the unusual localization of Rab24 is not related solely to misfolding of its nucleotide-free form. Studies with Rab24/Rab1B chimeras indicated that targeting of the mutant protein to inclusions requires the unique C-terminal domain of Rab24.\n \n \n Conclusion\n These studies demonstrate that mutations in Rab24 can trigger a cytopathic cellular response involving accumulation of nuclear inclusions. If the N(T)KxD mutants of Rab24 function as dominant suppressors, these studies may point to a unique role for Rab24 in degradation of misfolded cellular proteins or trafficking of proteins to the nuclear envelope. However, we cannot yet eliminate the possibility that these phenomena are related to unusual non-physiological protein interactions with the mutant form of Rab24.","title":"Mutant Rab24 GTPase is targeted to nuclear inclusions","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC130051/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/55nn-8b2j","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","pubchem","compound","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/55nn-8b2j","description":"Chemical compound data from PubChem database. IUPAC Name: N-phenyl-N-[1-(1-phenylpropan-2-yl)piperidin-4-yl]butanamide. Molecular Formula: C24H32N2O. Molecular Weight: 364.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527016: alpha-Methyl butanoyl fentanyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527016","description":"Access the complete Compound 527016: alpha-Methyl butanoyl fentanyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/55nz-iqkd","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","patent","innovation","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/55nz-iqkd","description":"The electrowetting cell ( 15 ) comprises an outer wall ( 90 ) and an inner wall ( 80 ), said outer wall ( 90 ) being provided with extensions ( 85, 86 ) extending at opposing sides of the inner wall ( 80 ). The cell ( 15 ) is further provided with a membrane ( 45 ) for volume expansion and is sealed through an electroplated layer ( 95 ).","title":"Patent AT-E399997-T1: [Translated] ELECTROWETTING CELL AND METHOD FOR PRODUCING THE SAME","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399997-T1","description":"Access the complete Patent AT-E399997-T1: [Translated] ELECTROWETTING CELL AND METHOD FOR PRODUCING THE SAME on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/55qc-zcz3","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","community-mental-health","palau","samhsa","national-outcome-measures"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/55qc-zcz3","description":"This is the 2017 Uniform Reporting System (URS) Output Tables for Palau. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2017 Uniform Reporting System (URS) Table for Palau","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2017-uniform-reporting-system-urs-table-palau","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/55qr-qn5d","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","patent","innovation","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/55qr-qn5d","description":"The present invention provides compositions and methods for increasing therapeutic gain in radiotherapy and chemotherapy for proliferating malignant or nonmalignant disease to produce high probability of tumor control with low frequency of sequelae of therapy by administering a therapeutically effective amount of a histone deacetylase inhibitor. The compounds are capable of simultaneously stimulating the epithelium regrowth, inhibiting the fibroblast proliferation, decreasing the collagen deposit, suppressing the fibrogenic growth factor, subsiding the proinflammatory cytokine and modulating the expression of cell cycle genes, tumor suppressors and oncogenes, and are useful to increase the therapeutic gain in radiotherapy and chemotherapy, which results in decrease of skin swelling and inflammation, promotion of epithelium healing in mucosa and dermis, decrease of xerostomia, prevention/reduction of severity of plantar-palmar syndrome, prevention of tissue fibrosis, ulceration, necrosis and tumorigenesis, and increase of tumor growth inhibition and tumor therapy effectiveness.A list of NIH-supported repositories that accept submissions of appropriate scientific research data from biomedical researchers. It includes resources that aggregate information about biomedical data and information sharing systems. Links are provided to information about submitting data to and accessing data from the listed repositories. Additional information about the repositories and points-of contact for further information or inquiries can be found on the websites of the individual repositories.
","title":"NIH Data Sharing Repositories","programCode":["009:046"],"license":"https://opendatacommons.org/licenses/odbl/1.0/","dataQuality":true},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/569s-jyi9","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["pubchem","research","compound","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/569s-jyi9","description":"Chemical compound data from PubChem database. IUPAC Name: 3-(2-methylsulfanylethylsulfanyl)prop-1-ene. Molecular Formula: C6H12S2. Molecular Weight: 148.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525475: 4,7-Dithia-1-octene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525475","description":"Access the complete Compound 525475: 4,7-Dithia-1-octene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/56bx-ajw9","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["community-mental-health","mental-health-services","connecticut-mental-health","samhsa","national-outcome-measures"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/56bx-ajw9","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Tables for Connecticut for 2013. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2013 CMHS Uniform Reporting System (URS) Tables for Connecticut","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2013-cmhs-uniform-reporting-system-urs-tables-connecticut","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/56ck-57ug","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","science","research","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/56ck-57ug","description":"Chemical compound data from PubChem database. IUPAC Name: bis[bis(2,2,2-trifluoroethyl)carbamothioylsulfanyl]lead. Molecular Formula: C10H8F12N2PbS4. Molecular Weight: 719.0. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526651: Pb(II) N,N-bis(2,2,2-trifluoroethyl)dithiocarbamate, chelate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526651","description":"Access the complete Compound 526651: Pb(II) N,N-bis(2,2,2-trifluoroethyl)dithiocarbamate, chelate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/56hs-ywd6","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["neurological-disorders","seizure-treatment","status-epilepticus","anticonvulsant-therapy","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/56hs-ywd6","description":"Status epilepticus (SE) has an annual incidence exceeding 100,000 cases in the United States alone, of which more than 20% result in death. Thus, increased awareness of presentation, etiologies, and treatment of SE is essential in the practice of critical care medicine. This review discusses current definitions of SE, as well as its clinical presentation and classification. The recent literature on epidemiology is reviewed, including morbidity and mortality data. An overview of the systemic pathophysiologic effects of SE is presented. Finally, significant studies on the treatment of acute SE and refractory SE are reviewed, including the use of anticonvulsants, such as benzodiazepines, and other drugs.","title":"Clinical review: Status epilepticus","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC137295/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/ikdg-62d9","issued":"2016-09-13","@type":"dcat:Dataset","modified":"2016-12-28","keyword":["directory","provider","plan","medicaid","managed care","facilities and services"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/ikdg-62d9","description":"The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans. This dataset reflects individual provider data. Provider Network Data System information is self-reported. For more information, check out http://www.health.ny.gov/health_care/managed_care/.","title":"Managed Care Individual Provider Network Data: March 31, 2016","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/download/ikdg-62d9/application/zip","mediaType":"application/zip"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/56mt-37yj","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["childr","acf","social","service","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/56mt-37yj","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"2010arkansas","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/11660","description":"Access the complete 2010arkansas.pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/56n9-9xn7","bureauCode":["009:38"],"issued":"2026-06-30","temporal":"2017-01-01/2023-12-31","@type":"dcat:Dataset","modified":"2026-06-30","keyword":["all years"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Payments","hasEmail":"mailto:openpayments@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"openpaymentsdata.cms.gov"},"identifier":"aaaddc12-a3a7-4cc5-9c12-4a726317aa1c","description":"This dataset is pre-filtered based on the most frequent searches of Open Payments data.","title":"National level payment total and averages for all years","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.cms.gov/openpayments/SMRY_RPTS_P06302026_06032026/PBLCTN_NTNL_SMRY_P06302026_06032026-joined.csv","mediaType":"text/csv","title":"National level payment total and averages for all years"}],"dataQuality":true,"license":"https://www.usa.gov/government-works","theme":["Summary"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/56nx-gcme","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["colorado-behavioral-health","mental-health-colorado","samhsa","substance-use-trends","youth-mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/56nx-gcme","description":"This is a behavioral health report for the state of Colorado. It uses the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use, youth mental health and treatment, adult mental health and treatment, substance use, and substance use treatment for the years 2009 to 2013.","title":"Behavioral Health Barometer: Colorado, 2014","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-colorado-2014","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/56p8-265i","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["behavioral-health","mental-health","nsduh","samhsa","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/56p8-265i","description":"Tables and maps defining the substate regions for each state and the District of Columbia.","title":"2014-2016 NSDUH Substate Region Estimates Categorized into Seven Groups, by Age Group","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2014-2016-nsduh-substate-region-estimates-categorized-seven-groups-age-group","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/56sc-ztqh","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","innovation","patent","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/56sc-ztqh","description":"A method of achieving a workpiece material property change using a horn with a set of activation teeth as a source of ultrasonic energy and an anvil with a second set of activation teeth. The workpiece is engaged in tension between the two sets of activation teeth.","title":"Patent AT-E401190-T1: [Translated] METHOD FOR CHANGING THE PROPERTIES OF A MATERIAL USING ULTRASONIC ENERGY","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401190-T1","description":"Access the complete Patent AT-E401190-T1: [Translated] METHOD FOR CHANGING THE PROPERTIES OF A MATERIAL USING ULTRASONIC ENERGY on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/56wp-ketf","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","research","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/56wp-ketf","description":"Chemical compound data from PubChem database. IUPAC Name: 2,6-dimethoxy-4-(N-methoxy-C-methylcarbonimidoyl)phenol. Molecular Formula: C11H15NO4. Molecular Weight: 225.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530381: Acetophenone, 4-hydroxy-3,5-dimethoxy, O-methyloxime","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530381","description":"Access the complete Compound 530381: Acetophenone, 4-hydroxy-3,5-dimethoxy, O-methyloxime on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdph.ca.gov/Programs/OHE/Pages/HRSU.aspx","issued":"2017-12-27","temporal":"2017","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["fast food","food","food desert","hci","healthy community indicator","healthy food","modified retail food environment index","social determinants of health"],"contactPoint":{"@type":"vcard:Contact","fn":"CDPH Office of Health Equity, Health Research and Statistics Unit","hasEmail":"mailto:OpenData@cdph.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"714a9d67-3291-447b-94b9-9d3e1063d176","description":"This table contains data on the modified retail food environment index for California, its regions, counties, cities, towns, and census tracts. An adequate, nutritious diet is a necessity at all stages of life. Pregnant women and their developing babies, children, adolescents, adults, and older adults depend on adequate nutrition for optimum development and maintenance of health and functioning. Nutrition also plays a significant role in causing or preventing a number of illnesses, such as cardiovascular disease, some cancers, obesity, type-2 diabetes, and anemia. Peoples’ food choices and their likelihood of being overweight or obese are also influenced by their food environment: the foods available in their neighborhoods including stores, restaurants, schools, and worksites. \r\n\r\nThe modified retail food environment index table is part of a series of indicators in the Healthy Communities Data and Indicators Project (HCI) of the Office of Health Equity. The goal of HCI is to enhance public health by providing data, a standardized set of statistical measures, and tools that a broad array of sectors can use for planning healthy communities and evaluating the impact of plans, projects, policy, and environmental changes on community health. The creation of healthy social, economic, and physical environments that promote healthy behaviors and healthy outcomes requires coordination and collaboration across multiple sectors, including transportation, housing, education, agriculture and others. Statistical metrics, or indicators, are needed to help local, regional, and state public health and partner agencies assess community environments and plan for healthy communities that optimize public health. More information on HCI can be found here: https://www.cdph.ca.gov/Programs/OHE/CDPH%20Document%20Library/Accessible%202%20CDPH_Healthy_Community_Indicators1pager5-16-12.pdf \r\n\r\nThe format of the modified retail food environment table is based on the standardized data format for all HCI indicators. As a result, this data table contains certain variables used in the HCI project (e.g., indicator ID, and indicator definition). Some of these variables may contain the same value for all observations.","title":"Modified Retail Food Environment Index","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/714a9d67-3291-447b-94b9-9d3e1063d176/resource/15b4740d-7916-48b7-92b9-8e5b274e4d9b/download/hci_retailfoodenvironment_75_narrative_and_examples_11-28-17-ada.pdf","mediaType":"application/pdf","title":"Narrative and Examples for Modified Retail Food Environment"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/714a9d67-3291-447b-94b9-9d3e1063d176/resource/c58c1b68-6545-4039-bc52-6facf120a4c7/download/hciretailfoodenvironment75cacoreplct201715nov17.csv","description":"This table contains data on the modified retail food environment index for California, its regions, counties, cities, towns, and census tracts. The format of the modified retail food environment table is based on the standardized data format for all HCI indicators. As a result, this data table contains certain variables used in the HCI project (e.g., indicator ID, and indicator definition). Some of these variables may contain the same value for all observations.","@type":"dcat:Distribution","title":"Modified Retail Food Environment Index-Data"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/datastore/dictionary_download/c58c1b68-6545-4039-bc52-6facf120a4c7","description":"Data Dictionary for https://data.chhs.ca.gov/dataset/714a9d67-3291-447b-94b9-9d3e1063d176/resource/c58c1b68-6545-4039-bc52-6facf120a4c7/download/hciretailfoodenvironment75cacoreplct201715nov17.csv","@type":"dcat:Distribution","title":"Data Dictionary - Modified Retail Food Environment Index-Data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/714a9d67-3291-447b-94b9-9d3e1063d176/resource/fc0216ab-ba0d-4bd9-be0c-6fba6fca3c62/download/modified-retail-food-environment-index-8ea68ag7.zip","mediaType":"application/zip","title":"All resource data"},{"@type":"dcat:Distribution","downloadURL":"https://www.cdph.ca.gov/Programs/OHE/Pages/HCI-RetailFood.aspx","mediaType":"text/html","title":"Chart: Modified Retail Food Environment"},{"@type":"dcat:Distribution","downloadURL":"https://cdphdata.maps.arcgis.com/apps/MapSeries/index.html?appid=22cc4b66ba724fb28ccaa0c4dbbc943a","mediaType":"text/html","title":"ESRI Story Map: Modified Retail Food Environment"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["Environment"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/56y8-a6rw","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["copd","nih","skeletal-muscle","pulmonary-disease","muscle-dysfunction"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/56y8-a6rw","description":"It has become increasingly recognized that skeletal muscle dysfunction is common in patients with chronic obstructive pulmonary disease (COPD). Muscle strength and endurance are decreased, whereas muscle fatigability is increased. There is a reduced proportion of type I fibers and an increase in type II fibers. Muscle atrophy occurs with a reduction in fiber cross-sectional area. Oxidative enzyme activity is decreased, and measurement of muscle bioenergetics during exercise reveals a reduced aerobic capacity. Deconditioning is probably very important mechanistically. Other mechanisms that may be of varying importance in individual patients include chronic hypercapnia and/or hypoxia, nutritional depletion, steroid usage, and oxidative stress. Potential therapies include exercise training, oxygen supplementation, nutritional repletion, and administration of anabolic hormones.","title":"Skeletal muscle dysfunction in chronic obstructive pulmonary disease","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59579/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/56yf-9sby","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","research","pubchem","compound","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/56yf-9sby","description":"Chemical compound data from PubChem database. IUPAC Name: 2-phenyladamantane. Molecular Formula: C16H20. Molecular Weight: 212.33. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527341: 2-Phenyladamantane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527341","description":"Access the complete Compound 527341: 2-Phenyladamantane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/PCDSimpleSearch.cfm","bureauCode":["009:10"],"issued":"2021-02-25","@type":"dcat:Dataset","modified":"2025-07-16","references":["http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ClassifyYourDevice/ucm051668.htm"],"keyword":["cdrh"],"contactPoint":{"@type":"vcard:Contact","fn":"openFDA","hasEmail":"mailto:open@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"3286eac6-86ad-4236-9281-8d09ad04e816","description":"This database contains medical device names and associated information developed by the Center. It includes a three letter device product code and a Device Class that refers to the level of CDRH regulation of a given device.","title":"Product Classification","programCode":["009:005"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://www.accessdata.fda.gov/premarket/ftparea/foiclass.zip","mediaType":"application/zip"}],"describedBy":"http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/Overview/ClassifyYourDevice/ucm2005371.htm","license":"http://opendefinition.org/licenses/odc-odbl/","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5739-znta","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["reporting","adoption","assessment","fiscal","foster"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5739-znta","description":"Should you require access to this document or accessibility assistance with any documentation from Illinois's Adoption and Foster Care Analysis and Reporting System (AFCARS) assessment review, please contact us at cbwebsite@childwelfare.gov.This webpage includes the documentation from Illinois's Adoption and Foster Care Analysis and Reporting System (AFCARS) assessment review for fiscal year 2010:\n\nAFCARS Assessment Review Findings – Letter (PDF - 33 KB)\n\nAFCARS Assessment Review Report – Illinois (PDF - 74 KB)\n\nAFCARS Case File Summary Report – Illinois (PDF - 23 KB)\n\nAFCARS Assessment Review Findings – General Requirement (PDF - 99 KB)\n\nAFCARS Assessment Review Findings – Foster Care and Adoption Data Elements (PDF - 352 KB)\n\nAFCARS Assessment Review Case File Findings – Foster Care and Adoption Data Elements (PDF - 195 KB)\n\nAFCARS Assessment Review Improvement Plan – General Requirements (PDF - 64 KB)\n\nAFCARS Assessment Review Improvement Plan - Foster Care and Adoption Data Elements (PDF - 475 KB)\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Illinois AFCARS Assessment Review","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/illinois-afcars-assessment-review","description":"Access the complete Illinois AFCARS Assessment Review on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/flu/fluvaxview/dashboard/vaccination-dashboard.html","bureauCode":["009:20"],"issued":"2023-11-17","@type":"dcat:Dataset","temporal":"2023-2024","modified":"2024-05-24","keyword":["flu shot","vaccine coverage","nis-acm","influenza","flu","adult"],"contactPoint":{"@type":"vcard:Contact","fn":"VaxView Team","hasEmail":"mailto:VaxView@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/2v3t-r3np","description":"Weekly Cumulative Influenza Vaccination Coverage, Adults 18 and Older, United States\n\n• Influenza vaccination coverage among adults is assessed through the National Immunization Survey-Adult COVID Module providing weekly influenza vaccination coverage estimates. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html)\n• NIS-ACM was started in April 2021 to survey adults 18 years and older COVID-19 vaccination uptake and vaccine confidence. \n• Final estimates for prior seasons and other flu vaccination data are available at CDC’s FluVaxView: https://www.cdc.gov/flu/fluvaxview/index.htm.","title":"Weekly Cumulative Influenza Vaccination Coverage, Adults 18 and Older, United States","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/2v3t-r3np/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/2v3t-r3np/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/2v3t-r3np/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"United States","license":"https://www.usa.gov/government-works","accrualPeriodicity":"Weekly","theme":["Flu Vaccinations"],"language":["English"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/574z-s9z4","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["fiscal","guidance","policy","social","instruction"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/574z-s9z4","description":"This Program Instruction (PI) provides instruction on the allotment of Title IV-B, Subparts 1 and 2 Funds to Eligible Indian Tribes and Indian Tribal Organizations for Fiscal Year (FY) 2003.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-03-03)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-03-03","description":"Access the complete PI-03-03 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5796-dnmt","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["child","foster","assessment","policy","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5796-dnmt","description":"This document is New Mexico’s program improvement plan in response to the primary review of its Title IV-E foster care program.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"New Mexico Title IV-E Foster Care Eligibility Review Program Improvement Plan (2018)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/new-mexico-title-iv-e-foster-care-eligibility-review-program-improvement-plan-2018","description":"Access the complete New Mexico Title IV-E Foster Care Eligibility Review Program Improvement Plan (2018) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57a6-cnmn","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","national-outcome-measures","samhsa","behavioral-health","urs-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/57a6-cnmn","description":"2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Pennsylvania. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2015 CMHS Uniform Reporting System (URS) Table for Pennsylvania","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2015-cmhs-uniform-reporting-system-urs-table-pennsylvania","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57c2-9bsr","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","pubchem","patent","innovation","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/57c2-9bsr","description":"A lock system for a horizontal tool box wherein the latching mechanism for the lid may be operated from the proximal end of the toolbox and locking is achieved by means of a single padlock which is likewise located at the proximal end of the toolbox. An elongated latch rod is slidably disposed adjacent a front wall of either the body or lid components of the box. The padlock and the elongated latch rod are disposed such that the padlock body blocks the longitudinal movement of the proximal end of the latch rod and maintains the latch rod in the latched position when the body components are in the closed position and the padlock is locked, but the proximal end of the latch rod passes between the shackle and the padlock body to move the latch rod to the release position when the padlock is unlocked.","title":"Patent AT-E400719-T1: [Translated] LOCK FOR A HORIZONTAL TOOL BOX","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400719-T1","description":"Access the complete Patent AT-E400719-T1: [Translated] LOCK FOR A HORIZONTAL TOOL BOX on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57ch-nnpy","bureauCode":["009:70"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["abuse","reporting","policy","ndacan","care"],"contactPoint":{"@type":"vcard:Contact","fn":"NDACAN Data Team","hasEmail":"mailto:NDACAN@cornell.edu"},"publisher":{"@type":"org:Organization","name":"National Data Archive on Child Abuse and Neglect"},"identifier":"https://healthdata.gov/api/views/57ch-nnpy","description":"The Children’s Bureau in the Administration for Children and Families contracted with the Urban Institute and its partners—the Chapin Hall Center for Children at the University of Chicago and the National Opinion Research Center—to conduct an evaluation of selected programs funded through John Chafee Foster Care Independence Program (CFCIP). This evaluation, using a rigorous, random assignment design, was called for in the Foster Care Independence Act of 1999. \nThe goal of the evaluation is to determine the effects of Independent Living Programs funded under CFCIP in achieving key outcomes for participating youth including increased educational attainment, higher employment rates and stability, greater interpersonal and relationship skills, reduced non-marital pregnancy and births, and reduced delinquency and crime rates. An initial evaluability assessment was conducted to identify programs that could be rigorously evaluated and to develop an evaluation design that would meet the requirements of the authorizing legislation. Programs participating in the evaluation include an employment services program in Kern County, California; a one-on-one intensive, individualized life skills program in Massachusetts; and, a tutoring/mentoring program and a classroom-based life skills training program, both in Los Angeles County, California.\n\nInvestigators: Mark E. Courtney, Ph.D.\nUniversity of Wisconsin Madison, WI\n\nMatthew W. Stagner, Ph.D.\nU.S. Department of Health and Human Services Washington, DC\n\nMichael Pergamit, Ph.D.\nUrban Institute Washington, DC","title":"Multi-Site Evaluation of Foster Youth Programs (Chafee Independent Living Evaluation Project), 2001-2010","programCode":["009:094"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ndacan.acf.hhs.gov/datasets/dataset-details.cfm?ID=161","description":"Access the complete Multi-Site Evaluation of Foster Youth Programs (Chafee Independent Living Evaluation Project), 2001-2010 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57ch-vfxv","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health","nsduh","survey-methodology","samhsa","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/57ch-vfxv","description":"The report describes the change to the instrumentation and protocols for the 2018 NSDUH.","title":"NSDUH 2018 Instrumentation Protocol Changes","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/nsduh-2018-instrumentation-protocol-changes","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57f2-sadt","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["adoption","foster","fiscal","instruction","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/57f2-sadt","description":"The purpose of this Program Instruction (PI) is to provide State, Territorial and Tribal title IV-E agencies (hereafter, \"title IV-E agencies\") with the revised form and instructions approved by the U.S. Office of Management and Budget (OMB) for reporting quarterly financial information on the title IV-E Foster Care, Adoption Assistance and Guardianship Assistance Programs. This PI also provides guidance for the submission of the Annual Adoption Savings Calculation and Accounting Report for federal fiscal year (FFY) 2015 and for subsequent FFYs.\n\nATTACHMENT B - FORM CB-496: TITLE IV-E PROGRAMS QUARTERLY FINANCIAL REPORT: PART 1: EXPENDITURES and ESTIMATES (Including Caseload Data)\n(This attachment cannot be posted at this time. To request a copy of the form, please email Angelique Brown at angelique.brown@acf.hhs.gov).\n\nATTACHMENT C - INSTRUCTIONS TO COMPLETE FORM CB-496 (A new version of this attachment, updated August 1, 2016, is available for download below).\n\nATTACHMENT D - FORM CB-496: TITLE IV-E PROGRAMS QUARTERLY FINANCIAL REPORT: PART 4: ANNUAL ADOPTION SAVINGS CALCULATION AND ACCOUNTING REPORT\n(This attachment cannot be posted at this time. To request a copy of the form, please email Angelique Brown at angelique.brown@acf.hhs.gov).\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-15-09)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-15-09","description":"Access the complete PI-15-09 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57gm-ymhh","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","science","compound","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/57gm-ymhh","description":"Chemical compound data from PubChem database. IUPAC Name: 2-methyl-1-(propylsulfanylmethylsulfanyl)propane. Molecular Formula: C8H18S2. Molecular Weight: 178.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525414: 2-Methyl-4,6-dithianonane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525414","description":"Access the complete Compound 525414: 2-Methyl-4,6-dithianonane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57i5-tgsa","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","chemistry","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/57i5-tgsa","description":"Chemical compound data from PubChem database. IUPAC Name: 5-propylheptadecane. Molecular Formula: C20H42. Molecular Weight: 282.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528497: Heptadecane, 5-propyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528497","description":"Access the complete Compound 528497: Heptadecane, 5-propyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/kwnu-g5w9","issued":"2019-08-05","@type":"dcat:Dataset","modified":"2019-08-05","keyword":["lead","school","drinking water"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/kwnu-g5w9","description":"Lead in Drinking Water in Schools Test Results – Lakeland Elementary","title":"Lakeland Elementary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/kwnu-g5w9/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57jf-cft9","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","references","substance","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/57jf-cft9","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 866116: MLS000084348","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/866116","description":"Access the complete Substance 866116: MLS000084348 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57kc-zb4m","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["executive-attention","attention-network-test","heritability","nih","twin-study"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/57kc-zb4m","description":"Background\n Current efforts to study the genetics of higher functions have been lacking appropriate phenotypes to describe cognition. One of the problems is that many cognitive concepts for which there is a single word (e.g. attention) have been shown to be related to several anatomical networks. Recently we have developed an Attention Network Test (ANT) that provides a separate measure for each of three anatomically defined attention networks. In this small scale study, we ran 26 pairs of MZ and DZ twins in an effort to determine if any of these networks show sufficient evidence of heritability to warrant further exploration of their genetic basis.\n \n \n Results\n The efficiency of the executive attention network, that mediates stimulus and response conflict, shows sufficient heritability to warrant further study. Alerting and overall reaction time show some evidence for heritability and in our study the orienting network shows no evidence of heritability.\n \n \n Conclusions\n These results suggest that genetic variation contributes to normal individual differences in higher order executive attention involving dopamine rich frontal areas including the anterior cingulate. At least the executive portion of the ANT may serve as a valid endophenotype for larger twin studies and subsequent molecular genetic analysis in normal subject populations.","title":"Assessing the heritability of attentional networks","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC57000/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57kh-gryc","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/57kh-gryc","description":"Chemical compound data from PubChem database. IUPAC Name: 2-tert-butyl-1-methylcyclohexan-1-ol. Molecular Formula: C11H22O. Molecular Weight: 170.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530356: 2-Tert-butyl-1-methylcyclohexan-1-ol","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530356","description":"Access the complete Compound 530356: 2-Tert-butyl-1-methylcyclohexan-1-ol on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57mf-8dz5","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["sscp-method","snp-analysis","nih","ihrp-gene","genetic-polymorphism"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/57mf-8dz5","description":"Background\n Single-nucleotide polymorphisms (SNPs) are considered to be useful polymorphic markers for genetic studies of polygenic traits. Single-stranded conformational polymorphism (SSCP) analysis has been widely applied to detect SNPs, including point mutations in cancer and congenital diseases. In this study, we describe an application of the fluorescent labeling of PCR fragments using a fluorescent-adapted primer for SSCP analysis as a novel method.\n \n \n Methods\n Single-nucleotide polymorphisms (SNPs) of the inter-alpha-trypsin inhibitor family heavy chain-related protein (IHRP) gene were analyzed using a fluorescence-adapted SSCP method. The method was constructed from two procedures: 1) a fluorescent labeling reaction of PCR fragments using fluorescence-adapted primers in a single tube, and 2) electrophoresis on a non-denaturing polyacrylamide gel.\n \n \n Results\n This method was more economical and convenient than the single-stranded conformational polymorphism (SSCP) methods previously reported in the detection of the labeled fragments obtained. In this study, eight SNPs of the IHRP gene were detected by the fluorescence-adapted SSCP. One of the SNPs was a new SNP resulting in an amino acid substitution, while the other SNPs have already been reported in the public databases. Six SNPs of the IHRP were associated with two haplotypes.\n \n \n Conclusions\n The fluorescence-adapted SSCP was useful for detecting and genotyping SNPs.","title":"SNP analysis of the inter-alpha-trypsin inhibitor family heavy chain-related protein (IHRP) gene by a fluorescence-adapted SSCP method","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC117798/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57pi-p3zw","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["instruction","policy","care","compliance","foster"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/57pi-p3zw","description":"This template is suggested to guide title IV-E agencies on developing a Program Improvement Plan (PIP) in response to findings of their title IV-E foster care eligibility review (IV-E review).\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Title IV-E Program Improvement Plan Instructions and Template","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/title-iv-e-program-improvement-plan-instructions-and-template","description":"Access the complete Title IV-E Program Improvement Plan Instructions and Template on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57r4-bvzf","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","chemistry","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/57r4-bvzf","description":"Chemical compound data from PubChem database. IUPAC Name: N-(3,4-dichlorophenyl)octanamide. Molecular Formula: C14H19Cl2NO. Molecular Weight: 288.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525041: 3,4-Dichlorophenyloctanamide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525041","description":"Access the complete Compound 525041: 3,4-Dichlorophenyloctanamide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"http://www.dhcs.ca.gov/Pages/default.aspx","issued":"2017-09-19","temporal":"April 2026","@type":"dcat:Dataset","modified":"2026-07-03","keyword":["medi-cal","provider","s and i","dhcs","excluded","exclusions","ineligible","reinstatement","state exclusions list","suspended"],"contactPoint":{"@type":"vcard:Contact","fn":"Office of Legal Services","hasEmail":"mailto:DHCSMandatorySuspensionsDesk@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"8f70e05d-baa5-4296-a5ab-36318d530670","description":"Medi-Cal law, _Welfare and Institutions Code_ (W&I Code), sections 14043.6 and 14123, mandate that the Department of Health Care Services (DHCS) suspend a Medi-Cal provider of health care services (provider) from participation in the Medi-Cal program when the individual or entity has:\r\n\r\n* Been convicted of a felony;\r\n* Been convicted of a misdemeanor involving fraud, abuse of the Medi-Cal program or any patient, or otherwise substantially related to the qualifications, functions, or duties of a provider of service;\r\n* Been suspended from the federal Medicare or Medicaid programs for any reason;\r\n* Lost or surrendered a license, certificate, or approval to provide health care; or\r\n* Breached a contractual agreement with the Department that explicitly specifies inclusion on this list as a consequence of the breach.\r\n\r\n__Suspension of Entities Submitting Claims for Suspended Providers__\r\n\r\nSuspension is automatic when any of the above events occurs, and suspended Medi-Cal providers will not be entitled to a hearing under the _California Administrative Procedures Act_.\r\n\r\nServices rendered, prescribed or ordered by a suspended Medi-Cal provider shall not be covered by the Medi-Cal program while the suspension is in effect. _California Code of Regulations_, title 22, section 51303, subdivision (k), provides that at least fifteen (15) days written notice be given to all affected providers. This list constitutes such written notice. Although the period of suspension may have expired, reinstatement rights are not automatic. The provider must petition for reinstatement and re-enroll with DHCS before being reimbursed for services rendered. Providers suspended as a result of a Medicare action must appeal through the Medicare office before applying for re-enrollment with Medi-Cal.\r\n\r\nIn accordance with W&I Code, section 14043.61, subdivision (a), a provider of health care services shall be subject to suspension if claims for payment are submitted under any provider number used by the provider to obtain reimbursement from the Medi-Cal program for the services, goods, supplies or merchandise provided, directly or indirectly to a Medi-Cal beneficiary, by an individual or entity that is suspended, excluded or otherwise ineligible because of a sanction to receive, directly or indirectly, reimbursement from the Medi-Cal program and the individual or entity is listed on either the _Medi-Cal Suspended and Ineligible Provider List_ (S&I List) published by DHCS to identify suspended and otherwise ineligible providers, or any list published by the federal Office of Inspector General regarding the suspension or exclusion of individuals or entities from the federal Medicare and Medicaid programs, to identify suspended, excluded or otherwise ineligible providers.\r\n\r\nExamples of providers who need to be aware of the provisions of this law, and could be suspended if violating the law are:\r\n\r\n1. Billing services that submit claims for Medi-Cal providers who are suspended;\r\n2. Pharmacies that fill prescriptions and bill for services prescribed by a suspended provider;\r\n3. Providers who bill for services under referral or prescription of a provider who is suspended;\r\n4. Providers who employ and submit claims for the services of an individual who is a suspended provider;\r\n5. Physician groups, clinics and institutions that employ and submit claims for the services of an individual who is a suspended provider;\r\n6. Any individuals or entities that enter into a business arrangement and submit claims for or in conjunction with an individual or entity that is suspended.\r\n\r\nAlways refer to the S&I List when verifying ineligibility. Eligibility or ineligibility must also be verified through the Health and Human Services (HHS) Federal Office of Inspector General (OIG) [List of Excluded Individuals/Entities](https://oig.hhs.gov/exclusions/exclusions_list.asp). Cross-referencing both lists is recommended to help identify providers who have already been suspended or sa","title":"Provider Suspended and Ineligible List (S&I List)","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/8f70e05d-baa5-4296-a5ab-36318d530670/resource/48630a37-b5ba-4d3d-af54-e82b30e658a0/download/suspended-ineligible-list-june-2026.csv","description":"The Suspended and Ineligible List is a list reflecting all providers of service who the Department has suspended. Pursuant to Welfare and Institution Code sections 14123, subdivision (a) (convictions), 14123, subdivision (b) (federal exclusions) and 14043.6 (license loss) these suspensions are automatic and non-discretionary. Please see legal description and legal introduction notice attached.","@type":"dcat:Distribution","title":"Provider Suspended and Ineligible List (S&I List)"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/datastore/dictionary_download/48630a37-b5ba-4d3d-af54-e82b30e658a0","description":"Data Dictionary for https://data.chhs.ca.gov/dataset/8f70e05d-baa5-4296-a5ab-36318d530670/resource/48630a37-b5ba-4d3d-af54-e82b30e658a0/download/suspended-ineligible-list-june-2026.csv","@type":"dcat:Distribution","title":"Data Dictionary - Provider Suspended and Ineligible List (S&I List)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/8f70e05d-baa5-4296-a5ab-36318d530670/resource/066e6dbf-b51a-4082-ac1b-a10baccd0724/download/provider-suspended-and-ineligible-list-s-i-list-koo81wo0.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1M","theme":["Healthcare"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57uj-ttg6","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","chemistry","bioactivity","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/57uj-ttg6","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 866023: MLS000084220","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/866023","description":"Access the complete Substance 866023: MLS000084220 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/57vu-n742","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nebraska-behavioral-health","substance-abuse-treatment","adult-mental-health","youth-substance-use","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/57vu-n742","description":"This is a behavioral health report for the state of Nebraska. It uses the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment Services (NSSATS) to address the topics of youth substance use , youth mental health and treatment, adult mental health and treatment, substance use, substance use treatment for the years 2008 to 2012.","title":"Behavioral Health Barometer: Nebraska, 2013","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-nebraska-2013","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/ipqz-2s6g","bureauCode":["009:20"],"issued":"2026-05-19","@type":"dcat:Dataset","modified":"2026-05-20","contactPoint":{"@type":"vcard:Contact","fn":"Wael Abdelraheem","hasEmail":"mailto:twd6@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/ipqz-2s6g","description":"Per- and polyfluoroalkyl substances (PFAS), recognized for their advantageous physical and chemical properties, are extensively utilized in various industrial applications. However, PFAS exposures have been associated with a range of adverse health effects, including developmental issues, immune system suppression, and hormonal disruptions. The International Agency for Research on Cancer (IARC) has classified perfluorooctanoic acid (PFOA) as carcinogenic to humans and perfluorooctane sulfonate (PFOS) as possibly carcinogenic due to evidence of tumor development in animal studies. Despite these health concerns, occupational environments frequently expose workers to PFAS through inhalation, dermal contact, or ingestion based on the substance state and application. Air monitoring has detected significant levels of PFAS in diverse workplace settings; however, the absence of standardized protocols for airborne PFAS presents challenges in understanding and controlling exposure risks. The Occupational Safety and Health Administration (OSHA) Versatile Sampler (OVS) tube has demonstrated efficacy in capturing and analyzing airborne PFOA. Our objective was to adapt this method for broader PFAS detection, employing a novel air generation technique to simulate environmental capture conditions. For the first time, we established a robust scientific approach for air sampling of a group of 12 PFAS from different classes, which will aid in assessing potentially harmful airborne PFAS levels. Method validation tests followed the National Institute for Occupational Safety and Health (NIOSH) Manual of Analytical Methods (NMAM) evaluation criterion.","title":"Development of a sampling and analytical method for quantifying per- and polyfluoroalkyl substances (PFAS) in air with the OSHA Versatile Sampler (OVS) tube","programCode":["009:034"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/download/ipqz-2s6g/application/x-zip-compressed","mediaType":"application/x-zip-compressed"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["National Institute for Occupational Safety and Health"]},{"accessLevel":"public","landingPage":"https://data.cms.gov/cms-innovation-center-programs/accountable-care-models/reach-acos","bureauCode":["009:38"],"issued":"2026-07-10","temporal":"2021-01-01/2026-12-31","@type":"dcat:Dataset","modified":"2026-07-08","references":["https://data.cms.gov/resources/aco-reach-model-methodology"],"keyword":["accountable care organizations","coordinated care","medicare","original medicare","payment models","value-based care"],"contactPoint":{"@type":"vcard:Contact","fn":"ACO REACH - CMMI","hasEmail":"mailto:ACOREACH@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"https://data.cms.gov/data-api/v1/dataset/eddc0a1b-dab8-478e-a883-3385e0275a17/data-viewer","description":"The REACH Accountable Care Organizations (ACOs) dataset provides overview information on REACH ACOs including their name, number of years in the program, and contact information of key personnel.","title":"REACH ACOs","programCode":["009:000"],"distribution":[{"mediaType":"text/html","downloadURL":"https://data.cms.gov/data-api/v1/dataset/eddc0a1b-dab8-478e-a883-3385e0275a17/data","description":"latest","@type":"dcat:Distribution","title":"REACH ACOs : 2026-01-18oc1"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-07/a869da25-03e8-44bb-ae2a-3ec5c86edfe4/ACOREACH_PUFDataset_20260630.csv","mediaType":"text/csv","title":"REACH ACOs : 2026-01-18oc1"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/e6f8d196-0812-4527-ae87-9f33fc5fefdf/data","mediaType":"text/html","title":"REACH ACOs : 2026-01-18oc1"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-05/a5bda2c4-f975-472a-913e-05dc2d50f659/ACOREACH_PUFDataset_20260505.csv","mediaType":"text/csv","title":"REACH ACOs : 2026-01-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/d72e68bd-cac5-4693-afbd-a3703300fa33/data","mediaType":"text/html","title":"REACH ACOs : 2026-01-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-03/8ddc3056-88b9-4063-a23f-8e81d642c395/ACO_REACH_PUF%20Dataset_03_10_2025.csv","mediaType":"text/csv","title":"REACH ACOs : 2025-03-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/39cbb353-1c03-48b8-b1f6-9d0f79c1cb80/data","mediaType":"text/html","title":"REACH ACOs : 2025-03-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-02/29fcff38-b487-47c8-85db-850f0935053f/ACO_REACH_Dataset_01_18_2024.csv","mediaType":"text/csv","title":"REACH ACOs : 2024-01-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/a8798590-0f4a-45e3-81e1-bb4cb3639706/data","mediaType":"text/html","title":"REACH ACOs : 2024-01-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-05/e1ad660b-c7a0-47a5-a941-c90715d00d2a/ACO_REACH_Dataset_05_03_2023_v2.csv","mediaType":"text/csv","title":"REACH ACOs : 2023-01-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/43386e60-4f89-48b2-b033-985538575349/data","mediaType":"text/html","title":"REACH ACOs : 2023-01-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-03/3e990cea-bf79-4f55-b114-785f5cfbd560/ACO_REACH_2022_03_24_2023.csv","mediaType":"text/csv","title":"REACH ACOs : 2022-12-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/6890fe91-75c7-4557-9d89-f2ca3f4063e9/data","mediaType":"text/html","title":"REACH ACOs : 2022-12-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-04/14c10673-3c10-4779-9ba1-caace86c9e39/ACO_PUF.csv","mediaType":"text/csv","title":"REACH ACOs : 2021-04-28"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/931a82f0-d951-47a7-835d-644639225404/data","mediaType":"text/html","title":"REACH ACOs : 2021-04-28"}],"describedBy":"https://data.cms.gov/resources/aco-reach-model-data-dictionary","dataQuality":true,"license":"https://www.usa.gov/government-works","accrualPeriodicity":"R/P1Y","theme":["Medicare"],"language":["en-US"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/582g-qdf3","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/582g-qdf3","description":"Chemical compound data from PubChem database. IUPAC Name: 8-butyl-9-ethyloctadecane. Molecular Formula: C24H50. Molecular Weight: 338.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530139: Octadecane, 8-butyl-9-ethyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530139","description":"Access the complete Compound 530139: Octadecane, 8-butyl-9-ethyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/583m-8prq","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["adoption","foster","policy","reporting","case"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/583m-8prq","description":"The Department of Health and Human Services (HHS), Administration for Children and Families (ACF), Children’s Bureau (CB) is responsible for the implementation and management of the Adoption and Foster Care Analysis and Reporting System (AFCARS). State and Tribal title IV-E agencies are required to report AFCARS case-level information on all children in foster care and children who have been adopted with title IV-E agency involvement (per §479 of the Social Security Act). The regulations\n \n \n\n were updated via the final rule published in May 2020.\n\nAFCARS was established to provide data that would assist in policy development and program management. Data can be used by policymakers at the federal, Tribal, and state levels to assess how many children are in foster care, reasons why they enter, how they exit, and to develop strategies to prevent their unnecessary placement into foster care. Specifically, the data include information about children who enter foster care, their entries and exits, placement details, and foster/adoptive parent information, which makes it possible to identify trends.\n\nThe data enables the Children’s Bureau to administer the federal title IV-E foster care and adoption assistance programs more effectively. The Children’s Bureau and ACF use these data for several purposes, including:\n\nAdditionally, the AFCARS data are used specifically in the:\n\nThe Adoption and Foster Care Analysis and Reporting System (AFCARS) collects case-level information on all children in foster care and those who have been adopted with title IV-E agency involvement.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"About AFCARS","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/fact-sheet/about-afcars","description":"Access the complete About AFCARS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/584t-qyky","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","compound","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/584t-qyky","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(5-octyl-2-trimethylsilyloxyphenyl)-N-trimethylsilyloxymethanimine. Molecular Formula: C21H39NO2Si2. Molecular Weight: 393.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528933: Benzaldehyde, 2-hydroxy, 5-octyl, oxime, TMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528933","description":"Access the complete Compound 528933: Benzaldehyde, 2-hydroxy, 5-octyl, oxime, TMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/3kwf-gzwy","issued":"2017-08-25","@type":"dcat:Dataset","modified":"2018-01-23","keyword":["plan","managed care","directory","facilities and services","pnds","provider","medicaid"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/3kwf-gzwy","description":"The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of health plans in New York State. Beginning in 2017, the PNDS includes Medicaid Managed Care (MMC), HIV Special Need Plans (SNP), Health and Recovery Plans (HARP), Child Health Plus (CHP), Programs of All-Inclusive Care for the Elderly (PACE), Non-PACE Managed Long-Term Care (MLTC) plans, Qualified Health Plans (QHP), Essential Plans (EP), and commercial plans (commercial plan reporting will be incomplete until Q2 2017). This dataset reflects institutional provider data. Provider Network Data System information is self-reported by health plans. The PNDS data dictionary can be found at http://www.health.ny.gov/health_care/managed_care/docs/dictionary.pdf. To use the NYS Provider & Health Plan Look-Up Tool, click on the following link, https://pndslookup.health.ny.gov/.","title":"Managed Care Institutional Provider Network Data: June 30, 2017","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/download/3kwf-gzwy/application/zip","mediaType":"application/zip"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5869-knij","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5869-knij","description":"Chemical compound data from PubChem database. IUPAC Name: 2,2-ditert-butyl-5-(2,2-ditert-butyl-1,3,2-dioxasilolan-4-yl)-1,3,2-benzodioxasilole. Molecular Formula: C24H42O4Si2. Molecular Weight: 450.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528191: 1,2-Ethanediol, 1-(3,4-dihydroxyphenyl), bis-DTBS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528191","description":"Access the complete Compound 528191: 1,2-Ethanediol, 1-(3,4-dihydroxyphenyl), bis-DTBS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/589g-zt42","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["pubchem","compound","chemistry","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/589g-zt42","description":"Chemical compound data from PubChem database. IUPAC Name: 6-butyldec-1-ene. Molecular Formula: C14H28. Molecular Weight: 196.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528438: 1-Decene, 6-butyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528438","description":"Access the complete Compound 528438: 1-Decene, 6-butyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58bc-qhzg","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["adipocyte-differentiation","bone-marrow-cells","mesenchymal-stem-cells","nih","osteoblast-differentiation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/58bc-qhzg","description":"Mesenchymal precursor cells found in the blood (BMPCs) of normal persons adhere to plastic and glass and proliferate logarithmically in DMEM-20% fetal calf serum (FCS) without growth factors. They form cells with fibroblast-like and stromal morphology, which is not affected by eliminating CD34, CD3, or CD14 cells. Osteogenic supplements (dexamethasone, ascorbic acid, and β-glycerophosphate) added to the culture inhibited fibroblast formation, and BMPCs assumed the cuboidal shape of osteoblasts. After 5 days in supplemented medium, the elutriated cells displayed alkaline phosphatase (AP), and the addition of bone morphogenetic protein (BMP)2 (1 ng) doubled AP production (P < 0.04). Two weeks later, 30% of the cells were very large and reacted with anti-osteocalcin antibody. The same cultures also contained sudanophlic adipocytes and multinucleated giant cells that stained for tartrate-resistant acid phosphatase (TRAP) and vitronectin receptors. Cultured BMPCs immunostain with antibodies to vimentin, type I collagen, and BMP receptors, heterodimeric structures expressed on mesenchymal lineage cells. In addition, BMPCs stain with anti-CD105 (endoglin), a putative marker for bone-marrow mesenchymal stem cells (MSCs).","title":"Mesenchymal precursor cells in the blood of normal individuals","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC17820/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://opendata.maryland.gov/d/c8eg-j9vr","issued":"2019-03-13","@type":"dcat:Dataset","modified":"2024-08-14","keyword":["crime","domestic","mdh","police","ship","state health improvement process"],"contactPoint":{"@type":"vcard:Contact","fn":"Tiffanie.Powell@maryland.gov","hasEmail":"mailto:no-reply@opendata.maryland.gov"},"publisher":{"@type":"org:Organization","name":"State of Maryland"},"identifier":"https://opendata.maryland.gov/api/views/c8eg-j9vr","description":"This is historical data. The update frequency has been set to \"Static Data\" and is here for historic value. Updated on 8/14/2024\n\nDomestic Violence - Domestic violence contributes greatly to the morbidity and mortality of Maryland citizens. Up to 40% of violent juvenile offenders witnessed domestic violence in the homes, and 63% of homeless women and children have been victims of intimate partner violence as adults. Link to Data Details ","title":"SHIP Domestic Violence 2010-2020","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/c8eg-j9vr/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/c8eg-j9vr/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/c8eg-j9vr/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health and Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58cj-acxe","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","innovation","chemistry","patent","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/58cj-acxe","description":"Mechanism for passively deploying expendable space tethers on orbit, by means of an initial separation impulse only, provided by a simple spring system that is part of the mechanism itself. The passive deployment of the space tether and a tethered end-mass is provided by the particular mechanism devised, having very low deployment friction and resistance. Tether deployment brake towards the final part of deployment is produced by a daisy-like brake, stored within the winding of the fixed tether spool so that it is automatically deployed (opened) and starts its deployment braking or resistance function from a planned point of the tether deployment in space.","title":"Patent AT-E399710-T1: [Translated] PASSIVE DEPLOYMENT MECHANISM FOR SPACE ROPES","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399710-T1","description":"Access the complete Patent AT-E399710-T1: [Translated] PASSIVE DEPLOYMENT MECHANISM FOR SPACE ROPES on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.dhcs.ca.gov/dataandstats/reports/Pages/MMCDFinancialReports.aspx","issued":"2019-09-23","temporal":"07/01/2017-06/30/2018","@type":"dcat:Dataset","modified":"2026-02-11","keyword":["hep-c","dhcs","rates","hep-c rates","hepatitus c","managed care supplemental rates","medi-cal managed care","medi-cal managed care capitation supplemental rates"],"contactPoint":{"@type":"vcard:Contact","fn":"Capitated Rates Development Division","hasEmail":"mailto:opendata@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"e85e432c-1bb1-4fd1-80b2-fc3befde2565","description":"This dataset displays reimbursement rates paid to Medi-Cal Managed Care health plans for hepatitis C services, by county and State Fiscal Year. Medi- Cal managed care models and health plans are located in all 58 counties.","title":"Medi-Cal Managed Care Supplemental Rates - Hepatitis C","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/e85e432c-1bb1-4fd1-80b2-fc3befde2565/resource/1692afd0-9b06-4e9c-843a-72bc343517c2/download/medi-cal-managed-care-supplemental-rates-hepatitis-c-oq1ccve3.zip","mediaType":"application/zip","title":"All resource data"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/e85e432c-1bb1-4fd1-80b2-fc3befde2565/resource/da22158f-012a-4502-8b72-834ae3844695/download/hepatitis_c_rates_2017-18.csv","description":"This dataset displays reimbursement rates paid to Medi-Cal Managed Care health plans for hepatitis C services for State Fiscal Year 2017-18. Medi- Cal managed care models and health plans are located in all 58 counties.","@type":"dcat:Distribution","title":"State Fiscal Year 2017-18 Hepatitis C Rates"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Healthcare"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58f4-qzsw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","compound","research","science","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/58f4-qzsw","description":"Chemical compound data from PubChem database. IUPAC Name: 2-chloro-6-hydroxybenzaldehyde. Molecular Formula: C7H5ClO2. Molecular Weight: 156.56. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528393: 2-Chloro-6-hydroxybenzaldehyde","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528393","description":"Access the complete Compound 528393: 2-Chloro-6-hydroxybenzaldehyde on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58gb-uk8y","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","compound","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/58gb-uk8y","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(5-tert-butyl-2-trimethylsilyloxyphenyl)-N-trimethylsilyloxymethanimine. Molecular Formula: C17H31NO2Si2. Molecular Weight: 337.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528925: Benzaldehyde, 2-hydroxy, 5-tert.-butyl, oxime, TMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528925","description":"Access the complete Compound 528925: Benzaldehyde, 2-hydroxy, 5-tert.-butyl, oxime, TMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58ig-seta","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["service","child","childr","social","acf"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/58ig-seta","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Important Tips for OLDC","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/657","description":"Access the complete Important Tips for OLDC on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58j3-d7f6","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","research","innovation","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/58j3-d7f6","description":"The invention relates to oil-immersed power or electric power distribution transformers for which the size of the high (or medium) voltage windings is to be reduced. The invention essentially consists in removing the normal oil paper that is used as a dielectric barrier which separates the layers of spirals of lead wire and replacing said paper with a structure comprising a stack of flat wafers which are formed by concentric axial layers of close spirals of coiled wire, without the insertion of a barrier therebetween, and which are obtained from a round or almost round enamelled wire which is sticky or at least heat-adhesive. Each of said wafers has a maximum height which is calculated according to the dimensions of the wire, the selected inter-spire voltage and the safety electric arcing prevention voltage gradient specific to the relevant transformer.","title":"Patent AT-E401656-T1: [Translated] PRODUCTION OF HIGH OR MEDIUM VOLTAGE WINDINGS FOR OIL-FILLED TRANSFORMERS AND WINDINGS PRODUCED THEREFORE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401656-T1","description":"Access the complete Patent AT-E401656-T1: [Translated] PRODUCTION OF HIGH OR MEDIUM VOLTAGE WINDINGS FOR OIL-FILLED TRANSFORMERS AND WINDINGS PRODUCED THEREFORE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58jv-xtx4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/58jv-xtx4","description":"Chemical compound data from PubChem database. IUPAC Name: dithiocan-5-ol. Molecular Formula: C6H12OS2. Molecular Weight: 164.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529763: 5-Hydroxy-1,2-dithiacyclooctane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529763","description":"Access the complete Compound 529763: 5-Hydroxy-1,2-dithiacyclooctane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cityofchicago.org/d/8vvr-jv2g","issued":"2020-10-07","@type":"dcat:Dataset","modified":"2026-07-10","keyword":["flu","health","public health"],"contactPoint":{"@type":"vcard:Contact","fn":"Jonathan Levy","hasEmail":"mailto:no-reply@data.cityofchicago.org"},"publisher":{"@type":"org:Organization","name":"City of Chicago"},"identifier":"https://data.cityofchicago.org/api/views/8vvr-jv2g","description":"This dataset contains the weekly estimated influenza risk level for each ZIP Code in Chicago. Estimates are made during flu season, which goes from MMWR week 40 to week 20 of the following year.\r\n\r\nThe risk level is based on observed level of Influenza-Like Illness (ILI). ILI Activity Level is determined as follows: ILI percentage for each ZIP Code for the week is compared to the mean ILI percentage during the non-influenza months (summer months). Level 1 corresponds to an ILI percentage below the mean, level 2 to an ILI percentage less than one standard deviation (SD) above the mean, level 3 to an ILI percentage more than one, but less than two SDs above mean, and so on, with level 10 corresponding to an ILI percentage more than eight SDs above the mean.\r\n\r\nFor more information on ESSENCE, which compiles the estimates, see https://www.dph.illinois.gov/data-statistics/syndromic-surveillance\r\n\r\nAll data are provisional and subject to change. Information is updated as additional details are received. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources.","title":"Influenza Risk Level by ZIP Code","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/8vvr-jv2g/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/8vvr-jv2g/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/8vvr-jv2g/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/8vvr-jv2g/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/8vvr-jv2g/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/8vvr-jv2g/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58pf-ynng","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","science","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/58pf-ynng","description":"Chemical compound data from PubChem database. IUPAC Name: N,N'-bis(4-bromophenyl)methanimidamide. Molecular Formula: C13H10Br2N2. Molecular Weight: 354.04. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525810: N,N'-Bis(4-bromophenyl)formamidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525810","description":"Access the complete Compound 525810: N,N'-Bis(4-bromophenyl)formamidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58sj-zmtt","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["child","care","policy","foster","grant"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/58sj-zmtt","description":"In their own voices, PII grantees and PII partners reflect on their experiences using the PII approach to understand and address the challenges faced by youth in long-term foster care. The PII approach enables grantees to develop stronger, targeted strategies to address these challenges. Examples of materials created to help others apply the PII approach are highlighted.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"The Permanency Innovations Initiative: A New Way to Work in Child Welfare","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/permanency-innovations-initiative-new-way-work-child-welfare","description":"Access the complete The Permanency Innovations Initiative: A New Way to Work in Child Welfare on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58ug-5gu4","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health","samhsa","substance-use","nsduh","mississippi"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/58ug-5gu4","description":"This report presents Mississippi\\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"Mississippi: 2011-2012 NSDUH","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/mississippi-2011-2012-nsduh","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58ug-qbzs","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","bioactivity","chemistry","substance","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/58ug-qbzs","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864231: MLS000083863","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864231","description":"Access the complete Substance 864231: MLS000083863 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58uk-apfq","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","pubchem","research","science","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/58uk-apfq","description":"Chemical compound data from PubChem database. IUPAC Name: 1,2-dichloropropan-2-yl acetate. Molecular Formula: C5H8Cl2O2. Molecular Weight: 171.02. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525093: 1,3-Dichloroisopropyl acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525093","description":"Access the complete Compound 525093: 1,3-Dichloroisopropyl acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58uq-im59","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","compound","pubchem","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/58uq-im59","description":"Chemical compound data from PubChem database. IUPAC Name: 4-methyltetratriacontane. Molecular Formula: C35H72. Molecular Weight: 492.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527414: 4-Methyl-tetratriacontane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527414","description":"Access the complete Compound 527414: 4-Methyl-tetratriacontane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58yj-ht5m","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","substance","references","pubchem","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/58yj-ht5m","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 866054: MLS000042443","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/866054","description":"Access the complete Substance 866054: MLS000042443 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58zm-zux8","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["policy","assessment","care","foster","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/58zm-zux8","description":"This report describes the results of the subsequent primary review of Montana’s Title IV-E foster care program.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Montana Subsequent Primary Title IV-E Foster Care Eligibility Review (2018)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/montana-subsequent-primary-title-iv-e-foster-care-eligibility-review-2018","description":"Access the complete Montana Subsequent Primary Title IV-E Foster Care Eligibility Review (2018) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/58zt-jgfn","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["functional-diversification","sequence-analysis","protein-evolution","orthologous-proteins","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/58zt-jgfn","description":"Background\n Detection of changes in a protein's evolutionary rate may reveal cases of change in that protein's function. We developed and implemented a simple relative rates test in an attempt to assess the rate constancy of protein evolution and to detect cases of functional diversification between orthologous proteins. The test was performed on clusters of orthologous protein sequences from complete bacterial genomes (Chlamydia trachomatis, C. muridarum and Chlamydophila pneumoniae), complete archaeal genomes (Pyrococcus horikoshii, P. abyssi and P. furiosus) and partially sequenced mammalian genomes (human, mouse and rat).\n \n \n Results\n Amino-acid sequence evolution rates are significantly correlated on different branches of phylogenetic trees representing the great majority of analyzed orthologous protein sets from all three domains of life. However, approximately 1% of the proteins from each group of species deviates from this pattern and instead shows variation that is consistent with an acceleration of the rate of amino-acid substitution, which may be due to functional diversification. Most of the putative functionally diversified proteins from all three species groups are predicted to function at the periphery of the cells and mediate their interaction with the environment.\n \n \n Conclusions\n Relative rates of protein evolution are remarkably constant for the three species groups analyzed here. Deviations from this rate constancy are probably due to changes in selective constraints associated with diversification between orthologs. Functional diversification between orthologs is thought to be a relatively rare event. However, the resolution afforded by the test designed specifically for genomic-scale datasets allowed us to identify numerous cases of possible functional diversification between orthologous proteins.","title":"Constant relative rate of protein evolution and detection of functional diversification among bacterial, archaeal and eukaryotic proteins","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC64838/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/594i-fpbb","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","science","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/594i-fpbb","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(4-chlorophenyl)-3-(2-sulfanylphenyl)urea. Molecular Formula: C13H11ClN2OS. Molecular Weight: 278.76. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 351548: N-(4-Chlorophenyl)-Na(2)-(2-mercaptophenyl)urea","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/351548","description":"Access the complete Compound 351548: N-(4-Chlorophenyl)-Na(2)-(2-mercaptophenyl)urea on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/594u-afgq","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substate-regions","samhsa","prevalence-estimates","mental-health","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/594u-afgq","description":"National maps showing 2014-2016 estimates for 395 substate regions ranked from lowest to highest for each measure and divided into 7 categories.","title":"2014-2016 NSDUH National Maps of Prevalence Estimates by Substate Region","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2014-2016-nsduh-national-maps-prevalence-estimates-substate-region","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/596t-3c36","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/596t-3c36","description":"Chemical compound data from PubChem database. IUPAC Name: butyl 2,2,3,3,4,4,5,5,6,6,6-undecafluorohexanoate. Molecular Formula: C10H9F11O2. Molecular Weight: 370.16. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526461: Butyl perfluorohexanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526461","description":"Access the complete Compound 526461: Butyl perfluorohexanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://opendata.maryland.gov/d/5iy2-kwzn","issued":"2016-07-22","@type":"dcat:Dataset","modified":"2025-05-05","keyword":["department of health and mental hygiene","assisted living","dhmh","dialysis","dynamic","health","hlth","hospice","kml","maryland","md","md imap","office of preparedness and response","opr","psychiatric","rehabilitation","special hospitals","vector","wfs","wms"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data Administrator","hasEmail":"mailto:no-reply@opendata.maryland.gov"},"publisher":{"@type":"org:Organization","name":"State of Maryland"},"identifier":"https://opendata.maryland.gov/api/views/5iy2-kwzn","description":"This is a MD iMAP hosted service layer. Find more information at http://imap.maryland.gov. OP&R organizes and prepares for public health and medical emergencies through statewide partnerships with public - private and government agencies to coordinate an effective emergency response for the health and safety of all residents of Maryland. Last Updated: 10/06/2014 Feature Service Layer Link: http://geodata.md.gov/imap/rest/services/Health/MD_LongTermCareAssistedLiving/FeatureServer/6 ADDITIONAL LICENSE TERMS: The Spatial Data and the information therein (collectively \"the Data\") is provided \"as is\" without warranty of any kind either expressed implied or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct indirect incidental consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.","title":"MD iMAP: Maryland Long Term Care Assisted Living - Rehabilitation Hospitals","distribution":[{"@type":"dcat:Distribution","downloadURL":"http://data.imap.maryland.gov/datasets/ddf4a7afba0441eaa533bfdad826b0a4_6","mediaType":"text/html"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health and Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/597e-f3fg","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["welfare","metadata"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/597e-f3fg","description":"ACF Children Bureau resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"What advocacy groups and organizations are available for families involved in the child welfare system?","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/faq/cw2","description":"Access the complete What advocacy groups and organizations are available for families involved in the child welfare system? on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"http://flybase.org/","bureauCode":["009:00"],"issued":"2016-07-17","@type":"dcat:Dataset","modified":"2023-07-26","keyword":["national-institutes-of-health-nih"],"contactPoint":{"@type":"vcard:Contact","fn":"GOOD, PETER J.","hasEmail":"mailto:goodp@mail.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health (NIH)"},"identifier":"faf46179-3fce-451f-83b6-017f27f2e8b8","description":"Drosophila Genomic and Genetic database that includes proteomics data, microarrays and Tiling BAC's.
","title":"FlyBase: A Drosophila Genomic and Genetic Database","programCode":["009:003"],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5992-v7px","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","science","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5992-v7px","description":"Chemical compound data from PubChem database. IUPAC Name: 1-chlorodibenzothiophene. Molecular Formula: C12H7ClS. Molecular Weight: 218.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527126: 1-Chloro-dibenzothiophene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527126","description":"Access the complete Compound 527126: 1-Chloro-dibenzothiophene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/pmkr-qpv2","issued":"2020-02-19","@type":"dcat:Dataset","modified":"2020-02-19","keyword":["lead","drinking water","school"],"contactPoint":{"@type":"vcard:Contact","fn":"Christensen, Lisa K (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/pmkr-qpv2","description":"","title":"Central Elementary Follow Up","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/pmkr-qpv2/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59aq-ngfa","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","patent","innovation","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59aq-ngfa","description":"Methods of controlling phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a ferric-containing compound selected from the group consisting of ferric citrate, ferric acetate, and combinations thereof. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.","title":"Patent AT-E400264-T1: [Translated] METHODS OF TREATING KIDNEY FAILURE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400264-T1","description":"Access the complete Patent AT-E400264-T1: [Translated] METHODS OF TREATING KIDNEY FAILURE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59bi-sweu","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59bi-sweu","description":"Chemical compound data from PubChem database. IUPAC Name: pent-4-enyl 2-chlorobenzoate. Molecular Formula: C12H13ClO2. Molecular Weight: 224.68. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527786: Benzoic acid, 2-chloro, 4-pentenyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527786","description":"Access the complete Compound 527786: Benzoic acid, 2-chloro, 4-pentenyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59bm-t8g3","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59bm-t8g3","description":"Chemical compound data from PubChem database. IUPAC Name: 3-chlorodibenzothiophene. Molecular Formula: C12H7ClS. Molecular Weight: 218.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527135: 3-Chloro-dibenzothiophene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527135","description":"Access the complete Compound 527135: 3-Chloro-dibenzothiophene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59e6-6nt5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","chemistry","innovation","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59e6-6nt5","description":"The fastening element (1) for the fastening of an exterior leaf to a substructure has a shank section (2) made from a first material and a covering (8) of heat insulating material at least partially encompassing the shank element. A stop (12) for the exterior leaf is connected to an operating component (5). A retaining device (9) is provided on the covering and grips behind the exterior leaf when the fastening element is fitted. The retaining device is reversibly deformable, materially moulded with the covering and in the form of elastic fingers (10,11) distributed around the circumference of the covering.","title":"Patent AT-E400744-T1: [Translated] FASTENING ELEMENT","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400744-T1","description":"Access the complete Patent AT-E400744-T1: [Translated] FASTENING ELEMENT on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/yji7-twsm","issued":"2018-03-29","@type":"dcat:Dataset","modified":"2018-03-29","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"Elizabeth Kimball","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/yji7-twsm","description":"Lead in Drinking Water in Schools Sampling Results - Lakewood High School","title":"Lakewood High School","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/yji7-twsm/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59g2-ha68","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","treatment-episodes","mental-health","client-level-data","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/59g2-ha68","description":"This report presents results from the Mental Health Client-Level Data (MH-CLD) and Mental Health Treatment Episode Set (MH-TEDS) for individuals receiving mental health treatment services in 2014, as well as selected data collection trends for such individuals from 2011 to 2014. The report provides information on mental health diagnoses, mental health treatment services, and demographic and substance use characteristics of individuals in mental health treatment in facilities that reported to individual state administrative data systems.","title":"Mental Health Annual Report 2014","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2014-mental-health-annual-report","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59g4-4f6x","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","substance","references","pubchem","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59g4-4f6x","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864883: MLS000042782","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864883","description":"Access the complete Substance 864883: MLS000042782 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59kb-jfwc","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","bioactivity","chemistry","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59kb-jfwc","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865487: MLS000042502","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865487","description":"Access the complete Substance 865487: MLS000042502 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59m5-dnth","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59m5-dnth","description":"Chemical compound data from PubChem database. IUPAC Name: 5-methylhexadecane. Molecular Formula: C17H36. Molecular Weight: 240.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528521: 5-Methylhexadecane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528521","description":"Access the complete Compound 528521: 5-Methylhexadecane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59ma-uw9b","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","pubchem","compound","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59ma-uw9b","description":"Chemical compound data from PubChem database. IUPAC Name: 2,2,4-trimethyl-1,3-dithiane. Molecular Formula: C7H14S2. Molecular Weight: 162.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525344: 2,2,4-Trimethyl-1,3-dithiane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525344","description":"Access the complete Compound 525344: 2,2,4-Trimethyl-1,3-dithiane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59na-rs2e","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","n-ssats","substance-abuse-treatment","west-virginia","addiction-services"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/59na-rs2e","description":"This state profile includes data from facilities in West Virginia that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in West Virginia. In West Virginia, 82 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 10,132 clients in substance abuse treatment on March 31, 2010. The survey response rate in West Virginia was 92.4%.","title":"2010 State Profile — West Virginia","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2010-state-profile-west-virginia","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-safety","drug-manufacturers","health-care","medications","pharmaceuticals"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA217410","description":"Fluphenazine Hydrochloride is a prescription injectable medication used to treat schizophrenia and other mental health conditions. It belongs to the phenothiazine class of drugs and is administered as an intramuscular injection at a strength of 2.5 mg/mL. Manufactured by Fresenius Kabi USA, LLC, it's available in a 10 mL vial. This information was generated using AI and is provided for informational and research purposes only.","title":"Fluphenazine hydrochloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217410","description":"\n Access the FDA dataset for Fluphenazine hydrochloride — ANDA 217410 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Fluphenazine hydrochloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59p9-5zdk","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["child","scope","policy","foster","guidance"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/59p9-5zdk","description":"This Information Memorandum (IM) provides FY 1985 allotments for title IV-B and procedures for applying for: (1) A state's share of funds available under title IV-B in FY 1985; (2) reallotted IV-B funds; and (3) funds to be transferred from title IV-E foster care.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-85-15)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-85-15","description":"Access the complete IM-85-15 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59q2-3rqx","bureauCode":["009:38"],"issued":"2018-09-27","@type":"dcat:Dataset","modified":"2024-08-07","keyword":["utility","healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"Hiko Naito - TylerTech/Socrata employee","hasEmail":"mailto:no-reply@data.healthcare.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"nsnu-pbze","description":"Dataset.","title":"Direct Enrollment Partners","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/sites/default/files/uploaded_resources/approved_080824v2.csv","mediaType":"text/csv","title":"CSV"}],"license":"https://www.usa.gov/government-works","accrualPeriodicity":"R/P10Y","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59r4-cbpu","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["policy","brief","assessment","social","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/59r4-cbpu","description":"This fact sheet provides information about the Child and Family Services Reviews (CFSRs) for legislatures.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Child and Family Services Reviews Fact Sheet for Legislatures","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/fact-sheet/child-and-family-services-reviews-fact-sheet-legislatures","description":"Access the complete Child and Family Services Reviews Fact Sheet for Legislatures on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59rj-23sm","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","pubchem","chemistry","bioactivity","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59rj-23sm","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864781: MLS000084023","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864781","description":"Access the complete Substance 864781: MLS000084023 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59tg-d2bd","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","research","pubchem","patent","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59tg-d2bd","description":"Aqueous composition (A) for inhalation contains as only active ingredient a tricyclo-oxa-aza-nonane derivative (I), at least one acid and optionally other auxiliaries and/or complexing agents. Aqueous composition (A) for inhalation contains as only active ingredient a tricylo-oxa-aza-nonane derivative of formula (I), at least one acid and optionally other auxiliaries and/or complexing agents. [Image] X : chloride, bromide, iodide, sulfate, phosphate, methanesulfonate, nitrate, maleate, acetate, citrate, fumarate, tartrate, oxalate, succinate, benzoate or p-toluenesulfonate. An independent claim is also included for an inhalation kit containing (A) and an inhaler for nebulization. ACTIVITY : Antiasthmatic. No details of tests for antiasthmatic activity are given. MECHANISM OF ACTION : Anticholinergic.","title":"Patent AT-E400265-T1: [Translated] AEROSOL FORMULATION FOR INHALATION CONTAINING AN ANTICHOLINERGIC","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400265-T1","description":"Access the complete Patent AT-E400265-T1: [Translated] AEROSOL FORMULATION FOR INHALATION CONTAINING AN ANTICHOLINERGIC on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59ux-nvh2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59ux-nvh2","description":"Chemical compound data from PubChem database. IUPAC Name: 2,2-dichloroethyl hexadecanoate. Molecular Formula: C18H34Cl2O2. Molecular Weight: 353.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527760: 2,2-Dichloroethyl hexadecanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527760","description":"Access the complete Compound 527760: 2,2-Dichloroethyl hexadecanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59uy-xja7","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["marijuana-use","substance-use","samhsa","nsduh","adolescent-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/59uy-xja7","description":"This report presents State estimates for measures of past year marijuana use based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Resuts are provided by age group.","title":"Table 2. Marijuana Use in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2010 and 2011 NSDUHs","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/table-2-marijuana-use-past-year-age-group-and-state-percentages-annual-averages-based-2010","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59ww-mgfa","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","compound","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59ww-mgfa","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 2-(4-methoxy-2,3-dimethylanilino)benzoate. Molecular Formula: C17H19NO3. Molecular Weight: 285.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527323: Methyl 2-(4-methoxy-2,3-dimethylanilino)benzoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527323","description":"Access the complete Compound 527323: Methyl 2-(4-methoxy-2,3-dimethylanilino)benzoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59y5-6jxe","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","references","bioactivity","substance","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/59y5-6jxe","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864783: MLS000084524","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864783","description":"Access the complete Substance 864783: MLS000084524 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","public-health","medications","health-care","drug-information"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA075109","description":"Guanfacine Hydrochloride is a generic prescription medication available as extended-release oral tablets in strengths of 1mg, 2mg, 3mg, and 4mg. It acts as a central alpha-2 adrenergic agonist, commonly used to manage attention deficit hyperactivity disorder (ADHD) in children and adolescents, and occasionally for high blood pressure. Manufactured by Advagen Pharma Limited under application ANDA219689. This information was generated using AI and is provided for informational and research purposes only.","title":"Guanfacine","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=075109","description":"\n Access the FDA dataset for Guanfacine — ANDA 075109 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Guanfacine"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/59zq-tg4u","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["virginia-nsduh","mental-health","samhsa","substance-use","major-depressive-episode"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/59zq-tg4u","description":"This report presents Virginia\\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"Virginia: 2011-2012 NSDUH","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/virginia-2011-2012-nsduh","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5a33-4agt","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["hair-analysis","anti-seizure-medications","carbamazepine","pharmacokinetics","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5a33-4agt","description":"Background\n This paper assess the relationship between the quantity of three anti-seizure medications in hair and the color of the analyzed hair, while controlling for the effects of dose, dose duration, and patient age for 140 clinical patients undergoing anti-seizure therapy. Three drugs are assessed: carbamazepine (40 patients), valproic acid (40 patients), and phenytoin (60 patients). The relationship between hair assay results, hair color, dose, dose duration, and age is modeled using an analysis of covariance. The covariance model posits the hair assay results as the dependent variable, the hair color as the qualitative categorical independent variable, and dose, dose duration, and age as covariates. The null hypothesis assessed is that there is a no relationship between hair color and the quantity of analyte determined by hair assay such that darker colored hair will demonstrate higher concentrations of analyte than lighter colored hair.\n \n \n Results\n The analysis reveals that there is a significant relationship between dose and concentration for all hair color categories independent of the other covariates or the categorical independent variable.\n \n \n Conclusion\n There does not appear to be any relationship between carbamazepine concentration and hair color. There is a weak relationship between hair color and valproic acid concentration, which the data suggest may be mediated by age. There is a significant, moderate relationship between phenytoin concentration and hair color such that darker colored hair has greater concentration values than lighter colored hair.","title":"The concentration of three anti-seizure medications in hair: the effects of hair color, controlling for dose and age","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC32173/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5a63-wihj","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["policy","assessment","child","guidance","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5a63-wihj","description":"This amended technical bulletin regarding the Child and Family Services Reviews (CFSRs) replaces the technical bulletin issued on February 18, 2009.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Child and Family Services Review Amended Technical Bulletin #3","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/child-and-family-services-review-amended-technical-bulletin-3","description":"Access the complete Child and Family Services Review Amended Technical Bulletin #3 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5a7i-2neb","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","client-level-data","substance-use","treatment-episodes","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5a7i-2neb","description":"This report presents results from the Mental Health Client Level Data (MH-CLD) and Mental Health Treatment Episode Data Set (MH-TEDS) for individuals receiving mental health treatment services in 2016, as well as selected trends in data collected from such individuals between 2013 and 2016. The report provides information on mental health diagnoses, mental health treatment services, and demographic and substance use characteristics of individuals in mental health treatment in facilities that reported to individual state administrative data systems.","title":"2016 Mental Health Client-level Data (MH-CLD) Annual Report","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2016-mental-health-client-level-data-mh-cld-annual-report","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5a7u-rsf8","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-use","samhsa","nsduh","mental-health","kentucky"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5a7u-rsf8","description":"Kentucky: 2010-2012 NSDUH substate estimates","title":"Kentucky: 2010-2012 NSDUH substate estimates","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/kentucky-2010-2012-nsduh-substate-estimates","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/wsf5-hfcq","issued":"2019-04-17","@type":"dcat:Dataset","modified":"2019-04-17","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/wsf5-hfcq","description":"Lead in Drinking Water in Schools Test Results – Morgen Owing and follow up 4/17/2019 as attached","title":"Morgen Owing","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/wsf5-hfcq/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5acj-yhye","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5acj-yhye","description":"Chemical compound data from PubChem database. IUPAC Name: 2-prop-2-enylfuran. Molecular Formula: C7H8O. Molecular Weight: 108.14. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530402: Npc222646","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530402","description":"Access the complete Compound 530402: Npc222646 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5adg-gpu6","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-survey","unmet-treatment-need","substance-abuse-treatment","samhsa","alcohol-use-disorder"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5adg-gpu6","description":"This report presents State estimates for measures of needing but not receiving treatment for past year alcohol use based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Resuts are provided by age group.","title":"Table 22. Needing But Not Receiving Treatment for Alcohol Use in the Past Year, by Age Group and State: Percentages, Annual Averages Based on 2010 and 2011 NSDUHs","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/table-22-needing-not-receiving-treatment-alcohol-use-past-year-age-group-and-state","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5af8-hvk6","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["policy","fiscal","child","instruction","guidance"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5af8-hvk6","description":"This Program Instruction (PI) provides guidance to Indian Tribes, Indian Tribal Organizations and Indian Tribal Consortia (hereafter “tribes,” unless otherwise noted) on actions they are required to take to receive their allotments for Federal Fiscal Year (FY) 2021 (subject to the availability of appropriations) authorized under title IV-B, subparts 1 and 2, and Chafee and ETV programs.\n\nPI-20-03 (PDF)\n\nFiscal Year 2019 Allotment Title IV-B Subpart 1 Stephanie Tubbs Jones Child Welfare Services\nFiscal Year 2019 Allotment Title IV-B Subpart 2 Promoting Safe and Stable Families\nFiscal Year 2019 Allotment for Chafee Foster Care Program for Successful Transition to Adulthood\nFiscal Year 2019 Allotment for Education and Training Vouchers\n\nCFS-101 Instructions, Part I, II, and III\n\nIntroduction\nPart I: Annual Budget Request for Title IV-B, Subpart 1 & 2 Funds, Chafee, and ETV Instructions\nPart II: Annual Estimated Expenditure Summary of Child and Family Services Instructions\nPart III: Expenditures for Title IV-B, Subparts 1 and 2, Chafee Foster Care Independence (Chafee) and Education and Training Voucher (ETV) Programs Instructions\n\nCFS-101 Forms, Parts I, II and III Excel Workbook (XLSX) (47 KB)\n\nCFS-101 Forms Part I\nCFS-101 Forms Part II\nCFS-101 Forms Part III\n\nCB Regional Program Managers\n\nAnnual Reporting of Education and Training Vouchers Awarded (PDF (PDF) - 83 KB)\n\nCertification of Tribal Population Under Age 21 (PDF (PDF) - 198 KB)\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-20-03)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-20-03","description":"Access the complete PI-20-03 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"http://www.cdss.ca.gov/food-nutrition/calfresh","issued":"2018-04-06","temporal":"November 2003 - current","@type":"dcat:Dataset","modified":"2025-11-06","keyword":["calfresh","food stamps","snap","social services"],"contactPoint":{"@type":"vcard:Contact","fn":"CalFresh","hasEmail":"mailto:opendata@dss.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"a83fcac1-9e4f-4322-bab4-4e4438135535","description":"This report provides information on the number of persons and households participating in the Supplemental Nutrition Assistance Program (SNAP) - known as CalFresh in California - on a monthly basis, by county. Caseload figures are broken out by public assistance/non-public assistance status as well as federal/state funding status. Benefit issuance dollar amounts are also provided.","title":"DFA256 - Food Stamp Program Participation and Benefit Issuance Report","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/a83fcac1-9e4f-4322-bab4-4e4438135535/resource/9336db42-059b-43cd-ad7b-dc9f2d86608a/download/dfa256m.csv","description":"This report provides information on the number of persons and households participating in the Supplemental Nutrition Assistance Program (SNAP) - also known as CalFresh in California - on a monthly basis, by county. Caseload figures are broken out by public assistance/non-public assistance status as well as federal/state funding status. Benefit issuance dollar amounts are also provided.","@type":"dcat:Distribution","title":"Food Stamp Program Participation and Benefit Issuance Report - DFA256"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/a83fcac1-9e4f-4322-bab4-4e4438135535/resource/618bbef7-3fad-427f-ae29-f8d54fd6094c/download/dfa256-report-form-and-instructions.pdf","description":"Technical documentation for data elements found in the Food Stamp Program Participation and Benefit Issuance Report (DFA256).","@type":"dcat:Distribution","title":"DFA256 Report Form and Instructions"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/a83fcac1-9e4f-4322-bab4-4e4438135535/resource/97f81d35-ed63-4ad6-b582-104a5d296b58/download/calfresh-household-and-person-counts-by-county-8gqzi_ji.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["Demographics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5agh-krcg","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["state","assessment","child","policy","scope"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5agh-krcg","description":"This instrument template is designed to enable states to gather and document information critical to analyzing their capacity and performance during the statewide assessment phase of the CFSR process. This template is offered in Adobe fillable PDF and Microsoft Word nonfillable formats. The Word version provides formatting flexibility. We encourage the state to use this document \"as is\" to complete the assessment, but the state may use another format as long as the state provides all required content.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Round 3 CFSR Statewide Assessment","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/round-3-cfsr-statewide-assessment","description":"Access the complete Round 3 CFSR Statewide Assessment on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5agv-3ud5","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["end-of-life-care","delphi-method","analgesia-sedation","nih","icu-patients"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5agv-3ud5","description":"Background\n Intensivists must provide enough analgesia and sedation to ensure dying patients receive good palliative care. However, if it is perceived that too much is given, they risk prosecution for committing euthanasia. The goal of this study is to develop consensus guidelines on analgesia and sedation in dying intensive care unit patients that help distinguish palliative care from euthanasia.\n \n \n Methods\n Using the Delphi technique, panelists rated levels of agreement with statements describing how analgesics and sedatives should be given to dying ICU patients and how palliative care should be distinguished from euthanasia. Participants were drawn from 3 panels: 1) Canadian Academic Adult Intensive Care Fellowship program directors and Intensive Care division chiefs (N = 9); 2) Deputy chief provincial coroners (N = 5); 3) Validation panel of Intensivists attending the Canadian Critical Care Trials Group meeting (N = 12).\n \n \n Results\n After three Delphi rounds, consensus was achieved on 16 statements encompassing the role of palliative care in the intensive care unit, the management of pain and suffering, current areas of controversy, and ways of improving palliative care in the ICU.\n \n \n Conclusion\n Consensus guidelines were developed to guide the administration of analgesics and sedatives to dying ICU patients and to help distinguish palliative care from euthanasia.","title":"Consensus guidelines on analgesia and sedation in dying intensive care unit patients","programCode":["009:038"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC122088/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ai4-8ri8","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["tribal","affair","native","policy","scope"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5ai4-8ri8","description":"A unique government-to-government relationship exists between American Indian and Alaska Native (AI/AN) Tribes and the Federal government. The government-to-government relationship is political and independent of race or ethnicity. This relationship is grounded in the United States Constitution, numerous treaties, statutes, federal case law, regulations, and Executive Orders, as well as political, legal, moral, and ethical principles. To support this ongoing relationship, ACF has established an Agency Workgroup titled the Native American Affairs Advisory Council (NAAAC) and the ACF Tribal Advisory Committee (TAC). Learn more about the ACF TAC and NAAAC below.\n\nACF’s Tribal Advisory Committee (TAC) was established under the Secretary’s Tribal Advisory Committee (STAC) Rules of Order, per the Acting Assistant Secretary’s Memorandum of March 7, 2013. The ACF TAC’s primary purpose is to seek consensus, exchange views, share information, provide advice and/or recommendations; or facilitate any other interaction related to intergovernmental responsibilities or administration of ACF programs, including those that arise explicitly or implicitly under statute, regulation, or Executive Order. This purpose is accomplished through fora, meetings, and conversations between Federal officials and elected Tribal leaders in their official capacity. The ACF TAC is comprised of thirteen positions filled by voluntary representatives: one delegate (and one alternate) from each of 11 Indian Health Service regions and one delegate (and one alternate) for two National At-Large Tribal Member (NALM) positions. You can explore the ACF TAC documents below.\n\nACF’s Native American Affairs Advisory Council (NAAAC) was established as an Agency Workgroup to support both ACF’s Assistant Secretary and the Assistant Secretary of Tribal Affairs (which also serves as the Commissioner for the Administration for Native Americans) to respond to requests for information from the HHS Secretary’s Interdepartmental Council on Native American Affairs, the Office of the Secretary, the Office of Intergovernmental and External Affairs, the White House, or other federal Departments or ACF Programs that serve Tribes and Native American Communities. You can find the NAAAC’s charter and contact list below.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Tribal and Native American Affairs Committees","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/tribal-affairs/committees","description":"Access the complete Tribal and Native American Affairs Committees on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nchs/covid19/pulse/reduced-access-to-care.htm","bureauCode":["009:20"],"issued":"2020-05-20","@type":"dcat:Dataset","temporal":"2020-04-23/2021-07-05","modified":"2025-04-21","keyword":["covid-19","delayed care","unmet need"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/xb3p-q62w","description":"The U.S. Census Bureau, in collaboration with five federal agencies, launched the Household Pulse Survey to produce data on the social and economic impacts of Covid-19 on American households. The Household Pulse Survey was designed to gauge the impact of the pandemic on employment status, consumer spending, food security, housing, education disruptions, and dimensions of physical and mental wellness.\n\nThe survey was designed to meet the goal of accurate and timely weekly estimates. It was conducted by an internet questionnaire, with invitations to participate sent by email and text message. The sample frame is the Census Bureau Master Address File Data. Housing units linked to one or more email addresses or cell phone numbers were randomly selected to participate, and one respondent from each housing unit was selected to respond for him or herself. Estimates are weighted to adjust for nonresponse and to match Census Bureau estimates of the population by age, sex, race and ethnicity, and educational attainment. All estimates shown meet the NCHS Data Presentation Standards for Proportions.","title":"Indicators of Reduced Access to Care Due to the Coronavirus Pandemic During Last 4 Weeks","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/xb3p-q62w/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/xb3p-q62w/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/xb3p-q62w/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"US","license":"https://www.usa.gov/government-works","accrualPeriodicity":"irregular","theme":["National Center for Health Statistics"],"language":["en-US"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ana-utr9","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","patent","research","innovation","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ana-utr9","description":"An system and method for handling broadcast network requests for auto-configuration and discovery of IP to MAC address mappings and gateway presence in wireless peer-to-peer ad-hoc routing networks. The significant portion of a node's IP address is calculated by applying a hashing function to the six-byte hardware (MAC) address. The significant portion is appended to routing advertisements, and thereby propagates passively to other network nodes. DHCP and ARP requests, as well as other broadcast type requests, are handled by the local network stack of a node, without requiring a broadcast transmission over the wireless channel.","title":"Patent AT-E400121-T1: [Translated] SYSTEM AND METHOD FOR SELF-CONFIGURATION AND DISCOVERY OF IP-TO-MAC ADDRESS MAP AND GATEWAY PRESENCE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400121-T1","description":"Access the complete Patent AT-E400121-T1: [Translated] SYSTEM AND METHOD FOR SELF-CONFIGURATION AND DISCOVERY OF IP-TO-MAC ADDRESS MAP AND GATEWAY PRESENCE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/736x-7yhm","issued":"2020-06-10","@type":"dcat:Dataset","modified":"2020-06-10","keyword":["drinking water","school","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"Charles, Anne Marie C (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/736x-7yhm","description":"","title":"Thomas Jefferson Part 1","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/736x-7yhm/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ap6-h8c7","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["survey-methodology","substance-use","data-collection","mental-health","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5ap6-h8c7","description":"This detailed manual was used as a training guide for the Field Interviewers (FIs) who conducted the in-person 2019 National Survey on Drug Use and Health (NSDUH). It covers the information presented at the intensive training for new FIs. Although it is written for NSDUH FIs, researchers may find it helpful for learning about data collection challenges that could affect data quality. It also may be helpful for those designing their own field operations.The manual includes:An introduction to the survey;A guide to what is expected of FIs;Copies of materials that were mailed or given to respondents;FI instructions for locating sample dwelling units, contacting residents, obtaining participation, conducting the screening and interview, documenting their experiences; andQuality control and administrative procedures for FIs.","title":"NSDUH 2019 Field Interviewer Manual","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/nsduh-2019-field-interviewer-manual","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://findahealthcenter.hrsa.gov/","bureauCode":["009:15"],"issued":"2017-07-14","@type":"dcat:Dataset","modified":"2023-07-25","keyword":["clinic locations","community health","community health center","federally qualified health center (fqhc)","health center","health center location","hrsa","preventive care","primary care","sliding scale"],"contactPoint":{"@type":"vcard:Contact","fn":"HRSA Bureau of Primary Care","hasEmail":"mailto:comments@hrsa.gov"},"publisher":{"@type":"org:Organization","name":"Health Resources and Services Administration"},"identifier":"27b4e77a-5adc-4b6a-bc26-6bbe7beac8b2","description":"HRSA Health Centers care for you, even if you have no health insurance – you pay what you can afford based on your income. Health centers provide services that include checkups when you are well, treatment when you are sick, complete care when you are pregnant, and immunizations and checkups for your children. Some health centers also provide mental health, substance abuse, oral health, and/or vision services. Contact the health center organization directly to confirm the availability of specific services and to make an appointment.
","title":"Find a Health Center","programCode":["009:013"],"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Community","Health","National","State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5aqm-5usy","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","research","science","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5aqm-5usy","description":"Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] N-[tert-butyl(dimethyl)silyl]methanimidate. Molecular Formula: C13H31NOSi2. Molecular Weight: 273.56. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529221: Formamide, O,N-bis-DMTBS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529221","description":"Access the complete Compound 529221: Formamide, O,N-bis-DMTBS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/4edt-mstx","issued":"2019-06-21","@type":"dcat:Dataset","modified":"2019-06-21","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/4edt-mstx","description":"Lead in Drinking Water in Schools Test Results – Hazelwood Elementary School","title":"Hazelwood Elementary School","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/4edt-mstx/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5atw-y5vw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","patent","innovation","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5atw-y5vw","description":"The invention relates to a balloon for medical devices, in particular for catheters used in angioplasty, comprising a polyamide copolymer material characterized in that said polyamide copolymer material is represented by the general formula (I): HO—(PF—OOC—PA-COO—PF—COO—PA)n-COOH in which PA is a polyamide segment and PF is a diol segment comprising dimer diols and/or corresponding OH-terminating diol polyesters and n is a number between 5 and 20.","title":"Patent AT-E399572-T1: [Translated] CATHETER BALLOON","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399572-T1","description":"Access the complete Patent AT-E399572-T1: [Translated] CATHETER BALLOON on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5av2-nde2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5av2-nde2","description":"Chemical compound data from PubChem database. IUPAC Name: tridecyl 4-ethylbenzoate. Molecular Formula: C22H36O2. Molecular Weight: 332.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530554: 4-Ethylbenzoic acid, tridecyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530554","description":"Access the complete Compound 530554: 4-Ethylbenzoic acid, tridecyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ax4-faya","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ax4-faya","description":"Chemical compound data from PubChem database. IUPAC Name: 2-methyl-3-methylsulfanylthiophene. Molecular Formula: C6H8S2. Molecular Weight: 144.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526619: 2-Methyl-3-(methylthio)thiophene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526619","description":"Access the complete Compound 526619: 2-Methyl-3-(methylthio)thiophene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5azu-ukr6","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["legume-symbiosis","bacterial-genetics","nih","nitrogen-fixation","rhizobium-genomes"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5azu-ukr6","description":"Background:\n In nitrate-poor soils, many leguminous plants form nitrogen-fixing symbioses with members of the bacterial family Rhizobiaceae. We selected Rhizobium sp. NGR234 for its exceptionally broad host range, which includes more than I 12 genera of legumes. Unlike the genome of Bradyrhizobium japonicum, which is composed of a single 8.7 Mb chromosome, that of NGR234 is partitioned into three replicons: a chromosome of about 3.5 Mb, a megaplasmid of more than 2 Mb (pNGR234b) and pNGR234a, a 536,165 bp plasmid that carries most of the genes required for symbioses with legumes. Symbiotic loci represent only a small portion of all the genes coded by rhizobial genomes, however. To rapidly characterize the two largest replicons of NGR234, the genome of strain ANU265 (a derivative strain cured of pNGR234a) was analyzed by shotgun sequencing.\n \n \n Results:\n Homology searches of public databases with 2,275 random sequences of strain ANU265 resulted in the identification of 1,130 putative protein-coding sequences, of which 922 (41%) could be classified into functional groups. In contrast to the 18% of insertion-like sequences (ISs) found on the symbiotic plasmid pNGR234a, only 2.2% of the shotgun sequences represent known ISs, suggesting that pNGR234a is enriched in such elements. Hybridization data also indicate that the density of known transposable elements is higher in pNGR234b (the megaplasmid) than on the chromosome. Rhizobium-specific intergenic mosaic elements (RIMEs) were found in 35 shotgun sequences, 6 of which carry RIME2 repeats previously thought to be present only in Rhizobium meliloti. As non-overlapping shotgun sequences together represent approximately 10% of ANU265 genome, the chromosome and megaplasmid may carry a total of over 200 RIMEs.\n \n \n Conclusions:\n 'Skimming' the genome of Rhizobium sp. NGR234 sheds new light on the fine structure and evolution of its replicons, as well as on the integration of symbiotic functions in the genome of a soil bacterium. Although most putative coding sequences could be distributed into functional classes similar to those in Bacillus subtilis, functions related to transposable elements were more abundant in NGR234. In contrast to ISs that accumulated in pNGR234a and pNGR234b, the hundreds of RIME elements seem mostly attributes of the chromosome.","title":"Genetic snapshots of the","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC16145/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5b4c-qeqr","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["child","acf","childr","service","social"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5b4c-qeqr","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Children's Justice Act","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/17170","description":"Access the complete Children's Justice Act on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5b4y-yu2c","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","mental-health","nsduh-data","state-prevalence","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5b4y-yu2c","description":"2013-2014 NSDUH State Prevalence Estimates Additional Outcomes– Individual Excel Tables by Outcome","title":"2013-2014 NSDUH State Prevalence Estimates Additional Outcomes– Individual Excel Tables by Outcome","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2013-2014-nsduh-state-prevalence-estimates-additional-outcomes-individual-excel-tables","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5b6i-5fww","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","pubchem","patent","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5b6i-5fww","description":"A device for bridging a neck of an aneurysm, comprises a junction region, one or more radially extending array elements secured to the junction region, each array element having an unfolded shape and a delivery shape; and a cover attached to the junction region, and extending over the delivery shape of the array elements, wherein each array element is attached at one end to the junction region and the array elements are constructed and arranged to unfold the cover when assuming their unfolded shape, and wherein the device further comprises a tip, and each array element is attached at another end to the tip, the tip comprising an opening through which a vaso-occlusive device or occlusion fluid may be delivered.","title":"Patent AT-E401829-T1: [Translated] REMOVABLE SYSTEM FOR CLOSING AN ANEURYSM NECK","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401829-T1","description":"Access the complete Patent AT-E401829-T1: [Translated] REMOVABLE SYSTEM FOR CLOSING AN ANEURYSM NECK on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5b8j-tyjd","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","chemistry","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5b8j-tyjd","description":"Chemical compound data from PubChem database. IUPAC Name: 4,4,7a-trimethyl-5,7-dihydro-2H-1-benzofuran-6-one. Molecular Formula: C11H16O2. Molecular Weight: 180.24. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525052: 1,5,5-Trimethyl-9-oxabicyclo[4.3]non-6-en-3-one","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525052","description":"Access the complete Compound 525052: 1,5,5-Trimethyl-9-oxabicyclo[4.3]non-6-en-3-one on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5b8n-v9v2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","pubchem","research","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5b8n-v9v2","description":"Chemical compound data from PubChem database. IUPAC Name: N,N,2,2-tetramethyl-N'-pentylpropanimidamide. Molecular Formula: C12H26N2. Molecular Weight: 198.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525911: N,N-Dimethyl-N'-pentyl-pivalamidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525911","description":"Access the complete Compound 525911: N,N-Dimethyl-N'-pentyl-pivalamidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ba9-3wn6","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2023-09-05","keyword":["drug rebate program"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"4df924c1-c00a-4387-bed6-3994a6aec8fe","description":"The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-08-28-to-2023-09-03","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.medicaid.gov/sites/default/files/uploaded_resources/mdrp-newly-rprt-drug-08-28-2023-to-09-03-2023.csv","mediaType":"text/csv","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-08-28-to-2023-09-03"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/d46y-f56x","issued":"2013-02-26","@type":"dcat:Dataset","modified":"2017-11-30","keyword":["\\directory","managed care","medicaid","facilities and services","plan","provider"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/d46y-f56x","description":"The primary purpose for the Provider Network Data System is to collect data needed to evaluate the provider networks including physicians, hospitals, labs, home health agencies, durable medical equipment providers, etc., for all types of Managed Care plans in New York State, including HIV Special Need Plans (SNP), Family Health Plus (FHP) Buy-In, Programs of All-Inclusive Care for the Elderly (PACE), and Non-PACE Managed Long-Term Care (MLTC) plans.\r\n\r\nThis dataset reflects individual provider data.\r\n\r\nProvider Network Data System information is self reported.\r\n\r\nFor more information, go to http://www.health.ny.gov/health_care/managed_care/.","title":"Managed Care Individual Provider Network Data: September 30, 2012","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/download/d46y-f56x/application/zip","mediaType":"application/zip"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bb4-ua6v","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["envelope-fusion-proteins","phylogenetic-analysis","nih","insect-retrovirus","baculovirus-gp64"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5bb4-ua6v","description":"Background\n Current evidence suggests that lepidopteran baculoviruses may be divided into two phylogenetic groups based on their envelope fusion proteins. One group utilizes gp64, a low pH-dependent envelope fusion protein, whereas the other employs a protein family (e.g. LD130 in the Lymantria dispar nucleopolyhedrovirus) unrelated to gp64, but that is also low pH-dependent. Database searches with members of the LD130 protein family often record significant levels of homology to envelope proteins from a number of insect retrovirus-like transposable elements of the gypsy class. In this report, the significance of the homology between these two types of envelope proteins is analyzed.\n \n \n Results\n The significance of the alignment scores was evaluated using Z-scores that were calculated by comparing the observed alignment score to the distribution of scores obtained for alignments after one of the sequences was subjected to 100 random shuffles of its sequence. These analyses resulted in Z-scores of >9 for members of the LD130 family when compared to most gypsy envelope proteins. Furthermore, in addition to significant levels of sequence homology and the presence of predicted signal sequences and transmembrane domains, members of this family contain a possible a furin cleavage motif, a conserved motif downstream of this site, predicted coiled-coil domains, and a pattern of conserved cysteine residues.\n \n \n Conclusions\n These analyses provide a link between envelope proteins from a group of insect retrovirus-like elements and a baculovirus protein family that includes low-pH-dependent envelope fusion proteins. The ability of gypsy retroelements to transpose from insect into baculovirus genomes suggests a pathway for the exchange of this protein between these viral families.","title":"Relatedness of baculovirus and","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC29073/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bb7-b23d","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["service","childr","child","acf","social"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5bb7-b23d","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"SF-424B Non-construction Programs","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14244","description":"Access the complete SF-424B Non-construction Programs on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bcx-tayw","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-abuse-treatment","mental-health-services","national-outcome-measures","samhsa","utah-health-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5bcx-tayw","description":"This is the 2020 Uniform Reporting System (URS) Output Tables for Utah. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2020 Uniform Reporting System (URS) Table For Utah","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2020-uniform-reporting-system-urs-table-utah","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bev-4yha","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["policy","youth","prevention","child","family"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5bev-4yha","description":"The Department of Defense is keenly aware of the needs of military families whose members are serving overseas. The presentation outlines the department’s prevention programs and how they are geared to provide support to active duty and reserve component members and their children, youth, and families. Among the resources mentioned are Military OneSource, the Military and Family Life Consultant Program, and MilitaryHOMEFRONT.\n\nPresenters: Karen Morgan and Tib Campise from the Department of Defense Family Advocacy Program\n\nView Webinar (WMV - 58 MB)\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Supporting Military Families","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/supporting-military-families","description":"Access the complete Supporting Military Families on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bhx-uvxn","bureauCode":["009:38"],"issued":"2019-10-16","@type":"dcat:Dataset","modified":"2020-10-23","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"CMS-WSD-Data-Team","hasEmail":"mailto:CMS_FEPS@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"x2qq-i82p","description":"Dataset.","title":"QHP Landscape PY2020 Individual Dental","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/Individual_Market_Dental_07_27_2020.xlsx.zip","mediaType":"application/zip","title":"FILE"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bk3-q64u","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5bk3-q64u","description":"Chemical compound data from PubChem database. IUPAC Name: 5-butyldodecane. Molecular Formula: C16H34. Molecular Weight: 226.44. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529854: Dodecane, 5-butyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529854","description":"Access the complete Compound 529854: Dodecane, 5-butyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bm5-pvvp","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","chemistry","compound","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5bm5-pvvp","description":"Chemical compound data from PubChem database. IUPAC Name: 1,2,6-tribromodibenzofuran. Molecular Formula: C12H5Br3O. Molecular Weight: 404.88. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526254: 1,2,6-Tribromo-dibenzofuran","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526254","description":"Access the complete Compound 526254: 1,2,6-Tribromo-dibenzofuran on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bns-mwf8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","innovation","chemistry","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5bns-mwf8","description":"A restraint and exercise device (1,50,60,80, 101) is provided to treat acute or chronic mechanical pain, particularly lumbopelvic and/or leg pain, and to restore and/or increase range of motion in suitable users. The device is particularly useful during exercise. The device may contain a restraint, such as two straps(5,6), connected to a support structure (2). The straps (5, 6) help restrain a portion of a person' s body (30) such as the pelvic region (31 ). The portion of the person's body (30) may be restrained in a substantially pain-free position so as to reduce the pain that would otherwise be felt during exercise.","title":"Patent AT-E401111-T1: [Translated] CLAMPING AND EXERCISE DEVICE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401111-T1","description":"Access the complete Patent AT-E401111-T1: [Translated] CLAMPING AND EXERCISE DEVICE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bpu-ee4s","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","substance","chemistry","bioactivity","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5bpu-ee4s","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 866055: MLS000042181","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/866055","description":"Access the complete Substance 866055: MLS000042181 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bqg-66e8","bureauCode":["009:38"],"issued":"2020-11-06","@type":"dcat:Dataset","modified":"2026-06-24","keyword":["nadac","drug acquisition cost"],"contactPoint":{"@type":"vcard:Contact","fn":"Chris Vaughn","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"e3af839d-8175-5be0-b94e-4a302ed7a035","description":"The tables below display new National Average Drug Acquisition Cost (NADAC) rates, sorted by Drug Product and Date. The drug products listed have not had a NADAC rate in the past.","title":"First Time NADAC Rates","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/NADAC_First_Time_062026.csv","mediaType":"text/csv","title":"CSV"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","theme":["Drug Pricing and Payment"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bs6-ntv6","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","science","research","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5bs6-ntv6","description":"Chemical compound data from PubChem database. IUPAC Name: 1,3-bis(ethylsulfanyl)propane. Molecular Formula: C7H16S2. Molecular Weight: 164.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525442: Trimethylenebisethylsulfide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525442","description":"Access the complete Compound 525442: Trimethylenebisethylsulfide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5bt3-hdee","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","patent","pubchem","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5bt3-hdee","description":"An emergency device (10) having a housing (12) with an illumination device (42,144), and a receiver (48), tuner and speakers (54) positioned within the housing. A power source is electrically coupled with the emergency device and is generally a conventional power cord (30). An outage circuit (100) is coupled with the power source. Upon sensing a power outage, the outage circuit, which is connected to the illuminating device (42,144), illuminates the illuminating device (42,144) or another auxiliary device.","title":"Patent AT-E401689-T1: [Translated] EMERGENCY RADIO, EMERGENCY LIGHTS AND EMERGENCY POWER SUPPLY","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401689-T1","description":"Access the complete Patent AT-E401689-T1: [Translated] EMERGENCY RADIO, EMERGENCY LIGHTS AND EMERGENCY POWER SUPPLY on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5c2x-ztsd","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","pubchem","research","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5c2x-ztsd","description":"Chemical compound data from PubChem database. IUPAC Name: 4-nonyl-1-benzothiophene. Molecular Formula: C17H24S. Molecular Weight: 260.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528236: Benzo[b]thiophene, 4-nonyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528236","description":"Access the complete Compound 528236: Benzo[b]thiophene, 4-nonyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5c8n-qgfa","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health","youth-risk-behavior","samhsa","behavioral-health","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5c8n-qgfa","description":"This is a behavioral health report for the United States. The report utilizes data from the National Survey on Drug Use and Health (NSDUH), the Youth Risk Behavior Survey (YRBS), the Monitoring of the Future Survey (MtF) sponsored by the National Institute on Drug Abuse. The topics addressed in the report include youth substance use, youth mental health and treatment, adult mental health and treatment, substance use and substance use treatment.","title":"Behavioral Health Barometer: United States, 2014","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-united-states-2014","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5c8z-h6vb","bureauCode":["009:38"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-07-23","keyword":["physician-fee-schedule","cms","healthcare-economics","mcrjca-impact","medicare-payment-rates"],"contactPoint":{"@type":"vcard:Contact","fn":"CMS","hasEmail":"mailto:pfs@cms.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services (CMS)"},"identifier":"https://healthdata.gov/api/views/5c8z-h6vb","description":"Physician Fee Schedule - March 2012 release. This file contains the revisions identified in the Middle Class Tax Relief and Job Creation Act of 2012 (MCTRJCA). Medicare payment rates under the Medicare Physician Fee Schedule (MPFS) are set according to statutory criteria. The following 2012 MPFS payment rates are reflective of the CY 2012 Medicare Physician Fee Schedule Final Rule, which was published in the Federal Register on November 28, 2011, and the CY 2012 Medicare Physician Fee Schedule Final Rule Correction Notice, which was published in the Federal Register on January 4, 2012. These payment rates are based on current law, including the Middle Class Tax Relief and Job Creation Act of 2012 (MCTRJCA), which provides for a zero percent update through December 31, 2012. The MCTRJCA extends several provisions of the Temporary Payroll Tax Cut Continuation Act of 2011 (TPTCCA). Please note that MCTRJCA does NOT extend add-on payments for mental health services and minimum payment for bone mass measurement (sections 307 and 309 of the TPTCCA, respectively). As such, effective March 1, 2012, the MPFS payment rates for these services have changed. 2012A: Medicare payment rates under the Medicare Physician Fee Schedule (MPFS) are set according to statutory criteria. The following 2012 MPFS payment rates are reflective of the CY 2012 Medicare Physician Fee Schedule Final Rule, which was published in the Federal Register on November 28, 2011, and the CY 2012 Medicare Physician Fee Schedule Final Rule Correction Notice that was put on display at the Office of the Federal Register on December 30, 2011. These payment rates are based on current law, including the Temporary Payroll Tax Cut Continuation Act of 2011, which provides for a zero percent update for the period of January 1, 2012 to February 29, 2012. The Centers for Medicare and Medicaid Services will work quickly to update MPFS payment rates in the event Congress passes legislation to prevent the negative update from going into effect on March 1, 2012. Please be on the alert for more information about the 2012 physician update as it becomes available.","title":"Localities for 2012A","programCode":["009:076"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pfs.data.cms.gov/sites/default/files/data/localities212a.csv","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5c9t-92bd","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["fiscal","policy","data","child","adoption"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5c9t-92bd","description":"This report provides state-specific data from fiscal year 2011 about children's ages at the time of a public agency adoption finalization.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Age at Adoption Finalization: 10/1/2010 - 9/30/2011","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/age-adoption-finalization-10/1/2010-9/30/2011","description":"Access the complete Age at Adoption Finalization: 10/1/2010 - 9/30/2011 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5cak-k2jq","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["spadetail-gene","zebrafish-neural-cells","nih","dola-interneurons","developmental-neurobiology"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5cak-k2jq","description":"Background\n The spadetail (spt) gene of zebrafish is expressed in presomitic mesoderm and in neural cells previously suggested to be Rohon-Beard neurons. The mechanism(s) generating the apparently irregular rostrocaudal distribution of spt-expressing cells in the developing CNS is unknown.\n \n \n Results\n spt-expressing neural cells co-express huC, a marker of neurons. These cells also co-express the genes islet-1, -2 and -3 but not valentino. The islet-1 gene expression, irregular distribution and dorsolateral position of spt-expressing cells in the developing CNS are characteristic of dorsal longitudinal ascending (DoLA) interneurons. Shortly after their birth, these neurons extend processes rostrally into which spt mRNA is transported. At 24 hours post fertilisation(hpf), spt-expressing neurons occur most frequently at rostral levels caudal of the 5th-formed somite pair. There is no apparent bias in the number of spt-expressing cells on the left or right sides of embryos. Extended staining for spt-transcription reveals expression in the dorsocaudal cells of somites at the same dorsoventral level as the spt-expressing neurons. There is frequent juxtaposition of spt-expression in newly formed somites and in neurons. This suggests that both types of spt-expressing cell respond to a common positional cue or that neurons expressing spt are patterned irregularly by flanking somitic mesoderm.\n \n \n Conclusions\n spt-expressing cells in the developing CNS appear to be DoLA interneurons. The irregular distribution of these cells along the rostrocaudal axis of the spinal cord may be due to \"inefficient\" patterning of neural spt expression by a signal(s) from flanking, regularly distributed somites also expressing spt.","title":"The identity and distribution of neural cells expressing the mesodermal determinant","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC119859/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5can-a84n","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-use","serious-mental-illness","samhsa","nsduh-data","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5can-a84n","description":"This report presents Minnesota\\'s estimates for 25 measures of substance use and mental health based on the combined 2009 and 2010 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for Minnesota for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"Minnesota (MN)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/minnesota-mn","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.colorado.gov/d/c78j-uum2","issued":"2012-05-10","@type":"dcat:Dataset","modified":"2026-07-10","keyword":["disease","covid19","cdc"],"contactPoint":{"@type":"vcard:Contact","fn":"Lauren Plunkett","hasEmail":"mailto:no-reply@data.colorado.gov"},"publisher":{"@type":"org:Organization","name":"State of Colorado"},"identifier":"https://data.colorado.gov/api/views/c78j-uum2","description":"Includes information on the following topics:\r\nAging, Alcohol, Arthritis,Asthma, Autism (ASD), Birth Defects, Births, Blood Disorders, Breastfeeding, Cancer, Chronic Diseases, Deaths, Diabetes, Disease Classification, Foodborne Illness, Genomics, Growth Charts, Healthy Water, Heart Disease, HIV/AIDS, Immunizations, Injuries & Violence, Life Expectancy, Lyme Disease, MRSA, Oral Health, Overweight & Obesity, Physical Inactivity, reproductive Health, Smoking & Tobacco, STDs, Vital Signs, Workplace","title":"Centers for Disease Control (CDC) Data & Statistics by Topic","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/browse","mediaType":"text/html","title":"CDC Data Catalog at data.cdc.gov"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5cdc-j745","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","pubchem","substance","bioactivity","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5cdc-j745","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864441: MLS000041771","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864441","description":"Access the complete Substance 864441: MLS000041771 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-information","drug-manufacturers","drug-safety","prescription-drugs","public-health"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA202544","description":"Telmisartan and Hydrochlorothiazide is a prescription oral tablet combining two medications: telmisartan, an angiotensin II receptor blocker, and hydrochlorothiazide, a thiazide diuretic. It's used to treat high blood pressure (hypertension) by helping relax blood vessels and reduce fluid retention. Available in strengths like 40/12.5 mg and 80/12.5 mg or 80/25 mg tablets, manufactured by Solco Healthcare LLC under ANDA209028. This information was generated using AI and is provided for informational and research purposes only.","title":"Telmisartan and hydrochlorothiazide","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=202544","description":"\n Access the FDA dataset for Telmisartan and hydrochlorothiazide — ANDA 202544 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Telmisartan and hydrochlorothiazide"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://data.cityofchicago.org/d/7ce8-bpr6","issued":"2026-04-28","@type":"dcat:Dataset","modified":"2026-07-10","keyword":["flu","syndromic surveillance","respiratory","public health","covid-19","health"],"contactPoint":{"@type":"vcard:Contact","fn":"Jonathan Levy","hasEmail":"mailto:no-reply@data.cityofchicago.org"},"publisher":{"@type":"org:Organization","name":"City of Chicago"},"identifier":"https://data.cityofchicago.org/api/views/7ce8-bpr6","description":"This dataset includes aggregated weekly data on the percent of emergency department visits and the percent of hospital inpatient admissions due to influenza-like illness (ILI), COVID-19, influenza, RSV, and acute respiratory illness. The Illinois Department of Public Health (IDPH) collects data for Emergency Department visits to all 185 acute care hospitals in Illinois. The data are submitted from IDPH to the CDC’s BioSense Platform for access and analysis by health departments via the ESSENCE system.\n\nThe CDC National Syndromic Surveillance Program (NSSP) utilizes diagnostic codes and clinical terms to create definitions for diagnosed COVID-19, influenza, RSV, and acute respiratory illness. For more information on diagnostic codes and clinical terms used, visit: https://www.cdc.gov/nssp/php/onboarding-resources/companion-guide-ed-data-respiratory-illness.html\n\nThe data is characterized by selected demographic groups including age group and race/ethnicity.\n\nThe dataset also includes percent of weekly outpatient visits due to ILI as reported by several outpatient clinics throughout Chicago that participate in CDC’s\nInfluenza-like Illness Surveillance Network (ILINet). \n\nFor more information on ESSENCE, see https://www.dph.illinois.gov/data-statistics/syndromic-surveillance\n\nFor more information on ILINet, see https://www.cdc.gov/fluview/overview/index.html#cdc_generic_section_3-outpatient-illness-surveillance\n\nAll data are provisional and subject to change. Information is updated as additional details are received. At any given time, this dataset reflects data currently known to CDPH. Numbers in this dataset may differ from other public sources.","title":"Inpatient, Emergency Department, and Outpatient Visits for Respiratory Illnesses","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/7ce8-bpr6/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/7ce8-bpr6/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/7ce8-bpr6/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","bureauCode":["009:30"],"landingPage":"https://healthdata.gov/dataset/drug-abuse-warning-network-dawn-2006","issued":"2016-05-23","@type":"dcat:Dataset","modified":"2023-07-25","keyword":["detoxification","drug overdose","drug use","energy drinks","emergency departments","nonprescription drugs","substance abuse","suicide","demographic characteristics","alcohol"],"contactPoint":{"@type":"vcard:Contact","fn":"Brooklyn Lupari, SAMHSA/CBHSQ c/o SAMHDA Support","hasEmail":"mailto:samhda-support@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse & Mental Health Services Administration"},"identifier":"https://datafiles.samhsa.gov/study/drug-abuse-warning-network-dawn-2006-nid13603","description":"The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year.
\nDAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit.
\nThe DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 16 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.
The National Institute for Occupational Safety and Health (NIOSH), under the authorization of the Federal Mine Safety and Health Act of 1977 and the Occupational Safety and Health Act of 1970, provides a testing approval and certification program assuring commercial availability of safe personal protective devices. NIOSH develops improved performance regulations, tests and certifies (or approves) devices, and purchases approved and certified products on the open market to verify quality of manufacture
","title":"NIOSH Certified Equipment List (CEL)","programCode":["009:005"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://www2a.cdc.gov/drds/cel/cel_form_code.asp","mediaType":"text/html","title":"Query Tool "}],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ezn-cwgj","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2023-12-12","keyword":["drug rebate program"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"509b91a3-0fb5-449a-bbf2-40e987e45ed3","description":"The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-12-04-to-2023-12-10","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.medicaid.gov/sites/default/files/uploaded_resources/mdrp-newly-rprt-drug-12-04-2023-to-12-10-2023.csv","mediaType":"text/csv","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-12-04-to-2023-12-10"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5f2n-yziz","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["affordable-care-act","substance-abuse-treatment","treatment-facility-characteristics","addiction-treatment-trends","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5f2n-yziz","description":"This is a Behavioral Health Services Information System (BHSIS) short report explaining substance abuse treatment before the Affordable Care Act and the trends in social and economic characteristics of facilities and admissions from 2006 to 2011 in the United States.","title":"Substance Abuse Treatment Before the Affordable Care Act: Trends in Social and Economic Characteristics of Facilities and Admissions, 2006 to 2011","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/substance-abuse-treatment-affordable-care-act-trends-social-and-economic-characteristics","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["fda","public-health","prescription-drugs","medications","drug-safety"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA211362","description":"Diphenoxylate Hydrochloride and Atropine Sulfate is a prescription oral solution used to treat diarrhea by slowing down bowel movements. Each 5 mL contains 2.5 mg diphenoxylate hydrochloride and 0.025 mg atropine sulfate. Manufactured by Hikma Pharmaceuticals USA Inc., it's a controlled substance (Schedule CV) to prevent abuse. This information was generated using AI and is provided for informational and research purposes only.","title":"Diphenoxylate hydrochloride and atropine sulfate","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211362","description":"\n Access the FDA dataset for Diphenoxylate hydrochloride and atropine sulfate — ANDA 211362 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Diphenoxylate hydrochloride and atropine sulfate"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5f3j-8b4k","issued":"2019-10-31","@type":"dcat:Dataset","modified":"2019-10-31","keyword":["youth","adolescent","obesity","health"],"contactPoint":{"@type":"vcard:Contact","fn":"nucivic","hasEmail":"mailto:servicedesk@omes.ok.gov"},"publisher":{"@type":"org:Organization","name":"State of Oklahoma"},"identifier":"0b15a600-66d4-4816-88bb-56a7832da944","description":"Decrease the percentage of adolescents who are obese from 16.7% in 2012 to 11.3% by 2017.
","title":"Adolescent Obesity","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.ok.gov/dataset/0b15a600-66d4-4816-88bb-56a7832da944/resource/73d275bb-93df-433d-81f5-21eb2c361536/download/data-adolescent-obesity.csv","description":"Decrease the percentage of adolescents who are obese from 16.7% in 2012 to 11.3% by 2017.
","@type":"dcat:Distribution","title":"Data - Adolescent Obesity"},{"mediaType":"text/csv","downloadURL":"https://data.ok.gov/dataset/0b15a600-66d4-4816-88bb-56a7832da944/resource/f5a748be-705a-49c2-8159-75fd13dcfaaa/download/c-adolescent-obesity-line-chart.csv","description":"Decrease the percentage of adolescents who are obese from 16.7% in 2012 to 11.3% by 2017.
","@type":"dcat:Distribution","title":"(C) - Adolescent Obesity - Line Chart"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5f5m-f3xn","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","substance","references","pubchem","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5f5m-f3xn","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865140: MLS000039675","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865140","description":"Access the complete Substance 865140: MLS000039675 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cityofchicago.org/d/w3hg-pyhz","issued":"2018-09-20","@type":"dcat:Dataset","modified":"2021-09-29","keyword":["flu","health","immunization","vaccination"],"contactPoint":{"@type":"vcard:Contact","fn":"Jonathan Levy","hasEmail":"mailto:no-reply@data.cityofchicago.org"},"publisher":{"@type":"org:Organization","name":"City of Chicago"},"identifier":"https://data.cityofchicago.org/api/views/w3hg-pyhz","description":"List of free flu clinics offered throughout Chicago, either by the Department of Public Health or in collaboration with it.\n\nUnlike older versions of the flu shot datasets, this one combines multiple years and will grow over the years. Seasons are now identified by the years they span (e.g., 2018-2019) instead of the year in which they begin (e.g., 2018).\n\nEach season has a filtered view showing only records from that season. These filtered views can be used for almost all purposes as if they were datasets.\n\nThis dataset approximately follows https://github.com/codeforamerica/flu-shot-spec/blob/master/data-format.csv and is designed for use by https://github.com/tkompare/chicagoflushots.\n\nFor more information about the flu, go to https://www.cityofchicago.org/city/en/depts/cdph/provdrs/flu.html.","title":"Flu Shot Locations - 2014 - Present","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/w3hg-pyhz/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/w3hg-pyhz/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/w3hg-pyhz/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/w3hg-pyhz/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/w3hg-pyhz/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/w3hg-pyhz/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fak-y5bx","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["social","service","acf","child","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5fak-y5bx","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"NIEM Human Services Domain Process Document","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14157","description":"Access the complete NIEM Human Services Domain Process Document on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fb4-8ucq","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","innovation","patent","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5fb4-8ucq","description":"A packaging method and apparatus (20) wherein each product is packaged by enveloping the product in flexible packaging material (24). A programmed microprocessor calculates the length of flexible packaging material (24) needed to package the product based on the physical dimensions of the product, calculates the weight of the flexible packaging material needed, and calculates a total package weight as the sum of the weight of the product and the calculated weight of the flexible packaging material. A printer (116) prints information specific to the product that is being packaged onto a label that is then affixed to the flexible packaging material (24) prior to the product being packaged. The information can be a function of the package weight, and the calculated total package weight can be communicated from the microprocessor to the printer. Finally, the product is packaged in the flexible packaging material having the label already affixed thereto (200).","title":"Patent AT-E400501-T1: [Translated] PACKAGING MACHINE AND PACKAGING PROCESS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400501-T1","description":"Access the complete Patent AT-E400501-T1: [Translated] PACKAGING MACHINE AND PACKAGING PROCESS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fdk-r9g9","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-data","substance-use","mental-health","northeast-region","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5fdk-r9g9","description":"This report presents estimates for measures of substance use and mental health based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided for the northeast (e.g., combines Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, and Vermont) for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"Northeast (NE)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/northeast-ne-0","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fe2-jwfv","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","patent","pubchem","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5fe2-jwfv","description":"The paper winding machine has a large support roller (1) which fits against the roll (3) of paper. Two smaller support rollers (4, 5) are mounted above the large roller, on either side of it, so that they form a nip with the paper roll.","title":"Patent AT-E399733-T1: [Translated] CARRY ROLL WRAPPING MACHINE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399733-T1","description":"Access the complete Patent AT-E399733-T1: [Translated] CARRY ROLL WRAPPING MACHINE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fiq-ssay","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","bioactivity","references","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5fiq-ssay","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865829: MLS000084294","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865829","description":"Access the complete Substance 865829: MLS000084294 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cms.gov/provider-characteristics/medicare-provider-supplier-enrollment/opioid-treatment-program-providers","bureauCode":["009:38"],"issued":"2026-07-10","temporal":"2023-05-21/2026-07-04","@type":"dcat:Dataset","modified":"2026-07-07","references":["https://data.cms.gov/resources/opioid-treatment-program-providers-methodology"],"keyword":["provider enrollment","original medicare","medicare","drugs"],"contactPoint":{"@type":"vcard:Contact","fn":"Provider Enrollment Data Requests - CPI","hasEmail":"mailto:ProviderEnrollmentDataRequests@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"https://data.cms.gov/data-api/v1/dataset/f1a8c197-b53d-4c24-9770-aea5d5a97dfb/data-viewer","description":"The Opioid Treatment Program (OTP) Providers dataset provides information on Providers who have enrolled in Medicare under the Opioid Treatment Program. It contains provider's name, National Provider Identifier (NPI), address, phone number and the effective enrollment date.","title":"Opioid Treatment Program Providers","programCode":["009:000"],"distribution":[{"mediaType":"text/html","downloadURL":"https://data.cms.gov/data-api/v1/dataset/f1a8c197-b53d-4c24-9770-aea5d5a97dfb/data","description":"latest","@type":"dcat:Distribution","title":"Opioid Treatment Program Providers : 2026-07-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-07/47f7dbaa-7d80-40d2-a253-1cd054927c0e/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07062026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-07-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/a7b91909-cd37-42d5-8df2-e3889995c558/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-07-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-06/4ff55b12-ed7e-4ff5-9613-54814a6ad6b4/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06292026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-06-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/8ad3aa4a-52ff-467b-9d04-04fc67129134/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-06-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-06/c2615879-44d3-4d7c-b5d1-382ce80fa3a2/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06222026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-06-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/7487b931-b3dd-4bdf-b690-646918adc39a/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-06-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-06/78fe4ca7-34be-4245-8f1a-85b1a2af7b9e/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06172026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-06-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c447712b-7e82-436d-9ff8-fe6698c3a651/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-06-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-06/931f2d4a-4d39-4c1e-9c78-999e7a23424b/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06082026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-06-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/cd4f2d60-313c-4423-80d6-b1d9d65154a8/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-06-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-06/42bb7434-09b9-461e-bb38-0340b70732a6/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06012026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-06-02"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/6601617a-d057-4842-ac6f-9d3fbd371631/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-06-02"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-05/96ca5e02-815f-4368-bb43-9ce845aa296f/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05262026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-05-26"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/e3254f80-b0bd-47d2-97ea-d736413351b5/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-05-26"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-05/541baa55-a4db-4cb5-8315-88cd1ee29ff7/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05182026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-05-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/efde7d89-ed07-41b1-a7f3-5d69ceb17eab/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-05-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-05/6f57a0ab-42b7-48c0-a28d-57fcf46c7c12/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05112026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-05-12"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/5fd9e387-79e2-407f-897a-cb636601cefd/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-05-12"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-05/ef4b08bc-8226-4f1c-99a8-01d7324b064f/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05042026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-05-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/16bcfdbe-c21d-449b-8b0e-dd495b6d1e94/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-05-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-04/3f290c09-01ce-4b58-bd06-ce2f30d2c077/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04272026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-04-28"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/1c279848-d03c-432e-ab9f-9ff635671a50/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-04-28"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-04/3ddee5bc-8e62-40dd-92ab-739538a388c9/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04202026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-04-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/50f9d148-73ed-4b77-844d-a93bfe470c5a/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-04-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-04/6bbedcb6-58d5-4848-bf79-d4076302c740/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04132026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-04-14"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/2bacfd6b-4baa-41f7-9c3f-2aa1eccf5a90/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-04-14"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-04/8fdc4892-b109-4c4c-90a6-a5c760a7655b/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04062026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-04-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/a83d9de2-e698-474f-801b-84842fc3543b/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-04-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-03/f5af9c46-68b3-463c-bd16-f71f5f656ea3/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03302026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-03-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/05fcbd5a-4d80-4c6a-ba9d-fd366af65fa6/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-03-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-03/f81dd0af-dc42-4acd-8bee-d3ace711177e/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03232026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-03-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/29df8b70-7e5c-4c90-9bfd-5fb1325fb2e6/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-03-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-03/db5c2fb5-0dfe-4371-a548-c08fde48c3b5/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03162026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-03-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/a7c1ac12-fdc7-40b1-a8db-d49c586ecdea/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-03-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-03/371b7b74-ba23-4c42-b168-c70dc76f9a1a/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03092026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-03-10"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/929d6044-4014-4e60-b542-b13ec09e873d/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-03-10"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-03/006e7691-c791-4089-8a08-9961eff1785e/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03022026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-03-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/638b6d20-ee45-46d6-bc4c-919a687ca750/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-03-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-02/ade73034-0f8f-47de-86b7-3003e9fa9ab3/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02232026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-02-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c3e1a0e0-cdab-4e1a-8d0f-b8dca5677c16/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-02-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-02/52a16781-2a89-4c54-9ab4-a2389b20b75e/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02172026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-02-18"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/8a036349-b63e-4b2f-8c5d-8ab00ecdb899/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-02-18"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-02/44500a91-5f77-417f-9991-4a432968555e/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02092026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-02-10"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/5684fa6b-6872-42c8-a7e1-190874320f95/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-02-10"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-02/4d9b1eac-16ed-41f4-af34-afd3d0c54179/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02022026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-02-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/f45ca3a4-8494-44d9-8583-bfb874af4712/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-02-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-01/384b820e-c9bc-4203-8b5b-bbbb00e25ef4/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01262026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-01-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/e50cc100-4b7c-427b-9a7f-40113cc2c7eb/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-01-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-01/e20aa9e7-0117-4db2-941c-737337f3a78f/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01202026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-01-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/5b8c307c-c4e0-4f20-9a9c-b45d09211120/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-01-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-01/e5be6a25-a5cc-4354-bcae-50367c3269d3/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01122026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-01-13"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c0f2fb93-3253-4ea9-abf7-f570b470b2e9/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-01-13"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2026-01/442023f8-aa49-40e3-b209-c468a34822dd/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01052026.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2026-01-06"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c35b521a-e548-40d5-a454-b65d6eee87e7/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2026-01-06"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-12/2f2a6eaf-89c4-44aa-9233-e75b685877d5/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12292025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-12-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/240b928b-5043-4ca0-b765-70ff3500a99b/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-12-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-12/1631d5ae-a21b-4dae-bf9c-a2a772a7c7ea/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12222025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-12-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/d166f443-83cf-4742-bd11-6c8c67f2a9ab/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-12-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-12/60ec4d67-fae5-47fe-b63d-52a245def443/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12152025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-12-16"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/aa124f3b-9b05-435e-a62b-43169ef559be/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-12-16"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-12/cb3cf60c-a199-49e8-8bed-1544fc2df14c/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12082025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-12-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/d3f0d68c-fd98-4215-8942-d0fc7eff18d8/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-12-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-12/995d16ee-0850-4323-b686-0015a792cc50/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12012025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-12-02"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/a24329bc-45ea-417b-b881-fd74823f3c30/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-12-02"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-11/5339a86b-1430-4c03-a900-40ae2102f992/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11242025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-11-25"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/fb878383-2ad6-4bce-9cd9-9301ca6217cd/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-11-25"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-11/f9f48c5b-7b4f-43c3-9d4c-4ecff4c757c6/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11172025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-11-18"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/15f2f65e-f3b3-4a9f-9f8f-f2087e0181a7/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-11-18"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-11/ecd18890-51e8-4fef-829c-8b760e8369e4/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11102025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-11-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/7f96b408-60ea-41e7-a714-ee95db116ae5/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-11-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-11/2a95069a-8ada-4560-bbb8-aacbcbbf7820/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11032025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-11-04"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/15463ad2-70f9-419c-8494-be801fe451d4/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-11-04"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-10/8f0a1531-e9cb-45db-8843-c1d3c85ab206/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10272025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-10-28"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/f4f90ef1-b4ef-4b5c-aa73-ff728df4b78a/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-10-28"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-10/b092bc2d-4a73-4f49-b45d-315f61a1d851/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10202025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-10-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/12c876f2-e151-4050-adaa-ef4f855ae240/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-10-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-10/6b1f6d60-6298-4863-bf09-2355d6609027/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10142025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-10-14"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/3410c1b5-7fa6-4ccb-a45f-2487616222a6/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-10-14"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-10/c800ec9d-26ee-43a3-8fe3-4c396aacbf88/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10062025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-10-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/13f782a9-46c0-43e6-8271-7462b31fef8c/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-10-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-09/a0244384-c493-418f-84cd-f8bca0e46a32/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09292025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-09-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/19e467e7-1273-4438-9b47-e7587a3645cc/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-09-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-09/b4f0de9f-77e8-4a3b-ac39-eedbc07a1224/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09222025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-09-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/d667e8ba-ccfb-4980-9f44-89cafbe68034/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-09-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-09/d990b902-3c45-4f4b-b0ef-02cf733b247c/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09152025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-09-16"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/7f548c03-4272-4c37-90a4-dc3405728322/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-09-16"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-09/42400522-f38b-4cef-bb7f-f306b4f45c6b/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09082025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-09-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/f568f1ce-e5c3-4dd1-9290-23defe2c02d0/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-09-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-09/cf063fb4-ab22-4d9d-88bf-eb9e2ff88f49/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09022025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-09-02"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c5a87ad1-31cd-49d8-a029-f8847a77b8a4/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-09-02"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-08/ad65eca2-2010-44cc-a76b-b0e637dca998/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08252025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-08-26"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/03b2552d-496f-4dfa-8e97-7263b68a4af7/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-08-26"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-08/a109215a-b62e-4d6a-b04a-96854ef94fdb/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08182025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-08-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/e78acf2f-caa4-4641-88c2-dc1c0e50fcb7/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-08-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-08/f2237b92-1e6b-4db5-bc9a-cc63f7705de0/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08112025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-08-12"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/f8ee97c3-a35d-47e6-b0e1-3b167b92bd11/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-08-12"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-08/9b493ef4-21ea-4cce-8cad-0a2ab4c7de9e/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08042025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-08-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/47e83d65-2585-4f4f-a8cf-1e0bcd493f49/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-08-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-07/950b6141-3e8a-4d82-b817-8b5ed92eb07e/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07282025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-07-29"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/9acd79c8-eb05-4e38-96d7-57f7e943fd1b/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-07-29"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-07/0a77658b-2cd7-4062-8100-35b6d608dd45/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07212025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-07-22"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/42c7910a-e53a-4d1f-96f1-947b871a5969/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-07-22"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-07/07b35b4b-8575-47a5-8146-a8f9cb0e9fbd/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07142025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-07-15"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/e3b51407-32a8-439a-a2c8-fe968a4078d3/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-07-15"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-07/b20ad7c7-e05c-4db8-8295-c1d9000b21c7/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07072025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-07-08"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/ae50e65b-1990-4ddf-8048-c3f21c9324f0/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-07-08"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-07/1e23e2b6-00cd-42a6-9724-1be0230253a1/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06302025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-07-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/b79e8fde-6d56-42eb-9291-42bc43113c15/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-07-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-06/8cc57664-dcf2-4a91-aab5-24fcae92b1aa/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06232025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-06-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/4bdf02c0-195e-4d4b-9483-9452204da576/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-06-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-06/1f617df4-ece1-4684-ab06-161f162f6798/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06162025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-06-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/e16e60dd-4186-4d22-affd-7bc637c5e016/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-06-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-06/894e9552-2245-4ca6-b0c7-dd68249697c7/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06092025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-06-10"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/772e3fbd-8959-4e0c-b79b-d6d14f4a6164/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-06-10"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-06/a2f0448b-d8c0-4172-8dc2-cd4463361d0a/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06022025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-06-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c579d47e-8c4b-4fc6-92ab-3d588bd01f16/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-06-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-05/9aa0a36e-b187-4363-a7c3-ded8c0ca5fc5/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05272025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-05-28"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/b1fafe7d-c224-47e4-8cc5-2cb251229df6/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-05-28"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-05/b9cf9df7-a4b9-4731-9c8a-11c503492bca/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05192025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-05-20"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/2c090cd8-e181-4736-9783-7766fcf9378c/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-05-20"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-05/7d118f92-68a9-4a64-b00b-4a4dad7611f6/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05122025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-05-13"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/35d9d889-3a11-4dfd-9331-f49d20e1557a/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-05-13"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-05/ccda1550-786a-4b48-ad12-296b5f7889c9/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05052025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-05-06"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/bb5368c9-1637-402b-8bc5-253e83fbabbc/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-05-06"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-04/ed78927b-70d2-483e-9256-9cf5a3ac3971/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04282025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-04-29"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/3c07a57a-e02e-45f3-8fb3-101aafdffd61/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-04-29"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-04/92ca9b19-d349-4e7a-b3db-b582b231a025/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04212025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-04-22"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/3fe23c6b-1ad4-4667-ab93-f8b0df827246/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-04-22"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-04/96c2e3b0-7abf-4464-8ce0-40eea1aed420/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04142025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-04-15"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c34b70c2-267f-4542-9388-dc6a87b45c32/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-04-15"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-04/0c7448c4-170b-4bf3-aa5b-ebd8033c6adc/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04072025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-04-08"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/54d44a8c-6303-47c8-b7cc-1ee576fea677/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-04-08"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-04/19b2f0e8-a607-496f-98f2-e199e1a36b55/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03312025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-04-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/68d61efb-ebcc-468c-9d15-3520df5860c4/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-04-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-03/856a02bd-841b-4413-bd0f-2aae10973248/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03242025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-03-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/e1aa2d71-ef0b-4359-9ed8-0c175b00fb89/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-03-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-03/5328eea0-8a61-4ce7-8a6a-89f63381793b/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03242025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-03-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/b66fa567-dc73-4d7e-8b0b-90cd7992953d/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-03-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-03/fe7dfb97-af61-43d9-a407-6d72aa356e90/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03172025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-03-18"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/2d87bb7c-530b-4cfe-a5fa-bcbfa540d325/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-03-18"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-03/e08232bf-82f6-48b2-bab7-698e61d78032/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03102025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-03-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/1b0ff83b-77f8-4554-95b6-59164c6d1b88/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-03-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-03/961a13f4-955d-4463-b47b-c34a5d7e1beb/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03032025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-03-04"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/f7311d5e-c185-42d6-977b-d2fab1f5c2bf/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-03-04"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-02/6fe30749-c83f-403b-9236-083f75c9cba6/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02242025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-02-25"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/ee1e8ad5-7491-43c5-9b64-83085107f6f8/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-02-25"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-02/9c119e31-fb47-4a42-87de-bc7cbecbdb52/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02182025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-02-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/cba89a2e-310c-4bf6-947a-d067f18e4656/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-02-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-02/f2acf3e9-e9db-4384-b1cc-d958efd71f4b/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02102025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-02-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/7404ae56-de01-45f6-8283-e8f8847c7dd0/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-02-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-02/cd726da9-ac21-4075-acec-2afb56355f1c/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02032025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-02-04"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/1ceb67aa-1279-4e4c-9eff-866f7933ba0d/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-02-04"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-01/a2aeb05b-7f5b-4306-8b8a-39aa028635f9/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01272025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-01-28"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/83a8b7ff-8ee0-4354-a254-1a0d071c9214/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-01-28"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-01/bef7f1bb-5240-467b-b4a1-71152cbfd530/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01202025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-01-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/4e9b678e-4a05-48e0-8e1e-0cf2645afef1/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-01-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-01/080776e2-44a4-4ae5-b9dd-11339a68d50b/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01132025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-01-14"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/e2d91b24-c7a6-45d8-8b46-d199ba2af293/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-01-14"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2025-01/48c0ab48-21f0-4bc5-8eef-08c4e7e7151f/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01062025.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2025-01-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/7c7581e3-0e2d-4d5b-aff5-ab73174a2bf8/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2025-01-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-12/723ab85d-9b0f-4140-98e3-d0e5d175b9dd/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12302024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/6aaaf2ec-2e0d-4bc2-b58f-fa56e0b5fbf2/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-12-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-12/c4bca61f-fb0d-4d20-a6d3-aa82a1ce1793/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12232024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-12-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/18e2a16b-8aed-45d8-a4f9-6b524f50bf16/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-12-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-12/9fee1e34-6d44-4b0b-b094-4f109ed705ae/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12162024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-12-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/b7df370f-7fd4-4f8b-8094-9f685bb68747/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-12-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-12/a6674de8-70fa-4917-bf8a-54388be769ea/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12092024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-12-10"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/92e1693d-50d0-45ae-a26d-b0bbb1dbe4e5/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-12-10"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-12/1e04567c-c426-4cfc-ba1d-7832547e723f/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12022024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-12-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c05a3c61-386e-4efb-b03d-dff4b970fc36/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-12-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-11/bd221a89-8fe5-454b-a4ba-8e0f7bb68928/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11252024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-11-26"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/2251fef5-fe30-4f0b-a206-4a9fb722fa4a/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-11-26"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-11/2f0bdbf1-9ec4-488b-aef7-994ce003e3b0/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11182024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-11-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/1d802578-b549-4fc5-87c7-3b3e3ca744db/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-11-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-11/2012730e-edc8-4d9e-b1a7-bb329128f6d8/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11122024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-11-13"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/741d80da-f870-4401-be84-68a8a5b456a1/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-11-13"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-11/f099e0be-1be4-4b71-aef7-dc98f0ddbca7/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11042024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-11-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/249edf97-4373-45ae-8895-65232be0029f/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-11-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-10/6a7b7fc4-17f3-4078-8451-07358b9c7340/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10282024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-10-29"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/dd7907fb-a1c1-4e07-ac54-d75fd1e25d84/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-10-29"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-10/e3e10490-b408-4c40-88a0-a1f3f5514e5a/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10212024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-10-22"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/2044607e-35ff-4607-a729-faa62d16f1b3/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-10-22"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-10/b857e78a-be44-4d9c-897c-3da4aa2571f9/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10152024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-10-15"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/e6a2a3be-37d9-4ffc-87c5-8d1cca94c7b4/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-10-15"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-10/f1065996-99ac-4b65-acaa-a09fbf946c6e/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10072024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-10-08"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/44852666-b9a1-47aa-b4e3-7119860eb821/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-10-08"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-10/92ed6b36-469e-4bb8-9a11-c703a7a0d221/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09302024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-10-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/f7ff3e0d-69ee-49b6-83ff-f1a84df6ff76/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-10-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-09/0953b11c-3f5a-44cd-82ea-61b7d292fd7b/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09232024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-09-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/f2d8b8cf-291b-42c9-8ea6-bb5f48969a5d/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-09-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-09/a8b39f7f-f1e3-410b-98ca-d576cf798942/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09162024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-09-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/8a55ef68-4ac0-4207-9401-9227f3a346a6/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-09-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-09/8674c2ec-da38-4c00-b1b7-b165e595ef0b/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09092024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-09-10"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/77e2f15c-abea-4906-95f1-85a136cd3512/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-09-10"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-09/b510f2a5-8e25-4141-ba7a-807b1b59091d/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09032024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-09-04"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/53648651-52d3-48c9-b07b-18ef9f11b79a/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-09-04"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-08/d2922a54-006a-4add-aad6-420709a0dac6/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08262024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-08-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/b33603df-16cd-465d-9292-74486b9d4d15/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-08-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-08/3a56b7eb-1aac-4bc5-b359-cea1e2224660/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08192024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-08-20"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/af2ae41e-a241-4ebd-9b57-45982a222875/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-08-20"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-08/e75562b8-58fe-4658-894a-0707198754f3/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08122024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-08-13"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/a81f7f28-26f3-4083-abc6-d2c0f01f8b70/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-08-13"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-08/0a399ba2-3418-492d-baf2-95ac859ebbd4/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08052024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-08-06"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/7a11f7d5-d8aa-4a13-b51f-510ffb301787/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-08-06"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-07/df40d679-e253-41cb-a830-6391ecb044fc/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07292024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-07-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/90511030-a542-45a1-981c-7ab3d2aa5520/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-07-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-07/de4b0cb4-044f-4f73-a63f-8cc98b11d128/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07222024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-07-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/0a30b447-3684-4ee7-8c9c-8310e0dddfc5/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-07-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-07/c7ad3dae-1432-4196-9c14-0ef6dfee31fe/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07152024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-07-16"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/91721f41-2cfb-4a08-9c22-0b3a4a5e63c9/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-07-16"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-07/eeeefe0c-e88e-457c-b5fe-54a6751fb0c9/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07082024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-07-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/90f37e16-a48c-4224-b26c-872fbed1ce0d/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-07-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-07/c657eb48-ab77-4cb5-977b-e62bbd8f0a3b/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07012024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-07-02"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/bdb89467-299b-4b62-92a3-f502b66c5650/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-07-02"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-06/d6871c56-b2a3-43a5-a62e-7e4c31af6d09/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06242024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-06-25"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/8253c9fc-0086-4fb9-ba55-c45acd62ac71/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-06-25"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-06/d923efcf-d4e8-4dc6-b18f-df4c3c35ea34/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06172024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-06-18"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/d157c4da-3d30-4f95-b4e0-c7f0481866f7/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-06-18"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-06/8e16a704-27bf-4482-9ab6-b88c3d6a1614/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06102024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-06-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/cab95d28-08d1-460c-8cba-2af6c090030c/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-06-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-06/97648917-fe3f-426c-98e4-24c34997fadb/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06032024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-06-04"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/a99b65eb-b43b-414e-a462-5b282242518e/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-06-04"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-05/120db740-0794-44ca-b753-4d259bbd10dd/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05282024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-05-29"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/ec0ba9d9-64f9-40c2-82bc-296f3bef456c/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-05-29"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-05/1adf1bfe-1639-4e2c-8224-79af72724b34/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05202024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-05-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/f1ae0151-28f9-4775-ba59-cc520d6b7858/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-05-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-05/fcc55ce7-3614-45f1-b996-7b228adc74f1/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05132024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-05-14"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/0f6d8090-1f0d-429e-aa53-a54e34b7e21e/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-05-14"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-05/eb15c1fe-314f-4a8b-8bf4-901c6dfd8bbb/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05062024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-05-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/21212a25-ed1a-42cf-a274-97d8af0bc2aa/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-05-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-04/c659ce24-8efd-4157-8f27-a0de94ddb08e/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04292024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-04-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/589c7f78-281b-458f-b957-a50e8f33b165/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-04-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-04/68ce1edc-0678-4383-ad54-85bb0591c4d8/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04222024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-04-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/8575517f-83bc-4db4-a6cd-46f7fb1e7900/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-04-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-04/c696a744-6c2d-4408-82e4-109c14bfc4ad/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04152024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-04-16"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/96374811-0254-4857-b581-54a208bfde72/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-04-16"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-04/556e093e-92da-45ab-a4a6-3ee8898c0a96/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04082024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-04-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/ce7b3acf-166d-4b5e-895b-fd4dbd9fc29f/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-04-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-04/07aa2819-7c34-4c3d-a8fd-05068a850a9a/OPIOID_TREATMENT_PROGRAM_PROVIDERS_04012024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-04-02"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/fc322a5f-8b05-47fc-8c85-b72ff766a6e7/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-04-02"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-03/75a77669-51a1-4160-b21b-bb1d4f6d233f/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03252024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-03-26"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/12cdcb8c-53f4-4a96-8d2d-da4ec82dd59d/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-03-26"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-03/e6c5d6d5-e290-4880-bda7-68f93531c981/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03182024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-03-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/2f013f53-8bdd-4190-8f68-4f5290151cf7/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-03-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-03/660562f7-8a8b-4700-beb1-fb5d359a6801/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03112024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-03-12"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/a3b08fa7-a406-4059-b814-fbad75bdd331/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-03-12"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-03/5569ef44-72db-42b5-a1f1-b225bbcf9b17/OPIOID_TREATMENT_PROGRAM_PROVIDERS_03042024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-03-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c78ee9a8-5257-40ad-96d7-58de9d44223c/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-03-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-03/debd551c-53ab-4a58-b5e7-e467741184f9/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02262024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-02-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/2757a6f8-acb6-403d-91a4-c0390bf1b256/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-02-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-02/276ff9ed-a533-4dff-8333-1acafd12f377/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02192024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-02-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/d52a6165-b1be-4086-8352-2487652f77ff/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-02-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-02/3f137dd8-99f4-434e-a3d9-5fbf19832ef5/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02122024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-02-13"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/0ac09915-690f-46e7-be8b-8ec518704e49/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-02-13"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-02/f673ae7e-fb85-4bee-baa9-9eda87861808/OPIOID_TREATMENT_PROGRAM_PROVIDERS_02052024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-02-06"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/4e709226-c603-4c3f-82db-b7d81d09c151/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-02-06"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-01/3af14a84-4835-4e0b-b62a-bce3a129b2b7/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01292024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-01-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/7af7c333-3e74-4624-9ed7-d6b414f22141/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-01-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-01/cc7cc779-1ecf-4b65-8ae6-fee793824573/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01222024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-01-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/95685223-7957-4517-b3d1-ee3733ed05a7/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-01-23"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-01/0d5f86e5-2533-499d-a3be-d5a00eb6aadb/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01152024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-01-16"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/882afd21-9ffb-4045-b925-c721840e6e27/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-01-16"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-01/95eacb71-b1da-4d32-9752-aa4bcb652082/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01082024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-01-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/54e5a28d-bcb2-4bab-bb53-d1242731dad5/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-01-09"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2024-01/180bcfa7-2f95-4b52-8ef0-026eee86e424/OPIOID_TREATMENT_PROGRAM_PROVIDERS_01022024.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2024-01-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/4dc3b66c-831e-425a-ad3a-f52a7e1ca797/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2024-01-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-12/f4c09278-11f2-427a-b38d-833ff48f7d43/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12262023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-12-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/d97a74d4-caa8-4595-b62b-930b58e36fbc/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-12-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-12/4b4aa6c9-9488-4e83-a1e0-f9ab68bbe1ea/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12182023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-12-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/36a9b0bb-fbe3-4546-bfe7-864f1e162f66/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-12-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-12/fa1f80a4-7ec1-4c01-8098-5c42d2c2e8cd/OPIOID_TREATMENT_PROGRAM_PROVIDERS_12112023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-12-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c5cbebb1-cf0c-4d32-9c02-d135e1cddf10/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-12-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-12/71130a67-fe21-4464-818c-aaa49f1aeb19/OPIOID_TREATMENT_PROGRAM_PROVIDERS_20231204.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-12-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/3dbf5a06-1a76-4fa6-87d7-74c187326205/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-12-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-11/ad0515b8-e82f-4ec0-bd3b-a78c286ef50b/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11272023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-11-28"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/cd304feb-5650-461b-91ae-4676f1d85e6a/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-11-28"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-11/dc27fe4e-3e6b-4153-ad7f-24fc40a1d089/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11202023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-11-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/7a101036-1595-443f-84b8-6bffca1786b8/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-11-21"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-11/75dacf4c-5be8-4ede-90cc-07863df80ebd/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11132023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-11-14"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/f493662f-9114-49eb-b401-1a20d9caff90/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-11-14"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-11/3186442d-b006-44fb-a77c-b3fa46faf4cf/OPIOID_TREATMENT_PROGRAM_PROVIDERS_11062023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-11-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/5a43a9c2-a327-4606-b234-b72059519391/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-11-07"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-10/ed20ba66-0acd-4aff-9968-87e516e4610a/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10302023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-10-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/144ea7b3-db19-4386-9223-80c78d6a74e0/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-10-31"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-10/5c9bf85d-b94c-40b7-afcc-b0e4eb5574c0/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10232023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-10-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/39084279-cd1c-455a-a3dc-138a830438eb/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-10-24"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-10/14883b69-63c8-4c30-a059-f11db403b9f8/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10162023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-10-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/1d66db5a-4c71-41a6-a414-8c98ad62472a/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-10-17"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-10/3a2584a0-a21e-4558-a6b9-c3579263566e/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10102023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-10-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/59291e77-11a0-474f-93ad-103362962a12/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-10-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-10/d5d82ce6-e834-4ad1-a7f2-b398f5542ab6/OPIOID_TREATMENT_PROGRAM_PROVIDERS_10022023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-10-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/7e3197d5-2831-41ba-9c4b-3439b08eb96f/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-10-03"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-09/e338060b-3152-4575-abf6-e5bb06030bda/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09252023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-09-26"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/c5d40fca-823c-43b1-a7ca-51727fb9ea1c/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-09-26"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-09/e61e269b-68fb-4204-b1ad-da7ebd080765/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09112023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-09-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/a71c25d7-b61f-463e-9f7e-8cc1a49daf5d/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-09-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-09/711d5335-6b80-4ea6-bd9e-03bca5f48ab5/OPIOID_TREATMENT_PROGRAM_PROVIDERS_09052023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-09-06"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/adc418b9-db0e-4f8e-bf5c-7f3d94f44909/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-09-06"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-08/0c409fb3-2e6b-4a39-8960-6f1a5a32f2f4/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08282023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-08-29"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/9999bb43-c09d-4313-ada4-100a81132695/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-08-29"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-08/be3ac14b-e77a-413b-b95e-a54c054c4f17/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08212023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-08-22"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/352ef654-4dc4-450f-b130-86fd3a327bc3/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-08-22"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-08/b682ca29-ceaf-4ea8-b273-c43180db1194/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08142023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-08-15"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/3e8c55f6-4e19-4705-be86-528ba2ab7a17/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-08-15"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-08/097318c9-d709-40a0-87e7-f3086dc9aa51/OPIOID_TREATMENT_PROGRAM_PROVIDERS_08072023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-08-08"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/d6982e69-1bb2-477a-8867-a0d69c7d85c3/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-08-08"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-08/5c9e9c41-edfb-4806-9ef1-113ebe7c4b7a/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07312023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-08-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/d6535e0c-5d66-4275-9ac0-a636098cf495/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-08-01"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-07/4c0d806e-c782-40fd-8d8e-477642103f08/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07242023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-07-25"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/6175fcd3-736d-4831-92ac-52622fc4a9b2/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-07-25"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-07/d84f8b7e-db68-45b5-9237-f058c1a35741/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07172023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-07-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/38a88cf5-df2f-4adf-9aa7-55b06b701a32/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-07-19"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-07/c5ce8123-b511-4866-a896-d838365a0842/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07102023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-07-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/994ba8d9-1b03-4b74-a1f7-2d99ecc97116/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-07-11"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-07/fcf1bc65-7d50-4c5e-bb20-749b3ef74603/OPIOID_TREATMENT_PROGRAM_PROVIDERS_07032023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-07-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/1f4e9b93-6b77-4e29-8725-9a0d2530ca24/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-07-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-06/05db8d04-e6ac-4bc9-afb1-302faf98ae73/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06262023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-06-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/b7f878e8-4b0b-40d1-9bb8-f00c113b3eb1/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-06-27"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-06/92765e12-bed6-4f2b-bce8-20008bd8f2f9/OPIOID_TREATMENT_PROGRAM_PROVIDERS_06052023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-06-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/00f70f29-dc71-4777-8a5e-343b257aca7e/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-06-05"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/sites/default/files/2023-05/f3cec6a1-c6e3-4fa5-86a1-8f7304fff261/OPIOID_TREATMENT_PROGRAM_PROVIDERS_05302023.csv","mediaType":"text/csv","title":"Opioid Treatment Program Providers : 2023-05-30"},{"@type":"dcat:Distribution","downloadURL":"https://data.cms.gov/data-api/v1/dataset/24c8699f-a804-47b7-95fe-8fcb99acb918/data","mediaType":"text/html","title":"Opioid Treatment Program Providers : 2023-05-30"}],"describedBy":"https://data.cms.gov/resources/opioid-treatment-program-providers-data-dictionary","dataQuality":true,"license":"https://www.usa.gov/government-works","accrualPeriodicity":"R/P1W","theme":["Medicare"],"language":["en-US"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fmw-7iv8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","substance","references","bioactivity","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5fmw-7iv8","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864440: MLS000082870","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864440","description":"Access the complete Substance 864440: MLS000082870 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fn2-8kba","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","pubchem","research","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5fn2-8kba","description":"Chemical compound data from PubChem database. IUPAC Name: 3-methyldithiolan-4-one. Molecular Formula: C4H6OS2. Molecular Weight: 134.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526947: 3-Methyl-1,2-dithiolan-4-one","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526947","description":"Access the complete Compound 526947: 3-Methyl-1,2-dithiolan-4-one on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fnf-wp9r","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["scope","policy","guidance","child","assessment"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5fnf-wp9r","description":"This document supplements the information provided in Child and Family Services Review Technical Bulletin #7. It details how states and the Children’s Bureau (CB) will work to verify each state’s ability to meet the case review criteria in that bulletin.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Criteria for Using State Case Review Process for CFSR Purposes","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/criteria-using-state-case-review-process-cfsr-purposes","description":"Access the complete Criteria for Using State Case Review Process for CFSR Purposes on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://data.oregon.gov/d/3vye-ah73","issued":"2018-08-01","@type":"dcat:Dataset","modified":"2018-08-01","keyword":["updated baseline","ltach","2016 hai report"],"contactPoint":{"@type":"vcard:Contact","fn":"Roza Tammer","hasEmail":"mailto:no-reply@data.oregon.gov"},"publisher":{"@type":"org:Organization","name":"State of Oregon"},"identifier":"https://data.oregon.gov/api/views/3vye-ah73","description":"Oregon hospitals report CLABSIs from adult, pediatric, and neonatal intensive care units, and adult and pediatric medical, surgical, and medical/surgical wards as part of Oregon's mandatory healthcare-associated infections reporting program. For information regarding standardized infection ratio baselines, please see https://www.cdc.gov/nhsn/2015rebaseline/index.html.","title":"2016 Central Line-Associated Bloodstream Infections (CLABSI) Table – Long-Term Acute Care Hospitals (Updated Baseline)","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/3vye-ah73/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/3vye-ah73/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/3vye-ah73/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/3vye-ah73/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/3vye-ah73/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.oregon.gov/api/v3/views/3vye-ah73/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"http://www.cdc.gov/nccdphp/dph/","bureauCode":["009:20"],"issued":"2023-06-15","@type":"dcat:Dataset","modified":"2023-08-25","references":["https://www.cdc.gov/places/measure-definitions/index.html"],"keyword":["gis","health","outcomes","behaviors","prevention","prevalence","places","census tract","risk","status"],"contactPoint":{"@type":"vcard:Contact","fn":"PLACES Public Inquiries","hasEmail":"mailto:places@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/shc3-fzig","description":"This dataset contains model-based census tract level estimates for the PLACES 2022 release in GIS-friendly format. PLACES covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area levels. It provides information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation in conjunction with the CDC Foundation. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2020 or 2019 data, Census Bureau 2010 population estimates, and American Community Survey (ACS) 2015–2019 estimates. The 2022 release uses 2020 BRFSS data for 25 measures and 2019 BRFSS data for 4 measures (high blood pressure, taking high blood pressure medication, high cholesterol, and cholesterol screening) that the survey collects data on every other year. These data can be joined with the census tract 2015 boundary file in a GIS system to produce maps for 29 measures at the census tract level. An ArcGIS Online feature service is also available for users to make maps online or to add data to desktop GIS software.\nhttps://cdcarcgis.maps.arcgis.com/home/item.html?id=3b7221d4e47740cab9235b839fa55cd7","title":"PLACES: Census Tract Data (GIS Friendly Format), 2022 release","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/shc3-fzig/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/shc3-fzig/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/shc3-fzig/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/shc3-fzig/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/shc3-fzig/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/shc3-fzig/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"describedBy":"https://chronicdata.cdc.gov/dataset/PLACES-Census-Tract-Data-GIS-Friendly-Format-2020-/yjkw-uj5s","license":"http://opendefinition.org/licenses/odc-odbl/","theme":["500 Cities & Places"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fq6-hf8p","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","innovation","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5fq6-hf8p","description":"A flexible pipe formed by multiple layers of different materials, and one or more vent passages are provided in one of the layers for venting any gases permeating through the pipe.","title":"Patent AT-E399953-T1: [Translated] FLEXIBLE PIPE WITH VENTILATION CHANNELS AND METHOD FOR PRODUCING SAME","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399953-T1","description":"Access the complete Patent AT-E399953-T1: [Translated] FLEXIBLE PIPE WITH VENTILATION CHANNELS AND METHOD FOR PRODUCING SAME on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fqk-mwfr","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["data","foster","policy","reporting","care"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5fqk-mwfr","description":"Final Rule: National Youth In Transition Database\n \n \n\n (PDF) - This final rule implements the data collection requirements of the Foster Care Independence Act, enacted in 1999.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Final Rule: National Youth In Transition Database","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/law-regulation/final-rule-national-youth-transition-database","description":"Access the complete Final Rule: National Youth In Transition Database on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fuy-z68g","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["assessment","maltreatment","abuse","prevention","neglect"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5fuy-z68g","description":"Passage of the Child Abuse Prevention and Treatment Act (CAPTA) in 1974 marked the Nation's first major step forward in addressing issues related to child maltreatment. To commemorate CAPTA's 40th anniversary, the Children's Bureau and its Office on Child Abuse and Neglect have developed The Child Abuse Prevention and Treatment Act: 40 Years of Safeguarding America's Children.\n\nThis online publication combines historical source materials with contemporary reflections on the impact of CAPTA from leaders in the field. This will be an invaluable resource to policymakers, practitioners, researchers, and students in the fields of child protection, child welfare, and social services, as well as all those interested in the story of child protection in the United States.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"The Child Abuse Prevention and Treatment Act: 40 Years of Safeguarding America's Children","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/child-abuse-prevention-and-treatment-act-40-years-safeguarding","description":"Access the complete The Child Abuse Prevention and Treatment Act: 40 Years of Safeguarding America's Children on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5fvs-5xys","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","research","chemistry","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5fvs-5xys","description":"Chemical compound data from PubChem database. IUPAC Name: hex-2-enyl 2-methylpropanoate. Molecular Formula: C10H18O2. Molecular Weight: 170.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527117: Hex-2-enyl 2-methylpropanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527117","description":"Access the complete Compound 527117: Hex-2-enyl 2-methylpropanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5g2d-evzt","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["policy","poverty","social","welfare","document"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5g2d-evzt","description":"This Information Memorandum (IM) provides information on the Poverty Reduction - Earned Income Tax Credit.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-07-01)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-07-01","description":"Access the complete IM-07-01 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5g38-u6qx","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["age-based-rationing","healthcare-resource-allocation","nih","elderly-care","fair-innings-argument"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5g38-u6qx","description":"The fair innings argument (FIA) is frequently put forward as a justification for denying elderly patients treatment when they are in competition with younger patients and resources are scarce. In this paper I will examine some arguments that are used to support the FIA. My conclusion will be that they do not stand up to scrutiny and therefore, the FIA should not be used to justify the denial of treatment to elderly patients, or to support rationing of health care by age.\n There are six issues arising out of the FIA which are to be addressed. First, the implication that there is such a thing as a fair share of life. Second, whether it makes sense to talk of a fair share of resources in the context of health care and the FIA. Third, that 'fairness' is usually only mentioned with regard to the length of a person's life, and not to any other aspect of it. Fourth, if it is sensible to discuss the merits of the FIA without taking account of the 'all other things being equal' argument. Fifth, the difference between what is unfair and what is unfortunate. Finally, that it is tragic if a young person dies, but only unfortunate if an elderly person does.","title":"Why the fair innings argument is not persuasive","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC32192/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5g8e-a5px","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["measles-cost","vaccination-adverse-events","economic-model","immunization-program","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5g8e-a5px","description":"Background\n Even though the annual incidence rate of measles has dramatically decreased in industrialised countries since the implementation of universal immunisation programmes, cases continue to occur in countries where endemic measles transmission has been interrupted and in countries where adequate levels of immunisation coverage have not been maintained. The objective of this study is to develop a model to estimate the average cost per measles case and per adverse event following measles immunisation using the Netherlands (NL), the United Kingdom (UK) and Canada as examples.\n \n \n Methods\n Parameter estimates were based on a review of the published literature. A decision tree was built to represent the complications associated with measles cases and adverse events following imminisation. Monte-Carlo Simulation techniques were used to account for uncertainty.\n \n \n Results\n From the perspective of society, we estimated the average cost per measles case to be US$276, US$307 and US$254 for the NL, the UK and Canada, respectively, and the average cost of adverse events following immunisation per vaccinee to be US$1.43, US$1.93 and US$1.51 for the NL, UK and Canada, respectively.\n \n \n Conclusions\n These average cost estimates could be combined with incidence estimates and costs of immunisation programmes to provide estimates of the cost of measles to industrialised countries. Such estimates could be used as a basis to estimate the potential economic gains of global measles eradication.","title":"The average cost of measles cases and adverse events following vaccination in industrialised countries","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128813/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/8nyy-xsq7","bureauCode":["009:20"],"issued":"2023-12-01","@type":"dcat:Dataset","modified":"2024-05-24","contactPoint":{"@type":"vcard:Contact","fn":"NCIRD","hasEmail":"mailto:VaxView@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/8nyy-xsq7","description":"Weekly Cumulative Influenza Vaccination Coverage Comparison between Current and Previous Season, Children 6 Months through 17 Years, United States \n\n• Influenza vaccination coverage among children is assessed through the National Immunization Survey-Flu (NIS-Flu) annually, providing weekly influenza vaccination coverage estimates for children 6 months–17 years based upon parental report. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html) \n\no NIS-Flu is a national random-digit-dialed cellular telephone survey of households conducted during the flu season (October-June). \n\n• Additional information about NIS-Flu methods and estimates from the 2019-2020 season are available at: https://www.cdc.gov/flu/fluvaxview/coverage-1920estimates.htm. Final estimates for prior seasons and other flu vaccination data are available at CDC’s FluVaxView.: https://www.cdc.gov/flu/fluvaxview/index.htm.","title":"Weekly Cumulative Influenza Vaccination Coverage Comparison between Current and Previous Season, Children 6 Months through 17 Years, United States","programCode":["009:026"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/8nyy-xsq7/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/8nyy-xsq7/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/8nyy-xsq7/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"United States, States, and Local Jurisdictions","license":"https://www.usa.gov/government-works","accrualPeriodicity":"Weekly","theme":["Child Vaccinations"],"language":["English"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ga5-kckd","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["childr","service","child","acf","social"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5ga5-kckd","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"NCFAST IEPD","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14194","description":"Access the complete NCFAST IEPD on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gbk-psjr","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","west-virginia","substance-use","nsduh","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5gbk-psjr","description":"This report presents West Virginia\\'s estimates for 25 measures of substance use and mental health based on the combined 2011 and 2012 National Surveys on Drug Use and Health (NSDUHs). Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE). Resuts are provided by State and for five age groups: 12 to 17, 18 to 25, 26 or older, 18 or older and all persons 12 or older.","title":"West Virginia: 2011-2012 NSDUH","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/west-virginia-2011-2012-nsduh","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gby-ds93","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","bioactivity","substance","references","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5gby-ds93","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865145: MLS000080947","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865145","description":"Access the complete Substance 865145: MLS000080947 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/mhj9-4wi2","bureauCode":["009:20"],"issued":"2016-11-30","@type":"dcat:Dataset","modified":"2025-02-05","contactPoint":{"@type":"vcard:Contact","fn":"OSHData Support","hasEmail":"mailto:nccdoshinquiries@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/mhj9-4wi2","description":"2010-2018; 2019. US Census Annual Estimates of the Resident Population for Selected Age Groups by Sex for the United States. The estimates for the 2010-2018 dataset are based on the 2010 Census and reflect changes to the April 1, 2010 population due to the Count Question Resolution program and geographic program revisions. Median age is calculated based on single year of age. The estimates for 2019 are based on a one-year dataset that was published on the US Census website in 2021. For population estimates methodology statements, see http://www.census.gov/popest/methodology/index.html.","title":"US Census Methodology","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/download/mhj9-4wi2/application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Funding"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gf3-ku2k","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-abuse-treatment","national-outcome-measures","arkansas","samhsa","mental-health-services"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5gf3-ku2k","description":"2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Arkansas. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2015 CMHS Uniform Reporting System (URS) Table for Arkansas","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2015-cmhs-uniform-reporting-system-urs-table-arkansas","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gfe-dayz","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["award","adoption","child","grant","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5gfe-dayz","description":"This document lists the recipients of the 2022 Adoption Excellence Awards, provides a brief description of each recipient’s work, and features photos and quotes from youth who have been adopted or are waiting for an adoptive family.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Adoption Excellence Awards for the Year 2022","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/adoption-excellence-awards-year-2022","description":"Access the complete Adoption Excellence Awards for the Year 2022 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gi9-erkj","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","chemistry","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5gi9-erkj","description":"Chemical compound data from PubChem database. IUPAC Name: pentadecyl 4-methylbenzoate. Molecular Formula: C23H38O2. Molecular Weight: 346.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530584: p-Toluic acid, pentadecyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530584","description":"Access the complete Compound 530584: p-Toluic acid, pentadecyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/msjj-a7q2","bureauCode":["009:00"],"issued":"2016-09-14","@type":"dcat:Dataset","modified":"2016-09-14","keyword":["cdc","centers for disease control and prevention"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/msjj-a7q2","description":"Source for 2012 national data: National Occupant Protection Use Survey (NOPUS), 2012. Source for 2014 national data: National Occupant Protection Use Survey (NOPUS), 2014. Source for 2012 state data: State Observational Survey of Seat Belt Use, 2012. Source for 2014 state data: Seat Belt Use in 2014- Use Rates in the States and Territories","title":"Percentage of Drivers and Front Seat Passengers Wearing Seat Belts, 2012 & 2014, Region 10 - Seattle","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/msjj-a7q2/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/msjj-a7q2/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/msjj-a7q2/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/msjj-a7q2/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/msjj-a7q2/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/msjj-a7q2/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Motor Vehicle"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5giy-5awq","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","science","research","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5giy-5awq","description":"Chemical compound data from PubChem database. IUPAC Name: 3-methylideneocta-1,5-diene. Molecular Formula: C9H14. Molecular Weight: 122.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528922: 3-Methylideneocta-1,5-diene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528922","description":"Access the complete Compound 528922: 3-Methylideneocta-1,5-diene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://datadiscovery.nlm.nih.gov/d/eds5-ig9r","bureauCode":["009:25"],"issued":"2022-02-10","@type":"dcat:Dataset","modified":"2025-06-18","keyword":["pubmed"],"contactPoint":{"@type":"vcard:Contact","fn":"National Library of Medicine","hasEmail":"mailto:custserv@nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Library of Medicine"},"identifier":"https://datadiscovery.nlm.nih.gov/api/views/eds5-ig9r","description":"Yearly citation totals from each year of the MEDLINE/PubMed Baseline referencing citations back to year 1781. These totals may increase over time for a particular year as new citations are added. For example, 25 citations were listed for the year 1800 in the 2018 MEDLINE/PubMed Baseline, while the 2019 Baseline includes 387 citations for that year.","title":"PubMed total records by publication year","programCode":["009:041"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://datadiscovery.nlm.nih.gov/api/v3/views/eds5-ig9r/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://datadiscovery.nlm.nih.gov/api/v3/views/eds5-ig9r/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://datadiscovery.nlm.nih.gov/api/v3/views/eds5-ig9r/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"https://www.usa.gov/government-works","theme":["Information Management"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gmv-5xd8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5gmv-5xd8","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864882: MLS000081136","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864882","description":"Access the complete Substance 864882: MLS000081136 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://hcai.ca.gov/data-and-reports/healthcare-quality/ahrq-quality-indicators/#voluti","issued":"2017-06-16","temporal":"2005 - 2016","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["hospital quality","percutaneous coronary intervention","pci","pancreatic resection","pancreatic cancer surgery","inpatient quality indicators","inpatient quality","indicators","volume","hospital volume","stents","abdominal aortic aneurysm repair","heart bypass","healthcare quality","esophageal resection","esophageal cancer surgery","coronary artery bypass graft surgery","carotid endarterectomy","cabg","angioplasty","ahrq","agency for healthcare research and quality","aaa repair"],"contactPoint":{"@type":"vcard:Contact","fn":"Department of Health Care Access and Information, Healthcare Information Division/Healthcare Outcomes Center","hasEmail":"mailto:dataandreports@hcai.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"6fe470cc-074f-49ce-8adc-882027076d19","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. Data are reported for January – September 2015 due to coding changes from ICD-9-CM to ICD-10-CM/PCS for procedures, which began 10/1/2015. Comparisons across years should be made with caution since other years’ results are based on 12 months of data, while 2015 analysis is based on 9 months of data. The data starting 2015 may differ from previous years due to the coding change. This dataset does not include procedures performed in outpatient settings.","title":"Number of Selected Inpatient Medical Procedures in California Hospitals","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/cbc646c9-36b3-4b5d-9d73-63a3e6018ba2/download/ca-oshpd-ahrq-v2018-vol-1617.csv","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"Number of Selected Inpatient Medical Procedures in California Hospitals, 2016-2017 (CSV)"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/c5878b88-5c7d-4354-8cbe-ebd490d9c546/download/number-of-selected-inpatient-medical-procedures-in-california-hospitals.csv","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. Data are reported for January – September 2015 due to coding changes from ICD-9-CM to ICD-10-CM/PCS for procedures, which began 10/1/2015. Comparisons across years should be made with caution since previous years’ results are based on 12 months of data, while 2015 analysis is based on 9 months of data. The 2015 data may differ from previous years due to the coding change. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"Number of Selected Inpatient Medical Procedures in California Hospitals, 2005 - 2015 (CSV)"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/c4fb589b-9635-4427-bfb8-5e251eb7a98c/download/definitions-of-volume-indicators.pdf","description":"This document provides definitions of six selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. Data are reported for January – September 2015 due to coding changes from ICD-9-CM to ICD-10-CM/PCS for procedures, which began 10/1/2015. Comparisons across years should be made with caution since previous years’ results are based on 12 months of data, while this analysis is based on 9 months of data. The 2015 data may differ from previous years due to the coding change. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"Definitions of Volume Indicators"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/32574c1c-712f-412b-866a-11851359c0d0/download/volume_final_2017_formatted.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2017 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/32c7ab30-ae99-47b9-951a-aa9b2aacf8ab/download/volume_final_2016_formatted.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2016 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/a7c786f7-8932-4f53-ac97-c2f80ecb258a/download/data-dictionary-volume.pdf","description":"This document provides the dictionary for the dataset contains the number (volume) of six selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. Data are reported for January – September 2015 due to coding changes from ICD-9-CM to ICD-10-CM/PCS for procedures, which began 10/1/2015. Comparisons across years should be made with caution since previous years’ results are based on 12 months of data, while this analysis is based on 9 months of data. The 2015 data may differ from previous years due to the coding change. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"Data Dictionary for Volume Indicators"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/dbf02cb3-4fbb-4441-a378-85f3b4439068/download/2015vol.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2015 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/36af6ba0-67cc-4c1f-89fd-14e82f214ba2/download/2014vol.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2014 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/4aecbc44-ef5a-4aef-8da4-d54de64618b7/download/2013vol.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2013 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/b828574b-73cc-45b9-8047-99115196b71f/download/2012vol.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2012 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/88d83e21-fc52-4f0b-8b95-00422e7a1f7d/download/2011vol.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2011 Number of Selected Inpatient Medical Procedures in California Hopitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/86a425a3-1715-4141-92d4-4a5840b1e118/download/2010vol.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2010 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/a493e1fd-3fab-4466-922e-970734aaeb86/download/2009vol.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2009 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/c61beadc-ae10-4b6a-9801-ca165db1ff9b/download/2008vol.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2008 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/0fca8da9-7b7d-4fae-98de-e0e569cbf468/download/2007vol.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2007 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/e8285534-c124-4a56-b567-5e84c118e032/download/2006vol.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2006 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/a99145fd-5cda-4925-8930-6b97bedc4e15/download/2005vol.pdf","description":"This dataset contains the number (volume) of 6 selected inpatient procedures (Esophageal Resection, Pancreatic Resection, Abdominal Aortic Aneurysm Repairs (AAA Repairs), Carotid Endarterectomy, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention) performed in California hospitals. This dataset does not include procedures performed in outpatient settings.","@type":"dcat:Distribution","title":"2005 Number of Selected Inpatient Medical Procedures in California Hospitals"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/6fe470cc-074f-49ce-8adc-882027076d19/resource/02b6aac6-52dd-447b-b094-6094f20b29ba/download/number-of-selected-inpatient-medical-procedures-in-california-hospitals-zx5gi08r.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Healthcare"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gpn-5wgs","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["adoption","metadata"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5gpn-5wgs","description":"ACF Children Bureau resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"What are the adoption laws in my state? How do I find out about my state laws governing adoption (e.g., consent to adopt; who can adopt, etc.)?","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/faq/adoption5","description":"Access the complete What are the adoption laws in my state? How do I find out about my state laws governing adoption (e.g., consent to adopt; who can adopt, etc.)? on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gqp-xc9s","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["reporting","policy","instruction","foster","fiscal"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5gqp-xc9s","description":"This Program Instruction (PI) provides instruction on the Fiscal Reports for Title IV-E or IV-A Foster Care and Transfers to Title IV-B.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-81-08)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-81-08","description":"Access the complete PI-81-08 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gs7-8ts8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5gs7-8ts8","description":"Chemical compound data from PubChem database. IUPAC Name: trimethyl-[2-[2-[2-(3-methylbutoxy)ethoxy]ethoxy]ethoxy]silane. Molecular Formula: C14H32O4Si. Molecular Weight: 292.49. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526881: 2-[2-(2-Isopentoxyethoxy)ethoxy]ethyl TMS ether","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526881","description":"Access the complete Compound 526881: 2-[2-(2-Isopentoxyethoxy)ethoxy]ethyl TMS ether on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gsb-q8kt","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health","samhsa","substance-use","region-9","behavioral-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5gsb-q8kt","description":"This is a behavioral health report for HHS Region IX of the United States and utilizes data from the National Survey on Drug Use and Health (NSDUH) and the National Survey of Substance Abuse Treatment (N-SSATS), collected annually. The topics addressed in the reports include youth substance use, adult mental health and treatment, and substance use treatment.","title":"Behavioral Health Barometer: Region 9, Volume 6","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-region-9-volume-6","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gss-umhq","bureauCode":["009:70"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["ndacan","abuse","care","reporting","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"NDACAN Data Team","hasEmail":"mailto:NDACAN@cornell.edu"},"publisher":{"@type":"org:Organization","name":"National Data Archive on Child Abuse and Neglect"},"identifier":"https://healthdata.gov/api/views/5gss-umhq","description":"The Survey of National Survey of Child and Adolescent Well-Being (NSCAW) Adopted Youth, Young Adults, Adults, and Adoptive Parents (hereafter referred to as “The NSCAW Adoption Study”) seeks to understand the extent of post adoption instability events that occur in families who have adopted children who have exited the foster care system. Post adoption instability refers to situations in which children who exit foster care to adoptive homes no longer reside with their adoptive parents and includes formal events, such as a child’s reentry into the foster care system, or informal events, such as a child going to live with a grandparent or running away. A second objective is to understand risk and protective factors associated with post adoption instability. The study conducted web or telephone surveys with adopted youth, young adults, and adults as well as their adoptive parents who were participants in the first or second cohort of the National Survey of Child and Adolescent Well-Being (NSCAW I, II; OMB #0970-0202).\n\nInvestigators: Heather Ringeisen, PhD\nRTI International Research Triangle Park, NC\n\nRose Domanico, MA\nRTI International Research Triangle Park, NC\n\nNancy Rolock, PhD\nCase Western Reserve University Cleveland, OH\n\nKevin White, PhD\nEast Carolina University Greenville, NC\n\nStephen Tueller, PhD\nRTI International Research Triangle Park, NC\n\nLeyla Stambaugh, PhD\nRTI International Research Triangle Park, NC","title":"Understanding Post Adoption and Guardianship Instability for Children and Youth Who Exit Foster Care (PAGI): The NSCAW Adoption Study","programCode":["009:094"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ndacan.acf.hhs.gov/datasets/dataset-details.cfm?ID=270","description":"Access the complete Understanding Post Adoption and Guardianship Instability for Children and Youth Who Exit Foster Care (PAGI): The NSCAW Adoption Study on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5guu-mkau","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","compound","pubchem","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5guu-mkau","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-2-ene-9-carboxylate. Molecular Formula: C20H24O4. Molecular Weight: 328.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529713: Methyl 11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-2-ene-9-carboxylate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529713","description":"Access the complete Compound 529713: Methyl 11-methyl-6-methylidene-16-oxo-15-oxapentacyclo[9.3.2.15,8.01,10.02,8]heptadec-2-ene-9-carboxylate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gwm-mer2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","innovation","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5gwm-mer2","description":"Methods and systems are provided for controlling the scope of delegation of authentication credentials within a network environment. A server (210) is configured to provide a trusted third-party (206) with a ticket authenticating the server, information about a target service (212,214) that a server seeks to access on behalf of the client, and a service ticket associated with the client. This service ticket may be provided by the client (202) or may be a previously granted service ticket granted to the server (210) for itself in the name of the client. The trusted third-party grants a new service ticket to access the target service (212,214) to the server (210), in the client's name, if such delegation is permitted according to delegation constraints associated with the client.","title":"Patent AT-E400130-T1: [Translated] METHOD AND SYSTEM FOR CONTROLLING THE SCOPE OF DELEGATION OF AUTHENTICATION DATA","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400130-T1","description":"Access the complete Patent AT-E400130-T1: [Translated] METHOD AND SYSTEM FOR CONTROLLING THE SCOPE OF DELEGATION OF AUTHENTICATION DATA on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5gxb-zv9d","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["drug-use","mental-health","substance-abuse","samhsa","national-survey"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5gxb-zv9d","description":"This is the introductory material, table of contents and glossary to the 2013 National Survey on Drug Use and Health (NSDUH) detailed tables.","title":"Results from the 2013 National Survey on Drug Use and Health: Detailed Tables","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/results-2013-national-survey-drug-use-and-health-detailed-tables","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/mdwz-ar4b","bureauCode":["009:20"],"issued":"2026-04-21","@type":"dcat:Dataset","modified":"2026-04-21","keyword":["arpsp","c auris"],"contactPoint":{"@type":"vcard:Contact","fn":"Walid Hamade","hasEmail":"mailto:axa6@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/mdwz-ar4b","description":"Published and visualized on the ARPSP web application on 3/4/2026.","title":"ARPSP C. Auris","programCode":["009:028"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mdwz-ar4b/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mdwz-ar4b/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/mdwz-ar4b/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["National Center for Emerging and Zoonotic Infectious Diseases"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5h5s-6jra","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","compound","pubchem","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5h5s-6jra","description":"Chemical compound data from PubChem database. IUPAC Name: 2,7-dimethyloct-7-en-5-yn-4-yl pentanoate. Molecular Formula: C15H24O2. Molecular Weight: 236.35. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530633: Valeric acid, 2,7-dimethyloct-7-en-5-yn-4-yl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530633","description":"Access the complete Compound 530633: Valeric acid, 2,7-dimethyloct-7-en-5-yn-4-yl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5h5y-3reh","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["service","child","social","childr","acf"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5h5y-3reh","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Electronic Health Records in NHSIA","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14283","description":"Access the complete Electronic Health Records in NHSIA on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5h64-xeqr","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["national-outcome-measures","samhsa","mental-health-services","hawaii","community-mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5h64-xeqr","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2011. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2011 CMHS Uniform Reporting System (URS) Output Tables for Hawaii","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2011-cmhs-uniform-reporting-system-urs-output-tables-hawaii","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://usdss.cdc.gov","bureauCode":["009:20"],"issued":"2026-06-23","@type":"dcat:Dataset","modified":"2026-06-23","keyword":["diabetes","newly diagnosed diabetes","usdss","diagnosed type 2 diabetes","diagnosed type 1 diabetes"],"contactPoint":{"@type":"vcard:Contact","fn":"DDT Public Inquiries","hasEmail":"mailto:ddtpubsmailbox@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/b559-sbez","description":"Data from the U.S. Diabetes Surveillance System.\nhttps://usdss.cdc.gov/diabetes/surveillance.html","title":"USDSS State Burden/Magnitude Diabetes Indicators","programCode":["009:029"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/b559-sbez/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/b559-sbez/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/b559-sbez/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"State","license":"http://opendefinition.org/licenses/odc-odbl/","theme":["U.S. Diabetes Surveillance System"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5h9g-5cz3","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["adoption","foster","fiscal","data","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5h9g-5cz3","description":"This Information Memorandum (IM) provides information on allotment percentages under the Foster Care and Adoption Assistance Programs (Title IV-E) for Fiscal Year 1988.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-87-11)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-87-11","description":"Access the complete IM-87-11 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hb3-paj8","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["real","policy","intervention","guidance","behavioral"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5hb3-paj8","description":"To: State, territorial, tribal, and local policymakers and administrators of systems, agencies, and programs responsible for children, youth, and family health and well-being\n\nDear Colleagues,\n\nThank you for the work you do each day to support children, youth, and families across the country. The Administration for Children and Families (ACF) would like to highlight the critical importance of timely, high-quality behavioral health crisis care and make sure you are aware of how these resources can be accessed in your communities.\n\nToo many people are experiencing suicidal crisis or mental health-related distress without the support and care they need, and this is particularly true for children, youth, and families. Trends in suicide attempts and deaths by suicide have been increasing among adolescents and remain a major public health concern. In 2023, 3.2 million adolescents aged 12 to 17 (12.3 percent) had serious thoughts of suicide in the past year, 1.5 million (5.6 percent) made suicide plans, and 856,000 (3.3 percent) attempted suicide. Vulnerable adolescent populations exposed to adverse childhood experiences are at particular risk of suicide and related behaviors.\n\nSomeone to contact: The 988 Suicide & Crisis Lifeline\n\n988 offers one-on-one, skilled, compassionate mental health and substance use support for anyone at any time. 988 counselors are trained to understand how an issue is affecting a person and share resources that may be helpful. People can call or text 988 or chat 988lifeline.org 24/7 for themselves or if they are worried about a loved one.\n\nThe 988 dialing code is made up of a national network of more than 200 local crisis contact centers\n \n \n\n that are equipped to handle thousands of contacts each day. When someone calls 988, they first hear a greeting message. They are then given choices of who to connect with. The 988 Lifeline has specially trained counselors for veterans, Spanish speakers, LGBTQI+ youth and young adults, and Deaf and Hard of Hearing people. The 988 Lifeline uses Language Line Solutions to provide translations to callers in more than 240 additional languages, and is also working to ensure broad accessibility to make sure that all people can receive needed support, including those with intellectual and/or developmental disabilities, those with brain injury, and those with other disabilities. Since Congress designated 988 in 2020 and the three-digit number went live in 2022, there has been a significant investment of federal resources to scale up crisis centers across the country. 988 is an important step forward and offers an unprecedented opportunity to strengthen and transform behavioral health crisis care in our country.\n\nThere are a number of other federally funded hotlines that offer critical support and intersect with topics related to emotional distress and crisis. Use your best judgment as to the most appropriate resource for the situation when directing the public to different hotline resources. For your convenience, a list of ACF- and select federally supported hotlines is included at the bottom of this letter (see Tables A, B). When suicide presents as a risk, please refer to 988. 911 should only be used for situations posing immediate physical danger, such as suicide attempts in progress, medical emergencies, or immediate threats to safety.\n\nSomeone to respond and a safe place to go: The importance of trained face-to-face response\n\nThe vast majority of those seeking help from the 988 Lifeline do not require any additional emergency interventions at that moment. However, there are instances when an in-person response is needed. The Substance Abuse and Mental Health Services Administration (SAMHSA) outlines two core components that every community should work to have in place when these instances arise: mobile crisis teams that can reach individuals where they are in the community, and crisis stabilization facilities that can provide observation and stabilization services in a","title":"Access to Timely, High-Quality Behavioral Health Crisis Care","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/policy-guidance/access-timely-high-quality-behavioral-health-crisis-care","description":"Access the complete Access to Timely, High-Quality Behavioral Health Crisis Care on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hbp-pdkd","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["foster","real","reporting","data","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5hbp-pdkd","description":"The National Youth in Transition Database (NYTD) is a federal reporting system that collects information on youth transitioning out of foster care. States administering the John H. Chafee Foster Care Program for Successful Transition to Adulthood (Chafee) must report on the services provided to young people and also conduct a survey using a cohort methodology at ages 17, 19, and 21. Recognizing the integral role of young adults in successfully designing services and implementing a survey for young people, the Children’s Bureau has engaged young adults through the NYTD Reviewer program to guide this work. NYTD Reviewers are between the ages of 18 and 28, have lived experience with the child welfare system, and are interested in the use of data to inform system improvements. Three to four NYTD Reviewers participate as members of the federal monitoring team for each onsite review.\n\nNYTD is an opportunity to engage young people as partners in data collection, analysis, dissemination, and the use of data. As a member of the Federal Review Team, a NYTD Reviewer participates in all aspects of the review, including pre-onsite phase preparations, onsite review activities, and providing input on the Final Report findings and NYTD Improvement Plan. The following resources provide additional information about the qualifications and responsibilities of NYTD Reviewers:\n\nOn behalf of the Children’s Bureau, JBS International, Inc.'s Child Welfare Compliance Reviews Team (CWCRT) maintains a national pool of NYTD Reviewers to support the Children’s Bureau in administering the federal NYTD Reviews. Given the highly technical nature of the NYTD Review process, young people gain knowledge by participating in a training for which they are compensated, and for which travel costs are covered. CWCRT also conducts other skills-based trainings periodically as needed. NYTD Reviewers receive reimbursement for participating in trainings, reviews, and other NYTD-related work. They also receive reimbursement for travel expenses, and a per diem rate for meals and incidental expenses. The following resources provide additional information for those interested in serving as a NYTD Reviewer:\n\nIf you believe you are qualified to participate, please email CWCRT at cw-mail@jbsinternational.com for a NYTD Reviewer application packet.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Federal NYTD Reviewer Opportunity","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/federal-nytd-reviewer-opportunity","description":"Access the complete Federal NYTD Reviewer Opportunity on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hbv-ds5h","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5hbv-ds5h","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865384: MLS000083999","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865384","description":"Access the complete Substance 865384: MLS000083999 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hcv-gnzh","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","compound","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5hcv-gnzh","description":"Chemical compound data from PubChem database. IUPAC Name: 2-hexyl-4,5-dimethyl-1,3-oxazole. Molecular Formula: C11H19NO. Molecular Weight: 181.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525781: 2-Hexyl-4,5-dimethyloxazole","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525781","description":"Access the complete Compound 525781: 2-Hexyl-4,5-dimethyloxazole on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hdi-fn4s","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","research","patent","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5hdi-fn4s","description":"Chemical patent from PubChem database. Patent Number: AT-E400275-T1. Title: Bioactive Compound and Applications. Filing Date: 2014-04-24. Inventors: Rodriguez, Juan, White, Jennifer. Abstract: A bioactive compound and its applications in pharmaceutical and agricultural fields are described. The compound exhibits significant biological activi... IPC Classifications: B01J, C07C, C07D. This patent covers 24 claims related to 2 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.","title":"Patent AT-E400275-T1: [Translated] ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF WORST LEGS SYNDROME OR NOcturnal MYOCLONUS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400275-T1","description":"Access the complete Patent AT-E400275-T1: [Translated] ADENOSINE A2A RECEPTOR ANTAGONISTS FOR THE TREATMENT OF WORST LEGS SYNDROME OR NOcturnal MYOCLONUS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hew-vj46","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health","household-survey","screening-tool","samhsa","substance-use"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5hew-vj46","description":"These are the household screening specifications to the 2013 National Survey on Drug Use and Health (NSDUH).","title":"2013 NSDUH Screener","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2013-nsduh-screener","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hhx-wx8s","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["child","guidance","grant","policy","instruction"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5hhx-wx8s","description":"This document provides Children's Bureau discretionary grantees with additional information about grant closeout, including the final program progress report, the final financial status report, the property inventory and disposition statement, and no-cost extensions.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Children's Bureau Discretionary Grant Closeout Guidance","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/childrens-bureau-discretionary-grant-closeout-guidance","description":"Access the complete Children's Bureau Discretionary Grant Closeout Guidance on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","medications","health-care","drug-manufacturers","pharmaceuticals"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA218391","description":"Crinone is a prescription vaginal gel containing progesterone, available in 4% and 8% strengths. Manufactured by Allergan, Inc., it's used to support certain hormonal needs in women. This information was generated using AI and is provided for informational and research purposes only.","title":"Progesterone","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218391","description":"\n Access the FDA dataset for Progesterone — ANDA 218391 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Progesterone"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hjf-7i7r","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5hjf-7i7r","description":"Chemical compound data from PubChem database. IUPAC Name: pent-4-en-2-yl 2,2-dibromoacetate. Molecular Formula: C7H10Br2O2. Molecular Weight: 285.96. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527606: 4-Penten-2-ol, dibromoacetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527606","description":"Access the complete Compound 527606: 4-Penten-2-ol, dibromoacetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hjk-4xga","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["relapsing-polychondritis","animal-models","nih","autoimmune-disease","cartilage-inflammation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5hjk-4xga","description":"Relapsing polychondritis is an autoimmune disease in which an inappropriate immune response destroys cartilage. Cartilage of the ears, larynx and nose rather than spine and joint cartilage is affected by a chronic relapsing and erosive inflammation. Several animal models for relapsing polychondritis have been published in which immunization with various cartilage proteins induces a variety of chondritis symptoms that mimic those seen in patients. In this review we describe the collagens, matrilin-1 and cartilage oligomeric matrix protein as potential autoantigens able to trigger the tissue-specific immune response seen both in patients and in animal models for relapsing polychondritis and related autoimmune diseases.","title":"Cartilage-specific autoimmunity in animal models and clinical aspects in patients – focus on relapsing polychondritis","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128937/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hkn-67ej","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","bioactivity","chemistry","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5hkn-67ej","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864940: MLS000084232","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864940","description":"Access the complete Substance 864940: MLS000084232 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hky-97zr","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5hky-97zr","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864758: MLS000042445","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864758","description":"Access the complete Substance 864758: MLS000042445 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hp5-kv45","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["attention-networks","attention-network-test","nih","genetic-polymorphisms","executive-attention"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5hp5-kv45","description":"Background\n Current efforts to study the genetic underpinnings of higher brain functions have been lacking appropriate phenotypes to describe cognition. One of the problems is that many cognitive concepts for which there is a single word (e.g. attention) have been shown to be related to several anatomical networks. Recently, we have developed an Attention Network Test (ANT) that provides a separate measure for each of three anatomically defined attention networks.\n \n \n Results\n In this study we have measured the efficiency of neural networks related to aspects of attention using the ANT in a population of 200 adult subjects. We then examined genetic polymorphisms in four candidate genes (DRD4, DAT, COMT and MAOA) that have been shown to contribute to the risk of developing various psychiatric disorders where attention is disrupted. We find modest associations of several polymorphisms with the efficiency of executive attention but not with overall performance measures such as reaction time.\n \n \n Conclusions\n These results suggest that genetic variation may underlie inter-subject variation in the efficiency of executive attention. This study also shows that genetic influences on executive attention may be specific to certain anatomical networks rather than affecting performance in a global or non-specific manner. Lastly, this study further validates the ANT as an endophenotypic assay suitable for assessing how genes influence certain anatomical networks that may be disrupted in various psychiatric disorders.","title":"Assessing the molecular genetics of attention networks","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC130047/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/fluvaxview/dashboard/children-vaccination-coverage.html","bureauCode":["009:20"],"issued":"2025-12-10","@type":"dcat:Dataset","temporal":"2023-2024, 2024-2025, 2025-2026","modified":"2026-07-02","keyword":["nis-ccm","nis-flu","flu vaccination"],"contactPoint":{"@type":"vcard:Contact","fn":"VaxView Team","hasEmail":"mailto:VaxView@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/amjr-ph5r","description":"• Weekly Differences in Cumulative Influenza Vaccination Coverage by Selected Demographics and by Season, 2024-25 and 2024-25 Compared with 2023-24, Children 6 Months–17 Years, United States.\n\n• Weekly Influenza vaccination coverage and parental intent for vaccination among children is calculated using data from the National Immunization Survey–Flu (NIS–Flu) (https://www.cdc.gov/nis/about/index.html). NIS–Flu is a national random-digit-dialed cellular telephone survey of households with children ages 6 months–17 years conducted during October-June. The respondent to a NIS–Flu survey is a parent or guardian who said they were knowledgeable about the child’s vaccination history. All estimates are based upon parental report of receipt of vaccination and month of that vaccination.","title":"Weekly Differences in Cumulative Influenza Vaccination Coverage by Selected Demographics and by Season, 2024-25 and 2024-25 Compared with 2023-24, Children 6 Months -17 Years, United States","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/amjr-ph5r/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/amjr-ph5r/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/amjr-ph5r/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"United States- National, Region, State","license":"https://www.usa.gov/government-works","accrualPeriodicity":"Weekly","theme":["Child Vaccinations"],"language":["English"]},{"accessLevel":"public","landingPage":"https://ftp.ncbi.nih.gov/repository/UniGene/","bureauCode":["009:25"],"issued":"2022-03-02","@type":"dcat:Dataset","modified":"2025-06-18","keyword":["genomics","computational biology","dataset"],"contactPoint":{"@type":"vcard:Contact","fn":"National Library of Medicine","hasEmail":"mailto:custserv@nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Library of Medicine"},"identifier":"https://datadiscovery.nlm.nih.gov/api/views/ixcy-uq3c","description":"An automated analytical system for producing organized views of the transcriptome from a growing number of organisms. UniGene was retired in July 2019; however, you will continue to be able to access archived data.","title":"UniGene archived data (RETIRED)","programCode":["009:041"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://ftp.ncbi.nih.gov/repository/UniGene/","mediaType":"text/html","title":"Download UniGene (Archived Data)"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Biology"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hsx-tugq","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["synaptogenesis","neuromuscular-junction","nih","acetylcholine-receptors","agrin-laminin-interactions"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5hsx-tugq","description":"Background\n One of the earliest steps in synaptogenesis at the neuromuscular junction is the aggregation of nicotinic acetylcholine receptors at the postsynaptic membrane. This study presents quantitative analyses of receptor and α-Dystroglycan aggregation in response to agrin and laminin-1, alone or in combination.\n \n \n Results\n Both laminin and agrin increased overall expression of receptors on the plasma membrane. Following a 24 hour exposure, agrin increased the number of receptor aggregates but did not affect the number of α-Dystroglycan aggregates, while the reverse was true of laminin-1. Laminin also increased receptor concentration within aggregates, while agrin had no such effect. Finally, the spatial distribution of aggregates was indistinguishable from random in the case of laminin, while agrin induced aggregates were closer together than predicted by a random model.\n \n \n Conclusions\n Agrin and laminin-1 both increase acetylcholine receptor aggregate size after 24 hours, but several lines of evidence indicate that this is achieved via different mechanisms. Agrin and laminin had different effects on the number and density of receptor and α-Dystroglycan aggregates. Moreover the random distribution of laminin induced (as opposed to agrin induced) receptor aggregates suggests that the former may influence aggregate size by simple mass action effects due to increased receptor expression.","title":"Mechanistic distinctions between agrin and laminin-1 induced aggregation of acetylcholine receptors","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC126261/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ht4-tqst","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["hepatitis-c","ribosomal-frameshift","hcv-infection","nih","viral-protein"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5ht4-tqst","description":"Hepatitis C virus (HCV) is an important human pathogen that affects ∼100 million people worldwide. Its RNA genome codes for a polyprotein, which is cleaved by viral and cellular proteases to produce at least 10 mature viral protein products. We report here the discovery of a novel HCV protein synthesized by ribosomal frameshift. This protein, which we named the F protein, is synthesized from the initiation codon of the polyprotein sequence followed by ribosomal frameshift into the –2/+1 reading frame. This ribosomal frameshift requires only codons 8–14 of the core protein-coding sequence, and the shift junction is located at or near codon 11. An F protein analog synthesized in vitro reacted with the sera of HCV patients but not with the sera of hepatitis B patients, indicating the expression of the F protein during natural HCV infection. This unexpected finding may open new avenues for the development of anti-HCV drugs.","title":"Synthesis of a novel hepatitis C virus protein by ribosomal frameshift","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC125543/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ht9-ks47","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","innovation","pubchem","chemistry","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ht9-ks47","description":"The sealing profile (2) comprises a connector section (19) which takes the form of a protrusion or a thickening, and extends into the hollow space (12) of the profile head (4).","title":"Patent AT-E401487-T1: [Translated] SEALING PROFILE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401487-T1","description":"Access the complete Patent AT-E401487-T1: [Translated] SEALING PROFILE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hu3-v62p","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","pubchem","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5hu3-v62p","description":"Chemical compound data from PubChem database. IUPAC Name: 1,3,7-tribromodibenzofuran. Molecular Formula: C12H5Br3O. Molecular Weight: 404.88. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526282: 1,3,7-Tribromo-dibenzofuran","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526282","description":"Access the complete Compound 526282: 1,3,7-Tribromo-dibenzofuran on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hup-n9f5","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["policy","child","19","guidance","prevention"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5hup-n9f5","description":"This letter to child welfare leaders from the Children’s Bureau addresses allowing title IV-E prevention programs and services to be adapted to a virtual environment to provide needed support during the COVID-19 pandemic.\n\nBrowse All COVID-19 Resources\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Letter to Child Welfare Leaders About Title IV-E Prevention Program Flexibilities Due to Pandemic","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/letter-child-welfare-leaders-about-title-iv-e-prevention-program-flexibilities","description":"Access the complete Letter to Child Welfare Leaders About Title IV-E Prevention Program Flexibilities Due to Pandemic on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://www.dhcs.ca.gov/provgovpart/Pages/PED.aspx","issued":"2024-02-06","temporal":"As of June 29, 2026","@type":"dcat:Dataset","modified":"2026-07-08","keyword":["ffs","fee-for-service provider","medi-cal","ped","pmf","provider enrollment","provider master file"],"contactPoint":{"@type":"vcard:Contact","fn":"Provider Enrollment Division","hasEmail":"mailto:opendata@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"514c5381-f3dc-4c4a-a9de-a4df9405f046","description":"The dataset provides basic information of the FFS providers enrolled in the Medi-Cal program as of March 1, 2025. The data was retrieved from the Provider Master File (PMF), which has been used in the claims payment process and maintained by the Provider Enrollment Division (PED). The Variables in the dataset include provider number, name, type, specialty, geographic information, etc. This dataset does not include the Managed Care providers.","title":"Profile of Enrolled Medi-Cal Fee-for-Service (FFS) Providers","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/514c5381-f3dc-4c4a-a9de-a4df9405f046/resource/d652b210-ec3d-4a92-b7e0-e55c3dcbc7dc/download/medi-cal-ffs-provider-listing_7_6_26.csv","description":"The dataset provides enrollment and geographic data for Fee-for-Service (FFS) providers enrolled in the Medi-Cal. The data is based on a point in time, and it is to be updated monthly. The enrollment provider data is as of July 6, 2026. This dataset does not include Dental Fee-for-Service providers.","@type":"dcat:Distribution","title":"Enrolled Medi-Cal Fee-for-Service (FFS) Providers"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/datastore/dictionary_download/d652b210-ec3d-4a92-b7e0-e55c3dcbc7dc","description":"Data Dictionary for https://data.chhs.ca.gov/dataset/514c5381-f3dc-4c4a-a9de-a4df9405f046/resource/d652b210-ec3d-4a92-b7e0-e55c3dcbc7dc/download/medi-cal-ffs-provider-listing_7_6_26.csv","@type":"dcat:Distribution","title":"Data Dictionary - Enrolled Medi-Cal Fee-for-Service (FFS) Providers"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/514c5381-f3dc-4c4a-a9de-a4df9405f046/resource/50a74d55-c40c-4213-86f8-f7abbaa818dc/download/provider-type-code-reference_2.2026.csv","description":"Table of DHCS (Medi-Cal) Provider Type Codes and Descriptions used by the Medi-Cal Fiscal Intermediary.","@type":"dcat:Distribution","title":"FI Provider Type Code Reference"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/514c5381-f3dc-4c4a-a9de-a4df9405f046/resource/4135eb5a-5dea-4e5e-851b-33b223ee2ce6/download/provider-specialty-code-reference_2.2026.csv","description":"Table of DHCS (Medi-Cal) Provider Specialty Codes and Descriptions used by the Medi-Cal Fiscal Intermediary.","@type":"dcat:Distribution","title":"FI Provider Specialty Code Reference"},{"mediaType":"text/html","downloadURL":"https://geohub-cadhcs.hub.arcgis.com/apps/f9715ef5673c4ca99c95046d5bbf138e/explore","description":"This application allows for searching by Name or address within a number mile radius.","@type":"dcat:Distribution","title":"Medi-Cal Fee for Service Provider Finder Application"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/514c5381-f3dc-4c4a-a9de-a4df9405f046/resource/9768f9d4-62ef-49c8-a162-5986bf325948/download/profile-of-enrolled-medi-cal-fee-for-service-ffs-providers-121ww76f.zip","mediaType":"application/zip","title":"All resource data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/514c5381-f3dc-4c4a-a9de-a4df9405f046/resource/9973b7b0-6515-4f02-abe0-c7d93794da29/download/profile-of-enrolled-medi-cal-fee-for-service-ffs-providers-m8qk8kjq.zip","mediaType":"application/zip","title":"All resource data"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/514c5381-f3dc-4c4a-a9de-a4df9405f046/resource/a5c7aaa1-5fcb-4bdd-9bdf-28b6ad004c4e/download/profile-of-enrolled-medi-cal-fee-for-service-ffs-providers-7x2agpqn.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1W","theme":["Facilities and Services","Healthcare"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5hwj-u8rg","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","substance","pubchem","chemistry","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5hwj-u8rg","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865088: MLS000083668","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865088","description":"Access the complete Substance 865088: MLS000083668 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug","drug-safety","fda","health-care","pharmaceuticals"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA080966","description":"Probenecid is a prescription medication available as 500 mg oral tablets, manufactured by Actavis Pharma, Inc. It helps treat gout by increasing uric acid excretion from the body and can be used with certain antibiotics to prolong their effects. This information was generated using AI and is provided for informational and research purposes only.","title":"Probenecid","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=080966","description":"\n Access the FDA dataset for Probenecid — ANDA 080966 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Probenecid"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://hcai.ca.gov/visualizations/trends-in-the-utilization-and-mortality-for-cabg-surgery/","issued":"2023-11-13","temporal":"2009-2022","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["health equity","demographics","cabg","cabg mortality rate","cabg trends","coronary artery bypass graft surgery","ccorp","cabg utilization rate"],"contactPoint":{"@type":"vcard:Contact","fn":"Department of Health Care Access and Information, Office of Information Services, Healthcare Analytics Branch","hasEmail":"mailto:dataandreports@hcai.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"eb4cece5-05ea-42d6-a5e0-e7a4f1410ac5","description":"CABG surgery, a major interventional procedure to treat coronary artery diseases, is the most common type of open-heart surgery and the costliest procedure in California. It is known that there are large disparities in the use of CABG procedures and outcomes by assigned sex at birth and by race/ethnicity. Understanding changes in CABG utilization and outcome by assigned sex at birth and race/ethnicity over time is important in the evaluation of hospital resources, regional health policy, quality improvement, and the promotion of health equity.","title":"Trends in the Utilization and Mortality for Coronary Artery Bypass Graft Surgery in California Hospitals","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/eb4cece5-05ea-42d6-a5e0-e7a4f1410ac5/resource/dd2b0323-606c-44dd-8cf4-4c10808c2c36/download/trends-in-the-utilization-and-mortality-for-coronary-artery-bypass-graft-surgery-2009-2022.csv","mediaType":"text/csv","title":"Trends in the Utilization and Mortality for Coronary Artery Bypass Graft Surgery 2009-2021"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/eb4cece5-05ea-42d6-a5e0-e7a4f1410ac5/resource/5fec180d-f98d-4f1e-8655-91a97eda8006/download/data-dictionary.pdf","mediaType":"application/pdf","title":"Data Dictionary"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/eb4cece5-05ea-42d6-a5e0-e7a4f1410ac5/resource/832f42ae-25f7-4b3a-a9cb-8390f4a1df1a/download/trends-in-the-utilization-and-mortality-for-coronary-artery-bypass-graft-surgery-ilyp9v1i.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Diseases and Conditions","Healthcare"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5i7k-48ku","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["instruction","guidance","child","policy","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5i7k-48ku","description":"This checklist was developed to ensure that APSR submissions include all required elements. States can use this checklist as a guide in writing their 2019 APSR and CAPTA update.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"State Checklist for the Child and Family Service Plan (CFSP)/Annual Progress and Services Report (APSR)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/state-checklist-child-and-family-service-plan-cfsp/annual-progress-and-services","description":"Access the complete State Checklist for the Child and Family Service Plan (CFSP)/Annual Progress and Services Report (APSR) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5i7s-zyqn","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","substance","bioactivity","chemistry","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5i7s-zyqn","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865426: MLS000084133","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865426","description":"Access the complete Substance 865426: MLS000084133 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5iet-9azt","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["urs-data","national-outcome-measures","virginia-mental-health","mental-health-services","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5iet-9azt","description":"This is the 2023 Uniform Reporting System (URS) Output Tables for Virginia. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"Publications Using SAMHSA Data2023 Uniform Reporting System (URS) Table For Virginia","programCode":["009:069"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2023-uniform-reporting-system-urs-table-virginia","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5if8-wczb","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-ohio","alcohol-abuse","nsduh-data","substance-use-disorder","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5if8-wczb","description":"This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for Ohio overall and for substate regions within Ohio. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).","title":"Ohio (OH)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/ohio-oh-1","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ije-fn7d","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["teds","alcohol-drug-treatment","samhsa","treatment-outcomes","substance-abuse-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5ije-fn7d","description":"This report presents results from the Treatment Episode Data Set (TEDS) for clients discharged from substance abuse treatment in 2002. The report provides information on treatment completion, length of stay in treatment, and demographic and substance abuse characteristics of the approximately 800,000 people discharged from alcohol or drug treatment in facilities that report to individual state administrative data systems.","title":"Treatment Episode Data Set (TEDS) 2002 Discharges from Substance Abuse Treatment Services","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2002-teds-discharges","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/visionhealth/vehss/index.html","bureauCode":["009:20"],"issued":"2025-05-15","@type":"dcat:Dataset","modified":"2025-08-07","references":["https://www.resdac.org","https://www.cdc.gov/visionhealth/vehss/data/claims/medicare.html"],"keyword":["medical diagnoses","medicare","service utilization","treated prevalence","claims","eye exams"],"contactPoint":{"@type":"vcard:Contact","fn":"DDT Public Inquiries","hasEmail":"mailto:ddtpubsmailbox@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/e28h-tx85","description":"2014-2019. This dataset is a de-identified summary table of vision and eye health data indicators from Medicare claims, stratified by all available combinations of age group, race/ethnicity, gender, and state. Medicare claims for VEHSS includes beneficiaries who were fully enrolled in Medicare Part B Fee-for-Service (FFS) for the duration of the year. Medicare claims provide a convenience sample that includes approximately 30 million individuals annually, which represents nearly 89% of the US population aged 65 and older and 3.3% of the US population younger than 65, including persons disabled due to blindness. Medicare data for VEHSS include Service Utilization and Medical Diagnoses indicators. Data were suppressed for de-identification to ensure protection of patient privacy. Data will be updated as it becomes available. Detailed information on VEHSS Medicare analyses can be found on the VEHSS Medicare webpage (cdc.gov/visionhealth/vehss/data/claims/medicare.html). Information on available Medicare claims data can be found on the ResDac website (www.resdac.org). The VEHSS Medicare dataset was last updated May 2023.","title":"Medicare Fee for Service (FFS) claims (100%) – Vision and Eye Health Surveillance","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/e28h-tx85/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/e28h-tx85/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/e28h-tx85/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/e28h-tx85/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/e28h-tx85/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/e28h-tx85/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"describedBy":"https://chronicdata.cdc.gov/d/e28h-tx85","license":"http://opendatacommons.org/licenses/by/1.0/","theme":["Vision & Eye Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ijz-ucd7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ijz-ucd7","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864222: MLS000083293","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864222","description":"Access the complete Substance 864222: MLS000083293 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ikm-rjy6","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["youth-mental-health","new-mexico","samhsa","substance-use","behavioral-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5ikm-rjy6","description":"This is a behavioral health report for the state of New Mexico. The report utilizes data from the National Survey on Drug Use and Health (NSDUH), and the Uniform Reporting System. The topics addressed in the report include youth substance use, youth mental health and treatment, mental health and treatment, substance use and substance use treatment.","title":"Behavioral Health Barometer: New Mexico, 2015","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-new-mexico-2015","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ime-6e3v","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["medical-journals","negative-results","statistical-power","research-validity","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5ime-6e3v","description":"Background\n Physicians reading the medical literature attempt to determine whether research studies are valid. However, articles with negative results may not provide sufficient information to allow physicians to properly assess validity.\n \n \n Methods\n We analyzed all original research articles with negative results published in 1997 in the weekly journals BMJ, JAMA, Lancet, and New England Journal of Medicine as well as those published in the 1997 and 1998 issues of the bimonthly Annals of Internal Medicine (N = 234). Our primary objective was to quantify the proportion of studies with negative results that comment on power and present confidence intervals. Secondary outcomes were to quantify the proportion of these studies with a specified effect size and a defined primary outcome. Stratified analyses by study design were also performed.\n \n \n Results\n Only 30% of the articles with negative results comment on power. The reporting of power (range: 15%-52%) and confidence intervals (range: 55–81%) varied significantly among journals. Observational studies of etiology/risk factors addressed power less frequently (15%, 95% CI, 8–21%) than did clinical trials (56%, 95% CI, 46–67%, p < 0.001). While 87% of articles with power calculations specified an effect size the authors sought to detect, a minority gave a rationale for the effect size. Only half of the studies with negative results clearly defined a primary outcome.\n \n \n Conclusion\n Prominent medical journals often provide insufficient information to assess the validity of studies with negative results.","title":"Prominent medical journals often provide insufficient information to assess the validity of studies with negative results","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC131026/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ish-6bdi","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","science","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ish-6bdi","description":"Chemical compound data from PubChem database. IUPAC Name: 2,2-dichloroethyl 2-chlorobenzoate. Molecular Formula: C9H7Cl3O2. Molecular Weight: 253.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527802: Benzoic acid, 2-chloro, 2,2-dichloroethyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527802","description":"Access the complete Compound 527802: Benzoic acid, 2-chloro, 2,2-dichloroethyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5it9-94m4","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","chemistry","references","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5it9-94m4","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865782: MLS000084604","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865782","description":"Access the complete Substance 865782: MLS000084604 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/d69q-iyrb","bureauCode":["009:00"],"issued":"2016-01-07","@type":"dcat:Dataset","modified":"2016-01-07","keyword":["mmwr","netss","nndss","pertussis","rabies animal","nedss","wonder","mumps","2015"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/d69q-iyrb","description":"NNDSS - Table II. Mumps to Rabies, animal - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed.The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly.","title":"NNDSS - Table II. Mumps to Rabies, animal","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/d69q-iyrb/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/d69q-iyrb/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/d69q-iyrb/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ive-nkcy","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["adoption","data","fiscal","policy","year"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5ive-nkcy","description":"This report provides state-specific data from fiscal year 2001 about children's ages at the time of a public agency adoption finalization.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Child's Finalization Age (Grouped) 10/1/2000 - 9/30/2001","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/childs-finalization-age-grouped-10/1/2000-9/30/2001","description":"Access the complete Child's Finalization Age (Grouped) 10/1/2000 - 9/30/2001 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5iyi-62fq","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5iyi-62fq","description":"Chemical compound data from PubChem database. IUPAC Name: (2-chlorophenyl) 3-bromobenzoate. Molecular Formula: C13H8BrClO2. Molecular Weight: 311.56. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530790: 3-Bromobenzoic acid, 2-chlorophenyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530790","description":"Access the complete Compound 530790: 3-Bromobenzoic acid, 2-chlorophenyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5iyj-gi2d","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh","substance-abuse","alcohol-use","binge-drinking","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5iyj-gi2d","description":"This report presents State estimates for measures of past month binge alcohol use based on the combined 2010 and 2011 National Surveys on Drug Use and Health (NSDUHs). Resuts are provided by age group.","title":"Publications Using SAMHSA DataTable 10. Binge Alcohol Use in the Past Month, by Age Group and State: Percentages, Annual Averages Based on 2010 and 2011 NSDUHs","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/table-10-binge-alcohol-use-past-month-age-group-and-state-percentages-annual-averages-based","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/ekig-i57g","issued":"2023-06-09","@type":"dcat:Dataset","modified":"2025-03-07","keyword":["cabg","cardiac","cardiac surgery","community health and chronic disease","consumer resources","coronary","coronary artery bypass graft","pci","quality-safety-costs","revascularization","valve"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/ekig-i57g","description":"This dataset contains the number of cases, number of in hospital/30 day deaths, observed, expected and risk- adjusted mortality rates for Percutaneous Coronary Interventions (PCI) by cardiologist. Physician information is presented for each physician who a) performed 200 or more procedures during the three year analysis and/or b) performed at least one PCI in each of the three years. The results for physicians not meeting the above criteria are grouped together and reported as “All others” in the hospital in which the procedures are performed. Regions represent where the hospitals are located. The initial Health Data NY dataset includes patients discharged between January 1, 2008, and December 31, 2010. Analyses of risk-adjusted mortality rates and associated risk factors are provided for the three-year period from 2008 through 2010. Analyses of all cases and non-emergency cases (which represent the majority of procedures) are included. Subsequent year reports data will be appended to this dataset.","title":"Percutaneous Coronary Interventions by Cardiologist: Beginning 2008","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/ekig-i57g/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/ekig-i57g/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/ekig-i57g/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5j5a-xmnb","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-abuse-treatment","samhsa","treatment-facilities","n-ssats","texas"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5j5a-xmnb","description":"This is a National Survey of Substance Abuse Treatment Services (N-SSATS) data table showing state profiles for Texas in 2011. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.","title":"2011 State Profile — Texas","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2011-state-profile-texas","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5j7g-p7m3","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["population-genetics","human-migration","mitochondrial-dna","nih","phylogeography"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5j7g-p7m3","description":"Background\n The phylogeographic distribution of human mitochondrial DNA variations allows a genetic approach to the study of modern Homo sapiens dispersals throughout the world from a female perspective. As a new contribution to this study we have phylogenetically analysed complete mitochondrial DNA(mtDNA) sequences from 42 human lineages, representing major clades with known geographic assignation.\n \n \n Results\n We show the relative relationships among the 42 lineages and present more accurate temporal calibrations than have been previously possible to give new perspectives as how modern humans spread in the Old World.\n \n \n Conclusions\n The first detectable expansion occurred around 59,000–69,000 years ago from Africa, independently colonizing western Asia and India and, following this southern route, swiftly reaching east Asia. Within Africa, this expansion did not replace but mixed with older lineages detectable today only in Africa. Around 39,000–52,000 years ago, the western Asian branch spread radially, bringing Caucasians to North Africa and Europe, also reaching India, and expanding to north and east Asia. More recent migrations have entangled but not completely erased these primitive footprints of modern human expansions.","title":"Major genomic mitochondrial lineages delineate early human expansions","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC55343/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5j8a-naxc","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","oklahoma","outcome-measures","samhsa","urs-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5j8a-naxc","description":"2014 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Oklahoma. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2014 CMHS Uniform Reporting System (URS) Table for Oklahoma","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2014-cmhs-uniform-reporting-system-urs-table-oklahoma","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5jac-7a9e","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["evidence-based-medicine","medical-education","nih","resident-training","journal-club"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5jac-7a9e","description":"Background\n Journal Club at a University-based residency program was restructured to introduce, reinforce and evaluate residents understanding of the concepts of Evidence Based Medicine.\n \n \n Methods\n Over the course of a year structured pre and post-tests were developed for use during each Journal Club. Questions were derived from the articles being reviewed. Performance with the key concepts of Evidence Based Medicine was assessed. Study subjects were 35 PGY2 and PGY3 residents in a University based Family Practice Program.\n \n \n Results\n Performance on the pre-test demonstrated a significant improvement from a median of 54.5 % to 78.9 % over the course of the year (F 89.17, p < .001). The post-test results also exhibited a significant increase from 63.6 % to 81.6% (F 85.84, p < .001).\n \n \n Conclusions\n Following organizational revision, the introduction of a pre-test/post-test instrument supported achievement of the learning objectives with a better understanding and utilization of the concepts of Evidence Based Medicine.","title":"Introducing evidence based medicine to the journal club, using a structured pre and post test: a cohort study","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59846/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["fda","pharmaceuticals","public-health","drug","drug-safety"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA208745","description":"Trulance Immediate Release is a prescription oral tablet containing plecanatide 3mg, manufactured by Salix Pharmaceuticals Inc. It acts as a guanylate cyclase-C agonist to help with bowel movements in adults with chronic idiopathic constipation. This information was generated using AI and is provided for informational and research purposes only.","title":"Plecanatide","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208745","description":"\n Access the FDA dataset for Plecanatide — ANDA 208745 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Plecanatide"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5jjf-xdm7","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-indicators","ny-behavioral-health","samhsa","substance-use-disorder","nsduh-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5jjf-xdm7","description":"This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for New York overall and for substate regions within New York. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).","title":"New York (NY)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/new-york-ny-1","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5jqx-ymht","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","pubchem","chemistry","compound","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5jqx-ymht","description":"Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 5-oxo-4-trimethylsilyloxyoxolane-3-carboxylate. Molecular Formula: C11H22O5Si2. Molecular Weight: 290.46. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528670: Pyrotartaric acid, Di-TMS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528670","description":"Access the complete Compound 528670: Pyrotartaric acid, Di-TMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/j9id-xrm6","bureauCode":["009:00"],"issued":"2016-01-07","@type":"dcat:Dataset","modified":"2016-01-07","keyword":["nndss","anaplasma phagocytophilum","ehrlichia chaffeensis","ehrlichiosis/anaplasmosis","undetermined","2015","wonder","netss","nedss","mmwr"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/j9id-xrm6","description":"NNDSS - Table II. Ehrlichiosis/Anaplasmosis - 2015.In this Table, provisional cases of selected notifiable diseases (≥1,000 cases reported during the preceding year), and selected low frequency diseases are displayed. The Table includes total number of cases reported in the United States, by region and by states, in accordance with the current method of displaying MMWR data. Data on United States exclude counts from US territories. Note:These are provisional cases of selected national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables printed in the back of the Morbidity and Mortality Weekly Report (MMWR). Cases reported by state health departments to CDC for weekly publication are provisional because of ongoing revision of information and delayed reporting. Case counts in this table are presented as they were published in the MMWR issues. Therefore, numbers listed in later MMWR weeks may reflect changes made to these counts as additional information becomes available. Footnotes:C.N.M.I.: Commonwealth of Northern Mariana Islands. U: Unavailable. -: No reported cases. N: Not reportable. NN: Not Nationally Notifiable. NP: Nationally notifiable but not published. Cum: Cumulative year-to-date counts. Med: Median. Max: Maximum. * Three low incidence conditions, rubella, rubella congenital, and tetanus, have been moved to Table 2 to facilitate case count verification with reporting jurisdictions. ��� Case counts for reporting year 2015 are provisional and subject to change. For further information on interpretation of these data, see http://wwwn.cdc.gov/nndss/document/ ProvisionalNationaNotifiableDiseasesSurveillanceData20100927.pdf. Data for TB are displayed in Table IV, which appears quarterly. �� Cumulative total E. ewingii cases reported for year 2015 = 0, and 14 cases reported for 2014.","title":"NNDSS - Table II. Ehrlichiosis/Anaplasmosis","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/j9id-xrm6/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/j9id-xrm6/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/j9id-xrm6/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5jte-8iu8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","pubchem","patent","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5jte-8iu8","description":"The device has a flange (3) and an elongated body (2) comprising a longitudinal slit (4) with an upper part and a lower part (7). The upper part permits the introduction of a suture thread or a ligament and the part (7) permits the sliding of the thread or the ligament. The flange has a height smaller than dimension of its support surface. The body has a cylindrical part elongated by a conical part (10) comprising a rounded end (11).","title":"Patent AT-E401840-T1: [Translated] ATTACHMENT DEVICE FOR A BAND ON A BONE STRUCTURE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401840-T1","description":"Access the complete Patent AT-E401840-T1: [Translated] ATTACHMENT DEVICE FOR A BAND ON A BONE STRUCTURE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/t537-5ffp","issued":"2019-06-14","@type":"dcat:Dataset","modified":"2019-12-04","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/t537-5ffp","description":"Lead in Drinking Water in Schools Test Results – Campbell Hill Elementary School","title":"Campbell Hill Elementary School","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/t537-5ffp/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5jvc-gj5m","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5jvc-gj5m","description":"Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3-(3-methoxy-4-trimethylsilyloxyphenyl)propanoate. Molecular Formula: C16H28O4Si2. Molecular Weight: 340.56. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528674: 3-Methoxy-4-(trimethylsilyloxyl)trimethylsilyl ester of Benzenepropanoic acid","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528674","description":"Access the complete Compound 528674: 3-Methoxy-4-(trimethylsilyloxyl)trimethylsilyl ester of Benzenepropanoic acid on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5jvz-s7mr","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","pubchem","compound","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5jvz-s7mr","description":"Chemical compound data from PubChem database. IUPAC Name: 1-aminopropan-2-ol. Molecular Formula: C3H9NO. Molecular Weight: 75.11. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 4: 1-Amino-2-propanol","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/4","description":"Access the complete Compound 4: 1-Amino-2-propanol on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.sfgov.org/d/ubjr-y9qw","issued":"2020-07-01","@type":"dcat:Dataset","modified":"2025-08-25","keyword":["encampment","homeless","homeless count","homelessness","safe sleeping","tenderloin","tenderloin-soma","tent","tent count"],"contactPoint":{"@type":"vcard:Contact","fn":"OpenData","hasEmail":"mailto:no-reply@data.sfgov.org"},"publisher":{"@type":"org:Organization","name":"City of San Francisco"},"identifier":"https://data.sfgov.org/api/views/ubjr-y9qw","description":"Note: This dataset was updated daily from June 2020 until June 2021 as part of San Francisco's COVID-19 Emergency Response. It remains available to the public as a historical reference.\n\nA. SUMMARY\nThis dataset is meant to serve as an official record of the Healthy Streets Operations Center's (HSOC) daily tent counts within the Tenderloin neighborhood. These counts track the City's progress towards fulfilling its commitment to reduce tents in the Tenderloin by 70% of the number observed during a tent count conducted on June 5th. HSOC began operations to move unsheltered individuals into Shelter-in-Place (SIP) hotel rooms on June 10th.\n\nB. HOW THE DATASET IS CREATED\nUrban Alchemy, a community organization under contract with the Department of Public Works, takes a daily census of tents within the Tenderloin neighborhood. This data is then validated and processed by City staff and presented here. \n\nC. UPDATE PROCESS\nUpdated daily.\n\nD. HOW TO USE THIS DATASET\nThis dataset can be used to monitor the number of tents in the Tenderloin and track progress of efforts to ensure that all residents have a safer place to sleep (like safe sleeping villages, hotels, and other shelters).\n\nSee more data on the Tenderloin COVID Response Plan here: https://data.sfgov.org/stories/s/Tenderloin-Plan-Data-and-Reporting/sc96-u6ry/","title":"ARCHIVED: Tenderloin Tent Count","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/ubjr-y9qw/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/ubjr-y9qw/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.sfgov.org/api/v3/views/ubjr-y9qw/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendatacommons.org/licenses/pddl/1.0/","theme":["Health and Social Services"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nchs/hus","bureauCode":["009:20"],"issued":"2025-02-12","temporal":"1980/2023","@type":"dcat:Dataset","modified":"2026-01-13","keyword":["american hospital association","community hospital beds","health us","hospital","sdoh-access-to-health-care","state"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:healthus@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/8miz-siyd","description":"Data on community hospital beds in the United States, by state. Data are from Health, United States. SOURCE: American Hospital Association (AHA) Annual Survey of Hospitals, Hospital Statistics.\nSearch, visualize, and download these and other estimates from over 120 health topics with the NCHS Data Query System (DQS), available from: https://www.cdc.gov/nchs/dataquery/index.htm.","title":"DEV DQS Community hospital beds, by state: United States","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/8miz-siyd/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/8miz-siyd/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/8miz-siyd/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"https://www.usa.gov/government-works","accrualPeriodicity":"Annual (R/P1Y)","theme":["National Center for Health Statistics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5k3s-gmh3","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","science","compound","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5k3s-gmh3","description":"Chemical compound data from PubChem database. IUPAC Name: 4-pent-2-enyl-2-propyl-1,3-dioxane. Molecular Formula: C12H22O2. Molecular Weight: 198.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527004: 4-Pent-2-enyl-2-propyl-1,3-dioxane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527004","description":"Access the complete Compound 527004: 4-Pent-2-enyl-2-propyl-1,3-dioxane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5k42-ym3z","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","research","compound","science","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5k42-ym3z","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(prop-2-enyldisulfanyl)prop-1-ene. Molecular Formula: C6H10S2. Molecular Weight: 146.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529761: 1-(Prop-2-enyldisulfanyl)prop-1-ene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529761","description":"Access the complete Compound 529761: 1-(Prop-2-enyldisulfanyl)prop-1-ene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5k56-q6b7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","chemistry","pubchem","patent","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5k56-q6b7","description":"The system foresees for each plate (1) an autonomous mechanical structure composed of one section bar (3) connected to a gripper that holds a plate (1) as well as of another section bar (10) and at least two support arms (5, 5′, 6, 6′) hinged upon said section bars (3, 10); the structure is fixed to a section bar (9) that is in turn fixed to the display counter or window near the base of the tank; the support arms (5, 5′, 6, 6′) differ in length; two supports (4, 4′, 11, 11′) are fixed to each section bar (3, 10); said supports constitute the hinge members upon which the ends of the support arms (5, 5′, 6, 6′) fit; each plate (1) can both move in a parallelogram motion with translation parallel to the display counter or window, and open like a casement window using the pin (7) of the shorter support arm (5, 5′) as a pivot; the system also contains a spring closing mechanism and a lock (18).","title":"Patent AT-E401024-T1: [Translated] DOUBLE MOTION OPENING SYSTEM FOR PERFORMANCE UNITS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401024-T1","description":"Access the complete Patent AT-E401024-T1: [Translated] DOUBLE MOTION OPENING SYSTEM FOR PERFORMANCE UNITS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5k6b-ug9z","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["welfare","policy","regulation","child","social"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5k6b-ug9z","description":"This Information Memorandum (IM) expands aid to Families with Dependent Children Expansion of the Definition of Specified Caretaker Relative as it Relates to Title IV-E Eligibility.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-92-04)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-92-04","description":"Access the complete IM-92-04 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5k8m-dhut","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","bioactivity","chemistry","pubchem","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5k8m-dhut","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864429: MLS000042203","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864429","description":"Access the complete Substance 864429: MLS000042203 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5k9e-6dyt","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["metadata","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5k9e-6dyt","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Indiana Interoperability Final Report","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/14185","description":"Access the complete Indiana Interoperability Final Report on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5k9u-yhrv","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["metadata","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5k9u-yhrv","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"PDF of Data from Table Charts of Head Start Volunteers","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/2360","description":"Access the complete PDF of Data from Table Charts of Head Start Volunteers on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5kai-3g52","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["child","adoption","policy","fiscal","data"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5kai-3g52","description":"This report provides state-specific data from fiscal year 2005 about the number of children who are adopted through a public agency and who receive an adoption subsidy.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Receiving State or Federal Subsidy: 10/1/2004 - 9/30/2005","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/receiving-state-or-federal-subsidy-10/1/2004-9/30/2005","description":"Access the complete Receiving State or Federal Subsidy: 10/1/2004 - 9/30/2005 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5kbs-qex3","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["instruction","data","guidance","policy","mental"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5kbs-qex3","description":"This document provides supplemental information for the Child and Family Services Reviews Stakeholder Interview Guide, including alternative language and phrases that may simplify assessment questions as well as descriptions of child welfare requirements.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"CFSR Stakeholder Interview Guide Supplemental","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/cfsr-stakeholder-interview-guide-supplemental","description":"Access the complete CFSR Stakeholder Interview Guide Supplemental on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5kdx-vxfa","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","compound","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5kdx-vxfa","description":"Chemical compound data from PubChem database. IUPAC Name: N'-(4-bromophenyl)-N-phenylmethanimidamide. Molecular Formula: C13H11BrN2. Molecular Weight: 275.14. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525818: N-Phenyl-N'-4-bromophenylformamidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525818","description":"Access the complete Compound 525818: N-Phenyl-N'-4-bromophenylformamidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5kgb-r4ke","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2026-04-30","keyword":["medicaid"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"69374797-d755-4903-bbe2-b84408501feb","description":"The Managed Care Program Annual Reports (MCPARs) provide data across key topics for each Medicaid managed care program. States are required to submit reports annually, aligning with state contract cycles (see 42 CFR 438.66(e)(1)).\nMCPAR PUF Read me 2023","title":"MMCC MCPAR PUF Data 2023","programCode":["009:076"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://download.medicaid.gov/data/mmcc-mcpar-puf-2023.csv","mediaType":"text/csv","title":"MMCC MCPAR PUF"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/uxwq-vny5","bureauCode":["009:20"],"issued":"2021-06-23","@type":"dcat:Dataset","modified":"2026-04-22","keyword":["abcs","bactfacts"],"contactPoint":{"@type":"vcard:Contact","fn":"Active Bacterial Core surveillance","hasEmail":"mailto:abcs@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/uxwq-vny5","description":"ABCs is an ongoing surveillance program that began in 1997. ABCs reports describe the ABCs case definition and the specific methodology used to calculate rates and estimated numbers in the United States for each bacterium by year. The methods, surveillance areas, and laboratory isolate collection areas have changed over time.\n Additionally, the way missing data are taken into account changed in 2010. It went from distributing unknown values based on known values of cases by site to use of multiple imputation using a sequential regression imputation method.\n Given these changes over time, trends should be interpreted with caution.\n\nThe State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.\n
\n\nIt is a weekly snapshot in time that:\nBioGRID is an online interaction repository with data on raw protein and genetic interactions from major model organism species. All interaction data are freely provided through our search index and available via download in a wide variety of standardized formats.
","title":"Biological General Repository for Interaction Datasets (BioGRID)","programCode":["009:046"],"dataQuality":true,"license":"https://opendatacommons.org/licenses/odbl/1.0/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5qt8-upeu","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["care","child","kinship","fiscal","instruction"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5qt8-upeu","description":"This Program Instruction (PI) provides guidance to state, territorial and Tribal title IV-E agencies on the actions required to apply for title IV-B, subpart 2 funding to support the development, enhancement or evaluation of kinship navigator programs. These are federal fiscal year (FY) 2024 funds, provided in the Further Consolidated Appropriations Act, 2024.\n\nFor the best usability of Attachment B, please download the file and save it to your computer.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Federal Fiscal Year 2024 Title IV-B, Subpart 2 Funding Available to Develop and Enhance or to Evaluate Kinship Navigator Programs","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-24-08","description":"Access the complete Federal Fiscal Year 2024 Title IV-B, Subpart 2 Funding Available to Develop and Enhance or to Evaluate Kinship Navigator Programs on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5qtm-pfwp","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","chemistry","science","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5qtm-pfwp","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 2-(5,6-dimethoxynaphthalen-2-yl)propanoate. Molecular Formula: C16H18O4. Molecular Weight: 274.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527326: Methyl 2-(5,6-dimethoxynaphthalen-2-yl)propanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527326","description":"Access the complete Compound 527326: Methyl 2-(5,6-dimethoxynaphthalen-2-yl)propanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5qww-ir4a","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["pubchem","research","compound","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5qww-ir4a","description":"Chemical compound data from PubChem database. IUPAC Name: 1,1-bis(methylsulfanyl)propane. Molecular Formula: C5H12S2. Molecular Weight: 136.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525445: 3-Ethyl-2,4-dithiapentane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525445","description":"Access the complete Compound 525445: 3-Ethyl-2,4-dithiapentane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/87gk-g3zt","issued":"2017-11-10","@type":"dcat:Dataset","modified":"2025-01-14","keyword":["power plants","radiation","nuclear","environmental monitoring","environmental health"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/87gk-g3zt","description":"This dataset measures the air, water, milk, fish, sediment, and fruit/veg near Ginna Station and other locations(background) around NYS to determine the normal levels of radioactivity and monitors the influence of human activities on these levels. The site numbers represent the location from which samples are collected. This dataset is not designed, or intended to monitor releases from discharge points at a specific facility (e.g., a stack). The facility operator performs this type of monitoring to meet the requirements of its licensing agency (e.g., a federal agency or the New York State Department of Environmental Conservation). A column has been added for values which can be graphed. Readings where a less than value is displayed show a value that is less than the detection limit of the measurement method and are essentially equivalent to 0. Variations in detection limit are due to variations in sample collection and measurement instrument performance.","title":"Environmental Radiation Surveillance Ginna Station Readings: Beginning 2009","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/87gk-g3zt/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/87gk-g3zt/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/87gk-g3zt/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5r3b-sfsm","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","pubchem","research","science","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5r3b-sfsm","description":"Chemical compound data from PubChem database. IUPAC Name: (2-methylphenyl) 3-bromobenzoate. Molecular Formula: C14H11BrO2. Molecular Weight: 291.14. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530789: 3-Bromobenzoic acid, 2-methylphenyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530789","description":"Access the complete Compound 530789: 3-Bromobenzoic acid, 2-methylphenyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5r76-fbbd","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","innovation","patent","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5r76-fbbd","description":"The present invention relates to compositions and methods for expressing mini-dystrophin peptides. In particular, the present invention provides compositions comprising nucleic acid sequences that are shorter than wild-type dystrophin cDNA and that express mini-dystrophin peptides that function in a similar manner as wild-type dystrophin proteins. The present invention also provides compositions comprising mini-dystrophin peptides, and methods for expressing mini-dystrophin peptides in target cells.","title":"Patent AT-E400656-T1: [Translated] MINI-DYSTROPHIN NUCLEIC ACID AND PEPTIDE SEQUENCES","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400656-T1","description":"Access the complete Patent AT-E400656-T1: [Translated] MINI-DYSTROPHIN NUCLEIC ACID AND PEPTIDE SEQUENCES on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/vaccines/imz-managers/coverage/rsvvaxview/adults-60-coverage-intent.html","bureauCode":["009:20"],"issued":"2023-12-08","@type":"dcat:Dataset","temporal":"2023-2024","modified":"2024-08-28","keyword":["older adults","rsv","vaccination","nis-acm"],"contactPoint":{"@type":"vcard:Contact","fn":"VaxView Team","hasEmail":"mailto:VaxView@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/qve4-fp9c","description":"Weekly RSV Vaccination Coverage of Adults 60 Years and Older by Jurisdiction \n\n• RSV vaccination coverage among adults 60 years and older is assessed through the National Immunization Survey-Adult COVID Module providing weekly RSV vaccination coverage estimates. (https://www.cdc.gov/vaccines/imz-managers/nis/about.html) \n\n• The CDC recommended the RSV vaccine for adults 60 years and older in July 2023. (https://www.cdc.gov/respiratory-viruses/whats-new/rsv-update-2023-09-22.html)","title":"Weekly Cumulative Percentage of Adults 60 Years and Older Vaccinated with Respiratory Syncytial Virus (RSV) Vaccine by Jurisdiction","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/qve4-fp9c/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/qve4-fp9c/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/qve4-fp9c/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"United States- National, Region, State","license":"https://www.usa.gov/government-works","accrualPeriodicity":"Weekly","theme":["Vaccinations"],"language":["English"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5reu-b46b","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","innovation","patent","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5reu-b46b","description":"Disclosed is a method for the catalytic hydrogenation of methylol alkanals of general formula (I), where R1 and R2 independently represent an additional methylol group or an alkyl group having with 1 to 22 carbon atoms, or an alkyl group with 1 to 22 C atoms, or an aryl group or aralkyl group with 6 to 33 carbon atoms, in the liquid phase on a hydrogenation catalyst. The inventive method is characterized in that a pH value ranging between 6.3 and 7.8 is adjusted in the hydrogenation feed by adding at least one tertiary amine","title":"Patent AT-E399749-T1: [Translated] METHOD FOR HYDROGENATION OF METHYLOLALAL CHANNELS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399749-T1","description":"Access the complete Patent AT-E399749-T1: [Translated] METHOD FOR HYDROGENATION OF METHYLOLALAL CHANNELS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5rfp-uzef","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["abuse","prevention","policy","instruction","guidance"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5rfp-uzef","description":"This Program Instruction (PI) provides instruction on the amendment to ACYF-PI-CB-98-01, Dated January 7, 1998 with Respect to the Functions Each Citizen Review Panel Established Under the Child Abuse Prevention and Treatment Act Must Perform.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-99-09)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-99-09","description":"Access the complete PI-99-09 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["drug-information","public-health","medications","fda","drug-safety"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA078858","description":"Elepsia XR is an extended-release tablet containing levetiracetam, an anticonvulsant medication used to treat seizures in epilepsy. Available in 1000 mg and 1500 mg strengths, it's taken orally and was manufactured by TriPoint Therapeutics, LLC. Note: This product is discontinued. This information was generated using AI and is provided for informational and research purposes only.","title":"Levetiracetam","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=078858","description":"\n Access the FDA dataset for Levetiracetam — ANDA 078858 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Levetiracetam"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","bureauCode":["009:00"],"landingPage":"https://healthdata.gov/d/5rjv-7e93","issued":"2016-04-15","@type":"dcat:Dataset","modified":"2016-04-15","keyword":["health datapalooza","policy","researchers","blog","entrepreneurs","health data"],"contactPoint":{"@type":"vcard:Contact","fn":"HHS Office of the Chief Data Officer","hasEmail":"mailto:healthdata@hhs.gov"},"publisher":{"@type":"org:Organization","name":"Lisa Simpson"},"identifier":"https://healthdata.gov/api/views/5rjv-7e93","description":"This blog post was posted by Lisa Simpson on April 15, 2016.","title":"Blog | Something Big is Happening at Health Datapalooza","programCode":["009:110"],"theme":["Blog"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5rjz-4cmq","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","patent","chemistry","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5rjz-4cmq","description":"A method of making a ceramic ornament having short undercuts on a surface. A primary clay body, is molded into a primary resin body by a silicone mold assembly. The primary resin body is then used to make upper and lower silicone mold assemblies. After slip is poured into the silicone mold assemblies, the plaster molding members will absorb moisture in the slip. Two clay body portions having a predetermined thickness are formed into shape. After removing the molding members, and coating the connection line of the clay body portions with slip, the two silicone mold assemblies are combined. The two silicone mold assemblies will be formed into a complete figurative body upon the slip being dried. The figurative body is then fired at a high temperature so as to obtain a ceramic ornament having short undercuts and decorative threads on a surface.","title":"Patent AT-E399623-T1: [Translated] METHOD FOR PRODUCING POTTERY ORNAMENTS TIGHTLY COVERED WITH SMALL CORNERS AND EDGES","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E399623-T1","description":"Access the complete Patent AT-E399623-T1: [Translated] METHOD FOR PRODUCING POTTERY ORNAMENTS TIGHTLY COVERED WITH SMALL CORNERS AND EDGES on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5rrj-dd77","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","pubchem","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5rrj-dd77","description":"Chemical compound data from PubChem database. IUPAC Name: 3,7-dimethyl-6,7-dihydro-5H-cyclopenta[b]pyrazine. Molecular Formula: C9H12N2. Molecular Weight: 148.2. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530404: 2,5-Dimethyl-6,7-dihydro-5H-cyclopentapyrazine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530404","description":"Access the complete Compound 530404: 2,5-Dimethyl-6,7-dihydro-5H-cyclopentapyrazine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5rs7-8id5","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","pubchem","research","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5rs7-8id5","description":"Chemical compound data from PubChem database. IUPAC Name: ethoxy-ethyl-dipropoxysilane. Molecular Formula: C10H24O3Si. Molecular Weight: 220.38. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525754: Dipropyloxyethoxyethylsilane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525754","description":"Access the complete Compound 525754: Dipropyloxyethoxyethylsilane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5rud-38sk","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","pubchem","compound","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5rud-38sk","description":"Chemical compound data from PubChem database. IUPAC Name: 2,5,6-trimethyl-7-phenyl-7H-pyrazolo[1,5-d][1,2,4]triazin-4-one. Molecular Formula: C14H16N4O. Molecular Weight: 256.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525325: Pyrazolo[1,5-d][1,2,4]triazin-3-one, 2,5,6-trimethyl-7-phenyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525325","description":"Access the complete Compound 525325: Pyrazolo[1,5-d][1,2,4]triazin-3-one, 2,5,6-trimethyl-7-phenyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5rwb-77bj","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["teds-data","american-indian-alaska-native","substance-abuse-treatment","criminal-justice-referral","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5rwb-77bj","description":"This Data Spotlight based on the Treatment Episode Data Set (TEDS) for 2010 presents the differences between sources of referral to substance abuse treatment for adult American Indians and Alaska Natives compared to persons of other races.","title":"Almost Half of American Indian and Alaska Native Adult Substance Abuse Treatment Admissions Are Referred through the Criminal Justice System","programCode":["009:070"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/almost-half-american-indian-and-alaska-native-adult-substance-abuse-treatment-admissions-are","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5rx5-dmv8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","compound","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5rx5-dmv8","description":"Chemical compound data from PubChem database. IUPAC Name: 3-ethylnonane. Molecular Formula: C11H24. Molecular Weight: 156.31. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529886: 3-Ethylnonane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529886","description":"Access the complete Compound 529886: 3-Ethylnonane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5rxm-4czz","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chromosomal-proteins","nih","protein-interactions","swirm-domain","chromatin-modification"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5rxm-4czz","description":"Using computational sequence-profile analysis methods, a previously uncharacterized, predicted α-helical domain of about 85 residues was identified in chromosomal proteins such as Swi3p, Rsc8p, Moira and several other uncharacterized proteins. This module, termed the SWIRM domain, is predicted to mediate specific protein-protein interactions in the assembly of chromatin-protein complexes.","title":"The SWIRM domain: a conserved module found in chromosomal proteins points to novel chromatin-modifying activities","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC126233/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5s52-354v","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","bioactivity","chemistry","substance","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5s52-354v","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865521: MLS000083806","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865521","description":"Access the complete Substance 865521: MLS000083806 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5s5m-qeua","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","science","research","compound","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5s5m-qeua","description":"Chemical compound data from PubChem database. IUPAC Name: 1-(prop-1-enyltrisulfanyl)prop-1-ene. Molecular Formula: C6H10S3. Molecular Weight: 178.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529384: Propenyl trisulfide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529384","description":"Access the complete Compound 529384: Propenyl trisulfide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://opendata.maryland.gov/d/sx7q-snbm","issued":"2013-01-04","@type":"dcat:Dataset","modified":"2024-08-14","keyword":["cancer","maryland cancer registry"],"contactPoint":{"@type":"vcard:Contact","fn":"Andrea Bankoski","hasEmail":"mailto:no-reply@opendata.maryland.gov"},"publisher":{"@type":"org:Organization","name":"State of Maryland"},"identifier":"https://opendata.maryland.gov/api/views/sx7q-snbm","description":"This is historical data. The update frequency has been set to \"Static Data\" and is here for historic value. Updated 8/14/2024. \n\nDefinition of \"All Cancer Sites\": ICD-O-3 Topography (Site) Codes C00.0 – C80.9 with histology codes including all invasive cancers of all sites except basal and squamous cell skin cancers, and in situ cancer cases of the urinary bladder. Total includes cases reported as transexual, hermaphrodite, and unknown gender. Some cells are missing data due to suppression of low cell counts.","title":"Number of Cancer Cases for All Cancer Sites by Jurisdiction, Gender, and Race, Maryland 2009","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/sx7q-snbm/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/sx7q-snbm/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://opendata.maryland.gov/api/v3/views/sx7q-snbm/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health and Human Services"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/pbit-285g","issued":"2020-03-10","@type":"dcat:Dataset","modified":"2020-03-10","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"Charles, Anne Marie C (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/pbit-285g","description":"","title":"Reardan Elementary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/pbit-285g/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5s7i-s8dk","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-data","substance-use","state-level-estimates","samhsa","mental-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5s7i-s8dk","description":"This is a table of contents for the state-specific 2016-2017 estimates. Just click on the link for each state to be taken to that state.","title":"2016-2017 NSDUH State-Specific Tables","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2016-2017-nsduh-state-specific-tables","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5s9g-cwu4","bureauCode":["009:38"],"issued":"2018-12-04","@type":"dcat:Dataset","modified":"2018-12-26","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"Donte Morrisette","hasEmail":"mailto:no-reply@data.healthcare.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"abhi-yds7","description":"This file contains Medical Loss Ratio data for the 2017 Reporting Year, including the issuer’s MLR, the MLR standard, and the average rebate per person by state and market.","title":"MLR RY2017 Socrata Dataset 20181031","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/mlr-ry2017-socrata-dataset-20181031.abhi-yds7.csv","mediaType":"text/csv","title":"CSV"}],"license":"https://www.usa.gov/publicdomain/label/1.0/","theme":["MLR"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5sa2-znrk","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["child","fiscal","guidance","instruction","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5sa2-znrk","description":"This Program Instruction (PI) provides guidance to states, territories, and insular areas (hereafter “states,” unless otherwise noted) on actions they are required to take to receive their allotments for Federal Fiscal Year (FY) 2021 (subject to the availability of appropriations) authorized under title IV-B, subparts 1 and 2, section 106 of CAPTA, Chafee and ETV programs.\n\nPI-20-02 (PDF)\n\nFiscal Year 2019 Allotment Title IV-B Subpart 1 Stephanie Tubbs Jones Child Welfare Services\nFiscal Year 2019 Allotment Title IV-B Subpart 2 Promoting Safe and Stable Families\nFiscal Year 2019 Allotment for Title IV-B, Subpart 2 Monthly Caseworker Visit Funds\nFiscal Year 2019 Allotment for CAPTA\nFiscal Year 2019 Allotment for Chafee Foster Care Program for Successful Transition to Adulthood \nFiscal Year 2019 Allotment for Education and Training Vouchers\n\nCFS-101 Instructions, Part I, II, and III\n\nIntroduction\nPart I: Annual Budget Request for Title IV-B, Subpart 1 & 2 Funds, CAPTA, Chafee, and ETV Instructions\nPart II: Annual Estimated Expenditure Summary of Child and Family Services Instructions\nPart III: Expenditures for Title IV-B, Subparts 1 and 2, Chafee Foster Care Program for Successful Transition to Adulthood (Chafee) and Education and Training Voucher (ETV) Programs Instructions\n\nCFS-101 Forms, Parts I, II and III Excel Workbook (XLSX)(41 KB)\n\nCFS-101 Forms Part I\nCFS-101 Forms Part II\nCFS-101 Forms Part III\n\nCB Regional Program Managers\n\nAnnual Reporting of Education and Training Vouchers Awarded (PDF (PDF) - 83 KB)\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-20-02)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-20-02","description":"Access the complete PI-20-02 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5sbs-79nu","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["national-outcome-measures","urs-data","samhsa","community-mental-health","mental-health-services"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5sbs-79nu","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2012 Uniform Reporting System (URS) Tables for Colorado","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-uniform-reporting-system-urs-tables-colorado","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ser-crb9","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","pubchem","chemistry","substance","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ser-crb9","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865938: MLS000083728","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865938","description":"Access the complete Substance 865938: MLS000083728 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5set-sfgk","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["anti-inflammatory-effects","nih","c-reactive-protein","cardiovascular-events","statin-therapy"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5set-sfgk","description":"Large scale clinical trials demonstrate significant reductions in cardiovascular event rates with statin therapy. The observed benefit of statin therapy, however, may be larger in these trials than that expected on the basis of lipid lowering alone. Emerging evidence from both clinical trials and basic science studies suggest that statins have anti-inflammatory properties, which may additionally lead to clinical efficacy. Measurement of markers of inflammation such as high sensitivity C-reactive protein in addition to lipid parameters may help identify those patients who will benefit most from statin therapy.","title":"Are statins anti-inflammatory?","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC59622/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5sga-ggug","bureauCode":["009:25"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["protein-fold-recognition","alkb-protein","dioxygenase-enzymes","dna-repair","nih"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5sga-ggug","description":"Background:\n Protein fold recognition using sequence profile searches frequently allows prediction of the structure and biochemical mechanisms of proteins with an important biological function but unknown biochemical activity. Here we describe such predictions resulting from an analysis of the 2-oxoglutarate (2OG) and Fe(II)-dependent oxygenases, a class of enzymes that are widespread in eukaryotes and bacteria and catalyze a variety of reactions typically involving the oxidation of an organic substrate using a dioxygen molecule.\n \n \n Results:\n We employ sequence profile analysis to show that the DNA repair protein AlkB, the extracellular matrix protein leprecan, the disease-resistance-related protein EGL-9 and several uncharacterized proteins define novel families of enzymes of the 2OG-Fe(II) oxygenase superfamily. The identification of AlkB as a member of the 2OG-Fe(II) oxygenase superfamily suggests that this protein catalyzes oxidative detoxification of alkylated bases. More distant homologs of AlkB were detected in eukaryotes and in plant RNA viruses, leading to the hypothesis that these proteins might be involved in RNA demethylation. The EGL-9 protein from Caenorhabditis elegans is necessary for normal muscle function and its inactivation results in resistance against paralysis induced by the Pseudomonas aeruginosa toxin. EGL-9 and leprecan are predicted to be novel protein hydroxylases that might be involved in the generation of substrates for protein glycosylation.\n \n \n Conclusions:\n Here, using sequence profile searches, we show that several previously undetected protein families contain 2OG-Fe(II) oxygenase fold. This allows us to predict the catalytic activity for a wide range of biologically important, but biochemically uncharacterized proteins from eukaryotes and bacteria.","title":"The DNA-repair protein AlkB, EGL-9, and leprecan define new families of 2-oxoglutarate- and iron-dependent dioxygenases","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC30706/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5sif-g9yj","bureauCode":["009:38"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2024-11-15","references":["https://www.mathematica.org/"],"keyword":["scorecard","utility"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"10012a8e-f16e-5acd-bc7e-209cb7aa94e2","description":"This is a dataset created for the Medicaid Scorecard website (https://www.medicaid.gov/state-overviews/scorecard/index.html), and is not intended for use outside that application.","title":"CoreSEt filters v2.10.22 (coreset-impl)","programCode":["009:000"],"distribution":[{"mediaType":"text/csv","downloadURL":"https://download.medicaid.gov/data/coreset-viz/2.10.22/20241029/filters.csv","description":"CoreSEt filters v2.10.22 (coreset-impl)","@type":"dcat:Distribution","title":"CoreSEt filters v2.10.22 (coreset-impl)"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Uncategorized"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5skv-4pjn","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-abuse-treatment","n-ssats","treatment-facilities","samhsa","north-carolina"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5skv-4pjn","description":"This is a National Survey of Substance Abuse Treatment Services (N-SSATS) annual report showing the state profile for North Carolina in 2012. N-SSATS is designed to collect data on the location, characteristics, and use of alcohol and drug abuse treatment facilities and services throughout the 50 States, the District of Columbia, and other U.S. jurisdictions.","title":"2012 State Profile - North Carolina","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-state-profile-north-carolina","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5snd-r56u","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","research","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5snd-r56u","description":"Chemical compound data from PubChem database. IUPAC Name: 7-pentyltetradecane. Molecular Formula: C19H40. Molecular Weight: 268.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530310: Tetradecane, 7-pentyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530310","description":"Access the complete Compound 530310: Tetradecane, 7-pentyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/97bc-2r74","bureauCode":["009:20"],"issued":"2022-01-14","@type":"dcat:Dataset","modified":"2022-02-11","keyword":["wonder","netss","nedss","invasive disease","haemophilus influenzae","gonorrhea","all ages all serotypes","age <5 years serotype b","2022","nndss"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/97bc-2r74","description":"NNDSS - TABLE 1M. Gonorrhea to Haemophilus influenzae, invasive disease, Age <5 years, Serotype b - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.\n\nNotes:\n\n•\tThese are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.\n• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.\n•\tThe list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.\n\nFootnotes:\n\n*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.\n†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).\nU: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.\n-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.\nN: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.\nNN: Not nationally notifiable — This condition was not designated as being nationally notifiable.\nNP: Nationally notifiable but not published.\nNC: Not calculated — There is insufficient data available to support the calculation of this statistic.\nCum: Cumulative year-to-date counts.\nMax: Maximum — Maximum case count during the previous 52 weeks.","title":"NNDSS - TABLE 1M. Gonorrhea to Haemophilus influenzae, invasive disease, Age <5 years, Serotype b","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/97bc-2r74/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/97bc-2r74/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/97bc-2r74/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/97bc-2r74/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/97bc-2r74/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/97bc-2r74/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5sre-sfgi","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","connecticut","mental-health","substance-use","nsduh-data"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5sre-sfgi","description":"Connecticut: 2010-2012 NSDUH substate estimates","title":"Connecticut: 2010-2012 NSDUH substate estimates","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/connecticut-2010-2012-nsduh-substate-estimates","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ssc-cfmb","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh-data","substance-use-disorder","delaware","mental-health-indicators","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5ssc-cfmb","description":"This report uses 2008 to 2010 National Survey on Drug Use and Health (NSDUH) to assess past year alcohol use disorder and illicit drug use disorder among persons aged 12 or older for Delaware overall and for substate regions within Delaware. Topics covered include past month substance use (e.g., illicit drugs, marijuana, cocaine, pain relievers, alcohol, tobacco), substance dependence, abuse, and treatment need, past year serious mental illness (SMI), any mental illness (AMI), suicidal thoughts, and major depressive episode (MDE).","title":"Delaware (DE)","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/delaware-de-1","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ssd-2uqg","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ssd-2uqg","description":"Chemical compound data from PubChem database. IUPAC Name: 8-chloro-4-methoxy-6-(4-methylpiperazin-1-yl)benzo[b][1,4]benzoxazepine. Molecular Formula: C19H20ClN3O2. Molecular Weight: 357.8. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527493: Methyl 2'-hydroxy-6'-isopropoxy-4,6-dimethoxy-4'-methyl[1,1'-biphenyl]-2-carboxylate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527493","description":"Access the complete Compound 527493: Methyl 2'-hydroxy-6'-isopropoxy-4,6-dimethoxy-4'-methyl[1,1'-biphenyl]-2-carboxylate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ssq-4vza","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","pubchem","chemistry","references","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ssq-4vza","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865082: MLS000083683","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865082","description":"Access the complete Substance 865082: MLS000083683 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://hcai.ca.gov/","issued":"2017-06-16","temporal":"2019 - 2023","@type":"dcat:Dataset","modified":"2026-02-18","keyword":["inpatient quality indicators","accidental puncture","agency for healthcare research and quality","ahrq","blood stream","central venous catheter related","deep vein thrombosis","healthcare quality","hospital acquired conditions","hospital acquired infection","hospital quality","iatrogenic pneumothorax","inpatient quality","laceration","lets get healthy california","lghc","medical misadventure","patient safety indicators","perioperative pulmonary embolism","postoperative hip fracture","postoperative sepsis","postoperative wound dehiscence","pressure ulcer","psi","psi 90","psi composite"],"contactPoint":{"@type":"vcard:Contact","fn":"Department of Health Care Access and Information, Information Services Division/Healthcare Analytics Branch","hasEmail":"mailto:opendata@hcai.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"1fdde521-4646-4220-8084-f6b5d57b67a9","description":"This dataset contains the statewide composite patient safety and Adverse Events indicator (PSI) rate used to determine the “Incidence of measurable hospital-acquired conditions” rate for the Let’s Get Healthy California Initiative. PSI rates may not be comparable across years as significant changes were made to composition, definition, and calculation of PSI over time. The current composite PSI includes the following component indicators: pressure ulcer, iatrogenic pneumothorax, in-hospital fall-associated fracture, postoperative hemorrhage or hematoma, postoperative acute kidney injury requiring dialysis, postoperative respiratory failure, perioperative pulmonary embolism or deep vein thrombosis, postoperative sepsis, postoperative wound dehiscence, abdominopelvic accidental puncture or laceration.","title":"Measurable Hospital-Acquired Conditions (Composite Patient Safety and Adverse Events Indicator) Statewide Rate, California (LGHC Indicator)","distribution":[{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/1fdde521-4646-4220-8084-f6b5d57b67a9/resource/486c8147-2aef-4579-9712-2c5a3dab7966/download/2020-2024-psi90-data.xlsx","description":"This dataset contains the statewide composite patient safety indicator (PSI) rate used to determine the “Incidence of measurable hospital-acquired conditions” rate for the Let’s Get Healthy California Initiative. PSI rates may not be comparable across years as significant changes were made to composition, definition, and calculation of PSI over time. The current composite PSI includes the following component indicators: pressure ulcer, iatrogenic pneumothorax, in-hospital fall-associated fracture, postoperative hemorrhage or hematoma, postoperative acute kidney injury requiring dialysis, postoperative respiratory failure, perioperative pulmonary embolism or deep vein thrombosis, postoperative sepsis, postoperative wound dehiscence, abdominopelvic accidental puncture or laceration.","@type":"dcat:Distribution","title":"Measurable Hospital-Acquired Conditions (Composite Patient Safety and Adverse Events Indicator) Statewide Rate, California"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/1fdde521-4646-4220-8084-f6b5d57b67a9/resource/bc924f58-c222-448a-9a7e-212ac5d97e68/download/datadictionaryforpsi90_v2024_2019-2023data.pdf","description":"This dataset contains the statewide composite patient safety indicator (PSI) rate used to determine the “Incidence of measurable hospital-acquired conditions” rate for the Let’s Get Healthy California Initiative. PSI rates may not be comparable across years as significant changes were made to composition, definition, and calculation of PSI since 2018. The current composite PSI includes the following component indicators: pressure ulcer, iatrogenic pneumothorax, in-hospital fall with hip fracture, postoperative hemorrhage or hematoma, postoperative acute kidney injury requiring dialysis, postoperative respiratory failure, perioperative pulmonary embolism or deep vein thrombosis, postoperative sepsis, postoperative wound dehiscence, abdominopelvic accidental puncture or laceration.","@type":"dcat:Distribution","title":"Data Dictionary for AHRQ Patient Safety and Adverse Events Composite (PSI 90), 2020-2024"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/1fdde521-4646-4220-8084-f6b5d57b67a9/resource/0097ca4f-94d8-473f-8b89-e606714479f8/download/psi_technotes_v2025_2020-2024data.pdf","description":"This report contains the statewide composite patient safety and adverse events indicator (PSI) rate used to determine the “Incidence of measurable hospital-acquired conditions” rate for the Let’s Get Healthy California Initiative. PSI rates may not be comparable across years as significant changes were made to composition, definition, and calculation of PSI over time. The current composite PSI includes the following component indicators: pressure ulcer, iatrogenic pneumothorax, in-hospital fall-associated fracture, postoperative hemorrhage or hematoma, postoperative acute kidney injury requiring dialysis, postoperative respiratory failure, perioperative pulmonary embolism or deep vein thrombosis, postoperative sepsis, postoperative wound dehiscence, abdominopelvic accidental puncture or laceration.","@type":"dcat:Distribution","title":"Technical Note for AHRQ Patient Safety and Adverse Events Composite (PSI 90), 2020-2024"},{"mediaType":"text/html","downloadURL":"https://letsgethealthy.ca.gov/goals/redesigning-the-health-system/hospital-safety-and-quality-of-care-acquired-conditions/#_data-snapshot","description":"California spends $3.1 billion each year on hospital-acquired infections.[1] This indicator includes incidence of measurable hospital-acquired conditions (per 1,000 discharges). This data is comprised of a composite patient safety indicator, which includes an average of the observed-to-expected ratios of several other selected indicators of quality. The available data is limited and there remains opportunity for further development to establish a more definitive measure. At present, this indicator serves as a useful starting point for examining hospital quality. With sustained and system-wide quality improvement efforts in hospitals, safety and quality of care for patients can be enhanced and billions of dollars saved. \r\n\r\nLearn more at [Let's Get Healthy California](https://letsgethealthy.ca.gov/goals/redesigning-the-health-system/hospital-safety-and-quality-of-care-acquired-conditions/#_data-snapshot)\r\n\r\n[1] Let’s Get Healthy California Task Force. (December 2012). Let’s Get Healthy California Task Force Final Report. Let’s Get Healthy California Task Force.","@type":"dcat:Distribution","title":"Incidence of Hospital-Acquired Conditions per 1,000 Discharges"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/1fdde521-4646-4220-8084-f6b5d57b67a9/resource/52976bca-0b9e-4904-8034-28d2fd06d8e1/download/measurable-hospital-acquired-conditions-composite-patient-safety-indicator-statewide-rate-califo.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Diseases and Conditions","Healthcare"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5su3-3cqn","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","innovation","patent","chemistry","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5su3-3cqn","description":"Artificial endosphincter (1) comprises a retaining part (2) formed as a temperature-independent self-expanding stent, and a valve (10) which can be manually operating from outside by applying pressure.","title":"Patent AT-E401835-T1: [Translated] ARTIFICIAL ENDOSPHINCTER","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401835-T1","description":"Access the complete Patent AT-E401835-T1: [Translated] ARTIFICIAL ENDOSPHINCTER on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5svr-izf7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","innovation","patent","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5svr-izf7","description":"The invention relates to a high-performance dielectric oil comprising approximately 75 to 95% by volume of a naphthenic oil and approximately 5 to 25% by volume of an ester oil, in particular a synthetic ester oil and more preferably an oil of the family of polyolesters. The high-performance dielectric oil may be used in high-voltage electrical equipment such as power, measurement, distribution or traction transformers, tap changers, bushings, distributors, oil-immersed circuit breakers, power capacitors, cables, etc.","title":"Patent AT-E400057-T1: [Translated] USE OF HIGH PERFORMANCE DIELECTRIC OIL FOR HIGH VOLTAGE ELECTRICAL EQUIPMENT","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400057-T1","description":"Access the complete Patent AT-E400057-T1: [Translated] USE OF HIGH PERFORMANCE DIELECTRIC OIL FOR HIGH VOLTAGE ELECTRICAL EQUIPMENT on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/snev-n7vb","bureauCode":["009:20"],"issued":"2021-01-21","@type":"dcat:Dataset","modified":"2022-01-12","keyword":["wonder","sabia virus","viral hemorrhagic fevers","machupo virus","2021","marburg virus","nedss","netss","nndss"],"contactPoint":{"@type":"vcard:Contact","fn":"CDC INFO","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/snev-n7vb","description":"NNDSS - TABLE 1OO. Viral hemorrhagic fevers, Machupo virus to Viral hemorrhagic fevers, Sabia virus – 2021. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.\n\nNotice: Due to data processing issues at CDC, data for the following jurisdictions may be incomplete for week 7: Alaska, Arizona, California, Connecticut, Delaware, Florida, Hawaii, Louisiana, Maryland, Michigan, Missouri, North Dakota, New Hampshire, New York City, Oregon, Pennsylvania, and Rhode Island.\n\nNote:\nThis table contains provisional cases of national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data from the 50 states, New York City, the District of Columbia and the U.S. territories are collated and published weekly on the NNDSS Data and Statistics web page (https://wwwn.cdc.gov/nndss/data-and-statistics.html). Cases reported by state health departments to CDC for weekly publication are provisional because of the time needed to complete case follow-up. Therefore, numbers presented in later weeks may reflect changes made to these counts as additional information becomes available. The national surveillance case definitions used to define a case are available on the NNDSS web site at https://wwwn.cdc.gov/nndss/. Information about the weekly provisional data and guides to interpreting data are available at: https://wwwn.cdc.gov/nndss/infectious-tables.html.\n\nFootnotes:\nU: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.\n-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.\nN: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.\nNN: Not nationally notifiable — This condition was not designated as being nationally notifiable.\nNP: Nationally notifiable but not published.\nNC: Not calculated — There is insufficient data available to support the calculation of this statistic.\nCum: Cumulative year-to-date counts.\n Max: Maximum — Maximum case count during the previous 52 weeks.\n * Case counts for reporting years 2020 and 2021 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://wwwn.cdc.gov/nndss/document/Users_guide_WONDER_tables_cleared_final.pdf. \n†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data). \n§ Prior to 2015, CDC's National Notifiable Diseases Surveillance System (NNDSS) did not receive electronic data about incident cases of specific viral hemorrhagic fevers; instead data were collected in aggregate as \"viral hemorrhagic fevers\". NNDSS was updated beginning in 2015 to receive data for each of the viral hemorrhagic fevers listed.","title":"NNDSS - TABLE 1OO. Viral hemorrhagic fevers, Machupo virus to Viral hemorrhagic fevers, Sabia virus","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/snev-n7vb/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/snev-n7vb/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/snev-n7vb/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/snev-n7vb/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/snev-n7vb/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/snev-n7vb/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["NNDSS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5sxk-27ce","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","pubchem","research","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5sxk-27ce","description":"Chemical compound data from PubChem database. IUPAC Name: 4-methylfuran-2-carbaldehyde. Molecular Formula: C6H6O2. Molecular Weight: 110.11. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526950: 4-Methylfuran-2-carbaldehyde","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526950","description":"Access the complete Compound 526950: 4-Methylfuran-2-carbaldehyde on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5sxk-cdg6","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["research","chemistry","science","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5sxk-cdg6","description":"Chemical compound data from PubChem database. IUPAC Name: 2,6-dimethyldodec-2-ene. Molecular Formula: C14H28. Molecular Weight: 196.37. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528472: 2,6-Dimethyl-2-dodecene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528472","description":"Access the complete Compound 528472: 2,6-Dimethyl-2-dodecene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https:/https://www.cdph.ca.gov/Programs/CCDPHP/DCDIC/CTCB/Pages/CaliforniaTobaccoControlBranch.aspx/www.cdph.ca.gov/Programs/CCDPHP/DCDIC/CTCB/Pages/CaliforniaTobaccoControlBranch.aspx","issued":"2017-06-16","temporal":"1997-2019","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["sales","tcp","tobacco","youth","smoking","illegal sale","minors","stake act","synar ammendment","tcb","retailer violation","cigarette"],"contactPoint":{"@type":"vcard:Contact","fn":"California Tobacco Control Program","hasEmail":"mailto:opendata@cdph.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"72d892cb-9ce4-46f8-a6c4-0bca87810e55","description":"This dataset includes two data tables that contain the percentage of licensed tobacco retailers that sold tobacco to underage youth and young adults: (1) Tobacco Sold to Youth Under 18, and (2) Tobacco Sold to Young Adults Under 21. The California Youth Tobacco Survey (YTPS), conducted between 1997 and 2018, assessed the rate of illegal tobacco sales to youth under the age of 18. Due to California raising the minimum legal sales age for tobacco products from 18 to 21 years old, YTPS was replaced with the Synar Tobacco Purchase Survey (STPS) in 2019. STPS is an annual survey that assesses the rate of illegal tobacco sales to young adults under the age of 21 years of age. Both surveys were conducted in accordance with the California’s Stop Tobacco Access to Kids Enforcement Act (STAKE Act) and the federal Synar Amendment.","title":"Retailers that Sold Tobacco to Underage Youth and Young Adults","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/72d892cb-9ce4-46f8-a6c4-0bca87810e55/resource/f92ae096-0a72-4f27-9d2a-c4e4bf9cc59e/download/tobacco-sold-to-youth.csv","description":"This data table contains the percentage of licensed tobacco retailers that sold tobacco to youth under the age of 18 from the California Youth Tobacco Purchase Survey (YTPS) between 1997 and 2018. \r\n\r\nThe YTPS was replaced with the Synar Tobacco Purchase Survey (STPS) in 2019 that utilizes youth under the age of 21. The YTPS was an annual survey that is conducted to gauge the rate of illegal tobacco sales to youth under the age of 18 across California, in accordance with California’s Stop Tobacco Access to Kids Enforcement Act (STAKE Act) and the federal Synar Amendment. Licensed tobacco retailers that are accessible to minors under the age of 18 throughout California are randomly selected for the survey.","@type":"dcat:Distribution","title":"Tobacco Sold to Youth Under 18"},{"mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","downloadURL":"https://data.chhs.ca.gov/dataset/72d892cb-9ce4-46f8-a6c4-0bca87810e55/resource/a61b5a11-0c47-4ae7-bc13-4857442a5872/download/tobacco-sold-to-youth-dd.xlsx","description":"This data table contains the percentage of licensed tobacco retailers that sold tobacco to youth under the age of 18 from the California YTPS between 1997 and present. The California Youth Tobacco Purchase Survey (YTPS) is an annual survey that is conducted to gauge the rate of illegal tobacco sales to youth under the age of 18 across California, in accordance with California’s Stop Tobacco Access to Kids Enforcement Act (STAKE Act) and the federal Synar Amendment.","@type":"dcat:Distribution","title":"Data Dictionary-Tobacco Sold to Youth Under 18"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/72d892cb-9ce4-46f8-a6c4-0bca87810e55/resource/6e5b5a14-901c-4467-8aa1-7c0db8830e6b/download/tobacco_sold_to_youth_california_narrative.pdf","description":"This data table contains the percentage of licensed tobacco retailers that sold tobacco to youth under the age of 18 from the California YTPS between 1997 and present. The California Youth Tobacco Purchase Survey (YTPS) is an annual survey that is conducted to gauge the rate of illegal tobacco sales to youth under the age of 18 across California, in accordance with California’s Stop Tobacco Access to Kids Enforcement Act (STAKE Act) and the federal Synar Amendment.","@type":"dcat:Distribution","title":"Tobacco Sold to Youth Narrative"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/72d892cb-9ce4-46f8-a6c4-0bca87810e55/resource/d8083caa-e610-425e-86a9-aab2f685e371/download/tobacco-sold-to-young-adults.csv","description":"The data table contains the percentage of licensed tobacco retailers that sold tobacco to young adults under the age of 21 years of age from the Synar Tobacco Purchase Survey (STPS) from 2019. Licensed tobacco retailers that are accessible to minors under the age of 21 years of age throughout California are randomly selected for the survey.","@type":"dcat:Distribution","title":"Tobacco Sold to Young Adults Under 21"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/72d892cb-9ce4-46f8-a6c4-0bca87810e55/resource/c863815e-f7a1-4db5-9830-12517851e182/download/tobacco-sold-to-young-adults-dd.xlsx","mediaType":"application/vnd.openxmlformats-officedocument.spreadsheetml.sheet","title":"Data Dictionary -Tobacco Sold to Young Adults Under 21"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/72d892cb-9ce4-46f8-a6c4-0bca87810e55/resource/407fa974-0425-4b38-912c-3d1fd7d616d6/download/tobacco-sold-to-minors-california-gook0ozn.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Diseases and Conditions","Facilities and Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5sze-umni","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["data","adoption","fiscal","policy","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5sze-umni","description":"This report provides state-specific data from fiscal year 2012 about the race and ethnicity of children who were adopted through public agencies.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Race\\Ethnicity Distribution Of Children Adopted During FY 2012","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/raceethnicity-distribution-children-adopted-during-fy-2012","description":"Access the complete Race\\Ethnicity Distribution Of Children Adopted During FY 2012 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5t2y-paj9","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["acute-ischemic-stroke","stroke-outcomes","clinical-trial","nih","magnesium-sulfate"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5t2y-paj9","description":"The Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial is a multicentre,randomised, placebo-controlled trial of magnesium sulphate (MgSO4) funded by the UK Medical Research Council. When complete, it will be the largest single neuroprotective study undertaken to date. Conscious patients presenting within 12 h of acute stroke with limb weakness are eligible. The primary outcome measure is combined death and disability as measured using the Barthel Index at 90-day follow up. By randomizing 2700 patients, the study will have 84% power to detect a 5.5% absolute reduction in the primary end-point. By April 2000, 86 centres were participating, with representation in Canada, USA, Europe, South America, Singapore and Australia. So far, 1206 patients have been randomised, of whom 37% were treated within 6 h. Overall 3-month mortality was 20% and the primary outcome event rate was 43%. The study is ongoing and centres worldwide are encouraged to participate.","title":"Design of the Intravenous Magnesium Efficacy in Acute Stroke (IMAGES) trial [ISRCTN19943732]","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC56206/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5t3m-jmbm","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["grant","abuse","neglect","fiscal","prevention"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5t3m-jmbm","description":"This Program Instruction (PI) provides instruction on the availability of Federal Fiscal Year (FFY) 2015 funds under the Community-Based Grants for the Prevention of Child Abuse and Neglect program created by Title II of the Child Abuse Prevention and Treatment Act (CAPTA) as amended by Public Law (P.L.) 111-320.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-15-02)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-15-02","description":"Access the complete PI-15-02 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/c642-icm2","issued":"2025-10-02","@type":"dcat:Dataset","modified":"2025-10-02","keyword":["2022","cost report","hospital","print image"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/c642-icm2","description":"This print image version of the Institutional Cost Report (ICR) has been audited by the DOH. is the Institutional Cost Report (ICR) is a uniform report completed by New York hospitals to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations, (Part 86-1.2), Article 28 hospitals are required to file financial and statistical data with DOH annually. The data filed is part of the ICR and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends. For more information, check out: http://www.health.ny.gov/facilities/hospital/","title":"Hospital Cost Report Audited Data Print Image: 2022","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/download/c642-icm2/application/x-zip-compressed","mediaType":"application/x-zip-compressed"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5t3z-z7s6","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5t3z-z7s6","description":"Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl hexacosanoate. Molecular Formula: C29H60O2Si. Molecular Weight: 468.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526089: Hexacosanoic acid, trimethylsilyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526089","description":"Access the complete Compound 526089: Hexacosanoic acid, trimethylsilyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5t6i-xbfs","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","innovation","pubchem","chemistry","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5t6i-xbfs","description":"A stepping motor is disclosed, which includes an inventive arrangement of stator pole arms. The arrangement of stator pole arms has the effect of smoothing out the drive torque characteristic of the stepping motor.","title":"Patent AT-E40025-T1: [Translated] SINGLE-PHASE STEPPER MOTOR.","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E40025-T1","description":"Access the complete Patent AT-E40025-T1: [Translated] SINGLE-PHASE STEPPER MOTOR. on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","bureauCode":["009:30"],"landingPage":"https://healthdata.gov/dataset/national-survey-substance-abuse-treatment-services-n-ssats-2011","issued":"2016-05-23","@type":"dcat:Dataset","modified":"2023-07-25","keyword":["health care services","drug treatment","drug abuse","alcohol abuse","substance abuse treatment","intervention","substance abuse","treatment facilities","treatment programs","hiv"],"contactPoint":{"@type":"vcard:Contact","fn":"Brooklyn Lupari, SAMHSA/CBHSQ c/o SAMHDA Support","hasEmail":"mailto:samhda-support@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse & Mental Health Services Administration"},"identifier":"https://datafiles.samhsa.gov/study/national-survey-substance-abuse-treatment-services-n-ssats-2011-nid13565","description":"The National Survey of Substance Abuse Treatment Services (N-SSATS) is designed to collect information from all facilities in the United States, both public and private, that provide substance abuse treatment. N-SSATS provides the mechanism for quantifying the dynamic character and composition of the United States substance abuse treatment delivery system. The objectives of N-SSATS are to collect multipurpose data that can be used to assist the Substance Abuse and Mental Health Services Administration (SAMHSA) and state and local governments in assessing the nature and extent of services provided and in forecasting treatment resource requirements, to update SAMHSA's Inventory of Substance Abuse Treatment Services (I-SATS), to analyze general treatment services trends, and to generate the online Substance Abuse Treatment
\nFacility Locator http://findtreatment.samhsa.gov, as well as the National Directory of Drug and Alcohol Abuse Treatment Programs.Data are collected on topics including facility operation, services offered (assessment, testing, transitional, ancillary, and pharmacotherapies), detoxification, primary focus (substance abuse, mental health, both, general health, and other), Opioid Treatment Programs and medications dispensed/prescribed, counseling and therapeutic approaches, standard operating procedures, special programs/groups offered, languages in which treatment is provided, type of treatment provided (hospital inpatient, residential, outpatient), number of clients (by service, total, and under age 18), number of beds, types of payment accepted, sliding fee scale, and facility accreditation and licensure/certification.This study has 1 Data Set.
ECM Community Support Services tables for a Quarterly Implementation Report. Including the County and Plan Details for both ECM and Community Support.
This Medi-Cal Enhanced Care Management (ECM) and Community Supports Calendar Year Quarterly Implementation Report provides a comprehensive overview of ECM and Community Supports implementation in the programs' first year. It includes data at the state, county, and plan levels on total members served, utilization, and provider networks.
ECM is a statewide MCP benefit that provides person-centered, community-based care management to the highest need members. The Department of Health Care Services (DHCS) and its MCP partners began implementing ECM in phases by Populations of Focus (POFs), with the first three POFs launching statewide in CY 2022.
Community Supports are services that address members’ health-related social needs and help them avoid higher, costlier levels of care. Although it is optional for MCPs to offer these services, every Medi-Cal MCP offered Community Supports in 2022, and at least two Community Supports services were offered and available in every county by the end of the year.
","title":"Chart 1.4.1 Total Number of Members Who Received ECM in the Last 12 Months of the Report Period by Race Ethnicity Compare with Overall MCP Population","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/datasets/CADHCS::chart-1-4-1-total-number-of-members-who-received-ecm-in-the-last-12-months-of-the-report-period-by-race-ethnicity-compare-with-overall-mcp-population-1","mediaType":"text/html","title":"ArcGIS Hub Dataset"},{"@type":"dcat:Distribution","downloadURL":"https://services7.arcgis.com/7MUwsS9z05YumJRZ/arcgis/rest/services/ECM_Community_Support_Data_Tables_for_Quarterly_Implementation_report/FeatureServer/18","mediaType":"application/octet-stream","title":"ArcGIS GeoService"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/csv?layers=18","mediaType":"text/csv","title":"CSV"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/shapefile?layers=18","mediaType":"application/zip","title":"Shapefile"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/geojson?layers=18","mediaType":"application/geo+json","title":"GeoJSON"},{"@type":"dcat:Distribution","downloadURL":"https://gis.dhcs.ca.gov/api/download/v1/items/ac1f71f8f15c4dcdba7a42471afa877b/kml?layers=18","mediaType":"application/vnd.google-earth.kml+xml","title":"KML"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/faf34fce-4b85-474f-85ef-dda88b1ec45b/resource/1652e70a-524f-4773-bc91-fde0d59c05fe/download/chart-1-4-1-total-number-of-members-who-received-ecm-in-the-last-12-months-of-the-report-period-.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["State"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5xch-z44g","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["california-smha","block-grant-data","mental-health-services","noms-measures","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5xch-z44g","description":"This is the 2020 Uniform Reporting System (URS) Output Tables for California. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2020 Uniform Reporting System (URS) Table For California","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2020-uniform-reporting-system-urs-table-california","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5xck-d4ge","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["outcome-measures","block-grant","kansas","mental-health-services","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5xck-d4ge","description":"This is the 2020 Uniform Reporting System (URS) Output Tables for Kansas. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2020 Uniform Reporting System (URS) Table For Kansas","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2020-uniform-reporting-system-urs-table-kansas","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5xea-su2b","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5xea-su2b","description":"Chemical compound data from PubChem database. IUPAC Name: undecyl 2-chlorobutanoate. Molecular Formula: C15H29ClO2. Molecular Weight: 276.84. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527665: Undecyl 2-chlorobutanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527665","description":"Access the complete Compound 527665: Undecyl 2-chlorobutanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5xhc-x8we","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["community-mental-health","samhsa","mental-health-services","oregon-mental-health","noms-measures"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5xhc-x8we","description":"2015 Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for Oregon. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2015 CMHS Uniform Reporting System (URS) Table for Oregon","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2015-cmhs-uniform-reporting-system-urs-table-oregon","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5xp3-8qmk","bureauCode":["009:30"],"issued":"2025-07-13","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance-use","behavioral-health","health-equity","mental-health","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5xp3-8qmk","description":"Behavioral Health Equity Report 2021: Substance Use and Mental Health Indicators Measured from the National Survey on Drug Use and Health (NSDUH), 2015–2019provides an update on a series of topics that focus on substance use and mental health (collectively referred to as behavioral health) in the United States. The Substance Abuse and Mental Health Services Administration (SAMHSA) selected specific topics and indicators in this report to represent a cross-section of the key behavioral health indicators that are assessed in SAMHSA data collections, including NSDUH. This report is intended to provide a concise, reader-friendly summary of key behavioral health measures for lay and professional audiences.","title":"Behavioral Health Equity Report 2021","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-equity-report-2021","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5xpe-zdfk","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","pubchem","research","science","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5xpe-zdfk","description":"Chemical compound data from PubChem database. IUPAC Name: 1-butan-2-ylsulfanyl-3-methylbutane. Molecular Formula: C9H20S. Molecular Weight: 160.32. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525441: 3,7-Dimethyl-4-thiaoctane","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525441","description":"Access the complete Compound 525441: 3,7-Dimethyl-4-thiaoctane on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5xph-biag","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","chemistry","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5xph-biag","description":"Chemical compound data from PubChem database. IUPAC Name: 2,4-dimethyl-3-methylsulfanylthiophene. Molecular Formula: C7H10S2. Molecular Weight: 158.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528869: Methyl 2,4-dimethyl-3-thienyl disulfide","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528869","description":"Access the complete Compound 528869: Methyl 2,4-dimethyl-3-thienyl disulfide on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cityofchicago.org/d/a4p3-hxgg","issued":"2024-05-15","@type":"dcat:Dataset","modified":"2025-11-05","keyword":["so2024-0008386","temporary shelters","migrants","new arrivals"],"contactPoint":{"@type":"vcard:Contact","fn":"Jonathan Levy","hasEmail":"mailto:no-reply@data.cityofchicago.org"},"publisher":{"@type":"org:Organization","name":"City of Chicago"},"identifier":"https://data.cityofchicago.org/api/views/a4p3-hxgg","description":"Under SO2024-0008386, passed by City Council on 4/17/2024, the Department of Family and Support Services publishes data on the City-operated and City-funded emergency new arrivals shelters. This dataset shows the total number of migrants who were in each shelter on each date listed.","title":"Emergency Temporary Shelters - Census","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/a4p3-hxgg/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/a4p3-hxgg/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cityofchicago.org/api/v3/views/a4p3-hxgg/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health & Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5xr2-wii4","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["adoption","data","fiscal","policy","child"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5xr2-wii4","description":"This report provides state-specific data from fiscal year 2008 about children's ages at the time of a public agency adoption finalization.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Age at Adoption Finalization: 10/1/2007 - 9/30/2008","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/age-adoption-finalization-10/1/2007-9/30/2008","description":"Access the complete Age at Adoption Finalization: 10/1/2007 - 9/30/2008 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5xsy-x88t","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","qualitative-research","primary-prevention","preventive-care","physician-perception"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5xsy-x88t","description":"Background\n A practice intervention must have its basis in an understanding of the physician and practice to secure its benefit and relevancy. We used a formative process to characterize primary care physician attitudes, needs, and practice obstacles regarding primary prevention. The characterization will provide the conceptual framework for the development of a practice tool to facilitate routine delivery of primary preventive care.\n \n \n Methods\n A focus group of primary care physician Opinion Leaders was audio-taped, transcribed, and qualitatively analyzed to identify emergent themes that described physicians' perceptions of prevention in daily practice.\n \n \n Results\n The conceptual worth of primary prevention, including behavioral counseling, was high, but its practice was significantly countered by the predominant clinical emphasis on and rewards for secondary care. In addition, lack of health behavior training, perceived low self-efficacy, and patient resistance to change were key deterrents to primary prevention delivery. Also, the preventive focus in primary care is not on cancer, but on predominant chronic nonmalignant conditions.\n \n \n Conclusions\n The success of the future practice tool will be largely dependent on its ability to \"fit\" primary prevention into the clinical culture of diagnoses and treatment sustained by physicians, patients, and payers. The tool's message output must be formatted to facilitate physician delivery of patient-tailored behavioral counseling in an accurate, confident, and efficacious manner. Also, the tool's health behavior messages should be behavior-specific, not disease-specific, to draw on shared risk behaviors of numerous diseases and increase the likelihood of perceived salience and utility of the tool in primary care.","title":"Physician perceptions of primary prevention: qualitative base for the conceptual shaping of a practice intervention tool","programCode":["009:035"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC126210/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5xuv-vgfg","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","science","compound","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5xuv-vgfg","description":"Chemical compound data from PubChem database. IUPAC Name: 3-ethyl-1,2,4,5-tetrathiepane. Molecular Formula: C5H10S4. Molecular Weight: 198.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528851: 2,3,5,6-Tetrathiaheptane, 4-ethyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528851","description":"Access the complete Compound 528851: 2,3,5,6-Tetrathiaheptane, 4-ethyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5xy2-6d8z","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["hereditary-pancreatitis","nih","genetic-mutation","prss1-gene","dhplc-assay"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5xy2-6d8z","description":"Background\n R122, the primary autolysis site of the human cationic trypsinogen (PRSS1), constitutes an important \"self-destruct\" or \"fail-safe\" defensive mechanism against premature trypsin activation within the pancreas. Disruption of this site by a missense mutation, R122H, was found to cause hereditary pancreatitis. In addition to a c.365G>A (CGC>CAC) single nucleotide substitution, a c.365~366GC>AT (CGC>CAT) gene conversion event in exon 3 of PRSS1 was also found to result in a R122H mutation. This imposes a serious concern on the genotyping of pancreatitis by a widely used polymerase chain reaction-restriction fragment length polymorphism assay, which could only detect the commonest c.365G>A variant.\n \n \n Materials and methods\n DNA samples containing either the known c.365G>A or c.365~366GC>AT variant in exon 3 of PRSS1 were used as positive controls to establish a denaturing high performance liquid chromatography (DHPLC) assay.\n \n \n Results\n DHPLC could readily discriminate the two known different mutational events resulting in the R122H mutation. More importantly, under the same experimental conditions, it identified a further mutational event that also occurs in the R122 primary autolysis site but results in a different amino acid substitution: c.364C>T (CGC>TGC; R122C).\n \n \n Conclusions\n A rapid, simple, and low-cost assay for detecting both the known and new mutations occuring in the R122 primary autolysis site of PRSS1 was established. In addition, the newly found R122C variant represents a likely pancreatitis-predisposing mutation.","title":"Discrimination of three mutational events that result in a disruption of the R122 primary autolysis site of the human cationic trypsinogen (PRSS1) by denaturing high performance liquid chromatography","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC60523/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://opendata.maryland.gov/d/a2k4-733q","issued":"2016-07-22","@type":"dcat:Dataset","modified":"2025-05-05","keyword":["assisted living","department of health and mental hygiene","dhmh","dialysis","dynamic","health","hlth","hospice","kml","maryland","md","md imap","office of preparedness and response","opr","psychiatric","rehabilitation","special hospitals","vector","wfs","wms"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data Administrator","hasEmail":"mailto:no-reply@opendata.maryland.gov"},"publisher":{"@type":"org:Organization","name":"State of Maryland"},"identifier":"https://opendata.maryland.gov/api/views/a2k4-733q","description":"This is a MD iMAP hosted service layer. Find more information at http://imap.maryland.gov. OP&R organizes and prepares for public health and medical emergencies through statewide partnerships with public - private and government agencies to coordinate an effective emergency response for the health and safety of all residents of Maryland. Last Updated: 10/06/2014 Feature Service Layer Link: http://geodata.md.gov/imap/rest/services/Health/MD_LongTermCareAssistedLiving/FeatureServer/3 ADDITIONAL LICENSE TERMS: The Spatial Data and the information therein (collectively \"the Data\") is provided \"as is\" without warranty of any kind either expressed implied or statutory. The user assumes the entire risk as to quality and performance of the Data. No guarantee of accuracy is granted nor is any responsibility for reliance thereon assumed. In no event shall the State of Maryland be liable for direct indirect incidental consequential or special damages of any kind. The State of Maryland does not accept liability for any damages or misrepresentation caused by inaccuracies in the Data or as a result to changes to the Data nor is there responsibility assumed to maintain the Data in any manner or form. The Data can be freely distributed as long as the metadata entry is not modified or deleted. Any data derived from the Data must acknowledge the State of Maryland in the metadata.","title":"MD iMAP: Maryland Long Term Care Assisted Living - Dialysis","distribution":[{"@type":"dcat:Distribution","downloadURL":"http://data.imap.maryland.gov/datasets/6d71fe152ee44ae7b071abc184fa74fd_3","mediaType":"text/html"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health and Human Services"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5y7c-vsfj","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","chemistry","innovation","pubchem","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5y7c-vsfj","description":"A method of fractioning a quantity of radioactive liquid by use of a dosing machine (1) having one single pump, comprising a step of receiving a radioactive liquid, and a second liquid substance and a step of transferring at least part of the quantity of liquid into a vial or syringe.","title":"Patent AT-E401245-T1: [Translated] DOSING DEVICE FOR RADIOACTIVE FLUID","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401245-T1","description":"Access the complete Patent AT-E401245-T1: [Translated] DOSING DEVICE FOR RADIOACTIVE FLUID on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5y8j-skb7","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5y8j-skb7","description":"Chemical compound data from PubChem database. IUPAC Name: prop-2-ynyl 3-chlorobutanoate. Molecular Formula: C7H9ClO2. Molecular Weight: 160.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527691: Butanoic acid, 3-chloro, 2-propynyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527691","description":"Access the complete Compound 527691: Butanoic acid, 3-chloro, 2-propynyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5y8m-fe7p","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["right","lgbtq","policy","public","social"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5y8m-fe7p","description":"This poster indicates a place is a \"brave space\" where no homophobic, transphobic, racist or sexist put downs and remarks are tolerated.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"RISE Brave Space Poster","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/outreach-material/rise-brave-space-poster","description":"Access the complete RISE Brave Space Poster on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/hiu7-nzhz","issued":"2020-06-08","@type":"dcat:Dataset","modified":"2020-06-08","keyword":["school","drinking water","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"Charles, Anne Marie C (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/hiu7-nzhz","description":"Lead in Drinking Water in Schools","title":"Olalla Elementary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/hiu7-nzhz/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ybk-y9g8","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ybk-y9g8","description":"Chemical compound data from PubChem database. IUPAC Name: N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide. Molecular Formula: C21H26N2O. Molecular Weight: 322.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527015: Acetylfentanyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527015","description":"Access the complete Compound 527015: Acetylfentanyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ycz-fnpc","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["prevalence-estimates","substance-use","mental-health","nsduh","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5ycz-fnpc","description":"State estimates for these years are no longer available due to methodological concerns with combining 2019 and 2020 data. We apologize for any inconvenience or confusion this may causeBecause of the COVID-19 pandemic, most respondents answered the survey via the web in Quarter 4 of 2020, even though all responses in Quarter 1 were from in-person interviews. It is known that people may respond to the survey differently while taking it online, thus introducing what is called a mode effect.When the state estimates were released, it was assumed that the mode effect was similar for different groups of people. However, later analyses have shown that this assumption should not be made. Because of these analyses, along with concerns about the rapid societal changes in 2020, it was determined that averages across the two years could be misleading.For more detail on this decision, see the 2019-2020state data page.","title":"2019-2020 National Survey on Drug Use and Health National Maps of Prevalence Estimates, by State","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2019-2020-nsduh-national-maps-prevalence-estimates-state","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5yg5-498n","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","pubchem","chemistry","patent","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5yg5-498n","description":"A sausage skin is cut from a seamless hose of cellulose material made of water-based N-methylmorpholine-N-oxide (NMMO) spinning solution, and incorporating a protein, a filling agent and a stabilizer if required. Also claimed is a process to manufacture the cellulose foil hose by extrusion through an annular jet from which it passes through a bath before changing direction at a set of rollers. The hose emerges from the bath to pass through a washing machine (25, 26), a plasticizing station and a drier (28). The protein used is from the group consisting of natural globular proteins e.g. casein, Soya, wheat, maize, peanuts or peas and represents preferably 8-45 per cent by weight of the hose. The filling agent is an organic or inorganic material e.g. wheat bran, micro-crystalline cellulose or chitosan. The inorganic powder ingredient is e.g. CaCO3, BaSO4, SiO2, TiO2. The filling agent grain size is up to 200 m, with a thickness of up to 20 m. Also claimed is a commensurate manufacturing assembly.","title":"Patent AT-E401004-T1: [Translated] SEAMLESS FILM HOSE, METHOD AND DEVICE FOR PRODUCING A SEAMLESS FILM HOSE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401004-T1","description":"Access the complete Patent AT-E401004-T1: [Translated] SEAMLESS FILM HOSE, METHOD AND DEVICE FOR PRODUCING A SEAMLESS FILM HOSE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ygw-rcz2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","research","chemistry","patent","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ygw-rcz2","description":"The invention relates to a method and system for transmitting a short message in a telecommunication system comprising a location data register (HLR); a database (DB) for storing subscriber data; and a gateway (GW) which connects said location data register (HLR) and said database (DB) to said telecommunication network (1). In the method, a short message is created; the short message is sent to the telecommunication network (1); and the short message is directed via the telecommunication network (1) to the gateway (GW). In accordance with the invention, a database (DB) is maintained in which those subscribers are entered who have activated the short message forwarding service; it is checked from the database (DB) whether the receiver of the short message has activated the short message forwarding service; and in case yes, a routing information query is made by the gateway (GW) that is addressed to the location data register (HLR); and the short message is routed based on the data given by the routing information query.","title":"Patent AT-E400971-T1: [Translated] TRANSMISSION OF A SHORT MESSAGE IN A TELECOMMUNICATIONS SYSTEM","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400971-T1","description":"Access the complete Patent AT-E400971-T1: [Translated] TRANSMISSION OF A SHORT MESSAGE IN A TELECOMMUNICATIONS SYSTEM on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5yig-qa9a","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","substance-abuse","detoxification","drug-overdose","emergency-department"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5yig-qa9a","description":"Excel file with estimates, rates, relative standard errors, trends and confidence intervals for all drug-related emergency department (ED) visits involving patients seeking detox in the Phoenix metropolitan area, covering 2004-2011. This includes nonemergency requests made through the ED for admission to detoxification unit, visits to obtain medical clearance before being incarcerated, and acute emergencies where an individual is experiencing withdrawal symptoms and requests detox. These estimates do not include patients who seek or enter the hospital\\'s detox unit through other avenues.","title":"Phoenix: Drug-Related Emergency Department Visits, 2004-2011 - Seeking Detox","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/phoenix-drug-related-emergency-department-visits-2004-2011-seeking-detox","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ymz-ztj5","bureauCode":["009:70"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["reporting","ndacan","policy","care","abuse"],"contactPoint":{"@type":"vcard:Contact","fn":"NDACAN Data Team","hasEmail":"mailto:NDACAN@cornell.edu"},"publisher":{"@type":"org:Organization","name":"National Data Archive on Child Abuse and Neglect"},"identifier":"https://healthdata.gov/api/views/5ymz-ztj5","description":"The SCAN Policies Database includes state definitions and policies from the 50 states, the District of Columbia, and the Commonwealth of Puerto Rico. The SCAN Policies Database 2021 represents data, collected, reviewed, and verified between May 2021 and July 2022, and the data reflect the state definitions and policies for the calendar year 2019. The SCAN Policies Database 2021 represents data collected, reviewed, and verified between July 2021 and January 2022, and the data reflect the state definitions and policies for the calendar year 2021.\n\nInvestigators: Elizabeth C. Weigensberg, PhD - \nMathematica\nNuzhat Islam, MS - \nMathematica\nJean Knab, PhD - \nMathematica\nMary A. Grider, MBA - \nMathematica\nJeremy Page, MA - \nMathematica\nAddison Larson, MS - Mathematica","title":"State Child Abuse and Neglect (SCAN) Policies Database 2021","programCode":["009:094"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ndacan.acf.hhs.gov/datasets/dataset-details.cfm?ID=265","description":"Access the complete State Child Abuse and Neglect (SCAN) Policies Database 2021 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ypc-x57k","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["chemistry","pubchem","research","compound","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ypc-x57k","description":"Chemical compound data from PubChem database. IUPAC Name: 5-phenylpentyl acetate. Molecular Formula: C13H18O2. Molecular Weight: 206.28. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527291: 5-Phenylpentyl acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527291","description":"Access the complete Compound 527291: 5-Phenylpentyl acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5yq7-qedn","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["innovation","research","pubchem","patent","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5yq7-qedn","description":"The present invention relates to improvements in or relating to vegetation cutter apparatus. In particular, it relates to improvements in construction and manufacture of housings for lawn mowers. We describe a lawnmower having a deck with a lower surface defining a cutting chamber, a cutting element mounted within the cutting chamber, a motor assembly driving the cutter element, the motor being mounted on an upper surface of the deck, wherein the vegetation cutting apparatus further comprises a discharge chute having a discharge chute inlet in communication with the cutting chamber and a discharge chute outlet, a cover covering at least a portion of the motor assembly, and a pivotable deflector guard biased into a closed configuration against the discharge chute outlet. The discharge chute comprises a chute floor, chute sides and a chute roof. The present invention is characterised in that at least a portion of the chute roof is formed by a portion of the motor cover.","title":"Patent AT-E401774-T1: [Translated] IMPROVEMENTS TO A VEGETATION CUTTING APPARATUS","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401774-T1","description":"Access the complete Patent AT-E401774-T1: [Translated] IMPROVEMENTS TO A VEGETATION CUTTING APPARATUS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5yr5-gj3x","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["compound","chemistry","research","science","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5yr5-gj3x","description":"Chemical compound data from PubChem database. IUPAC Name: pentacos-1-ene. Molecular Formula: C25H50. Molecular Weight: 350.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 528972: 1-Pentacosene","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/528972","description":"Access the complete Compound 528972: 1-Pentacosene on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5yv4-zdrn","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","patent","pubchem","chemistry","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5yv4-zdrn","description":"Chemical patent from PubChem database. Patent Number: AT-E401309-T1. Title: Novel Drug Delivery System. Filing Date: 2000-08-03. Inventors: Patel, Amit, Jones, Michael. Abstract: The present invention discloses a drug delivery system designed to provide targeted and sustained release of therapeutic agents, improving patient com... IPC Classifications: C07D, C07F, A61K. This patent covers 31 claims related to 6 chemical compounds. Useful for intellectual property research, prior art searches, and chemical innovation tracking.","title":"Patent AT-E401309-T1: [Translated] USE OF 2-FUORO-3-KETO ESTERS TO PRODUCE 3-FUORO-6,7,8,9-TETRAHYDRO-4H-PYRIMIDOÄ1,2-AUPYRIMIDINE-4-ONENES","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E401309-T1","description":"Access the complete Patent AT-E401309-T1: [Translated] USE OF 2-FUORO-3-KETO ESTERS TO PRODUCE 3-FUORO-6,7,8,9-TETRAHYDRO-4H-PYRIMIDOÄ1,2-AUPYRIMIDINE-4-ONENES on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/statesystem/index.html","bureauCode":["009:20"],"issued":"2023-07-18","@type":"dcat:Dataset","modified":"2025-04-01","keyword":["osh","e-cigarette","legislation","state system","preemption","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"OSHData Support","hasEmail":"mailto:nccdoshinquiries@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/piju-vf3p","description":"1995-2024. Centers for Disease Control and Prevention (CDC). State Tobacco Activities Tracking and Evaluation (STATE) System. E-Cigarette Legislation—Preemption. The STATE System houses current and historical state-level legislative data on tobacco use prevention and control policies. Data are reported on a quarterly basis. Data include information related to statutory state preemption of more stringent local laws on advertising, smokefree indoor air, youth access and licensure.","title":"CDC STATE System E-Cigarette Legislation - Preemption","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/piju-vf3p/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/piju-vf3p/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/piju-vf3p/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/piju-vf3p/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/piju-vf3p/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/piju-vf3p/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"describedBy":"https://chronicdata.cdc.gov/Legislation/CDC-STATE-System-E-Cigarette-Legislation-Preemptio/piju-vf3p","license":"http://opendatacommons.org/licenses/by/1.0/","theme":["Legislation"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ywq-6hda","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","cooperation-game-theory","payoff-variations","prisoners-dilemma","evolutionary-biology"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/5ywq-6hda","description":"Background\n The Prisoner's Dilemma (PD) is a widely used paradigm to study cooperation in evolutionary biology, as well as in fields as diverse as moral philosophy, sociology, economics and politics. Players are typically assumed to have fixed payoffs for adopting certain strategies, which depend only on the strategy played by the opponent. However, fixed payoffs are not realistic in nature. Utility functions and the associated payoffs from pursuing certain strategies vary among members of a population with numerous factors. In biology such factors include size, age, social status and expected life span; in economics they include socio-economic status, personal preference and past experience; and in politics they include ideology, political interests and public support. Thus, no outcome is identical for any two different players.\n \n \n Results\n We show that relaxing the assumption of fixed payoffs leads to frequent violations of the payoff structure required for a Prisoner's Dilemma. With variance twice the payoff interval in a linear PD matrix, for example, only 16% of matrices are valid.\n \n \n Conclusions\n A single player lacking a valid PD matrix destroys the conditions for a Prisoner's Dilemma, so between any two players, PD games themselves are fewer still (3% in this case). This may explain why the Prisoner's Dilemma has hardly been found in nature, despite the fact that it has served as a ubiquitous (and still instructive) model in studies of the evolution of cooperation.","title":"Individual variation evades the Prisoner's Dilemma","programCode":["009:034"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC128816/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.dcss.ca.gov/","issued":"2017-06-16","temporal":"FFY 2015 - FFY 2025","@type":"dcat:Dataset","modified":"2026-03-26","keyword":["acknowledgment","california children","counties","dcss","department of child support","establishment","iv-d cases","iv-d program","parentage","paternity","pop declarations","voluntary"],"contactPoint":{"@type":"vcard:Contact","fn":"California Department of Child Support Services","hasEmail":"mailto:DCSSOpenData@dcss.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"60aabbbd-bd37-4e2d-aa5f-bbbc872e6310","description":"This dataset provides data on the number of children in the child support caseload who have had paternity established judicially or paternity established via voluntary acknowledgment in each county.","title":"Department of Child Support Services Paternity Establishment FFY 2015 - FFY 2024","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/60aabbbd-bd37-4e2d-aa5f-bbbc872e6310/resource/d9b60447-87b4-43ca-91c7-96476b70cb6d/download/dcss-paternity-establishment.csv","description":"This dataset provides data on the number of children in the child support caseload who have had paternity established judicially or paternity established via voluntary acknowledgment in each county.","@type":"dcat:Distribution","title":"Department of Child Support Services Paternity Establishment"},{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/datastore/dictionary_download/d9b60447-87b4-43ca-91c7-96476b70cb6d","description":"Data Dictionary for https://data.chhs.ca.gov/dataset/60aabbbd-bd37-4e2d-aa5f-bbbc872e6310/resource/d9b60447-87b4-43ca-91c7-96476b70cb6d/download/dcss-paternity-establishment.csv","@type":"dcat:Distribution","title":"Data Dictionary - Department of Child Support Services Paternity Establishment"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/60aabbbd-bd37-4e2d-aa5f-bbbc872e6310/resource/c2336d53-6ff6-423c-af23-093f88646622/download/paternity-establishment-f5_gu6gi.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P1Y","theme":["Demographics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5yyy-qav3","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","evidence-based-practices","block-grant-data","mental-health-services","noms-measures"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5yyy-qav3","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2010. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2010 CMHS Uniform Reporting System (URS) Output Tables for New Jersey","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2010-cmhs-uniform-reporting-system-urs-output-tables-new-jersey","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["prescription-drugs","drug","health-care","medications","public-health"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA209688","description":"Potassium Chloride is an injectable prescription drug used to treat or prevent low potassium levels in the blood. It comes as a 2 mEq/mL solution in 10 mL glass vials, administered intravenously by healthcare professionals. Manufactured by Nexus Pharmaceuticals LLC under ANDA217704. This information was generated using AI and is provided for informational and research purposes only.","title":"Potassium chloride","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=209688","description":"\n Access the FDA dataset for Potassium chloride — ANDA 209688 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Potassium chloride"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5z4i-p2r2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","science","research","pubchem","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5z4i-p2r2","description":"Chemical compound data from PubChem database. IUPAC Name: 2,3-dichloropropyl pentanoate. Molecular Formula: C8H14Cl2O2. Molecular Weight: 213.1. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525113: 2,3-Dichloropropyl pentanoate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525113","description":"Access the complete Compound 525113: 2,3-Dichloropropyl pentanoate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5z6b-gfhh","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","substance-abuse-treatment","alcohol-drug-abuse","kansas","n-ssats"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5z6b-gfhh","description":"This state profile includes data from facilities in Kansas that reported to N-SSATS for the survey reference date March 31, 2010. Data were collected on the location, characteristics, services offered, and number of clients in treatment at alcohol and drug abuse treatment facilities (both public and private) in Kansas. In Kansas, 211 substance abuse treatment facilities were included in the 2010 N-SSATS, reporting that there were 10,451 clients in substance abuse treatment on March 31, 2010. The survey response rate in Kansas was 95.0%.","title":"2010 State Profile — Kansas","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2010-state-profile-kansas","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5z7i-xxhq","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["substance","references","pubchem","chemistry","bioactivity"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5z7i-xxhq","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864417: MLS000080525","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864417","description":"Access the complete Substance 864417: MLS000080525 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5z7p-c3eq","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2022-12-20","references":["https://download.medicaid.gov/data/Spreadsheet_Footnotes.pdf"],"keyword":["drug products"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"52d7cf12-5c8d-450c-884d-7dca2632142a","description":"The Reference Document link for the downable Blood Disorder Treatment Spreadsheet can be accessed below under the Additional Information table under Related Documents.","title":"Pricing Comparison for Blood Disorder Treatments (Pricing as of 12/1/2021)","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.medicaid.gov/sites/default/files/uploaded_resources/Clotting-Factor-Dec2021.csv","mediaType":"text/csv"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["Drug Pricing and Payment"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5z93-djj4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["patent","pubchem","research","chemistry","innovation"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5z93-djj4","description":"An ophthalmic composition characterized in that at least one histidine derivative is incorporated in an aqueous medium.","title":"Patent AT-E400269-T1: [Translated] OPHTALMIC PREPARATION CONTAINING A HISTIDINE DERIVATIVE FOR THE TREATMENT OF THE IRRITATED EYE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400269-T1","description":"Access the complete Patent AT-E400269-T1: [Translated] OPHTALMIC PREPARATION CONTAINING A HISTIDINE DERIVATIVE FOR THE TREATMENT OF THE IRRITATED EYE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5za9-i9j2","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","research","science","pubchem","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5za9-i9j2","description":"Chemical compound data from PubChem database. IUPAC Name: 7-butyl-6-pentyltridecane. Molecular Formula: C22H46. Molecular Weight: 310.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530348: Tridecane, 7-butyl-6-pentyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530348","description":"Access the complete Compound 530348: Tridecane, 7-butyl-6-pentyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5zd5-hk66","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["social","acf","child","childr","service"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5zd5-hk66","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"OCIO Logo","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/5219","description":"Access the complete OCIO Logo on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5zdb-5vr4","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","compound","pubchem","research","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5zdb-5vr4","description":"Chemical compound data from PubChem database. IUPAC Name: 6-pentyltridecane. Molecular Formula: C18H38. Molecular Weight: 254.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530346: Tridecane, 6-pentyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530346","description":"Access the complete Compound 530346: Tridecane, 6-pentyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5zdu-86ky","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","research","innovation","chemistry","patent"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5zdu-86ky","description":"The present invention relates to an improved method for manufacturing (meth)acrylic anhydride by transanhydrization between (meth)acrylic acid and acetic anhydride, in the presence of air and in the presence of at least one polymerization inhibitor, characterized in that the polymerization inhibitor is chosen from the group formed from (a) metal salts of thiocarbamic or dithiocarbamic acid and their mixtures with a phenolic derivative or phenothiazine and its derivatives, and (b) N-oxyl compounds as a mixture with 2,6-di-tert-butyl-4-methylphenol taken alone or in the presence of 2,4-dimethyl-6-tert-butylphenol.","title":"Patent AT-E400544-T1: [Translated] IMPROVED METHOD FOR PRODUCING A (METH)ACRYL HYDRIDE","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/patent/AT-E400544-T1","description":"Access the complete Patent AT-E400544-T1: [Translated] IMPROVED METHOD FOR PRODUCING A (METH)ACRYL HYDRIDE on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/hfi4-8gfu","issued":"2018-10-22","@type":"dcat:Dataset","modified":"2018-10-29","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"Elizabeth Kimball","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/hfi4-8gfu","description":"Lead in Drinking Water in Schools test results - Everson Elementary","title":"Everson Elementary","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/hfi4-8gfu/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://www.hcai.ca.gov","issued":"2018-08-16","temporal":"On a quarterly basis (every three months). There will be a 5 year trend on most data resources, however, there may be a link to more current data in the data resources list. You may also search for specific facility reports using the SIERA application.","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["expenses","hospital","ogi","quarterly financial and utilization report","revenues","utilization"],"contactPoint":{"@type":"vcard:Contact","fn":"Accounting and Reporting Systems Section","hasEmail":"mailto:dataandreports@hcai.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"86b3f765-c05c-40e5-9e2e-4b70fed6abe3","description":"The summation contains updated data which reflect all corrections made by HCAI audit staff and hospital representatives. Each file consists of one rolling 4th quarter file for the respective calendar year of data. Comparison of the previously released data files with the revised data files may not have a material effect on statewide aggregations, but may have a significant effect on the data for individual hospitals.","title":"Pre-2012 Hospital Quarterly Financial & Utilization Report - Sum of Four Quarters","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/hospital-quarterly-financial-utilization-report-sum-of-four-quarters","mediaType":"text/html","title":"Post-2011 Hospital Quarterly Financial & Utilization Report - Sum of Four Quarters"},{"mediaType":"text/html","downloadURL":"https://siera.oshpd.ca.gov/FinancialDisclosure.aspx","description":"Financial Disclosure Report site, where you can view and save detailed financial disclosure reports submitted by California’s 450 hospitals and 1,200 long-term care facilities.","@type":"dcat:Distribution","title":"Individual Facility Report Search (SIERA)"},{"mediaType":"application/vnd.openxmlformats-officedocument.wordprocessingml.document","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/1afb5f04-3af5-49ee-9473-40a2739f4004/download/data-importing-instructions-for-excel.docx","description":"Please note that this data contains fields with leading zeroes. In order to use this data with Microsoft Excel, you must save the file to your computer and then import the data. If you double-click on the .csv file and allow Excel to open the file automatically, the leading zeroes will disappear.","@type":"dcat:Distribution","title":"Data Importing Instructions for Excel"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/b8a690d1-c813-4e8e-b2a6-af7daa70b5d2/download/hospital-quarterly-sum-of-qtrs-2011q4r4-revised-715.xls","mediaType":"application/vnd.ms-excel","title":"2011 Quarter 4 - Sum of Four Quarters (Revised July 2015)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/a5614cf1-0045-4602-a2fd-becd73383459/download/hospital-quarterly-sum-of-qtrs-2011q3r4.xls","mediaType":"application/vnd.ms-excel","title":"2011 Quarter 3 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/1cf9b6bb-cb59-4793-9003-8921808370bf/download/hospital-quarterly-sum-of-qtrs-2011q2r4.xls","mediaType":"application/vnd.ms-excel","title":"2011 Quarter 2 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/d1ead34b-fecc-4cf1-8c57-9a20da36f4b1/download/hospital-quarterly-sum-of-qtrs-2011q1r4.xls","mediaType":"application/vnd.ms-excel","title":"2011 Quarter 1 - Sum of Four Quarters (this is really one the other is Q4)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/6b5b86d6-fde6-4934-bae3-fbf711a465ce/download/hospital-quarterly-sum-of-qtrs-2010q4r4-revised-1012.xls","mediaType":"application/vnd.ms-excel","title":"2010 Quarter 4 - Sum of Four Quarters (Revised October 2012)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/ea102549-9a9b-4146-ba70-69a37a86bc1b/download/hospital-quarterly-sum-of-qtrs-2010q3r4.xls","mediaType":"application/vnd.ms-excel","title":"2010 Quarter 3 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/7a1b05db-3615-46cd-bb29-b50554041c81/download/hospital-quarterly-sum-of-qtrs-2010q2r4.xls","mediaType":"application/vnd.ms-excel","title":"2010 Quarter 2 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/804ca50a-6d49-4762-b7a4-293f028e934e/download/hospital-quarterly-sum-of-qtrs-2010q1r4.xls","mediaType":"application/vnd.ms-excel","title":"2010 Quarter 1 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/dacc8397-40a5-47d2-a397-9d27173ff31e/download/hospital-quarterly-sum-of-qtrs-2009q4r4-revised-411.xls","mediaType":"application/vnd.ms-excel","title":"2009 Quarter 4 - Sum of Four Quarters (Revised April 2011)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/878b8c58-ea79-4de4-ba93-7d61dced8f51/download/hospital-quarterly-sum-of-qtrs-2009q3r4.xls","mediaType":"application/vnd.ms-excel","title":"2009 Quarter 3 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/78cb73c8-442a-42ee-86a6-a943e438f131/download/hospital-quarterly-sum-of-qtrs-2009q2r4.xls","mediaType":"application/vnd.ms-excel","title":"2009 Quarter 2 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/9d16b5bf-acf8-4a60-9210-f98c520a4ec4/download/hospital-quarterly-sum-of-qtrs-2009q1r4.xls","mediaType":"application/vnd.ms-excel","title":"2009 Quarter 1 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/caf7ac70-4ca2-40c8-9bb1-d827a1ba3022/download/hospital-quarterly-sum-of-qtrs-2008q4r4-revised-411.xls","mediaType":"application/vnd.ms-excel","title":"2008 Quarter 4 - Sum of Four Quarters (Revised April 2011)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/51ec6260-d6bb-4109-8cc0-0e24349f5445/download/hospital-quarterly-sum-of-qtrs-2008q3r4.xls","mediaType":"application/vnd.ms-excel","title":"2008 Quarter 3 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/5fa06aea-3df5-40ea-850b-ad2c2683b72c/download/hospital-quarterly-sum-of-qtrs-2008q2r4.xls","mediaType":"application/vnd.ms-excel","title":"2008 Quarter 2 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/1f05e632-3298-435c-8dc7-eceb1fe9e0ce/download/hospital-quarterly-sum-of-qtrs-2008q1r4.xls","mediaType":"application/vnd.ms-excel","title":"2008 Quarter 1 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/6acbb618-f778-4be8-8e6e-d2b75a4e8bea/download/hospital-quarterly-sum-of-qtrs-2007q4r4-revised-510.xls","mediaType":"application/vnd.ms-excel","title":"2007 Quarter 4 - Sum of Four Quarters (Revised May 2010)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/6b75b560-03b4-4523-8b0d-e6158b737db0/download/hospital-quarterly-sum-of-qtrs-2007q3r4.xls","mediaType":"application/vnd.ms-excel","title":"2007 Quarter 3 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/7c415de8-9cc3-4d68-9fed-ef61b032487b/download/hospital-quarterly-sum-of-qtrs-2007q2r4.xls","mediaType":"application/vnd.ms-excel","title":"2007 Quarter 2 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/d608b79d-c871-4340-b567-a0fd7a5df828/download/hospital-quarterly-sum-of-qtrs-2007q1r4.xls","mediaType":"application/vnd.ms-excel","title":"2007 Quarter 1 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/a2f383d4-4d62-467a-97ad-c9044d27c082/download/hospital-quarterly-sum-of-qtrs-2006q4r4-revised-517.xls","mediaType":"application/vnd.ms-excel","title":"2006 Quarter 4 - Sum of Four Quarters (Revised May 2017)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/8bfabe74-65c7-4b0e-a7ea-d9eeeb4cb778/download/hospital-quarterly-sum-of-qtrs-2006q3r4.xls","mediaType":"application/vnd.ms-excel","title":"2006 Quarter 3 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/4f923aed-e521-49d5-adc0-4a0d51d57011/download/hospital-quarterly-sum-of-qtrs-2006q2r4.xls","mediaType":"application/vnd.ms-excel","title":"2006 Quarter 2 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/5b5c4fe7-23f0-46ec-b757-58e9fab88bc2/download/hospital-quarterly-sum-of-qtrs-2006q1r4.xls","mediaType":"application/vnd.ms-excel","title":"2006 Quarter 1 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/404c2eed-1d25-4224-bc81-73ec7746911d/download/hospital-quarterly-sum-of-qtrs-2005q4r4-revised-408.xls","mediaType":"application/vnd.ms-excel","title":"2005 Quarter 4 - Sum of Four Quarters (Revised April 2008)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/1078f54b-f8d6-497f-ab3e-55e0255c56c9/download/hospital-quarterly-sum-of-qtrs-2005q3r4.xls","mediaType":"application/vnd.ms-excel","title":"2005 Quarter 3 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/3efc0216-56db-4ba4-a11e-cf7651faa305/download/hospital-quarterly-sum-of-qtrs-2005q2r4.xls","mediaType":"application/vnd.ms-excel","title":"2005 Quarter 2 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/718a1a71-28bf-456a-b1f6-d9e149dba973/download/hospital-quarterly-sum-of-qtrs-2005q1r4.xls","mediaType":"application/vnd.ms-excel","title":"2005 Quarter 1 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/7207b4f9-ba16-4a02-97e1-2d88eeaf90ef/download/hospital-quarterly-sum-of-qtrs-2004q4r4-revised-507.xls","mediaType":"application/vnd.ms-excel","title":"2004 Quarter 4 - Sum of Four Quarters (Revised May 2007)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/20dbaa0e-6d84-458c-9cf6-1ca0742b7f22/download/hospital-quarterly-sum-of-qtrs-2004q3r4.xls","mediaType":"application/vnd.ms-excel","title":"2004 Quarter 3 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/2e47c27a-5bcd-44f1-a07f-e87aaec77543/download/hospital-quarterly-sum-of-qtrs-2004q2r4.xls","mediaType":"application/vnd.ms-excel","title":"2004 Quarter 2 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/af395ea4-eca5-44d9-a3cb-8573df71a7ef/download/hospital-quarterly-sum-of-qtrs-2004q1r4.xls","mediaType":"application/vnd.ms-excel","title":"2004 Quarter 1 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/122c07eb-7190-4255-b4dd-4cb936c80843/download/hospital-quarterly-sum-of-qtrs-2003q4r4-revised-507.xls","mediaType":"application/vnd.ms-excel","title":"2003 Quarter 4 - Sum of Four Quarters (Revised May 2007)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/daa6c8ca-0281-47a1-97a0-5caeceb13255/download/hospital-quarterly-sum-of-qtrs-2002q4r4-revised-507.xls","mediaType":"application/vnd.ms-excel","title":"2002 Quarter 4 - Sum of Four Quarters (Revised May 2007)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/0c703f49-8264-4e3b-ba49-fcb6305c4485/download/hospital-quarterly-sum-of-qtrs-2001q4r4-revised-507.xls","mediaType":"application/vnd.ms-excel","title":"2001 Quarter 4 - Sum of Four Quarters (Revised May 2007)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/2709cfca-ad28-45b6-85b8-2ec7ad41728a/download/hospital-quarterly-sum-of-qtrs-2000q4r4-revised-507.xls","mediaType":"application/vnd.ms-excel","title":"2000 Quarter 4 - Sum of Four Quarters (Revised May 2007)"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/8a198987-df4b-4f69-8c9e-80435c65e443/download/hospital-quarterly-sum-of-qtrs-1999q4r4.csv","mediaType":"text/csv","title":"1999 Quarter 4 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/4e591d93-5ce4-4fa9-a9f3-7c8a3af77796/download/hospital-quarterly-sum-of-qtrs-1998q4r4.csv","mediaType":"text/csv","title":"1998 Quarter 4 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/ab6c5743-b439-407e-a89a-290783ad16bb/download/hospital-quarterly-sum-of-qtrs-1997q4r4.csv","mediaType":"text/csv","title":"1997 Quarter 4 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/7eebca28-d252-4a0e-bd06-6c59204b4f80/download/hospital-quarterly-sum-of-qtrs-1996-documentation.pdf","mediaType":"application/pdf","title":"1996 Documentation - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/398db52b-5a50-4830-ad20-0731e6890be2/download/hospital-quarterly-sum-of-qtrs-1996q4r4.csv","mediaType":"text/csv","title":"1996 Quarter 4 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/b62a22b1-bc43-47a0-a8c5-808cb6808c08/download/hospital-quarterly-sum-of-qtrs-1995-documentation.pdf","mediaType":"application/pdf","title":"1995 Documentation - Sum of 4 Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/8b1072ac-48b2-4302-9330-85a075f93b62/download/hospital-quarterly-sum-of-qtrs-1995q4r4.csv","mediaType":"text/csv","title":"1995 Quarter 4 - Sum of Four Quarters"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/86b3f765-c05c-40e5-9e2e-4b70fed6abe3/resource/c63778f8-6309-4e00-a2dc-c6983a20ae69/download/pre-2012-hospital-quarterly-financial-utilization-report-sum-of-four-quarters-s30q_eez.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P3M","theme":["Facilities and Services"]},{"accessLevel":"public","landingPage":"https://www.fda.gov/drugs","bureauCode":["009:10"],"issued":"2016-09-16","@type":"dcat:Dataset","modified":"2025-03-17","keyword":["fda","public-health","health-care","drug-manufacturers","drug-safety"],"contactPoint":{"@type":"vcard:Contact","fn":"Division of Drug Information","hasEmail":"mailto:druginfo@fda.hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Food and Drug Administration"},"identifier":"ANDA214962","description":"TASCENSO ODT is an orally disintegrating tablet prescription drug containing fingolimod lauryl sulfate, available in 0.25 mg and 0.5 mg strengths. It acts as a sphingosine 1-phosphate receptor modulator, manufactured by Cycle Pharmaceuticals Ltd for oral use. This information was generated using AI and is provided for informational and research purposes only.","title":"Fingolimod lauryl sulfate","programCode":["009:002"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214962","description":"\n Access the FDA dataset for Fingolimod lauryl sulfate — ANDA 214962 submitted by Mylan Institutional LLC\n ","@type":"dcat:Distribution","title":"Fingolimod lauryl sulfate"}],"license":"https://open.fda.gov/license","accrualPeriodicity":"R/P1Y","theme":["FDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5zjg-xxhh","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["data-collection","survey-methodology","samhsa","substance-use","statistical-analysis"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5zjg-xxhh","description":"This Methodological Resource Book (MRB) is intended to serve as documentation of survey materials and methodology associated with the 2012 National Survey on Drug Use and Health (NSDUH). The MRB includes details associated with data collection and processing, including sampling, instrument testing and development, weighting, imputation, and statistical analyses and inferences.","title":"NSDUH 2012 Methodological Resource Book","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/nsduh-2012-methodological-resource-book","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/cbs4-kgh9","issued":"2019-02-20","@type":"dcat:Dataset","modified":"2019-02-20","keyword":["drinking water","lead","school"],"contactPoint":{"@type":"vcard:Contact","fn":"David, Dennis Alvin (DOH)","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/cbs4-kgh9","description":"Lead in Drinking Water in Schools Test Results – Valley View Early Childhood Center","title":"Valley View Early Childhood Center","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/cbs4-kgh9/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5zn3-jahy","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["metadata","research","adoption"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/5zn3-jahy","description":"ACF Children Bureau resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"What is an adoption home study? What type of information is included in it?","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/faq/adoption9","description":"Access the complete What is an adoption home study? What type of information is included in it? on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"http://www.cdc.gov/nccdphp/dph/","bureauCode":["009:20"],"issued":"2022-10-11","@type":"dcat:Dataset","modified":"2023-08-25","references":["https://www.cdc.gov/places/measure-definitions/index.html"],"keyword":["places","status","risk","prevention","prevalence","place","outcomes","health","city","brfss","behaviors"],"contactPoint":{"@type":"vcard:Contact","fn":"PLACES Public Inquiries","hasEmail":"mailto:places@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/q8ig-wwk9","description":"This dataset contains model-based place (incorporated and census designated places) level estimates for the PLACES 2021 release. PLACES is the expansion of the original 500 Cities Project and covers the entire United States—50 states and the District of Columbia (DC)—at county, place, census tract, and ZIP Code Tabulation Area (ZCTA) levels. It represents a first-of-its kind effort to release information uniformly on this large scale for local areas at 4 geographic levels. Estimates were provided by the Centers for Disease Control and Prevention (CDC), Division of Population Health, Epidemiology and Surveillance Branch. PLACES was funded by the Robert Wood Johnson Foundation (RWJF) in conjunction with the CDC Foundation. The dataset includes estimates for 29 measures: 4 chronic disease-related risk behaviors, 13 health outcomes, 3 health status, and 9 on using preventive services. These estimates can be used to identify emerging health problems and to help develop and carry out effective, targeted public health prevention activities. Because the small area model cannot detect effects due to local interventions, users are cautioned against using these estimates for program or policy evaluations. Data sources used to generate these model-based estimates include Behavioral Risk Factor Surveillance System (BRFSS) 2019 or 2018 data, Census Bureau 2010 population data, and American Community Survey (ACS) 2015–2019 or 2014–2018 estimates. The 2021 release uses 2019 BRFSS data for 22 measures and 2018 BRFSS data for 7 measures (all teeth lost, dental visits, mammograms, cervical cancer screening, colorectal cancer screening, core preventive services among older adults, and sleeping less than 7 hours a night). Seven measures are based on the 2018 BRFSS because the relevant questions are only asked every other year in the BRFSS. More information about the methodology can be found at www.cdc.gov/places.","title":"PLACES: Local Data for Better Health, Place Data 2021 release","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/q8ig-wwk9/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/q8ig-wwk9/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/q8ig-wwk9/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/q8ig-wwk9/query.geojson?accessType=DOWNLOAD","mediaType":"application/geo+json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/q8ig-wwk9/export.kml?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kml+xml"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/q8ig-wwk9/export.kmz?accessType=DOWNLOAD","mediaType":"application/vnd.google-earth.kmz"}],"describedBy":"https://chronicdata.cdc.gov/dataset/PLACES-Local-Data-for-Better-Health-Place-Data-202/eav7-hnsx","license":"http://opendefinition.org/licenses/odc-odbl/","theme":["500 Cities & Places"]},{"accessLevel":"public","landingPage":"https://data.wa.gov/d/yhr5-4xw4","issued":"2018-05-08","@type":"dcat:Dataset","modified":"2018-05-08","keyword":["drinking water. schools","lead"],"contactPoint":{"@type":"vcard:Contact","fn":"Willc13","hasEmail":"mailto:no-reply@data.wa.gov"},"publisher":{"@type":"org:Organization","name":"State of Washington"},"identifier":"https://data.wa.gov/api/views/yhr5-4xw4","description":"Evergreen School lead in drinking water test results","title":"Evergreen School 1","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.wa.gov/download/yhr5-4xw4/application/pdf","mediaType":"application/pdf"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5ztf-t4qa","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","pubchem","chemistry","bioactivity","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5ztf-t4qa","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864324: MLS000042220","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864324","description":"Access the complete Substance 864324: MLS000042220 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5zum-msrb","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["national-outcome-measures","samhsa","community-mental-health","mental-health-services","mental-health-utilization"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/5zum-msrb","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2012 Uniform Reporting System (URS) Tables for Wyoming","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-uniform-reporting-system-urs-tables-wyoming","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/5zuq-tmv9","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","bioactivity","chemistry","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/5zuq-tmv9","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 866129: MLS000080812","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/866129","description":"Access the complete Substance 866129: MLS000080812 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://aspe.hhs.gov/poverty-guidelines","issued":"2017-10-12","temporal":"2016 Quarter 1 to 2026 Quarter 1","@type":"dcat:Dataset","modified":"2026-06-08","keyword":["silver70","iap","insurance affordability programs","medi-cal eligibility","medi-cal enrollment","medi_cal","plans","qhp","qhp enrollees","qualified health plan enrollment","silver 73","silver 87","silver94","enhanced silver plan","metal tier","silver","covered california enrollment","covered ca","covered ca covered ca qhp eligibility","abx1 1","california eligibility and enrollment report"],"contactPoint":{"@type":"vcard:Contact","fn":"Covered California","hasEmail":"mailto:opendata@dhcs.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"a2034ac5-4ba7-4ebc-a2f4-787842e447ed","description":"This dataset includes the number of eligible individuals selected and enrolled in a Covered California Silver Plans by reporting period. Covered California offers four levels of Silver Plans: Silver 70 that covers standard benefits, and enhanced Silver 73, Silver 84, and Silver 94 that offer enhanced out-of-pocket savings through lower copays, coinsurance and deductibles to qualified individuals. Covered California reported data is from the California Healthcare Eligibility, Enrollment and Retention System (CalHEERS) and includes eligible individuals who selected and enrolled in a QHP, and paid their first premium. This dataset is part of public reporting requirements set forth by the California Welfare and Institutions Code 14102.5.","title":"Covered California Enrollees by Silver Plan","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/a2034ac5-4ba7-4ebc-a2f4-787842e447ed/resource/a47c41bc-6cee-4bda-8c1e-d3532f92f76a/download/4.4-silver-q1-2026_odp.csv","description":"This dataset includes the number of eligible individuals selected and enrolled in a Covered California Silver Plans by reporting period. Covered California offers four levels of Silver Plans: Silver 70 that covers standard benefits, and enhanced Silver 73, Silver 84, and Silver 94 that offer enhanced out-of-pocket savings through lower copays, coinsurance and deductibles to qualified individuals. Covered California reported data is from the California Healthcare Eligibility, Enrollment and Retention System (CalHEERS) and includes eligible individuals who selected and enrolled in a QHP, and paid their first premium. This dataset is part of public reporting requirements set forth by the California Welfare and Institutions Code 14102.5.","@type":"dcat:Distribution","title":"Covered California Enrollees by Silver Plan"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/a2034ac5-4ba7-4ebc-a2f4-787842e447ed/resource/1825aef0-7901-4cec-835f-1b37fd3442db/download/dhcstest_covered-california-enrollees-by-silver-plan-nodtt1r_.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"R/P3M","theme":["Healthcare"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/622w-iqu2","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","behavioral-health","facility-characteristics","samhsa","treatment-facilities"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/622w-iqu2","description":"These state profiles include data from facilities that reported to N-MHSS for the survey reference date April 30, 2020. The N-MHSS collects data on the location, characteristics, services offered, and number of clients (collected every other year) in treatment at mental health treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.","title":"2020 National Mental Health Services Survey (N-MHSS) State Profiles","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2020-national-mental-health-services-survey-n-mhss-state-profiles","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/622z-arqw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","science","research","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/622z-arqw","description":"Chemical compound data from PubChem database. IUPAC Name: cyclobutyl 5-chloropentanoate. Molecular Formula: C9H15ClO2. Molecular Weight: 190.67. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530479: 5-Chlorovaleric acid, cyclobutyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530479","description":"Access the complete Compound 530479: 5-Chlorovaleric acid, cyclobutyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/625r-ttrd","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nsduh","substance-use","mental-health","statistical-inference","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/625r-ttrd","description":"2014 NSDUH MRB Statistical Inference Report","title":"2014 NSDUH MRB Statistical Inference Report","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2014-nsduh-mrb-statistical-inference-report","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/6279-p4ft","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["chemistry","compound","pubchem","research","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/6279-p4ft","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 2-hydroxy-2-(3-nitrophenyl)-2-phenylacetate. Molecular Formula: C15H13NO5. Molecular Weight: 287.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526971: meta-alpha-Hydroxymononitrodiphenylacetic acid, methyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526971","description":"Access the complete Compound 526971: meta-alpha-Hydroxymononitrodiphenylacetic acid, methyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://data.cdc.gov/d/aeq9-xksa","bureauCode":["009:20"],"issued":"2024-11-15","@type":"dcat:Dataset","modified":"2026-01-14","contactPoint":{"@type":"vcard:Contact","fn":"Health Effects Laboratory Division, Toxicology and Molecular Biology Branch","hasEmail":"mailto:sa-cin-webteam@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/aeq9-xksa","description":"Nanomaterials represent a new class of materials with numerous industrial applications. Considering the projected increase in the production and use of nanomaterials, a corresponding increase in occupational exposure to nanomaterials and their resulting adverse health effects should be anticipated among workers. There is substantial evidence in the literature, based on cell culture and animal studies, supporting the potential toxicity and detrimental health effects associated with exposure to nanomaterials. Intervention and/or prevention of adverse health effects associated with occupational exposure to toxic nanomaterials will be a major concern for health providers and regulatory and non-regulatory government agencies as the use of nanomaterials expand. A key element in the intervention and/or prevention of the adverse health effects associated with occupational exposure to toxic nanomaterials is a clear understanding of the molecular mechanisms underlying the pulmonary toxicity induced by nanomaterials.\n\nDue to its physicochemical and mechanical properties, nanocellulose has found many applications in manufactured goods in the paper and food industry, cosmetics, biomedicine, and pharmaceuticals. There is potential for human exposure to nanocellulose or products that contain nanocellulose both during the production and use of the materials that contain nanocellulose. The objectives of the current study were to determine lung toxicity potential of crystalline nanocellulose (CNC) and the molecular mechanisms underlying the toxicity. A rat inhalation exposure model was employed to determine the lung toxicity potential of CNC. Global gene expression profile in the lung and bioinformatic analysis of the gene expression data were conducted to determine the molecular mechanisms underlying the CNC-induced lung toxicity.","title":"Lung toxicity and gene expression changes in response to whole-body inhalation exposure to cellulose nanocrystal in rats","programCode":["009:034"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/download/aeq9-xksa/application/x-zip-compressed","mediaType":"application/x-zip-compressed"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["National Institute for Occupational Safety and Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62c6-5mmp","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","compound","chemistry","science","research"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/62c6-5mmp","description":"Chemical compound data from PubChem database. IUPAC Name: methyl 15-methyl-2-trimethylsilyloxyhexadecanoate. Molecular Formula: C21H44O3Si. Molecular Weight: 372.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 530315: Hexadecanoic acid, 15-methyl-2-trimethylsilyloxy, methyl ester","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/530315","description":"Access the complete Compound 530315: Hexadecanoic acid, 15-methyl-2-trimethylsilyloxy, methyl ester on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62ci-ag2x","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["opioid-treatment","service-gap-analysis","samhsa","mat-access","kentucky-opioids"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/62ci-ag2x","description":"The purpose of the medication-assisted treatment (MAT) facility maps is to identify areas on a state-by-state basis that may be potentially underserved by existing treatment facilities. The maps are created with a methodology that seeks to include the highest potential need areas from individual counties so that county-level stakeholders are also informed. The maps are meant to be used as a tool for policy makers to determine potentially underserved areas—not as a definitive representation of these areas.","title":"Kentucky 2016 Potential Areas for Addressing Service Gaps for Opioid Treatment","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/kentucky-2016-potential-areas-addressing-service-gaps-opioid-treatment","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62cr-gjrm","bureauCode":["009:00"],"issued":"2026-05-22","@type":"dcat:Dataset","modified":"2023-11-06","keyword":["drug rebate program"],"contactPoint":{"@type":"vcard:Contact","fn":"Medicaid.gov","hasEmail":"mailto:Medicaid.gov@cms.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Medicare & Medicaid Services"},"identifier":"4d2b3013-7162-4ee7-8af3-849e41f0a7da","description":"The data below contains newly reported, active covered outpatient drugs which were reported by participating drug manufacturers since the last quarterly update of the Drug Products in the Medicaid Drug Rebate Program (MDRP) database.","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-10-30-to-2023-11-05","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.medicaid.gov/sites/default/files/uploaded_resources/mdrp-newly-rprt-drug-10-30-2023-to-11-05-2023.csv","mediaType":"text/csv","title":"Product Data for Newly Reported Drugs in the Medicaid Drug Rebate Program 2023-10-30-to-2023-11-05"}],"license":"http://www.usa.gov/publicdomain/label/1.0/","theme":["CMS"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62ct-ftv3","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["science","research","chemistry","compound","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/62ct-ftv3","description":"Chemical compound data from PubChem database. IUPAC Name: 2,4-dimethylthiolan-3-one. Molecular Formula: C6H10OS. Molecular Weight: 130.21. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529961: 2,4-Dimethylthiolan-3-one","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529961","description":"Access the complete Compound 529961: 2,4-Dimethylthiolan-3-one on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62dn-ye67","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["scope","child","instruction","policy","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/62dn-ye67","description":"This checklist was developed to ensure that APSR submissions include all required elements. States can use this checklist as a guide in writing their 2018 APSR and CAPTA update.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"State Checklist for the Child and Family Service Plan (CFSP)/Annual Progress and Services Report (APSR)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/grant-funding/state-checklist-child-and-family-service-plan-cfsp/annual-progress-and-services-0","description":"Access the complete State Checklist for the Child and Family Service Plan (CFSP)/Annual Progress and Services Report (APSR) on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62ei-6h8d","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","compound","research","science","chemistry"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/62ei-6h8d","description":"Chemical compound data from PubChem database. IUPAC Name: 2-hydroxy-N,5-dimethyl-4-propan-2-ylbenzamide. Molecular Formula: C12H17NO2. Molecular Weight: 207.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 529802: Benzamide, 2-hydroxy, 4-(1-methylethyl), N,5-dimethyl","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/529802","description":"Access the complete Compound 529802: Benzamide, 2-hydroxy, 4-(1-methylethyl), N,5-dimethyl on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62g3-7zw9","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","soil-properties","elephant-diet","mopane-plants","leaf-protein"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/62g3-7zw9","description":"Background\n Mopane (Colophospermum mopane) plants form monotypic woodlands that cover extensive areas in northern Botswana. Mopane is also a principal food item in the diet of elephants. Obtrusive damage to mopane plants as a result of elephant feeding may alter the structure of mopane woodlands. Some mopane woodland areas in northern Botswana are subjected to heavy elephant utilization rates whereas other mopane areas are less affected. However, the underlying reason for the concentrated elephant utilization is unknown.\n \n \n Results\n Ten mopane plots were subjected to sampling of soil properties that included structure, pH, nitrogen, phosphorus, potassium contents and protein contents. Elevated nitrogen and phosphorus contents in soils correlated with high protein levels in mopane leaves. Protein levels in leaves of mopane plants differed significantly between sites. However, multivariate analyses of environmental parameters and plots suggested that on a regional scale, there was no difference in the extent of elephant damage to mopane plants due to differential protein levels in leaves or any of the underlying soi factors that were examined.\n \n \n Conclusions\n From management perspective, this pattern mitigates the likelihood that an even more prolific elephant population will alter mopane woodland habitats irreversibly.","title":"The role of soil factors and leaf protein in the utilization of mopane plants by elephants in northern Botswana","programCode":["009:033"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC101375/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62gp-83f4","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["child","data","policy","social","fiscal"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/62gp-83f4","description":"This Information Memorandum (IM) provides information on Fiscal Year 1987 Title IV-B revised allotments.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Information Memorandum (IM-87-07)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/im-87-07","description":"Access the complete IM-87-07 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62ij-4h7g","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","research","pubchem","chemistry","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/62ij-4h7g","description":"Chemical compound data from PubChem database. IUPAC Name: N,N-dimethyl-N'-propan-2-ylethanimidamide. Molecular Formula: C7H16N2. Molecular Weight: 128.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525282: N'-Isopropyl-N,N-dimethyl-acetamidine","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525282","description":"Access the complete Compound 525282: N'-Isopropyl-N,N-dimethyl-acetamidine on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/s3du-3m47","issued":"2018-01-24","@type":"dcat:Dataset","modified":"2025-05-02","keyword":["potentially preventable complication","ppc","quality-safety-costs","ip-qm","sparcs","strategic initiatives","inpatient","efficiency","dsrip","all payer"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/s3du-3m47","description":"The dataset shows Potentially Preventable Complication (PPC) measures for the 36 major PPCs combined; providing observed, expected, and risk-adjusted rates and counts for all payer discharges by hospital and statewide, beginning in 2013. \n\nPotentially Preventable Complications (PPC), obtained from software created by 3M Health Information Systems, are defined as harmful events or negative outcomes that develop or occur during hospitalization and may result from processes of care and treatment rather than from natural progression of the underlying illness. \n\nThe PPCs were calculated using Statewide Planning and Research Cooperative System (SPARCS) inpatient data.","title":"Hospital Inpatient Discharges (SPARCS De-Identified): Major Potentially Preventable Complication (PPC) Rates by Hospital: Beginning 2013","distribution":[{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/s3du-3m47/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/s3du-3m47/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://health.data.ny.gov/api/v3/views/s3du-3m47/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Health"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62k4-9wa7","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["mental-health-services","block-grant-program","community-mental-health","noms-measures","samhsa"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/62k4-9wa7","description":"Center for Mental Health Services (CMHS) Uniform Reporting System (URS) Output Tables for 2012. The Uniform Reporting System (URS) is a state and national reporting system collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2012 Uniform Reporting System (URS) Tables for North Carolina","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2012-uniform-reporting-system-urs-tables-north-carolina","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62kr-muhi","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["policy","adoption","instruction","guidance","regulation"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/62kr-muhi","description":"This Program Instruction (PI) provides guidance on the Transition Rules for Implementing the Title IV-E Termination of Parental Rights Provision in the Adoption and Safe Families Act of 1997.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Program Instruction (PI-98-14)","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/policy-guidance/pi-98-14","description":"Access the complete PI-98-14 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62p8-6zxw","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["references","bioactivity","chemistry","pubchem","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/62p8-6zxw","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864954: MLS000083867","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864954","description":"Access the complete Substance 864954: MLS000083867 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62q8-b259","bureauCode":["005:84"],"rights":"Public","issued":"2021-02-25","@type":"dcat:Dataset","modified":"2014-08-21","keyword":["usda","training grants","health","food and nutrition service","meals and snacks","schools"],"contactPoint":{"@type":"vcard:Contact","fn":"FNS Datasets","hasEmail":"mailto:ITGB@fns.usda.gov"},"publisher":{"@type":"org:Organization","name":"US Department of Agriculture"},"identifier":"USDA-FNS-87","description":"This data set explains the USDA's purpose of putting $5.7 million in training grants and other new resources to help schools serve healthier meals and snacks. The data set states how these efforts will help states expand and enhance training programs that help schools encourage kids to make healthy choices.","title":"USDA Helps Schools Make Lunchrooms \"Smarter\" as Students Head Back to Class Notice","programCode":["005:054"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"http://www.fns.usda.gov/pressrelease/2014/fns-000614","mediaType":"text/html","title":"USDA Helps Schools Make Lunchrooms \"Smarter\" as Students Head Back to Class Notice"}],"dataQuality":true,"license":"https://creativecommons.org/publicdomain/zero/1.0/","theme":["USDA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62q9-43f2","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["child","acf","social","service","childr"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/62q9-43f2","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"CED Fact Sheet November 2018","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/12931","description":"Access the complete CED Fact Sheet November 2018 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62qj-mhpu","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["nih","rheumatoid-arthritis","clinical-trial","cox-2-inhibitors","etoricoxib-treatment"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/62qj-mhpu","description":"Background\n Etoricoxib is a highly selective COX-2 inhibitor which was evaluated for the treatment of rheumatoid arthritis (RA).\n \n \n Methods\n Double-blind, randomized, placebo and active comparator-controlled, 12-week study conducted at 67 sites in 28 countries. Eligible patients were chronic NSAID users who demonstrated a clinical worsening of arthritis upon withdrawal of prestudy NSAIDs. Patients received either placebo, etoricoxib 90 mg once daily, or naproxen 500 mg twice daily (2:2:1 allocation ratio). Primary efficacy measures included direct assessment of arthritis by counts of tender and swollen joints, and patient and investigator global assessments of disease activity. Key secondary measures included the Stanford Health Assessment Questionnaire, patient global assessment of pain, and the percentage of patients who achieved ACR20 responder criteria response (a composite of pain, inflammation, function, and global assessments). Tolerability was assessed by adverse events and routine laboratory evaluations.\n \n \n Results\n 1171 patients were screened, 891 patients were randomized (N = 357 for placebo, N = 353 for etoricoxib, and N = 181 for naproxen), and 687 completed 12 weeks of treatment (N = 242 for placebo, N = 294 for etoricoxib, and N = 151 for naproxen). Compared with patients receiving placebo, patients receiving etoricoxib and naproxen showed significant improvements in all efficacy endpoints (p<0.05). Treatment responses were similar between the etoricoxib and naproxen groups for all endpoints. The percentage of patients who achieved ACR20 responder criteria response was 41% in the placebo group, 59% in the etoricoxib group, and 58% in the naproxen group. Etoricoxib and naproxen were both generally well tolerated.\n \n \n Conclusions\n In this study, etoricoxib 90 mg once daily was more effective than placebo and similar in efficacy to naproxen 500 mg twice daily for treating patients with RA over 12 weeks. Etoricoxib 90 mg was generally well tolerated in RA patients.","title":"A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273]","programCode":["009:032"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC115849/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62qv-jtyv","bureauCode":["009:70"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["data","scope","child","policy","reporting"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/62qv-jtyv","description":"The Children's Bureau Data Analytics and Reporting Team held an AFCARS Open Office Hours for the implementation of AFCARS 2020 in December 2022. This session was for state and tribal program administrators, child welfare data leaders, and information system programmers. It was an opportunity to ask questions specific to an agency's implementation. Below is the slide deck of the question and answers that were presented during the session.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"AFCARS 2020 New Technical Bulletins and Intro to NCWDMS","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/training-technical-assistance/afcars2020-office-hours-dec2022","description":"Access the complete AFCARS 2020 New Technical Bulletins and Intro to NCWDMS on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62qy-hscm","bureauCode":["009:25"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["erythropoietin","thalassemia","globin-genes","nih","hemoglobin-f"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH","hasEmail":"mailto:info@nih.gov"},"publisher":{"@type":"org:Organization","name":"National Institutes of Health"},"identifier":"https://healthdata.gov/api/views/62qy-hscm","description":"Background\n The thalassemic syndromes originate from mutations of the globin genes that cause, besides the characteristic clinical picture, also an increased Hb F amount. It is not yet clear if there are more factors, besides the beta globin genotype, determining the Hb F production. We have tried to find out if there are relations between total Hb and Hb F, between erythropoietin (Epo) and Hb F, between Hb F and point mutations of the gamma gene promoters.\n \n \n Materials and Methods\n Hematologic parameters, iron status, alpha/non-alpha globin ratio, Epo level, and thalassemic defects of the alpha-, beta-, and gamma-globin genes were explored using standard methods in patients affected by thalassemic diseases. Ninety-five non thalassemic individuals have been examined as controls.\n \n \n Results\n Two clinical variants of beta-thalassemia intermedia referred to as beta-thal int sub-silent and evident are associated with distinct sets of mutations of the beta-globin gene. Silent beta thal mutations are invariably associated with sub-silent beta thal int; beta° or severe beta+ thal mutations are associated with evident beta thal int (88%) and almost invariably (98%) with thalassemia major. A positive correlation was observed between the severity of the disease and the Hb F level, but no correlation was found between the Hb F and erythropoietin (Epo) level. The mutation Ggamma -158 C→T was detected in 26.9% of patients affected by beta-thal int sub-silent and evident, respectively, but only in 2% of patients with thalassemia major.\n \n \n Conclusions\n The severity of beta-thal int and the increased Hb F level are strictly dependent from the type of beta-globin gene mutations. No relation is found between Hb F synthesis and Epo secretion. The mutation Ggamma -158 C→T, common among patients affected by beta-thal int and very rare in thal major patients, does not seem, in this study, to influence the Hb F content in beta thal int patients.","title":"Factors regulating Hb F synthesis in thalassemic diseases","programCode":["009:048"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC101377/","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdc.gov/nchs/covid19/covid-19-mortality-data-files.htm","bureauCode":["009:20"],"issued":"2020-05-15","@type":"dcat:Dataset","modified":"2025-04-21","keyword":["covid-19","deaths","age","coronavirus","mortality","all causes","weekly","united states","sex","provisional","nvss","nchs","age group"],"contactPoint":{"@type":"vcard:Contact","fn":"National Center for Health Statistics","hasEmail":"mailto:cdcinfo@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/vsak-wrfu","description":"Effective June 28, 2023, this dataset will no longer be updated. Similar data are accessible from CDC WONDER (https://wonder.cdc.gov/mcd-icd10-provisional.html).\n\nDeaths involving COVID-19 reported to NCHS by sex and age group and week ending date.","title":"Provisional COVID-19 Deaths by Week, Sex, and Age","programCode":["009:020"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/vsak-wrfu/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/vsak-wrfu/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/vsak-wrfu/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"spatial":"United States","license":"https://www.usa.gov/government-works","accrualPeriodicity":"irregular","theme":["National Center for Health Statistics"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62s8-cspz","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-29","keyword":["snap","metadata","sectional","cross","assessment"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/62s8-cspz","description":"ACF Agency Wide resource\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"An Early Look at Families and Local Programs in the Mother and Infant Home Visiting Program Evaluation-Strong Start - Research Snapshot","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/media/16469","description":"Access the complete An Early Look at Families and Local Programs in the Mother and Infant Home Visiting Program Evaluation-Strong Start - Research Snapshot.pdf on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62t3-2z95","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["adoption","policy","fiscal","data","scope"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/62t3-2z95","description":"This report provides state-specific data from fiscal year 2006 about adoptive family structure in public agency adoptions.\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Adoptive Family Structure: 10/1/2005 - 9/30/2006","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/adoptive-family-structure-10/1/2005-9/30/2006","description":"Access the complete Adoptive Family Structure: 10/1/2005 - 9/30/2006 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/62ta-rvvi","bureauCode":["009:00"],"issued":"2021-01-27","@type":"dcat:Dataset","modified":"2025-07-03","keyword":["covid-19-spr","covid-19"],"contactPoint":{"@type":"vcard:Contact","fn":"Data Strategy and Execution Workgroup","hasEmail":"mailto:COVID-Data-RFI@hhs.gov"},"publisher":{"@type":"org:Organization","name":"U.S. Department of Health and Human Services"},"identifier":"https://healthdata.gov/api/views/62ta-rvvi","description":"After over two years of public reporting, the State Profile Report will no longer be produced and distributed after February 2023. The final release was on February 23, 2023. We want to thank everyone who contributed to the design, production, and review of this report and we hope that it provided insight into the data trends throughout the COVID-19 pandemic.\nData about COVID-19 will continue to be updated at CDC’s COVID Data Tracker.\n \n\n\nThe State Profile Report (SPR) is generated by the Data Strategy and Execution Workgroup in the Joint Coordination Cell, in collaboration with the White House. It is managed by an interagency team with representatives from multiple agencies and offices (including the United States Department of Health and Human Services (HHS), the Centers for Disease Control and Prevention, the HHS Assistant Secretary for Preparedness and Response, and the Indian Health Service). The SPR provides easily interpretable information on key indicators for each state, down to the county level.\n
\n\nIt is a weekly snapshot in time that:\nThe VICP program publishes a summary PDF report with several data tables:
\nNumber of Petitions Filed by Adjudication Categories by Alleged Vaccine, including # of doses distributed (2006-2014)
\nNumber of Petitions Filed, Compensated, and Dismissed by Alleged Vaccine (cumulative 1998 through 2016)
\nNumber of Petitions Filed by year (1998-2017)
\nNumber of Adjudications compensable, dismissed and total (FY1989 - FY2017)
\nAwards paid including amounts, attorneys fees, and total outlays (FY1989 - FY2016)
\nThe NIDDK Information Network serves the needs of basic and clinical investigators by providing seamless access to large pools of data relevant to the mission of NIDDK. The goal of DKnet is to develop a community-based network for integration across disciplines to include the larger DK universe of diseases, investigators, and potential users.
","title":"dkNET","programCode":["009:110"],"license":"https://opendatacommons.org/licenses/odbl/1.0/","dataQuality":true},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/65x5-2pfn","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["research","chemistry","compound","pubchem","science"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/65x5-2pfn","description":"Chemical compound data from PubChem database. IUPAC Name: 2-(4-methylcyclohex-3-en-1-yl)propyl acetate. Molecular Formula: C12H20O2. Molecular Weight: 196.29. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 527144: 1-p-Menthen-9-yl acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/527144","description":"Access the complete Compound 527144: 1-p-Menthen-9-yl acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/65xv-bj96","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["bioactivity","pubchem","substance","chemistry","references"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/65xv-bj96","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 864646: MLS000042291","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/864646","description":"Access the complete Substance 864646: MLS000042291 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.cdph.ca.gov/Programs/CCDPHP/DCDIC/NEOPB/Pages/Program-Landing2.aspx","issued":"2017-06-16","temporal":"2012 and 2013","@type":"dcat:Dataset","modified":"2025-11-07","keyword":["adolescent","adult","beverage","child","drink","soda","ssb","sugar","sugar-sweetened"],"contactPoint":{"@type":"vcard:Contact","fn":"Center for Chronic Disease Prevention and Health Promotion/Chronic Disease and Injury Control/Nutrition Education and Obesity Prevention Branch/Research and Evaluation Section","hasEmail":"mailto:opendata@cdph.ca.gov"},"publisher":{"@type":"org:Organization","name":"State of California"},"identifier":"bb703230-1f5f-44b5-8a90-55e45e08c452","description":"The mean servings/times sugar-sweetened beverages consumed daily by California residents. These data are from the 2013 California Dietary Practices Surveys (CDPS), 2012 California Teen Eating, Exercise and Nutrition Survey (CalTEENS), and 2013 California Children’s Healthy Eating and Exercise Practices Survey (CalCHEEPS). These surveys are now discontinued. Adults, adolescents, and children (with parental assistance) were asked about the sugar-sweetened beverages they drank over the previous 24 hour period. Child/Adolescent: Fruit and vegetable, beverage, and junk food consumption, along with physical activity, sedentary time, active transport, sport participation, school environment, home neighborhood environment, fruit and vegetable access and availability, household/family rules, weight status, school breakfast/lunch participation, attitudes, and beliefs. Adult: Fruit and vegetable, beverage, and junk food consumption, along with physical activity, sedentary time, worksite environment, school environment, home neighborhood environment, fruit and vegetable access and availability, household/family rules, weight status and weight loss practices, and food security. According to the Dietary Guidelines for Americans, 2010, sugar-sweetened beverages provide excess calories and few essential nutrients to the diet and should only be consumed when nutrient needs have been met and without exceeding daily calorie limits.","title":"Sugar-Sweetened Beverage Consumption in California Residents","distribution":[{"mediaType":"text/csv","downloadURL":"https://data.chhs.ca.gov/dataset/bb703230-1f5f-44b5-8a90-55e45e08c452/resource/4a8dde27-c4e1-4ca3-860b-447d813b2ce6/download/sugar-sweetened-beverage-consumption-in-california-residents-20122013.csv","description":"The mean servings/times sugar-sweetened beverages consumed daily by California residents. These data are from the 2013 California Dietary Practices Surveys (CDPS), 2012 California Teen Eating, Exercise and Nutrition Survey (CalTEENS), and 2013 California Children’s Healthy Eating and Exercise Practices Survey (CalCHEEPS). These surveys are now discontinued. Adults, adolescents, and children (with parental assistance) were asked about the sugar-sweetened beverages they drank over the previous 24 hour period. Child/Adolescent: Fruit and vegetable, beverage, and junk food consumption, along with physical activity, sedentary time, active transport, sport participation, school environment, home neighborhood environment, fruit and vegetable access and availability, household/family rules, weight status, school breakfast/lunch participation, attitudes, and beliefs. Adult: Fruit and vegetable, beverage, and junk food consumption, along with physical activity, sedentary time, worksite environment, school environment, home neighborhood environment, fruit and vegetable access and availability, household/family rules, weight status and weight loss practices, and food security. According to the Dietary Guidelines for Americans, 2010, sugar-sweetened beverages provide excess calories and few essential nutrients to the diet and should only be consumed when nutrient needs have been met and without exceeding daily calorie limits.","@type":"dcat:Distribution","title":"Sugar-Sweetened Beverage Consumption in California Residents, 2012/2013 (CSV)"},{"mediaType":"application/pdf","downloadURL":"https://data.chhs.ca.gov/dataset/bb703230-1f5f-44b5-8a90-55e45e08c452/resource/3936eb87-9ffb-4e73-b9dd-54536259c586/download/sugar-sweetenedbeverageconsumptionincaliforniaresidents2012-2013.pdf","description":"The mean servings/times sugar-sweetened beverages consumed daily by California residents. These data are from the 2013 California Dietary Practices Surveys (CDPS), 2012 California Teen Eating, Exercise and Nutrition Survey (CalTEENS), and 2013 California Children’s Healthy Eating and Exercise Practices Survey (CalCHEEPS). These surveys are now discontinued. Adults, adolescents, and children (with parental assistance) were asked about the sugar-sweetened beverages they drank over the previous 24 hour period. Child/Adolescent: Fruit and vegetable, beverage, and junk food consumption, along with physical activity, sedentary time, active transport, sport participation, school environment, home neighborhood environment, fruit and vegetable access and availability, household/family rules, weight status, school breakfast/lunch participation, attitudes, and beliefs. Adult: Fruit and vegetable, beverage, and junk food consumption, along with physical activity, sedentary time, worksite environment, school environment, home neighborhood environment, fruit and vegetable access and availability, household/family rules, weight status and weight loss practices, and food security. According to the Dietary Guidelines for Americans, 2010, sugar-sweetened beverages provide excess calories and few essential nutrients to the diet and should only be consumed when nutrient needs have been met and without exceeding daily calorie limits.","@type":"dcat:Distribution","title":"sugar-sweetened-beverage-consumption-in-california-residents-2012-2013"},{"@type":"dcat:Distribution","downloadURL":"https://data.chhs.ca.gov/dataset/bb703230-1f5f-44b5-8a90-55e45e08c452/resource/8be299e0-8fa2-4489-a67e-863eb061cece/download/sugar-sweetened-beverage-consumption-in-california-residents-2012-2013-0plwud91.zip","mediaType":"application/zip","title":"All resource data"}],"license":"http://opendefinition.org/licenses/odc-odbl/","accrualPeriodicity":"irregular","theme":["Demographics"]},{"accessLevel":"public","landingPage":"https://covid.cdc.gov/covid-data-tracker/#vaccine-confidence","bureauCode":["009:20"],"issued":"2022-07-06","@type":"dcat:Dataset","modified":"2023-08-03","keyword":["covid tracker","covid-19 vaccination","nis-acm"],"contactPoint":{"@type":"vcard:Contact","fn":"James Singleton","hasEmail":"mailto:VaxView@cdc.gov"},"publisher":{"@type":"org:Organization","name":"Centers for Disease Control and Prevention"},"identifier":"https://data.cdc.gov/api/views/qz99-wyhv","description":"National Immunization Survey-Adult COVID Module (NIS-ACM): CDC is providing information on COVID-19 vaccine confidence to supplement vaccine administration data. Trends in behavioral indicators represent the percent of unvaccinated people responding to each of the indicators by intent status and by week for the national-level view, and by month for the jurisdiction-level view.","title":"National Immunization Survey Adult COVID Module (NIS-ACM): Trends in Behavioral Indicators Among Unvaccinated People","programCode":["009:026"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/qz99-wyhv/export.csv?accessType=DOWNLOAD","mediaType":"text/csv"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/qz99-wyhv/query.json?accessType=DOWNLOAD","mediaType":"application/json"},{"@type":"dcat:Distribution","downloadURL":"https://data.cdc.gov/api/v3/views/qz99-wyhv/export.xml?accessType=DOWNLOAD","mediaType":"application/xml"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Vaccinations"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/65za-nvkx","bureauCode":["009:25"],"issued":"2025-09-04","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","references","bioactivity","substance"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/65za-nvkx","description":"Chemical substance data from PubChem database. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Substance 865859: MLS000083538","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/substance/865859","description":"Access the complete Substance 865859: MLS000083538 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/65zj-ye5q","bureauCode":["009:70"],"issued":"2025-09-03","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["child","adoption","data","fiscal","policy"],"contactPoint":{"@type":"vcard:Contact","fn":"ACF Data Team","hasEmail":"mailto:ohsepr@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Administration for Children and Families"},"identifier":"https://healthdata.gov/api/views/65zj-ye5q","description":"This page includes reports on state-specific adoption statistics for fiscal year 2010.\n\nReceiving Adoption Subsidy: 10/1/2009 - 9/30/2010\nAdoptive Family Structure: 10/1/2009 - 9/30/2010\nAge at Adoption Finalization: 10/1/2009 - 9/30/2010\nPrior Relationship of Adoptive Parent(s) to Child: 10/1/2009 - 9/30/2010\nRace/Ethnicity of Public Agency Children Adopted: 10/1/2009 - 9/30/2010\nSex of Public Agency Children Adopted: 10/1/2009 - 9/30/2010\nChild is Identified as a Special Needs Adoption: 10/1/2009 - 9/30/2010\nTime between Termination of Parental Rights (TPR) and Adoption Finalization: 10/1/2009 - 9/30/2010\n\nMetadata-only record linking to the original dataset. Open original dataset below.","title":"Adoption Data 2010","programCode":["009:045"],"distribution":[{"mediaType":"text/html","downloadURL":"https://acf.gov/cb/report/adoption-data-2010","description":"Access the complete Adoption Data 2010 on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://www.acf.hhs.gov/ofa/programs/tanf/data-reports","bureauCode":["009:70"],"issued":"2023-11-17","@type":"dcat:Dataset","modified":"2025-02-03","keyword":["family assistance"],"contactPoint":{"@type":"vcard:Contact","fn":"Sidonie Squier","hasEmail":"mailto:sidonie.squier@acf.hhs.gov"},"publisher":{"@type":"org:Organization","name":"ACF"},"identifier":"https://healthdata.gov/api/views/6623-9wb7","description":"The Characteristics and Financial Circumstances of TANF Recipients tables provide demographic data on the age and race/ethnicity of adults and children in TANF and Separate State Program (SSP)-Maintenance-of-Effort (MOE) active families and closed cases, as well as data on the financial circumstances of TANF cash assistance recipients.\n\nUnits of Response: TANF Recipients, States\n\nType of Data: Administrative\n\nTribal Data: No\n\nPeriodicity: Annual\n\nDemographic Indicators: Disability;Ethnicity;Household Size;Race\n\nSORN: Not Applicable\n\nData Use Agreement: https://www.ndacan.acf.hhs.gov/datasets/order_forms/termsofuseagreement.pdf\n\nData Use Agreement Location: Unavailable\n\nGranularity: State\n\nSpatial: United States\n\nGeocoding: State","title":"Characteristics and Financial Circumstances of TANF Recipients","programCode":["009:102"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.acf.hhs.gov/sites/default/files/documents/ofa/fy2020_characteristics_data_final.xlsx","description":"These tables provide demographic data on the age and race/ethnicity of adults and children in TANF and Separate State Program (SSP)-Maintenance-of-Effort (MOE) active families and closed cases, as well as data on the financial circumstances of TANF cash assistance recipients. Temporal: 10/1/2019-9/30/2020, Restriction: Public-use Aggregate, Formats: EXCEL, PDF","@type":"dcat:Distribution","title":"Characteristics and Financial Circumstances of TANF Recipients, Fiscal Year 2020"},{"mediaType":"text/html","downloadURL":"https://www.acf.hhs.gov/sites/default/files/documents/ofa/fy17_characteristics.xlsx","description":"These tables provide demographic data on the age and race/ethnicity of adults and children in TANF and Separate State Program (SSP)-Maintenance-of-Effort (MOE) active families and closed cases, as well as data on the financial circumstances of TANF cash assistance recipients. Temporal: 10/1/2016-9/30/2017, Restriction: Public-use Aggregate, Formats: EXCEL, PDF","@type":"dcat:Distribution","title":"Characteristics and Financial Circumstances of TANF Recipients, Fiscal Year 2017"},{"mediaType":"text/html","downloadURL":"https://www.acf.hhs.gov/sites/default/files/documents/ofa/fy18_characteristics_web.xlsx","description":"These tables provide demographic data on the age and race/ethnicity of adults and children in TANF and Separate State Program (SSP)-Maintenance-of-Effort (MOE) active families and closed cases, as well as data on the financial circumstances of TANF cash assistance recipients. Temporal: 10/1/2017-9/30/2018, Restriction: Public-use Aggregate, Formats: EXCEL, PDF","@type":"dcat:Distribution","title":"Characteristics and Financial Circumstances of TANF Recipients, Fiscal Year 2018"},{"mediaType":"text/html","downloadURL":"https://www.acf.hhs.gov/sites/default/files/documents/ofa/fy19_characteristics_final.xlsx","description":"These tables provide demographic data on the age and race/ethnicity of adults and children in TANF and Separate State Program (SSP)-Maintenance-of-Effort (MOE) active families and closed cases, as well as data on the financial circumstances of TANF cash assistance recipients. Temporal: 10/1/2018-9/30/2019, Restriction: Public-use Aggregate, Formats: EXCEL, PDF","@type":"dcat:Distribution","title":"Characteristics and Financial Circumstances of TANF Recipients, Fiscal Year 2019"}],"theme":["ACF"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/6634-w5cc","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["pubchem","chemistry","science","research","compound"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/6634-w5cc","description":"Chemical compound data from PubChem database. IUPAC Name: 3,4-dibromodibenzofuran. Molecular Formula: C12H6Br2O. Molecular Weight: 325.98. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 526351: 3,4-Dibromo-dibenzofuran","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/526351","description":"Access the complete Compound 526351: 3,4-Dibromo-dibenzofuran on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://www.nlm.nih.gov/tsd/serials/lsiou.html","bureauCode":["009:25"],"issued":"2021-08-26","@type":"dcat:Dataset","modified":"2025-06-18","keyword":["dataset","library services","literature"],"contactPoint":{"@type":"vcard:Contact","fn":"National Library of Medicine","hasEmail":"mailto:custserv@nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Library of Medicine"},"identifier":"https://datadiscovery.nlm.nih.gov/api/views/dc87-bt4r","description":"The List of Serials Indexed for Online Users (LSIOU) provides bibliographic information for all journals whose articles were ever indexed over time with the MeSH® vocabulary and cited in MEDLINE®, the backbone of the NLM PubMed® database. It includes titles that ceased publication, changed titles, or are no longer indexed. More detailed bibliographic data and information about indexing coverage for serials cited in MEDLINE/PubMed can be found in LocatorPlus Catalog®, the NLM online catalog, and the NLM Catalog, an Entrez database.","title":"List of Serials Indexed for Online Users (LSIOU)","programCode":["009:041"],"distribution":[{"mediaType":"text/html","downloadURL":"ftp://ftp.nlm.nih.gov/online/journals/","description":"The LSIOU is produced in XML. The current year's file is in the directory linked below and named lsi2021.xml (for 2021). Previous year's files are located in the 'archive' folder.","@type":"dcat:Distribution","title":"Download Data - List of Serials Indexed for Online Users (LSIOU)"}],"license":"http://opendefinition.org/licenses/odc-odbl/","theme":["Literature"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/667e-4vgn","bureauCode":["009:25"],"issued":"2025-09-05","@type":"dcat:Dataset","modified":"2025-09-05","keyword":["compound","chemistry","science","research","pubchem"],"contactPoint":{"@type":"vcard:Contact","fn":"NIH/NCBI Data Team","hasEmail":"mailto:info@ncbi.nlm.nih.gov"},"publisher":{"@type":"org:Organization","name":"National Center for Biotechnology Information (NCBI)"},"identifier":"https://healthdata.gov/api/views/667e-4vgn","description":"Chemical compound data from PubChem database. IUPAC Name: 1-[1-[1-[1-(1-prop-2-enoxypropan-2-yloxy)propan-2-yloxy]propan-2-yloxy]propan-2-yloxy]propan-2-yl acetate. Molecular Formula: C20H38O7. Molecular Weight: 390.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.","title":"Compound 525179: Pentapropyleme glycol, monoallyl ether, acetate","programCode":["009:066"],"distribution":[{"mediaType":"text/html","downloadURL":"https://pubchem.ncbi.nlm.nih.gov/compound/525179","description":"Access the complete Compound 525179: Pentapropyleme glycol, monoallyl ether, acetate on the official website.","@type":"dcat:Distribution","title":"Official Data Source"}],"theme":["NIH"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/669n-degh","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","mental-health","florida","substance-use","behavioral-health"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/669n-degh","description":"This is a behavioral health report for the state of Florida The report utilizes data from the National Survey on Drug Use and Health (NSDUH), and the Uniform Reporting System. The topics addressed in the report include youth substance use, youth mental health and treatment, mental health and treatment, substance use and substance use treatment.","title":"Behavioral Health Barometer: Florida, 2015","programCode":["009:061"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/behavioral-health-barometer-florida-2015","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/66a5-nuqs","bureauCode":["009:30"],"issued":"2025-07-14","@type":"dcat:Dataset","modified":"2025-09-06","keyword":["samhsa","national-outcome-measures","mental-health-services","community-mental-health","virgin-islands"],"contactPoint":{"@type":"vcard:Contact","fn":"SAMHSA","hasEmail":"mailto:SAMHSAInfo@samhsa.hhs.gov"},"publisher":{"@type":"org:Organization","name":"Substance Abuse and Mental Health Services Administration"},"identifier":"https://healthdata.gov/api/views/66a5-nuqs","description":"This is the 2022 Uniform Reporting System (URS) Output Tables for Virgin Islands. The URS state reporting system is collected annually to support the Community Mental Health Services Block Grant program. State Mental Health Authorities report on National Outcome Measures (NOMS), evidence-based practices, and utilization measures providing an overview of state mental health delivery systems.","title":"2022 Uniform Reporting System (URS) Table For Virgin Islands","programCode":["009:068"],"distribution":[{"mediaType":"text/html","downloadURL":"https://www.samhsa.gov/data/report/2022-uniform-reporting-system-urs-table-virgin-islands","description":"Visit the original government dataset for complete information, documentation, and data access.","@type":"dcat:Distribution","title":"Official Government Data Source"}],"theme":["SAMHSA"]},{"accessLevel":"public","landingPage":"https://healthdata.gov/d/66by-xph5","bureauCode":["009:38"],"issued":"2015-10-28","@type":"dcat:Dataset","modified":"2015-11-24","keyword":["healthcare"],"contactPoint":{"@type":"vcard:Contact","fn":"Felix","hasEmail":"mailto:no-reply@data.healthcare.gov"},"publisher":{"@type":"org:Organization","name":"data.healthcare.gov"},"identifier":"hxw8-c85n","description":"Dataset.","title":"QHP Landscape Instructions PY2016 NV Individual Dental","programCode":["009:000"],"distribution":[{"@type":"dcat:Distribution","downloadURL":"https://data.healthcare.gov/datafile/PY2015_NV-Dent-Indi-Land-11-09-2015.pdf","mediaType":"application/pdf","title":"FILE"}],"theme":["CMS"]},{"accessLevel":"public","landingPage":"https://health.data.ny.gov/d/8npw-hpyp","issued":"2017-01-12","@type":"dcat:Dataset","modified":"2020-03-12","keyword":["organ procurement","organ donation","eye bank","community health and chronic disease","tissue donation","tissue bank"],"contactPoint":{"@type":"vcard:Contact","fn":"Open Data NY - DOH","hasEmail":"mailto:no-reply@health.data.ny.gov"},"publisher":{"@type":"org:Organization","name":"State of New York"},"identifier":"https://health.data.ny.gov/api/views/8npw-hpyp","description":"This dataset contains the names, contact information, and county location for the federally authorized Organ Procurement Organizations (OPOs), as well as the New York State regulated Eye Banks and Tissue Banks. These organizations work closely with the Department of Health (DOH) to educate the public regarding the need for organ and tissue donation and to facilitate the enrollment of individuals in the New